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Zika virus (ZIKV) is an emerging mosquito-borne member of the Flaviviridae family that has
historically been known to cause sporadic outbreaks, associated with a mild febrile illness, in Africa
and Southeast Asia. However, the recent outbreaks of ZIKV in the Americas and its association with
severe neurological disorders, including fetal microcephaly, Guillain-Barré syndrome, and ocular
abnormalities, have caused a great social and sanitary alarm. The significance of ZIKV in human
health, together with a lack of approved therapeutic (antivirals) or prophylactic (vaccines) interventions,
has triggered a global effort to develop effective countermeasures against this pathogen, which has
the potential to affect millions of people worldwide.
Since the re-emergence of the virus in 2015 in Brazil, massive advances have been made in
practically all areas of the biology of ZIKV. In this Special Issue, we have assembled a collection
of 32 research papers and reviews that cover recent advances on ZIKV research in molecular
biology, replication and transmission, virus-host interactions, pathogenesis, epidemiology, vaccine
development, antivirals, and diagnosis.
The first part of this Special Issue focuses on the development of ZIKV reverse genetic approaches,
which constitute a powerful tool to answer important questions on the biology of ZIKV and for
vaccine development. This theme is covered by a complete review of all ZIKV reverse genetic systems
developed in the last years (Ávila-Pérez et al. [1]) and two research papers describing the generation
of a ZIKV infectious clone by the mutational silencing of cryptical bacterial promoters present in the
viral genome (Münster et al. [2]) and a Tet-inducible ZIKV infectious clone (Zhang et al. [3]).
The second topic of the Special Issue addresses recent advances in viral replication and
transmission and is covered by three research articles (Barnard et al. [4]; Mlera and Bloom [5];
and Oliveira et al. [6]).
The third topic, virus-host interactions, includes two comprehensive reviews, one describing the
molecular insights into ZIKV-host interactions (Lee et al. [7]) and other discussing the type I interferon
(IFN) antagonist mechanisms used by flaviviruses, with a focus on the non-structural (NS)5 protein
(Thurmond et al. [8]). In addition, this topic includes five research manuscripts that describe the impact
of viral and host genetic variations on ZIKV infection (Yun et al. [9]), the effect of ZIKV infection on
Heme Oxygenase expression (Kalamouni et al. [10]), the different effects of ZIKV infection in placenta
and microglia cells (Martinez-Viedma and Pickett [11]), the effect of permethrin resistance on the
vector transcriptome after ZIKV infection (Zhao et al. [12]), and the microRNA and mRNA profiling in
infected neurons (Azouz et al. [13]).
The fourth subject area address new advances in ZIKV pathogenesis. This theme is covered by
two reviews that describe ZIKV pathogenesis in the male reproductive tract (Stassen et al. [14]) and
the ocular abnormalities induced by flavivirus infection (Singh et al. [15]), and five research articles
that define fetal brain infection with ZIKV isolates not associated with microcephaly (Setoh et al. [16]),
the pathogenesis of Asian and African ZIKV isolates in Indian Rhesus macaques (Rayner et al. [17]),
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the consequences of ZIKV infection in human pluripotent stem cell-derived neural progenitor cells
and neurons (Goodfellow et al. [18]), the effect of a single mutation in the NS2A protein in virus
pathogenesis (Márquez-Jurado et al. [19]), and the roles of the premembrane (prM) and envelop (E)
proteins in ZIKV-mediated infection and neurocytotoxicity (Li et al. [20]).
The fifth section in the Special Issue covers the new advances in epidemiology and virus evolution,
including a manuscript describing the evolutionary insight of ZIKV strains isolated in Latin America
(Simón et al. [21]).
The next section focuses on ZIKV vaccines and antivirals, and contains three review documents
(Garg et al. [22]; Alves et al. [23]; Saiz et al. [24]) and two research articles that describe the
antiviral effect of silvestrol (Elgner et al. [25]) and oxysterol 7-ketocholesterol (Willard et al. [26])
in ZIKV replication.
The last section in this Special Issue covers new advances in the molecular diagnostic of ZIKV,
and includes a comprehensive review (Mantke et al. [27]) and five research articles that describe
the development and characterization of several ZIKV diagnostic methods (Bhadra et al. [28];
de Ory et al. [29]; Zhang et al. [30]; Taylor et al. [31]; Amaro et al. [32]).
We would like to thank all contributing authors for their participation, effort and hard work in
putting together this Special Issue. We would also like to thank the Editorial Office at Viruses for all the
help, support, and advice with this Special Issue. We hope this Special Issue offers a comprehensive
view of the recent advances in ZIKV research and stimulates research for future studies aimed at
understanding ZIKV evolution, virus-host-interaction, pathogenesis, and the development of effective
countermeasures to combat ZIKV infection.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ávila-Pérez, G.; Nogales, A.; Martín, V.; Almazán, F.; Martínez-Sobrido, L. Reverse Genetic Approaches for
the Generation of Recombinant Zika Virus. Viruses 2018, 10, 597. [CrossRef]
2. Münster, M.; Płaszczyca, A.; Cortese, M.; Neufeldt, C.J.; Goellner, S.; Long, G.; Bartenschlager, R. A Reverse
Genetics System for Zika Virus Based on a Simple Molecular Cloning Strategy. Viruses 2018, 10, 368.
[CrossRef]
3. Zhang, L.; Ji, W.; Lyu, S.; Qiao, L.; Luo, G. Tet-Inducible Production of Infectious Zika Virus from the
Full-Length cDNA Clones of African- and Asian-Lineage Strains. Viruses 2018, 10, 700. [CrossRef] [PubMed]
4. Barnard, T.R.; Rajah, M.M.; Sagan, S.M. Contemporary Zika Virus Isolates Induce More dsRNA and Produce
More Negative-Strand Intermediate in Human Astrocytoma Cells. Viruses 2018, 10, 728. [CrossRef] [PubMed]
5. Mlera, L.; Bloom, M.E. Differential Zika Virus Infection of Testicular Cell Lines. Viruses 2019, 11, 42. [CrossRef]
[PubMed]
6. Oliveira, D.B.L.; Durigon, G.S.; Mendes, É.A.; Ladner, J.T.; Andreata-Santos, R.; Araujo, D.B.; Botosso, V.F.;
Paola, N.D.; Neto, D.F.L.; Cunha, M.P.; et al. Persistence and Intra-Host Genetic Evolution of Zika Virus
Infection in Symptomatic Adults: A Special View in the Male Reproductive System. Viruses 2018, 10, 615.
[CrossRef] [PubMed]
7. Lee, I.; Bos, S.; Li, G.; Wang, S.; Gadea, G.; Desprès, P.; Zhao, R.Y. Probing Molecular Insights into Zika
Virus–Host Interactions. Viruses 2018, 10, 233. [CrossRef]
8. Thurmond, S.; Wang, B.; Song, J.; Hai, R. Suppression of Type I Interferon Signaling by Flavivirus NS5. Viruses
2018, 10, 712. [CrossRef] [PubMed]
9. Yun, S.-I.; Song, B.-H.; Frank, J.C.; Julander, J.G.; Olsen, A.L.; Polejaeva, I.A.; Davies, C.J.; White, K.L.;
Lee, Y.-M. Functional Genomics and Immunologic Tools: The Impact of Viral and Host Genetic Variations on
the Outcome of Zika Virus Infection. Viruses 2018, 10, 422. [CrossRef]
10. El Kalamouni, C.; Frumence, E.; Bos, S.; Turpin, J.; Nativel, B.; Harrabi, W.; Wilkinson, D.A.; Meilhac, O.;
Gadea, G.; Desprès, P.; et al. Subversion of the Heme Oxygenase-1 Antiviral Activity by Zika Virus. Viruses
2019, 11, 2. [CrossRef]
2
Viruses 2019, 11, 258
11. Martinez Viedma, M.P.; Pickett, B.E. Characterizing the Different Effects of Zika Virus Infection in Placenta
and Microglia Cells. Viruses 2018, 10, 649. [CrossRef]
12. Zhao, L.; Alto, B.W.; Shin, D.; Yu, F. The Effect of Permethrin Resistance on Aedes aegypti Transcriptome
Following Ingestion of Zika Virus Infected Blood. Viruses 2018, 10, 470. [CrossRef]
13. Azouz, F.; Arora, K.; Krause, K.; Nerurkar, V.R.; Kumar, M. Integrated MicroRNA and mRNA Profiling in
Zika Virus-Infected Neurons. Viruses 2019, 11, 162. [CrossRef]
14. Stassen, L.; Armitage, C.W.; Van der Heide, D.J.; Beagley, K.W.; Frentiu, F.D. Zika Virus in the Male
Reproductive Tract. Viruses 2018, 10, 198. [CrossRef]
15. Singh, S.; Kumar, A. Ocular Manifestations of Emerging Flaviviruses and the Blood-Retinal Barrier. Viruses
2018, 10, 530. [CrossRef]
16. Setoh, Y.X.; Peng, N.Y.; Nakayama, E.; Amarilla, A.A.; Prow, N.A.; Suhrbier, A.; Khromykh, A.A. Fetal Brain
Infection Is Not a Unique Characteristic of Brazilian Zika Viruses. Viruses 2018, 10, 541. [CrossRef]
17. Rayner, J.O.; Kalkeri, R.; Goebel, S.; Cai, Z.; Green, B.; Lin, S.; Snyder, B.; Hagelin, K.; Walters, K.B.; Koide, F.
Comparative Pathogenesis of Asian and African-Lineage Zika Virus in Indian Rhesus Macaque’s and
Development of a Non-Human Primate Model Suitable for the Evaluation of New Drugs and Vaccines.
Viruses 2018, 10, 229. [CrossRef]
18. Goodfellow, F.T.; Willard, K.A.; Wu, X.; Scoville, S.; Stice, S.L.; Brindley, M.A. Strain-Dependent Consequences
of Zika Virus Infection and Differential Impact on Neural Development. Viruses 2018, 10, 550. [CrossRef]
19. Márquez-Jurado, S.; Nogales, A.; Ávila-Pérez, G.; Iborra, F.J.; Martínez-Sobrido, L.; Almazán, F.
An Alanine-to-Valine Substitution in the Residue 175 of Zika Virus NS2A Protein Affects Viral RNA Synthesis
and Attenuates the Virus In Vivo. Viruses 2018, 10, 547. [CrossRef]
20. Li, G.; Bos, S.; Tsetsarkin, K.A.; Pletnev, A.G.; Desprès, P.; Gadea, G.; Zhao, R.Y. The Roles of prM-E Proteins
in Historical and Epidemic Zika Virus-mediated Infection and Neurocytotoxicity. Viruses 2019, 11, 157.
[CrossRef]
21. Simón, D.; Fajardo, A.; Moreno, P.; Moratorio, G.; Cristina, J. An Evolutionary Insight into Zika Virus Strains
Isolated in the Latin American Region. Viruses 2018, 10, 698. [CrossRef] [PubMed]
22. Garg, H.; Mehmetoglu-Gurbuz, T.; Joshi, A. Recent Advances in Zika Virus Vaccines. Viruses 2018, 10, 631.
[CrossRef] [PubMed]
23. Alves, M.P.; Vielle, N.J.; Thiel, V.; Pfaender, S. Research Models and Tools for the Identification of Antivirals
and Therapeutics against Zika Virus Infection. Viruses 2018, 10, 593. [CrossRef] [PubMed]
24. Saiz, J.-C.; Oya, N.J.; Blázquez, A.-B.; Escribano-Romero, E.; Martín-Acebes, M.A. Host-Directed Antivirals:
A Realistic Alternative to Fight Zika Virus. Viruses 2018, 10, 453. [CrossRef] [PubMed]
25. Elgner, F.; Sabino, C.; Basic, M.; Ploen, D.; Grünweller, A.; Hildt, E. Inhibition of Zika Virus Replication by
Silvestrol. Viruses 2018, 10, 149. [CrossRef]
26. Willard, K.A.; Elling, C.L.; Stice, S.L.; Brindley, M.A. The Oxysterol 7-Ketocholesterol Reduces Zika Virus
Titers in Vero Cells and Human Neurons. Viruses 2019, 11, 20. [CrossRef] [PubMed]
27. Donoso Mantke, O.; McCulloch, E.; Wallace, P.S.; Yue, C.; Baylis, S.A.; Niedrig, M. External Quality
Assessment (EQA) for Molecular Diagnostics of Zika Virus: Experiences from an International EQA
Programme, 2016–2018. Viruses 2018, 10, 491. [CrossRef]
28. Bhadra, S.; Saldaña, M.A.; Han, H.G.; Hughes, G.L.; Ellington, A.D. Simultaneous Detection of Different
Zika Virus Lineages via Molecular Computation in a Point-of-Care Assay. Viruses 2018, 10, 714. [CrossRef]
29. De Ory, F.; Sánchez-Seco, M.P.; Vázquez, A.; Montero, M.D.; Sulleiro, E.; Martínez, M.J.; Matas, L.;
Merino, F.J.; Working Group for the Study of Zika Virus Infections. Comparative Evaluation of Indirect
Immunofluorescence and NS-1-Based ELISA to Determine Zika Virus-Specific IgM. Viruses 2018, 10, 379.
[CrossRef]
30. Zhang, L.; Du, X.; Chen, C.; Chen, Z.; Zhang, L.; Han, Q.; Xia, X.; Song, Y.; Zhang, J. Development and
Characterization of Double-Antibody Sandwich ELISA for Detection of Zika Virus Infection. Viruses 2018,
10, 634. [CrossRef]
3
Viruses 2019, 11, 258
31. Taylor, C.T.; Mackay, I.M.; McMahon, J.L.; Wheatley, S.L.; Moore, P.R.; Finger, M.J.; Hewitson, G.R.;
Moore, F.A. Detection of Specific ZIKV IgM in Travelers Using a Multiplexed Flavivirus Microsphere
Immunoassay. Viruses 2018, 10, 253. [CrossRef]
32. Amaro, F.; Sánchez-Seco, M.P.; Vázquez, A.; Alves, M.J.; Zé-Zé, L.; Luz, M.T.; Minguito, T.; De La Fuente, J.;
De Ory, F. The Application and Interpretation of IgG Avidity and IgA ELISA Tests to Characterize Zika Virus
Infections. Viruses 2019, 11, 179. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Reverse Genetic Approaches for the Generation of
Recombinant Zika Virus
Ginés Ávila-Pérez 1, Aitor Nogales 1, Verónica Martín 2 , Fernando Almazán 2,* and
Luis Martínez-Sobrido 1,*
1 Department of Microbiology and Immunology, University of Rochester Medical Center,
601 Elmwood Avenue, Rochester, NY 14642, USA; Gines_Perez@urmc.rochester.edu (G.A.-P.);
aitor_nogales@urmc.rochester.edu (A.N.)
2 Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Campus
Universidad Autónoma de Madrid, 3 Darwin street, 28049 Madrid, Spain; veronica.martin@inia.es
* Correspondence: falmazan@cnb.csic.es (F.A.); luis_martinez@urmc.rochester.edu (L.M.-S.)
Received: 10 October 2018; Accepted: 28 October 2018; Published: 31 October 2018
Abstract: Zika virus (ZIKV) is an emergent mosquito-borne member of the Flaviviridae family that
was responsible for a recent epidemic in the Americas. ZIKV has been associated with severe clinical
complications, including neurological disorder such as Guillain-Barré syndrome in adults and severe
fetal abnormalities and microcephaly in newborn infants. Given the significance of these clinical
manifestations, the development of tools and reagents to study the pathogenesis of ZIKV and to
develop new therapeutic options are urgently needed. In this respect, the implementation of reverse
genetic techniques has allowed the direct manipulation of the viral genome to generate recombinant
(r)ZIKVs, which have provided investigators with powerful systems to answer important questions
about the biology of ZIKV, including virus-host interactions, the mechanism of transmission and
pathogenesis or the function of viral proteins. In this review, we will summarize the different
reverse genetic strategies that have been implemented, to date, for the generation of rZIKVs and the
applications of these platforms for the development of replicon systems or reporter-expressing viruses.
Keywords: flavivirus; Zika virus (ZIKV); reverse genetics; infectious clone; full-length molecular
clone; bacterial artificial chromosome; replicon; infectious RNA
1. Introduction
1.1. Importance of Zika Virus in Human Health
Zika virus (ZIKV) is a recently emerged mosquito-borne virus, which in 2016 was declared as an
international public health emergency by the World Health Organization (WHO, http://www.who.
int/csr/en/) [1]. ZIKV is a member of the Flavivirus genus that belongs to the Flaviviridae family
and is closely related to other mosquitoes-transmitted flaviviruses of public health relevance such
as Dengue virus (DENV), Yellow fever virus (YFV), Japanese encephalitis virus (JEV) and West Nile
virus (WNV) [2,3]. ZIKV was first isolated in 1947 of a sentinel rhesus monkey in the Zika forest
of Uganda [4] and has been associated with sporadic human cases detected across Africa and Asia,
resembling a mild version of DENV or Chikungunya virus (CHIKV) [5]. These similarities with DENV
and CHIKV has interfered with ZIKV diagnosis and most probably underestimated the number of
cases for ZIKV infections [6]. Symptomatic disease generally is present with a mild febrile illness
characterized by fever, rash, muscle pain, headache and conjunctivitis, although as up to 80% of the
ZIKV cases are asymptomatic [7–9]. However, the outbreak in the island of Yap in 2007 [10], French
Polynesia in 2013–2014 [11,12] and the massive epidemic that emerge in Brazil in 2015 [13,14] have
caused major concerns due to the association of ZIKV infection with severe congenital abnormalities,
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including microcephaly in infants and an increased risk of Guillain-Barré syndrome in adults [15–18].
ZIKV is mainly transmitted to people through the bite of an infected Aedes spp. mosquito (Ae. Aegypti
and Ae. Albopictus) [19], which carries a high risk for pregnant woman due to the ability to cross
the placenta and infected fetal nervous tissues [20]. In addition to maternal-fetal transmission, ZIKV
can also be transmitted from mother to child during pregnancy or spread through sexual contact,
breastfeeding, blood transfusion and non-human primate bites [21–23].
1.2. ZIKV Biology
ZIKV is an enveloped virus containing three structural proteins (Figure 1): the capsid (C) protein,
the membrane (M) protein and the envelope (E) glycoprotein (Figure 1A). Inside the virion, the viral
(v)RNA genome is complexed with multiple copies of the C protein, surrounded by the E and M
proteins, which are anchored in a lipid membrane (Figure 1A). The surface of the mature virion has a
icosahedral shell consisting of 90 E:M heterodimers (Figure 1A) [24]. The viral genome is made of a
positive single-stranded RNA molecule of approximately 10.8 kb with a single open reading frame,
flanked at the 5′- and 3′-ends by the viral untranslated regions (UTRs) (Figure 1B). ZIKV vRNA is
translated by cap-dependent initiation producing a single polyprotein of approximately 3423 amino
acids, which is co- and post-transcriptionally processed by both viral and cellular proteases into the
three structural proteins (C, pre-Membrane (prM) and E) and seven non-structural (NS) proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5) (Figure 1B). The structural proteins are essential components
of the virion and are involved in viral entry, fusion and assembly. The NS proteins are mainly
involved in vRNA synthesis, assembly and regulation of the host cell responses [25]. Phylogenetic
analysis of ZIKV have revealed two major genetic lineages (African and Asian), which have undergone
substantial changes during the past 50 years. Sequence homology analysis indicated that the strains
that have been responsible for the recent human outbreaks throughout the Pacific and the Americas
are phylogenetically related to the most recent Asian lineage [26,27].
Figure 1. Zika virus (ZIKV) virion structure and genome organization. (A) Schematic representation of
ZIKV virion structure: ZIKV virion surface is decorated with the E and M proteins, anchored in a lipid
bilayer with an icosahedral-like symmetry. Under the viral lipid bilayer is the nucleocapsid composed of
the vRNA genome associated with the C protein. (B) Genome organization and polyprotein processing:
ZIKV genome (approximately 10.8 kb) is translated as a single polyprotein that is cleaved co- and
post-translationally by viral (arrows) and host (diamonds) proteases to yield the three structural
proteins C, M and E; and seven NS proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. The 5′ and
3′ untranslated regions (UTR) are indicated as black lines at the end of the viral genome.
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Like other flaviviruses, ZIKV entry occurs via attachment of the virions to the cell surface, a
mechanism mediated by the viral E glycoprotein, followed by internalization by receptor-mediated
endocytosis [28]. After virus internalization, the acid environment inside the endosome induces
major conformational changes in the E glycoprotein that promote fusion of the viral and endosome
membranes and the subsequent release of the viral genome into the cytoplasm of the infected cell. Once
the genomic vRNA is released, it is translated to the viral polyprotein. As other positive-stranded RNA
viruses, flaviviruses replication occurs on virus-induced host cell membranes, mainly characterized
by invaginations of the endoplasmic reticulum (ER) membrane termed vesicle packets, which serve
as scaffold for anchoring the viral replication complexes [29–31]. The immature viral particles are
assembled within the ER, where the genomic vRNA is associated with the C protein and is packaged
into ER-derived membranes containing the prM and E proteins. Virion maturation occurs in the
trans-Golgi network during its transit through the cellular secretory pathway. Cellular furin protease
mediate the cleavage of the prM, resulting in the release of the pr peptide and formation of mature
virions containing the M protein that will be released from infected cells [32–34].
Because the very recent emergence of ZIKV, there are not currently approved vaccines or antivirals
available to combat infection by this important human pathogen. Therefore, the generation of
prophylactic (vaccines) and therapeutic (antivirals) options for the treatment of ZIKV are urgently
required. The development of ZIKV reverse genetic systems provide investigators with a powerful
tool for the development of vaccines and antivirals to counteract disease caused by this important
human pathogen.
2. ZIKV Reverse Genetics
In 1981, Racaniello et al. reported, for the first time, the production of infectious virus by
transfecting mammalian cells with a DNA plasmid containing the entire viral genome of poliovirus [35].
Since then, numerous reverse genetic technologies have been employed to recover recombinant viruses
for the majority of viral families, including positive-sense RNA viruses such as coronavirus [36],
picornavirus [37,38], flavivirus [39]; or negative-sense RNA viruses such as influenza [40] and
arenavirus [41,42], among many others. Reverse genetic techniques have allowed investigators
to generate recombinant viruses containing specific mutations to evaluate their contribution in
viral replication and transcription, pathogenicity, virus-host interactions, inhibition of host cellular
responses and host range or transmissibility [37]. Importantly, reverse genetic approaches have also
been used for the developing of vaccines based on attenuated forms of the virus [37,40] and the
generation of recombinant viruses harboring reporter genes to easily track viral infection, which
have been resourceful to identify antivirals, host factors or for the in vitro and in vivo study of viral
infections [43,44]. Viral reverse genetic approaches allow to recover infectious recombinant viruses
upon transfection of a single (non-segmented viruses) or multiple (segmented viruses) DNAs into
susceptible cells [40].
Similar to other viruses, the recent emergence of ZIKV as an important human pathogen, has
promoted the rapid development of numerous reverse genetic approaches to increase our knowledge
of the molecular biology and pathogenesis of ZIKV. To date, three major reverse genetic strategies have
been described to generate rZIKVs: (i) infectious RNA transcripts from a full-length complementary
(c)DNA copy; (ii) DNA plasmids that are directly transfected to produce infectious ZIKV; and (iii)
Infectious Subgenomic Amplicons (ISA) (Figure 2 and Table 1). The first strategy involves the in vitro
transcription of an infectious RNA genome from a full-length cDNA copy containing the ZIKV genome
under the control of a prokaryotic RNA polymerase promoter (e.g., T7 or SP6) (Figure 2A). In this
case, the last nucleotide of the viral genome is followed by the hepatitis delta virus ribozyme (HDVr)
sequence to produce synthetic RNAs bearing an accurate 3′ end (Figure 2A). Once transcribed, the
vRNA is transfected into susceptible cells to recover infectious rZIKV. The second approach consist
in the construction of a full-length infectious cDNA clone containing the viral genome flanked by a
eukaryotic polymerase II-driven promoter at the 5′ end, mainly the cytomegalovirus (CMV) promoter
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and the HDVr sequence followed by a polymerase II terminator and polyadenylation signal (pA) at
the 3′ end of the viral genome (Figure 2B). The full-length cDNA is usually assembled in a low-copy
plasmid for its stable propagation in bacteria. In this system, the full-length infectious cDNA clone is
directly transfected into susceptible cells where the vRNA is primarily transcribed in the nucleus by
the cellular RNA polymerase II with further amplification steps in the cytoplasm driven by the viral
polymerase. The last approach is based on the generation of overlapping double-stranded (ds)DNA
fragments, covering the entire genome of ZIKV. In this case, the 5′ end fragment contains a polymerase
II driven promoter (e.g., CMV) and the 3′ end fragment a HDVr sequence followed by a polymerase II
terminator and polyadenylation signal (Figure 2C). This ISA approach involves the co-transfection
of all the cDNA fragments into susceptible cells followed by the self-assembly of a full-length cDNA
copy inside of the transfected cells by homologous recombination.
 
Figure 2. Schematic representation of ZIKV reverse genetic approaches. (A) Infectious RNA transcripts
from full-length cDNA clones: A full-length genomic cDNA clone containing the ZIKV genome flanked
by a prokaryotic promoter (e.g., T7 or SP6) and the hepatitis delta virus ribozyme (HDVr) is usually
assembled in a low-copy plasmid. In this approach, in vitro transcription is required to produce
viral RNA that is transfected into susceptible cells to initiate viral replication and transcription in
the cytoplasm of transfected cells. (B) Full-length infectious genomic cDNA clones: A full-length
infectious genomic cDNA clone containing the viral genome flanked by a polymerase II-driven
promoter from cytomegalovirus (CMV) and the HDVr followed by a polymerase II terminator and
polyadenylation signal (pA) is assembled in a low-copy plasmid. In this case, the full-length cDNA
clone is transcribed in the nucleus of transfected cells by the cellular RNA polymerase II. Primary
transcripts are translocated to the cytoplasm where further amplifications steps are conducted by the
viral polymerase. (C) Infectious Subgenomic Amplicons (ISA): The ISA approach can be used for
the production of infectious viruses from genomic DNA material, including pre-existing infectious
cDNA clones, viral RNA or de novo synthesized DNA genomic sequences. The entire viral genome
is amplified by overlapping PCR reactions with each PCR product containing 30–40 base pairs
overlapping regions [45]. The first and last PCR products are flanked by the CMV promoter and
the HDVr followed by a polymerase II terminator and pA signal, respectively. Co-transfected cDNAs
result in self-assembly in the cytoplasm of susceptible cells and virus production.
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Table 1. ZIKV reverse genetics techniques.




 vRNAs are directly electroporated
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 Need an in vitro RNA
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 Plasmid containing the viral genome
is directly transfected into the cells
 In vitro transcription is not required
 Genome instability of flavivirus
cDNA clones in bacteria [48,56–59]
Infectious subgenomic
amplicons (ISA)
 Rapid and easy construction
 cDNA assembly occurs into the cells
 Nonhomogeneous populations by
error in the recombination events [45,60,61]
The construction of full-length cDNA clones for ZIKV has been hampered due to the toxicity
of the viral genome, similar to other flavivirus, which is known to be toxic and unstable during its
propagation in bacteria using standard plasmids [62–65]. This is attributed to the leaky expression of
toxic viral proteins from cryptic prokaryotic promoters within the E and the NS1 coding sequences [66].
Therefore, several approaches have been developed to overcome the genome instability of flavivirus
cDNA clones, including ZIKV. Those methods are summarized in Table 2 and described in detail in
the following sections.
Table 2. Strategies to avoid toxicity of full-length constructs.
Approaches Advantages Disadvantages Ref.
Low-copy number plasmid Cryptic promoters are maintained at lowlevel of expression
Low plasmid yield
Flavivirus genome are often unstable [46–49]
Bacterial artificial
chromosome (BAC)
Minimization of toxicity by a strictly
controlled replication leading to only one
plasmid per cell.
Stable maintenance of large DNA
fragments
Low plasmid yield
Manipulation of big DNA constructs [48,56]
Inactivation of cryptic E. coli
promoters (CEP) CPEs are inactivated
Introduction of punctual mutation can
disrupt the viral RNA structure and viral
fitness
[50,51]
Intron insertion Expression of toxic regions is interrupted inbacteria
Introduction of external sequences in the
viral genome [42,57,58]
In vitro ligation Non-required propagation of full-lengthcDNA in bacteria
Viral genome is maintained in multiple
fragments in bacteria
Low ligation efficiency
Low virus recovery efficiency
[52,53]
Gibson assembly or Circular
polymerase extension
cloning (CPEC)
Non-required propagation of full-length
cDNA in bacteria
Rapid assembly in one step
Viral genome is maintained in multiple
fragments in bacteria
Low virus recovery efficiency
Error rate of the reaction can produce
undesired mutations
[54,55,59]
2.1. Infectious RNA Transcripts from Full-Length ZIKV cDNAs
In the last two years, several approaches based on the use of infectious RNA transcripts from
full-length ZIKV cDNAs have been developed to overcome the toxicity problems associated with
several sequences of ZIKV genome when amplified in bacteria. Those methods involve the use of
low-copy number plasmids [46–51], the incorporation of an intron in the genome to disrupt toxic
regions [42], in vitro ligation of cDNA fragments [52,53] and Gibson assembly [54,55], amount others.
2.1.1. Construction of Full-Length ZIKV cDNA Clones Using Low-Copy Number Plasmids
A widely employed approach to overcome the toxicity of ZIKV and facilitate the stability
of full-length cDNA clones consist in the use of low-copy number plasmids in which the cryptic
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prokaryotic promoters are maintained at a low level of expression, along with the use of prokaryotic
transcription terminators to prevent the spurious transcription of foreign DNA sequences in bacterial
host cells [63] (Table 2). Following this strategy, Shan-June et al. in 2016 [46] engineered the first ZIKV
reverse genetic approach for the ZIKV FSS13025 strain that was isolated in 2010 from a 3-year-old
patient from Cambodia [67]. In this approach, five RT-PCR fragments spanning the complete viral
genome were individually cloned and assembled into a low-copy number plasmid using unique
restriction sites present in the viral genome. Authors chose the low-copy number plasmid pACYC177
(15 copies of plasmid per cell) because it was previously used with other flavivirus cDNA clones [68,69].
Importantly, during the cloning procedure, the fragment spanning the viral prM-E-NS1 genes was
reported to be toxic using a high-copy number plasmid. The T7 promoter and the HDVr sequence
were engineered at the 5′ and 3′ ends of the ZIKV cDNA for in vitro transcription and the generation
of the authentic 5′ and 3′ ends of the viral RNA, respectively. Using this approach, a rZIKV was
successfully recovery after transfection of the infectious in vitro transcribed RNA in mammalian Vero
cells. However, in vitro analysis showed that the rZIKV replicated at lower efficiency than the natural
ZIKV isolate in both mammalian (Vero) and mosquito (C6/36) cells. Moreover, whereas the rZIKV
produced plaques with homogenous morphology in Vero cells, the parental viral strain formed plaques
with heterogeneous sizes. This phenotype correlated with what was observed in vivo using interferon
receptor deficient (IFNAR−/−) A129 mice, where rZIKV was less virulent that the parental ZIKV.
In 2017, Mutso et al. [48] constructed a reverse genetic system based on the ZIKV Brazilian
BeH81915 strain using a single low-copy plasmid. In this case, the bacterial artificial chromosome
(BAC) plasmid pCC1-BAC was used to assemble the ZIKV genome under the control of a bacterial SP6
promoter. Notably, the rescued rZIKV showed similar in vitro grow kinetics in mammalian Vero cells,
human brain endothelial cells (hCMEC/D3) or human choriocarcinoma placental epithelial (BeWo)
cells than the natural ZIKV strain PRVABC59 isolated in Puerto Rico in 2015 [70].
Similarly, Nannamaliai et al. in 2017 [49] described the construction of a full-length cDNA clone
of the historical 1947 Uganda ZIKV strain MR766 using a low-copy number plasmid. To that end,
four RT-PCR fragments spanning the complete ZIKV MR766 genome were assembled in the plasmid
pBR322 (around 20 copies per cell). However, the fragment containing the NS1 coding region was
systematically instable during its propagation in bacteria, introducing deletion of 1 or 2 nucleotides.
To bypass this problem, they cloned the toxic fragment in the linear vector pJAZZ-OC [71], which
was used to assemble the full-length cDNA clone. pJAZZ-OC plasmid is derived from the linear
dsDNA genome of coliphage N15 and can be maintained with 2–4 copies/cells [71] in the bacteria
host. This plasmid has prokaryotic transcription terminators flanking the cloning site to eliminate
the transcription into and out of the insert, which increases the stability of the insert in the bacterial
host. Viral RNA transcripts were produced in vitro using the T7 RNA polymerase and infectious virus
was obtained from RNA-transfected Vero cells. Importantly, the rZIKV MR766 showed similar grow
kinetics in vitro in mammalian Vero or mosquito C6/36 cells than the parental MR766 ZIKV strain.
Moreover, rZIKV MR766 recapitulated the pathogenic properties in vivo of the parental MR766 virus
(IFNAR−/− A129 mice).
2.1.2. Stabilization of Full-Length ZIKV cDNA by Mutational Inactivation of Cryptic E. coli Promoters (CEPs)
An alternative approach to reduce the toxicity related with the expression of CEPs consist in the
inactivation of these sequences by the introduction of punctual silent mutations in the viral genome
(Table 2). This approach was previously described to stabilize the full-length cDNA clones of JEV
and DENV-2 [66]. Following this strategy, Münters et al. in 2018 [50] described the construction of
full-length cDNA clones of the African 1947 Uganda MR766 and the Asian French Polynesia 2013
(H/PF/2013) strains of ZIKV. In this case, four fragments spanning the entire ZIKV genomes were
assemble into the low-copy pFK plasmid [72] under the control of the phage T7 promoter using unique
restriction sites. However, they consistently observed that the full-length cDNA clones were unstable
during their propagation in bacteria. This problem was avoided with the introduction of punctual silent
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mutations to disrupt the CEPs present in the viral genome. Mutational inactivation of these cryptic
promoters, which were predicted in silico to reside in the structural regions of MR766 and H/PF/2013
genomes, was sufficient to stabilize the full-length cDNA clones of both ZIKV strains. Furthermore,
ZIKV cDNA clones were stable after five serial passages in E. coli. Both viruses were successfully
rescue after transfection of Vero cells with RNA produced in vitro using the T7 RNA polymerase.
Recently, Zhao et al. in 2018 [51] also described the stabilization of a full-length cDNA clone from a
ZIKV Brazilian isolated (SPH2015) by introducing silent mutations into the ZIKV genome to eliminate
the activity of CEPs. However, one potential problem in this approach is that the introduction
of multiple silent mutations can disrupt the viral RNA structure and affect viral replication and
transcription, affecting the successful rescue or the phenotype of the recovered virus in cultured cells
or in vivo (Table 2).
2.1.3. Stabilization of Full-Length ZIKV cDNA Clones Using Intron Insertions
The introduction of short eukaryotic introns in the viral genome to disrupt toxic regions has
been previously described to stabilize flavivirus cDNA clones [73]. Following this strategy, a full
length cDNA clone of ZIKV GZ01, a virus strain isolated from a patient in China [74], was successful
assembled by Liu Z-Y et al. [42] in 2017 to successfully rescue a rZIKV. Authors introduced a modified
version of the group II self-splicing P.li.LSUI2 intron [75,76] between the E and NS1 ZIKV coding
regions to disrupt the toxic regions located in that region of the viral genome. The intronic sequences
generally contain multiple stop codons, which interrupt the translation of the gene in bacteria (Table 2).
The P.li.LSUI2 intron, from the brown alga Pylaiella littoralis [77], was shown to have the ability to carry
out efficient self-splicing under in vitro conditions [75]. Thus, authors used this P.li.LSUI2 intron to
produce vRNA transcripts with an intact ZIKV sequence. To construct the full-length cDNA clone,
four RT-PCR fragments covering the entire full-length ZIKV genome were assembled under the control
of the SP6 promoter in the low-copy plasmid pACNR1180 [78]. The intron sequence was chemically
synthesized and cloned into the first fragment using overlapping PCR. Importantly, the intron-encoded
protein sequence, required for self-splicing, was removed to prevent the splicing of the ZIKV cDNA in
bacteria cells. In addition, the exon binding sequences of the inserted intron were modified to recognize
the flanking ZIKV sequences in order to ensure the correct splicing. Using this approach, a rZIKV GZ01
was successfully recovered after the transfection of the in vitro-spliced RNA in BHK-21 cells (baby
hamster kidney cell line). The recovered rZIKV GZ01 and the parental virus had similar grown kinetics
and plaque morphology in vitro in both mammalian BHK-21 and mosquito C6/36 cells. Moreover,
both viruses caused similar levels of neurovirulence in neonatal BALB/c mice, demonstrating that this
approach can be a feasible option for rescue rZIKV [42].
2.1.4. Construction of Full-Length ZIKV cDNA Clones Using In Vitro Ligation
A common strategy to overcome the instability associated with the construction of full-length
cDNA clones of some flaviviruses has been the transfection of infectious vRNA transcripts from
a full-length cDNA template, which is produced by in vitro ligation [79]. This method involved
the partition of the viral genome in multiples fragments flanked by natural or engineered specific
restriction sites that allows the systematic and precise assembly of a full-length cDNA by in vitro
ligation. Following this method, Widman et al. [52] described in 2017 the successfully rescue of
representative strains of ZIKV from the African (MR766) and Asian (H/PF/2013) lineages. In addition,
they were able to rescue two rZIKV from two strains (SPH2015 and BEH819015) isolated in Brazil [52].
Authors generated a quadripartite system to disrupt the toxic ZIKV genomic regions by cloning
the genome in four stable plasmids. Furthermore, natural nonpalindromic restriction endonuclease
sites located near of toxic regions [52,80] were used to allow the directional ligation of the digested
subgenomic fragments to generate a full-length cDNA clone. The resulting assembled product was
then transcribed into RNA in vitro using the T7 polymerase. This method avoids the use of a bacterial
host for the propagation of the full-length cDNA and therefore overcome the problems associated
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with cDNA instability (Table 2). Importantly, rZIKVs generated using this approach replicate in
cultured cells similarly than their parental viral isolates. Moreover, rZIKVs were virulent in type I and
type III interferon deficient AG129 mice, although slightly attenuated compared to their natural viral
isolates [52].
Recently, the same reverse genetic approach was used by Gorman et al. in 2018 to rescue the
African ZIKV strain Dakar 41525 [53]. Likewise, Deng et al. in 2017 also described the successful
rescue of rZIKV SZ-WIV01, a ZIKV strain belonging to the Asian lineage [81]. In this case, authors
combined the use of a quadripartite system with BglI overhang restrictions sites for in vitro ligation
and assembly of the full-length cDNA clone.
2.1.5. Construction of Full-Length ZIKV cDNA Clones Using Gibson Assembly
Gibson assembly is a molecular cloning method which allows the assembly of multiple
overlapping DNA molecules in one reaction using a 5′ exonuclease, a DNA polymerase and a DNA
ligase [82]. Like the in vitro ligation method described above, the entire viral genome is generated
and maintained in multiples overlapping fragments to disrupt the toxic regions present in the viral
genome (Table 2) [82]. Following this approach, in 2017, Weger-Lucarelli et al. developed a reverse
genetic system for the ZIKV PRVABC59 strain [54]. In this manuscript, the viral genome of PRVABC59
was cloned in two separated pieces into the pACYC177 vector to disrupt the unstable NS1 region.
To that end, the authors generated one vector with the T7 polymerase promoter sequence followed
by the first third of the ZIKV genome. A second pACYC177 vector with the rest of the viral genome
followed by the HDVr sequence was also generated. Both pACYC177 plasmids were engineered
containing overlapping regions with unique restriction sites to allow reassemble of the viral genome.
The full-length cDNA of ZIKV PRVABC59 was then generated by digestion and ligation using the
Gibson assembly method. The resulting assembled product was then transcribed into RNA using the
phage T7 polymerase and the product was transfected in Vero cells for the successful rescue of rZIKV
PRVABC59. Like in the in vitro ligation approach described above, this method avoids the need to use
a bacterial host for the propagation of the cDNA after the final assembly (Table 2). Importantly, the
rZIKV PRVABC59 was able to replicate at similar levels to the natural virus isolate in both mammalian
(Vero cells, BHK-21 cells, Huh7 human hepatoma cell line, JAR human placental cell line, amount
others) or mosquito (C6/36 or Aag2) cells. Moreover, the levels of transmission in mosquitos and
pathogenesis in type I and type III interferon deficient AG129 mice were also comparable between the
genetically engineered and the natural ZIKVs isolates.
2.2. Full-Length Infectious ZIKV cDNA Clones
The use of reverse genetic approaches containing eukaryotic polymerase II-dependent promoters
significantly simplifies the recovery of recombinant viruses as compared to the previously described
procedures using phage T7 or SP6 RNA polymerase-based promoters, since direct plasmid transfection
in susceptible cultured cells allows the rescue of recombinant viruses (Table 1). This approach involves
the expression of the viral RNA in the nucleus of transfected cells from a polymerase II-dependent
promoter with subsequent amplification steps in the cytoplasm by the viral polymerase. However, as
described above, the main concern with this approach is the construction of full-length infectious ZIKV
cDNA clones and the problems associated with stability of the viral genome during its propagation
in bacteria. Several approaches have been developed to overcome the problems associated with
genome instability of full-length infectious ZIKV cDNAs, including the use of intron sequences [57,58],
assembly by circular polymerase extension cloning [59] or the use of BACs [48,56] (Table 2).
2.2.1. Stabilization of Infectious Full-Length ZIKV cDNA Clones Using Introns
The first reverse genetic approach for the construction of a full-length infectious ZIKV cDNA clone
was reported by Tsetsarkin et al. in 2016 [57]. Authors described the generation of an infectious cDNA
clone for ZIKV Paraiba_01/2015, a virus isolated from serum of a febrile female subject in the Paraiba
12
Viruses 2018, 10, 597
state in Brazil during the 2015 epidemic. To that end, four overlapping cDNA fragments spanning
the entire ZIKV genome were individually cloned and assembled into the low-copy number plasmid
pACNR1811 using conventional molecular cloning techniques. To restrict plasmid toxicity during the
propagation of the cDNA in bacteria, they inserted two intron sequences in the NS1 and NS5 regions of
the viral genome. Authors observed that the insertion of a single intron into the NS1 was sufficient for
stable propagation of the infectious ZIKV cDNA clone but insertion of a second intron copy into the
NS5 region was necessary to increase the plasmid yield in E. coli. The RNA polymerase II dependent
CMV promoter and the HCVr sequences were engineered to flank the complete viral cDNA genome
to ensure the successful rescue of the virus after plasmid transfection in Vero cells. Excision of the
introns was carried out by the cellular machinery in the nucleus of transfected cells and, therefore,
the resulting RNA was identical to the virus sequence and could initiate the replication/transcription
steps in the cytoplasm (Table 2). The cDNA-derived rZIKV replicated efficiently in multiple cell lines,
including those of placental and neuronal origin. Likewise, Schwarz et al. in 2016 also reported the
construction of a plasmid carrying the complete genome of the prototype MR766 ZIKV African strain
under the control of a CMV promoter [58]. In this case, the full-length cDNA clone was toxic during
propagation in bacteria but incorporation of an intron in the NS1 region was sufficient to stabilize the
cDNA clone.
2.2.2. Assembly of Full-Length Infectious ZIKV cDNA Clones Using Circular Polymerase Extension
Cloning (CPEC)
As an alternative to bypass the inherent problem associated with the toxicity of ZIKV cDNA
genomes during the propagation in bacteria, Setoh et al. in 2017 used a CPEC reaction approach [83]
to construct a full-length infectious cDNA clone of the Brazilian ZIKV strain Rio Grande do Natal
(RGN) [59]. The approach is based on the assembling of multiple cDNA fragments in the right order
using a polymerase extension mechanism (Table 2). Briefly, eight overlapping cDNA fragments
covering the entire viral genome flanked by the CMV promoter (5′ end) and HDVr and pA signal
(3′ end), were mixed and subjected to a CPEC reaction using the Q5 high fidelity DNA polymerase.
During the denaturalization step associated with the PCR reaction, the overlapping ends of contiguous
cDNA anneal to each other and the PCR reaction generates a circular end product. The CPEC products
were then used to directly transfect Vero cells without any additional manipulations, allowing the
rescue of the rZIKV. The rZIKV-RGN was able to replicate in Vero, human A459 and mosquito C6/36
cells. Due to the absence of an RGN natural isolated, the author compared the replication of the
rZIKV-RGN with the Asian strain ZIKV MR766, showing that rZIKV-RGN replicated less efficiently
than ZIKV MR766. Moreover, ZIKV-RGN was detected in serum of infected IFNAR−/− A129 mice
after 4 -5 days, however the infection was asymptomatic with 100% of survival. In contrast, ZIKV-RGN
infection of pregnant IFNAR−/− A129 dams showed severe fetal disorder.
2.2.3. Construction of Full-Length Infectious ZIKV cDNA Clones Using BACs
Another strategy used to engineer infectious full-length cDNA clones of positive-strand RNA
viruses is the use of BACs [62,84–88]. Following this strategy, we have recently developed an infectious
cDNA clone of ZIKV RGN strain [56]. To that end, the full-length cDNA copy of the ZIKV RGN genome
was assembled in the BAC plasmid pBeloBac11 [89], a synthetic low-copy number plasmid based on
the E. coli F-Factor [90]. This plasmid allows the stable maintenance of large DNA fragments and
minimizes the toxicity associated with the propagation of full-length viral genomes in bacteria (Table 2).
The full-length copy of the viral genome was cloned using four overlapping synthesized individual
cDNA fragments and assembled into the pBeloBac11 using conventional cloning methods and unique
restriction sites present in the viral genome. In this case, the viral genome was flanked at the 5′ end
by the CMV promoter and at the 3′ end by the HDVr followed by the bovine growth hormone (BGH)
termination and polyadenylation sequence to produce synthetic RNAs bearing authentic 3′-ends of
the viral genome. The ZIKV-RGN clone was highly stable during passage in E. coli and infectious
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virus was recovered after direct transfection of susceptible Vero cells. Grown kinetics and plaque
morphology showed than the recover rZIKV-RGN replicated efficiently in Vero and human A549
cells, with a homogeneous plaque morphology. Importantly, IFNAR−/− A129 mice succumbed to
infection with the rZIKV-RGN in a dose-dependent manner. As the manipulation of BAC cDNA clones
is relatively easy, we also used our system to construct a full-length infectious rZIKV clone containing
an amino acid change (A175V) in the viral NS2A protein. Notably, this single and conserved amino
acid change impaired viral RNA synthesis and viral production in cultured cells and attenuated the
virus in vivo.
Likewise, Mutso et al. [48] in 2017 used a similar strategy to construct an infectious full-length
cDNA clone based on the Brazilian ZIKV strain BeH81915. To that end, four DNA fragments spanning
the entire viral genome were assembled into the BAC plasmid pCC1-BAC. In this case, the second
intron of the human beta globin gen was introduced in the capsid region to increase the stability of the
cDNA clone.
2.3. Infectious Subgenomic Amplicons (ISA) for the Generation of rZIKVs
ISA reverse genetics were development a few years ago by Aubry et al. [91]. In this approach,
simple transfection of overlapping dsDNA fragments, covering the entire genome of an RNA virus
flanked at the 5′ end by a CMV promoter and at the 3′ end by the HDVr sequence and pA signals,
were sufficient to rescue multiple flaviviruses, including DENV, JEV or WNV [91,92]. This approach
is based on spontaneous recombination between the overlapping cDNA fragments that allows the
assembly and synthesis of a full-length cDNA copy of the complete viral genome in transfected cells.
This approach could facilitate the rescue of recombinant RNA viruses from cDNA without requiring
propagation in bacteria or in vitro RNA transcription. Following this strategy, Gadea et al. described
in 2016 the rescue of rZIKV MR766 African [45] and BeH819015 Asian [61] strains. In addition, Atieh
et al. in 2016 used the ISA technology for the generation of two reverse genetic systems based on the
genome of ZIKV H/PF/2013 and Dakar 1984, representative members of Asian and African ZIKV
lineages, respectively [60]. However, a potential concern with this method could be associated to a low
efficiency of recombination of the cDNA fragments into transfected cells. Therefore, the amount of
virus produced after the transfection using the ISA approach could be low, negatively impacting the
successful rescue of recombinant viruses harboring, for instance, mutations that affect one or several
steps in the replication cycle of the virus.
3. Rescue of rZIKVs Using Reverse Genetics Approaches
The generation of rZIKVs using reverse genetic approaches is currently well established and
although is used by multiple laboratories worldwide, it is possible to find multiple variations between
these approaches among different research groups. Moreover, the origin of the ZIKV strain used and
the reverse genetic approach selected might require introducing modifications and/or optimization
procedures for the successful rescue of rZIKVs.
To generate rZIKVs (Figure 3), susceptible cells (commonly mammalian Vero cells) are transiently
transfected with the genetic material encoding the viral genome, as infectious RNA transcribed in vitro
from a full-length cDNA clone (Figure 2A), full-length infectious cDNA clones (Figure 2B) or using
infectious subgenomic amplicons (Figure 2C). Like the viral RNAs, the infectious RNA transcripts are
directly expressed into the cytoplasm producing the viral proteins required for viral replication and
transcription. However, both full-length infectious clones and subgenomic amplicons require a primary
transcription in the nucleus by the cellular RNA polymerase II and the successive translocation of the
vRNA into the cytoplasm. In general, after transfection of either cDNA clones or infectious RNAs, a
clear cytopathic effect is observed at 3-4 days post-transfection with viral titers ranging between 1×104
and 1×107 plaque forming units (PFU) per mL in the tissue culture supernatants of transfected cells.
However, both time and titers will depend on the viral strain and the reverse genetic approach used
to generate the rZIKVs. Moreover, after transfection, one or multiple steps of viral amplification in
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mammalian (e.g., Vero) or mosquito (e.g., C6/36) cells could be required to obtain a working stock with
higher viral titers (Figure 3). The successful rescue of rZIKVs using reverse genetic approaches can
be evaluated by performing classical plaque (PFU/mL) or immunofluorescence (immunofluorescent
forming units, FFU/mL) assays.
 
Figure 3. Schematic representation for the generation of rZIKV: Mammalian Vero cells are transiently
transfected with infectious RNA transcribed in vitro from a full-length cDNA clone (top), full-length
infectious cDNA clones (left) or infectious subgenomic amplicons (right) (see also Figure 2). After
3–4 days post-transfection, when cytopathic effect is observed, rZIKVs present in tissue-culture
supernatants can be recover for titration or viral amplification in mammalian (Vero, left) or insect
(C6/36, right) cells.
4. Applications of ZIKV Reverse Genetic Approaches
4.1. ZIKV Replicons
Subgenomic replicons systems are powerful tools to study viral replication in the absence of
virus entry or virion assembly, since they contain all the elements needed to produce effective viral
replication in susceptive host cells but lack one or multiple viral structural genes [36,72,93–95]. Due to
the lack of viral structural genes, these replicon systems are non-infectious, allowing the study of viral
replication without biosafety concerns associated with the work of infectious viruses [85,96]. Thus,
replicons represent a safe tool to study, among others, viral replication, transcription or the subcellular
localization of the viral replication complexes. Moreover, replicons systems have been used for the
identification of compounds with antiviral activity or host factors involved in viral replication using
high-throughput screening settings [97–100].
The first ZIKV replicon was described by Xie et al. in 2016 [101] (Figure 4A). The replicon was
constructed using the infectious cDNA clone of ZIKV FSS13025 strain by replacing the viral structural
genes with the Renilla luciferase (Rluc) reporter gene, followed by the foot-and-mouse disease virus
(FMDV) 2A protease sequence to allow the cleavage of Rluc from the viral polyprotein. Importantly,
the Rluc-2A cassette was flanked by the first 38 amino acids of the viral C protein (C38) that contain
the flavivirus-conserved cyclization sequence required for viral RNA replication [102,103] and the
last 30 amino acids of E protein (E30) fused in-frame with the downstream NS1 protein (Figure 4A).
The E30 region was maintained to ensure proper translocation of the NS1 protein into the lumen
of the ER [103]. To evaluate viral replication, in vitro RNA transcripts synthesized by the T7 RNA
polymerase were electroporated into Huh-7 cells and Rluc signal was evaluated. As a proof of concept
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and to demonstrate the susceptibility of this replicon approach to identify compounds with anti-ZIKV
activity, the authors showed that Rluc signal was suppressed using the broad antiviral NITD-008 in a
dose-dependent manner [104]. Moreover and to obtain a Huh-7 stable cell line expressing the viral
replicon, they engineered a second ZIKV replicon containing Rluc and the Neomycin (Neo) resistance
gene (Figure 4B). The Neo gene driven by an encephalomyocarditis virus internal ribosomal entry
site (IRES) was introduced downstream of the first 28 nucleotides of 3′ UTR. Importantly, authors
demonstrated that the generated Neo resistant stable cell line maintains the ZIKV replicon for several
passages and expressed high levels of Rluc.
An alternative strategy was performed by Li et al. in 2017 [105] (Figure 4C). Authors generated
a bicistronic ZIKV replicon of SZ-WIV001 strain [81], in which the selection gene puromycin
N-acetyl-transferase (PAC) and the reporter Rluc were separated by a FMDV 2A protease sequence
(Figure 4C). In this case, the PAC-2A-Rluc construct was followed by a second 2A protease
sequence and the cassette was introduced, in frame, between the C38 and the E30 sequences
(C38-PAC-2A-Rluc-2A-E30) (Figure 4C). Murine BHK-21 stable cell lines constitutively expressing
the viral replicon were produced after transfection of the ZIKV RNA replicon produced in vitro (T7)
and selection with puromycin. In addition, the replicon was stably maintained in BHK-21 cells during
multiple passages. Importantly, authors were able to adapt this technology to evaluate ZIKV inhibitors
using a high throughput screening assay.
Recently, in 2018, Münters et al. described the construction of a set of Rluc ZIKV replicons using
the full-length cDNA clones of ZIKV Asian H/PF/2013 or African MR766 strains, which contained
silent mutation to disrupt the CEPs [50]. The viral structural proteins were replaced by the Rluc-2A
cassette flanked by the first 34 amino acids of ZIKV C protein (C34) and the last 24 amino acids of
the E protein (E24). Authors found that Rluc signal correlated with the amount of viral NS proteins.
Moreover, the replicon induced morphological changes resembling ZIKV infection, highlighting the
potential of this approach to study some steps of ZIKV infection.
Lastly, a ZIKV replicon expressing the Gaussian luciferase (Gluc) reporter gene was designed
by Mutso et al. in 2017 using the full-length cDNA clone of the Brazilian ZIKV strain BeH819015
(Figure 4D) [48]. In this case, the Gluc reporter gene was inserted followed by the FMVD 2A protease
sequence between the C protein and the last 30 amino acids of the E protein (E30) fused in-frame with
the NS1 protein. The activity of the replicon was demonstrated in mammalian (BHK-21 and Vero) and
mosquito (C6/36) cells.
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Figure 4. ZIKV replicons. (A,B) Schematic diagram of Rluc-expressing ZIKV replicons: ZIKV replicons
expressing Rluc constructed by Xie et al. [101] are shown. In these replicons, ZIKV structural proteins
were replaced by the Rluc reporter gene followed by the FMDV 2A protease sequence (2A, yellow).
This cassette was flanking by the N-terminal 38 amino acids of C protein (C38, dark gray) and the last
30 amino acids of E protein (E30, orange) fused in-frame with the viral downstream NS proteins (A).
A stable reporter ZIKV Rluc-expressing replicon was constructed inserting the encephalomyocarditis
virus internal ribosomal site (IRES, blue) followed by a neomycin resistance gene (Neo, pink) into
the first 28 nucleotides of 3′ UTR (B). (C) Schematic representation of a PAC- and Rluc-expressing
ZIKV replicon: The ZIKV replicon expressing a PAC and a Rluc genes separated by the FMDV 2A
protease sequence is shown [105]. Both foreign viral genes, PAC and Rluc, followed by the FMDV 2A
protease sequence were introduced between of the first N-terminal 38 amino acids of C protein (C38,
dark gray) and the last 30 amino acids of E protein (E30, orange) in-frame with the viral NS1 protein.
(D) Schematic diagram of a Gluc-expressing ZIKV replicon: The ZIKV replicon expressing the Gluc
reporter gene constructed by Mutso et al. is indicated [48]. The Gluc reporter gene followed by the
FMDV 2A protease sequence was introduced downstream of the C protein (dark gray) and the last
N-terminal 30 amino acids of E protein (E30, orange) fused in-frame with the NS1 ZIKV protein. T7
and SP6: prokaryotic T7 or SP6 promoters. HDVr: Hepatitis delta virus ribozyme sequence.
4.2. Replicating Competent, Reporter Gene-Expressing rZIKVs
The development of reverse genetic approaches has provided investigators with the possibility of
generating replication-competent viruses expressing fluorescent or luminescent reporter genes [106].
The stable incorporation of foreign reporter genes in viruses have allowed the effective tracking of
viral infection in vitro and in vivo without the need of laborious secondary approaches to identify
the presence of the virus [43,44,106]. Moreover, recombinant reporter-expressing viruses have the
advantage that they can be used in high throughput screenings assays for multiple applications,
including the identification of compounds with antiviral activity [107,108], host factor involved in
viral infection [109,110] and the presence of neutralizing antibodies [111–114], among others. To date,
several rZIKVs expressing reporter genes have been described [45,46,48,50]. In all cases, independently
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of the reverse genetic approach used to generate the reporter gene expressing rZIKV, a similar strategy
was used, consisting in the introduction of the reporter genes followed by the FMDV 2A protease
sequence upstream of the viral open reading frame. In addition, a copy of the C protein or part of
the its N-terminal region that contains the flavivirus-conserved cyclization sequence [102,103] was
introduced upstream of the reporter gene to allow successful viral replication (Figure 5).
Shan et al. in 2016 engineered a full-length cDNA ZIKV FSS13025 infectious clone expressing
Rluc (rZIKV-Rluc) (Figure 5A) [46]. In this system, Rluc was introduced downstream of the first 25
amino acid of the C protein (C25) followed by the FMDV 2A protease sequence and in frame with
the ZIKV downstream proteins (Figure 5A). Importantly, silent mutations were introduced into the
original C protein in the flavivirus-cyclization sequence (amino acids 14–17) to reduce the potential
recombination between the parental and the duplicated C protein regions (Figure 5A). The rZIKV-Rluc
was successful rescued after transient transfection in Vero cells of the full-length in vitro transcribed
(T7) ZIKV RNA. However, the rZIKV-Rluc had a reduced plaque size phenotype compared with the
parental rZIKV, indicating that insertion of Rluc was deleterious for the virus.
Münters et al. in 2018, described the construction of two Rluc-expressing rZIKVs using the
full-length cDNA clones of ZIKV MR766 and H/PF/2013 [50]. In this case, the Rluc-2A cassette
was introduced downstream of the first 34 amino acids of the C protein (C34) and in frame with the
ZIKV downstream proteins (Figure 5B). In this case, the duplicated region of the C protein was not
altered. Expression of Rluc was confirmed for both rescued viruses. However, as in the previous case,
rZIKV-Rluc (MR766 or H/PF/2013) replicated at lower extend as compare to non Rluc-expressing
rZIKV MR766 or H/PF/2013, further suggesting that insertion of Rluc affected viral fitness. Notably,
the reporter gene was unstable and lost after 3 passages. In this case, the rapid loss of the Rluc could
be due to recombination events between the partial duplication of the capsid regions. To have a system
suitable for microscopy, Münters et al. replaced the Rluc reporter gene by the coding sequence of
turbo far-red fluorescent protein FP635, a mutant version of the red fluorescent protein from the sea
anemone Entacmaea quadricolor [115]. In this case, a SV40 nuclear localization sequence was introduced
in frame with the FP635 protein for nuclear export of the fluorescent protein and to avoid interference
with viral replication events in the cytoplasm of infected cells. Although, authors did not evaluate the
replication properties of these viruses, they demonstrated that FP635-expressing rZIKVs were suitable
for live cell imaging.
Using the ISA method, Gadea et al. described in 2016 the generation of a rZIKV MR766 expressing
the green fluorescent protein (GFP) reporter gene (rZIKV-GFP) [45] (Figure 5C). GFP was introduced
downstream of the first 33 amino acids of C protein (C33) followed by the FMDV 2A protease
sequence in-frame with the viral ORF (Figure 5C) [45]. The rZIKV-GFP was successfully rescued
after electroporation of several fragments covering the complete genome under the control of the CMV
promoter. However, rZIKV-GFP titers were ~1.5 log lower compared with the rZIKV without GFP.
Likewise, the plaque phenotype of the rZIKV-GFP was smaller than rZIKV without GFP, indicating
that insertion of GFP resulted in viral attenuation. Moreover, rZIKV-GFP was unstable and the virus
lost GFP expression after a limited number of passages on Vero cells.
More recently, Mutso et al. described the construction of several reporter-expressing rZIKVs using
a BAC system and a SP6 promoter (Figure 5D) [48]. They inserted the sequences of the foreign reporter
genes fused to the FMDV 2A protease sequence between two copies of C protein, altering the codon
usage of the downstream copy to reduce potential recombination events (Figure 5D). Using this strategy,
they generated rZIKVs expressing Firefly luciferase (FlLuc), red shift luciferase from Luciola italica
(RSLuc) [116], NanoLuc, mCherry or GFP (Figure 5D). Moreover, they inserted a ubiquitin sequence
between the FMDV 2A protease sequence and the viral polyprotein in order to help the proteolytic
cleavage. However, inclusion of the ubiquitin sequence after the 2A protease sequence was irrelevant
for viral rescue and stability. Although the replication of these reporter-expressing rZIKVs were not
directly compared with either a rZIKV or a natural isolated, as previously described for the other
reporter-expressing rZIKVs, limited stability of the rZIKVs expressing reporter genes was observed,
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except for NanoLuc which remained stable during four serial passages in cultured cells. These and
previous results highlight the important concerns related to the instability of reporter-expressing
rZIKVs. Further investigation, including new approaches for the expression of reporter genes in the
viral genome are necessary to generate stable rZIKV expressing reporter genes for their use as valid
viral surrogates to study ZIKV infection in cultured cells or in validated animal models of infection.
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Figure 5. Reporter gene-expressing rZIKVs. (A) Schematic diagram of a Rluc-expressing ZIKV cDNA
clone: A full-length cDNA clone expressing the Rluc reporter gene (white box) was constructed by
Shan et al. [46]. Rluc was introduced downstream of the first 25 amino acids of the C protein (C25,
dark gray) followed by the FMDV 2A protease sequence (yellow box) fused in-frame with the viral
ORF. Silent mutations changing the flavivirus-cyclization sequence were introduced in the full-length
C protein (mut CS). (B) Schematic representation of a full-length ZIKV cDNA expressing Rluc or
FP635: Full-length cDNA clones expressing Rluc (white box) or FP635 (red box) were generated by
Münters et al. [50]. Reporter genes were introduced downstream the first 34 amino acid of the C protein
(C34, dark gray) followed by the FMDV 2A protease sequence in-frame with the viral downstream
proteins. (C) Schematic diagram of a GFP-expressing ZIKV generated by ISA: A ZIKV cDNA clone
expressing GFP was constructed by Gadea et al. [45] using the ISA approach. The GFP was introduced
downstream of the first 33 amino acid of the C protein (C33, dark gray) followed by the FMDV
2A protease sequence in-frame with the viral ORF. (D) Representation of full-length ZIKV cDNAs
expressing luciferase and fluorescent proteins: Full-length ZIKV cDNA clones expressing NanoLuc,
FfLuc, RSLuc (white boxes), GFP (green box) or mCherry (red box) were constructed by Mutso et al. [48].
Reporter genes were individually introduced downstream of the complete C protein followed by the
FMDV 2A protease sequence fused in-frame with the downstream viral ORF. The codon sequence of
the downstream copy of the viral C protein was altered to reduce potential recombination (dotted gray).
T7 and SP6: prokaryotic T7 or SP6 promoters. CMV: cytomegalovirus promoter. HDVr: Hepatitis delta
virus ribozyme sequence. pA: simian virus 40 late polyadenylation signal.
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5. Conclusions
The development of ZIKV reverse genetic systems has provided researchers with powerful
methods to study multiple aspects of the biology and pathogenesis of ZIKV in vitro and in vivo.
For instance, the ability to manipulate the genome of ZIKV to generate recombinant viruses with
specific mutations have allowed investigators to gain a detailed understanding of the ZIKV-host
interactions and associated disease [49,56,57]. Moreover, reverse genetic approaches have been essential
to develop novel and more effective strategies to prevent and control ZIKV infections [117–119].
Likewise, generation of ZIKV replicons or replicating-competent rZIKV expressing reporter genes
represent and excellent approach for the identification of compounds with anti-viral activity for the
treatment of ZIKV infection [45,46,101,105]. In this review, we have discussed the three major strategies
that have been reporter for the generation of rZIKVs: i) generation of infectious RNA transcripts from a
full-length cDNA copy; ii) full-length infectious genomic cDNA clones; and, iii) Infectious Subgenomic
Amplicons (ISA) (Figure 2 and Table 1). Like other flavivirus, ZIKV cDNA sequences in bacterial
has been hindered by the presence of cryptic bacterial promoter in the viral genome. To overcome
the problems associated with the instability of ZIKV cDNA clones, several approaches based on the
use of low-copy number plasmids, BACs, intron-insertion, in vitro ligation of cDNA fragments and
in vitro assembly by Gibson method or by CPEC have been used. Although all those approaches have
their advantages and disadvantages (Table 2), they have been not compared side by side. Therefore,
it cannot be possible to determine which systems are better for the genetic stability and successful
generation of rZIKV. Moreover, successful rescue of rZIKVs could strongly dependent of several
biological factors such as the viral strain selected and technical factors such as transfection methods.
Finally, the generation of rZIKVs expressing reporter genes, together with the development of ZIKV
replicons, constitute important tools for the identification of antiviral drugs against this important
human pathogen that are compatible with the use of high throughput screenings settings. However, to
date, there are some concerns regarding the stability of currently available reporter-expressing rZIKVs,
which will require and guarantee further investigation.
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Abstract: The Zika virus (ZIKV) has recently attracted major research interest as infection
was unexpectedly associated with neurological manifestations in developing foetuses and with
Guillain-Barré syndrome in infected adults. Understanding the underlying molecular mechanisms
requires reverse genetic systems, which allow manipulation of infectious cDNA clones at will. In the
case of flaviviruses, to which ZIKV belongs, several reports have indicated that the construction of
full-length cDNA clones is difficult due to toxicity during plasmid amplification in Escherichia coli.
Toxicity of flaviviral cDNAs has been linked to the activity of cryptic prokaryotic promoters within
the region encoding the structural proteins leading to spurious transcription and expression of toxic
viral proteins. Here, we employ an approach based on in silico prediction and mutational silencing
of putative promoters to generate full-length cDNA clones of the historical MR766 strain and the
contemporary French Polynesian strain H/PF/2013 of ZIKV. While for both strains construction of
full-length cDNA clones has failed in the past, we show that our approach generates cDNA clones
that are stable on single bacterial plasmids and give rise to infectious viruses with properties similar
to those generated by other more complex assembly strategies. Further, we generate luciferase and
fluorescent reporter viruses as well as sub-genomic replicons that are fully functional and suitable
for various research and drug screening applications. Taken together, this study confirms that in
silico prediction and silencing of cryptic prokaryotic promoters is an efficient strategy to generate
full-length cDNA clones of flaviviruses and reports novel tools that will facilitate research on ZIKV
biology and development of antiviral strategies.
Keywords: ZIKV; reporter virus; cryptic promoter silencing; full-length molecular clone; subgenomic
replicon; plasmid toxicity
1. Introduction
The Zika virus (ZIKV), a member of the Flavivirus genus within the Flaviviridae family,
was identified almost 70 years ago in Uganda [1] but until recently was not associated with severe
symptoms. However, outbreaks outside of Africa and Asia, in the Yap Islands (2007) [2], French
Polynesia (2013) [3] and the Americas (2015) [4], raised major interest as infection was associated with
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an increased incidence of microcephaly and other neurological manifestations in developing foetuses
as well as Guillain-Barré syndrome in infected adults [5,6]. Two lineages of ZIKV have been identified,
African and Asian, with the currently circulating strains belonging to the Asian lineage [7]. Although
48 countries have confirmed ZIKV infections associated with Aedes mosquito-borne transmission of the
virus, neither a prophylactic vaccine nor antiviral therapies are available to date [8]. As a consequence,
there is an urgent need for tools, which facilitate studying the molecular determinants that underlie
ZIKV pathogenesis and allow testing of potential antiviral therapies. In this respect, stable and
traceable reverse genetic systems to generate isogenic mutants, are of great advantage [9,10]. However,
construction of ZIKV molecular clones has been hampered by the instability of the viral cDNA genome
during propagation via bacterial plasmids. The instability of flaviviral cDNA clones in Escherichia coli
(E. coli) has been linked to the expression of toxic viral proteins from cryptic E. coli promoters (CEPs)
encoded in the flavivirus genome [11,12]. Strategies to disrupt toxic protein expression and to
overcome these toxicity problems include insertion of introns into the viral open-reading frame [13,14]
or propagation of ZIKV genome fragments on multiple plasmids and subsequent assembly of the
fragments [15–19]. Those strategies, however, have some disadvantages compared to a single plasmid
system that allows in vitro transcription of full-length infectious viral RNAs. For instance, the intron
insertion method requires nuclear transcription to generate the viral genome with the risk of undesired
splicing rendering the RNA non-functional. In the case of multi-plasmid systems, laborious and
potentially error prone in vitro assembly steps complicate the protocol. Although Shan and co-workers
were able to amplify a full-length ZIKV cDNA clone from Cambodia (FSS13025 strain, isolated in
2010) on a single plasmid in E. coli, ours and others’ data indicate that this is neither possible for the
prototypic African strain MR766 nor for the French Polynesian strain H/PF/2013 (Asian lineage) or
isolates from the Americas [13,15–17].
Here we present a different approach that overcomes these problems and is based on the
observation that full-length Japanese encephalitis virus (JEV) and Dengue virus 2 (DENV2) infectious
cDNAs could be stabilized by CEP silencing [11]. We show that mutational inactivation of multiple
CEPs predicted in silico to reside in the structural regions of the MR766 and H/PF/2013 genomes is
sufficient to stabilize the full-length cDNA genomes of both ZIKV strains enabling the construction
of a single-plasmid based reverse genetic system. Authentic virus genomes and engineered reporter
viruses generated with this approach are fully functional in cell culture and suitable for multiple
research and development purposes.
2. Materials and Methods
2.1. Cell Lines and Antibodies
VeroE6 and Huh7 cells were cultured at 37 ◦C and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies, Darmstadt, Germany), supplemented with 10% foetal calf serum
(FBS; Sigma-Aldrich, Taufkirchen, Germany), 2 mM L-glutamine, nonessential amino acids (all from
Gibco, Life Technologies, Darmstadt, Germany), 100 U/mL penicillin and 100 μg/mL streptomycin
(DMEMcplt). Primary antibodies used in this study were: rabbit anti-ZIKV NS3 and anti-NS4B (both
from GeneTex, Irvine, CA, USA), mouse pan-flavivirus-anti-E (4G2, ATCC®, Manassas, VA, USA),
mouse J2 anti-dsRNA antibody (Scicons, Szirák, Hungary), mouse anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Santa Cruz Biotechnology, Heidelberg, Germany). Secondary horseradish
peroxidase-conjugated antibodies were purchased from Sigma-Aldrich. AlexaFluor-conjugated
secondary antibodies were obtained from Life Technologies.
2.2. Source of Virus Sequences
For the construction of the ZIKV genome we used the reference genomes KJ776791 (H/PF/2013,
accession date August 2016) and DQ859059 (MR766, accession date August 2016). In addition,
we amplified the MR766 and the H/PF/2013 strains (obtained from the European Virus Archive;
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Marseille, France) by passaging once in C6/36 mosquito cells and once in VeroE6 cells. Viral RNA was
isolated from cell lysates using the NucleoSpin RNA II kit (Machery-Nagel, Düren, Germany) and
reverse transcribed using SuperScript III RT (Thermo Fisher Scientific Waltham, MA, USA). cDNA was
amplified by PCR and amplicons were sequenced by Sanger sequencing (GATC Biotech, Constance,
Germany) using primers spanning the complete ZIKV genome. Sequences of the 5′ and 3′UTRs were
obtained by the rapid amplification of cDNA ends (RACE) using the 5′/3′ RACE second generation
kit (Roche, Basel, Switzerland) with a polyA-tail added to the cDNA prior to the 3′ RACE reaction by
using the poly(A) polymerase (New England Biolabs, Ipswich, MA, USA).
2.3. In Silico Prediction of CEPs and Sequence Modifications
Cryptic E. coli promoters were predicted with the publicly available Neural Network promoter
program from the Berkeley Drosophila Genome Project [20,21] similar to an earlier report [11].
The ZIKV sequences were analysed for CEPs from nucleotide position 1–2683 for H/PF/2013 and
1–2664 for MR766. Putative promoters with a score >0.85 were eliminated by silent nucleotide
exchanges introduced into the −10 regions (Pribnow/Schaller box) and/or the −35 regions (Figure S1).
CEPs in the 5′UTR were not modified to avoid changes in RNA secondary structures (Acosta et al.,
2014 [22]). In addition, in order to facilitate assembly and reverse genetic studies, several restriction
sites were inserted or removed by silent nucleotide exchanges (Tables S1 and S2). The T7 promoter
sequence (5′-TAATACGACTCACTATAG-3′) was inserted upstream of the 5′UTR to allow for in vitro
transcription of viral RNA. The final sequences were re-analysed with the Neural Network promoter
program to confirm that the scores were below 0.85. The sequences were ordered as synthetic
DNA fragments (four fragments/strain) from the GeneArt Gene Synthesis service (Invitrogen,
Darmstadt, Germany).
2.4. Generation of synZIKV Constructs
The pFK vector used for the assembly of the synthetic ZIKV (synZIKV) sequences has been
described previously (Lohmann et al., 1999 [23]). A synthetic DNA linker encoding the restriction sites
required for assembly of the synZIKV cDNA clones (Figure 1A) was inserted into the vector via HindIII
and SpeI. For assembly of the full-length wild-type synZIKV plasmids (pFK-synZIKV) the synthetic
DNA fragments were inserted into the modified pFK vector using the indicated restriction enzymes
(Figure 1A) and in four steps in the order of fragment 4 to fragment 1. Plasmids were amplified
in dcm+/dam+ DH5α cells. To generate full-length Renilla luciferase (RLuc) reporter constructs
(pFK-synZIKV-R2A), we used a construct design similar to the one reported by us for the synthetic
DENV-2 16681 reporter genome [10]. In brief, we constructed a synthetic DNA fragment encoding
the T7 promoter followed by the 5′UTR of ZIKV, the first 102 nts of Capsid required for genome
circularization, the RLuc gene flanked by NotI and NruI restriction sites and the auto-proteolytic
FMDV 2A peptide directly fused to the first nucleotide of the ZIKV coding region. This fragment was
inserted into the pFK-synZIKV plasmid via MLuI/KpnI restriction sites. Sub-genomic synZIKV RLuc
reporter replicons (pFK-synZIKV-sgR2A) were constructed in an analogous way but with the difference
that the reporter cassette was inserted between the last 24 codons of E that we retained to ensure
proper membrane insertion of NS1 (cloning via MLuI and AgeI restriction sites). To generate turbo
far-red fluorescent protein FP635 expressing viruses (pFK-synZIKV-FP635 constructs), the reporter
gene was amplified by PCR using the FP635-encoding DENV2 16681 construct reported earlier [24]
and inserted into the pFK-synZIKV-R2A plasmids via the NotI and NruI restriction sites flanking the
RLuc gene. Note that a coding sequence for the SV40 NLS (PKKKRKV) was fused in frame to the 3′end
of the turbo far-red fluorescent protein FP635-encoding sequence by using PCR (primer sequences
available on request). All nucleotide sequences of the final constructs were validated by using Sanger
sequencing (GATC Biotech).
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Figure 1. Construction and stability of synthetic full length Zika virus (synZIKV) cDNA clones.
(A) Schematic representation of the synZIKV MR766 construct and the four fragments used to assemble
the genome. The 5′ and 3′UTRs are indicated with bold black lines, the promoter for the T7 RNA
polymerase with a black arrow. Restriction sites used for the assembly of the fragments are indicated.
An enlargement of fragment #1 is shown below with putative CEPs (score > 0.85) indicated by red
arrow heads. CEP 1 was not mutated (indicated with the pink arrow head). (B) Same as in panel (A)
but for synZIKV-H/PF/2013. (C) Restriction patterns of pFK-synZIKV constructs obtained after digest
with EcoRI (MR766) or XmnI (H/PF/2013) and agarose gel electrophoresis. Plasmids were analysed
directly after assembly (original prep) and after five passages (P5) in E. coli (five DNA clones of P5
are shown).
2.5. In Vitro Transcription and RNA Transfection
The protocol for in vitro transcription has been described earlier [23]. Briefly, synZIKV sequences
were linearized with XhoI (located at the end of the 3′UTR of the viral genome) and the DNA purified
with the Nucleo-Spin Extract II kit (Macherey-Nagel, Düren, Germany). The in vitro transcription
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reaction was carried out with 10 μg of linearized plasmid DNA in a total volume of 100 μL containing
20 μL 5× RRL buffer (400 mM HEPES (pH 7.5), 60 mM MgCl2, 10 mM spermidine and 200 mM DTT),
NTP-Mix (3.125 mM ATP, CTP and UTP and 1.56 mM GTP), 1 U/μL RNasin (Promega, Madison, WI,
USA), 2 U/μL T7 RNA polymerase (New England Biolabs) and 1 mM anti-reverse cap analogue (ARCA;
3′-O-Me- m7G(5′)ppp(5′)G; New England Biolabs). After incubation at 37 ◦C for 2.5 h, 1 U/μL T7
RNA polymerase was added followed by additional 2.5 h incubation at 37 ◦C. DNA was digested with
DNaseI for one hour and RNA was purified by acidic phenol-chloroform extraction and isopropanol
precipitation. The integrity and size of the RNAs was validated by agarose gel electrophoresis. For
electroporation, subconfluent and trypsinized cells were collected in DMEMcplt, washed once with
PBS and resuspended in cytomix buffer (120 mM KCl, 0.15 mM CaCl2, 10 mM potassium phosphate
buffer, 25 mM HEPES (pH 7.6), 2 mM EGTA, 5 mM MgCl2, freshly supplemented with 2 mM ATP and
5 mM glutathione) at a concentration of 1 × 107 cells/mL for Huh7 and 1.5 × 107 cells/mL for VeroE6
cells. Four hundred μL of the cell suspension was mixed with 10 μg of in vitro transcribed RNA,
transferred into an electroporation cuvette (Bio-Rad, Hercules, CA, USA; 0.4-cm gap width) and pulsed
once with a Gene Pulser II system (Bio-Rad) at 975 μF and 270 V. Finally, the cells were transferred into
pre-warmed DMEMcplt in case of synZIKV-sgR2A replicons or DMEMcplt supplemented with 15 mM
HEPES (pH 7.5) in case of the full-length synZIKV. For replication assays, Huh7 cells transfected
with synZIKV-sgR2A RNAs were seeded into 12-well plates at a density of 2 × 105 cells/well. VeroE6
cells transfected with full-length synZIKV RNAs were seeded into 24-well plates at a density of
2 × 105 cells/well.
2.6. Virus Stocks and Passaging
Stocks of parental ZIKV strains were produced exactly as described [25]. For production of
wild-type synZIKV stocks, two electroporation reactions of the same construct were pooled in 20 mL
DMEMcplt and seeded into a single 15 cm-diameter dish. After 48 h, the medium was changed to
DMEMcplt containing 15 mM HEPES (pH 7.5). Supernatants were harvested at least twice (between
72–96 h for synZIKV-MR766 and 96–120 h for synZIKV-H/PF/2013). Virus-containing cell culture
supernatants were filtered through a 0.45 μm syringe filter and plaque-forming units (PFU) were
determined. For final stock production, 7 × 106 VeroE6 cells were seeded into 15 cm-diameter dishes
and infected at a multiplicity of infection (MOI) of 0.1 on the next day. Infected cells were cultured
in DMEMcplt containing 15 mM HEPES (pH 7.5) and supernatants were collected from day 3–7
post-infection as described above. Aliquots of the virus stocks were stored at −80 ◦C. For cell culture
adaptation of the synZIKVs, multiple rounds of infection were performed in Huh7 cells. Virus stocks
(passage 0; P0) were prepared as described above and used to infect Huh7 cells at MOI = 0.1. Virus
containing supernatants were harvested at 72 h post infection (P1) and passaged two more times in 72
h hour intervals (P2–P3).
2.7. Virus Titration by Plaque Assay
For titration of wild-type viruses, VeroE6 cells were seeded into 24-well plates at a density of
2.5 × 105 cells/well one day prior to infection. The cells were infected with serial 10-fold dilutions
of virus containing supernatants for one hour at 37 ◦C. All plaque assays were performed in
duplicates. After infection, the inoculum was removed and replaced with serum-free MEM (Gibco,
Life Technologies) containing 1.5% carboxy-methylcellulose (Sigma-Aldrich). After four days, cells
were fixed by the addition of 5% formaldehyde for at least 2 h at room temperature. Fixed cells were
washed with water and stained with 1% crystal violet in 10% ethanol for at least 15 min. After rinsing
the cells with water, the number of plaques was counted and virus titres were calculated as plaque
forming units/mL (PFU/mL).
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2.8. RLuc Assays
RLuc activity was determined as previously described [26]. At the indicated time points cells
were lysed by addition of 100 μL (full-length synZIKV-R2A) or 125 μL (synZIKV-sgR2A replicons)
luciferase lysis buffer (25 mM Glycine-Glycine (pH 7.8), 15 mM MgSO4; 4 mM EGTA, 10% (v/v)
glycerol, 0.1% (v/v) Triton X-100, freshly added 1 mM DTT) to each well. The lysates were stored
at −80 ◦C until use for luciferase assays. Luciferase activity was determined with a Lumat LB9507
luminometer (Berthold Technologies, Bad Wildbad, Germany). For each sample, 20 μL of cell lysate
were mixed with 100 μL freshly prepared luciferase assay buffer (25 mM Glycine-Glycine (pH 7.8),
15 mM K4PO4 buffer (pH 7.8), 15 mM MgSO4, 4 mM EGTA, 1.42 μM coelenterazine).
2.9. Antiviral Assays and Stability of synZIKV-R2A Viruses
For characterization of RLuc-encoding synZIKV-R2A clones, VeroE6 cells transfected with the
respective in vitro transcripts were seeded into 24-well plates at densities of 2 × 105 cells/well.
Supernatants were collected 72 h post-electroporation (Passage 0; P0) and stored at −80 ◦C until use for
antiviral assays or further passaging. For antiviral assays VeroE6 cells were seeded into 24-well plates
at a density of 1 × 105 cells/well and on the next day infected with a 1:10 dilution of P0 of the respective
virus at 37 ◦C. One hour later the inoculum was removed and replaced with DMEMcplt containing
the indicated concentrations of 2′-C-methylcytidine (2′CMC; Sigma-Aldrich). RLuc activities were
determined 72 h post-infection. For assessment of the stability, synZIKV-R2A P0 reporter viruses
were subjected to multiple rounds of infection of VeroE6 cells (72 h infection/passage). To determine
reporter virus stability, Huh7 cells were seeded into 24-well plates at a density of 7.5 × 104 cells/well
and infected on the next day with supernatants from each passage as described above. After 72 h
supernatants were collected and subjected to plaque assay analysis. Cells were lysed in luciferase
lysis buffer and RLuc activities were determined as described above. To check for the integrity of the
reporter genomes, RNA was isolated from P0–P3 virus-containing supernatants using NucleoSpin
RNA II kit (Machery Nagel, Düren, Germany), reverse transcribed with SuperScript III RT using
random hexamer primer (Thermo Fisher Scientific) and amplified by PCR using the forward primer
5′CGACAGTTCGAGTTTGAAGC3′ hybridizing to the 5′UTR of both strains and the reverse primers
5′AGGCTAGAATCGCCAAGACC3′ and 5′GTTGATGAGGCCCAGTGATG3′ complementary to the
capsid coding region of H/PF/2013 and MR766, respectively. Amplicons were analysed by agarose
gel electrophoresis using Midori Green (Biozym, Hessisch Oldendorf, Germany) staining of DNA.
2.10. Immunofluorescence Microscopy and Western Blotting
For immunofluorescence microscopy 2.5–3.5 × 104 cells/well were seeded in DMEMcplt into
24-well plates containing glass coverslips. At the indicated time points the cells were washed twice
with PBS and fixed for 20 min by addition of 500 μL PBS containing 4% paraformaldehyde. After three
washes with PBS, the cells were permeabilized with 0.2% Triton-X100 in PBS for 5 min. Permeabilized
cells were blocked for one hour in PBS containing 0.01% Tween20 (PBS-T-0.01%) and 5% bovine
serum albumin (BSA). The cells were incubated with the respective primary antibodies at appropriate
concentrations for 2 h at room temperature. After three washes, the cells were incubated with the
respective AlexaFluor (488, 568)-conjugated anti-mouse or anti-rabbit secondary antibodies (Life
Technologies), respectively, diluted in PBS-T-0.01% containing 5% BSA. After three washes the nuclear
DNA was stained with DAPI (Sigma-Aldrich) for 10 min. Finally, the coverslips were mounted on
slides with FluoromountG (SouthernBiotech, Birmingham, AL, USA). The images were acquired with
a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan) or a Leica SP8 (Leica, Wetzlar, Germany) confocal
microscope. Western blotting was performed exactly as described earlier [27].
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3. Results
3.1. In Silico Prediction of CEPs and Assembly of Synthetic Full Length ZIKV cDNAs
We focused on the development of infectious clones for two different ZIKV strains: MR766, which
is a historical strain isolated from a rhesus monkey in 1947 [28] and H/PF/2013, a clinical isolate
obtained in 2013 from a patient returning from French Polynesia [29]. Nucleotide sequences of the
clones were based on the reference sequence DQ859059 for MR766 and KJ776791 for H/PF/2013.
In addition, we determined the nucleotide sequences of these two virus strains that we propagated
once in C6/36 mosquito cells and once in VeroE6 cells. We found that the H/PF/2013 isolate cultured in
our cells was almost identical to the reference sequence with the exception of one nucleotide exchange
resulting in an E1399Q amino acid substitution residing in NS2B, while the MR766 isolate differed
by four nucleotide changes, two of them leading to E2197G and T3078A amino acid substitutions,
residing in the NS4A and the NS5 coding region, respectively.
To assemble the complete genomes of these two strains, we introduced the mutations found in the
viruses propagated in our laboratory and inserted in addition several silent nucleotide substitutions
removing or creating restriction sites for convenient DNA cloning (Tables S1 and S2). These two
sequences were dissected into 4 fragments that were generated by DNA synthesis (Figure 1A,B).
The synthetic DNA fragments were assembled and inserted into a pFK-based vector via unique
restriction sites [23]. A T7 promoter was inserted upstream of the ZIKV-5′UTR to allow for in vitro
transcription of viral RNA. However, while fragments #2–#4 could be combined and amplified
in E. coli with ease, insertion of fragment #1 repeatedly failed as we were not able to propagate
a full-length ligation product. We reasoned that toxicity associated with fragment #1 might be the
reason for our failure. In fact, for ZIKV it has been hypothesized that translation products generated
from transcripts initiated at CEPs present in the structural region and NS1 might cause toxicity in
bacteria [13]. Therefore, we decided to inactivate these bacterial promoters, a strategy successfully
applied to the molecular cloning of DENV2 and JEV [11] and analysed our ZIKV sequences by using
the promoter prediction tool from the Berkeley Drosophila Genome Project [20,21]. For MR766,
12 putative CEPs with a score >0.85 were detected within the first 2664 nucleotides (Figure 1A,B;
Figure S1). By contrast, only eight putative CEPs were predicted within the first 2683 nucleotides of the
H/PF/2013 genome (Figure 1B; Figures S1 and S2). To inactive these CEPs, nucleotide substitutions
were inserted affecting the -10 region (Pribnow/ Schaller box) and/or the −35 region of all but one
putative promoter. We did not alter the CEPs in the 5′ untranslated region (5′UTR) of our ZIKV strains
because they contain complex RNA structures essential for RNA replication [22]. In total, 18 point
mutations were introduced for MR766 and 12 for H/PF/2013 (Figures S1 and S2). For both strains, the
modified sequence of fragment #1 was generated synthetically and inserted into the corresponding
preassembled ZIKV constructs containing fragments #2–#4 without notable problems (Figure 1A,B).
To confirm the stability of these synthetic full length ZIKV (synZIKV) cDNAs, the plasmids were
passaged five times in E. coli and 5 clones of passage 5 were analysed by analytical restriction digest
in comparison to the parental clone (Figure 1C). No obvious changes of the restriction patterns were
found. Importantly, nucleotide sequences of the ZIKV genomes isolated after five bacterial passages
were identical to the original genome and matched exactly the one generated in silico. Together,
this result demonstrates that the synZIKV cDNA clones contained in the single bacterial plasmid
vector are stable and that CEP silencing is a very simple and versatile approach to overcome stability
problems of difficult-to-clone sequences.
3.2. Functionality of Full-Length synZIKV Wild-Type Genomes
With the aim to determine functionality of the cloned full length synZIKV genomes VeroE6 cells
were transfected with in vitro transcripts of synZIKV-MR766 and synZIKV-H/PF/2013. Peak virus titres
of about 106 plaque-forming units (PFU/mL) were detected in cell culture supernatants; maximum titres
were reached faster by the MR766 strain than the HP/F/2013 strain arguing for different replication
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kinetics (Figure 2A). A comparison of the replication kinetics of the two synZIKV strains with the
parental strains in Huh7 cells revealed virtually identical viral fitness in the case of the MR766 strain
(Figure 2B). By contrast, wild-type synZIKV-H/PF/2013 replication was attenuated in this cell line
relative to the parental H/PF/2013 strain but titres still reached ~106 PFU/mL (Figure 2C). Similar
results were obtained after infection with lower MOI [30]. Irrespective of that, plaque morphology
was well comparable between the two synZIKVs and their parental strains (Figure 2D). The synMR766
strain formed smaller and more defined plaques, whereas synZIKV-H/PF/2013 formed large more
diffuse and heterogeneous plaques but in both cases just like the corresponding WT strains (Figure 2D).
Figure 2. Replication kinetics of viruses obtained with the full-length synZIKV clones. (A) Replication
kinetics of the two synZIKV clones as determined by plaque assay. VeroE6 cells were transfected
with in vitro transcribed synZIKV RNAs and virus contained in culture supernatant at different time
points after transfection was measured. Mean ± SEM of two independent experiments is shown.
(B,C) Comparison of replication kinetics of synZIKV and parental viruses. Huh7 cells were infected
with either ZIKV using a multiplicity of infection (MOI) of 1. Supernatants from infected cells were
harvested at indicated times post-infection and titres were determined by plaque assay. Mean ± SEM
of three independent experiments is shown. (D) Comparison of plaque morphology of synZIKV and
the parental viruses. (E,F) Replication kinetics of passaged synZIKVs. Virus stocks were prepared as
described in Materials and methods (P0). Huh7 cells were infected with MOI = 0.1 of P0 virus, cell
culture supernatants were collected 72 h post-infection (P1) and passaged two more times by infection
of Huh7 cells (P2–P3) in 72 h intervals. Huh7 cells were then infected using a MOI of 0.01 of P0 and P3
virus, respectively and virus titres were measured at indicated time points by plaque assay.
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To determine whether passaging in cell culture could increase the fitness of our synZIKVs,
we performed three serial passages in Huh7 cells and compared the replication kinetics of P0 and P3
viruses (Figure 2E,F). For both strains titres obtained with passaged viruses were higher than the ones
of the corresponding P0 stock arguing for rapid adaptation of synZIKVs to cell culture conditions.
Whether distinct adaptive mutations or the viral quasispecies in P3 virus cultures were responsible for
increased fitness remains to be determined.
3.3. Replication and Stability of synZIKV Luciferase Reporter Virus Genomes
Reverse genetic systems are powerful tools to study virus biology and pathogenesis but for
some applications such as high-content screens reporter systems are superior because of the ease to
measure virus replication in high-throughput formats [10]. We therefore manipulated both synZIKV
genomes by insertion of a Renilla luciferase (RLuc) reporter gene (Figure 3A). In these genomes, the 5′
UTR is followed by the first 102 nts of the C-coding region containing an element that is required for
genome circularization (CAE; capsid-circularization sequence). Downstream of the CAE we inserted
the RLuc gene via engineered NotI and NruI restriction sites followed by the ribosome-skipping 2A
sequence of the foot-mouth-disease virus (FMDV) to allow the release of the RLuc protein from the viral
polyprotein. The functionality of these two synZIKV-R2A genomes was evaluated by electroporation of
in vitro transcripts into VeroE6 cells. Virus replication was confirmed in transfected cells by E-specific
immunofluorescence (Figure 3B) and quantified by measuring RLuc reporter activity in lysates of cells
harvested at different time points after transfection (Figure 3C). As a reference, we constructed for both
synZIKV-R2A clones a mutant, in which the catalytic site of the RNA-dependent-RNA-polymerase
was inactivated by site-directed mutagenesis (mutants “GAA”). In addition, values were normalized
to the 4 h-value reflecting transfection efficiency. For both synZIKV-R2A clones, robust replication
was detected with faster kinetics in the case of the MR766 strain (Figure 3C) but comparable values
detected at later time points after transfection (>96 h). However, as reported earlier [31], synZIKV-R2A
viruses did not form plaques when harvested at early times post-transfection arguing that the insertion
of the reporter gene caused attenuation [32].
Therefore, we determined the stability of the reporter virus genomes by multiple passaging of
synZIKV-R2A particles collected 72 h post-transfection in VeroE6 cells. Virus contained in supernatants
of each passage was used to infect Huh7 cells to determine RLuc reporter activity and plaque formation
(Figure 3D,E). While RLuc activities were steadily decreasing with each passage and lost after passage
3 (Figure 3D), virus titres (PFU/mL) were increasing (Figure 3E) indicating a loss of the reporter gene
and selection for synZIKV viruses with high replication fitness and plaque forming capability.
To support this assumption, synZIKV-R2A viruses released into culture supernatants were
harvested after each passage, RNA was isolated and the region encompassing the RLuc coding
sequence was amplified by RT-PCR (Figure 3F). In virus released from transfected cells (P0 supernatant),
the amplicon had the expected size for the luciferase reporter gene (~1350 bp) although trace amounts
of a smaller amplicon were also detected. However, already in P1 supernatant we could only amplify
a fragment with a size expected for a WT clone (~250 bp). Sequence analysis of this PCR product
confirmed a perfect match to the WT clone sequence, consistent with a rapid loss of the reporter
gene. Nevertheless, by using virus contained in the supernatant of synZIKV-R2A transfected cells
(i.e., P0 virus), virus replication was robustly detected and could be used for various assays, including
antiviral drug testing. For instance, in line with a previous report [33], we found that the nucleoside
2′CMC strongly reduced the replication of both reporter viruses, thus demonstrating the versatility of
our synZIKV system (Figure 3F).
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Figure 3. Construction and characterization of synZIKV-R2A reporter virus genomes. (A) Schematic
representation of the synZIKV-R2A reporter virus genomes. For both strains the R2A reporter
cassette (light red) was inserted into the wild-type pFK-synZIKV plasmids via MLuI/KpnI restriction
sites. The NotI/NruI sites flanking the RLuc gene allow for the exchange of the reporter gene.
(B) Immunofluorescence analysis of VeroE6 cells transfected with synZIKV-R2A in vitro transcripts.
Cells were grown on coverslips, fixed 72 h and 96 h after transfection and stained with E-specific antibody
(green). Nuclear DNA was counterstained with DAPI (grey). Scale bar = 15 μm. (C) Replication kinetics
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of the synZIKV-R2A reporter viruses in VeroE6 cells. After electroporation (EPO) cells were harvested at
given time points and RLuc activity was determined. Values were normalized to the 4 h-value reflecting
transfection efficiency. Mean ± SEM of three independent experiments is shown. Replication deficient
mutants containing two mutations affecting the active site of the RNA-dependent-RNA polymerase
in NS5 (GAA) served as negative controls. (D) VeroE6 cells were transfected with synZIKV-R2A
RNAs, cell culture supernatants were collected 72 h post- transfection (P0) and passaged three times by
infection of VeroE6 cells (P1-P3) in 72 h intervals. Culture supernatants obtained from each passage
were used to inoculate Huh7 cells. In the case of supernatant obtained directly from transfected
VeroE6 cells (P0), Huh7 cells were inoculated with undiluted (undil) or 1:10 diluted supernatant.
After 72 h cells were harvested and RLuc activity in cell lysates was determined. Mean ± SEM from
two independent experiments is shown. (E) Virus titres as determined by plaque assay for each
synZIKV-R2A passage; values are mean ± SEM of two independent experiments. (F) Stability of the
reporter gene. SynZIKV-R2A viruses released into culture supernatants were harvested after each
passage as described in panel D, RNA was isolated and the region encompassing the RLuc coding
sequence was amplified by using random hexamer primers for reverse transcription and specific
primers for subsequent PCR. The ~1350 bp long DNA fragment in the P0 virus sample corresponds to
the reporter gene, while the ~250 bp long fragment corresponds to the WT sequence. (G) Antiviral
assay using synZIKV-R2A viruses. VeroE6 cells were inoculated with a 1:10 dilution of a P0 stock and
one hour later the medium was replaced with DMEM containing the indicated amount of 2′CMC.
RLuc activity was measured in cell lysates 72 h post-infection. Mean ± SEM from two independent
experiments is shown.
3.4. SynZIKV Reporter Viruses Suitable for Live Cell Imaging
In order to have at hand an easy to handle ZIKV system suitable for microscopy-based studies such
as live-cell imaging, we replaced the RLuc reporter gene by a gene encoding the turbo far-red fluorescent
protein FP635 (Figure 4A) [24]. Since ZIKV replicates in the cytoplasm we added a nuclear localization
sequence (NLS) to the FP635 marker protein to avoid interference with imaging of cytoplasmic events.
We used the well-studied NLS of the Simian Virus 40 (SV40) large T antigen that was fused to the
C-terminus of FP635. Ninety-six hours after transfection with synZIKV-FP635 in vitro transcripts,
cells were analysed by immune fluorescence to detect the E protein whereas FP635 was detected by
its fluorescence (Figure 4B). Virtually all of the E-positive cells also expressed detectable amounts of
FP635 (Figure 4B,C) suggesting that the synZIKV-FP635 reporter genomes are functional and allow
the detection of infected cells just by means of the fluorescent marker protein. We noted that FP635
primarily accumulated within defined sub-nuclear regions, in line with a previous study reporting the
accumulation of a GFP-SV40-NLS fusion protein in the nucleoli [34].
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Figure 4. Construction and characterization of synZIKV-FP635 reporter viruses suitable for live cell
imaging. (A) Schematic representation of the synZIKV-FP635 reporter genomes. The FP635 gene fused
at the 3′ end to the coding sequence of the SV40 NLS (not indicated) was inserted into the synZIKV
constructs via NotI/NruI restriction sites. (B) Detection of E-antigen by immunofluorescence analysis
of VeroE6 cells 96 h post-transfection with synZIKV-FP635 RNAs. The FP635 signal (red) was detected
by its fluorescence. Note the accumulation of FP635 in distinct nuclear sites, most likely corresponding
to nucleoli. Nuclear DNA was counterstained with DAPI (grey). Scale bar = 15 μm. (C) Quantification
of E- and FP635-positive VeroE6 cells 96 h post-transfection of synZIKV-FP635 RNAs. Results show the
mean from two independent experiments ± SEM. At least 150 cells per condition were counted.
3.5. Sub-Genomic synZIKV Replicons
In addition to full-length reporter viruses, sub-genomic replicons are powerful tools as they allow
studying virus replication without biosafety concerns. Therefore, by using our full-length synZIKV
molecular clones, we established sub-genomic RLuc reporter replicons. The overall construct design
was analogous to the one of the synZIKV-R2A reporter genomes but the replicons lacked the region
encoding the ZIKV structural proteins (Figure 5A). Replication of these sgR2A-synZIKV replicons
was assessed in Huh7 cells (Figure 5B). RLuc activities detectable in the cell lysates at different
time points after transfection correlated well with the amounts of ZIKV NS3 and NS4B proteins
detectable by Western blot revealing that also in this case replication kinetics of the MR766 strain
was faster than the H/PF/2013 strain (Figure 5C). NS3 as well as double-stranded RNA (dsRNA),
a replication intermediate [22], were detectable by immunofluorescence (Figure 5C). As described
for ZIKV-infected Huh7 cells, sgR2A-synZIKV-transfected cells had a kidney shaped nucleus [25].
This observation suggests that the non-structural proteins of ZIKV are sufficient to induce changes of
nucleus morphology. In summary, these results show that sgR2A-synZIKV replicons are functional
and induce morphological changes resembling a ZIKV infection.
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Figure 5. Properties of synZIKV sub-genomic reporter replicons. (A) Schematic representation of
the synZIKV-sgR2A subgenomic reporter replicons. The reporter cassette (grey) was inserted into
the synZIKV genomes via the MLuI and AgeI restriction sites and replaces the region encoding the
structural proteins. (B) RLuc activity in Huh7 cells transfected with wild-type or replication-deficient
(mutant GAA) synZIKV-sgR2A replicon RNAs measured at given times post-transfection. Shown
RLuc values were normalized to the 4 h value to correct for transfection efficiency. Mean ± SEM of
three independent experiments is presented. (C) Western blot showing the abundance of ZIKV NS3
and NS4B proteins in Huh7 cells transfected with synZIKV-sgR2A replicon RNAs. Cells were lysed
at indicated times post-transfection and ZIKV-specific antibodies were used to detect viral proteins.
β actin served as loading control. Numbers on the left refer to the positions of marker proteins that are
given in kilodalton (kDa). (D) Immunofluorescence analysis of Huh7 cells 48 h post-transfection of
synZIKV-sgR2A RNAs. Cells were stained with a dsRNA- (green) and a NS3-specific antibody (red).
Nuclear DNA was stained with DAPI (grey). Scale bars = 15 μm. Boxed areas indicate regions that are
shown in the left panels as enlargements.
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4. Discussion
Here we describe a straightforward and very simple approach to establish a ZIKV reverse genetics
system. The key feature is to remove CEPs, responsible for genome instability [9], by using in
silico prediction with an open-access online tool and subsequent elimination in the virus sequence
by silent nucleotide substitutions. This strategy was successfully applied to two different ZIKV
strains—MR766 and H/PF/2013—for which construction of full-length cDNA clones has failed in the
past [13,15,17,18] (A.P. and R.B., unpublished). Our approach allows the amplification of functional
ZIKV infectious clones on a single, low-copy plasmid, which is superior to time consuming and error
prone multi-vector systems reported earlier [15–19]. Moreover, in vitro transcripts generated from
our synZIKV clones are infectious, thus mimicking an infection better than DNA-launched systems
requiring nuclear transcription of the viral RNA genome. Finally, the possibility to stably propagate
the ZIKV genome in a pBR-derived vector circumvents several disadvantages inherent to the use of
bacterial artificial chromosome (BAC) systems, such as low DNA yield and complicated procedures to
introduce mutations into the genome [35–37].
We did not observe a difference in replication dynamics between the wild-type synZIKV-MR766
molecular clone and the parental MR766 virus, suggesting that the molecular clone fully recapitulates
the properties of the parental strain. Also, the plaque morphologies produced by both synZIKV-MR766
and synZIKV-H/PF/2013 closely resembled those of reference viruses. However, we observed that the
synZIKV-H/PF/2013 molecular clone was attenuated (Figure 2E). The reasons underlying the reduced
fitness are currently unknown. Although the sequence of the synZIKV-H/PF/2013 clone was modified
to silence the CEPs and introduce unique restriction sites, these changes are unlikely to contribute to
decreased viral fitness as all of the inserted mutations were silent and the regions known to contain
regulatory RNA elements were omitted. We note however, that the attenuation observed by us is
in line with the study of Widman and co-workers who constructed an H/PF/2013 molecular clone
by using an in vitro ligation strategy and observed a similar degree of attenuation [15]. The fitness
difference between the synZIKV-H/PF/2013 clone and the reference strain might be due to the
genetic homogeneity of the molecular clone whereas the genome population of the H/PF/2013 isolate
most likely is more heterogeneous, thus allowing for faster adaption to the cell culture conditions.
Additionally, studies on poliovirus and influenza viruses showed that individual variants within viral
quasispecies can cooperate to increase the fitness of the total virus population [38,39]. For MR766
this might not apply because this virus has been well adapted to cell culture conditions through
intensive passaging since its isolation in 1947 [7]. This adaptation probably is already reflected in
the cDNA sequence that served as reference for our clone (DQ859059). Nevertheless, fitness of both
synZIKVs could be increased by cell culture passaging, arguing for rapid adaptation of both synZIKV
strains and selection for variants with fitness even higher than the parental strains. Although we do
not know whether distinct mutations in these synZIKV genomes or the -most likely- higher genetic
heterogeneity in P3 stocks account for increased fitness, the use of extensively cell culture passaged
virus is less desirable as it might have altered in vivo properties that are not necessarily detectable
in vitro. Therefore, it is preferable to work with strains of low passage and defined sequence, which is
the case with molecular clones as described here. Moreover, we note that the MR766 strain belongs
to the early ZIKV isolates whereas H/PF/2013 is a more recent clinical strain that is closely related
to strains isolated during the ZIKV epidemic in Brazil. For instance, the HP/F/2013 strain that we
constructed has ~99.5% nucleotide sequence identity with the PE243 strain isolated from a Brazilian
patient in 2015 (accession number KX197192) and only one amino acid change. Thus, our synZIKV
clones should be useful for comparative studies between historical and contemporary ZIKV strains.
Owing to the reduction of replication fitness by the insertion of the RLuc reporter gene this
ZIKV reporter virus was rather unstable and reporter-less variants with higher replication fitness
were rapidly enriched during cell passage and already after one passage WT was the predominant
species. This rapid deletion might be due to recombination occurring in E. coli during plasmid
amplification and being facilitated by the partial duplication of the capsid coding region (i.e., the first
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103 nts containing important cis-acting sequences of ZIKV), up- and downstream of the reporter
gene. Alternatively, recombination might occur during virus propagation in cell culture. In any
case, owing to higher fitness the WT virus rapidly out-competes the reporter virus and becomes the
predominant species. Although this problem can be overcome by using ZIKV RLuc reporter viruses
contained in culture supernatant of transfected (producer) cells, in which WT virus was not detected
(Figure 3D,F), long-term propagation is not possible, which is a limitation when large stocks of reporter
viruses are required. Therefore, further attempts are required to stabilize the inserted reporter gene,
for example, by altering the sequences flanking the reporter gene, or inserting it into another region
of the ZIKV genome. An alternative strategy might be the use of trans-complemented particles as
we have developed for hepatitis C virus and DENV [40,41]. In this case the subgenomic replicon is
transfected into a packaging cell line stably expressing the structural proteins. Virus-like particles are
released from these cells that retain infectivity but contain the subgenomic RNA, thus requiring only
low biosafety level. Importantly, since the size of the subgenomic replicon is much smaller than the
complete genome it allows the insertion of rather long heterologous sequences without exceeding the
size of the full-length genome.
In summary, this study reports a comprehensive toolbox for ZIKV research and an easy
ZIKV cloning strategy that is based on CEP silencing, initially described for DENV2 and JEV [11].
As continuing globalization supports spreading of flaviviruses and their arthropod hosts, it is possible
that outbreaks of other poorly characterized flaviviruses might occur in the future. Therefore, the
strategy described here for ZIKV should allow the rapid construction and stable propagation of
functional molecular clones of potentially emerging flaviviruses and other difficult-to-clone viruses.
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Abstract: Zika virus (ZIKV) is a mosquito-borne flavivirus that has emerged as an important human
viral pathogen, causing congenital malformation including microcephaly among infants born to
mothers infected with the virus during pregnancy. Phylogenetic analysis suggested that ZIKV can be
classified into African and Asian lineages. In this study, we have developed a stable plasmid-based
reverse genetic system for robust production of both ZIKV prototype African-lineage MR766 and
clinical Asian-lineage FSS13025 strains using a tetracycline (Tet)-controlled gene expression vector.
Transcription of the full-length ZIKV RNA is under the control of the Tet-responsive Ptight promoter
at the 5′ end and an antigenomic ribozyme of hepatitis delta virus at the 3′ end. The transcription
of infectious ZIKV RNA genome was efficiently induced by doxycycline. This novel ZIKV reverse
genetics system will be valuable for the study of molecular viral pathogenesis of ZIKV and the
development of new vaccines against ZIKV infection.
Keywords: Zika virus; reverse genetics; infectious cDNA; Tet-inducible; MR766; FSS13025
1. Introduction
Zika virus (ZIKV), an arthropod-borne virus, belongs to the Flavivirus genus of the Flaviviridae
family, which includes several other important human pathogens such as yellow fever virus (YFV),
dengue virus (DENV), and West Nile virus (WNV). ZIKV was first discovered in the Zika forest area
of Uganda in 1947 [1]. In recent years, it has emerged as an important human viral pathogen, causing
several major epidemics in Yap Island and Micronesia, French Polynesia, and South America [2].
Although ZIKV infection is often asymptomatic or mild in clinical manifestation, it can cause congenital
malformations, including microcephaly, intrauterine growth retardation, and neurodevelopmental
delays, in infants born to mothers infected with the virus during pregnancy [3]. Its infection is also
associated with the neurologic disorder Guillain–Barre syndrome in adults [4]. In contrast to other
mosquito-borne flaviviruses, ZIKV can cause persistent infection in humans and primates [5,6] and
can be transmitted sexually [7–9]. Currently, there are no antiviral drugs or vaccines for the control of
ZIKV infection.
ZIKV is an enveloped RNA virus with a positive-sense and single-stranded RNA genome of about
10,800 nucleotides. The viral genomic RNA contains a single open reading frame encoding a large viral
polyprotein of 3423 amino acids. Upon translation, the viral polyprotein is cleaved by host and viral
proteases into structural proteins (capsid [C], premembrane [prM], and envelope [E]) and nonstructural
(NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [10,11]. Phylogenetic analysis classified
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ZIKV into two major lineages: African lineage and Asian lineage, which exhibit different growth
capacity and virulence in vitro and in vivo [12–15]. However, the underlying molecular aspects for
distinct viral growth and pathogenesis between African and Asian lineages remain unknown.
The recent development of ZIKV reverse genetics systems has made it possible to determine the
role and underlying molecular mechanism of viral proteins in viral replication and pathogenesis as
well as for attenuated virus vaccine development [16–21]. Over the course of ZIKV cDNA construction,
its genetic instability and toxicity in bacteria were found to be major obstacles to obtaining the
full-length infectious cDNA, particularly for the prototype MR766 virus. It was speculated that the
presence of cryptic bacterial promoters permits expression of viral peptides/proteins that are toxic
to bacteria [22–24]. Several strategies have been explored to overcome the problems associated with
viral toxicity and genetic instability in bacteria. The first full-length cDNA of ZIKV (Asian-lineage
FSS13025 strain) was successfully constructed by using a very-low-copy plasmid as the vector in
conjunction with a T7 promoter for in vitro transcription of ZIKV RNA by a T7 RNA polymerase [18].
Similarly, another group used an SP6 promoter to drive in vitro transcription of the full-length ZIKV
RNA. In the latter case, a self-splicing intron was inserted into the C-terminal coding region of
the E protein. The SP6 RNA transcripts were subjected to in vitro splicing in order to produce the
infectious ZIKV RNA [25]. Alternatively, ZIKV cDNA fragments were amplified separately and
cloned into different plasmids, followed by Gibson assembly or DNA ligation in vitro to produce
the full-length ZIKV cDNA [20,21,26]. The resulting full-length cDNA was subsequently used as
the template for in vitro T7 transcription to produce infectious ZIKV RNAs. Apart from in vitro
transcription of infectious ZIKV RNA, infectious ZIKV RNA could be directly produced in the cell
by cloning its cDNA into a mammalian expression vector. Transcription of infectious ZIKV RNA
is driven by a polymerase II promoter at the 5′ end of ZIKV cDNA. In the case of infectious ZIKV
cDNA, a synthetic intron sequence had to be inserted into the NS1 or NS5 gene in order to avoid
viral toxicity to bacteria [16,19]. The silence of the cryptic bacterial promoters was also reported to
get around toxicity [23]. In present study, we have constructed infectious ZIKV cDNA independent
of in vitro RNA transcription or intron insertion using a tetracycline (Tet)-controlled transcription
vector. The full-length ZIKV cDNAs were cloned into the pTRE-Tight vector under the control of
the Tet-responsive Ptight promoter and the antigenomic ribozyme of hepatitis delta virus (HDV).
Both African- and Asian-lineage ZIKV were robustly produced upon DNA transfection and treatment
with doxycycline. This novel ZIKV reverse genetics system will facilitate genetic determination
of the underlying molecular mechanism of ZIKV replication and pathogenesis as well as genetic
manipulation of infectious ZIKV for vaccine development.
2. Materials and Methods
2.1. Cell Culture and Virus
Vero and C6/36 (CRL-1660) cell lines were obtained from America type culture collection (ATCC,
Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA), 0.1 mM nonessential amino
acids, penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA and HyClone, Logan, UT, USA)
at 37 ◦C in a 5% CO2 incubator. ZIKV African-lineage MR766 strain was obtained from ATCC and
propagated in C6/36 and Vero cells.
2.2. DNA Construction
pTRE-Tight vector containing the Tet-responsive element and a minimal cytomegalovirus (CMV)
promoter (Ptight) was described previously [27]. pTet-On vector expressing a reverse Tet-responsive
transcriptional activator (rtTA) was from Takara Bio. The full-length infectious cDNA of ZIKV/MR766
was amplified by reverse transcription polymerase chain reaction (RT-PCR) similar to the methods
used previously by others [16,18]. The virion RNA (vRNA) was isolated from the supernatant of the
45
Viruses 2018, 10, 700
ZIKV/MR766-infected Vero cells using QIAamp Viral RNA Kits (Qiagen, Inc., Valencia, CA, USA).
The full-length viral cDNA was initially amplified as five subgenomic cDNA fragments by RT-PCR
using specific primers containing unique restriction enzyme sites and cloned into the pEASY-Blunt
vector (Transgen Biotech, Beijing, China), resulting in five subgenomic cDNA clones, which were
confirmed by DNA sequence analysis. These five cDNA fragments were sequentially inserted into
a modified pTRE-Tight vector that allows inducible transcription of infectious ZIKV RNA in the cell.
Initially, the pTRE-Tight vector was modified by replacing the high-copy-number ColE1 origin of
replication with the low-copy-number p15A origin of replication from the vector pACYC177 [18].
For construction of infectious ZIKV/MR766 cDNA, a DNA fragment containing a unique Sbf I
restriction enzyme site, partial 3′ end sequence (nucleotides 10,779–10,807 with a unique Eag I
site) of the MR766 genome, and the antigenomic ribozyme of HDV were amplified by PCR and
introduced into the low-copy pTRE-Tight vector between the restriction enzyme sites Sac I and
Xba I. Lastly, the nucleotides 1 to 1711 of the MR766 cDNA were fused with the minimal CMV
promoter sequence by PCR using synthetic primers containing unique Sac I and Sbf I sites and
inserted into the above modified pTRE-Tight vector, resulting in the pTight-ZIKV/MR766 entry
vector. For subsequent cloning of other cDNA fragments excised from subgenomic cDNA clones,
partial Fragment 1 between EcoR I and Age I sites and Fragment 2 between Age I and Sbf I sites
were simultaneously inserted into the pTight-ZIKV/MR766 Entry Vector digested with restriction
enzymes EcoR I and Sbf I. The rest of the three cDNA fragments (3, 4, and 5) were then cloned into
the Sbf I/Eag I-digested pTight-ZIKV/MR766 Entry vector containing Fragments 1 and 2, resulting in
a full-length MR766 cDNA clone. Similarly, the Asian-lineage ZIKV strain FSS13025 cDNA was cloned
into the pTRE-Tight vector, resulting in pTight-ZIKV/FSS13025. The full-length FSS13025 cDNA
(GenBank number KU955593.1) was synthesized and cloned into the vector pCCI-Brick by GenScript,
resulting in a plasmid designated pCCI-Brick-ZIKV_FSS13025. The FSS13025 cDNA between restriction
enzyme sites Nhe I and Eag I was excised from the synthetic pCCI-Brick-ZIKV_FSS13025 vector and
inserted into the pTight-ZIKV/FSS13025 entry vector cut by the same Nhe I and Eag I enzymes.
The pTight-ZIKV/FSS13025 entry vector was modified from the pTight-ZIKV/MR766 Entry vector
by replacing the DNA fragment between restriction enzyme sites Sac I and Eag I with a synthetic
DNA fragment containing part of the minimal CMV promoter and 5′ end nucleotides 1–57 of the
FSS13025 genome. DNA ligation was carried out by incubation of the above-described DNA vectors
and inserts with T4 DNA ligase (NEB, M0202) at 16 ◦C overnight. The ligated DNA was concentrated
by ethanol precipitation and resuspended in distilled water prior to DNA transformation. One Shot
TOP10 Electrocomp Escherichia coli (E. coli) was from Invitrogen (cat. no. C404052, Carlsbad, CA, USA)
and used for DNA transformation by electroporation, which was carried out in a 2 mm cuvette in the
following conditions: 2500 V, 25 μF, 200 Ω. The DNA-transformed E. coli was spread onto lysogeny
broth (LB) plate containing 100 μg/mL of Ampicillin with about 20-h incubation at 30 ◦C. The clones
were cultured in LB medium by shaking (170 rpm) at 30 ◦C overnight. Plasmid DNA was extracted
using QIAGEN kits and confirmed by DNA sequence analysis.
2.3. DNA Mutagenesis
To engineer a genetic marker for rescued MR766 virus, the restriction enzyme Nhe I site at the
nucleotide 3862 of the MR766 cDNA was mutated by an overlapping PCR method using synthetic
oligonucleotide primers containing nucleotide mutations that did not change amino acid sequence
(silent mutation). The PCR products were digested by Sal I and Sbf I and inserted into the infectious
cDNA clone pTight-ZIKV/MR766 which was similarly cut by Sal I and Sbf I. Likewise, the Nsi I site at
the nucleotide 7178 of the FSS13025 cDNA was destroyed by introducing silent mutations into the DNA
fragment between Kas I and Afl II sites of the infectious FSS13025 cDNA vector pTight-ZIKV/FSS13025.
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2.4. DNA Transfection and Virus Production
Vero cells were seeded in a 12-well plate at a density of 2.5 × 105 per well and cultured in DMEM
containing 10% FBS overnight. After washing with 1× Phosphate-buffered saline (PBS) twice, Vero cells
were transfected with 1 μg of pTight-ZIKV/MR766 or pTight-ZIKV/FSS13025 DNA with 1 μg of either
pTRE-Tight or pTet-On vector DNA in Opti-MEM containing 4 μL lipofectamine 2000 (Invitrogen,
cat. no. 11668019, Carlsbad, CA, USA). At 4 h post-transfection (p.t.), Opti-MEM was replaced with
1 mL of DMEM containing 3% FBS and 1 μg/mL of doxycycline (Sigma, D9891). The supernatants from
DNA-transfected Vero cells were collected at 3 (MR766) or 6 (FSS13025) days after DNA transfection
for determining the titers of infectious ZIKV.
2.5. Immunofluorescence Assay (IFA)
The expression of ZIKV proteins in the DNA-transfected or virus-infected Vero cells was
determined by immunofluorescence assay (IFA) using a monoclonal antibody specific to the
envelope protein (EMD Millipore, clone D1-4G2-4-15, Billerica, MA, USA). The DNA-transfected
or virus-infected Vero cells were fixed with methanol at −20 ◦C for 15 min and then blocked with a PBS
buffer containing 1% FBS, 1% BSA, and 0.05% Tween-20 at room temperature (RT) for 1 h. Cells were
then incubated with the E monoclonal antibody at RT for 2 h, followed by incubation with a goat
anti-mouse secondary antibody conjugated with Alexa Fluor 488 (Life Technologies, cat. no. A21202,
Carlsbad, CA, USA) at RT for 1 h. The cell nucleus was stained with Hoechst 33342 at RT for 10 min.
Fluorescent images were captured using Nikon Eclipse Ti microscope.
2.6. Virus Titration and Plaque Assay
A plaque assay was used to determine the titer of infectious ZIKV recovered from Vero cells
transfected with infectious ZIKV cDNA clones as described above. Infectious ZIKV in the cell culture
supernatant was titrated by a 10-fold serial dilution. Vero cells in 12-well cell culture plates were
infected with 10-fold serially diluted ZIKV in triplicate. The virus-infected cells were incubated at
37 ◦C for two hours with gentle swirling several times. The virus-infected cells were then grown
in DMEM containing 5% of FBS and 1% of methyl cellulose at 37 ◦C. At 4 to 6 days post-infection,
the virus-infected cells were fixed with 4% formaldehyde solution at RT for 1 h. Viable cells were
stained with 1% crystal violet solution at RT for 15 min. The numbers of plaques were manually
counted and converted to infectious virus titers per milliliter.
2.7. Determination of the Stability of Infectious Zika Virus (ZIKV) cDNA Clone
To determine the stability of infectious ZIKV cDNA clones pTight-ZIKV/MR766 and pTight-ZIKV/
FSS13025 in E. coli, the plasmid DNA was amplified in TOP10 Electrocomp E. coli by several rounds of
DNA transformation and amplification. Purified plasmid DNA after each round of amplification was
initially validated by restriction enzyme digestion to determine the sizes of plasmid DNA. Purified
plasmid DNA after each round of transformation and amplification was also used for DNA transfection
into Vero cells to determine its ability to produce infectious ZIKV.
2.8. Statistical Analysis
Graphical representation and statistical analyses were performed by Prism6 software (GraphPad
Software, La Jolla, CA, USA). Mean values and standard deviation (SD) were calculated from at least
three independent experiments. Comparisons between samples were done using the Students t-test.
p < 0.05 was considered statistically significant.
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3. Results
3.1. Construction of the Full-Length Infectious ZIKV cDNA
Genetic instability of Flavivirus cDNA in bacteria is a common problem encountered during the
course of developing reverse genetics for certain members of the Flaviviridae family. The full-length
cDNA clones of different ZIKV strains have been constructed recently by others using a T7/SP6
transcription vector or a mammalian expression vector that requires the insertion of intron sequence
into the NS1 or NS5 gene in order to obtain the infectious cDNA clones [16,18–21]. In the present study,
we sought to develop a more convenient and robust reverse genetics system for inducible production
and genetic manipulation of infectious ZIKV of various lineages independent of in vitro T7/SP6
polymerase transcription or insertion of intron sequence using a strategy similar to our previous work
on the hepatitis C virus (HCV) [28]. The construction of infectious cDNAs of MR766 and FSS13025
strains is described in materials and methods. The full-length cDNA of MR766 was sequentially
spliced from 5 subgenomic cDNAs (Figure 1A) and cloned into pTight-ZIKV/MR766 entry vector
(Figure 1B), whereas the full-length cDNA of FSS13025 strain was chemically synthesized by GenScript
(Figure 1C) and cloned into pTight-ZIKV/FSS13025 entry vector (Figure 1D). The transcription of
the full-length ZIKV RNA genome is under the control of the Tet-responsive Ptight promoter, and the
HDV antigenomic ribozyme is placed immediately downstream of the 3′ end of ZIKV RNA genome
(Figure 1B). Since Ptight promoter contains 7× repeat tetracycline responsive operator, the ZIKV RNA
transcription would be driven by the binding of reverse Tet-responsive transcriptional activator (rtTA)
to the operator in the presence of tetracycline or its derivatives doxycycline. Upon co-transfection of
pTight-ZIKV with pTet-On which express rtTA and the addition of doxycycline, the full-length ZIKV
RNA genome is transcribed and further processed by the HDV ribozyme-mediated cleavage at the 3′ end,
resulting in an infectious RNA with precise 5′ and 3′ ends in the cell. This vector design was successfully
used for the construction of the full-length cDNAs of both African-lineage MR766 and Asian-lineage
FSS13025 strains of ZIKV, which exhibited genetic instability in bacteria as reported by others [16,18].
3.2. Tet-Inducible Production of Infectious ZIKV from Its cDNA
To demonstrate the functionality of the full-length ZIKV cDNA constructs described above,
we have carried out DNA transfection experiments and determined the production of infectious ZIKV.
We also sought to determine the Tet-inducible production of infectious ZIKV by co-transfection of
Vero cells with both pTight-ZIKV/MR766 and pTet-On with and without the addition of doxycycline,
a tetracycline analogue. Initially, the pTight-ZIKV/MR766 DNA was transfected into Vero cells
with or without co-transfection with the pTet-On vector. The DNA-transfected Vero cells were then
cultured in DMEM medium with or without doxycycline (1 μg/mL). At 3 days post-transfection (p.t.),
the cytopathic effect (CPE) could be observed in the DNA-transfected Vero cells when doxycycline
was added. The cell culture supernatants were harvested for the determination of infectious ZIKV,
whereas the DNA-transfected cells were fixed and stained with a monoclonal antibody specific to the
ZIKV E protein (Figure 2A). The expression of viral E protein was detected in cells transfected with
the pTight-ZIKV/MR766 DNA regardless of co-transfection with the pTet-On vector or presence of
doxycycline, suggesting leaky transcription from the PTight promoter (Figure 2A). However, the number
of E-positive cells and the level of E protein expression were the highest in the cells co-transfected
with the pTet-On vector and cultured in the presence of doxycycline (top-right corner, Figure 2A),
demonstrating Tet-inducible expression of ZIKV RNA from its cDNA vector. Likewise, infectious
ZIKV in the cell culture supernatant was detected by IFA (bottom images of Figure 2A). At 3 days
post-infection (p.i.), CPE was observed in Vero cells infected with the cell culture supernatants from
the pTight-ZIKV/MR766 DNA-transfected cells (middle panels of Figure 2A). Again, infectious
ZIKV in the supernatant of the cells co-transfected with pTight-ZIKV/MR766 and pTet-On in the
presence of doxycycline resulted in the highest level of CPE. Similarly, the E protein was detected
by IFA staining in the ZIKV-infected cells (bottom panel of Figure 2A). It should be noted that fewer
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E-positive cells observed in the cells infected with the supernatants from Vero cells co-transfected
with both pTight-ZIKV/MR766 and pTet-On were due to cell death caused by more infectious virus
(detached from the plate). Taken together, these findings demonstrate that the full-length cDNA of the
African-lineage MR766 strain is able to produce infectious virus in a Tet-inducible manner.
 
Figure 1. Schematic diagrams of the infectious Zika virus (ZIKV) cDNA amplification and cloning.
(A) Illustration of subgenomic cDNA amplification and cloning of the African-lineage ZIKV/MR766
strain. Five subgenomic cDNA fragments (1 to 5) of the full-length MR766 genome were initially
amplified from its vRNA by reverse transcription polymerase chain reaction (RT-PCR) using specific
primers containing unique restriction enzyme sites highlighted in bold on the top. (B) Diagram of
the pTight-ZIKV/MR766 entry vector. The entry vector was modified from pTRE-Tight by replacing
the high-copy-number ColE1 origin of replication with the low-copy-number p15A origin and then
inserting the partial MR766 genomic sequence with EcoR I, Sbf I and Eag I sites and hepatitis delta virus
(HDV) antigenomic ribozyme sequence at the multiple clone sites region. The rest of the subgenomic
cDNA fragments were sequentially inserted into the pTight-ZIKV/MR766 entry vector through the
unique enzyme sites, resulting in an infectious MR766 cDNA clone designated pTight-ZIKV/MR766.
(C) Diagram of the FSS13025 ZIKV genome organization. Two unique restriction enzyme sites Nhe
I and Eag I at the 5′ and 3′ ends are highlighted in bold on the top. (D) Schematic map of the
pTight-ZIKV/FSS13025 entry vector. A DNA fragment containing the 3′ end 21 nucleotides of the
minimal CMV promoter, the 5′ end 57 nucleotides and the 3′ end 29 nucleotides of the FSS13025 cDNA
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with a 16-nucleotides spacer, and the HDV antigenomic ribozyme were inserted into the low-copy-
number pTRE-Tight vector, resulting in the pTight-ZIKV/FSS13025 entry vector. The FSS13025
cDNA between Nhe I and Eag I sites was released from the full-length FSS13025 cDNA vector
pCCI-Brick-ZIKV_FSS13025 (synthesized by GenScript) and cloned into the pTight-ZIKV/FSS13025
entry vector, resulting in an infectious FSS13025 cDNA clone designated pTight-ZIKV/FSS13025.
Figure 2. Production of cDNA-derived infectious ZIKV. (A) Production of infectious ZIKV/MR766
virus upon DNA transfection with or without Tet-induction. Vero cells (2.5 × 105/well) in 12-well cell
culture plates were transfected with 1 μg of pTight-ZIKV/MR766 DNA and 1 μg of empty vector or
pTet-On vector using lipofectamine 2000. At 3 days p.t., the viral E protein in the DNA-transfected cells
was detected by immunofluorescence assay (IFA) using an E-specific monoclonal antibody (D1-4G2-4-15).
At the same time, the supernatants were used to infect fresh Vero cells. At 3 days p.i., the cytopathic
effect (CPE) was recorded and the E protein in the ZIKV/MR766-infected cells was determined by
IFA. (B) Determination of cDNA-derived ZIKV/FSS13025 replication and production by CPE and
IFA. Experiments were carried out in the same way as in (A) except that the pTight-ZIKV/FSS13025
DNA was used. At 6 days p.t., the E protein was detected by IFA in the pTight-ZIKV/FSS13025
DNA-transfected Vero cells. The ZIKV/FSS13025 in the supernatant was used to infect Vero cells.
At 3 days p.i., CPE was photographed and the E protein was measured by IFA as described in (A).
Images in (A,B) were 200× magnification.
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Similar to MR766 cDNA clone, the Asian-lineage FSS13025 cDNA also resulted in the expression
of E protein and production of infectious virus upon DNA transfection into Vero cells although
at a much later time (6 days post-transfection), as determined by IFA (Figure 2B). In contrast to
MR766 cDNA, transfection with FSS13025 cDNA per se failed to express the E protein or produce
infectious virus. The expression of E protein and the production of infectious virus were only
detected in Vero cells co-transfected with pTight-ZIKV/FSS13025 and pTet-On DNAs in the presence
of doxycycline (Figure 2B). CPE and E protein could only be seen in Vero cells infected with the cell
culture supernatant derived from cells co-transfected with pTight-ZIKV/FSS13025 and pTet-On in the
presence of doxycycline (Figure 2B). These results suggest that the transcription and expression of
infectious FSS13025 RNA from its cDNA clone in the cell are highly dependent on the expression of
rtTA and the presence of doxycycline.
To further determine the Tet-inducible expression and production of infectious ZIKV from its
cDNA, Vero cells were co-transfected with the pTight-ZIKV/MR766 or pTight-ZIKV/FSS13025 and
pTet-On with addition of varying concentrations (0, 0.5, and 1 μg/mL) of doxycycline. The expression
of the E protein in the DNA-transfected or virus-infected cells was determined by IFA using
an E-specific monoclonal antibody. CPE formation in the virus-infected cells was documented by
photography under an optical microscope. Indeed, the E protein expression in the pTight-ZIKV/MR766
DNA-transfected cells was significantly enhanced by increasing concentrations of doxycycline
(top images, Figure 3A). CPE in the supernatant-infected cells was also increased in proportion
to doxycycline concentrations. More importantly, the titers of infectious ZIKV/MR766 virus
were significantly higher when doxycycline was added to the cell culture medium (Figure 3C).
More significantly, the E protein expression and infectious virus production from the ZIKV/FSS13025
cDNA were strictly dependent on the presence of doxycycline in a dose-dependent manner
(Figure 3B,C). Collectively, these findings demonstrate the Tet-inducible production of infectious
ZIKV from its cDNA under the control of a Tet-responsive promoter, especially for ZIKV with less
replication efficiency like the Asian-lineage FSS13025 strain.
Figure 3. Cont.
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Figure 3. Doxycycline dose-dependent production of cDNA-derived ZIKV. Vero cells in 12-well
plates were co-transfected with 1 μg of pTight-ZIKV/MR766 or pTight-ZIKV/FSS13025 DNA and
1 μg of an empty vector or pTet-On. The DNA-transfected Vero cells were cultured with different
concentrations (0, 0.5, and 1 μg/mL) of doxycycline. The viral E protein in the DNA-transfected cells
was determined by IFA at 3 d p.t. (for MR766) or 6 d p.t. (for FSS13025). The supernatants harvested at
3 d p.t. (MR766) or 6 d p.t. (FSS13025) were used to infect naïve Vero cells. CPE formation was recorded
and the E protein was detected by IFA in the virus-infected cells at 3 d p.i. Infectious virus titers were
quantified by a limiting dilution and plaque assay in the same way as Figure 3. (A) Determination of
the E protein in Vero cells co-transfected with pTight-ZIKV/MR766 DNA and vector or pTet-On or
infected with cDNA-derived ZIKV/MR766 virus by IFA. CPE formation was also documented in the
cDNA-derived ZIKV/MR766 virus. (B) IFA detection of the E protein in Vero cells co-transfected with
pTight-ZIKV/FSS13025 and pTet-On DNAs or infected with cDNA-derived ZIKV/FSS13025 virus.
CPE formed by the cDNA-derived ZIKV/FSS13025 virus is shown in the middle. The images of (A,B)
were taken under 200× magnification. (C) Doxycycline dose-dependent production of cDNA-derived
ZIKV between the pTight-ZIKV/MR766 and pTight-ZIKV/FSS13025 DNAs. The supernatants from the
DNA-transfected Vero cells as described in (A,B) were 10-fold serially diluted and were used for plaque
assay. Infectious ZIKV titers were converted from plaque numbers and calculated as plaque-forming
units per milliliter (PFU/mL). Values represent the means ± standard deviations (SD) from three
independent experiments. Statistical significance was analyzed by Student’s t-test: ** p < 0.01. ns
indicates no significant difference.
3.3. Comparison of Virus Growth between the cDNA-Derived MR766 and FSS13025 Viruses
Transfection of pTight-ZIKV/MR766 cDNA into Vero cells resulted in higher titers of infectious
virus than that of pTight-ZIKV/FSS13025 cDNA (Figure 3C), suggesting that MR766 grows more
efficiently than the FSS133025 virus. To compare their growth capacity in Vero cells, we have determined
the plaque-forming ability and growth curves of the cDNA-derived MR766 and FSS13025 ZIKVs.
As shown in Figure 4A, MR766 virus formed bigger plaques than FSS13025 virus (Figure 4A). Likewise,
MR766 virus grew to 6-, 9-, and 35-times higher titers than FSS13025 virus after 1, 2, and 3 days p.i.
(Figure 4B). These results are consistent with the previous findings that African-lineage ZIKVs are more
virulent and have higher growth capacity than Asian-lineage ZIKVs [15,29–31]. These observations
may partially explain the higher titers of infectious MR766 virus and leaking transcription of MR766
RNA upon DNA transfection compared to FSS13025 virus (Figures 2 and 4).
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Figure 4. Comparison of cDNA-derived MR766 and FSS13025 virus growth. Vero cells (2.5 × 105/well)
in 12-well plates were co-transfected with 1 μg pTight-ZIKV/MR766 or pTight-ZIKV/FSS13025 DNA
and 1 μg pTet-On vector, followed by the addition of 1 μg/mL Doxycycline to cell culture media.
Infectious virus titers in the supernatants collected at day 3 (MR766) or day 6 (FSS13025) were quantified
by a plaque assay. (A) Plaque formation by cDNA-derived ZIKV/MR766 and ZIKV/FSS13025 viruses.
Vero cells in 12-well cell culture plate were infected with 30 PFU of either MR766 or FSS13025. Plaques
were stained and visualized after 4 days (for MR766) or 6 days (for FSS13025) p.i. (B) Growth curves
of cDNA-derived MR766 and FSS13025 viruses. To compare the growth ability between MR766 and
FSS13025, 4 × 105 Vero cells seeded in 6-well plates were infected with MR766 or FSS13025 virus at
0.01 MOI at 37 ◦C for 1 h. Upon washing with phosphate-buffered saline (PBS) three times, infected
Vero cells were incubated with 2 mL DMEM containing 10% FBS. At day 1, 2, and 3 post-infection,
virus in the supernatant was collected and stored at −80 ◦C. Virus yields at different time points were
determined by a plaque assay. Data points represent the mean titer of triplicates. Statistical significance
was analyzed by Student’s t-test: ** p < 0.01.
3.4. Validation of Infectious ZIKV by the Identification of Genetic Markers
To discriminate cDNA-derived recombinant virus from potentially contaminated ZIKV, one of the
two Nhe I sites present in the MR766 cDNA was mutated by introducing silent nucleotide mutations as
genetic markers for the cDNA-derived ZIKV (Figure 5A). Similarly, one of the two Nsi I sites found in
the FSS13025 cDNA was mutated (Figure 5B). Upon DNA transfection, resulting infectious MR766
(Figure 5C) and FSS13025 virus (Figure 5D) were confirmed by RT-PCR (Figure 5E) and digestion
with restriction enzymes Nhe I for MR766 virus (Figure 5F) and Nsi I for FSS13025 virus (Figure 5G).
The RT-PCR DNAs amplified from wild type but not recombinant viruses were digested with Nhe I
(MR766) or Nsi I (FSS13025). The presence of genetic markers introduced into viral cDNA confirms the
authenticity of the cDNA-derived ZIKV.
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Figure 5. Confirmation of cDNA-derived ZIKV by detection of genetic markers. (A) Diagram of the
pTight-ZIKV/MR766 DNA containing two nucleotide mutations as genetic markers. The Nhe I site at
the nucleotide 3862 of the MR766 cDNA was mutated by changing two nucleotides (red) that do not
alter amino acids (shown on the top). (B) Diagram of the pTight-ZIKV/FSS13025 DNA containing two
nucleotide mutations at the 7178Nsi I site of the FSS13025 cDNA as genetic markers. (C,D) Validation
of cDNA-derived infectious ZIKV by IFA. The genetic markers-harboring pTight-ZIKV/MR766
and pTight-ZIKV/FSS13025 DNAs were co-transfected into Vero cells as described in Figure 3.
The supernatants of the DNA-transfected cells were used for infection of Vero cells. At 3 d p.i.,
the expression of the E protein of MR766 (C) or FSS13025 (D) was detected by IFA. The images of (C,D)
were taken under 200× magnification. The vRNAs were extracted from the supernatants using a Qiagen
viral RNA isolation kit and used for reverse transcription (RT, indicated by +). The RT products were
amplified by PCR using vRNA without RT as controls (E). The RT-PCR products from MR766 vRNA
were digested with the restriction enzyme Nhe I (F), whereas the RT-PCR products of FSS13025 were
cut with Nsi I (G). Wild type MR766 and FSS13025 RT-PCR products were used as controls.
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3.5. Stability of Infectious ZIKV cDNA in E. coli
Previous studies by others suggested that infectious ZIKV cDNA is genetically unstable during
amplification in bacteria. To determine the genetic stability of our infectious MR766 and FSS13025
cDNA clones based on the Tet-On system, the pTight-ZIKV/MR766 and pTight-ZIKV/FSS13025
plasmids were sequentially transformed to and amplified in E. coli up to 5 rounds, similar to the
study described previously by others [18]. Plasmid DNA extracted at each round of transformation
and amplification was digested with restriction enzyme EcoR I (for MR766 cDNA) or Nhe I and
Eag I (for FSS13025 cDNA). The patterns of restriction enzyme digestion remained the same between
different rounds of transformation and amplification in E. coli (Figure 6A,D), suggesting that there was
no large DNA deletion or insertion during plasmid DNA amplification in E. coli. More importantly,
transfection of Vero cells with plasmid DNA purified from the first round (R1) and fifth round (R5)
of transformation resulted in similar levels of the E protein expression and comparable plaque size
and numbers (Figure 6B,E) as well as the same titers of infectious ZIKV (Figure 6C,F). These results
demonstrate the genetic stability of the infectious ZIKV cDNA cloned into the Tet-inducible vector
modified in the lab.
 
Figure 6. Determination of genetic stability of infectious ZIKV cDNA clones in E. coli. (A) Analysis of
the pTight-ZIKV/MR766 DNA stability by EcoR I digestion. The pTight-ZIKV/MR766 plasmid was
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sequentially transformed to and amplified in E. coli for five consecutive rounds (R1 to R5). The Plasmid
DNA purified from each round was digested with EcoR I and analyzed by electrophoresis on 1% of
agarose gel. The DNA fragment released from ZIKV/MR766 cDNA upon EcoR I digestion is indicated
by a solid arrow on the left. GeneRuler 1 kb plus DNA ladder (Fisher Scientific, Waltham, MA, USA)
is used as DNA size marker (M) shown on the right. (B) Confirmation of the pTight-ZIKV/MR766
DNA stability by functional analysis in Vero cells. 1 μg of pTight-ZIKV/MR766 DNAs purified from
the first (R1) and fifth (R5) rounds of amplification were co-transfected with 1 μg of pTet-On into
Vero cells with the addition of 1 μg/mL of doxycycline to cell culture medium. At 3 d p.t., the viral E
protein expression was detected by IFA (up panel, 200× magnification), whereas infectious virus in the
supernatant was measured by a plaque assay (lower panel). (C) Comparison of infectious virus titers
resulting from the pTight-ZIKV/MR766 DNA between R1 and R5. (D) Analysis of genetic stability of
the pTight-ZIKV/FSS13025 DNA by digestion with restriction enzymes Nhe I and Eag I. The FSS13025
cDNA released from the pTight-ZIKV/FSS13025 DNA upon digestion with Nhe I and Eag I (Figure 1C)
is indicated by a solid arrow on the left. (E) Validation of cDNA-derived ZIKV/FSS13025 upon
transfection with R1 and R5 pTight-ZIKV/FSS13025 DNA. Experiments were the same as B except
R1 and R5 pTight-ZIKV/FSS13025 DNAs were used. (F) Comparison of infectious ZIKV/FSS13025
tiers resulting from R1 and R5 DNA transfection. Values represent the means ± standard deviations
(SD) from three independent experiments. Statistical significance was analyzed by Student’s t-test. ns
indicates no significant difference.
4. Discussion
In the present study, we have developed a robust reverse genetics system for production and
genetic manipulation of infectious ZIKV using the Tet-inducible (Tet-On) gene expression strategy [32].
The Tet-inducible ZIKV reverse genetics system is superior in many respects to previous ones based
on the in vitro T7/SP6 transcription [18,25], in vitro DNA ligation or recombination from multiple
DNA fragments [20,21,26], and the insertion of the intron sequence into the NS1 or NS5 gene of ZIKV
cDNA [16,19]. The Tet-responsive Ptight promoter used in our ZIKV cDNA constructs is able to drive
the transcription of infectious ZIKV RNA in the cell upon DNA transfection. In the case of T7/SP6
promoter-based vectors, in vitro transcription of infectious ZIKV RNA by T7/SP6 RNA polymerases
requires the use of a 7-methyl guanosine nucleotide (m7G(5′)ppp(5′)G) or cap structure derivative [18,25].
The low efficiency of incorporation of the cap structure into T7/SP6 transcripts could affect the
quantity of infectious RNA transcripts. Also, RNA transfection is less efficient than DNA transfection.
Similarly, in vitro DNA ligation or recombination from multiple subgenomic cDNAs for construction
of infectious ZIKV cDNA are laborious, time-consuming, and very inefficient [20,21,26]. Comparing to
in vitro RNA transcription methods, our DNA-based vectors for the production of infectious ZIKV
in the cell are robust, convenient, and cost-effective. More importantly, the Tet-inducible production
of infectious ZIKV from the DNA-based vector transfected into the cell is highly efficient and can
be induced by the addition of doxycycline. Although mammalian gene expression vectors were
successfully used for production of infectious ZIKV, they require the insertion of the intron sequence
into the NS1 or NS5 gene in order to be genetically stable in E. coli [16,19]. Subsequent production of
infectious ZIKV depends on the splicing of RNA transcripts to remove the intron sequence inserted
into the NS1 or NS5 gene. It is not clear whether the intron sequence inserted into the ZIKV cDNA
will affect the efficiency of virus production in the cell. It was recently found that dengue virus NS5
protein is predominantly localized in the nucleus and is able to suppress RNA splicing by binding
to core components of the spliceosome [33]. Although the ZIKV NS5 protein is also exclusively
localized in the nucleus [34], its role in RNA splicing has not been determined. This appeared not
to be a problem for production of more infectious ZIKV like MR766 strain from its cDNA in the cell
given the facts that leaky RNA transcription from the pTight-ZIKV/MR766 DNA was sufficient to
produce infectious virus (Figures 2A and 3A). This could be partially due to higher growth capacity
of ZIKV/MR766 in the cell (Figure 4). A higher efficiency of RNA transcription is likely required
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for the production of those ZIKV strains with lower replication efficiency like the FSS13025 strain.
Unlike MR766, FSS13025 virus production from its cDNA requires co-transfection with the pTet-On
vector and the addition of doxycycline (Figures 2B and 4). In this aspect, the newly developed reverse
genetics system through this study will be particularly useful for pathogenesis study and genetic
manipulation of clinical isolates of ZIKV. Inducible production of the recombinant virus of clinical
ZIKV isolates will be suitable for the study of viral pathogenesis in transgenic animals, which can be
controlled by treatment with doxycycline. For instance, transgenic mice carrying the full-length cDNA
of ZIKV under the control of pTight promoter can be used for studying congenital ZIKV infection by
administrating animals with doxycycline. For genetic studies, robust production of infectious ZIKV
as shown by our system may facilitate the study of virus–host interaction and the development of
attenuated viruses. This may explain why the intron-based DNA vector for transposon mutagenesis
of the ZIKV/MR766 resulted in fewer transposon insertion mutants [35]. Future investigations are
warranted to determine if the Tet-inducible ZIKV reverse genetics system will be more efficient than the
intron-based system for genome-wide analysis of viral sequence and proteins in viral replication and
pathogenesis. Taken together, our findings suggest that the newly developed Tet-inducible ZIKV cDNA
vector is highly efficient and robust for the production of infectious ZIKV, especially for attenuated
viruses or virus strains with lower replication efficiency. This new DNA-based ZIKV reverse genetics
system will facilitate genetic analysis and genetic manipulation of various ZIKV strains regardless of
their replication efficiency.
Over the years, the development of reverse genetics systems for flaviviruses has been proven
difficult due to their genetic instability in and/or toxicity to E. coli during cDNA cloning [36].
The underlying molecular mechanism of viral genetic instability and/or toxicity in E. coli. remains
elusive. In general, it is believed that cryptic bacterial promoters present in viral cDNA or promoters
used to drive the transcription of viral RNA are active in E. coli, resulting in the expression of toxic
peptides or proteins [22,24,36]. To circumvent the difficulties in ZIKV cDNA cloning, several strategies
have been used, including but not limited to the use of low-copy plasmids as vectors for in vitro
RNA transcription; the separate cloning of the full-length cDNA as subgenomic DNA fragments in
conjunction with in vitro DNA ligation or assembly; the insertion of a spacer sequence such as the
intron to disrupt the open-reading frame [36]; and the silencing of cryptic prokaryotic promoters [23].
The immediate early CMV promoter was previously shown to be able to initiate gene expression
in E. coli [37]. This may explain the viral toxicity observed during the MR766 cDNA cloning to
a vector under the control of a CMV promoter, resulting in large deletions in the NS1 to NS3 coding
regions [16]. To avoid this potential problem, we decided to choose the Tet-responsive Ptight promoter,
which contains the minimal CMV promoter sequence of 59 nucleotides and can inducibly initiate the
transcription of infectious ZIKV RNA. Additionally, we have replaced the high copy-number origin of
replication present in the pTRE-Tight vector with the low-copy-number origin sequence of the vector
pACYC177, which was successfully used for cloning of the first ZIKV cDNA [18]. It is most likely that
the combination of the Ptight promoter and the low-copy-number origin of replication eliminated viral
toxicity and, therefore, confer genetic stability of the pTight-ZIKV/MR766 and pTight-ZIKV/FSS13025
DNA vectors in E. coli (Figure 6). The modified pTight-ZIKV entry vectors (Figure 1) can be used for
the construction of infectious cDNAs of all other ZIKV strains.
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Abstract: The recent emergence and rapid geographic expansion of Zika virus (ZIKV) poses a
significant challenge for public health. Although historically causing only mild febrile illness,
recent ZIKV outbreaks have been associated with more severe neurological complications, such
as Guillain-Barré syndrome and fetal microcephaly. Here we demonstrate that two contemporary
(2015) ZIKV isolates from Puerto Rico and Brazil may have increased replicative fitness in human
astrocytoma cells. Over a single infectious cycle, the Brazilian isolate replicates to higher titers
and induces more severe cytopathic effects in human astrocytoma cells than the historical African
reference strain or an early Asian lineage isolate. In addition, both contemporary isolates induce
significantly more double-stranded RNA in infected astrocytoma cells, despite similar numbers of
infected cells across isolates. Moreover, when we quantified positive- and negative-strand viral RNA,
we found that the Asian lineage isolates displayed substantially more negative-strand replicative
intermediates than the African lineage isolate in human astrocytoma cells. However, over multiple
rounds of infection, the contemporary ZIKV isolates appear to be impaired in cell spread, infecting a
lower proportion of cells at a low MOI despite replicating to similar or higher titers. Taken together,
our data suggests that contemporary ZIKV isolates may have evolved mechanisms that allow them
to replicate with increased efficiency in certain cell types, thereby highlighting the importance of
cell-intrinsic factors in studies of viral replicative fitness.
Keywords: Zika virus; flavivirus; astrocytomas; dsRNA; viral fitness
1. Introduction
The recent emergence and rapid geographic expansion of the mosquito-borne Zika Virus (ZIKV)
poses a significant burden on the global health infrastructure [1]. The virus was initially isolated
in 1947 from sentinel rhesus macaques in the Zika forest region of Uganda [2]. ZIKV circulated
throughout Africa as well as in Southeast Asia over the latter half of the twentieth century, where
it caused sporadic infections resulting in mild febrile illness [3,4]. The first major transmission of
ZIKV outside of its endemic zone occurred in 2007, where 73% of the population of Yap Island,
Federated States of Micronesia contracted the virus within a four-month period [4,5]. However, the
clinical manifestations of ZIKV infection during the Yap Island epidemic were relatively similar to
historical descriptions; resulting in mild, self-limiting, febrile illness characterized by rash, arthralgia,
conjunctivitis, and headaches [3,5]. Interestingly, the continued geographic expansion of the ZIKV
epidemic coincided with reports of novel neurological pathogenesis, starting with the 2013 French
Polynesian epidemic, which saw a drastic increase in reports of Guillain-Barré syndrome [6].
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Following the French Polynesian outbreak, the trans-Pacific transmission of ZIKV resulted
in several epidemics throughout the Americas, the most salient being the Brazilian epidemic
(2014–2016), which coincided with a 20-fold increase in incidence of congenital malformations,
including fetal microcephaly from 2014 to 2015 [7]. Notably, ZIKV outbreaks in South America were
also associated with neurological complications, and several investigations now suggest a connection
between ZIKV infection and the development of Guillain-Barré syndrome, as well as congenital
birth defects, including fetal microcephaly [4,8–12]. In addition to epidemiological factors, such as
the increased mobility of infected individuals and the immunological naivety of recently-afflicted
human populations, novel genomic polymorphisms acquired by contemporary outbreak strains likely
contributed to ZIKV pathogenicity and dissemination in recent outbreaks [13]. Studies conducted
in human neurospheres, cerebral organoids, and primary astrocytes, as well as in murine models of
infection, have demonstrated differences in neurotropism, pathogenicity, and the antiviral responses
between Asian and African lineage isolates [14–17]. Furthermore, a recent investigation uncovered a
single nucleotide substitution in the prM region of the viral polyprotein that increases ZIKV infectivity
in human and mouse neural progenitor cells and leads to significant fetal microcephaly in mice,
resulting in greater mortality of neonatal mice [18]. Additionally, another polymorphism found in the
NS1 region of contemporary ZIKV isolates results in increased NS1 antigenemia in mice, enhanced
infectivity in Aedes mosquitoes, and reduced induction of antiviral signaling in human cells [19,20].
Thus, characterizing the difference in viral replicative fitness between the contemporary epidemic
strains to the pre-epidemic strains could help to provide an evolutionary context for the emergence
and rapid dissemination of ZIKV in the recent outbreaks.
Herein, we sought to compare viral replicative fitness by investigating viral growth kinetics,
cytopathicity, and viral RNA accumulation of contemporary epidemic (2015–2016) and pre-epidemic
ZIKV isolates in two cell culture models of ZIKV infection. First, we chose to use the A549 human lung
epithelial carcinoma cells in order to contextualize our results within the literature, since A549 cells are
widely used in ZIKV research [21–23]. Although A549 cells were reported to be a resilient model of
ZIKV infection [21], the lung is not a target of ZIKV infection in vivo [24]. In contrast, several studies
have shown that astrocytes are a primary target of ZIKV infection in vivo [16,25,26], and a recent study
demonstrated that the U-251 MG human astrocytoma cell line is more permissive to ZIKV infection
than A549 cells [27]. Therefore, we chose to use the U-251 MG cell line because an astrocyte-derived
cell type may be a more relevant model for ZIKV-induced neuropathology and be better able to
distinguish differences between ZIKV isolates. We found that contemporary ZIKV isolates (from
Puerto Rico and Brazil) appear to have an increase in viral replicative fitness in astrocytoma cells over
a single infectious cycle, with significantly more double-stranded RNA (dsRNA)-positive cells when
compared to pre-epidemic isolates, despite similar numbers of infected cells. Moreover, when we
investigated viral RNA accumulation, we found that the Asian lineage isolates had a substantially
greater proportion of negative-strand intermediates than the African lineage isolate in both A549 and
astrocytoma cells. However, over multiple rounds of infection, the contemporary ZIKV isolates appear
to be impaired in cell spread, infecting a lower proportion of cells, despite the production of similar or
higher titers. Our results suggest that the contemporary ZIKV isolates may have evolved mechanisms
that allow them to replicate with increased efficiency in certain cell types and highlight the importance
of cell-intrinsic factors in studies of viral replicative fitness.
2. Materials and Methods
2.1. Phylogenetic Analysis
Translated amino acid sequences of 50 ZIKV polyproteins (Table S1) were aligned using
ClustalW [28]. Trees were constructed by neighbor joining of pairwise amino acid distances with the
program MEGA7 (according to the distance scale provided) [29]. Bootstrap resampling was used to
determine robustness of branches; values of ≥50% (from 1000 replicates) were used.
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2.2. Cells and Viruses
African green monkey kidney (Vero) cells, human embryonic kidney (293T) cells, human lung
carcinoma (A549) cells, and human astrocytoma (U-251 MG) cells were kindly provided by Martin J.
Richer (McGill University, Montreal, QC, Canada), Connie Krawczyk (McGill University, Montreal,
QC, Canada), Russell Jones (McGill University, Montreal, QC, Canada), and Anne Gatignol (Lady
Davis Research Institute, Montreal, QC, Canada), respectively. All cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% nonessential
amino acids, 1% L-glutamine, and 1% penicillin/streptomycin at 37 ◦C/5% CO2.
An infectious cDNA of ZIKV strain MR-766 (ZIKVAF; Genbank accession: HQ234498.1) was
kindly provided by Matthew Evans (Mount Sinai, NY, USA) [30]. ZIKVAF viral stocks were generated
by transfection of 293T cells with the infectious cDNA using Lipofectamine 2000 (Life Technologies,
Thermo Fisher Scientific, Waltham, MA, USA) followed by a single passage in Vero cells. ZIKV isolate
PLCal_ZV (ZIKVCDN; Genbank accession: KF99378) was generously provided by David Safronetz
(National Microbiology Laboratories, Winnipeg, MB, Canada) [31]. Isolates PRVABC59 (ZIKVPR;
Genbank accession: KU501215) and HS-2015-BA-01 (ZIKVBR; Genbank accession: KX520666) were
provided by Tom Hobman (University of Alberta, Edmonton, AB, Canada) and Mauro Teixeira
(Universidade Federal de Minas Gerais, Belo Horizonte, Brazil), respectively. The passage history of
each ZIKV isolate is described in Table S2.
2.3. ZIKV Infections
A549 and U-251 MG cells were seeded at a density of 4 × 104 cells per well in 12-well plates the
day before infection. Virus was diluted to the indicated MOI in Eagle’s minimum essential medium
(EMEM; Wisent Inc., St-Bruno, QC, Canada) and was allowed to bind to cells for 1 h at 37 ◦C/5% CO2,
after which the inoculum was removed, cells were washed with PBS, and media was replaced with
fresh media containing 15 mM HEPES (Wisent Inc.) and 2% FBS. At the specified time points, the
supernatant was collected and clarified by centrifugation at 4 ◦C for 10 min at 3000× g, and stored at
−80 ◦C prior to titration.
Viral titers were determined by plaque forming unit (PFU) assay on Vero cells. Briefly, 500 μL of
10-fold serial dilutions were incubated for 2 h on Vero cell monolayers in 12-well plates. The virus
inoculum was removed, and the cells were overlaid with DMEM containing 1.2% Carboxymethyl
cellulose (Sigma-Aldrich, Oakville, ON, Canada), 2% FBS, and 1% penicillin/streptomycin. Four
days post-infection, cells were fixed with 5% formaldehyde and stained with 0.1% crystal violet
(Sigma-Aldrich) to visualize plaques.
2.4. Cell Viability
Cell viability was monitored using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium
bromide (MTT) assay similar to what has been previously described [32]. Briefly, cells were plated at
density of 2000 cells per well in flat-bottom 96-well plates and allowed to adhere overnight. Ten wells per
strain were infected with 100 μL of ZIKV diluted to the indicated MOI. At the specified time points, 10 μL
of 5 mg/mL MTT salt (Sigma-Aldrich) in EMEM solution was added to each well and incubated for 4 h
at 37 ◦C, after which 100 μL of 10% SDS in 0.01 M HCl was added per well and the plates were incubated
overnight at 37 ◦C. Absorbance at 550 nm with a reference wavelength of 650 nm was read on a Spark
10M plate reader (Tecan, Männedorf, Switzerland). The average absorbance of 10 wells was used and
viability experiments were carried out in triplicate. The data was expressed in % Cytopathicity, which
was defined as: % Cytopathicity = 100% − ((Uninfected Absorbance − Infected Absorbance)/(Uninfected
Absorbance) × 100%).
62
Viruses 2018, 10, 728
2.5. Flow Cytometry
A549 and U-251 MG cells were seeded at a density of 1 × 106 cells per 15-cm2 plate the day
before infection. Cells were infected with ZIKV at indicated MOI as described above and harvested at
the indicated time points. Prior to fixation, cells were stained with Fixable Viability Dye eFluor 780
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Cells
were fixed using Cytofix/Cytoperm (BD Bioscience, Mississauga, ON, Canada) for 20 min and then
stained with anti-J2 dsRNA (Scicons, Szirák, Hungary) diluted 1:1000, anti-4G2 (Millipore, Etobicoke,
ON, Canada) diluted 1:200, or anti-cleaved Caspase-3 (Cell Signaling, Danvers, MA, USA) diluted
1:800 in PermWash (BD Bioscience) for 1 h followed by secondary staining with goat anti-mouse
Alexafluor 488 or goat anti-rabbit Alexafluor A546 (Thermo Fisher Scientific, Waltham, MA, USA)
diluted 1:300 for dsRNA or 1:500 for 4G2 and Caspase-3 in PermWash. Data were acquired on an
LSRFortessa Analyzer (BD Bioscience) with BD FACSDiva software. Data analysis was performed
using FlowJo software version 10.5 (BD Bioscience, Mississauga, ON, Canada). Debris and doublets
were excluded from the analysis using forward-scatter width discrimination, and the percentage of
dsRNA-, 4G2-, or Caspase-3-positive cells was determined by comparison to mock-infected cells.
2.6. Immunofluorescence Microscopy
A549 and U-251 MG cells were seeded at a density of 2 × 104 cells per well in eight-well chamber
slides the day before infection. Cells were infected with ZIKV at indicated MOI as described above
and harvested at the indicated time points. Cells were fixed in 4% formaldehyde in 1× PBS, washed
three times in PBS, and blocked with 0.3% Triton X-100 and 5% FBS in PBS for 1 h at room temperature.
Samples were incubated with anti-J2 dsRNA (Scicons) diluted 1:1000 in PBS containing 1% BSA and
0.3% Triton X-100 at room temperature for 1 h followed by washing three times in PBS. Samples
were then incubated with goat anti-mouse Alexafluor 488 (Thermo Fisher Scientific) diluted 1:300 in
PBS containing 1% BSA and 0.3% Triton X-100 followed by three PBS washes before mounting with
VectaShield containing DAPI (Cedarlane, Burlington, ON, Canada). Z-stack images were acquired
using a Zeiss AxioObserver inverted microscope with a 63× oil objective. The number of dsRNA foci
per cell was quantified using Imaris version 9.1.2 (Bitplane Inc., South Windsor, CT, USA). Foci of size
0.3 × 0.3 × 4 μm above quality 17.0 were automatically detected using the spot detection function and
manually verified for at least 100 cells per condition.
2.7. Quantitative Reverse-Transcription PCR
Total RNA was extracted from cells using Trizol reagent (Thermo Fisher Scientific) following the
manufacturer’s protocol. Quantification of positive- and negative-strand intracellular viral RNA was
determined by quantitative reverse-transcription PCR (qRT-PCR) on a Bio-Rad CFX96 Touch Real-Time
System using the iTaQ Universal Probe One-Step Kit (Bio-Rad, Mississauga, ON, Canada) with 0.5 μL
of PrimePCR GAPDH primers and probe (HEX, Bio-Rad) per reaction. The primers used to detect
ZIKV RNA were as follows: forward, 5′-CCG CTG CCC AAC ACA AG-3′; reverse, 5′-CCA CTA ACG
TTC TTT TGC AGA CAT-3′; probe, 5′-/56-FAM/AGC CTA CCT/ZEN/TGA CAA GCA ATC AGA
CAC TCA A/3IABkFQ/-3′ [33]. A strand-specific reverse transcription (RT) reaction was carried out
by addition of either the forward or the reverse primer during RT at 50 ◦C for 10 min, after which the
other ZIKV primer and ZIKV probe was added to the reaction. The cycling conditions were: 95 ◦C for
3 min, then 45 cycles of 95 ◦C for 5 s and 60 ◦C for 60 s. The amount of viral RNA was normalized to
GAPDH using the ΔCt method, and compared to a standard curve of log10 (PFU equivalents) which
was extracted from cell culture supernatants [8], using the NucleoSpin RNA virus kit (Macherey-Nagel,
Bethlehem, PA, USA) following the manufacturer’s instructions. The relative amount of positive- and
negative-strand viral RNA was calculated using the 2(−ΔΔCT) method using GAPDH as the internal
control after normalization to the relative PCR efficiencies of the different ZIKV isolates.
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2.8. Statistical Analysis
All statistical analyses were performed using Prism 6 software (GraphPad, San Diego, CA, USA).
At each time point, viral titers from growth curves, % cytopathicity, % infected cells, or viral RNA were
compared using a one-way analysis of variance (ANOVA) with Tukey’s multiple-comparison test.
3. Results
3.1. Phylogenetic and Amino Acid Variance across ZIKV Isolates Selected for Comparative Analyses
Phylogenetic analyses demonstrate that ZIKV can be divided into two main lineages: African and
Asian (Figure S1) [34,35]. The African lineage has caused sporadic infections over the last century, typically
resulting in mild, febrile illness [1]. All of the strains identified in the 2014–2016 epidemic are of the
Asian lineage and are more closely related to the H/PF/2013 French Polynesia strains than the FSM/2007
Micronesia (Yap Island) strain, suggesting that these sub-lineages may have evolved independently from
a common ancestor, anchored by the P6-740 strain (Malaysia, 1966) (Figure S1) [34]. Notably, ZIKV
outbreaks in French Polynesia and South America were the first to be associated with neurological
symptoms, including Guillain-Barré syndrome and fetal microcephaly [4,9,36]. As such, we sought to
perform a comparative analysis of historical and contemporary ZIKV isolates to study the impact of
genetic polymorphisms on viral replicative fitness and cytopathicity in cell culture. We chose a panel
of ZIKV isolates including: Uganda 1947 (MR766, ZIKVAF); an early Asian lineage strain, isolated from
a Canadian traveller whom returned from Thailand viremic in 2013 (PLCal_ZV, ZIKVCDN); and two
isolates from the 2015 outbreaks in Puerto Rico (PRVABC59, ZIKVPR) and Brazil (HS-2015-BA-01, ZIKVBR).
Notably, ZIKVAF was mouse passaged and all of the other viral isolates were passaged through Vero cells
or a combination of Vero and C6/36 mosquito cells (Table S2). A detailed amino acid sequence comparison
of these strains is available in File S1. Comparison of the overall amino acid composition across strains
demonstrates that the maximum amino acid differences are between the ZIKVAF and ZIKVPR isolates
(Table S3). Polymorphisms are located throughout the viral polyprotein; however, several regions (prM, E,
NS2A, NS4B, and NS5 proteins) have a higher accumulation of amino acid polymorphisms, particularly
between the African and Asian lineages (File S1).
3.2. Zika Virus Isolates Display Unique Plaque Morphology and Different Growth Kinetics in Cell Culture
While preparing viral stocks we noticed differences in plaque morphology on Vero cells between
the four ZIKV isolates (Figure 1). Plaques from the historical ZIKVAF were smaller than plaques
from the Asian lineage isolates and were more uniform in size (Figure 1A). Of the Asian lineage
isolates, both ZIKVCDN and ZIKVPR produced plaques with indefinite borders, whereas the plaques
from the ZIKVBR had clearly defined edges (Figure 1A). In order to better characterize each viral
isolate, we investigated strain-specific differences in growth kinetics, cytopathicity, infectivity, and viral
RNA accumulation.
We first sought to determine the viral growth kinetics for each of the four ZIKV isolates
(Figure 1B–E). Viral titers were assessed using both one-step and multi-step growth curves after
infection at an MOI of 10 and 0.01, respectively (Figure 1B–E). At MOI of 10, ZIKVBR grew to
significantly higher titers at 8 h post-infection in both cell types, suggesting that ZIKVBR has an
advantage in terms of growth kinetics (Figure 1B,C). In A549 cells, the increased titer of ZIKVBR was
much less pronounced by 24 h post-infection, at which time the titers of the other isolates have nearly
caught up to within 1-log of ZIKVBR (Figure 1B). In contrast, in U-251 MG cells, ZIKVBR continues to
replicate to significantly higher titers than all other isolates at all time points post-infection, even when
titers have begun to plateau by 24 h post-infection (Figure 1C). Interestingly, the ZIKVBR titers are
already increasing by 8 h post-infection, whereas titers for the other isolates do not increase until after
8 h post-infection based on titers at 0 h [37]. Overall, this suggests that ZIKVBR replicates to higher
titers in U-251 MG cells, with faster replication kinetics over a single infectious cycle.
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Figure 1. ZIKV isolates demonstrate unique plaque morphology and different growth kinetics in A549
and U-251 MG cell lines. (A) Representative images of Vero cell plaque assays of the indicated ZIKV
isolates. (B–E) Cell culture supernatants were collected at the indicated time points and viral titer was
determined by plaque assay. (B) A549 and (C) U-251 MG cells were infected with ZIKV at MOI = 10.
(D) A549, and (E) U-251 MG cells were infected with ZIKV at MOI = 0.01. Values represent mean ± SD
of at least three independent experiments. Asterisks indicate significant differences in viral titer relative
to ZIKVAF: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
To further investigate the differences in viral replication kinetics between isolates, we also performed
a multi-step growth curve at MOI of 0.01 (Figure 1D,E). In A549 cells, although at 48 h post-infection
ZIKVCDN and ZIKVPR have lower titers than ZIKVAF, there are no significant strain-dependent differences
in viral titers at any other time point post-infection (Figure 1D). In contrast, in the U-251 MG cells, ZIKVBR
grew to significantly higher titers at all time points post-infection when compared to all other viral
isolates (Figure 1E). There were no significant differences in viral titers between the remaining isolates
in U-251 MG cells, although ZIKVAF tended to have slightly higher titers than ZIKVCDN and ZIKVPR
(Figure 1E). Overall, the data demonstrates that over multiple rounds of infection, ZIKVBR appears to have
a significant replicative advantage in U-251 MG cells, growing to higher titers than all other ZIKV isolates.
3.3. Cytopathic Effects Induced by ZIKV Isolates in Cell Culture Depends on MOI
We next wanted to determine whether there was a connection between viral particle production
and the ability to induce cytopathic effects (CPE) in cell culture. Using an MTT assay to investigate
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strain-specific differences in cytopathicity, we observed that when cells were infected at MOI of 10, CPE
induced by the four ZIKV isolates was consistent with the viral load (Figure 2). More specifically, in the
A549 cells, all isolates induced similar CPEs with approximately 25% cytopathicity, which represents
a 25% reduction in cell viability at 24 h post-infection (Figure 2A), with similar viral titers at this time
point (Figure 1B). In contrast, in the U-251 MG cells, ZIKVBR was significantly more cytopathic at the
high MOI, inducing approximately 37% cytopathicity compared with an average of 18% cytopathicity
at 24 h post-infection induced by the other ZIKV isolates (Figure 2B). Again, this finding is in good
agreement with the relative viral titers at this time point (Figure 1C). To determine whether CPEs were
apoptosis-driven or due to other forms of cell death, we quantified cleaved caspase-3 positive cells by
flow cytometry at MOI of 10 in both cell types (Figure S2). In A549 cells, apoptosis appears to account for
a small proportion of cell death with 3.5%, 1.9%, and 7.2% cleaved caspase-3-positive cells during ZIKVAF,
ZIKVCDN, and ZIKVPR infection, respectively; however, during ZIKVBR infection approximately 47% of
cells stained positive for cleaved caspase-3 (Figure S2A). In U251-MG cells, a similar pattern was observed
with fewer cells staining positive for cleaved caspase-3 (between 0.6–1.43% for ZIKVAF, ZIKVCDN and
ZIKVPR), whereas approximately 17.1% of cells were cleaved caspase-3-positive during ZIKVBR infection
(Figure S2B). This suggests that, at least for ZIKVAF, ZIKVCDN, and ZIKVPR, apoptosis is not the main
driver of CPEs during ZIKV infection, and thus, other forms of cell death are likely to contribute to this
phenotype. However, apoptosis appears to have a greater contribution to CPEs observed during infection
with ZIKVBR. Taken together, this suggests that over a single infectious cycle, ZIKVBR induces more CPEs
in U-251 MG cells than the other ZIKV isolates, likely due to an increase in apoptosis. In addition, at least
at an MOI of 10, CPEs appear to be directly correlated with the viral titer for all four ZIKV isolates.
Figure 2. ZIKV isolates elicit different cytopathic effects in A549 and U-251 MG cell lines. (A) A549 and
(B) U-251 MG cells were infected with ZIKV at MOI = 10 and cell viability was determined by MTT
assay at 24 h post-infection. (C) A549 and (D) U-251 MG cells were infected with ZIKV at MOI = 0.01
and cell viability was determined by MTT assay 72 h post-infection. % Cytopathicity = 100% −
((Uninfected Absorbance − Infected Absorbance)/(Uninfected Absorbance) × 100%). Values represent
the mean ± SEM of three independent experiments. Asterisks indicate significant differences in %
cytopathicity: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Next, we determined the relative CPEs induced by the four ZIKV isolates over multiple rounds of
infection at a low MOI. In contrast to the high MOI condition, where strain-specific differences in CPE
66
Viruses 2018, 10, 728
were dependent on cell type, at low MOI, the strain-specific trend in CPE was consistent across cell
lines (Figure 2C,D). At 72 h post-infection with MOI 0.01, ZIKVBR induced the least CPEs in both A549
and U-251 MG cells with approximately 2% and 7% cytopathicity, respectively (Figure 2C,D), despite
generating similar or higher titers at this time point (Figure 1D,E). ZIKVPR and ZIKVCDN induced
intermediate CPE in both cell types (approximately 40% and 20% cytopathicity, respectively). However,
ZIKVAF induced the greatest CPE of all isolates at 72 h post-infection at MOI 0.01, with approximately
60% cytopathicity in both A549 and U-251 MG cells (Figure 2C,D). Taken together, these results suggest
that although ZIKVBR appears to have a replicative advantage that is more pronounced in astrocytoma
cells, this advantage is likely due to increased viral replication in the initial infection rather than to
increases over subsequent rounds of infection. As this could imply differences in cell spread across the
ZIKV isolates, we next wanted to assess the percentage of infected cells across isolates.
3.4. Flow Cytometry Analysis Reveals Strain-Specific Differences in Viral Infectivity and Cell Spread
Due to the discrepancies in CPEs elicited at different MOIs, we set out to determine the percent of
ZIKV-infected cells at high and low MOI using flow cytometry (Figure 3 and Figure S3). We initially
determined the % infected cells by staining for the envelope glycoprotein using a pan-flavivirus (4G2)
antibody (Figure 3A,B). At MOI 10, ZIKVCDN infected a lower proportion of A549 cells (36%) when
compared to ZIKVAF (82%) and ZIKVPR (61%) at 24 h post-infection (Figure 3A). A similar trend was
observed in the U251-MG cells, where ZIKVAF, ZIKVCDN, and ZIKVPR infected 88%, 60%, and 72% of
cells, respectively (Figure 3B). However, we were unable to detect ZIKVBR using the envelope antibody
in either cell line. Given that viral epitopes may have changed over the course of the viral evolutionary
history, we stained for dsRNA as a marker for active viral replication, to ensure similar sensitivity of
detection across all isolates. At MOI 10, we detected significantly more dsRNA in a higher proportion
of A549 cells during ZIKVPR infection (40%), whereas only approximately 7% of A549 cells were
dsRNA-positive in the other three isolates (ZIKVAF, ZIKVCDN, and ZIKVBR) at 24 h post-infection
(Figure 3C). In the U251-MG cells, the rate of infection was similar to that in A549 cells for ZIKVAF and
ZIKVCDN, with approximately 10% and 6% dsRNA-positive cells, respectively (Figure 4D). However,
for both the contemporary isolates (ZIKVPR and ZIKVBR), a significantly higher percentage of cells
were dsRNA-positive in U-251-MG cells, with approximately 36% and 51% dsRNA-positive cells,
respectively (Figure 3D). These results suggest that ZIKVPR may induce more viral RNA replication (as
indicated by dsRNA staining) than ZIKVAF and ZIKVCDN, since all three isolates display a similar %
of infected cells when staining for the viral envelope, but vastly different amounts of dsRNA-positive
cells. This may also be true for ZIKVBR, which had a similar percentage of dsRNA-positive cells;
however, we were not able to assess the % infected cells for this isolate using the envelope antibody.
Taken together, these results suggest that over a single infectious cycle, ZIKVPR infection results in a
greater proportion of dsRNA-positive cells in both cell types, while ZIKVBR selectively induces more
dsRNA-positive cells in U-251 MG cells.
At the low MOI (0.01), the trend in % of dsRNA-positive cells closely mirrored the trend in
cytopathicity (Figure 2 and Figure S3). At 72 h post-infection at MOI 0.01, ZIKVAF has the highest %
of dsRNA-positive cells in both the A549 and U-251-MG cells, with 30% and 15% dsRNA-positive
cells, respectively (Figure S3A,B). All of the other ZIKV isolates had a lower % dsRNA-positive cells
in both cell types (Figure S3A,B), consistent with the intermediate or low CPEs observed at this MOI
(Figure 2C,D). However, dsRNA staining is likely an underestimation the % infected cells if the viral
isolates do not induce high levels of dsRNA. Nonetheless, these results suggest that although ZIKVBR,
and possibly also ZIKVPR, appear to have a replicative fitness advantage over a single infectious cycle
that is more pronounced in astrocytoma cells, they appear to be impaired in cell spread when subjected
to multiple rounds of infection at low MOI.
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Figure 3. Contemporary ZIKV isolates induce more dsRNA than pre-epidemic isolates, despite similar
numbers of infected cells. (A) A549 and (B) U-251 MG cells were infected with ZIKV at MOI = 10 and
at 24 h post-infection cells were stained with the pan-flavivirus (4G2) antibody and the percentage of
infected cells was determined by flow cytometry. (C) A549 and (D) U-251 MG cells were infected with
ZIKV at MOI = 10 and 24 h post-infection the percentage of dsRNA-positive cells was determined by
flow cytometry. The percentage of positive cells was determined by comparison to mock-infected cells.
Values represent mean ± SEM of at least three independent experiments. Asterisks indicate significant
differences in % infected cells: * p < 0.05, ** p < 0.01, *** p < 0.001.
3.5. The Number of dsRNA Foci and Ratio of Negative- to Positive-Strand RNA Differ across African and
Asian Lineage Isolates
We next wanted to determine whether the increase in the % of dsRNA-positive cells observed
during ZIKVPR and ZIKVBR infection was due to an increased number of replication complexes
induced per cell. Thus, we quantified the number of dsRNA foci by immunofluorescence microscopy
and image analyses at MOI of 10 in A549 and U-251 MG cells (Figure 4A,B). In A549 cells, ZIKVAF
yielded the greatest number of dsRNA foci per infected cell, with on average >250 dsRNA foci/cell,
while the Asian lineage isolates had, on average, approximately 124–166 dsRNA foci/cell (Figure 4C).
In contrast, in the U-251 MG cells, the Brazilian isolate had the greatest number of dsRNA-positive
foci, with >225 dsRNA-positive foci/cell, while all other isolates had <100 dsRNA foci/cell on average
(Figure 4D). To further confirm these findings, we calculated the mean fluorescence intensity (MFI) of
dsRNA-positive cells by flow cytometry (Figure 4E,F). The MFI revealed similar fluorescent intensities
across ZIKV isolates in A549 cells, with the exception of ZIKVPR, which were significantly more intense
in this cell type (Figure 4E). Moreover, in U-251 MG cells, the contemporary isolates displayed a
higher MFI for dsRNA-positive cells, suggesting that there were greater amounts of dsRNA per cell
(Figure 4F). Taken together, this suggests that although the ZIKVAF isolate induced more dsRNA
foci in A549 cells, they were on average of low fluorescence intensity. In contrast, in U-251 MG cells,
ZIKVBR produced substantially more dsRNA-positive foci, and together with ZIKVPR, the foci were
brighter than those of the ZIKVAF and ZIKVCDN isolates. However, we cannot rule out the existence
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of a larger proportion of small dsRNA foci in these cells as our image analysis relied on a minimum
foci size (0.3 × 0.3 × 4 μm) for quantification.
Figure 4. Isolate-specific differences are observed in number and fluorescence intensity of dsRNA
foci in infected cell. (A) A549 and (B) U-251 MG cells were infected with ZIKV at MOI = 10 and 24 h
post-infection dsRNA expression was analyzed by immunofluorescence microscopy. Scale bar, 20 μm.
The number of dsRNA foci per cell in (C) A549 and (D) U-251 MG cells was quantified using Imaris
software (>100 cells/condition). (E) A549 and (F) U-251 MG cells were infected with ZIKV at MOI = 10
and 24 h post-infection the mean fluorescence intensity (MFI) of dsRNA-positive cells was determined
by flow cytometry. Values represent mean ± SEM of at least three independent experiments. Asterisks
indicate significant differences: * p < 0.05, ** p < 0.01, *** p < 0.001.
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Finally, to further investigate whether the number and brightness of dsRNA foci was related to
an increase in viral replication, we also quantified negative- and positive-strand viral RNA (vRNA)
by qRT-PCR analyses (Figure 5). Given that three of the ZIKV isolates used in this study are patient
isolates and therefore we are not able to determine absolute vRNA copy numbers using a standard
curve of in vitro-transcribed RNA, we quantified positive-strand vRNA relative to a standard curve
of vRNA from ZIKV stocks of known titer (log PFU equivalents) as has been done previously [8].
While ZIKVCDN produced less positive-strand vRNA than ZIKVAF in A549 cells, possibly due to the
lower proportion of ZIKVCDN-infected cells (Figure 3A), there were no other statistically significant
differences in intracellular positive-strand vRNA across ZIKV isolates in either cell type. This indicates
that all of the ZIKV isolates produce similar levels of intracellular positive-strand vRNA after infection
at high MOI.
Figure 5. Asian lineage ZIKV isolates induce a higher ratio of negative:positive strand RNA. (A) A549
and (B) U-251 MG cells were infected with ZIKV at MOI = 10 and 24 h post-infection intracellular
positive strand viral RNA was quantified by qRT-PCR. Data are normalized to GAPDH and expressed
relative to a standard curve of PFU equivalents per ng input RNA. (C) A549 cells and (D) U-251 MG
cells were infected with ZIKV at MOI = 10 and 24 h post-infection the relative amounts of positive
and negative strand ZIKV genomes was quantified by qRT-PCR. Data are expressed as a ratio of
negative:positive strand RNA. Values represent mean ± SEM of two or three independent experiments.
Asterisks indicate significant differences: * p < 0.05, ** p < 0.01.
Next, we wanted to determine the relative amount of the replicative intermediate, negative-strand
vRNA (Figure 5C,D). Interestingly, on average ZIKVAF produced approximately one copy of
negative-strand intermediate vRNA for every 100 positive-strand vRNAs in both A549 and U-251
MG cells. In contrast, the Asian lineage isolates produced 1.9 to 2.6 negative strands for every 100
positive-strand vRNAs in A549 cells, and 2.2 to 3.9 negative-strands for every 100 positive strands in
U-251 MG cells. This indicates that approximately 1.8 to 4.5-fold more negative-strand intermediate
RNA is produced during infection with Asian lineage isolates when compared with ZIKVAF. Taken
together, this data suggests that the Asian lineage isolates are able to produce more negative-strand
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intermediate vRNA than the African lineage isolate, and that the contemporary isolates, particularly
ZIKVBR, induce more dsRNA in U-251 MG cells.
4. Discussion
The recent expansion of the previously obscure ZIKV beyond its historical endemic range in
equatorial Africa and Southeast Asia has piqued scientific and public health interest in emerging viral
diseases. Phylogenetic analyses and investigations into recently acquired genetic polymorphisms
suggest that recent evolutionary changes may have contributed to the rapid emergence and novel
neurological pathogenesis observed in contemporary ZIKV outbreaks in the Americas [1,18]. In this
study, we selected four ZIKV isolates from different points in its phylogenetic history (Figure S1) and
compared viral replicative fitness in human lung carcinoma (A549) and human astrocytoma (U-251
MG) cell lines. We compared two ZIKV isolates from the 2015–2016 outbreaks in Puerto Rico and
Brazil (ZIKVPR and ZIKVBR) to an earlier Asian lineage isolate (ZIKVCDN) and the historical Uganda
1947 reference isolate (ZIKVAF). We found that Asian lineage isolates produce more negative-strand
intermediate vRNA, and that the contemporary ZIKV isolates, and in particular ZIKVBR, produce more
dsRNA and significantly higher viral titers over a single infectious cycle (which was more pronounced
in U-251 MG cells), although these contemporary isolates may be impaired in cell spread over multiple
infectious cycles.
Several groups have shown strain-dependent differences in ZIKV infection in cell culture and
mouse models of infection, albeit with conflicting results [38]. Our data suggests that strain-dependent
differences in viral replicative fitness are highly dependent on both cell type and the MOI used,
which may explain some of these discrepancies in the literature. For example, several groups have
demonstrated enhanced infectivity and replication by contemporary American ZIKV isolates, similar
to what we observed herein at high MOI [39,40]. In contrast, other groups have shown that African
lineage ZIKV isolates display higher infectivity and increased cytopathicity in cell culture than Asian
lineage isolates when low MOIs (≤1) were used, where few cells are predicted to be infected, similar
to what we observed herein [41–44]. Although it is postulated that the highly-passaged African
lineage isolate (MR766) may not accurately represent the phenotype of circulating African lineage
ZIKV isolates, it should be noted that a recent study suggests that MR766 behaves similarly to other
low-passage African lineage isolates in cell culture, and that all African lineage ZIKV isolates tested
were more cytopathic than Asian lineage isolates at low MOIs [42]. The observed trend in relative
CPEs is consistent with our flow cytometry data and the viral titers observed herein, suggesting that
there is not an inherent difference in cytopathicity of the four ZIKV isolates, but rather CPE elicited is a
consequence of active viral replication. Notably, we found that apoptosis does not appear to be the
main driver of cell death during infection, with the exception of ZIKVBR, which induced substantially
more cleaved caspase-3 positive cells in both cell types. Moreover, we found that ZIKV infection
induced more apoptosis in A549 cells than the U-251 MG cells, which is consistent with a recent study
that suggests that human fetal astrocytes are resistant to ZIKV-induced apoptosis [16]. However, we
cannot rule out the possibility that apoptosis may be more prevalent at later time points post-infection,
as a recent study suggests a higher proportion of activated caspase-3 positive cells at later time points
in both A549 cells and human fetal astrocytes with proportions similar to what we report here at earlier
time points [16].
In addition, our data suggests that contemporary ZIKV isolates may be impaired in cell spread
when compared with the African and early Asian ZIKV isolates, resulting in lower CPE in cell culture
when infected at a low MOI. Several factors may contribute to this reduced infectivity and our results
do not exclude the possibility that reduced viral binding may account for the differences in cell
spread. Correspondingly, a recent study suggests that the structural proteins of a Brazilian ZIKV
isolate are impaired in their ability to initiate an infection [41]. Moreover, it is also possible that
the increased viral replication induced by the contemporary isolates in the initial round of infection
induces a more robust antiviral response in bystander cells, which then restricts viral spread. Further
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research into strain-dependent differences in induction of innate immune responses may thus help to
elucidate mechanisms by which the antiviral response is able to restrict ZIKV infection and whether
the contemporary isolates are altered in their abilities to counter host antiviral defenses.
Interestingly, we noticed that both the contemporary isolates induced significantly higher amounts
of dsRNA in the U-251 MG astrocytoma cells, while ZIKVBR specifically was able to replicate to
significantly higher titers in these cells. Moreover, the contemporary isolates had a higher MFI of
dsRNA-positive cells, with ZIKVBR in particular having a greater number of dsRNA foci per cell
in the astrocytomas. Further quantification of positive- and negative-strand vRNA during infection
revealed that the Asian lineage isolates generate more negative-strand replicative intermediate RNA
than the African lineage isolate. Overall, this data supports the hypothesis that Asian lineage isolates
may have a higher replicative fitness in astrocytoma cells. This is supported by the greater ratio of
negative-strand replicative intermediate vRNA, and greater amounts of dsRNA foci per cell, as well
as the significant increase in titer observed in ZIKVBR in this cell type (which correlates well with
the increase in negative-strand vRNA and dsRNA foci). On the other hand, it could be argued that
ZIKVAF may have the replicative advantage since it produces similar levels of positive-strand vRNA
from fewer negative-strand intermediates; however, this does not appear to translate into higher viral
infectious titers for this isolate. In addition to the higher infectious titers observed in ZIKVBR infection,
it is also possible that, consistent with the greater amount of dsRNA-positive cells during ZIKVPR
infection, this isolate may also mirror the increase in titer observed at later time points post-infection.
However, our data suggests that ZIKVPR titers have plateaued by 24 h post-infection at MOI 10 in
both cell types (Figure 1B,C). As such, ZIKVBR may have an additional advantage over ZIKVPR in
a post-replication step of the viral life cycle. In addition to the kinetic advantage ZIKVBR has over
a single infectious cycle, this isolate also appears to have a viral replicative fitness advantage over
the other ZIKV isolates at low MOI when fewer cells are infected. The similar or higher viral titers
produced by ZIKVBR at the low MOI implies more infectious particles are released per cell during
infection with this isolate. However, the higher titers of ZIKVBR observed in the multistep growth
curve, even when the % infected cells are low, may be due to compounded differences in replication
kinetics over several rounds of viral replication.
An increase in viral replicative fitness of contemporary ZIKV isolates in astrocyte-derived cell
types may translate into more severe neurological pathogenesis over the course of an infection.
A current perspective on the neurotropic potential of ZIKV suggests that infected macrophages could
potentially carry the virus into the developing brain through a “Trojan-horse” mechanism [45]. Once the
virus is in the brain, other investigations conducted in mice and primary human tissue samples suggest
that ZIKV preferentially infects astrocytes [16,25,26]. In concordance with these studies, all of the
ZIKV isolates examined herein were able to efficiently infect and replicate in human astrocytoma cells.
This affinity for astrocytes is likely due to their high expression of AXL, a putative receptor for ZIKV,
which interacts with Gas6 to promote ZIKV infection [46,47]. Thus, examining the differential affinity
displayed by different isolates in binding to the AXL/Gas6 viral entry receptor(s) may help to further
elucidate the mechanism by which the contemporary strains elicit increased infection kinetics.
Taken together, our data suggests that the contemporary American ZIKV isolates may have evolved
mechanisms to increase viral replication and/or infectious particle production in astrocyte-derived cell
types. Furthermore, our comparative analysis in human lung carcinoma (A549) and astrocytoma (U-251
MG) cells further highlights the importance of cell-intrinsic factors in studies of ZIKV replicative fitness.
Although similar levels of positive-strand intracellular vRNA were observed across isolates, the Asian
lineage isolates had substantially more negative-strand replicative intermediate vRNA when compared
with the African lineage isolate, suggesting that the Asian lineage isolates may have a greater replicative
fitness. The strain-specific differences in ZIKV replication were more pronounced in astrocytoma
cells than in the lung carcinoma cells, and thus, the U-251 MG astrocytoma cells may serve as a more
appropriate cell culture model for investigating isolate-dependent differences in ZIKV replicative
fitness. However, it is important to note that with the exception of ZIKVAF, which was derived from an
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infectious cDNA, all other isolates were low passage patient isolates and, hence, we cannot rule out the
possibility that they may harbor additional mutations resulting from adaptation to and/or propagation
in cell culture. Thus, further investigations of these strain-specific polymorphisms that contribute to the
observed differences in viral replicative fitness will be conducted by introduction of polymorphisms
into infectious cDNAs that are now available for some of the isolates used herein [30,48]. Moreover,
thorough investigation of cell-type-specific responses to infection may help elucidate the propensity for
ZIKV to invade placental and neural tissues. Future studies must therefore consider the relationship
between cell-intrinsic and strain-specific factors when examining ZIKV-host interactions.
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Abstract: Background: Zika virus is a mosquito-borne flavivirus responsible for recent outbreaks
of epidemic proportions in Latin America. Sexual transmission of the virus has been reported in
13 countries and may be an important route of infection. Sexual transmission of ZIKV has mostly
been male-to-female, and persistence of viral RNA in semen for up to 370 days has been recorded.
The susceptibility to ZIKV of different testicular cell types merits investigation. Methods: We infected
primary Sertoli cells, a primary testicular fibroblast Hs1.Tes, and 2 seminoma cell lines SEM-1 and
TCam-2 cells with ZIKV Paraiba and the prototype ZIKV MR766 to evaluate their susceptibility and
to look for viral persistence. A human neuroblastoma cell line SK-N-SH served as a control cell type.
Results: Both virus strains were able to replicate in all cell lines tested, but ZIKV MR766 attained
higher titers. Initiation of viral persistence by ZIKV Paraiba was observed in Sertoli, Hs1.Tes, SEM-1
and TCam-2 cells, but was of limited duration due to delayed cell death. ZIKV MR766 persisted
only in Hs1.Tes and Sertoli cells, and persistence was also limited. In contrast, SK-N-SH cells were
killed by both ZIKV MR766 and ZIKV Paraiba and persistence could not be established in these cells.
Conclusions: ZIKV prototype strain MR766 and the clinically relevant Paraiba strain replicated in
several testicular cell types. Persistence of ZIKV MR766 was only observed in Hs1.Tes and Sertoli cells,
but the persistence did not last more than 3 or 4 passages, respectively. ZIKV Paraiba persisted in
TCam-2, Hs1.Tes, Sertoli and SEM-1 cells for up to 5 passages, depending on cell type. TCam-2 cells
appeared to clear persistent infection by ZIKV Paraiba.
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1. Introduction
Zika virus (ZIKV) is a mosquito-borne flavivirus originally described in captive Macaca mulatta
monkeys in Uganda [1]. ZIKV recently caused an outbreak of epidemic proportions in Latin American
countries and was associated with devastating microcephaly in neonates that contracted the infection
in utero [2]. Other complications of ZIKV are varied and include Guillian Barre syndrome [3–6].
Although ZIKV is primarily transmitted by Aedes mosquito bites, sexual transmission is now
well-documented. The first description of sexual transmission is probably that of 2 American scientists
who were bitten by Aedes mosquitoes while working in Senegal in 2008 [7]. The male transmitted ZIKV
to his wife and she presented clinical signs of disease consistent with ZIKV infection [7]. Additional
recent reports described infection in partners following travel to outbreak regions [8,9]. An interesting
example is that of an asymptomatic French couple who were only diagnosed when they sought assisted
reproductive health services after returning from the French island of Martinique [8]. Most of the
sexual transmission cases reported have been male-to-female, but a suspected female-to-male case has
been reported [10]. To date, 13 countries have documented sexual transmission of ZIKV [11]. In the US
in 2016, 47/5168 ZIKV cases were attributed to sexual transmission [12], whereas 8/451 cases could
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have been sexually transmitted in 2017 [13]. Thus, sexual transmission may be an important route
of acquiring infection although it would be difficult to assess such transmission in the face of a large
vector-borne outbreak [14].
The testes are male organs that contain germ cells which differentiate into mature spermatozoa.
Sertoli cells are interspaced between germinal epithelial cells and provide support for the germ cells. Leydig
cells are irregularly shaped interstitial cells that produce the hormone testosterone. Sexual transmission
of ZIKV by males and the presence of virus in semen suggests that cells in the male genitourinary
tract are infected [15]. Animal studies have also shown that the testes are infected with various
consequences, including testicular atrophy with implications in male fertility [16,17]. Virus was
reported to be mainly in the interstitial Leydig cells and Sertoli cells, but this varied from study
to study [16,18,19]. Govero and colleagues showed that Sertoli cells detached from the basement
membrane and that there was a decline in the germ cell population in ZIKV infected mice [17].
Thus, the different cells in the testes may play different roles in harboring virus for transmission or
pathogenesis, which leads to the destruction of organ integrity.
In this paper, we infected several human testicular cells lines to evaluate the extent to which the
cells permitted ZIKV replication in vitro; primary Sertoli cells, a primary testicular fibroblast Hs1.Tes
and the 2 seminoma cell lines SEM-1 and TCam-2. The infection in the testicular cell lines was compared
to infection in a human neuroblastoma cell line SK-N-SH. We were also interested in determining if
ZIKV would persist in any of these cell lines. Our results showed that ZIKV differentially infected
the testicular cell lines tested and could persist in some cells in a strain-dependent manner. Delayed
apoptotic cell death was observed during viral persistence, thus limiting duration of persistence to 5
passages at most.
2. Materials and Methods
2.1. Viruses and Cells
The Ugandan ZIKV strain MR766 were generously provided by Dr. Stephen Whitehead
(Laboratory of Infectious Disease, NIAID/NIH). The Brazilian ZIKV Paraiba was isolated by Dr. Pedro
F.C Vasconcelos, Instituto Evandro Chagas, Brazil and it was a kind gift from Dr. Stephen Whitehead
(Laboratory of Infectious Disease, NIAID/NIH). Virus stocks were prepared by infecting Vero (ATCC)
cells and harvesting the supernatants 3 days post infection. Virus in the supernatants was semi-purified
by ultracentrifugation over a 20% sucrose solution, followed by quantification using a plaque assay on
Vero cells.
The neuroblastoma SK-N-SH cell line [20] was purchased from ATCC and maintained in
antibiotic-free Eagle’s minimum essential medium (EMEM; Gibco, Hampton, NH, USA) containing 10%
fetal bovine serum (FBS). Fibroblast Hs1.Tes cells (ATCC) and the TCam-2 seminoma cell line (a kind
gift from Dr. Constantine Stratakis, NICHD/NIH) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS and 1× antibiotic-antimycotic (Gibco). Doubling time
for the TCam-2 seminoma cell line in culture is approximately 50 h. Sertoli cells (Lonza, Basel,
Switzerland) were grown in DMEM/F12 medium with 10% FBS and penicillin/streptomycin (Gibco)
and the cells grow to confluence in 7–10 days when seeded at 450–500 cells/cm2. SEM-1 seminoma
cells were a kind gift from Dr. Alan Epstein (USC Keck School of Medicine, Los Angeles, CA, USA),
and they were maintained in RPMI 1640 (Gibco/ThermoFischer) supplemented with 10% FBS and
penicillin/streptomycin. SEM-1 cell doubling time is 50 h.
2.2. ZIKV Infection
Two million cells were seeded in 75 cm2 flasks a day before the infection and allowed to grow
at 37 ◦C and 5% CO2. ZIKV infections with either MR766 or Paraiba strains were performed at
a multiplicity of infection of 0.1 with adsorption at 37 ◦C and rocking for 1 h. All infections were
performed in triplicate (biologically independent replicates). The inoculum was removed, and cells
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were washed 3 times with phosphate buffered saline (PBS; Gibco). Twenty mL of the appropriate
cell culture medium was added prior to incubation at 37 ◦C and 5% CO2. Supernatant aliquots were
removed daily for 7 days and stored at −80 ◦C until virus titration. The infected cells were also
microscopically observed daily for the development of cytopathic effect (CPE). At 7 dpi, intact cell
monolayers were washed twice in PBS, trypsinized and passaged at 1:10 in new flasks with fresh
culture media.
2.3. ZIKV Titration by Immunofocus Assay
Supernatants from infected cultures were harvested at different time points post infection. Serial
10-fold dilutions were carried out and 250 μL of each dilution was plated onto confluent Vero cells
(ATCC) in 12-well plates. Each dilution was plated in duplicate. ZIKV was adsorbed for 1 h at 37 ◦C
with rocking, followed by washing twice with PBS. The infected monolayer was overlaid with DMEM
containing 0.8% methylcellulose, 2% FBA and antibiotics. Plates were incubated at 37 ◦C for 3 days
after which the overlay was removed, and the cells were washed with PBS twice. The cells were fixed
with 100% methanol for 15 min, washed twice with PBS and probed with an anti-ZIKV E antibody
(BioFront Technologies, Tallahassee, FL, USA) at a 1:1000 dilution. Cells in the primary antibody were
incubated at 37 ◦C for 1 h. Following primary antibody incubation, cells were washed twice with PBS
and an anti-mouse secondary antibody (Dako, Santa Clara, CA, USA) was added at a 1:1000 dilution
and incubated with the cells at 37 ◦C for 1 h. Next, the cells were washed twice with PBS followed by
development of immunofoci with a diaminobenzidine/peroxide substrate (Sigma-Aldrich, St. Louis,
MO, USA) and enumeration.
2.4. Monolayer Staining with Giemsa Stain
To visualize the cytopathic effect of ZIKV on infected cell monolayers, cells were washed twice
in PBS and fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature. The PFA was
aspirated followed by washing twice with PBS. Cells were stained with a 1:5 Giemsa stain for 30 min.
The stain was removed, and cells were washed twice with PBS and imaged using an AxioVert.A1
microscope equipped with Zeiss Axiocam 503 monochromatic camera.
2.5. Immunofluorescence Microscopy
ZIKV-infected Sertoli cells at P1 were plated into a 4-well chamber slide at 1 × 104 cells/well
and allowed to attach overnight at 37 ◦C in 5% CO2. The medium was aspirated, and cells were
washed twice with PBS. The cells were fixed with 4% paraformaldehyde/5% sucrose in PBS for 10 min.
The fixed cells were permeabilized with 0.1% Triton X/4% PFA in PBS for 10 min with shaking.
Aldehydes were quenched using 50 mM glycine for 10 min. Blocking was done with 2% bovine
serum albumin for 1 h. Cells were probed with a mouse anti-ZIKV E monoclonal antibody (BioFront
Technologies) at 1:1000 dilution, and a rabbit anti-cleaved caspase 3 (BD Biosciences, San Jose, CA,
USA) at 1:1000 dilution. The primary antibodies were detected with anti-mouse (conjugated with Alexa
Flour 647) and Alexa Flour 488-conjugated anti-rabbit antibodies (Invitrogen, Carlsbad, CA, USA).
Images were captured using a Laser Scanning Microscope (LSM) 710 (Zeiss, Oberkochen, Germany) at
40× magnification.
3. Results
3.1. ZIKV Infection of the Fibroblast Hs1.Tes Cell Line
The Hs1.Tes cell line is a fibroblast which represents testicular connective tissue. Both ZIKV
MR766 and Paraiba strains were able to infect this cell line in culture, and ZIKV MR766 replicated to
higher titers than ZIKV Paraiba (Figure 1). The ZIKV MR766 titer peaked to 1.8 × 107 ffu/mL at 4 dpi,
whereas ZIKV Paraiba titers peaked to 1.0 × 106 at 5 dpi (Figure 1). Infection of Hs1.Tes cells with
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either ZIKV Paraiba or ZIKV MR766 did not result in any obvious cytopathic effect (CPE) by 7 dpi
(Figures 2 and 3).
To determine if ZIKV could persist in Hs1.Tes fibroblast cell line, we passaged the ZIKV
infected cells after 7 dpi. Infectious ZIKV Paraiba and ZIKV MR766 was recovered from the Hs1.Tes
supernatants at each passage for 3 passages, suggesting that ZIKV could persist in these cells (Figure 4).
However, we observed a decline in the cell population upon passage each, suggesting delayed and
slowly progressive cell death and a 4th passage was not possible (Figure 5a,b). Thus, the duration of
ZIKV persistence in Hs1.Tes cells was limited by continued cell death.
Figure 1. Replication kinetics of ZIKV MR766 and Paraiba over the course of 7 days. Error bars
represent standard deviation (SD) from the mean for 3 independent replicates.
3.2. ZIKV Infection of Sertoli Cells
Sertoli cells are testicular cells, which support the germ cells. In culture, we observed that these
cells were also permissive to infection by both ZIKV Paraiba and MR766 strains, which replicated to
maximal titers at 4 and 5 dpi, respectively (Figure 1). The ZIKV Paraiba titers did not proceed beyond
106 ffu/mL for 7 dpi, but MR766 titers neared 107 ffu/mL at 5 dpi. Similar to Hs1.Tes cells, infection of
Sertoli cells with ZIKV Paraiba did not cause an observable cytopathic effect (CPE) by 7 dpi (Figure 2),
but ZIKV MR766 caused minimal CPE which was observed at 7 dpi (Figure 3).
After 7 dpi, we passaged Sertoli cells infected with either ZIKV Paraiba or ZIKV MR766 and
observed that ZIKV Paraiba persistently infected Sertoli cells for up to 5 passages before the delayed
cell death, like that observed in Hs1.Tes cells, rendered the cells unfit for a 6th passage. Detection of
cleaved caspase 3 by immunofluorescence (Figure 5c) suggested that cell death was via apoptosis.
We also observed that not all ZIKV-infected cells stained positive for cleaved caspase 3 (Figure 5c).
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The progressive cell death was accompanied by a decline in the ZIKV Paraiba titers from 1.0 × 106
ffu/mL at passage 1, to 1.5 × 104 ffu/mL at passage 5 (Figure 4). ZIKV MR766 infection persisted in
Sertoli cells for only 4 passages and the viral titers were constant at ~105 ffu/mL from passage 1 to
passage 3, but the titer declined to 1.6 × 104 at the 4th passage (Figure 4).
Figure 2. Microscopic evaluation of testicular cell lines infected with ZIKV Paraiba. No obvious
cytopathic effect was observed in all testicular cell lines infected with ZIKV Paraiba. Images were
captured at a magnification of 400×.
Figure 3. Cytopathic effect of ZIKV MR766 on testicular cell lines at 7 dpi. We noted that ZIKV
MR766-infected Sertoli and SEM-1 cells appeared smaller than uninfected controls. TCam-2 and
Hs1.Tes cells did show any CPE at 7 dpi. Images were obtained at a magnification of 400×.
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Figure 4. ZIKV titers in persistently infected testicular cell lines. The clinical isolate ZIKV Paraiba was
able to persist in all cell lines tested for up to 5 passages (P1 through to P5), depending on cell line.
ZIKV MR766 was only able to persist in Sertoli and Hs1.Tes cells. Virus titration was performed using
supernatants collected at the end of each 7-day period and each data point represents an average of 3
biological replicates. Error bars represent standard deviation from the mean. Each passage was done
after 7 days by washing the monolayer twice with PBS, trypsinizing the cells and seeding into new
flasks with fresh culture medium at 1:10.
Figure 5. Cont.
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Figure 5. Analysis of continued cell death in ZIKV-infected testicular cells. (a) Cell count graph
showing that there were 2-times more cells in the uninfected Hs1.Tes control, compared to ZIKV
Paraiba-infected Hs1.Tes cells at P1. For both control and ZIKV-infected cells, the count was done
after 7 days of cell passage. ****, p < 0.0001 (unpaired t-test). (b) Microscopic images showing loss
of the Hs1.Tes monolayer in ZIKV-infected cells at P3. The morphology of infected cells at this time
point appeared grossly aberrant and pleomorphic when compared to that of uninfected control cells.
Cells were imaged at a magnification of 400×. (c) Confocal microscopy images showing cleaved
caspase 3 in some ZIKV-infected Sertoli cells at P1. Not all ZIKV E protein-expressing cells stained
positive for cleaved caspase 3, supporting the notion that cell death in persistently infected cells was
progressive. Cells were imaged at a magnification of 400×.
3.3. ZIKV Infection of Seminoma Cell Lines
TCam-2 cells are a germ cell seminoma cell line, and SEM-1 cells are a testicular cell line which
is an intermediate between a non-seminoma and a true seminoma [21,22]. Compared to all cell
lines tested, SEM-1 seminoma cells supported the highest titers of both ZIKV MR766 and ZIKV
Paraiba replication (Figure 1). The ZIKV MR766 titer peaked to 7.1 × 107 at 4 dpi, whereas the peak
ZIKV Paraiba titer was attained at 7 dpi (Figure 1). Interestingly, the ZIKV replication graph in
SEM-1 cells suggested that ZIKV Paraiba was still replicating upwards of the peak attained at 7 dpi.
No obvious CPE was observed in ZIKV Paraiba-infected SEM-1 cells (Figure 2), but ZIKV MR766
caused notable cell death by 7 dpi and the infected cells appeared smaller in comparison to uninfected
controls (Figure 3). Upon a single passage, ZIKV MR766 infection induced a lytic crisis in SEM-1
seminoma cells. The culture of ZIKV MR766 infected cells did not recover, and thus, a persistent ZIKV
MR76 6 infection of SEM-1 cells could not be established. However, a persistent ZIKV Paraiba infection
was maintained in SEM-1 cells up to 5 passages (Figure 4).
In TCam-2 seminoma cells, ZIKV titers peaked at 4 dpi, with the MR766 strain at 3 × 106 ffu/mL
and the Paraiba strain at 1.4 × 105 ffu/mL (Figure 1). By 7 dpi, ZIKV MR766 and ZIKV Paraiba titers
declined to 6 × 104 ffu/mL and 4 × 103 ffu/mL, respectively. Interestingly, both ZIKV strains did not
cause any CPE in TCam-2 cells by 7 dpi (Figures 2 and 3). Although ZIKV Paraiba persisted in TCam-2
cells for 4 passages, ZIKV MR766 killed the cells upon passage into P1, suggesting a strain-dependent
delayed cell death mechanism.
3.4. ZIKV Infection in a Human Neuroblastoma SK-N-SH Cell Line
Our laboratory has previously reported infection of the human neuroblastoma SK-N-SH cell
line [23]. We used the SK-N-SH cells to compare ZIKV infection in testicular cells lines, and to
determine if ZIKV would also persist in these cells. ZIKV MR766 replicated to higher titers than ZIKV
Paraiba (Fig 6a) as expected [23]. Infection of SK-N-SH cells with either ZIKV MR766 or ZIKV Paraiba
resulted in extensive CPE by day 4 or 5, respectively (Figure 6b). Following the lytic crises, the few
remaining cells (Figure 6b) died a few days after media replenishment. Thus, no persistent ZIKV
infection of SK-N-SH cells could be established.
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Figure 6. ZIKV infection in a human neuroblastoma SK-N-SH cell line. (a) Replication kinetics of ZIKV
MR766 and Paraiba strains in SK-N-SH cells. Error bars represent SD from the mean for 3 independent
experiments. (b) Cell death in SK-N-SH cell monolayers infected with ZIKV Paraiba or ZIKV MR766.
ZIKV MR766 was more aggressive at killing SK-N-SH cells. Images of the SK-N-SH monolayer were
acquired at a magnification of 400×.
4. Discussion
ZIKV has recently been shown to cause devastating effects in neonates following in utero
infection [2,24]. In adults, sexual transmission has been well documented and was associated with
testicular atrophy and male sterility [16,17,25,26]. A few reports have subsequently reported infection
of testicular cells lines, particularly Sertoli cells [27–29]. In order to further evaluate these reports,
we infected 4 testicular cell lines representing connective tissue (Hs1.Tes cells) and germ cells (SEM-1
and TCam-2 cells) as well as Sertoli cells with the prototype ZIKV MR766 and a clinical isolate ZIKV
Paraiba to determine the extent to which the viruses would persist in these cells.
All the cells we tested were permissive to both ZIKV MR766 and ZIKV Paraiba, but the former
replicated to higher titers than the clinical isolate (Figure 1). These results suggested that any of the
testicular cells may be responsible for disseminating virus in the infected organ. However, Leydig cells
were reportedly less susceptible to ZIKV infection [27], and their role in virus dissemination may
be limited. The higher replication levels of ZIKV MR766 could be related to the fact that this strain
has been passaged extensively in mouse brains [1,30]. In addition, ZIKV MR766 and ZIKV Paraiba
are 89% identical at nucleotide sequence level and 97% (3313/3423) identical at amino acid level
(BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi). Thus, the ZIKV MR766 strain may have adapted
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to mammalian cell culture better than the ZIKV Paraiba strain which was passaged only <5 times.
However, replication kinetics of ZIKV Paraiba and ZIKV MR766 in Vero E6 cells is similar from 24
to 60 hpi, but ZIKV MR766 replicates to higher titers from 72 to 96 hpi [31]. Therefore, the MR766
replication advantage may be time and cell-type dependent.
Our primary aim was to establish ZIKV persistence in the testicular cell culture systems. All the
cells were able to support persistent infection for a few passages, but ZIKV MR766 was more aggressive
at killing cells during persistence. ZIKV MR766 persistence in Sertoli cells has been reported for up to
6 weeks [27], but we only observed persistence of this strain for only 4 weeks. This could be a result
of the higher ZIKV MR766 titers, which may trigger the host-cell responses leading to cell death.
Persistence of ZIKV Paraiba was also limited to a few passages (5 at most in Sertoli and SEM-1 cells;
Figure 4). In humans and animals, ZIKV persistence has been reported for time periods longer than
the ones we observed in vitro and persistence was mostly of viral RNA in the absence of infectious
virus [15,26,32]. In addition, the testes as an organ is immune privileged to protect the organ from
highly inflammatory immune reactions [26]. The cells in our study were infected in the absence of
the other cells they would normally be associated with in an organ/tissue context, making them
more susceptible to rampant virus replication, which kills the cells faster. This notion is supported by
a previous report showing that Sertoli cells infected with ZIKV were less adept at mounting an innate
immune response in comparison to A549 cells [27].
It is noteworthy that the cell death we observed was slow and progressive until there were not
enough cells for continued culture. In vivo, testicular atrophy and associated male infertility has
been reported in mice [16,25]. The mechanism of slow cell death we observed in vitro in Hs1.Tes
and Sertoli cells persistently infected with ZIKV may be comparable to the mechanism by which
testicular atrophy occurs in vivo. Using Sertoli cells, we showed that cell death was via apoptosis
because we could detect cleaved caspase 3 by immunofluorescence. Interestingly, not all ZIKV E
protein-positive cells were positive for cleaved caspase 3, suggesting that the death signal(s) were not
transmitted or activated uniformly in all virus-infected cells. Kumar et al. also showed that the level of
apoptosis in Sertoli cells was lower (4–10%) than in A549 cells (58–72%) when infected with ZIKV at
72 hpi [27]. In another study, it was demonstrated that early ZIKV infection was associated with the
suppression of cellular growth and proliferation, but antiviral responses were predominate in later
stages of infection [28]. However, the specific mechanism which prevents overt apoptosis in testicular
cells is yet to be elucidated and this will be an interesting avenue for further investigation using single
cell sequencing approaches.
We were puzzled that TCam-2 seminoma cells infected with ZIKV MR766 prevailed up to 7 dpi
without CPE, but the cells died upon passage. This intriguing result contrasted with that observed
in SEM-1 cells, an intermediate seminoma cells line, which underwent extensive cell death by 7 dpi.
These observations supported the hypothesis that ZIKV MR766 was more of an aggressive strain and
the phenotype was also dependent on cell type.
We also attempted to comparatively establish a persistent infection of the neuroblastoma cell line
(SK-N-SH) cells, but both ZIKV MR766 and ZIKV Paraiba killed the cells leaving no surviving cells.
Thus, these observations further indicated that the outcome of ZIKV infection and persistence is cell
type dependent.
In summary, we infected several testicular cell lines with ZIKV MR766 and ZIKV Paraiba with
the aim of establishing persistent viral infection. The testicular cell lines we used represented germ
cells (SEM-1 and TCam-2) and the connective tissue in the form of the fibroblast Hs1.Tes cell line.
We also infected germ cell-supporting Sertoli cells, which have been shown to be permissive to ZIKV
replication [28,29]. All the cells we tested allowed ZIKV replication and the prototype MR766 strain
replicated to higher titers, compared to ZIKV Paraiba. ZIKV Paraiba persisted in Hs1.Tes, TCam-2,
SEM-1 and Sertoli cells for up to 5 passages. ZIKV MR766 killed both TCam-2 and SEM-1 seminoma
cells but persisted for 3 passages in Hs1.Tes cells and 4 passages in Sertoli cells. Compared to testicular
cell lines, the neuroblastoma SK-N-SH cells were killed by both ZIKV strains, thus preventing viral
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persistence. Our results are consistent with reports that ZIKV persists in testicular cells and suggest
that testicular atrophy may be a result of a slow and progressive cell death.
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Abstract: We followed the presence of Zika virus (ZIKV) in four healthy adults (two men and
two women), for periods ranging from 78 to 298 days post symptom onset. The patients were
evaluated regarding the presence of the virus in different body fluids (blood, saliva, urine and
semen), development of immune responses (including antibodies, cytokines and chemokines),
and virus genetic variation within samples collected from semen and urine during the infection
course. The analysis was focused primarily on the two male patients who shed the virus for up to
158 days after the initial symptoms. ZIKV particles were detected in the spermatozoa cytoplasm and
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flagella, in immature sperm cells and could also be isolated from semen in cell culture, confirming
that the virus is able to preserve integrity and infectivity during replication in the male reproductive
system (MRS). Despite the damage caused by ZIKV infection within the MRS, our data showed
that ZIKV infection did not result in infertility at least in one of the male patients. This patient was
able to conceive a child after the infection. We also detected alterations in the male genital cytokine
milieu, which could play an important role in the replication and transmission of the virus which
could considerably increase the risk of ZIKV sexual spread. In addition, full genome ZIKV sequences
were obtained from several samples (mainly semen), which allowed us to monitor the evolution of
the virus within a patient during the infection course. We observed genetic changes over time in
consensus sequences and lower frequency intra-host single nucleotide variants (iSNV), that suggested
independent compartmentalization of ZIKV populations in the reproductive and urinary systems.
Altogether, the present observations confirm the risks associated with the long-term replication and
shedding of ZIKV in the MRS and help to elucidate patterns of intra-host genetic evolution during
long term replication of the virus.
Keywords: Zika virus; flavivirus; arbovirus; sexual transmission; host genetic variation;
immune response
1. Introduction
Zika virus (ZIKV) was first identified in 1947 in Africa and subsequently reached Asia and, more
recently, the Americas [1,2]. Today, more than 80 countries around the globe have reported cases of
active ZIKV transmission and the recent outbreaks have associated the virus with several neurological
disorders, including Guillain-Barré syndrome and congenital neurologic birth defects [3–6]. Due to its
rapid spread, there is a need to understand how the virus interacts with the human host which includes
persistence and shedding in biological fluids in order to improve diagnosis, prevention and treatment.
Reports have shown that ZIKV RNA is present in several body fluids, including urine, blood,
saliva, breast milk and secretions from the vaginal tract [7–10], being cleared early from serum but
still detected in whole blood, saliva and urine for more than two weeks after symptoms onset [11–14].
ZIKV can also replicate and persist in the male reproductive system and ZIKV RNA has been detected
within semen for up to 6 months after initial infection in the male reproductive system (MRS) [15,16].
The potential for persistent ZIKV infections in the MRS raises concerns ranging from the demonstrated
sexual transmission of the virus to the damage of germ cells and generation of poor-quality sperm.
In fact, ZIKV infection has been shown to cause infertility in mice [17,18]. In addition, since the ZIKV
genome is RNA-based, the occurrence of spontaneous mutations may lead to the accumulation of
genetic variants during persistent infection, particularly at the MRS, with unpredicted outcomes for
the virus–host interactions.
In the present study, we followed the natural course of ZIKV infection in four symptomatic
adults (two men and two women) infected with ZIKV in Brazil. The patients were monitored for
the presence of the virus in different body fluids, including blood, saliva, urine and semen and for
the development of an associated immune response, with emphasis on two male patients who shed
the virus for up to 158 days after the initial symptoms. The presence of virus within semen samples,
capable of replicating in cell cultures, allowed us to obtain almost full ZIKV genome sequences and
evaluate the intra-host virus genetic evolution. These results led us to suggest that ZIKV shows
an independent compartmentalization in MRS that may impact the fate of the virus and its interaction
with the human host. In addition, we detected alterations in the genital cytokine milieu and a lack of
detectable proinflammatory cytokines/chemokines in the blood.
89
Viruses 2018, 10, 615
2. Materials and Methods
2.1. Case Definition and Sample Collection
The cases were defined as individuals with ZIKV-like illness (acute onset of rash associated with
at least one of the following symptoms: fever, conjunctivitis, pruritus or arthralgia) and the presence of
ZIKV RNA in at least one of these clinical samples: serum, saliva, urine and semen. During the outbreak
of ZIKV in Brazil, 117 patients with ZIKV illness were tested at the Clinical and Molecular Virology
Laboratory in the Institute of Biomedical Sciences at University of São Paulo—USP, São Paulo, Brazil.
From the six qRT-PCR positive patients, four of them accepted to be included in this study: ZIKV01,
ZIKV17, ZIKV18 and ZIKV19. The study protocol was approved by the Ethics Committee on Research
with Human Beings at the University of São Paulo and also evaluated and determined to be exempt
by the US Army Medical Research Institute of Infectious Diseases (USAMRIID) Office of Human Use
and Ethics. All four patients provided their informed consent for the use of their samples in this study.
Following the initial positive result by qRT-PCR, all patients were tested weekly for the presence of
ZIKV RNA in urine, serum, saliva and semen (for male patients), until all samples tested negative in at
least two consecutive visits. Each patient had the first sample collected between days 3 and 7 after
the onset of symptoms and the final sample collected up to a minimum of 78 days and a maximum
of 235 days later (ZIKV01, ZIKV17, ZIKV18 and ZIKV19 for 78, 235, 119 and 155 days, respectively).
The study timeframe for patient ZIKV01 was between February/2016–May/2016, for patient ZIKV17
between March/2016 until January/2017 and from April/2016 until September/2016 for patients
ZIKV18 and ZIKV19.
Clinical Case
Case-ZIKV01 is a 32-year-old woman who presented with a maculopapular rash on her trunk and
upper limbs associated with abdominal pain and diarrhea. Two to four days after symptom onset,
the exanthema became pruriginous and reached the lower limbs with the appearance of petechiae.
She experienced intense epigastralgia that resolved after the fifth day. Arthralgia on ankles and edema
of fingers were noticed on day 4 and lasted until day 7. No other symptoms, including fever, were
reported. No significant laboratory findings were noted. The patient was subsequently followed for 78
days with no additional complications. The patient, who lives in São Paulo state, reported a trip to
Espirito Santo state two weeks before the onset of symptoms.
Case-ZIKV17 is a 33-year-old man who initially reported a fever lasting 2 days, followed by headache
and retro-orbital pain (days 2–3). On day 4 he reported a maculopapular rash accompanied by intense
itching and diffuse arthralgia. All symptoms cleared up by day 5. The patient was subsequently
studied for 298 days. He experienced pain and edema of his right testicle at 25 days post-symptomatic
onset. Orchitis due to ZIKV infection was diagnosed after confirmation through serology and qRT-PCR.
No other potential agents were identified.
Further monitoring of ZIKV shedding was conducted, with express patient consent, since he was
planning to conceive a baby with his partner. During the study period, the patient underwent two
prostate ultrasounds (USG prostate) and two spermograms. The patient presented with prostatitis at
71 days post symptoms onset, which normalized by 218 days post symptoms onset. The spermograms
were normal at days 100 and 223 post symptoms onset. The couple adopted strict preventive measures
with daily use of insect repellent and barrier contraception during sexual intercourse for the entire
period of confirmed virus shedding. After the first negative semen sample (day 168), the patient
provided weekly samples (day 174) for 2 consecutive weeks, followed by two more biweekly collections
(day 200) and finally a monthly collection (day 235), totaling 67 days with negative qRT-PCR results
for all tested samples. At 235 days post symptoms onset the patient and his wife began actively
trying to conceive. After two months (day 298) the patient’s wife confirmed pregnancy. At the time,
and further during pregnancy, she was monitored for ZIKV infection by qRT-PCR, IgG and IgM. She
remained negative.
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Cases-ZIKV18 and -ZIKV19 are a husband and wife who experienced ZIKV-like illness in close
succession. ZIKV19 is a 64-year-old man, who reported lumbar pain, fever and malaise at onset.
After 3 days of symptoms a macular rash appeared which resolved after 6 days. The patient was
subsequently studied for 155 days.
ZIKV18 is a 68-year-old woman who began experiencing symptoms of malaise five days after
her husband. Three days after onset, a macular rash appeared on the face, body and limbs and
erythematous plaque in the right leg, accompanied by fever, headache, ocular hyperemia and articular
edema. On the fourth day the exanthema became more intense, followed by somnolence, chills and
tiredness. The articular edema remained for 5 weeks. The patient was subsequently studied for 108
days. There were no other reports of complications during the study period.
Timelines for all four patients with the principle clinical events and laboratorial results are shown
in Figure 1.
 
Figure 1. Timelines of ZIKV exposure, symptoms and sample collection in the four subjects enrolled in
the present study. Periods of exposure, symptom onset, serology and molecular detection results of
ZIKV in the followed subjects are described as: (A) case 1—female (ZIKV01), (B) case 2—male (ZIKV17),
(C) case 3—female (ZIKV18) and case 4—male (ZIKV19). Day 0 denotes the onset of symptoms.
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2.2. Molecular and Classical Virology
For the serological analysis, ZIKV-specific IgG antibodies were measured using a nonstructural
protein ΔNS1-ELISA [19] and ZIKV-specific IgM antibodies were detected using capture ELISA with
a specific viral antigen for ZIKV [20]. For the molecular test, quantitative reverse transcription
(qRT-PCR) TaqMan assays for detection of ZIKV, Dengue virus (DENV) and Chikungunya virus
(CHIKV) RNA were performed. The assays, as well as the RNA extraction methods, are described
in the Supplementary Appendix. To ensure RNA integrity and sample quality, all extracts were also
tested for the presence of the human RNase P (RNP) gene by qRT-PCR. All extracts showed robust
RNP cycle threshold (Ct) values ranging from 16.3 to Ct 33.5 (see Supplementary Appendix for details)
demonstrating the integrity of the material collected. Assays for DENV [21] and CHIKV [22] were
performed as controls for co-infection, as they have been reported in Brazil during the ZIKV outbreak.
To evaluate infectivity, viral isolation was attempted for a subset of positive samples from the two
male patients ZIKV17 and ZIKV19. For virus isolation, Aedes albopictus mosquito cells (C6/36) were
inoculated with 500 μL of saliva, urine or semen. After 8–12 days of incubation, cells were collected
and tested for ZIKV RNA presence by qRT-PCR. All samples were passaged in cell culture at least 3
consecutive times before being considered negative for ZIKV presence by qRT-PCR (for details see
Supplementary Materials).
2.3. Virus Particle Detection in Semen by Immunofluorescence and Transmission Electron-Microscopy (IFA and
TEM, Respectively)
The immunofluorescence assays were conducted using suspensions from semen samples collected
on day 39 from patient ZIKV17 and day 40 from patient ZIKV19. The presence of ZIKV particles were
also analyzed by TEM in semen from patient ZIKV17 (day 39) and in Aedes albopictus mosquito cells
(C6/36) inoculated with the ZIKV17 semen sample. Thin sections were stained with uranyl acetate
and lead citrate, and observed with a JEOL 1010 transmission electron microscope (for details see
Supplementary Materials). C6/36 cells infected with ZIKV isolated from patient ZIKV17 were used as
a positive control for both IFA and TEM assays.
2.4. Measurement of Cytokines and Chemokines in Serum and Seminal Plasma
The serum and semen samples from the male patients ZIKV17 and ZIKV19 were analyzed for the
presence of the cytokines IL-17, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and the chemokines CXCL8/IL-8,
CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1 and CXCL10/IP-10 using Cytometric Bead Arrays kits
(Human Th1/Th2/Th17 and Human Chemokine from Becton Dickinson, CA, USA), according to
the manufacturer’s instructions. The range of detection for cytokines was 20 to 5000 pg/mL and for
chemokines was 10 to 2500 pg/mL. Samples were analyzed using a FACSCanto II flow cytometer,
with FCAP Array 3.0 software, version 3.0, both from BD Biosciences. One-way ANOVA with Tukey
post-tests were used to evaluate significant differences between groups. For correlation analyses,
Pearson coefficient (r) was used. Statistical analysis was performed using GraphPad Prism software.
Differences were considered statistically significant when p values were less than 0.05.
2.5. Genome Sequencing and Analysis
For samples that tested positive for ZIKV RNA by qRT-PCR, viral genetic diversity was
characterized directly from the clinical specimens using next-generation sequencing. Sequencing
libraries were prepared using the TruSeq RNA Access Library Prep kit (Illumina, Menlo Park, CA,
USA) with custom ZIKV probes and sequenced using the MiSeq Reagent kit v3 (Illumina, Menlo Park,
CA, USA) on an Illumina MiSeq (for details see supplementary appendix). Consensus-level ZIKV
genome sequences were assembled for each sample using both de novo and reference-based approaches
(for details see Supplementary Materials). These two approaches resulted in nearly identical sequences.
However, for several lower coverage samples, contiguous assemblies could only be constructed with
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the reference-based approach. Consensus genomes were compared using median-joining haplotype
networks (PopART v1.7.2) and an approximate maximum-likelihood phylogenetic reconstruction
(FastTree v2.1.5). BEAST v1.8.3 [23] was used to estimate dN/dS and the rate of ZIKV evolution
within the male reproductive system (MRS), HyPhy v2.3 was used to identify codons with evidence
for positive, diversifying selection, and for samples with >50× average coverage, we examined intra
host genetic variation using FreeBayes v1.0.2 [24] (for details see Supplementary Materials).
3. Results
3.1. Long Term Monitoring of Four Symptomatic ZIKV-Infected Patients
Four symptomatic ZIKV-infected individuals (two males; patients ZIKV17 and ZIKV19 with
33 and 64 years of age, respectively, and two females; patients ZIKV01 and ZIKV18 with 32 and
68 years) were followed for periods up to 298 days after the onset of symptoms (Figure 1). All patients
became serological positive for ZIKV, both for IgM and IgG, during the course of the study. ZIKV IgM
was detected in serum of patients ZIKV01, ZIKV17, ZIKV18 and ZIKV19 until day 78, 95, 59 and 54,
respectively. All serum samples were positive for ZIKV IgG at the first time point tested, between 12 to
25 days after symptoms onset, and remained positive throughout the study (Figure 1).
In the two females (ZIKV01 and ZIKV18) the ZIKA RNA was detected by qRT-PCR in urine,
serum and saliva. ZIKV01 was the only patient in this study that developed viremia, which was
detected at day 5 (6.2 × 107 genome equivalents (ge)/mL) and lasted until day 12 (2.2 × 102 ge/mL).
ZIKV RNA was also detected in her saliva at day 12 (2 × 102 ge/mL). Both patients had ZIKV RNA
detected in urine samples from day 12 (102 ge/mL) through day 30 (20 ge/mL) for patient ZIKV01
and at day 8 (5.7 × 104 ge/mL) for patient ZIKV18 (Figure 2A,C).
Both males (ZIKV17 and ZIKV 19) had the virus detected in semen and urine and only one
(ZIKV17) had it detected in saliva from day 25 (5.2 × 106 ge/mL) through day 32 (4.2 × 105 ge/mL).
This patient also showed high viruria at day 6 (2.5 × 107 ge/mL) which waned by day 32 and
persistent viral shedding in semen, which was detected from day 18 (6.5 × 108 ge/mL) through day
158 (15 ge/mL) after symptoms onset (Figure 2B). Similarly to patient ZIKV17, prolonged virusemia
was detected as early as day 19 (3.13 × 105 RNA ge/mL) through day 82 (1.33 × 102 RNA ge/mL)
in the other male patient (ZIKV19) (Figure 2C). The presence of virus in semen has been directly
demonstrated by IFA and TEM, where it was verified in both spermatozoids and immature sperm
cells (Figure 3, and Figures S1 and S2). All four patients remained negative for DENV and CHIKV
RNA detection throughout the study period.
Replication competent ZIKV particles were successfully isolated from saliva (day 25), urine (days
18, and 25), and semen (days 18, 25, 32, 53, and 117) samples of patient ZIKV17 and from semen samples
(days 19, 26 and 40) of patient ZIKV19 (Figure 2B,D). The viral isolation was confirmed by qRT-PCR,
IFA and TEM (Figure 3A,B). Although cytokines and chemokines have not been detected in serum by
the methodology used, seminal fluids of patients ZIKV17 and ZIKV19 showed enhanced levels of some
of them when compared to normal control (semen from a ZIKV-uninfected individual). Patient ZIKV17
showed concentrations of IP-10, MIG, IL-6, IL-10, INF-γ, IL-8, MCP-1and RANTES higher than control,
with the highest values found at the beginning of the infection (p < 0.05), highlighting a local persistent
inflammation in the MRS. Statistical correlation (Pearson’s r) between the Zika load and the level of
all these chemokines and cytokines were verified, except for IP-10 (Figure 4A and Supplementary
Figure S3A). For patient ZIKV19 the same cytokines/chemokines were higher than control, except by
IL-10 that remained undetectable. But a statistical correlation was verified only for IFN-γ and IP-10.
In addition, an increased concentration of IL-6, IP-10, MCP-1, IL-8 and RANTES in the seminal plasma
sample of this patient was also detected after 60 days of the symptoms onset, which was coincident
with the period immediately before the viral clearance (Figure 4B and Supplementary Figure S3B).
More, IL-2, IL-4, IL17A and TNF–α were not detected in the seminal plasma of both patients.
93
Viruses 2018, 10, 615
Figure 2. ZIKV RNA load in patient’s body fluids and clinical isolates on culture. The graph
shows the viral load (genome copies/mL) versus excretion time (days after symptoms onset) of the
weekly collection of urine (orange), saliva (green) and serum (red) samples from patients ZIKV01 (A),
ZIKV17 (B), ZIKV18 (C) and ZIKV19 (D), in addition to the semen (blue) of the two men involved in
the study (C,D). To confirm the viability of the excreted virus, the urine samples collected from days 18
and 25 after symptoms, saliva from day 25 and the semen from days 18, 25, 32, 53 and 117 for patient
ZIKV17 and semen samples from patient ZIKV19 from days 19, 26 and 40 after symptoms onset were
tested and the ones with positive results in cell culture are exhibited. All clinical samples and isolated
samples were analyzed by qRT-PCR.
Figure 3. Cont.
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Figure 3. Detection of ZIKV in semen and C636 cells. (A) Detection by Indirect Immunofluorescence
assay using anti-ZIKV specific antibody. Spermatozoa from semen sample collected from patient
ZIKV17 at day 39 stained with FITC conjugate (in green) for virus location and with DAPI for nucleus
staining (in blue). The viruses were located in the cytoplasm and flagella. C6/36 cell culture infected
with virus from ZIKV17 semen sample. The cell infected presents with a green color (lower right panel).
(B) Electron Microscopy of ultrathin sections of semen sample. (B1) A lower-power view of ZIKV
particles inside an infected cell, with the characteristic of an immature sperm cell. (B2) Viral particles
in a magnified view of the same cell in (B1). (B3) C6/36 cell infected with a semen sample from patient
ZIKV17 with a cluster of dense virions located in the cytoplasm (red arrow).
Figure 4. Cont.
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Figure 4. Concentration of cytokines, chemokines and RNA viral load determined on semen of
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patients ZIKV17 (A) and ZIKV19 (B). The levels of the following cytokines and chemokines were
measured in blood and seminal plasma—IL-2, IL-4, IL-6, CXCL8 (IL-8), IL-10, IL-17, IFN-γ, TNF–α,
CCL2 (MCP-1), CCL5 (RANTES), CXCL9 (MIG), CXCL10 (IP-10). The results are representative
of two distinct experiments performed in duplicate. Values of p less them 0.05 were considered
statistically significant (* p < 0.05; ** p < 0.001; *** p < 0.0001—concentration of cytokines/chemokines
in ZIKV patients versus control (semen from Zika—uninfected individual), ### p < 0.0001 correlation
of concentration of cytokine/chemokines in different days after symptoms onset). IL-2, IL-4, IL17A
and TNF–α were not detected in the seminal plasma of both patients. No cytokines or chemokines
were detected in serum of both patients—serum results were below the limit of detection of the kit
(20 pg/mL for cytokines and 10 pg/mL for chemokines).
3.2. ZIKV Evolution during Prolonged Infection
The isolation of replicative ZIKV particles from different body fluids, mainly seminal fluids,
in the same individuals, particularly the two male patients (ZIKV17 and ZIKV19), allowed us to
evaluate the extent of genetic variations observed in prolonged persistence of ZIKV in human hosts.
With ZIKV17, we obtained near complete genome sequences directly from fourteen sequentially
collected semen samples and two urine samples. For patient ZIKV19, five semen and two urine
samples yielded near complete genome sequences (Table S2). We also assembled a near complete
ZIKV genome from one urine sample of one female patient (ZIKV18, day 15). Phylogenetic inference
indicated that all three patients were infected with viruses closely related to those previously circulating
in Brazil (Figure S4). As expected from individual prolonged infections, all of the ZIKV genomes
obtained from each patient formed well-supported monophyletic clades (Figure S3). Within both
patients, we observed ZIKV genetic changes over time both in consensus sequences (Figure 5A,B) and
intra-host single nucleotide variant (iSNV) frequencies (Figure 5C,D, Table S3). This is consistent with
active viral replication during prolonged ZIKV infections. With the exception of a few low frequency
insertions/deletions associated with homopolymer repeats (Table S3), patterns of genetic variation
(iSNVs and consensus-level changes) were distinct between urine and semen samples from the same
patient (Figure 5; Table S3), consistent with independent compartmentalization of ZIKV populations
in the reproductive and urinary systems.
Using time-structured phylogenies, we estimated the rate of evolution during the prolonged
infection of the MRS in ZIKV17. Our estimates were highly consistent across multiple models and were
indistinguishable from published rates for the entire ZIKV outbreak in the Americas (Figure S3 and
Table S4). ZIKV evolution within the MRS was dominated by synonymous substitutions, consistent
with strong purifying selection across most of the ZIKV genome. We observed one nonsynonymous
and six distinct synonymous substitutions in the MRS of ZIKV17 (dN/dS via robust counting = 0.06)
and only a single synonymous substitution in ZIKV19. We also observed a significant difference
between the ratio of nonsynonymous:synonymous variants present at different frequencies in samples
with a high depth of coverage. Synonymous changes were most prevalent among variants that
reached high frequencies (≥50%) during the course of infection, while nonsynonymous changes were
more common in variants that were maintained at low frequencies (Figure 5D; Fisher’s exact test
p-value = 0.01). This pattern is consistent with incomplete purifying selection acting on low frequency
variants [25].
Despite the overall signal of purifying selection, positive diversifying selection may have affected
some regions of the genome. We utilized several phylogenetic-based methods to look for signatures of
positive selection at the codon-level. The reconstructed most parsimonious amino acid changes along
the ZIKV ML tree topology (Figure 6, Table S5) indicated four synapomorphic changes (K242R, K408R,
K985R and I1484V) defining the lineage infecting both patients ZIKV18 and ZIKV19. In addition,
the virus in the urine sample of patient ZIKV19 had two additional unique changes in the NS5 peptide
(V2650A and R3121K); however, these changes were not observed after the removal of duplicate
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sequencing reads. Patient ZIKV17 had four defining synapomorphic changes (K1202R, L1298V,
A1428V and V1862I). In the urine samples, only one substitution in the NS5 (E2693G) was identified
(present in one sample). Semen samples from patient ZIKV17 had a change in the NS5 (R2562H)
that was present in genomes reconstructed from eight time points (39, 53, 63, 68, 88, 95, 102 and 109
days after onset symptoms). Interestingly, the consensus genome showed the initial state (2562R) at
day 76, which suggests that distinct haplotypes were circulating at varying frequencies over time.
Substitutions observed in patients ZIKV17 and ZIKV19 did not alter the conformation of the proteins
as measured by homology modeling and structural alignments.
Figure 5. Evolution of ZIKV populations throughout the infection course. Median-joining haplotype
networks constructed from full genome alignments of the consensus sequences from patients ZIKV19
(A) and ZIKV17 (B). Colors indicate sample type and collection date relative to symptoms onset.
Each dash represents a single nucleotide substitution differentiating consensus sequences from
different samples. (C) Intra host single nucleotide variant (iSNV) frequencies over time in semen
samples collected from patient ZIKV17. The legend indicates the nucleotide position of each iSNV
relative to KX197192.1 (GenBank) and for non-synonymous changes, the affected protein and amino
acid change. Only positions with a minimum frequency ≥25% in at least one sample are shown.
See Table S3 for details about these mutations and others present at lower frequencies. (D) Proportion
of nonsynonymous and synonymous ZIKV iSNVs observed in semen samples from patients ZIKV17
and ZIKV19. The relative counts of nonsynonymous and synonymous variants observed above
(consensus-level) and below 50% frequency (minor population) in at least one sample were significantly
different (Fisher’s exact test p-value = 0.01).
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Figure 6. Dendogram showing the most parsimonious unique amino acid changes with high
consistency index (CI=1) (black framed red boxes). Reconstructions were made using a set of ZIKV
polyproteins from African and Asian lineage viruses. Branch lengths are shown proportional to the
number of most parsimonious reconstructions (MPR) of amino acid changes. Amino acid changes that
define patient clades are shown as well as the viral proteins affected. Each patient clade (which had
100% support in ML tree shown in Figure S3) was supported by four synapomorphic changes. For both
patients ZIKV19 and ZIKV17 changes were observed in the NS5 protein. Although we only show
the results for selection detection methods for the three patients, elevated rates of non-synonymous
changes were detected for all of the codons containing unique amino acid changes shown. The multiple
EM for motif elicitation (MEME) algorithm detected significant positive selection (p-value = 0.03) acting
on the codons containing the two NS5 changes observed during infection of patient ZIKV17. All MPRs
were detected with FUBAR with a Bayes factor >3 and had elevated dN. Sites detected by 2-rates FEL
had nonsynonymous changes in the absence of detectable synonymous changes. Significant negative,
purifying selection was detected by all methods used on several sites of the polyprotein.
4. Discussion
The aim of the present study was to follow the kinetics of ZIKV persistence and secretion
in different host compartments and body fluids. The study included four (two males and two
females) ZIKV-infected symptomatic adults who were followed for up to 298 days. Our initial
conclusions supported previous evidence of prolonged ZIKV shedding in the semen of several
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different mammalian species, including humans [13,16,17,26,27] and confirmed the importance of
semen analyses as a diagnostic tool for males with ZIKV disease. The study also confirmed the
presence of ZIKV particles inside spermatic cells and seminal fluids as late as 117 days post the initial
onset of symptoms. In contrast to previous reports based on the detection of RNA material, our results
confirmed that complete infectious viral particles can be detected in the semen up to 117 days after the
onset of symptoms.
On the other hand, the early detection of anti-ZIKV IgG and IgM antibody responses and the
rapid clearance of ZIKV from serum strongly suggest that the immune system can easily handle the
systemic phase of the infection. The detection of proinflammatory cytokine responses and the presence
of infectious virus in seminal fluids long after viral clearance from serum indicate that the local immune
system does not efficiently control ZIKV replication in the MRS. Similarly to other flaviviruses, ZIKV
may promote some sort of local immunosuppression allowing viral replication despite activation of
systemic immune responses. In cases of DENV infection, the virus is capable of antagonizing the
innate host responses using multiple strategies including degradation of key proteins, such as STAT2,
2’-O, methylation of adenosine in the viral genome and interfering with RNAi mechanisms [28–30].
It remains to be seen if ZIKV proteins are capable of exerting local negative regulatory effects on the
host’s immune system, which may contribute to viral persistence. Besides, the alteration in the genital
cytokine milieu could play an important role in replication and transmission of the virus as has been
seen for other viruses, such as HIV-1 [31], which could considerably increase the risk of ZIKV sexual
spread and potentially play a role on the viral spread. In addition, despite, experimental evidence in
mice that persistent ZIKV infections can cause infertility in males [17], patient ZIKV17 was able to
inseminate his wife approximately two months after virus clearance and the couple had a healthy baby.
The availability of ZIKV-containing semen and urine samples of two patients allowed us to
study the genetic evolution of the virus during prolonged replication in the MRS. For the first time,
we demonstrated a high level of evolutionary constraint on ZIKV during the prolonged MRS infections.
High levels of constraint, as evidenced by low long-term rates of amino acid substitution, have
commonly been observed for arthropod-borne viruses like ZIKV [32]. However, the primary source of
this constraint is generally thought to be the continual alternation of these viruses between vertebrate
and invertebrate hosts, each of which exerts unique selective pressures. By examining ZIKV genetic
diversity over time in the semen of patients with prolonged MRS infections, we obtained a rare
glimpse into the selective pressures exerted by a single host species. Although a large number of
nonsynonymous variants were detected within both patients, few of these mutations ever reached high
frequencies (Figure 5). In fact, our estimate of dN/dS from the semen samples of ZIKV17 is very similar
to recent long-term dN/dS estimates for ZIKV, which average across the selective pressures from both
vertebrate and invertebrate hosts [7]. Our findings, therefore, indicate that the strong evolutionary
constraint observed for ZIKV and other arthropod-borne viruses may not simply represent the long
term effect of alternating between hosts, but is likely also related to the pressures experienced within
individual host species.
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Abstract: The recent Zika virus (ZIKV) outbreak in the Americas surprised all of us because of its
rapid spread and association with neurologic disorders including fetal microcephaly, brain and ocular
anomalies, and Guillain–Barré syndrome. In response to this global health crisis, unprecedented
and world-wide efforts are taking place to study the ZIKV-related human diseases. Much has
been learned about this virus in the areas of epidemiology, genetic diversity, protein structures,
and clinical manifestations, such as consequences of ZIKV infection on fetal brain development.
However, progress on understanding the molecular mechanism underlying ZIKV-associated
neurologic disorders remains elusive. To date, we still lack a good understanding of; (1) what
virologic factors are involved in the ZIKV-associated human diseases; (2) which ZIKV protein(s)
contributes to the enhanced viral pathogenicity; and (3) how do the newly adapted and pandemic
ZIKV strains alter their interactions with the host cells leading to neurologic defects? The goal of
this review is to explore the molecular insights into the ZIKV–host interactions with an emphasis
on host cell receptor usage for viral entry, cell innate immunity to ZIKV, and the ability of ZIKV to
subvert antiviral responses and to cause cytopathic effects. We hope this literature review will inspire
additional molecular studies focusing on ZIKV–host Interactions.
Keywords: zika virus; ZIKV–host interactions; viral pathogenesis; cell surface receptors;
antiviral responses; viral counteraction; cytopathic effects; microcephaly; ZIKV-associated
neurologic disorders
1. Introduction
1.1. The Zika Virus (ZIKV): An Emerging Public Health Threat
The 2015 Zika virus (ZIKV) epidemic in the Americas surprised the world because of its
rapid global spread and the findings that it associates with various neurologic disorders including
microcephaly in newborns and Guillain–Barré syndrome (GBS) in adults. ZIKV was thought to be a
mild virus that had little or no threat to humans. Through studies of this new ZIKV pandemic, we have
now learned that ZIKV is a rather severe human pathogen that can cause significant neuropathology
such as fetal microcephaly, GBS, and various other congenital neurologic and ocular disorders [1–5].
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So, it begs the question of what has transformed a benign ZIKV over the past seventy years to generate
the contemporary pathogenic ZIKV.
The goal of this article is to review the current literature on ZIKV–host interactions with a focus on
molecular aspects. We herein summarize insights on host cell receptor usage for viral entry, cell innate
immunity to ZIKV, and the ability of ZIKV to subvert antiviral responses and to cause cytopathic
effects. The molecular mechanisms underlying these ZIKV–host interactions, and their potential
impacts on ZIKV-induced fetal microcephaly or other neurologic disorders are discussed.
1.2. The Organization of Zika Virus
ZIKV belongs the flavivirus genus of the Flaviviridae family which includes a number of medically
important arboviruses such as Dengue Virus (DENV), Japanese Encephalitis Virus (JEV), and West Nile
Virus (WNV). Structurally, ZIKV is similar to other flaviviruses. The nucleocapsid is approximately
25–30 nm in diameter, surrounded by a host membrane-derived lipid bilayer that contains envelope (E)
and membrane (M) proteins. The virus particle is approximately 40–65 nm in diameter, with surface
projections that measure roughly 5–10 nm [6], leading an overall average size of 45–75 nm. The surface
proteins are arranged in an icosahedral-like symmetry [7]. Like its flaviviral siblings, ZIKV contains
a positive sense single-stranded RNA [ssRNA(+)] viral genome of approximately 10.7 kilobases (kb)
(Figure 1). The genomic RNA is flanked by two terminal non-coding regions (NCR), i.e., the 5′ NCR
(107 nt) and the 3′ NCR (428 nt) [8]. The ZIKV genome includes a single large open reading frame
encoding a polyprotein of about 3300 amino acids, which is processed co- and post-translationally
by viral and host proteases (PRs) to produce a total of fourteen immature proteins, mature proteins,
and small peptides [9]. A total of ten mature viral proteins, i.e., three structural proteins (C, M, and
E) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins are produced
after viral processing [6,9,10]. The 2K signal peptide, which is situated between NS4A and NS4B,
plays a regulatory role in viral RNA synthesis and viral morphogenesis in other flaviviruses [11,12].
Among the structural proteins, the mature capsid (C) protein is produced by cleavage of the anchor-C
(anaC) protein by a viral PR (anaC→C), which in turn triggers the cleavage of the precursor membrane
(prM) protein by the host protease Furin. As a result, a mature membrane (M) protein and a Pr
protein are produced (PrM→M + Pr) [11,13]. In the case of DENV, noninfectious and immature viral
particles contain prM that forms a heterodimer with the E protein [14]. The transition of prM to M
by Furin cleavage results in mature and infectious particles [15,16]. The E protein, composing the
majority of the virion surface, is involved in binding to the host cell surface and triggering subsequent
membrane fusion and endocytosis [8]. Post-translational processing of the non-structural protein
region produces four viral enzymes, i.e., PR, helicase, methyl-transferase, and RNA-dependent RNA
polymerase (RdRP). A fully active ZIKV PR consists of two protein components, namely the N-terminal
domain of NS3 (NS3pro) and a membrane-associated NS2B cofactor [17,18]. The NS3pro is responsible
for proteolytic processing of the viral polyprotein, whereas the NS2B cofactor is required for enhancing
enzymatic activity and substrate specificity. The C-terminal domain of NS3 protein produces ZIKV
helicase, which plays a critical role in NTP-dependent RNA unwinding and translocation during viral
replication [19]. The methyl-transferase and RdRP are generated from the N-terminal and C-terminal
of NS5, respectively. NS1, NS3, and NS5 are large proteins that are highly-conserved [6]. NS2A,
NS2B, NS4A, and NS4B proteins are smaller, hydrophobic proteins [6]. The 3′ NCR forms a loop
structure that may play a role in translation, RNA packaging, cyclization, genome stabilization and
recognition [8]. The 5′ NCR allows translation via a methylated nucleotide cap or a genome-linked
protein [7]. In addition, ZIKV produces abundant non-coding subgenomic flavivirus RNA (sfRNA)
from the 3′UTR in infected cells, which may play a role in the viral life cycle and viral subversion of
innate immunity [20].
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Figure 1. Schematic structure of the Zika virus genome. Each of the viral proteins is drawn based on
the relative orientation in the RNA genome. The ZIKV viral protease, host protease and Furin protease
are represented by different arrows, as shown. Each arrow points to the specific protease cleavage site.
The numbers shown above each protein product indicate the start/end position. Abbreviations: anaC,
anchored capsid protein C; C, capsid protein C; prM, precursor membrane protein; M, membrane
protein; Pr, protein pr; E, envelope protein; NS, nonstructural protein; *, protease consists of N-terminal
of NS3 and C-terminal NS2B as described in the text. C-terminal of NS3 encodes helicase; 2K, signal
peptide 2K; NS5 encodes methyltransferase at its N-terminal end and RNA-dependent RNA (RdR)
polymerase at its C-terminal end. UTR, untranslated region. The structures of 5′ UTR and 3′ UTR are
based on [21]. The information of ZIKV protein products is based on [9].
1.3. The Infectious Cycle of ZIKV and Human Transmission
The ZIKV infectious cycle starts with the virus binding to host cell surface receptors and
attachment factors via the E protein, leading to clathrin-dependent endocytosis. Internalized virus
particles fuse with the endosomal membrane in a pH-dependent manner, releasing the genomic
RNA into the cytoplasm of the host cell. The positive-sense viral genomic ssRNA is translated
into a polyprotein that is subsequently cleaved to form structural and non-structural proteins.
Viral replication takes place in intracellular membrane-associated compartments located on the surface
of the endoplasmic reticulum (ER), resulting in a dsRNA genome synthesized from the genomic
ssRNA(+) by viral RdRP. The dsRNA genome is subsequently transcribed and replicated, resulting in
additional viral mRNAs/ssRNA(+) genomes. Immature virus particles are assembled within ER. They
are then transported through the trans-Golgi network (TGN) where the fully mature infectious virus
particles are formed as soon as prM is processed to M by a Furin-like protease. The new virus particles
are released into the extracellular environment where they move on to a new infectious life cycle [7].
ZIKV is an arbovirus that is primarily transmitted to mammalian hosts by mosquito vectors
from the Aedes (Ae.) genus including Ae. africanus, Ae. aegypti, Ae. vitattus, Ae. furcifer, Ae.
apicoargenteus, and Ae. luteocephalus [22,23]. The incubation time for ZIKV in mosquito vectors is
approximately 10 days [22]. Blood contact via blood transfusion or sexual contact is another route of
ZIKV infection [24–26]. Consistent with this notion, human testis has been found to be a reservoir
for ZIKV [22,27–29]. In addition, ZIKV can also be transmitted vertically from mother to child
via placenta–fetal transmission [30,31]. This has become a main route for the development of fetal
microcephaly [32,33].
1.4. A Brief History of ZIKV
The first ZIKV strain was isolated in 1947 from caged monkeys in the Zika forest of Uganda,
Africa. A ZIKV strain MR766 (ZIKVMR766) from that isolation was established and has been used since
for research purpose [34]. Therefore, the ZIKVMR766 is often referred to as the historical or ancestral
ZIKV strain. Initial characterization of ZIKVMR766 showed that it is highly neurotropic in mice,
and no virus has been recovered from tissues other than the brains of infected mice [35]. That report
further showed that mice at all ages were susceptible to ZIKVMR766 by intracerebral inoculations.
In contrast, cotton-rats, Guinea pigs, and rabbits showed no sign of ZIKVMR766 infection by using the
same intracerebral inoculations. Monkeys showed either mild fever (pyrexia) or no signs of infection.
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Interestingly, mice younger than two weeks were highly susceptible to intraperitoneal inoculation,
whereas mice older than two weeks can rarely be infected by the same route of intraperitoneal
injection [35], suggesting established blood-brain barriers in the older mice may prevent ZIKV from
accessing the brain.
In a different study, the effect of ZIKV infection on the central nervous system (CNS) of mice was
examined by using intracerebral inoculation [36]. Histologic H & E staining showed that ZIKV infects
the Ammon’s horn (hippocampus proper) area of seven-day-old mouse brain. Detailed examination
suggested that ZIKV infected pyriform cells of the Ammon’s horn and induced hyperchromatic debris
in those cells, suggesting possible DNA or chromosomal aberration. In addition, ZIKV induced gross
enlargement (hypertrophy) of astroglial cells of the Ammon’s horn, but had little effect on microglial
cells of the same area [36]. Ultra-structural studies by electron microscopy (EM) further revealed that
ZIKV replicates exclusively in the ER compartment of astroglial cells and neurons, an indication of
membrane-associated viral replication [36].
Those early findings in the mouse model suggest that (1) ZIKV is a neurotropic virus with
preference to embryonic brains [34,35], (2) ZIKV specifically infect astroglial cells and pyriform cells
in the Ammon’s horn, and (3) ZIKV primarily replicates in the ER network [36]. At the cellular
level, ZIKV appeared to induce gross cell enlargement, chromosomal or DNA aberrations, and
mitochondrial dysfunction [36]. Although early data showed that ZIKV was pathogenic to mice, there
was no indication that ZIKV was pathogenic to humans [35]. Therefore, some types of virological
change are likely to have taken placed during the viral evolution in the past seventy years, leading to
pathogenic ZIKV infection of humans.
The first ZIKV infection in human was documented in 1952 [34], and the virus was subsequently
isolated from human hosts in Nigeria in 1968 [22]. Since then, multiple studies have confirmed
the presence of ZIKV antibodies in human sera from a number of countries in Africa and Asia [22].
However, no severe diseases were clearly linked to those infections. In the recorded history, ZIKV
infection appears to have migrated eastward from Africa. A number of outbreaks have taken place
over the past seventy years including several minor outbreaks in 1977–1978 in Pakistan, Malaysia,
and Indonesia. Two major outbreaks were documented in Yap Island of Micronesia in 2007, and in
French Polynesia, New Caledonia, the Cook Islands, and Easter Island in 2013 and 2014 [26,37].
The affected individuals in those outbreaks were in the order of hundreds to thousands. However,
in the most recent outbreak, ZIKV infection had been reported in eighty-five countries, territories,
or subnational areas with an estimate of over 1.5 million affected individuals according to the World
Health Organization (WHO). Brazil was the most affected country, with an estimated 440,000 to
1.3 million cases reported through December of 2015.
Although human ZIKV infection is mostly self-limiting, manifestations of neurological disorders
such as GBS became increasingly apparent during the recent outbreaks in French Polynesia and
Brazil [32,38]. The number of microcephaly in newborns also increased dramatically, which for the
first time indicated a possible link between ZIKV infections and fetal malformations [32,39,40]. More
than 4700 suspected cases of microcephaly were reported from mid-2015 through to January 2016 [41],
spurring an unprecedented and world-wide effort to unravel this mystery. By March of 2016, the causal
relationship between microcephaly in newborn and ZIKV infection was first established [32,39,40]. By
April of 2016, a total of 3530 newborns with confirmed microcephaly were reported. In the same year,
WHO declared an international public health emergency. In-depth research now shows that ZIKV
infection is also associated with a number of other congenital and ocular diseases [1,2].
1.5. What Has Been Learned from the Recent ZIKV Break?
We have learned a great deal about the ZIKV and its etiology through the above described studies.
The knowledge we have gained is that fetal microcephaly and other congenital malformations can
indeed be caused by ZIKV infection [32,42,43]. Furthermore, those circulating and pathogenic ZIKV
strains are most likely derived from the Asian lineage [44,45]. The Asian lineage is likely evolved
107
Viruses 2018, 10, 233
from the African lineage through viral gene mutations by adaptation of higher cytopathicity that
led to enhanced viral pathogenicity. Particular efforts have been put to investigate whether the
emergence of new ZIKV epidemic strains was associated with accumulation of specific mutations that
would be the leading cause of increased pathogenic effects [44–46]. Also, investigations have been
conducted to determine whether pathogenic strains of ZIKV could preferentially infect certain human
tissues or cells, especially neural progenitor cells (NPCs) in the brain, or they have acquired greater
virulence through accumulated effects of ZIKV gene mutations [47–49]. The antibody-dependent
enhancement (ADE) may also contribute to the acquired virulence [50]. This scenario could occur if
individuals have previously been exposed to other flaviviruses and have acquired antibodies that
partially cross-react with ZIKV. Instead of neutralizing ZIKV, these antibodies could paradoxically
argument ZIKV infectivity [50]. As a matter of fact, the opposite scenario has been observed in
which pre-exposure of ZIKV was associated with enhanced DENV-2 infection in vitro [51] and in
monkeys [52]. Therefore, enhanced ZIKV infection as the result of prior exposure of other flaviviral
infection could certainly be feasible [53–56]. However, ADE is less likely to be the predominant mode
of enhanced ZIKV pathogenicity in the recent break since ZIKV is known to cause fetal microcephaly
in the absence of antibody response to other flaviviruses. We should also be mindful that despite
these theories, we cannot exclude another possibility that ZIKV-induced microcephaly may not be
the result of ZIKV evolution, but rather a reflection of the advanced technology in disease monitoring
and diagnosis. In other words, microcephaly is intrinsic to all ZIKV strains but its evasion from
public awareness could be due to the lack of sensitive detection methods in the past. This possibility
may not totally be far-fetched, insofar that the very first ZIKV isolate, ZIKVMR766, also induced
microcephaly in animal and human brain-specific organoid models [40,43,57]. In fact, both African
and Asian ZIKV strains (MR766, FSS13025, PF/2013/KD507, SZ01, and various epidemic Brazilian
strains, e.g., ZIKV-BR/2015), have been shown to induce microcephaly-like phenotypes in animal and
human brain-specific organoid models (Table 1) [40,43,57–59]. Nevertheless, virological activities of
the ancestral ZIKVMR766 did appear to be different from Asian lineage in embryonic mouse brains [60].
Therefore, as it says that the devil is in the detail. It is very likely that the neurological defects caused
by the epidemic Brazilian ZIKV in humans were attributed by subtle but important virological changes.
Those newly adapted virological changes could include preferable infection to certain brain and neural
cells such as hNPCs, persistent viral replication in host cells, and enduring neuropathic damages that
lead to those observed ZIKV-associated neurological disorders. Further and detailed dissections of
those virological traits certainly are warranted.
In short, even though we have learned a great deal about the ZIKV etiology, much still remains
unknown. Some of the critical questions include; (1) what type of virological changes have taken place
to result in increased viral pathogenicity, (2) which ZIKV protein(s) is responsible for the enhanced
viral pathogenicity, and (3) how do the newly adapted ZIKV strains alter their interactions with host
cells that lead to those neurologic defects? In particular, the specific mechanisms underlying the
molecular actions of ZIKV-mediated neurologic disorders such as microcephaly and other neurologic
disorders need to be thoroughly investigated.
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Table 1. Zika viral strains that are known to cause microcephaly or microcephaly-like phenotypes.

























via induction of TLR3
[57]
FSS 13025 Human brain-specificorganoids Human/Cambodia/2010






ZIKV(BR) Human organoids Human/Brazil/2015
Reduction of proliferative





KU527068 Aborted human fetalbrain Human/Brazil/2016
Microcephaly with
calcification in the fetal brain
and placenta
[32]
FB_GWUH Aborted human fetalbrain Human/USA/2016
Fetal brain abnormalities










of microcephaly and vertical
transmission
[59]
SZ01 Mouse verticaltransmission Human/Samoa/2016
Infection of radial glia cells
of dorsal ventricular zone of
the fetuses resulting in




SZ01 Embryonic mousebrain Human/Samoa/2016
Cell cycle arrest, apoptosis,





CAM/2010AndVEN/2016Neonatal mouse brain Human/Cambodia/2010Human/Venezuela/2016
Neonatal ZIKV infection of
VEN/2016 leads to more
severe microcephaly than
CAM/2010. VEN/2016
strain infection leads to
stronger immune response,
more severe calcification,
more neuronal death and
abolished oligodendrocyte
development, but less
activation of microglial cells.
[62]
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Viral pathogenicity is normally referred to the state of a virus and its ability to cause disease.
The attributes of viral pathogenicity are often constituted by the target of organ, tissue, and cells
(cell tropism), the level and persistence of viral replication in host cells, and the ability of the
virus to cause damage to host cells that is referred to as cytopathic effects (CPEs). Both historical
and contemporary ZIKV strains have the capacity to replicate in brain-specific neuronal cells [34].
However, so far, only the epidemic strains were associated to congenital fetal microcephaly and
other neurologic disorders, highlighting that viral factors other than the cell tropism are more likely
contributing to the increased viral pathogenicity. Furthermore, multifactorial viral functions might
have contributed to those ZIKV-associated diseases. Conceivably, it could be the changing balance in
ZIKV–host interactions that leads to favorable and persistent ZIKV viral replication in host cells such as
hNPCs, increased and lasting CPEs that ultimately contribute to those observed fetal development and
neurologic disorders. In the following sections, we will discuss the molecular aspects of ZIKV–host
interactions, which include (1) host target cells and cell surface receptors for viral entry, (2) host
cellular and immune responses to ZIKV replications, (3) counteracting effects of ZIKV to host antiviral
responses, and (4) ZIKV-induced cytopathic effects (restricted cell growth, cell cycle dysregulation,
and cell death/apoptosis) that are all known contributing factors to fetal brain development and
neurologic impairments [42,57,61].
2. Cellular Targets and Viral Entry
2.1. Cellular Targets
ZIKV primarily infects NPCs in embryonic brains [42,61,63]. In the adult brain, it also infects
astroglial and microglial cells, and to lesser extent, neurons [36,42]. In addition, ZIKV infects other
tissues such as skin (including dermal fibroblasts and epidermal keratinocytes), testis, and placenta
(Table 2). As an arbovirus, ZIKV transmission is predominately through skin by mosquitoes such
as Ae. aegypti and Ae. africanus [22,23]. Consistent with this route of transmission, immature and
mature dendritic cells are susceptible to ZIKV infection [64–66]. ZIKV can also be transmitted through
sexual contacts [24–26]. Infected Sertoli cells in human testis are known ZIKV reservoirs [27–29].
Several placenta-specific cells have been shown to be prone to ZIKV infection including Hofbauer
cells, trophoblasts, and placental endothelial cells, supporting an important role of the placenta in
transmitting ZIKV via blood to fetal brains [33,67,68]. In line with the idea that crossing the blood-brain
barrier might be required to transmit the virus to the brain compartment [35], ZIKV persistently
infects primary human brain microvascular endothelial cells (hBMECs) or established cell lines [69].
Interestingly, a hepatoma cell line Huh-7 appears to be highly permissive to ZIKV infection. However,
liver has not yet been documented to be the target organ of ZIKV, even though DENV is well-known
to infect liver [70,71].
2.2. The Cellular Receptors for ZIKV Entry
Flaviviruses enter host cells by clathrin-dependent endocytosis, which is initiated when viral
particles interact with cell surface receptors. The cell surface receptors bind to the infectious viral
particles and direct them to the endocytic pathway. Several cell surface receptors facilitate ZIKV
viral entry (Table 2), which include the tyrosine-protein kinase receptor AXL, Tyro3, DC-SIGN,
and TIM-1 [64,65]. AXL and Tyro3 are part of the TAM receptor tyrosine kinase family that normally
binds to Gas6 and Pros1 ligands. These receptors are known to regulate an array of cellular activities
including cell adhesion, migration, proliferation, and survival, as well as the release of inflammatory
cytokines, which play pivotal roles in innate immunity [72]. DC-SIGN is an innate immune receptor
present on the surface of both macrophages and dendritic cells (DCs). It recognizes a broad range of
pathogen-derived ligands and mediates antigen uptake and signaling [73]. The TIM-1 receptor, also
known as HAVcr-1 (Hepatitis A virus cellular receptor 1), plays an important role in host response to
viral infection.
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Even though all of the aforementioned cell surface receptors participate in ZIKV viral entry,
they are not unique to ZIKV infection. For example, AXL, Tyro3, and DC-SIGN are used by Lassa
virus [74]. The TIM-1 receptor mediates infections of the deadly Ebola virus [75]. In fact, both TAM
and TIM families of phosphatidylserine receptors also mediate viral entry of other flaviviruses such as
DENV [76] and WNV [77]. For instance, in the case of DENV, TIM receptors facilitate viral entry by
directly interacting with virus-associated phosphatidylserine, whereas TAM-mediated infection relies
on indirect viral recognition, in which the TAM ligand Gas6 acts as a bridging molecule by binding to
phosphatidylserine within the viral particle [76]. Reviews of this topic can be found in [78,79].
Involvement of AXL, Tyro3, DC-SIGN, and, to a lesser extent, TIM-1 was initially described
by Hamel et al. when they studied ZIKV entry in skin cells [64]. AXL was subsequently shown
to be a prime target receptor for ZIKV viral entry in a variety of cell types including human
endothelial cells (hECs) [61], neural stem cells [80], microglia and astrocytes [81], and oligodendrocyte
precursor cells [82]. Examination of the AXL expression levels of diverse cell types suggests that
AXL is highly expressed on the surface of human radial glial cells, astrocytes, hECs, oligodendrocyte
precursor cells, and microglia in the developing human cortex as well as in progenitor cells of the
developing retina [80,82]. Other ZIKV permissive and non-neuronal human cell types, which are
known to express AXL, Tyro3, and/or TIM1 and likely to mediate viral entry, include placental cells,
explants-cytotrophoblasts, endothelial cells, fibroblasts, and Hofbauer cells in chorionic villi as well as
amniotic epithelial cells and trophoblast progenitors in amniochorionic membranes [83].
The susceptibility of human ECs to ZIKV positively correlates with the cell surface levels
of AXL [61]. Gain- and loss-of-function tests revealed that AXL is required for ZIKV entry at a
post-binding step, and small-molecule inhibitors of the AXL kinase significantly reduced ZIKV
infection of hECs [61]. In human microglia and astrocytes of the developing brain, like DENV,
AXL-mediated ZIKV entry requires the AXL ligand Gas6 to serve as a bridge linking ZIKV particles to
glial cells [81]. Following binding, ZIKV is internalized through clathrin-mediated endocytosis and
is transported to Rab5+ endosomes to establish productive infection. Downregulation of AXL by an
AXL inhibitor R428 or an AXL decoy receptor MYD1 significantly reduced but did not abolish the
ZIKV infection, suggesting the AXL receptor might be the primary but not the only receptor that is
required for ZIKV infection [81]. Genetic knockdown of AXL in a glial cell line nearly abolished ZIKV
infection [82]. It should be mentioned that elimination of any known entry receptor does not result in
complete protection from viral infection, as flaviviruses use many different receptors, there is always
redundancy and alternatives.
Interestingly, genetic ablation of the AXL receptor by CRISPR/CAS9 did not protect hNPCs
and cerebral organoids from ZIKV Infection [84]. In particular, genetic ablation of AXL has no effect
on ZIKV entry or ZIKV-mediated cell death in human induced pluripotent stem cell (iPSC)-derived
NPCs or cerebral organoids. It is not yet clear what contributes to the observed discrepancy between
this and other studies. One possibility is that ZIKV may use different cell surface receptors on
iPSC-derived NPCs [84]. For example, TIM-1 plays a more prominent role than AXL in placental
cells [83]. Duramycin, a peptide that binds phosphatidylethanolamine in enveloped viral particles and
precludes TIM1 binding, reduced ZIKV infection in placental cells and explants. In a mouse study,
comparison of homozygous or heterozygous AXL knock-out showed no significant differences in
ZIKV viral replication and clinical manifestation, suggesting AXL is dispensable for ZIKV infection in
those mice [85].
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Table 2. Cellular targets and receptor usages.
Primary Cell Receptor References
Brain
Neural progenitor cells (NPCs) AXL, TLR3 [80,84,85]
Astroglial cells AXL [36,81,86–88]
Microglial cells AXL [81]
Placenta
Hofbauer cells AXL, Tyro3, TIM1 [67,68,83]
Trophoblasts AXL, Tyro3, TIM1, TLR3, TLR8 [67,68,83]
Endothelial cells AXL, Tyro3, TIM1 [33,83]
Skin
Dermal fibroblasts AXL, TIM-1, TYRO3, TLR3, RIG-I, MDA5 [64,89]
Epidermal keratinocytes AXL, TIM-1, TYRO3, TLR3, RIG-I, MDA5 [64]
Immune cells
Immature dendritic cells DC-SIGN [64,65]
Dendritic cells DC-SIGN [66]
CD14+ monocytes Unknown [90–92]
CD14+CD16+ monocytes Unknown [91]
Testis
Sertoli cell AXL [28,93,94]
Spermatozoa Tyro3 [95,96]
Kidney





Retinal pericytes Tyro3, AXL
[1,98]Retinal microvascular
endothelial cells Tyro3, AXL
Permissive human cell lines
Cell line Origins Permissiveness References
SK-N-SH Brain/Bone marrow ** [99]
SH-SY5Y Nerve ** [100]
SF268 CNS in brain *** [42,70]
HBMEC Brain *** [69,94]
SNB19 CNS in brain *** [42]
Huh-7 Liver *** [70]
HFF-1 Skin *** [64]
A549 Lung *** [100,101]
HOBIT Osteoblast-like Cells *** [102]
Note: **, moderate permissive; ***, highly permissive.
3. Cellular and Immune Responses to ZIKV Infection
Inflammation is one of the first line responses of the cellular immune system to viral infection,
which is typically ignited by releasing cytokines including chemokines (Table 3). ZIKV triggers
various host cell pro-inflammatory responses (Figure 2) [64,65,101,103]. For example, ZIKV stimulates
CD8+ T cell-mediated polyfunctional immune responses to induce NF-κB-mediated production of
cytokines such as IL-1β, IL-6, MIP1α, as well as chemokines including IP10 and RANTES [87,103]
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(Figure 2, left). These ZIKV-induced T cell immune responses are antiviral because when CD8+
isolates from previously ZIKV infected mice are introduced to naive mice prior to ZIKV infection,
viral clearance is enhanced. Conversely, depletion of CD8+ T cells from infected animals compromises
viral clearance [65]. ZIKV structural proteins (C, prM, and E) are the major targets of CD8+ T cell and
CD4+ T cell responses [104].
 
Figure 2. This figure illustrates Zika virus interactions with host cells. The Zika virus or proteins are
colored in red. Cellular receptors or proteins that are affected by ZIKV are shown in blue. Cellular
proteins shown in green are regulatory proteins such as kinases. Three Zika viruses are used here
to show ZIKV-induced T-cell responses (left), ZIKV-mediated type I and type III IFNs productions
(middle) and ZIKV-triggered autophagy (right). → indicates a positive interaction. denotes inhibitory
action. Small red dots are used to indicate phosphorylation.
ZIKV also elicits humoral immune responses by producing protective and neutralizing antibodies
in humans [34,45]. However, this antibody-mediated protection effect against ZIKV could be
jeopardized in individuals who have previously been exposed to other flaviviruses such as DENV,
which is the closest sibling of ZIKV. Pre-existing neutralizing antibodies against DENV presented in
those individuals could, instead of neutralizing ZIKV, actually augment ZIKV infection and lead to
more severe diseases [50]. This ADE effect of prior flaviviral infections on ZIKV pathogenicity has
been thoroughly reviewed elsewhere [105,106].
Aside from ZIKV-mediated inflammatory and humoral responses, ZIKV also triggers a series of
host cell innate immune responses, which are crucial for the recognition of viral invasion, activation
of antiviral responses, and determination of the fate of viral infected cells (Figure 2, middle).
Generally, primed by the pathogen-associated molecular pattern (PAMP) of different viruses, host
cells recognize the invading virus by activating different types of pattern recognition receptors (PRRs),
which could be cell surface receptors or endosomal receptors. For example, ZIKV is recognized
by an endosomal toll-like receptor 3 (TLR3), which is a PRR that specifically recognizes dsRNA
virus [57,64,65]. TLR3 belongs to a class of endosomal receptors that can be found in first line of
defense cells such as macrophages or Langerhans cells. TLR3 activation plays a key role in host cell
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innate immune responses to viral infection. Consistent with the innate immune responses to dsRNA
virus, ZIKV-induced TLR3 activation promotes phosphorylation of interferon regulatory factor 3
(IRF3) by TBK1 kinase, leading to induction of type 1 interferon (IFN) signaling pathways [65,107].
This initiates a cascade that further activates cytoplasmic RIG-I-like receptors (RLRs) responses,
subsequently inducing transcription of RIG-I, MDA5, and several type I and III IFN-stimulated genes
including OAS2, ISG15, and MX1 [64]. Activation of the type I IFN signaling pathway results in
production and secretion of IFN-β. Secreted IFN-β binding to IFN-β receptor activates JAK1 and
Tyk2 kinases that in turn phosphorylate STAT1 and STAT2 (Figure 2, middle). Upon ZIKV infection,
association of the phosphorylated STAT1/STAT2 heterodimer with IRF9 promotes ISRE3-mediated
transcription of antiviral interferon stimulated genes (ISGS) [65]. One of the ISGS proteins, viperin
(virus-inhibitory protein, endoplasmic reticulum-associated, IFN-inducible), shows strong antiviral
activity against ZIKV. Specifically, it restricts ZIKV viral replication by targeting the NS3 protein for
proteasomal degradation [108]. Therefore, the production of TLR3- and RIG-1/MDA5-mediated type I
IFN production and subsequent activation of the JAK/STAT innate immune pathway confer increased
resistance to ZIKV infection [109].
ZIKV is a membrane-associated virus that utilizes host ER for its replication and reproduction
along the cellular secretory pathway. Through those cellular membrane interactions, ZIKV can trigger
autophagy in a cell-dependent manner (Figure 2, right). This cellular process is normally involved in
removal of aggregated or erroneously folded proteins through lysosomal degradation. Activation of
cellular autophagy is a hallmark of flavivirus infection, which was thought to be part of the host innate
immune response to eliminate invading intracellular pathogens [36,110–112]. Because autophagy
activation could halt cellular growth and trigger apoptosis, ZIKV-induced autophagy was implicated
in the ZIKV-mediated microcephaly [59,111,112]. Activation of autophagy elicits antiviral activities
by removing viral proteins through reticulophagy, a selective form of autophagy that leads to ER
degradation, or inclusion of viral proteins in autophagosomes destined for lysosomal degradation [113].
The ER-localized reticulophagy receptor FAM134B serves as a host cell restriction factor to ZIKV
and other flaviviruses [114]. However, ZIKV-induced autophagy could be a double edged sword,
which shows activities of both pro- and anti-ZIKV infection [113]. Activation of cellular autophagy
counteracts ZIKV infection by actively removing viral proteins. As part of the host cell’s antiviral
responses, type I IFN signaling also limits ZIKV replication by promoting autophagic destruction of the
viral NS2B/NS3pro protease in a STAT1-dependent manner [115]. Conversely, ZIKV takes advantage
of autophagosome formation, whose presence was associated with enhanced viral replication [64].
ZIKV activates autophagy through the cellular mTOR stress pathway that connects oxidative stress
and reactive oxygen species (ROS) production. This virus–host interaction appears to be highly
conserved, as in human fetal neural stem cells, ZIKV triggers autophagy through inhibition of the
mammalian mTOR pathway via AKT [111]. Similarly, in fission yeast cells, the ZIKV effect on TOR
is mediated through a parallel pathway via Tor1 and Tip41, the human equivalents of TSC1 and
TIP41 proteins [116,117]. Altogether, ZIKV infection elicits RIG-1/MDA5- and TLR3-mediated innate
immune responses leading to releases of type I and type III IFNs to protect cells from viral invasion.
ZIKV concurrently triggers cellular activation of the stress TOR signaling pathway that induces
autophagy. The balance between pro- and anti-ZIKV activities of autophagy, at least in some cells,
determines whether infected cells are protected through viral elimination, or destined to apoptosis as
the result of viral propagation in host cells.
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Table 3. Cellular antiviral responses and viral counteractions during Zika infection.
Cellular Antiviral Responses to Zika Infection
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4. Viral Counteraction to Host Antiviral Responses and ZIKV-Induced Cytopathic Effects
4.1. Viral Counteraction to Host Antiviral Responses
To establish successful viral infection, ZIKV has adopted various strategies to counteract host
antiviral responses (Table 3). The final infection outcome depends on the balance between the host
antiviral responses and the viral counteracting actions. A number of ZIKV-mediated counteracting
actions are known. For example, once ZIKV infection is successfully established, it becomes resistant
to IFN treatment, suggesting ZIKV might have deployed effective counteractive measures against host
innate immune responses [101,125]. Resultant to this finding, no secreted type I and type III IFNs were
detectable from ZIKV-infected cells [65]. Indeed, ZIKV impairs the induction of type I IFN by binding to
IRF3, a member of the IRF family [49,125,128]. These ZIKV-mediated counteracting effects are achieved
through multiple non-structural ZIKV proteins (NS1, NS2A, NS2B, NS4A, NS4B, and NS5). All of
these ZIKV proteins suppress, to various degrees, IFN-β production by targeting distinct components
of the RIG-I pathway [49]. For instance, the NS1, NS4A, and NS5 proteins specifically inhibit IRF3 and
NFkB [125], and the NS1 and NS4B proteins block IRF3 activation [49,115]. Interestingly, an A188V
mutated NS1, which was found during the ZIKV epidemic starting in 2012, showed enhanced ability
to block IFN-β induction, and facilitated mosquito-mediated virus transmission [49]. This acquired
mutation enables NS1 binding to TBK1 and reduces TBK1 phosphorylation. Reversion of this mutation
to the pre-epidemic genotype weakens the ability of ZIKV to counteract IFN-β production. Consistent
with the idea that ZIKV blocks the IFN-β production through IRF3, IRF3 knockout cells lost this ZIKV
effect [48,49].
ZIKV has also developed mechanisms to block the JAK/STAT pathway [65] (Figure 2, middle).
For example, it blocks JAK1/Tyk2-mediated STAT1 and STAT2 phosphorylation resulting in ISGF3
transcription and ISGS translation shutdown [65]. On one hand, ZIKV utilizes its PR to inhibit
JAK1 kinase [115]. On the other, ZIKV uses NS5 protein through direct binding to promote STAT2
proteasome-mediated degradation [125,126,128].
4.2. ZIKV-Induced Cytopathic Effects
Persistent viral replication and propagation inevitably confer adverse CPEs to host cells (Table 4).
Like many other viruses, ZIKV encodes a limited number of proteins and, conceivably, has to rely on
host cell resources to ensure its successful viral reproduction. Thus, a variety of devious approaches
are utilized in order to commandeer host cell resources to create an environment for its own benefit.
One common viral strategy is to deter host cell growth, or to subvert the host cell cycle into a specific
phase whereby the virus gains optimal benefit by maximizing availability of cellular resources for
its transcription, translation and assembly. This indeed is true for ZIKV in that ZIKV infection of
hNPCs restricts cell growth and induces cell cycle dysfunction and apoptosis [42,61,63]. Further,
these ZIKV-mediated CPEs appear to be associated with clinical neurological manifestations such
as microcephaly [42,129]. For instance, ZIKV-induced CPEs correlate with the decrease of neuronal
cell-layer volume of the brain organoids reminiscent of processes resulting in microcephaly, supporting
that ZIKV-induced microcephaly is likely the result of ZIKV-mediated increase of CPEs [40,43,57,59].
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Table 4. ZIKV proteins and associated cytopathic effects.
Protein Primary Function Main Phenotypes References
Structural Proteins
anaC Anchored capsid protein
In the fission yeast cells, it restricts cellular growth and
affects cell cycling. It also induces cellular oxidative
stress leading to cell death.
[9]
C Capsid protein
In the fission yeast cells, it restricts cellular growth. It
also induces cellular oxidative stress leading to cell
death; in hNPCs, it induces ribosomal stress and
apoptosis.
[9,130]
prM Precursor membrane protein
In the fission yeast cells, it restricts cellular growth and
affects cell cycling. It also induces cellular oxidative
stress and autophagy leading to cell death; a single
prM mutation contributes to fetal microcephaly
[9,131]
M Membrane protein
In the fission yeast cells, it restricts cellular growth and
affects cell cycling. It also induces cellular oxidative
stress and autophagy, leading to cell death.
[9]
Pr Cleaved product from prM Unknown
E Envelope protein
A putative cytopathic factor based on a yeast study.
E protein facilitates viral entry. A single residue in the
αB helix of the E protein is critical for Zika virus




NS1 Viral replication, pathogenesisand immune evasion
In the fission yeast cells, it induces cellular oxidative
stress and autophagy leading to cell death;
An essential role in viral replication and immune
evasion. It presents on the cell surface and presents as
a dimer within cells, and as a hexamer once being
secreted. NS1-mediated CPEs in mammalian cells
have not yet been established.
[47–49,133]
NS2A Unknown
In the fission yeast cells, it induces cellular oxidative
stress and autophagy leading to cell death;
ZIKV-encoded NS2A disrupts mammalian cortical
neurogenesis by degrading adherens junction (AJ)
proteins, leading to reduced proliferation and
premature differentiation of radial glial cells and
aberrant positioning of newborn neurons.
[131]
NS2B Protease cofactor
In fission yeast cells, it restricts cellular growth. Forms
a protease complex with NS3; a putative cytopathic
factor based on a yeast study
[9,134]
NS3 Protease and helicase NS3-mediated CPEs in mammalian cells have not yetbeen established. [131]
NS4A Viral RNA synthesis and viralmorphogenesis
In the fission yeast cells, it restricts cellular growth and
affects cell cycling. It also induces cellular oxidative
stress and autophagy leading to cell death. It induces
autophagy by inhibiting Atk-mediated TOR pathway
through Tor1/TSC1 and Tip41 in both yeast and
mammalian cells.
[9,111]
2K A signal peptide Viral RNA synthesis and viral morphogenesis.2K-mediated CPEs have not yet been established. [9,11,12]
NS4B Viral RNA synthesis and viralmorphogenesis
Synergistic to NS4A on inhibiting Akt-mediated TOR
pathway [111]
NS5 Methyltrasferase;RNA-dependent polymerase
NS5-mediated CPEs in mammalian cells have not yet
been established. [128]
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Although ZIKV confers various CPEs as described above, the identity of which ZIKV protein(s)
is responsible, and the mechanism by which ZIKV mediates those effects, remains elusive. To assist
in identifying which ZIKV viral protein(s) is responsible for those observed CPEs, we performed
a genome-wide analysis of ZIKV proteins by using fission yeast (Schizosaccharomyces pombe) as
a surrogate system [9,135]. Fission yeast is particularly useful here because the aforementioned
ZIKV-mediated CPEs affect highly conserved cellular activities among all eukaryotes [136–139]. Each of
the fourteen ZIKV viral cDNA encoding a specific protein or a small peptide was cloned into previously
described fission yeast gene expression systems [140,141]. All of the ZIKV viral activities were
measured simultaneously under the same inducible conditions, thus allowing concurrent functional
characterization of each ZIKV protein. Consistent with the idea that ZIKV is a cell membrane-associated
virus, and that the ER is the major “viral factory” [36,110,142], nine of the fourteen ZIKV proteins
and peptides were found to associate with the ER network, including the nuclear membrane, ER,
and Golgi [36,142,143]. Seven ZIKV proteins, including five mature and immature structural proteins
(anaC/C, prM/M, and E), and two non-structural proteins (NS2B and NS4A), conferred a number
of the same CPEs as reported in the ZIKV-infected mammalian cells infected by ZIKV [9,36,40,42,43].
Specifically, the ZIKV protein-producing yeast cells displayed restricted cellular growth, cellular
autophagy, cell hypertrophy, cell cycle dysfunction, and cell death [9]. As described below, some of the
same ZIKV protein-mediated CPEs have also been reported in mammalian cells.
4.3. The Structural Proteins
Cytopathic effects induced by ZIKV structural proteins are summarized in Table 4. Briefly,
the yeast study showed that both the anaC and C proteins localize to the nuclei, triggering cellular
oxidative stress leading to cell death [9]. Consistently, C protein is known to localize in the nucleus
for other flaviviruses [144,145]. ZIKV C protein is present in human NPC nucleoli, sub-nuclear
structures where ribosome biogenesis takes place, and also plays a role in cellular response to
stress [130]. The presence of C protein in nucleoli was associated with activation of ribosomal stress
and apoptosis [130]. Deleting part of the C protein prevented nucleolar localization, ribosomal stress,
and apoptosis [130].
The E protein is a major viral surface protein that is responsible for the viral entry. Thus, it is a
crucial viral determinant for initiating the ZIKV–host interaction. Comparison of E protein sequence
and structure with that of other flaviviruses suggest ZIKV E protein is unique among flaviviruses,
although some portions of it resemble its counterparts in WNV, JEV, and DENV [146,147]. During
flaviviral assembly, E interacts with prM to form the prM-E heterodimers that protrude from the
viral surface in the non-infectious and immature viral particles [14]. It is also involved in fusing
the viral membrane with the host endosome membrane. As with other flaviviruses, the ZIKV E
protein is glycosylated at amino acid N154. The E glycosylation appears to be critical for ZIKV
infection of mammalian and mosquito cells, because a glycosylation mutant N154Q diminished oral
infectivity by Ae. aegypti vector and showed reduced viremia and diminished mortality in mouse
models [148]. Interestingly, knockout of E glycosylation does not significantly affect neurovirulence
in mouse models [148]. While ZIKV encoding non-glycosylated E protein displayed attenuated and
defective neuroinvasion when delivered subcutaneously, it replicated well following intracranial
inoculation, suggesting possible involvement of E in passing through the blood-brain barrier [149].
Furthermore, ZIKV viral particles lacking the E protein glycan were still able to infect Raji cells
expressing the lectin DC-SIGN receptor, indicating the prM glycan of partially mature particles can
facilitate the viral entry [150]. The E protein, specifically its extended CD-loop, may confer viral
stability, cell cycle-dependent viral replication, and in vivo pathogenesis, as shortening the CD-loop
destabilizes the virus, and Δ346 mutation in this loop disrupts thermal stability of the virus [151].
In DENV, the prM protein forms a heterodimer with the E protein and affects viral particle
formation and secretion [14]. The resultant non-infectious and immature viral particles are transported
through the TGN, where prM is cleaved by a host protease Furin, resulting in mature infectious
118
Viruses 2018, 10, 233
particles [15,16]. The transition from prM to M via the cleavage of host protease Furin is required
for viral infectivity [11,13]. Therefore, both prM and M play important roles in viral pathogenesis.
Consistent with the prM/M activities in host cells, in the yeast study, we showed that both prM
and M proteins localize in ER [9]. Similarly, prM also localizes in ER in Vero cells [47]. In addition,
the prM protein restricts cellular growth, and affects cell cycling leading to cell death in the yeast [9].
At the time of this writing, no description has yet been reported on the effect of individual prM or M
protein on those basic cellular functions in mammalian cells. However, mutational analysis shows
that the activity of prM protein contributes to fetal microcephaly [152]. Specifically, evolutionary
analysis shows that a S139N substitution in the prM protein has persisted in the circulating ZIKV
strains since the 2013 outbreak in French Polynesia to the subsequent spread to the Americas.
A single serine(S)-to-asparagine(N) substitution (S139N) in the viral polyprotein of a presumably less
neurovirulent Cambodian ZIKVFSS13025 strain [153], substantially increased ZIKV infectivity in both
human and mouse NPCs, and led to more severe microcephaly in the mouse fetus, as well as higher
mortality rates in neonatal mice [152]. Results of this study underscore the important contribution of
prM to fetal microcephaly. However, the manner in which prM contributes to microcephaly, and the
impact of S139N mutation on the prM function, are presently unknown. It is intriguing to note that
residue 139 is actually located in the Pr region of the prM protein. Since neither prM nor Pr are present
in the mature and infectious viral particles [15,16], it would be interesting to learn the molecular
mechanism underlying the effect of the S139N mutation causing increased viral infectivity.
4.4. The Non-Structural Proteins
ZIKV PR, which consists of forty residues of the NS2B cofactor and the NS3pro domain of the
NS3 [154], has been actively investigated for its PR activities (Table 4) [134,155,156]. In addition
to ZIKV PR-mediated proteolysis for its own replication, ZIKV PR also cleaves the ER-localized
reticulophagy receptor FAM134B to counteract host cell restriction through a selective form of
autophagy known as reticulophagy [114]. Indeed, depletion of FAM134B by RNAi significantly
enhanced ZIKV replication [114]. The production of the same PRs by other flaviviruses causes cell
death by apoptosis [157,158]. However, whether ZIKV PR causes apoptosis is presently unknown.
The yeast study showed that expression of the NS2B gene, which encodes the co-factor of the ZIKV PR,
does induces cellular autophagy and cell death [9]. It would be of interest to test if fully active ZIKV
PR can induce cell death in yeast and mammalian cells.
The NS4A protein, in conjunction with NS4B, activates cellular autophagy through inhibition
of the mammalian TOR pathway via AKT [111]. Similarly, NS4A also inhibits the Tor1 pathway
in the fission yeast. Furthermore, the yeast study showed that the inhibitory NS4A effect on
TOR was mediated through Tor1 and Tip41, which are the human equivalents of TSC1 and TIP41
proteins [116,117].
Expression of NS2A reduces cell proliferation and causes premature differentiation of radial
glial cells in the developing mouse brain [131]. In addition, NS2A interacts with adherens junction
(AJ) proteins that are present at the epithelial–endothelial cell junctions, resulting in degradation and
malformation of the AJ complex [131]. These NS2A-induced growth defect in the embryonic mouse
cortex are unique to ZIKV, as the same effects were not seen in DENV. These NS2A effects could
pay a role in the pathogenic mechanism underlying ZIKV infection in the developing mammalian
brain [131].
NS1 is a highly conserved protein among flaviviruses. It is an essential viral glycoprotein
that plays a major role in virus–host interaction as it participates in viral replication, pathogenesis,
and immune evasion [159]. As with other flaviviruses, NS1 is expressed at the cell surface and exists
in diverse forms. Intracellular NS1 exists as a dimer that is required for viral replication, whereas
the secreted NS1 hexamer interacts with host factors and plays a role in immune evasion [159,160].
Freire et al. [161] first revealed adaptation of the NS1 codon to human housekeeping genes in ZIKV
Asian lineage, which could facilitate viral replication in humans. Indeed, an alanine(A)-to-valine(V)
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amino acid substitution at residue 188 (A188V) of the NS1 protein was acquired by the ancient ZIKV
strain since the turning of the century in Southeastern Asia. This A188V-carrying ZIKV strain circulated
in that region before dissemination to Southern Pacific islands and the Americas [162]. Residue 188
is located within the interface of two NS1 monomers. However, this A188V substitution does not
affect NS1 dimerization, instead increasing its secretability [48]. Strikingly, the A188V-carrying ZIKV
epidemic strains were much more infectious in mosquitoes (Ae. aegypti) than the earlier Cambodia
ZIKVFSS13025 strain, resulting in increased NS1 antigenemia. Enhancement of NS1 antigenemia in
infected hosts promotes ZIKV infectivity and prevalence in mosquitoes, which could have facilitated
transmission during the recent ZIKV epidemics [48]. Consistent with this idea, acquisition of the
A188V substitution also correlates with enhanced ZIKV evasion of host interferon induction [49].
Interestingly, another pathogenic mutation T233A was isolated from the brain tissue of a ZIKV
infected fetus with neonatal microcephaly [47]. The ZIKV NS1 T233A mutation, also located at the
dimer interface, was not found in any other flaviviruses. This finding could potentially be significant
because wildtype T233 organizes a central hydrogen bonding network at the NS1 dimer interface, while
the T233A mutation disrupts this network and destabilizes the NS1 dimeric assembly in vitro [47].
However, the pathogenic potential of this mechanism has not yet been tested. Together, these studies on
the NS1 protein suggest that ZIKV has acquired specific mutation(s) that increases its ability to evade
host immune responses, and favors persistent viral replication, leading to enhanced viral pathogenicity.
5. Concluding Remarks
Since the global ZIKV pandemic in 2015, an unprecedented world-wide effort is being made to
understand the ZIKV etiology and its associated human diseases. We have learned a great deal about
its epidemiology, genetic diversity, viral pathogenicity, and clinical manifestations that are linked to
ZIKV-associated human neurological diseases. In this article, we describe molecular interactions of
ZIKV with its host cells. In particular, we briefly outline different cell types and receptors utilized
by ZIKV for viral entry and infection. We then describe host cellular and immune responses to
fight against ZIKV invasion. In response, ZIKV has adopted various counteracting strategies to
defeat those host antiviral responses. The overall balance between host antiviral defenses and viral
countermeasures determine the outcome of host cells, and the success of viral propagation and survival.
Persistent viral replication and propagation inevitably damage human host cells, tissues, and organs,
ultimately resulting in fetal microcephaly and a number of other neurologic disorders. Yet, we have
only just begun to understand the molecular mechanisms underlying ZIKV interactions with host
cells, and how those interactions relate to the observed neurological disorders caused by those newly
adopted pathogenic ZIKVs. Much work is still needed to answer some of those same questions as we
asked at the beginning, e.g., (1) what specific virological changes have taken place that transformed
the ZIKV from a benign virus to a highly pathogenic virus, (2) how could viral mutations, such as
those described in this review, alter the viral pathogenicity enabling recently observed neurological
disorders, and (3) what specific changes in ZIKV–host interactions ultimately tilt the balance in favor
of enhanced CPEs and viral pathogenicity? Ongoing and future research will no doubt continue to
strive to provide answers to these questions. We hope this review will serve as a helpful reference to
those who study ZIKV–host interactions, and that the information described herein will encourage
additional studies focusing on the molecular mechanisms of this virus.
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Abstract: Type I interferon (IFN-I) is the first line of mammalian host defense against viral infection.
To counteract this, the flaviviruses, like other viruses, have encoded a variety of antagonists,
and use a multi-layered molecular defense strategy to establish their infections. Among the most
potent antagonists is non-structural protein 5 (NS5), which has been shown for all disease-causing
flaviviruses to target different steps and players of the type I IFN signaling pathway. Here,
we summarize the type I IFN antagonist mechanisms used by flaviviruses with a focus on the role of
NS5 in regulating one key regulator of type I IFN, signal transducer and activator of transcription 2
(STAT2).
Keywords: flavivirus; ZIKV; NS5; type I IFN antagonist
1. Introduction
Flaviviruses are globally significant arthropod-borne viruses that cause disease in hundreds of
millions of people each year. The Flavivirus genus is part of the Flaviviridae family and comprises over
70 species, including dengue, Zika, yellow fever, West Nile, Japanese encephalitis, and tick-borne
encephalitis viruses. Facilitated by the warming climate, urbanization, and increasing travel to endemic
areas, many of these pathogens have expanded into new territories, and flaviviral infections have
increased worldwide [1]. Despite the enormous burden on public health posed by flaviviruses, there are
currently no antiviral therapies available and limited vaccines.
To establish successful infection in vertebrates, flaviviruses must first overcome the host antiviral
response, which is primarily mediated by type I interferons (IFN-I) [2]. IFN-I stimulates expression
of hundreds of genes that disrupt various stages of the viral life cycle. The power and importance of
this host defense is demonstrated by the fact that all flaviviruses have evolved elaborate mechanisms
to antagonize and evade the type I IFN response. The ability of individual viruses to suppress this
pathway determines host and tissue tropisms and severity of disease [3,4]. Therefore, understanding
the interaction between the host immune response and viral antagonism of this defense at the molecular
level elucidates mechanisms of pathogenesis and facilitates the development of safe and effective
antiviral therapies and vaccines.
Flaviviruses employ diverse strategies to subvert the host immune system. To avoid being
recognized as “non-self,” which triggers IFN-I production, flaviviruses mask their genome with RNA
caps that mimic that of the host and the intermediate RNAs are hidden from cytoplasmic sensors by
membranes hijacked by viral replication proteins [5]. Flaviviruses also actively antagonize proteins
that function within the IFN-I signaling pathway by inhibiting their post-translational modifications,
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competing for protein–protein interactions, or targeting them for degradation [2]. These diverse
mechanisms of IFN antagonism are typically carried out by flavivirus non-structural proteins.
Non-structural protein 5 (NS5) is the largest and most conserved flavivirus protein [6]. It is
responsible for replicating and capping the viral genome, but is also a potent innate immune antagonist
in all flaviviruses studied thus far [7]. However, the mechanisms utilized by the NS5 proteins from
related viruses have been shown to diverge significantly. This review discusses the IFN-I-mediated
defense mounted by flavivirus-infected hosts and the various mechanisms employed by flaviviruses
to counteract this defense, with special emphasis given to NS5-mediated suppression of human signal
transducer and activator of transcription 2 (hSTAT2)-dependent IFN signaling. Three of the major
disease-causing flaviviruses’ NS5 proteins interact with and inhibit hSTAT2, a central regulator of the
type I IFN response. We discuss the ways in which this interaction diverges among the highly related
flaviviruses and the impact of hSTAT2 inhibition on viral pathogenesis.
2. Flavivirus Disease and Transmission
Disease caused by flaviviruses ranges from mild symptoms such as fever, rash, and joint pain to
more severe illness that includes hemorrhagic fever, encephalitis, and neurological sequelae. However,
very few infected individuals experience serious illness, and most are entirely asymptomatic. It is
currently not possible to predict an individual’s disease outcome due to our inadequate understanding
of the molecular basis of the pathogenesis of severe disease. There are no vaccines available for
dengue, Zika, or West Nile viruses. Even for flaviviruses with effective vaccines, such as yellow fever,
Japanese encephalitis, and tick-borne encephalitis viruses, outbreaks still occur from time to time in
developing countries.
Dengue virus (DENV) is responsible for the highest incidence of disease among the flaviviruses
(≈400 million annually) [8]. There are four genetically distinct serotypes of DENV and infection with
one serotype confers long-lasting immunity against only the infecting serotype. Primary infections are
frequently asymptomatic but can result in fever and rash, whereas secondary infections, especially
with a heterologous serotype, can cause dengue hemorrhagic fever and shock syndrome, likely due
to antibody-dependent enhancement (ADE) [9]. Zika virus (ZIKV), which emerged recently in
several major epidemics in Asia and the Americas, causes similar symptoms to dengue fever and
has additionally been causally linked to congenital microcephaly and Guillain-Barré syndrome [10].
West Nile virus (WNV) is common in Africa, the Middle East, and Europe, and appeared in North
America in 1999 [11]. In addition to febrile illness, WNV is a major cause of viral encephalitis [12].
The human pathogen flaviviruses are vector-borne, although different tick and mosquito species
are utilized by different viruses. Yellow fever virus (YFV), DENV, and ZIKV are transmitted primarily
by Aedes mosquitoes [13], whereas WNV and Japanese encephalitis virus (JEV) are transmitted
through the Culex species [14,15]. Flaviviruses are also zoonotic and rely on non-human animal
vectors for widespread circulation. For example, pigs and birds are amplifying hosts for JEV [16],
and non-human primates are ZIKV amplification hosts [17]. Flaviviruses alternate between two distinct
transmission cycles: sylvatic and urban. The sylvatic transmission cycle refers to the transmission
of the virus between the arboreal vector and non-human animal hosts, and the urban cycle consists
of circulation between arthropods and humans [18]. The recent ZIKV epidemics have revealed
additional mechanisms of transmission that may be unique to Zika, such as sexual contact and
perinatal transmission [19,20].
Because of the necessity of alternating between vertebrate and arthropod hosts, flaviviruses have
adapted their immune restriction mechanisms for distinct species. For example, DENV proteins can
cleave the human immune factors stimulator of interferon genes (STING) and STAT2 (discussed below)
but not non-human primate STING or murine STAT2 [3,21,22]. Similarly, ZIKV causes the degradation
of human but not murine STAT2 [3]. These species-specific immune suppression mechanisms help
to explain in part why DENV fails to reach high titers non-human primate models [23,24], and why
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immunocompetent mice are poor disease models for many flaviviruses, including ZIKV and DENV [25,
26].
3. Flavivirus Genome and Life Cycle
Flavivirus genomes are 10-11 kb single-stranded positive-sense RNA molecules flanked by
structured 5’ and 3’ UTRs. A recent study demonstrated pervasive higher-order structures throughout
the ZIKV [27] and DENV2 RNA genomes, spanning at least eight distinct regions [28]. A virally
encoded methyltransferase provides a m7GpppN cap structure to the 5’ end of the genome similar to
mammalian mRNA caps [29], but the flaviviral genome lacks a 3’ polyadenylation tail. The genome is
translated as a single polyprotein, which is then proteolytically processed by host and viral proteases
to generate three structural proteins (capsid (C), pre-membrane (prM), and envelope (E)), and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The non-structural (NS)
proteins are responsible for replication of the viral genome, polyprotein processing, and host immune
response antagonism. Mature virions are ≈50 μm in diameter and consist of the RNA genome
encapsulated by a lipid envelope and the three structural proteins C, prM, and E [6].
Flaviviruses enter the cell via endocytosis and traffic to endosomes where the envelope protein
undergoes a low pH-induced conformational change to induce fusion of the endosomal membrane
with the viral membrane. This fusion event allows the nucleocapsid to be released from the endosome,
and the genome is rapidly translated at the surface of the endoplasmic reticulum (ER) [30]. The viral
NS proteins facilitate the formation of replication complexes by hijacking host cytoplasmic membranes.
These compartments coordinate the replication and translation of the viral genome and help to shield
viral components from host recognition. The NS proteins form a replication complex that generates
negative-sense RNAs that function as templates for positive-sense genome RNA. Newly synthesized
viral RNA is packaged, and the immature virion is transported through the host secretory pathway
where it is further processed by host proteases to generate a mature virion that is released from the
infected cell by exocytosis [6].
4. Host Innate Immune Response to Flavivirus Infection
The type I IFN signaling pathway is one of the first lines of defense against flavivirus infection
of mammals. Type I IFNs are produced by mammalian cells in response to viral infection and
play a pivotal role in counteracting viral pathogenesis [31]. Flavivirus-infected individuals have
elevated levels of immune-related gene transcripts and serum IFN [32–36]. In mouse and cell models,
similar elevations have been reported [37–39] and production has been shown to play a protective
role [10–13]. Several proteins that function within this signaling pathway have been identified with
direct and specific antiviral roles during flavivirus infection [37,38,40,41]. IFN-I has even been tested
as a treatment for clinical flavivirus disease, but has not been successful [42,43]. This may be explained
by the universal ability of flaviviruses to inhibit the Janus kinase-signal transducer and activator of
transcription (JAK-STAT) pathway. As discussed below, the NS proteins are the primary actors in
this suppression, and understanding the molecular mechanisms mediating this suppression would
contribute to the development of effective antiviral therapies.
The innate immune response against flaviviruses is triggered by sensing the pathogen-associated
molecular patterns (PAMPs) via the cytosolic and endosomal pattern recognition receptors (PRRs)
retinoic acid-inducible gene-1 (RIG-I), melanoma differentiation-associated protein 5 (MDA5),
Toll-like receptor (TLR) 7/8, or TLR3 [44–46]. PAMP sensing PRRs activate various kinases including
inhibitor of nuclear factor kappa-B (NF-κB) kinase subunit epsilon (IKKε), tumor necrosis factor (TNF)
receptor-associated factor (TRAF) family member-associated NF-κB (TANK)-binding kinase-1 (TBK-1),
and TRAF3, which ultimately result in the phosphorylation of NF-κB and interferon regulatory factor
3 (IRF3) [45,47]. Activated NF-κB and IRF3 translocate to the nucleus to stimulate the production of
type I IFNs.
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The type I IFNs consist primarily of two secreted cytokines, IFN-α and IFN-ß. Upon secretion,
IFN-α/ß bind to their cognate receptor IFNAR on infected and neighboring cells. IFNAR consists
of two subunits (IFNAR1 and IFNAR2) whose intracellular domains are constitutively associated
with the Janus kinases JAK1 and Tyk2. IFN binding to IFNAR activates JAK1 and Tyk2 to
phosphorylate the latent cytoplasmic signal transducers of activation 1 and 2 (STAT1 and STAT2).
Tyrosine phosphorylated STAT1 and STAT2 dimerize and then associate with a third protein, interferon
regulatory factor 9 (IRF9). This trimeric complex, known as interferon-stimulated gene factor 3 (ISGF3),
translocates into the nucleus where it binds to interferon stimulated response elements (ISRE) to drive
transcription of over 300 interferon stimulated genes (ISGs) that directly or indirectly counter flavivirus
infection. IRF9 binds to the ISRE, STAT2 contributes a potent transactivation domain, and STAT1
stabilizes the complex through additional DNA interactions [48,49].
The components of ISGF3 are constitutively expressed at a low level and reside in the cytoplasm in
their latent forms. Upon IFN stimulation and tyrosine phosphorylation of STATs 1 and 2, ISGF3 rapidly
assembles and directs a robust, transient antiviral response that includes the upregulation of ISGF3
components themselves. This response, however, additionally increases the expression of pro-apoptotic
and anti-proliferative genes that can be damaging to the host cell, so downregulation of these
genes occurs quickly after IFN stimulation. This response is mediated by several negative feedback
mechanisms, such as the suppressor of cytokine signaling (SOCS) proteins, which are also induced by
type I IFN [50]. In contrast, a subset of the antiviral ISGs upregulated by the initial IFN stimulation,
including STAT1, STAT2, and IRF9, are sustained for several days, resulting in increased levels of
the unphosphorylated forms of these proteins [51]. These proteins interact to form the trimeric
unphosphorylated ISGF3 (U-ISGF3), which is responsible for the sustained ISG transcription, allowing
for extended resistance to viral infection [52].
Recently, evidence has emerged for the existence of STAT1-independent complexes that can
drive IFN-I-stimulated ISG expression [53]. For example, STAT2 can interact with IRF9 to form an
“ISGF3-like” complex that activates ISRE-promoted genes in response to type I IFN [54]. This complex
can direct a similar but prolonged ISGF3-like transcriptome in the absence of STAT1. However,
some STAT2/IRF9-specific ISGF3-independent ISGs have been identified, including CCL8 and CX3CL1.
The promoter regions of these genes do not contain the classical ISRE sequences, suggesting that a DNA
sequence distinct from ISRE may be involved in STAT2/IRF9-specific gene regulation. Additionally it
has been demonstrated that this alternative pathway can mediate antiviral responses to several viruses
including dengue, vesicular stomatitis, encephalomyocarditis, measles, Crimean-Congo hemorrhagic
fever, and lymphocytic choriomeningitis viruses [55–59]. The cyclic guanosine monophosphate
(GMP)–adenosine monophosphate (AMP) synthase (cGAS) is a cytosolic DNA sensor that directs the
synthesis of cyclic GMP-AMP (cGAMP) upon binding to DNA. cGAMP activates the stimulator of
the IFN gene (STING), which promotes type I IFN production via IRF3 activation [60]. It was recently
demonstrated that the cGAS/STING pathway becomes activated during DENV infection, even in the
absence of viral DNA intermediates [21]. DENV infection induces mitochondrial swelling, causing the
release of mitochondrial DNA, which activates cGAS [61]. The involvement of the cGAS/STING
pathway in other flavivirus infections has yet to be determined.
Although type I IFNs are produced by nearly all cells in the body and are essential for restricting
viral replication, two additional IFN signaling pathways exist and have been shown to respond to
viral infection. The type III IFNs (IFN-λ1-4) are the primary antiviral IFNs generated by epithelial
cells and have similar functions and signaling pathways as IFN-I, but the cellular receptor is not
ubiquitously expressed [62]. An antiviral effect for IFN-λ has been demonstrated for West Nile
and Zika viruses. Mice deficient in the IFN-λ receptor exhibited increased blood–brain barrier
(BBB) permeability after WNV infection [63], suggesting type III IFN signaling is involved in WNV
neurotropism. Primary human trophoblast cells from human placenta were found to release type III
IFN constitutively, conferring resistance to ZIKV infection [64]. The ability of ZIKV to be vertically
transmitted from mother to fetus suggests the existence of a viral factor that may be able to overcome
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the type III IFN response in placental cells. The NS5 protein from ZIKV is a likely candidate as it was
shown to inhibit the type III response in HEK293T cells [65].
While ZIKV NS5 was shown to suppress both the type I and III IFN responses, it was also able to
activate type II IFN signaling [65]. The type II IFNs (IFN-γ) are generated mainly by immune cells
and have some antiviral functions. ZIKV infection, however, is enhanced by type II IFN signaling,
which generates proinflammatory cytokines that can facilitate viral spread and exacerbate Zika
disease [66]. The concurrent NS5-mediated suppression of type I and III pathways and activation of
the type II pathway was suggested to occur through increased homodimerization of STAT1, which
upregulates gene expression at γ-activated sites (GAS). Because ZIKV NS5 induces the degradation of
STAT2 (discussed below), which is required for the formation of transcription complexes involved
in type I and III IFN signaling, the intracellular balance of STAT-containing complexes shifts to
STAT1-STAT1 dimers, resulting in increased IFN-γ-induced gene expression. To date, ZIKV NS5 is the
only viral protein known to concurrently suppress type I and III IFN pathways while activating type
II [65].
5. Flavivirus Antagonism of Host Type I IFN Response
Just as hosts have evolved multiple mechanisms for inhibiting viral infection, viral proteins have
gained the ability to antagonize the host IFN response over time. One mechanism by which the
type I IFN response is passively avoided by flaviviruses is evasion of the host PRRs, described above.
Flaviviruses encode their own methyltransferase that caps the RNA genome to mimic the RNAs present
in the host cell. The cap structure hides the viral genome from members of the interferon-induced
tetratricopeptide repeats (IFIT) protein family, which binds to and sequesters viral RNA, and prevents
recognition by the RIG-I [67]. Flaviviruses also shield their genome from host sensing by enclosing
their replication complex (RC) in membranes on the ER surface, a mechanism that has been observed in
the early stages of DENV, WNV, and tick-borne encephalitis virus (TBEV) infections [68,69]. However,
late in the infection, newly synthesized viral RNA is abundant, and the RC loses some integrity,
which may lead to the release of RNA intermediates that could activate RIG-I or MDA5 signaling [70].
Flaviviruses have also been demonstrated to actively abrogate the activity of protein functioning
within the type I IFN signaling pathway. One common mechanism is interference with
post-translational modifications of these proteins. For example, the DENV, WNV, and YFV NS4B
inhibit STAT1 phosphorylation [71,72]. WNV NS4B is additionally implicated in preventing the
phosphorylation of JAK1 and Tyk2 [27,28], and NS2A, NS2B, NS3, NS4A, and NS4B from Kunjin virus
(KUN), a close relative to WNV, are all implicated in JAK-STAT inhibition [73]. This mechanism is
not always mediated by NS proteins, however. Flaviviruses produce small RNAs called subgenomic
flavivirus RNAs (sfRNAs) that are generated by the incomplete degradation of the viral genome by
the host endonuclease XrnI [74]. In DENV, this sfRNA binds to TRIM25, which normally interacts
with RIG-I to promote its ubiquitination and interaction with mitochondrial antiviral signaling protein
(MAVS) [75]. The DENV sfRNA prevents the deubiquitination of TRIM25, an essential upstream
activator for RIG-I activation [76].
Another mechanism of active interference with the type I IFN system is competitive binding.
DENV and WNV NS3 proteins compete with RIG-I for 14-3-3ε binding, a chaperone responsible
for trafficking RNA-bound RIG-I to the mitochondrial membrane [77]. Additionally, the DENV
NS4A protein sequesters MAVS, preventing RIG-I-MAVS interaction, IRF3 activation, and IFN-I
production [78].
Finally, many flavivirus NS proteins have evolved mechanisms to degrade host immune proteins,
or to induce the degradation of these proteins by hijacking the host proteasome system. For example,
the DENV NS2B/NS3 viral protease suppresses the DNA sensing pathway and RIG-I sensing by
cleaving STING, resulting in reduced type I IFN production [21]. Additionally, NS2B by itself promotes
the autophagy-lysosome-dependent degradation of cGAS [21].
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6. NS5 Structure and Function
NS5 is the most conserved flavivirus protein, with less than 45% amino acid difference reported
among the vector-borne flaviviruses [3]. The N-terminus encodes the viral methyltransferase (MTase),
while the C-terminus encodes the RNA-dependent RNA polymerase (RdRp) [79]. The RdRp
generates positive- and negative-sense RNAs from the RNA genome de novo [80,81], and the
replication process is thought to involve three different conformational states: pre-initiation, initiation,
and elongation [82,83]. The MTase domain caps the RNA genome via a two-step reaction and also
serves as the guanylyltransferase [29].
To date, structures of full-length NS5 from JEV [84], DENV3 [85], and ZIKV [79,86,87] have
been reported. The ZIKV and JEV NS5 conformations exhibit a high degree of similarity, suggesting
structural conservation among the flaviviruses [79]. In contrast, the domain orientations of ZIKV and
DENV NS5s differ significantly, although the residues at the domain interface are highly conserved
among ZIKV, DENV, and JEV [79]. These observations support an earlier observation that the
flavivirus NS5 exhibits a high degree of flexibility in solution and can adopt a compact or extended
conformation [88], which may impact on the diverse functions of NS5. Indeed, mutagenesis of the
conserved interface residues of the DENV3 NS5 caused enhanced RdRp activity, but inhibited viral
infectivity [85]. Furthermore, recent structural evidence suggests that the two subdomains cooperate
in the execution of the sequential replication and capping functions, although the mechanism remains
unknown [84,89]. Taken together, these reports suggest that the flexibility and distinct conformations
of the flavivirus NS5 may be linked to the various steps involved in RNA capping and replication.
More experiments are needed to clarify the potential role of the conformational changes in regulating
NS5 activities.
Several post-translational modifications of flavivirus NS5s have also been documented with
potential regulatory roles. Serine/threonine phosphorylation appears to be conserved throughout the
Flaviviridae family [90,91], but the function of this modification and the identity of the host kinases
involved are largely unknown. The DENV NS5 protein is phosphorylated by both mammalian
and mosquito protein kinase G at a conserved Thr449 in the RdRp domain [92,93]. The differential
phosphorylation of DENV NS5 was shown to affect its interaction with the viral helicase, NS3, which is
required for genome replication [94]. The WNV NS5 MTase domain is also phosphorylated by,
and interacts with, protein kinase G, and abolishing this interaction inhibits viral replication [95].
SUMOylation of the DENV NS5 was shown to be important for DENV replication [96]. In addition,
glutathionylation of the DENV and ZIKV NS5s has been reported [97].
Replication of the flavivirus genome occurs exclusively in the cytoplasm [69,98]. However,
a significant portion of the NS5 protein is observed within the nucleus during YFV [99], JEV [100],
ZIKV [3], WNV [101], and DENV [102] infections. Inhibiting the nuclear localization of DENV and
WNV NS5 significantly decreases viral titers [101,103]. Inversely, inhibiting the nuclear export of DENV
NS5 decreased the induction of IL-8, which plays a role in induction of inflammation [104], suggesting
nuclear localization of NS5 may be important for immune modulation [105]. This observation is
further supported by a study showing that interaction of NS5 with host spliceosome components
leads to changes in mRNA isoform abundance of antiviral factors [106]. There are differences,
however, in the level of NS5 nuclear localization among the different DENV serotypes. NS5 from
serotypes 2 and 3 accumulate in the nucleus, while DENV1 and 4 NS5 reside in the cytoplasm [107].
For serotype 4, cytoplasmic localization is likely due to the lack of a functional nuclear localization
signal (NLS) [107]. Levels of IL-8 did not change with the different serotypes, and the function of the
differential localization is still unknown [107].
7. IFN Suppressor Function of Flavivirus NS5 Protein
While multiple proteins capable of IFN antagonism have been described for the major
disease-causing flaviviruses, NS5 is the most potent and direct antagonist [3]. This is significant
because NS5-mediated IFN antagonism is required for counteraction of IFN in cell culture [108] and
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for virulence in mouse models [109]. Remarkably, even though this protein utilizes similar MTase
and RdRp mechanisms no matter the flavivirus species to replicate and cap their RNA genomes,
the mechanism of NS5-mediated IFN suppression diverges within the genus. The evolution and
divergence of this role for NS5 may have been facilitated by the strategy of expression of flaviviral
proteins from a single open reading frame. This results in excess expression of NS5, while only small
amounts are needed for RdRp and MTase functions. Due to the lack of high-resolution structures for
the complexes of various NS5s and their interacting host partners, how NS5 is able to retain its roles as
MTase and RdRp while evolving divergent IFN suppression mechanisms remains elusive.
NS5 frequently employs multiple strategies to suppress the JAK-STAT signaling pathway not only
among different species of Flavivirus, but also within the same species. For example, the ZIKV NS5
protein has been shown to both inhibit the phosphorylation of STAT1 and induce the degradation of
STAT2. The JEV, DENV, and WNV NS5 proteins have similarly been shown to antagonize this pathway
at multiple steps. STAT2 is a common target for NS5-mediated IFN suppression, and at least two
flavivirus NS5 proteins have been demonstrated to target this protein for degradation. The mechanisms
by which the DENV and ZIKV NS5s degrade STAT2 diverge, however, and the molecular details of
these mechanisms are still being elucidated.
7.1. Dengue Virus
DENV NS5 binds to human STAT2 and inhibits its phosphorylation, resulting in reduced ISG
transcription. The mechanism of this inhibition has not been elucidated, but the IFN suppression
activity was mapped to the RdRp domain [110]. Expression of NS5 also reduces IFN-α-, but not IFN-γ-,
mediated STAT1 phosphorylation, although NS5 does not directly interact with STAT1 [110].
Ashour et al. demonstrated STAT2 degradation as an additional mechanism of DENV
NS5-mediated IFN antagonism [111,112]. However, while this study also found that binding of NS5 to
STAT2 is sufficient to prevent IFN signaling, STAT2 degradation is detected only when the N-terminus
of NS5 is proteolytically processed, as it would be in the context of viral infection. NS5 is separated
from NS4B during polyprotein processing by the viral NS2B/NS3 protease, and co-expression of
NS5 with NS2B/NS3 induces STAT2 degradation. Replacement of the viral cleavage site at the
N-terminus of NS5 with a host protease cleavage site, however, also allows for the efficient degradation
of STAT2, suggesting the cleavage does not need to be mediated by the viral protease. Additionally,
the identity of the N-terminal residue of NS5 does not appear to be important to this processing
event, as replacing the glycine residue at position 1 of NS5 with methionine resulted in efficient STAT2
degradation [112]. This study also demonstrated that NS5-mediated STAT2 degradation is dependent
on the ubiquitin-proteasome pathway, implying the involvement of a host E3 ligase. In a follow-up
study, the García-Sastre group identified this protein as UBR box N-recognin-4 (UBR4), which is part
of the N-recognin family [113]. Members of this family target proteins that undergo conformational
changes to expose a destabilizing N-terminal residue for degradation, a mechanism for the N-end rule
pathway [114]. UBR4 binds to the first five amino acids of NS5; deleting the first ten amino acids of NS5
eliminates its ability to induce STAT2 degradation [112,113]. The binding domain for STAT2, however,
was mapped to residues 202–306 [112], suggesting that the DENV NS5 central and N terminal regions
together serve as a bridge between STAT2 and UBR4. In this scenario, it is possible that NS5 and STAT2
are both targeted by UBR4 and similarly degraded [7]. Experimental evidence, however, is still needed
for verification of the role of the N-end rule pathway in DENV NS5-mediated STAT2 degradation.
7.2. Zika Virus
Similar to DENV NS5, ZIKV NS5 binds to human STAT2, triggering its degradation. However,
unlike what was observed for DENV NS5, ZIKV NS5 does not need to undergo proteolytic processing
for depletion of STAT2 [3]. Additionally, it was demonstrated that the first ten amino acids of NS5 are
dispensable for depletion of STAT2, suggesting that the N-end rule does not apply to ZIKV NS5 [115].
STAT2 is ubiquitinated prior to degradation, and proteasome inhibitors rescue STAT2 protein levels
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in the presence of NS5 [65]. However, unlike that occurs for DENV NS5, UBR4 is not involved in
mediating STAT2 degradation [3]. This suggests that ZIKV NS5-mediated STAT2 degradation utilizes
the host ubiquitin proteasome system and the participating host E3 ligase has yet to be identified.
Chaudhary et al. demonstrated an additional consequence of ZIVK NS5-mediated STAT2
degradation, aside from decreased ISG induction. In an uninfected cell, unphosphorylated STAT2
can bind to both unphosphorylated and phosphorylated STAT1 to prevent translocation of STAT1
and activation of the type II IFN response [116]. In ZIKV-infected and NS5-transfected cells, however,
an increase in STAT1 homodimerization is observed, concurrent with an increase in type II IFN and
a decrease in type I IFN signaling. In this model, the degradation of STAT2 frees up STAT1 proteins
to homodimerize and translocate to the nucleus to selectively activate ISGs controlled by gamma
activated sites (GAS) [65].
7.3. Yellow Fever Virus
The YFV NS5 also targets STAT2 as part of its IFN-I suppression mechanism. YFV NS5 binds
to STAT2, but this interaction is uniquely dependent on host cell stimulation with type I or III IFNs.
This stimulation induces several intracellular events required for NS5 association with STAT2. First,
as in an uninfected cell, stimulation with IFN induces the phosphorylation and heterodimerization
of STAT1 and STAT2. STAT2 does not need to be phosphorylated for NS5 interaction. Instead,
the association of STAT1 and STAT2 induces a conformational change within STAT2 that allows
for NS5 binding. Second, IFN stimulation promotes the ubiquitination of YFV NS5 by TRIM23;
non-ubiquitinated NS5 cannot interact with STAT2. Unlike the DENV and ZIKV NS5s, YFV NS5 does
not induce the degradation of STAT2, and is able to bind STAT2 both in the cytoplasm and in the
nucleus. YFV NS5 blocks IFN production either by directly interfering with ISGF3 binding to ISRE
promoter elements in the nucleus, or by preventing IRF9 association with STAT1/2 heterodimers
in the cytoplasm. A domain mapping study identified the first ten amino acids of the YFV NS5 as
essential for both STAT2 interaction and IFN-I inhibition, consistent with the requirement of TRIM23
ubiquitinating K6 of NS5 [117].
8. Other NS5 Interactions
8.1. Spondweni Virus
Spondweni virus (SPOV) is the closest known relative of ZIKV [118], and their NS5 proteins share
77% amino acid identity [3]. While SPOV NS5 does not directly interact with STAT2 as the ZIKV NS5
does, it is an inhibitor of JAK-STAT signaling, as SPOV NS5-transfected cells inhibit ISRE-dependent
gene expression [3]. The STATs are also phosphorylated and translocated to the nucleus upon IFN
stimulation. SPOV NS5 is localized primarily to the nucleus of the cell, so it is possible the mechanism
of ISG suppression occurs inside the nucleus [3].
8.2. Japanese Encephalitis Virus
The JEV NS5 protein alone can inhibit Tyk2 and STAT1 phosphorylation via protein tyrosine
phosphatase (PTP) activity, as PTP inhibitors rescue phosphorylation, but specific NS5 interactions
with innate immune proteins have not yet been implicated in this suppression mechanism [119].
The region of NS5 required for suppression of STAT1 activation was mapped to the N terminus [119].
JEV NS5 has also been shown to inhibit the nuclear translocation of IRF3 and NF-κB by competitively
interacting with importin-α4 and importin-α3 [120]. These interactions are mediated by the NLS of
JEV NS5 and mutagenesis of key residues in this region restored ISG expression [120].
8.3. Tick-Borne Encephalitis, Langat, and West Nile Viruses
Langat virus (LGTV) is a member of the tick-borne encephalitis virus (TBEV) serogroup.
Both LGTV and TBEV NS5s suppress phosphorylation of STAT1, STAT2, Tyk2, and JAK1 [121].
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The region of LGTV NS5 responsible for this suppression mechanism was mapped to the RdRp
domain of NS5 [122]. The minimal linear sequence required was mapped to residues 355–735 which
overlap with the finger region and the eight conserved RdRp motifs [122]. The specific amino acids
required lay within two noncontiguous stretches of amino acids: 374–380 within the finger domain
and 624–647 within the palm domain [122]. When modeled on the crystal structure of the WNV RdRp,
these two amino acid stretches are adjacent to one another, suggesting cooperative action [122].
It was later determined that LGTV and TBEV NS5s also interact with prolidase (PEPD), a host
protein that is required for IFNAR1 maturation [109]. This interaction was mapped to the same
region as that required for LGTV NS5-mediated STAT1 phosphorylation inhibition [121]. STAT1,
STAT2, Tyk2, and JAK1 phosphorylation occur downstream of IFNAR1, so this NS5 interaction
elucidated the mechanism of NS5-mediated IFN suppression in addition to the mechanism of IFNAR1
downregulation. LGTV and TBEV NS5s are also known to interact with IFNAR2 and IFNGR1, but the
function of these interactions is still unknown [121].
TBEV NS5 has also been shown to interact with the mammalian membrane protein Scribble which
has been implicated in T cell activation [123]. The interaction was mapped to the MTase domain of
TBEV NS5 and the PSD-95, Discs-large, ZO-1 domain 4 (PDZ4) of Scribble [123]. In IFN-stimulated
cells depleted for Scribble, phosphorylation and nuclear localization of STAT1 was restored [123].
WNV NS5, like LGTV and TBEV, was also shown to interact with PEPD to downregulate IFNAR
expression [110]. This interaction may be the mechanism by which WNV NS5 inhibits STAT1 and
STAT2 phosphorylation, but further investigation is required for this conclusion [3,108].
9. Summary
Effective inhibition of type I IFN production is necessary for flaviviruses to establish infection in
mammalian hosts. The viral non-structural proteins have evolved to be multi-functional, encoding
diverse IFN suppression mechanisms in addition to their essential roles in the viral life cycle.
NS5 is one of the most important IFN-I antagonists. Three of the most pervasive disease-causing
flaviviruses—YFV, ZIKV, and DENV—inhibit human STAT2 through NS5-hSTAT2 interaction.
Detailed mechanistic understanding of these interactions provides at least two opportunities for
translational research. First, recombinant viruses that incorporate loss-of-function mutations in NS5 are
attractive candidates for live-attenuated vaccine strains. Second, antivirals that target the NS5-hSTAT2
interaction would inhibit an early step common to these flaviviruses, despite divergent downstream
mechanisms employed by the NS5s. These applications require deeper mechanistic understandings of
the interaction between NS5 and hSTAT2.
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Abstract: Zika virus (ZIKV) causes no-to-mild symptoms or severe neurological disorders.
To investigate the importance of viral and host genetic variations in determining ZIKV infection
outcomes, we created three full-length infectious cDNA clones as bacterial artificial chromosomes
for each of three spatiotemporally distinct and genetically divergent ZIKVs: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). Using the three molecularly
cloned ZIKVs, together with 13 ZIKV region-specific polyclonal antibodies covering nearly the entire
viral protein-coding region, we made three conceptual advances: (i) We created a comprehensive
genome-wide portrait of ZIKV gene products and their related species, with several previously
undescribed gene products identified in the case of all three molecularly cloned ZIKVs. (ii) We found
that ZIKV has a broad cell tropism in vitro, being capable of establishing productive infection in 16 of
17 animal cell lines from 12 different species, although its growth kinetics varied depending on both
the specific virus strain and host cell line. More importantly, we identified one ZIKV-non-susceptible
bovine cell line that has a block in viral entry but fully supports the subsequent post-entry steps.
(iii) We showed that in mice, the three molecularly cloned ZIKVs differ in their neuropathogenicity,
depending on the particular combination of viral and host genetic backgrounds, as well as in the
presence or absence of type I/II interferon signaling. Overall, our findings demonstrate the impact
of viral and host genetic variations on the replication kinetics and neuropathogenicity of ZIKV and
provide multiple avenues for developing and testing medical countermeasures against ZIKV.
Keywords: Zika virus; flavivirus; infectious cDNA; replication; gene expression; neuropathogenesis;
viral genetic variation; host genetic variation
1. Introduction
Discovered in Uganda in 1947 in a febrile rhesus macaque [1], Zika virus (ZIKV) is a medically
important flavivirus [2] related to Japanese encephalitis (JEV), West Nile (WNV), dengue, and yellow
fever viruses [3]. Originally, it was confined within an equatorial belt running from Africa to Asia,
with only about a dozen cases of human illness reported [4]. In 2007, however, it caused a major
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outbreak of mild illness characterized by fever, rash, arthralgia, and conjunctivitis on the western
Pacific Island of Yap [5,6]. Since then, it has spread eastward across the Pacific Ocean, invading
French Polynesia and other Pacific Islands in 2013–2014 [7], reaching the Americas and Caribbean in
2015–2016 [8,9], and now threatening much of the world [10,11]. ZIKV is spread to humans mainly
through the bite of an infected Aedes species mosquito, e.g., Aedes aegypti or Aedes albopictus [12],
but it can also be transmitted from a mother to her child during pregnancy [13,14] or through sexual
contact [15,16]. Serious concerns have been raised over links to congenital neurological malformations
(e.g., microcephaly) and severe neurological complications (e.g., Guillain–Barré syndrome) [17,18].
Despite its continuous rapid spread and high pandemic potential, no vaccine or drug is available to
prevent or treat ZIKV infection.
ZIKV is an enveloped RNA virus with a nucleocapsid core comprising an ~11 kb plus-strand
RNA genome and multiple copies of the C protein; this core is surrounded by a lipid bilayer bearing
the anchored M and E proteins [19,20]. With regard to the molecular events that occur during ZIKV
infection, our current understanding of the molecular biology of closely related flaviviruses offers a
promising starting point for ZIKV research [21]. As the first step in flavivirus replication, the virion
binds to one or more cellular proteins on the surface of a host cell, and is then internalized via
clathrin-mediated endocytosis in a viral glycoprotein E-dependent manner [22–24]. Within endosomes,
the E glycoprotein undergoes low pH-induced conformational changes, followed by fusion of the viral
and host cell membranes [25–27]. In the cytoplasm, the viral genomic RNA functions initially as an
mRNA for the translation of a single long open reading frame (ORF) flanked by 5′ and 3′ non-coding
regions (NCRs) [28,29]; the resulting polyprotein is cleaved by viral and cellular proteases to generate
at least 10 mature proteins [30,31]: three structural (C, prM, and E) and seven nonstructural (NS1, 2A,
2B, 3, 4A, 4B, and 5). In JEV and WNV, ribosomal frameshifting is also used for the expression of
NS1’, a C-terminally extended form of NS1 [32–34]. A complex of the seven nonstructural proteins
directs viral RNA replication on the distinct virus-induced membranous compartments derived from
endoplasmic reticulum (ER) [35,36]. This replication process is catalyzed by two main viral components:
(i) NS3, with serine protease (and its cofactor, NS2B) and RNA helicase/NTPase/RTPase activity,
and (ii) NS5, with methyltransferase/guanylyltransferase and RNA-dependent RNA polymerase
activity [37]. Virus assembly begins with budding of the C proteins, complexed with a newly made viral
genomic RNA, into the ER lumen, and acquisition of the viral prM and E proteins. The prM-containing
immature virions travel through the secretory pathway; in the trans-Golgi network, a cellular furin-like
protease cleaves prM to yield the mature M protein, converting the immature particle to a mature
virion [38].
The clinical presentation of ZIKV infection is highly variable, ranging from no apparent symptoms
or mild self-limiting illness, to severe neurological disorders, such as microcephaly and Guillain–Barré
syndrome [10,17]. Fundamentally, the varied outcomes after infection with a pathogen depend on the
specific combination of pathogen and host genotypes [39]. On the virus side, a limited but significant
number of ZIKVs have been isolated from Africa, Asia, and the Americas during the past 70 years.
Recent phylogenetic analyses based on complete or near-complete viral genome sequences have
revealed that the spatiotemporally distinct ZIKV strains are grouped into two major genetic lineages,
African and Asian, with the 2015–2016 American epidemic strains originating from a common ancestor
of the Asian lineage [40–42]. Despite the continuous expansion of its genetic diversity, little is known
about the effect of viral genetic variation on the pathogenicity of ZIKV between the two lineages or
between different strains within a particular lineage. On the host side, much progress has recently been
made in developing murine models for ZIKV infection [43], including mice genetically engineered to
lack one or more components of the innate and adaptive immune systems that affect the development,
severity, and progression of ZIKV-induced disease [44–49]. However, the influence of host genetic
variation on susceptibility to ZIKV infection is largely unknown.
To assess, experimentally, the impact of viral and host genetic variations on the outcome of ZIKV
infection, we have now generated (i) a unique panel of three functional bacterial artificial chromosomes
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(BACs), each containing a full-length infectious cDNA for one of three genetically divergent ZIKV
strains, and (ii) an exclusive collection of 13 rabbit antisera capable of detecting almost all of the
ZIKV gene products and their related species. Using these functional genomics and immunologic
tools, together with various cell culture and mouse infection model systems, we show that the three
molecularly defined cDNA-derived ZIKVs have a similar viral protein expression profile, but display
biologically significant differences in in vitro growth properties and in vivo neuropathogenic potential
that depend on both viral and host genetic traits. Our study not only provides a powerful system for
the functional study of viral and host genetics in ZIKV replication and pathogenesis, but also offers a
valuable platform for the rational design of vaccines and therapeutics against ZIKV.
2. Materials and Methods
2.1. Cells and Viruses
Details of the 17 cell lines used in this study, including their growth medium and culture
conditions, are presented in Table 1. ZIKV MR-766 and P6-740 were obtained from the World Reference
Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch (Galveston, TX,
USA), and ZIKV PRVABC-59 was provided by the Centers for Disease Control and Prevention (Fort
Collins, CO, USA). In the case of all three ZIKVs, viral stocks were amplified once in Vero cells at a
multiplicity of infection (MOI) of 1.
Table 1. Cells used in this study.





Human HEK Embryo, kidney MEM supplemented with 10% FBS, 2 mM L-glutamine, 0.1
mM NEAA, 1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CRL-1573)
Human Huh-7 Liver DMEM supplemented with 10% FBS, 0.1 mM NEAA, and
PS
37oC, 5% CO2 Charles M. Rice,
RU
Human SH-SY5Y Bone marrow A 1:1 mixture of MEM and Ham's F-12 nutrient medium
supplemented with 10% FBS, 0.1 mM NEAA, and PS
37oC, 5% CO2 ATCC
(CRL-2266)
Mouse MEF Embryo (C57BL/6),
fibroblast
DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(SCRC-1008)
Mouse NIH/3T3 Embryo (NIH/Swiss),
fibroblast
DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CRL-1658)
Mouse NSC-34 Motor neuron-like
hybrid
DMEM (without SP) supplemented with 10% FBS and PS 37oC, 5% CO2 Cedarlane
(CLU140)
Monkey Vero Kidney α-MEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(WHO-Vero)
Cow BT Turbinate DMEM (without SP) supplemented with 10% HS and PS 37oC, 5% CO2 ATCC
(CRL-1390)
Cow MDBK Kidney DMEM (without SP) supplemented with 10% HS and PS 37oC, 5% CO2 ATCC
(CCL-22)
Pig ST Testis α-MEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CRL-1746)
Sheep SFF-6 Fetus, fibroblast DMEM supplemented with 15% FBS and PS 37oC, 5% CO2 Irina A.
Polejaeva,
USU
Goat GFF-4 Fetus, fibroblast DMEM supplemented with 15% FBS and PS 37oC, 5% CO2 Irina A.
Polejaeva,
USU
Horse NBL-6 Skin, dermis EMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CCL-57)
Dog MDCK Kidney MEM supplemented with EBSS, 10% FBS, 0.1 mM NEAA,
1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CCL-34)
Cat CRFK Kidney, cortex MEM supplemented with EBSS, 10% HS, 0.1 mM NEAA,
1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CCL-94)
Chicken CEF Embryo, fibroblast DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 Sung-June Byun,
KNIAS
Mosquito C6/36 Larva (Aedes albopictus) MEM supplemented with EBSS, 10% FBS, 2 mM
L-glutamine, 0.1 mM NEAA, 1.0 mM SP, and PS
28oC, 5% CO2 ATCC
(CRL-1660)
a MEM, minimum essential medium; α-MEM, alpha minimum essential medium; DMEM, Dulbecco’s modified
eagle medium; EMEM, Eagle’s minimum essential medium; EBSS, Earle’s balanced salt solution; FBS, fetal bovine
serum; HS, horse serum; NEAA, nonessential amino acids; SP, sodium pyruvate; PS, penicillin-streptomycin.
b ATCC, American Type Culture Collection; RU, Rockefeller University; USU, Utah State University; KNIAS, Korea
National Institute of Animal Science.
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2.2. Sequence Alignment and Phylogenetic Analysis
Multiple sequence alignments were performed via ClustalX, and the phylogenetic tree was
constructed using MEGA and visualized via TreeView, as described [50]. Sequence identities between
aligned nucleotide and amino acid sequences were calculated using ClustalX.
2.3. Cloning
Standard molecular cloning techniques were used to create three full-length ZIKV cDNAs [51],
one each for MR-766, P6-740, and PRVABC-59 in the BAC plasmid pBeloBAC11 [52], designated
pBac/MR-766, pBac/P6-740, and pBac/PRVABC-59. The same cloning strategy was used to construct
all three full-length ZIKV cDNAs with the appropriate primer sets listed in Table 2. Essentially,
each full-length ZIKV cDNA flanked by the 5′ SP6 promoter and the 3′ PsrI/BarI restriction enzyme
site was created by joining five overlapping RT-PCR-generated cDNA fragments at four natural
restriction enzyme sites found in the viral genome (see below for detailed description of cloning
strategy). The cloned cDNAs were checked by restriction enzyme mapping and sequencing.
Table 2. Oligonucleotides used in this study.
Oligonucleotide Sequence a (5’ to 3’) Position b Direction
Z1RT GCTATTGGGTTCATGCCACAGATGGTCATCA 4531–4561 Reverse
Z1F tatgtttaaacAGTTGTTGATCTGTGTGAATCAGACTGCGA 1–30 Forward
Z1R tatggcgcgccAGGACCACCTTGAGTATGATCTCTCTCATG 4502–4531 Reverse
Z2RT ATTGTCATTGTGTCAATGTCAGTCACCACTA 7369–7399 Reverse
Z2F tatgtttaaacTCATTGTTTGGAGGAATGTCCTGGTTCTCA 2340–2369 Forward
Z2R tatggcgcgccTCAATGTCAGTCACCACTATTCCATCCACA 7358–7387 Reverse
Z3RT CTCCAGTTCAGGCCCCAGATTGAAGGGTGGGG 10603–10634 Reverse
Z3F tatgtttaaacGGAAGTCCCAGAGAGAGCCTGGAGCTCAGG 5627–5656 Forward
Z3R tatggcgcgccAAGGGTGGGGAAGGTCGCCACCTTCTTTTC 10583–10612 Reverse
S123-5sp1F ctaggatccttaattaacctgcagggggctgtta Forward
S123-5sp1R GATCAACAACTctatagtgtcccctaaatc 1–11 Reverse
S1-5sp2F ggacactatagAGTTGTTGATCTGTGTGAGTC 1–21 Forward
S1-5sp2R tatccgcggTAGCGCAAACCCGGGGTTCCTGAAT 860–884 Reverse
S1-3roF tatccgcggGGAAAAAGGGAGGACTTATGGTGTG 10191–10215 Forward
S1-3roR agggcggccgcgtatgtcgcgttccgtacgttctagAGAAACCATGGATTTCCCCACACC 10785–10807 Reverse
S23-5sp2F ggacactatagAGTTGTTGATCTGTGTGAATC 1–21 Forward
S23-5sp2R tatccgcggAACGCAAAGCCAGGGTTCCTGAATA 859–883 Reverse
S23-3roF tatccgcggGGGAAAAAGGGAAGACTTATGGTGT 10190–10214 Forward
S23-3roR agggcggccgcgtatgtcgccttccgtacgttctagAGACCCATGGATTTCCCCACACCG 10784–10807 Reverse
ZikaC-F tttgaattcGGTCTCATCAATAGATGGGGT 297–317 Forward
ZikaC-R tttctcgagctattaTCGTCTCTTCTTCTCCTTCCT 399–419 Reverse
ZikaM-F tttgaattcGCTGTGACGCTCCCCTCCCAT 753–773 Forward
ZikaM-R tttctcgagctattaGACTCTAATCAAGTGCTTTGT 828–848 Reverse
ZikaE-F tttgaattcCAGCACAGTGGGATGATCGTT 1416–1436 Forward
ZikaE-R tttctcgagctattaTCCTAGGCTTCCAAAACCCCC 1518–1538 Reverse
ZikaNS4A-F tttgaattcGGAGCGGCTTTTGGAGTGATG 6465–6485 Forward
ZikaNS4A-R tttctcgagctattaGGTCTCCGGCAATTGGGCCGC 6597–6617 Reverse
ZikaNS4B-F tttgaattcGTGACTGACATTGACACAATG 7374–7394 Forward
ZikaNS4B-R tttctcgagctattaGGAAGTTGCGGCTGTGATCAG 7506–7526 Reverse
ZikaF GAAGTGGAAGTCCCAGAGAG 5622–5641 Forward
ZikaR TGCTGAGCTGTATGACCCG 5757–5775 Reverse
ZikaProbe FAM-TGGAGCTCAGGCTTTGATTGGGTGAC-BHQ1 5646–5671 Forward
VeroF AGCGGGAAATCGTGCGTGAC 624–643 Forward
VeroR CAATGGTGATGACCTGGCCA 742–761 Reverse
VeroProbe HEX-CACGGCGGCTTCTAGCTCCTCCC-BHQ2 694–716 Forward
a ZIKV-specific sequences are indicated in uppercase normal letters, and Vero β-actin-specific sequences are shown
in uppercase italic letters. Other nonviral sequences are indicated in lowercase letters. Restriction enzyme sites
used for cDNA cloning are underlined. FAM, 6-Carboxyfluorescein; HEX, Hexachlorofluorescein; BHQ, Black hole
quencher. b Nucleotide position refers to the complete genome sequence of ZIKV PRVABC-59 (GenBank accession
number KX377337) or to the mRNA sequence of Vero β-actin (GenBank accession number AB004047).
(1) pBac/MR-766: The genomic RNA of ZIKV MR-766 (GenBank accession no. KX377335)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-AMR-766 (4552 bp), Z1RT, and Z1F + Z1R; Frag-BMR-766 (5070 bp),
Z2RT, and Z2F + Z2R; and Frag-CMR-766 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA
amplicons was subcloned into pBACSP6/JVFLx/XbaI [53], a derivative of the pBeloBAC11 plasmid,
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by ligating the 8381 bp PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with the 4538, 5056, and 4994
bp PmeI-AscI fragments of the Frag-AMR-766, Frag-BMR-766, and Frag-CMR-766 amplicons, respectively.
This generated pBac/Frag-AMR-766 to -CMR-766. To introduce an SP6 promoter immediately upstream
of the first adenine residue of the viral genome, two cDNA fragments were first amplified individually
by (i) PCR of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R
contains the antisense sequence of the SP6 promoter) and (ii) PCR of pRs/5′NCRMR-766 [54] with
another pair of primers, S1-5sp2F + S1-5sp2R. Subsequently, these two fragments were fused by a
second round of PCR with the outer forward and reverse primers S123-5sp1F + S1-5sp2R. The 1025
bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII
fragment of pRs2, creating pRs/5′SPMR-766. To engineer a unique PsrI run-off site just downstream
of the last thymine residue of the viral genome, one cDNA fragment was amplified by PCR of
pRs/3′NCRMR-766 [54] with primers S1-3roF + S1-3roR (S1-3roR contains the antisense sequence of the
PsrI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was
ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROMR-766. The full-length MR-766
cDNA clone pBac/MR-766 was then assembled by sequentially joining the 7456 bp PacI-NotI fragment
of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 1004 bp PacI-XmaI fragment of
pRs/5’SPMR-766, (ii) the 3160 bp XmaI-XhoI fragment of pBac/Frag-AMR-766, (iii) the 3144 bp XhoI-NsiI
fragment of pBac/Frag-BMR-766, (iv) the 3041 bp NsiI-BamHI fragment of pBac/Frag-CMR-766, and (v)
the 619 bp BamHI-NotI fragment of pRs/3′ROMR-766.
(2) pBac/P6-740: The genomic RNA of ZIKV P6-740 (GenBank accession no. KX377336) was used
as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with the following
primer sets: Frag-AP6-740 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BP6-740 (5070 bp), Z2RT, and Z2F + Z2R;
and Frag-CP6-740 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA amplicons was subcloned
into pBACSP6/JVFLx/XbaI, by ligating the 8381 bp PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with
the 4539, 5056, and 4994 bp PmeI-AscI fragments of the Frag-AP6-740, Frag-BP6-740, and Frag-CP6-740
amplicons, respectively. This generated pBac/Frag-AP6-740 to -CP6-740. To introduce an SP6 promoter
immediately upstream of the first adenine residue of the viral genome, two cDNA fragments were
first amplified individually by (i) PCR of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F
+ S123-5sp1R (S123-5sp1R contains the antisense sequence of the SP6 promoter) and (ii) PCR of
pRs/5′NCRP6-740 [54] with another pair of primers, S23-5sp2F + S23-5sp2R. Subsequently, these two
fragments were fused by a second round of PCR with the outer forward and reverse primers S123-5sp1F
+ S23-5sp2R. The 1025 bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the
2718 bp BamHI-SacII fragment of pRs2, creating pRs/5′SPP6-740. To engineer a unique BarI run-off site
just downstream of the last thymine residue of the viral genome, one cDNA fragment was amplified
by PCR of pRs/3′NCRP6-740 [54] with primers S23-3roF + S23-3roR (S23-3roR contains the antisense
sequence of the BarI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting
amplicons was ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROP6-740. The
full-length P6-740 cDNA clone pBac/P6-740 was then assembled by sequentially joining the 7456
bp PacI-NotI fragment of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 187
bp PacI-NheI fragment of pRs/5′SPP6-740, (ii) the 2930 bp NheI-SpeI fragment of pBac/Frag-AP6-740,
(iii) the 3359 bp SpeI-NgoMIV fragment of pBac/Frag-BP6-740, (iv) the 4059 bp NgoMIV-StuI fragment
of pBac/Frag-CP6-740, and (v) the 433 bp StuI-NotI fragment of pRs/3′ROP6-740.
(3) pBac/PRVABC-59: The genomic RNA of ZIKV PRVABC-59 (GenBank accession no. KX377337)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-APRVABC-59 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BPRVABC-59
(5070 bp), Z2RT, and Z2F + Z2R; and Frag-CPRVABC-59 (5008 bp), Z3RT, and Z3F + Z3R. Each of
the three cDNA amplicons was subcloned into pBACSP6/JVFLx/XbaI, by ligating the 8381 bp
PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with the 4539, 5056, and 4994 bp PmeI-AscI fragments
of the Frag-APRVABC-59, Frag-BPRVABC-59, and Frag-CPRVABC-59 amplicons, respectively. This generated
pBac/Frag-APRVABC-59 to -CPRVABC-59. To introduce an SP6 promoter immediately upstream of the first
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adenine residue of the viral genome, two cDNA fragments were first amplified individually by (i) PCR
of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R contains the
antisense sequence of the SP6 promoter) and (ii) PCR of pRs/5′NCRPRVABC-59 [54] with another pair of
primers, S23-5sp2F + S23-5sp2R. Subsequently, these two fragments were fused by a second round of
PCR with the outer forward and reverse primers S123-5sp1F + S23-5sp2R. The 1025 bp BamHI-SacII
fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII fragment of pRs2,
creating pRs/5′SPPRVABC-59. To engineer a unique BarI run-off site just downstream of the last thymine
residue of the viral genome, one cDNA fragment was amplified by PCR of pRs/3′NCRPRVABC-59 [54]
with primers S23-3roF + S23-3roR (S23-3roR contains the antisense sequence of the BarI and NotI
recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was ligated with
the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROPRVABC-59. The full-length PRVABC-59
cDNA clone pBac/PRVABC-59 was then assembled by sequentially joining the 7456 bp PacI-NotI
fragment of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 187 bp PacI-NheI
fragment of pRs/5′SPPRVABC-59, (ii) the 4426 bp NheI-EcoNI fragment of pBac/Frag-APRVABC-59, (iii) the
2114 bp EcoNI-SacII fragment of pBac/Frag-BPRVABC-59, (iv) the 3808 bp SacII-StuI fragment of
pBac/Frag-CPRVABC-59, and (v) the 433 bp StuI-NotI fragment of pRs/3′ROPRVABC-59.
A total of five bacterial expression plasmids were constructed, each of which was used to express a
32 to 51 aa non-hydrophobic region of the ZIKV polyprotein as a glutathione S-transferase (GST) fusion
protein. In all cases, a defined region of the ZIKV ORF was amplified by PCR using pBac/PRVABC-59
as a template and the appropriate pair of primers listed in Table 2: (i) Frag-zC (147 bp), ZikaC-F
+ ZikaC-R; (ii) Frag-zM (120 bp), ZikaM-F + ZikaM-R; (iii) Frag-zE (147 bp), ZikaE-F + ZikaE-R;
(iv) Frag-zNS4A (177 bp), ZikaNS4A-F + ZikaNS4A-R; and (v) Frag-zNS4B (177 bp), ZikaNS4B-F +
ZikaNS4B-R. Each of the resulting amplicons was cloned into pGex-4T-1 (GE Healthcare, Piscataway,
NJ, USA) by ligating the 4954 bp EcoRI-XhoI fragment of the pGex-4T-1 vector with 135, 108, 135, 165,
and 165 bp EcoRI-XhoI fragments of the Frag-zC, -zM, -zE, -zNS4A, and -zNS4B amplicons, respectively.
This created pGex-zC, -zM, -zE, -zNS4A, and -zNS4B.
2.4. Transcription and Transfection
Infectious transcripts were synthesized from PsrI/BarI-linearized BAC plasmid DNA with SP6
RNA polymerase as described [53] in reactions containing m7GpppA (New England Biolabs, Ipswich,
MA, USA). RNA integrity was examined by agarose gel electrophoresis. RNA was transfected into
Vero cells by electroporation using the BTX ECM 830 electroporator with a 2-mm-gap cuvette under
optimized conditions (980 V, 99 μs pulse length, and 3 pulses); RNA infectivity was quantified by
infectious center assay [55,56]. The infectious centers of plaques/foci formed on the monolayer of Vero
cells were visualized at 5 days after transfection either nonspecifically by counterstaining of uninfected
cells with crystal violet [55] or specifically by immunostaining of ZIKV-infected cells with rabbit
anti-ZIKV NS1 (α-ZNS1) antiserum and horseradish peroxidase-conjugated goat α-rabbit IgG (Jackson
ImmunoResearch, West Grove, PA, USA), followed by developing with 3,3′-diaminobenzidine [56].
2.5. Growth Kinetics and Cytopathogenicity
Viral growth kinetics and cytopathogenicity were analyzed in 17 animal cell lines from 12 different
species. In each case, naïve cells were seeded into 35 mm culture dishes at a density of 3 × 105 cells/dish
for 12 h, and then mock-infected or infected with viruses at an MOI of 1 for 1 h at 37 ◦C. Following
incubation, cell monolayers were washed and incubated with complete medium. At 6, 12, 18, 24, 36,
48, 60, 72, and 96 h post-infection (hpi), ZIKV-infected cells were examined morphologically under a
light-inverted microscope (Primo Vert, Carl Zeiss, Jena, Germany) to assess the degree of ZIKV-induced
cytopathic effect (CPE) as compared to mock-infected cells, and culture supernatants were collected to
evaluate the levels of virus production by plaque assays on Vero cells, as described [57]. The infectious
centers of plaques were visualized at 5 days after infection by counterstaining of uninfected cells with
crystal violet [55].
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2.6. Real-Time RT-PCR
ZIKV RNA levels in infected Vero cells were quantified as described [57] by real-time RT-PCR
with the primer pairs and fluorogenic probes listed in Table 2: the ZikaF + ZikaR and ZikaProbe
specific for the ZIKV NS3-coding region that has the identical sequences in all three ZIKVs, and the
VeroF + VeroR and VeroProbe specific for the Vero β-actin coding region. Each ZIKV RNA level was
normalized to the corresponding β-actin mRNA level as an internal control.
2.7. Immunoblotting, Confocal Microscopy, and Flow Cytometry
Individual ZIKV proteins were identified by immunoblotting [31] using each of our six previously
characterized JEV region-specific rabbit antisera that cross-react with their ZIKV counterparts, or seven
newly generated ZIKV region-specific rabbit antisera. The rabbit antibody was detected using alkaline
phosphatase (AP)-conjugated goat α-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA),
and the AP enzyme was visualized using colorimetric detection with 5-bromo-4-chloro-3-indolyl
phosphate and nitro blue tetrazolium (Sigma, St. Louis, MO, USA). ZIKV E proteins were visualized by
confocal microscopy [57] with rabbit α-ZE antiserum, followed by secondary labeling with fluorescein
isothiocyanate-conjugated goat α-rabbit IgG (Jackson ImmunoResearch). ZIKV NS4A proteins were
detected by flow cytometry [58] with rabbit α-ZNS4A antiserum, followed by secondary labeling with
Alexa 488-conjugated goat α-rabbit IgG (Invitrogen, Carlsbad, CA, USA).
2.8. Mouse Studies
ZIKV neuropathogenicity was examined in male and female mice of four strains: CD-1 (1, 2,
and 4 weeks, Charles River, Wilmington, MA, USA), C57BL/6J (4 weeks, the Jackson Laboratory, Bar
Harbor, ME, USA), A129 (4 weeks, bred in-house), and AG129 (4 weeks, bred in-house). Groups of
mice were inoculated via the intramuscular (im, 50 μL) or intracerebral (ic, 20 μL) route with 10-fold
serial dilutions of virus stock in α-minimal essential medium and monitored for any ZIKV-induced
clinical signs, weight loss, or death daily for 20 days. The im and ic lethal dose 50% (LD50) values for
each virus were calculated from the respective dose-dependent survival curves of the infected mice, as
described [57].
2.9. Ethics Statement
All mouse studies were conducted in strict accordance with the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, United States of America. The animal protocol
was approved by the Institutional Animal Care and Use Committee (IACUC) of Utah State University
(approved IACUC protocol #2505, 30/03/2016). Discomfort, distress, pain, and injury were minimized
as much as possible through limited handling and euthanization of mice when they were moribund.
3. Results
3.1. Characterization of Three Spatiotemporally Distinct and Genetically Divergent ZIKV Strains
As an initial step in examining the genetic diversity of ZIKV and its biological significance for viral
replication and pathogenesis, we selected three historically important strains of distinct geographical
and temporal origins: (i) MR-766, the first ZIKV identified from the blood of a rhesus macaque
monkey in Uganda in 1947 [1]; (ii) P6-740, the first non-African strain, isolated from a pool of A.
aegypti mosquitoes in Malaysia in 1966 [59]; and (iii) PRVABC-59, the recent American strain recovered
from the blood of a human patient in Puerto Rico in 2015 [60]. To compare the genome sequence and
composition of these three ZIKVs, we determined the consensus nucleotide sequence for each of their
full-length genomic RNAs [54]. In all three strains of ZIKV, we found that the genomic RNA is 10,807
nt long, with a single ORF of 10,272 nt flanked by a 106 or 107 nt 5′NCR and a 428 or 429 nt 3′NCR
(Figure 1A). Also, the three genomic RNAs all begin with the dinucleotide 5′-AG and end with the
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dinucleotide CU-3′, both of which are conserved among all mosquito- and tick-borne flaviviruses.
However, pairwise sequence comparisons of the three complete genomes showed a considerable
degree of genetic diversity, with a range in sequence identity of 89.1–95.6% at the nucleotide level
and 96.8–98.8% at the amino acid level over the 3423 aa polyprotein encoded by the single ORF of the
genomic RNA (Figure 1B).
Figure 1. A spectrum of ZIKV genetic diversity is represented by three historically important and
spatiotemporally distinct strains: MR-766, P6-740, and PRVABC-59. The consensus nucleotide sequence
for each of their full-length genomic RNAs was determined by sequencing three overlapping uncloned
cDNA amplicons collectively representing the entire genomic RNA, except for the 5′ and 3′ termini,
which were subsequently defined by performing both 5′- and 3′-rapid amplification of cDNA ends
(RACE); each of these RACEs was followed by cDNA cloning and sequencing of ~20 randomly
picked clones. (A) Genomic organization of the three ZIKV strains; (B) Pairwise comparison of the
complete nucleotide (nt) and deduced amino acid (aa) sequences of the three ZIKV genomes; (C)
Phylogenetic tree based on the nucleotide sequence of 29 ZIKV genomes, including the 15 complete
(MR-766, green; P6-740, orange; PRVABC-59, red; and 12 others, black) and 14 near-complete (gray)
genomes, with Japanese encephalitis virus (JEV) K87P39 included as an outgroup. Bootstrap values
from 1000 replicates are shown at each node of the tree. The scale bar represents the number of
nucleotide substitutions per site. The strain name is followed by a description in parenthesis of the
country, year, and host of isolation and the GenBank accession numbers. Note that MR-766 has been
fully sequenced in this study and by three other groups (designated MR-766/CDC, MR-766/NIID,
and MR-766/USAMRIID).
To examine the genetic relationship between the three spatiotemporally distinct ZIKVs and their
associations with other strains, we performed a multiple sequence alignment for phylogenetic analysis
using the nucleotide sequence of all 29 ZIKV genomes (15 complete, 14 near-complete) in GenBank at
the time of analysis (June 2016), including our complete nucleotide sequence of the genomes of MR-766,
P6-740, and PRVABC-59. Construction of a genome-based rooted phylogenetic tree using JEV K87P39
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as an outgroup revealed two distinct phylogenetic groups (Figure 1C), in agreement with previous
ORF-based phylogenetic studies that classified 10–40 ZIKV isolates into two major genetic lineages,
African and Asian [40–42]. The African lineage branches into two clusters, one including four different
versions of the Ugandan MR-766 strain (1947) that are not identical in genome sequence, mainly
because of a variation in the passage history of the virus, and the other including the three Senegalese
isolates 41671-DAK, 41525-DAK, and 41662-DAK, all isolated in 1984. On the other hand, the Asian
lineage contains a single cluster of the Malaysian P6-740 (1966), Cambodian FSS13025 (2010), Philippine
CPC-0740 (2012), and Thai SV0127-14 (2014) strains, as well as 18 other isolates collected during the
2015–2016 American epidemic, including the Puerto Rican PRVABC-59 strain (2015). Notably, the four
pre-epidemic Asian strains (P6-740, FSS13025, CPC-0740, and SV0127-14) are closely related to the
2015–2016 American epidemic strains, but each forms a single minor branch. Overall, our data indicate
that MR-766 belongs to the African lineage, whereas both P6-740 and PRVABC-59 belong to the Asian
lineage, with PRVABC-59 being derived from an ancestor of the Asian lineage.
3.2. Development of Genetically Stable Full-Length Infectious cDNA Clones for the Three ZIKV Strains
We constructed three full-length infectious ZIKV cDNAs for the MR-766, P6-740, and PRVABC-59
strains, each capable of serving as a template for the rescue of molecularly cloned ZIKVs (Figure 2).
In each strain, five overlapping cDNA fragments representing the 10,807 nt genomic RNA were
sequentially assembled into a full-length cDNA in the single-copy BAC vector pBeloBAC11, in order
to ensure the stable maintenance of the cloned cDNA during propagation in Escherichia coli,
with an SP6 promoter sequence positioned immediately upstream of the viral 5′-end and a unique
restriction endonuclease recognition site (PsrI for MR-766, BarI for P6-740 and PRVABC-59) placed
just downstream of the viral 3′-end. Both the SP6 promoter and the unique restriction site were
engineered so that in vitro run-off transcription could be used to produce m7G-capped synthetic RNAs
bearing authentic 5′ and 3′ ends of the viral genomic RNA. Using this BAC-based cloning strategy,
we thus created a panel of three full-length ZIKV cDNAs, designated pBac/MR-766, pBac/P6-740,
and pBac/PRVABC-59 (Figure 2A).
To evaluate the functionality of the three full-length ZIKV BACs, we determined the viability of
the synthetic RNAs transcribed in vitro from each BAC by measuring their specific infectivity after
RNA transfection into a ZIKV-susceptible African green monkey kidney (Vero) cell line. To prepare a
DNA template for in vitro run-off transcription, the three full-length ZIKV BACs were first linearized
by digestion with PsrI (for pBac/MR-766) or BarI (for pBac/P6-740 and pBac/PRVABC-59). Each was
then used as a template for a run-off transcription reaction using SP6 RNA polymerase in the
presence of the m7GpppA cap structure analog. After removal of the DNA template by DNase I
digestion, we transfected Vero cells with the RNA transcripts, quantifying their infectivity as the
number of plaque-forming units (PFU) per μg of transfected RNA. In all three BACs, the RNA
transcripts invariably had a high infectivity of 8.1–8.6 × 105 PFU/μg and were capable of producing
a high-titer stock of infectious ZIKVs in culture medium that reached 1.3–5.0 × 106 PFU/mL at 36 h
after transfection (Figure 2B). Each of the three recombinant BAC-derived ZIKVs (designated by
the prefix “r”) formed a homogeneous population of plaques that differed from the others in size,
with mean diameters of 5.7 (rMR-766), 1.6 (rP6-740), and 5.2 (rPRVABC-59) mm (Figure 2C). We also
demonstrated that using pBac/P6-740, the infectivity of its RNA transcripts was decreased by ~4 logs
to a barely detectable level (55–105 PFU/μg), with a single C9804→U substitution (an unintended
mutation introduced during the overlapping cDNA synthesis by RT-PCR) replacing a His with Tyr
at position 713 of the viral NS5 protein (Figure S1A,B). On the crystal structure of ZIKV NS5 [61,62],
the His-713 residue is located within the conserved structural motif E region near the priming loop in
the RNA-dependent RNA polymerase domain (Figure S1C), suggesting a critical role for His-713 in
the polymerase function of ZIKV NS5.
Next, we examined the genetic stability of the three full-length ZIKV BACs that are important
for reliable and efficient recovery of infectious viruses from the cloned cDNAs. A single colony of
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E. coli DH10B carrying each of the three full-length ZIKV BACs was grown in liquid medium and
serially passaged for 4 days by diluting it 106-fold daily, such that each passage represented ~20
generations, as we described previously [53]. In all three cases, we found no differences in specific
infectivity of the RNA transcripts made from the BAC plasmids even after 80 generations, indicating
that the three full-length ZIKV BACs are stable during propagation in bacteria (Figure S2). In sum,
we have established genetically stable BAC-based reverse genetics platforms for the recovery of three
molecularly cloned, genetically distinct ZIKVs.
Figure 2. A trio of functional ZIKV cDNAs was created for the rescue of three molecularly cloned
genetically divergent strains: rMR-766, rP6-740, and rPRVABC-59. (A) Construction of three full-length
ZIKV cDNAs as BACs for MR-766, P6-740, and PRVABC-59. In all three cases, each genomic RNA
(top panel) was first subcloned into five overlapping cDNAs (middle panel), which were then joined
at four shared restriction sites as indicated to assemble its full-length cDNA without introducing
any point mutations for cloning (bottom panel). Presented below the three full-length cDNAs are
the sequences corresponding to the 5′ and 3′ termini conserved in all three ZIKVs (black lowercase),
an SP6 promoter placed just upstream of the viral genome (magenta uppercase), and a run-off site
positioned immediately downstream of the viral genome (PsrI or BarI, blue uppercase). Marked
below the sequences are the transcription start (white arrowhead) and run-off (black arrowhead)
sites; (B) Functionality of the three full-length ZIKV cDNAs. After linearization with PsrI or BarI, as
appropriate, each full-length cDNA was used as a template for in vitro transcription with SP6 RNA
polymerase in the presence of the dinucleotide cap analog m7GpppA. Capped RNA transcripts were
transfected into Vero cells to determine the number of infectious centers (plaques) counterstained
with crystal violet at 5 days after transfection (RNA infectivity). At 36 h post-transfection, culture
supernatants from RNA-transfected cells were harvested to estimate the level of virus production by
plaque assays on Vero cells (Virus yield). Means and standard deviations from three independent
experiments are shown; (C) Plaque morphology. The average plaque sizes were estimated by measuring
20 representative plaques.
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3.3. Differential Replication Kinetics and Cytopathogenicity among Three Molecularly Cloned ZIKVs in
Human, Mosquito, and Animal Cell Lines
To test whether the genetic variation in ZIKV can have differential effects on its replication kinetics
and cytopathogenicity, we infected monkey kidney-derived Vero cells at an MOI of 1, then examined
the replicative and cytopathic properties of the three cloned cDNA-derived ZIKVs (rMR-766, rP6-740,
and rPRVABC-59) as compared to those of the uncloned parental ZIKVs (MR-766, P6-740, and
PRVABC-59) used for cDNA construction. In all three strains, we saw no noticeable differences
between the cloned and uncloned viruses in the accumulation of viral genomic RNA over the first
24 hpi (Figure 3A), paralleling not only the kinetics of viral growth and CPE development over the
first 3 days post-infection (Figure 3B) but also the average sizes of the α-ZNS1 antibody-reactive
foci immunostained at 5 days post-infection (Figure 3C). However, we did observe clear differences
between the three strains, regardless of whether they were cloned or uncloned viruses, with respect to
their replication kinetics and cytopathogenicity (Figure 3A–C). Our specific findings are as follows:
(i) rMR-766/MR-766 displayed the fastest rate of RNA replication, induced complete lysis of the
infected cells by 36 hpi, achieved the highest virus titer of 2.0–3.3 × 107 PFU/mL at 36–48 hpi, and
formed the largest foci of 6.3 mm diameter. (ii) rP6-740/P6-740 had the slowest rate of RNA replication,
did not cause complete CPE until 72 hpi, reached its maximal virus titer of 1.1–1.2 × 107 PFU/mL at
60–72 hpi, and generated the smallest foci of 2.4 mm diameter. (iii) rPRVABC-59/PRVABC-59 had a rate
of RNA replication slightly slower than rMR-766/MR-766 but much faster than that of rP6-740/P6-740;
it caused complete CPE by 48 hpi, with a peak virus titer of 0.9–1.4 × 107 PFU/mL at 36–48 hpi, and
produced foci of 5.9 mm diameter.
We further analyzed the replicative and cytopathic potential of the three cDNA-derived ZIKVs
in 16 other animal cell lines from 11 different species, over the first 4 days after infection of the cells
with each virus at an MOI of 1. Our data revealed seven distinct patterns of viral growth kinetics
and cytopathogenesis, depending on a combination of the viral strain and host cell line (Figure 3D
and Figure S3): (1) In all three human cell types (embryonic kidney HEK, hepatocarcinoma Huh-7,
and neuroblastoma SH-SY5Y), rMR-766 and rP6-740 grew equally well, to maximum titers of 107–108
PFU/mL at 48–72 hpi, but rPRVABC-59 always grew at a slower rate, attaining a peak titer 1–2 logs
lower than that of the other two strains at 72–96 hpi (HEK and SH-SY5Y) or reaching a peak titer
similar to that of the other two strains only at 96 hpi (Huh-7); all three ZIKVs induced cell death, with a
correlation between the degree of CPE and the magnitude of viral replication. (2) In swine testis (ST)
and equine skin (NBL-6) cells, the three ZIKVs replicated to their peak titers of 106–107 PFU/mL at
48 hpi, with differential growth rates similar to those seen in Vero cells (rMR-766, fastest; rP6-740,
slowest; rPRVABC-59, intermediate) that paralleled the kinetics of CPE development. (3) In sheep fetal
fibroblast (SFF-6) and A. albopictus (C6/36) cells, the three ZIKVs shared a superimposable growth
curve, characterized by a steady increase in virus titers up to ~107 PFU/mL by 96 hpi, except for rP6-740,
which had an exponential growth during 24–48 hpi in C6/36, but not SFF-6 cells. None of the three
ZIKVs produced any visible CPE. (4) In goat fetal fibroblast (GFF-4), canine kidney (MDCK), and feline
kidney (CRFK) cells and in all three mouse cell types (C57BL/6-derived embryonic fibroblast MEF,
NIH/Swiss-derived embryonic fibroblast NIH/3T3, and motor neuron-like hybrid NSC-34), rMR-766
was the fastest-growing, reaching its highest titer of 106–107 PFU/mL at 48–96 hpi; rPRVABC-59 was
the slowest-growing, gaining a maximum titer of only 103–104 PFU/mL during the same period;
and rP6-740 was intermediate in growth rate. However, none of these viruses produced visible CPE.
(5) In chicken embryo fibroblast (CEF) cells, both rMR-766 and rP6-740 had a relatively long lag period
of 36 h, followed by a gradual increase in virus titer up to 105–106 PFU/mL by 96 hpi; in contrast,
rPRVABC-59 grew extremely poorly, resulting in a slow decrease in virus titer to 45 PFU/mL by
96 hpi. No CPE was observed for any of the three ZIKV-infected CEF cells. (6) In bovine turbinate (BT)
cells, the three ZIKVs showed substantial differences in growth kinetics, reaching a plateau at 96 hpi,
with peak titers of 4.4 × 105 (rMR-766), 5.0 × 104 (rPRVABC-59), and 8.8 × 102 (rP6-740) PFU/mL.
However, no visible CPE was induced in any of the ZIKV-infected cells. (7) In bovine kidney (MDBK)
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cells, the titers of all three ZIKVs declined to undetectable levels at 60–96 hpi, with no overt signs of
viral replication.
Figure 3. ZIKV replication kinetics and cytopathogenicity in cell cultures depend on the particular
combination of virus strain and host cells. (A–C) Replicative and cytopathic properties of three
cloned cDNA-derived ZIKVs (rMR-766, rP6-740, and rPRVABC-59) and their uncloned parental ZIKVs
(MR-766, P6-740, and PRVABC-59) in Vero cells. Cells were infected with each of the six ZIKVs (MOI = 1).
At the time points indicated after infection, cells were lysed to examine the accumulation levels of
viral genomic RNA by real-time RT-PCR with a ZIKV-specific fluorogenic probe (A), and supernatants
were collected to analyze the production levels of progeny virions by plaque assays on Vero cells
(B). At 5 days post-infection, cell monolayers maintained under a semisolid overlay medium were
immunostained with rabbit α-ZNS1 antiserum to visualize the infectious foci (C). (D) Growth kinetics
and cytopathogenicity of the three cloned cDNA-derived ZIKVs in a wide range of animal cells (see
also Figure S3). Each virus was used to infect the cell lines (MOI = 1) specified in the figure. At the
indicated time points, cells were examined microscopically for the degree of ZIKV-induced cytopathic
effect (CPE) (–, 0%; +, 0–25%; ++, 25–50%; +++, 50–75%; ++++, 75–100% cell death), and supernatants
were assayed for virus production by plaque assays on Vero cells. hpi, hours post-infection.
Subsequently, we showed that MDBK cells are not susceptible to ZIKV infection, but instead are
permissive for ZIKV RNA replication, by using (i) single cell-based immunofluorescence (Figure 4A)
and flow cytometry (Figure 4B) assays to determine the number of cells expressing ZIKV proteins
(E or NS4A), when MDBK cells were either infected with each of the three cDNA-derived ZIKVs
or transfected with each of the three infectious RNAs transcribed in vitro from their corresponding
cDNAs; and (ii) total cell lysate-based immunoblot analyses to assess the accumulation levels of ZIKV
NS1 protein in the virus-infected vs RNA-transfected MDBK cells (Figure 4C). In all these experiments,
we used Vero cells, a ZIKV-susceptible cell line, as a control. Our results led us to postulate that MDBK
cells might lack one or more host factors required for ZIKV entry; alternatively, they might have a
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general defect in the clathrin-dependent endocytic pathway that ZIKV utilizes for internalization [63].
We thus investigated the functional integrity of the clathrin-dependent endocytic pathway in MDBK
cells, by analyzing the susceptibility of these cells to infection by two other enveloped RNA viruses
whose entry depends on clathrin-mediated endocytosis: bovine viral diarrhea virus (BVDV) and
vesicular stomatitis virus (VSV). In contrast to their resistance to ZIKV infection, we found that MDBK
cells were highly susceptible to infection with both BVDV and VSV, as demonstrated by their plaque
formation and high level of progeny virion production (Figure S4A,B). These results indicate that the
cellular machinery associated with the clathrin-dependent endocytic pathway is functional in MDBK
cells, and they support our hypothesis that MDBK cells lack a host factor(s) promoting ZIKV entry.
Figure 4. MDBK cells are permissive for ZIKV RNA replication but are not susceptible to infection
with the virus. MDBK cells were mock-infected or infected with rMR-766, rP6-740, or rPRVABC-59 at
an MOI of 3 (for virus infection experiments), or mock-transfected or transfected with 3 μg of synthetic
RNAs transcribed in vitro from their respective infectious cDNAs (for RNA transfection experiments).
At the indicated time points, the expression of three ZIKV proteins (E, NS1, and NS4A) within the cells
was analyzed by confocal microscopy for E (A), flow cytometry for NS4A (B), and immunoblotting
for NS1 (C). The insets in panel A show enlarged views of the boxed areas with the fluorescence of
propidium iodide (PI)-stained nuclei excluded. In all experiments, ZIKV-susceptible Vero cells were
included in parallel. hpi, hours post-infection; hpt, hours post-transfection.
3.4. Genome-Wide Landscape of the Viral Gene Products and Their Related Species Produced by the Molecularly
Cloned ZIKVs
To identify all the viral proteins produced by rMR-766, rP6-740, and rPRVABC-59, we examined
total cell lysates of mock- and ZIKV-infected Vero cells in two series of immunoblotting experiments.
In the first series, we probed with each of our 15 JEV region-specific rabbit antisera (Figure S5),
originally produced to detect all JEV gene products [31], which we estimated to have the potential for
cross-reactivity with their ZIKV counterparts, given the relatively high levels (35–71%) of amino acid
sequence identity between their antigenic regions (Figure 5A). Indeed, six (α-JEN-term, α-JNS1C-term,
α-JNS2B, α-JNS3C-term, α-JNS5N-term, and α-JNS5C-term) of the 15 antisera showed moderate-to-strong
cross-reactivity with their respective ZIKV gene products, but the remaining nine had no reactivity
(Figure 5B). To cover the remaining undetected parts of ZIKV ORF, we then generated seven ZIKV
region-specific rabbit antisera, using rPRVABC-59 as the viral strain of choice, immunizing the rabbits
with five bacterially expressed GST fusion proteins (α-ZC, α-ZM, α-ZE, α-ZNS4A, and α-ZNS4B) or
two chemically synthesized oligopeptides (α-ZNS1 and α-ZNS2B) (Figure S6A,B). In all cases, the 19
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to 51 aa antigenic regions of ZIKV were selected to have relatively low levels (16–42%) of amino acid
sequence identity with those of JEV (Figure 6A). The resulting seven ZIKV region-specific antisera were
used for a second series of immunoblots, in which we detected their respective ZIKV gene products
(Figure 6B). In all immunoblots, we included two additional cell lysates (as a reference for JEV proteins)
extracted from Vero cells infected with the virulent JEV strain SA14 or its attenuated strain SA14-14-2;
both JEVs share the same genome-wide viral protein expression profile, except that the NS1′ protein is
expressed only by SA14 [57].
 
Figure 5. A subset of 15 JEV region-specific polyclonal antibodies detects the cross-reactive ZIKV E, NS1,
NS2B, NS3, NS5, and their related species in ZIKV-infected cells. (A) Schematic illustration showing
the antigenic regions recognized by 15 JEV region-specific rabbit antisera. The 10,977 nt genomic RNA
of JEV SA14 has a 95 nt 5′NCR, a 10,299 nt ORF, and a 583 nt 3′NCR (top panel). The ORF encodes a
3432 aa polyprotein that is processed by viral and cellular proteases into at least 10 mature proteins
(middle panel). Marked on the polyprotein are one or two transmembrane domains (vertical black bar)
at the C-termini of three structural proteins (C, prM, and E) and at the junction of NS4A/NS4B, as well
as four N-glycosylation sites (asterisk) in the pr portion of prM (15NNT), E (154NYS), and NS1 (130NST
and 207NDT). During viral morphogenesis, prM is cleaved by furin protease into a soluble pr peptide
and a virion-associated M protein. NS1′ is the product of a −1 ribosomal frameshift (F/S) event that
occurs at codons 8–9 of NS2A, adding a 52 aa C-terminal extension to the NS1 protein. The bottom
panel displays the antigenic regions (horizontal blue bar) recognized by 15 JEV region-specific rabbit
antisera. (B) Identification of viral proteins in ZIKV-infected cells by immunoblotting. Vero cells were
mock-infected or infected at MOI 1 with each of three ZIKVs (rMR-766, rP6-740, and rPRVABC-59) or
two JEVs (SA14 and SA14-14-2, for reference). At 20 h post-infection, total cell lysates were separated
by SDS-PAGE on a glycine (Gly) or tricine (Tri) gel and analyzed by immunoblotting with each of the
15 JEV region-specific rabbit antisera or α-GAPDH rabbit antiserum as a loading and transfer control.
Molecular size markers are given on the left of each blot, and major JEV proteins for reference are
labeled on the right. Provided below each blot are the estimated molecular sizes of the predicted ZIKV
proteins, and marked on the blot are the predicted proteins (yellow or pink dot) and presumed cleavage
intermediates or further cleavage/degradation products (white circle). CHO, N-glycosylation.
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Figure 6. A panel of seven ZIKV region-specific polyclonal antibodies identifies ZIKV C, prM/M, E,
NS1, NS2B, NS4A’, NS4B, and their related species in ZIKV-infected cells. (A) Schematic illustration
showing the antigenic regions recognized by seven ZIKV region-specific rabbit antisera. The 10,807 nt
genomic RNA of ZIKV PRVABC-59 consists of a 107 nt 5′NCR, a 10,272 nt ORF, and a 428 nt 3′NCR
(top panel). The ORF encodes a 3423 aa polyprotein that is predicted to be cleaved by viral and cellular
proteases into at least 10 mature proteins (middle panel). Marked on the polyprotein and its products
are one or two transmembrane domains (vertical black bar) at the C-termini of three structural proteins
(C, prM, and E) and at the junction of NS4A/NS4B, as well as four N-glycosylation sites (asterisk)
in the pr portion of prM (70NTT), E (154NDT), and NS1 (130NNS and 207NDT). The bottom panel
shows the antigenic regions (horizontal magenta bar) recognized by seven ZIKV region-specific rabbit
antisera. (B) Identification of viral proteins in ZIKV-infected cells by immunoblotting. Vero cells were
mock-infected or infected at MOI 1 with each of three ZIKVs (rMR-766, rP6-740, and rPRVABC-59)
or two JEVs (SA14 and SA14-14-2, for comparison). At 20 h post-infection, total cell lysates were
separated by SDS-PAGE on a glycine (Gly) or tricine (Tri) gel and analyzed by immunoblotting with
each of the seven ZIKV region-specific rabbit antisera or α-GAPDH rabbit antiserum as a loading and
transfer control. Molecular size markers are given on the left of each blot, and major ZIKV proteins are
labeled on the right. Provided below each blot are the estimated molecular sizes of predicted ZIKV
proteins, and marked on the blot are the predicted proteins (yellow or pink dot) and presumed cleavage
intermediates or further cleavage/degradation products (white circle). CHO, N-glycosylation.
Our immunoblot analysis using a collection of 13 ZIKV antigen-reactive region-specific rabbit
antisera allowed us to create a full catalog of viral gene products and their related species, except
for the predicted 24 kDa NS2A (Figures 5 and 6): (1) α-ZC recognized the 13 kDa C protein, with no
accumulation of the further-processed 12 kDa C’ (see below for description of virion-associated
proteins), but with appearance of one or two cleavage products of 10–11 kDa in rPRVABC-59- or
rP6-740-infected cells, respectively; however, this antiserum did not react with any of the C-related
proteins of rMR-766. (2) α-ZM reacted strongly with the 9 kDa M protein and its 24 kDa precursor
prM, with the ratio of M:prM varying in the presence of equal amounts of the loading control GAPDH
protein, depending on the viral strain; the observed size of prM was 5 kDa larger than its predicted
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size, consistent with an addition of N-glycans at Asn-70 (70NTT) to its pr domain [64] that is conserved
in all three ZIKVs. Also, the α-ZM reacted weakly with at least two minor proteins of 15 and 19
kDa. (3) α-JEN-term/α-ZE detected four E-related proteins (of 54/56, 43/45, 24/26, and 14 kDa).
Among these, the first three proteins from rP6-740 were all 2 kDa smaller than those from rMR-766
and rPRVABC-59, in agreement with a missense mutation of the N-glycosylation site at Asn-154
(154NDT→NDI) in the E protein of rP6-740 relative to that of rMR-766 and rPRVABC-59 [19,20]. Indeed,
the three 2 kDa smaller proteins from rP6-740 became similar in size to those from rMR-766 and
rPRVABC-59, when the mutated N-glycosylation motif in rP6-740 was restored by changing 154NDI
into 154NDT, but not by changing 154NDI into 154QDT (Figure S7A–C). (4) Both α-JNS1C-term and
α-ZNS1 identified the 45 kDa NS1 exclusively. This protein was 5 kDa larger than predicted by its
amino acid sequence because of the addition of N-glycans at Asn-130 (130NNS) and Asn-207 (207NDT),
both of which are conserved in all three ZIKVs [65,66]. As expected, these data also showed that only
NS1, and not its frameshift product NS1’, was produced by all three ZIKVs. (5) α-JNS2B/α-ZNS2B
revealed the 14 kDa NS2B, together with a minor protein of 11 kDa at a barely detectable level.
(6) α-JNS3C-term recognized the 69 kDa NS3; it also reacted more strongly with a major cleavage
product of 34 kDa, representing the C-terminal half of the full-length NS3 [31], and less intensely
with at least seven minor proteins of 33–60 kDa. Intriguingly, α-JNS3C-term detected a species with
a mass of 85 kDa, corresponding to the calculated size of an NS2B-3 or NS3-4A/4A’ processing
intermediate. (7) α-ZNS4A did not detect the predicted 16 kDa NS4A, but did predominantly recognize
its further-processed 14 kDa NS4A’, which ran as a single species in tricine–SDS-PAGE but migrated as
a doublet in glycine–SDS-PAGE. Unexpectedly, this antiserum also identified two clusters of multiple
protein bands, one at 29 kDa (NS4Ap29) and the other at 35 kDa (NS4ABp35, which also reacted with
α-ZNS4B; Figure S8A,B). (8) α-ZNS4B stained the predicted major 27 kDa NS4B, along with two minor
proteins at 11 kDa (NS4Bp11) and 35 kDa (NS4ABp35, which again reacted with α-ZNS4A; Figures
S8A,B). (9) α-JNS5N-term and α-JNS5C-term reacted with the predicted 103 kDa NS5.
In addition to the three full-length structural proteins (C, prM/M, and E) of ZIKV, their multiple
smaller products were accumulated to lower but still significant amounts in Vero cells infected with
each of the three ZIKVs, with nearly the same protein expression profile (Figure 6). To define the
actual viral structural proteins incorporated into ZIKV particles, rPRVABC-59 was used to profile
all the structural proteins associated with extracellular virions, which were purified by pelleting
through a 20% sucrose cushion. We then compared them with their cell-associated counterparts by
immunoblotting with α-ZC, α-ZM, and α-ZE (Figure 7). The purified ZIKV particles were shown
to contain (i) the 12 kDa C’ protein, which appeared as a closely spaced doublet with the lower
band being more prominent than the upper band and migrating in a gel marginally faster than
one cell-associated major 13 kDa C protein, but slower than the other cell-associated minor 10 kDa
C-derived cleavage product; (ii) the 9 kDa M protein and a trace amount of its glycosylated precursor
prM, which appeared as two bands, the slightly less intense and faster one migrating with a mass of
23–24 kDa and the slightly more intense and slower one at 25–26 kDa, reflecting the trimming of high
mannose and the addition of more complex sugars to the cell-associated 24 kDa prM protein during
virus release through the cellular secretory pathway [67]; and (iii) the glycosylated 58 kDa E protein,
which ran slightly slower than the cell-associated 56 kDa E protein, again reflecting the difference in its
glycosylation status. Collectively, we have demonstrated that the extracellular ZIKVs are composed of
three post-translationally modified full-length structural proteins, excluding their smaller species.
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Figure 7. Profiling of virion-associated ZIKV proteins compared to their cell-associated counterparts.
Vero cells were left uninfected (Uninf) or infected (Inf) with ZIKV rPRVABC-59 at an MOI of 1. For
cell-associated viral proteins, total cell lysates were prepared by lysing the cell monolayers at 20 h
post-infection. For virion-associated viral proteins, cell culture supernatants were collected at the
same time point, and extracellular virions were pelleted by ultracentrifugation through a 20% sucrose
cushion. Equivalent portions of total cell lysates and pelleted virions were resolved by SDS-PAGE on a
glycine (Gly) or tricine (Tri) gel and analyzed by immunoblotting with α-ZC, α-ZM, or α-ZE. Molecular
weight markers are shown on the left of each blot. The molecular weights of predicted C, C’, prM, M,
and E proteins are indicated below each blot. Marked on each blot are the predicted proteins (yellow or
pink dot) and presumed further cleavage/degradation products (white circle). CHO, N-glycosylation.
3.5. Wide Range of Differences in Age-Dependent Neuropathogenicity among Three Molecularly Cloned ZIKVs
in Outbred CD-1 Mice
We compared the virulence of rMR-766, rP6-740, and rPRVABC-59 in CD-1 mice at three different
ages (1, 2, and 4 weeks) by examining two neuropathogenic properties: (i) neuroinvasiveness
(the ability to penetrate the central nervous system from a peripheral site), quantified by generating
the dose-dependent survival curve and determining the LD50 after an im inoculation; and (ii)
neurovirulence (the ability to establish a lethal infection within the central nervous system), quantified
by creating the dose-dependent survival curve and measuring the LD50 after an ic inoculation. For both
im and ic inoculations, we first determined the appropriate dose ranges for calculating the LD50 values,
and we optimized the study designs prior to the performance of full-scale experiments. For these
pilot experiments, we injected all three age groups of the mice with a maximum dose of each virus:
1.2 × 105 PFU/mouse for im inoculations and 3.6 × 104 PFU/mouse for ic inoculations. If necessary,
we then performed a series of large-scale dose-response studies, inoculating groups of the mice at
1, 2, and 4 weeks of age via the im or ic route with serial 10-fold dilutions of the virus. Following
infection, the mice were monitored daily for mortality, weight loss, and other clinical signs of illness
over 20 days.
The comparative assessments of our dose-dependent survival curves and LD50 values revealed the
following (Figure 8A): (i) rMR-766 exhibited age-dependent neuroinvasiveness, as evidenced by an im
LD50 of 90.2 PFU for 1-week-old mice and >1.2 × 105 PFU for 2- and 4-week-old mice, yet it displayed
a high level of neurovirulence at all three ages, as evidenced by an ic LD50 of <3.6, 3.6, and 5.7 PFU
for 1-, 2-, and 4-week-old mice, respectively. (ii) rP6-740 showed barely detectable neuroinvasiveness
in 1-week-old mice, with only 1 or 3 of 10 infected mice dying when inoculated with the two highest
doses, 3.6 × 103 or 3.6 × 104 PFU/mouse, respectively (im LD50, >3.6 × 104 PFU). Similarly, it had
no detectable neuroinvasiveness in 2- and 4-week-old mice, with no infected mice dying even when
inoculated with the highest dose, 1.2 × 105 PFU/mouse (im LD50, >1.2 × 105 PFU). However, rP6-740
showed age-dependent neurovirulence, as it was highly neurovirulent in 1-week-old mice (ic LD50,
<3.6 PFU) but non-neurovirulent in 2- and 4-week-old mice (ic LD50, >3.6 × 104 PFU). (iii) rPRVABC-59
was essentially non-neuroinvasive and non-neurovirulent, regardless of the mouse age, with its im and
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ic LD50 values estimated to be greater than the highest dose used for each route of infection, without
a single death. Of the three ZIKVs, therefore, rMR-766 was the most virulent, rPRVABC-59 was the
least virulent, and rP6-740 showed intermediate virulence. The observed differences in virulence are
correlated with the variations in viral passage history in mice (Figure 1A).
Moreover, we recognized not only the lethal virulence displayed by rMR-766 and rP6-740 but also
the non-lethal virulence exhibited by all of the three ZIKVs, including rPRVABC-59. This effect was
most prominent in 1-week-old mice (Figure 8B). The lethal virulence was invariably associated with a
sharp drop in the body weight of infected mice that began ~3 days prior to death, in conjunction with
clinical signs. It began with decreased activity, ruffled fur, and hunched posture, and often progressed
to tremors and hind limb paralysis. Various viral loads were detected postmortem in the brains of all
mice that died (8.0 × 103–3.9 × 108 PFU/brain). Non-lethal virulence, in contrast, was characterized
by an initial weight loss of various degrees, albeit without obvious clinical signs, and a subsequent
recovery, to some extent, that was not complete. At the end of the study, no infectious ZIKV was
detected in the brains of any of the mice that survived. In both the lethal and non-lethal virulent cases,
no changes in body temperature were observed. Altogether, we found that in CD-1 mice, the three
ZIKVs had a wide range of virulence, depending on the virus strain, mouse age, and route of infection.
Figure 8. Three molecularly cloned ZIKVs display a full range of variation in neuropathogenicity
for outbred CD-1 mice in an age-dependent manner. Groups of CD-1 mice (n = 8–10, half male,
half female) were mock-inoculated or inoculated at 1, 2, and 4 weeks of age via the intramuscular (im)
or intracerebral (ic) route with a maximum dose of 3.6 × 104 or 1.2 × 105 PFU, or serial 10-fold dilutions
of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were generated by the Kaplan–Meier method,
and LD50 values were determined by the Reed–Muench method and are presented in the bottom left
corner of each curve. (B) Weight changes are plotted, with each mouse represented by one color-coded
line. dpi, days post-infection.
3.6. High Degree of Variation in Interferon (IFN) Sensitivity among Three Molecularly Cloned ZIKVs in Mice
Lacking Type I (IFNAR−/−) or Both Type I and II IFN (IFNAR−/−/IFNGR−/−) Receptors
To compare the contributions of the host IFN response to the virulence of rMR-766, rP6-740,
and rPRVABC-59, we examined their neuroinvasiveness and neurovirulence by using groups
of 4-week-old A129 (IFNAR−/−) mice and groups of age-matched wild-type inbred C57BL/6J
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mice as a control (Figure 9A). In the control mice, rMR-766 was non-neuroinvasive (im LD50,
>1.2 × 105 PFU) but neurovirulent (ic LD50, 7.8 PFU). In contrast, both rP6-740 and rPRVABC-59
were non-neuroinvasive (im LD50, >1.2 × 105 PFU) as well as non-neurovirulent (ic LD50, >3.6 × 104
PFU), in agreement with the data obtained in age-matched outbred CD-1 mice (Figure 8A). In A129
mice, however, the neurovirulence of all three ZIKVs was increased sharply, and they became
highly neurovirulent (ic LD50, <3.6 PFU), with median survival times estimated to be 4 (rMR-766),
5 (rP6-740), and 7 (rPRVABC-59) days, with a lethal dose of 3.6 × 102 PFU/mouse. Similarly,
the neuroinvasiveness of the three ZIKVs was also elevated but to different degrees, as evidenced
by the estimated im LD50 of <1.2 (rMR-766), 576.1 (rP6-740), and >1.2 × 105 (rPRVABC-59) PFU.
Noticeably, rPRVABC-59 was nearly non-neuroinvasive in A129 mice. This finding prompted us
to further test the neuroinvasiveness of rPRVABC-59, as compared to that of the other two ZIKVs,
in 4-week-old AG129 (IFNAR−/−/IFNGR−/−) mice (Figure 9A). In AG129 mice, all three ZIKVs
were highly neuroinvasive (im LD50, <1.2 PFU), although the median survival times for the three
viruses varied from 7 (rMR-766) to 12 (rP6-740) and 13 (rPRVABC-59) days, with a lethal dose of
1.2 × 102 PFU/mouse. Furthermore, in all three mouse strains (C57BL/6J, A129, and AG129), the two
LD50-based neuropathogenic properties of the three ZIKVs were always corroborated by the decreases
in body weight (Figure 9B), accompanied by the typical clinical signs seen in CD-1 mice. In all the
mice that died, various viral loads were detected in their brains postmortem, with higher loads
being found in the absence of IFN signaling, i.e., 4.7 × 104–2.0 × 108 PFU/brain for C57BL/6J,
1.3 × 106–1.0 × 109 PFU/brain for A129, and 8.5 × 106–3.6 × 109 PFU/brain for AG129. In the case of
all mice that survived, however, we detected no infectious ZIKV in the brain at the end of the study.
Taken together, these data show a full range of variation in IFN sensitivity among the three cloned
ZIKVs in mice.
Figure 9. Three molecularly cloned ZIKVs show a full spectrum of variation in IFN sensitivity in mice
lacking type I or both type I and II IFN receptors. Groups of 4-week-old C57BL/6J (n = 8), A129 (n = 5),
or AG129 (n = 5) mice, approximately half of each sex, were mock-inoculated or inoculated through
the intramuscular (im) or intracerebral (ic) route with a maximum dose of 3.6 × 104 or 1.2 × 105 PFU,
or serial 10-fold dilutions of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were created by the
Kaplan–Meier method, and LD50 values were calculated by the Reed–Muench method and are given
in the bottom left corner of each curve; (B) Weight changes are plotted, with each mouse indicated by
one color-coded line. NT, not tested; dpi, days post-infection.
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4. Discussion
Here, we report the first development of three full-length infectious ZIKV cDNAs as BACs for
each of three spatiotemporally distinct and genetically divergent ZIKV strains [54]: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). We have also produced 13 ZIKV
region-specific polyclonal rabbit antisera capable of identifying all the viral structural and nonstructural
proteins and their related species, except for NS2A. Using our functional cDNAs and antibodies in
combination with various cell culture and murine model systems, we have demonstrated that the
three molecularly cloned cDNA-derived ZIKVs have the nearly same genome-wide viral protein
expression profile but differ in their replication kinetics and neuropathogenicity (neuroinvasiveness
and neurovirulence), depending on the particular combination of viral and host genetic backgrounds,
as well as in the presence or absence of type I/II IFN signaling. In particular, our results demonstrate
that type I IFN regulates ZIKV neuroinvasiveness in a virus strain-dependent manner. In all, these
reagents offer a new toolbox for viral genome engineering and protein analysis. Together with a roster
of in vitro and in vivo infection models, these tools will not only provide an ideal platform for defining
the viral and host genetic factors that contribute to ZIKV replication and pathogenesis at the cellular
and organismic levels, but also offer promising new avenues for developing and testing an effective,
critically needed vaccine against ZIKV.
The advent of functional cDNA-based reverse genetics has revamped the field of RNA viruses [68].
For flaviviruses, however, the cloned cDNAs are commonly unstable because of the toxicity of their
prM-E genes in host cells, posing a major technical challenge to functional cDNA construction [69].
In the present study, we cloned a complete cDNA copy of the ZIKV genomic RNA into a BAC vector
that is capable of stably housing a DNA fragment of >300 kb in bacteria [70], as we have already
done for JEV [53,58]. In the case of all three ZIKVs (MR-766, P6-740, and PRVABC-59), we showed
that the structural and functional integrity of their full-length BACs remained stable for at least 80
generations of growth in E. coli. To date, the BAC cloning technology has been applied to constructing
full-length infectious cDNAs for ~10 members of three plus-strand RNA virus families (Flaviviridae,
Arteriviridae, and Coronaviridae), all of which have a large genome size of 11–31 kb [52]. Moreover, we
performed site-directed mutagenesis to introduce a point mutation(s) into the full-length infectious
cDNA BAC clone of ZIKV P6-740, which demonstrated (i) the functional importance of His-713 within
the conserved structural motif E region in the RNA-dependent RNA polymerase domain of ZIKV NS5
for viral RNA replication and (ii) the functional significance of the N-glycosylation site at Asn-154 in
the viral E protein for its biogenesis. These results indicate that targeted mutations can be engineered
by manipulating the infectious ZIKV BACs in E. coli. Thus, our BAC-based reverse genetics for ZIKV
will facilitate genetic studies of both viral RNA elements and gene products associated with all aspects
of ZIKV biology.
We formulated a strategy to assemble three full-length infectious ZIKV cDNAs, each capable of
generating m7G-capped in vitro-transcribed RNAs identical in nucleotide sequence to their respective
genomic RNAs, particularly regarding the 5′- and 3′-end sequences. On the 5′ side, we positioned an
SP6 promoter sequence (5′-ATTTAGGGGACACTATAG, with transcription starting at the underlined
G) upstream of the first adenine nucleotide of the viral genome to incorporate the dinucleotide cap
analog m7GpppA in SP6 RNA polymerase-driven in vitro transcription reactions. The importance
of an m7G cap at the 5′-end of transcribed RNAs in maximizing RNA infectivity was shown by our
finding that uncapped RNAs derived from each of the three functional ZIKV cDNAs always had
an infectivity >3-logs lower than that of their m7G-capped counterparts. On the 3′ side, we placed
a unique restriction endonuclease recognition site, PsrI [(N7↓N12)GAACN6TAC(N12↓N7)] or BarI
[(N7↓N12)GAAGN6TAC(N12↓N7)], downstream of the last thymine nucleotide of the viral genome.
The use of PsrI/BarI for cDNA linearization is particularly advantageous because both are extremely
rare-cutting endonucleases that cut out their recognition sequences after any nucleotide, which makes
this approach applicable for all plus-strand RNA viruses, regardless of the identity of the nucleotide at
the 3′ end of the viral genome. We found that RNA transcripts with 11 ZIKV-unrelated nucleotides
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hanging on their 3′ ends were ~1-log less infectious than those with authentic 3′ ends, indicating the
importance of the authentic 3′ end for the production of infectious ZIKV RNAs.
Several functional cDNAs for ZIKV have hitherto been made using two different strategies,
depending on the vector adopted to clone its full-length cDNA and the method applied to create
the viral 5′ and 3′ ends: (i) The low-copy plasmid pACYC177 (~15 copies/cell) has been utilized to
house a complete cDNA flanked by a 5′ bacteriophage T7 promoter and a 3′ hepatitis delta virus
ribozyme (HDVr). This T7-HDVr system, analogous to our SP6-PsrI/BarI system, requires an in vitro
transcription and transfection of transcribed RNAs into cells for virus recovery. This “RNA-initiated”
approach has been implemented to clone the viral genomic RNA of the 2010 Cambodian FSS13025
strain [71]. To circumvent the need for a single plasmid containing a full-length cDNA, in vitro
ligation of two or four cDNA fragments pre-cloned individually into the low-copy pACYC177 or
high-copy pUC57 (500–700 copies/cell) plasmid, although relatively inefficient, has been done to
generate a full-length cDNA template prior to in vitro transcription using the T7-HDVr system for
the Ugandan MR-766 (1947), French Polynesian H/PF/2013 (2013), Puerto Rican PRVABC-59 (2015),
and Brazilian SPH2015 (2015) and BeH819015 (2015) strains [49,72]. (ii) The low-copy pACNR1811
(10–20 copies/cell) or high-copy pcDNA6.2 (500–700 copies/cell) plasmid is used to house a full-length
cDNA containing one or two artificial introns to restrict its instability during propagation in E. coli. In
this case, a eukaryotic RNA polymerase (RNAP) II-dependent cytomegalovirus (CMV) promoter is
positioned before the viral 5′ end, and a pair of HDVr and an SV40 poly(A) signal/RNAP II terminator
are placed after the viral 3′ end. Unlike our SP6-PsrI/BarI system, the CMV-HDVr system requires
transfection of cells with a plasmid carrying the intron-bearing full-length cDNA. This “DNA-initiated”
approach has been applied to clone the viral genomic RNA of the Ugandan MR-766 (1947) and Brazilian
Paraiba (2015) strains [73,74]. Alternatively, a circular form of the intronless full-length cDNA for
the 2015 Brazilian Natal strain has been generated by PCR-mediated joining of eight overlapping
cDNA fragments that are pre-cloned individually into the high-copy pUC plasmid [75]. Although far
less efficient, a similar PCR-based method has also been reported that uses three overlapping cDNA
fragments covering the viral genomic RNA with no joining of these fragments into a circular cDNA [76].
In the present study, we developed a single plasmid-based RNA-initiated reverse genetics system for
ZIKV that not only maximizes the genetic stability of its cloned cDNA using a single-copy BAC as a
vector, but also optimizes the synthesis of infectious RNAs in vitro using the SP6-PsrI/BarI system.
ZIKV circulates in a sylvatic cycle between nonhuman primates (NHPs) and forest-dwelling
mosquitoes, as well as in an urban cycle between humans and town-dwelling mosquitoes [12]. Apart
from NHPs, however, information is scarce on any potential animal hosts or reservoirs for ZIKV
transmission. Using our three cDNA-derived genetically distinct ZIKVs, we evaluated their ability to
infect and replicate in 17 animal cell lines from 12 different species (monkeys, humans, mosquitoes,
mice, cows, pigs, sheep, goats, horses, dogs, cats, and chickens). Our data showed that ZIKV has a
broad cell tropism in vitro, being capable of establishing productive infection in 16 of the 17 cell lines
we tested, although its growth rate and ability to induce CPE varied widely depending on both the
specific virus strain and host cell line. Of particular note, all three ZIKVs grew readily in both porcine
ST and equine NBL-6 cells, with their growth kinetics similar to those observed in simian Vero cells;
generally, they also replicated and spread equally well in ovine SFF-6 cells and in aedine C6/36 cells.
These results raise a question as to whether several agriculturally important domestic animals (e.g.,
pigs, sheep, and horses) are susceptible to ZIKV infection, particularly when young. With respect
to this question, two recent studies have reported that fetal and neonatal piglets are susceptible to
experimental infection with ZIKV [77,78]. Another pilot study has suggested that a range of adult
animals, including rabbits, goats, pigs, cattle, chickens, and ducks, are less likely to act as animal
hosts for ZIKV, based on the levels of viremia and neutralizing antibody titer induced following ZIKV
infection; of these animals, however, rabbits and pigs are proposed to be able to serve as sentinels
for ZIKV surveillance [79]. Clearly, further investigation is needed to elucidate the susceptibility of
these animals to ZIKV infection, preferentially in the presence or absence of type I IFN signaling,
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and might provide new opportunities to increase our understanding of ZIKV biology and to develop
a non-murine model for ZIKV research. Moreover, we discovered a nonsusceptible bovine MDBK
cell line that has a block in ZIKV entry but fully supports the subsequent post-entry steps; however,
this cell line remained highly susceptible to infection by two other enveloped RNA viruses, BVDV [80]
and VSV [81], which like ZIKV [63], enter the cells through clathrin-dependent endocytic pathway.
This ZIKV-nonsusceptible bovine cell line thus offers a unique opportunity to identify the host factors
involved in ZIKV entry.
To our knowledge, this work is the first to generate such a large panel of 13 ZIKV region-specific
antibodies that can identify experimentally nearly all the viral gene products and their related species
in ZIKV-infected Vero cells and define all three structural proteins associated with extracellular
virions. Our data are in overall good agreement with the current model for flavivirus polyprotein
processing [21], but they have also revealed a considerable number of previously undescribed,
presumed cleavage intermediates or further cleavage/degradation products. The main findings from
our study are as follows: (1) While the full-length 13 kDa C and its one or two processed 10 to 11 kDa
proteins were accumulated intracellularly, the extracellular virion-associated C’ protein appeared as
a tightly spaced 12 kDa doublet. (2) For each of the two viral surface glycoproteins (24 kDa prM
and 54/56 kDa E), two or three smaller products were also cell-associated but not virion-associated.
(3) Only the 45 kDa NS1, and not its theoretically frameshift-derived product NS1’, was expressed. (4) In
addition to the intact 14 kDa NS2B, its processed 11 kDa product was also stained, although weakly.
(5) The full-length 69 kDa NS3 was processed to yield multiple truncated species of 33–60 kDa, of which
the C-terminal 34 kDa fragment was the most prominent species. (6) The predicted 16 kDa NS4A was
completely undetectable, but three unpredicted NS4A-related proteins were readily identified, i.e.,
a major doublet at 14 kDa (NS4A’) and two minor protein clusters at 29 kDa (NS4Ap29) and 35 kDa
(NS4ABp35). (7) Not only the predicted 27 kDa NS4B but also two unpredicted NS4B-related proteins
were observed, one at 11 kDa (NS4Bp11) and the other at 35 kDa (NS4ABp35). However, the functional
importance of the previously undescribed cleavage intermediates or further cleavage/degradation
products in ZIKV biology remains to be determined.
Much progress has been made over the past year in developing animal models (i.e., mice and
NHPs) for ZIKV [43]. To date, the mouse is the most feasible small animal that mimics aspects of
ZIKV infection in humans, albeit with some limitations resulting from species differences in innate
immunity, reproductive system, and fetal development. Previously, no productive infection was
detected when several strains of immunocompetent adult mice were inoculated peripherally with
diverse ZIKVs, but robust peripheral ZIKV infection causing substantial morbidity and mortality was
observed in both immunocompromised adult and immunocompetent neonatal mice [44,46,82–89].
We call attention, however, to the large variation in ZIKV pathogenicity among the previous studies,
which were conducted by inoculating a variety of ZIKVs into different strains of mice via various
routes. In the current report, we have shown in immunocompetent CD-1 mice at 1, 2, and 4 weeks
of age that ZIKV neuropathogenicity can only be defined in the context of a virus-host combination,
particularly depending on both viral strain and mouse age, as evidenced by comparison of the
neuroinvasiveness and neurovirulence of our three molecularly cloned, genetically distinct ZIKVs: (i)
rMR-766 exhibited neonate-specific age-dependent neuroinvasiveness but displayed a high level of
neurovirulence at all three ages. (ii) rP6-740 had little-to-no neuroinvasiveness at all three ages but
possessed neonate-specific age-dependent neurovirulence. (iii) rPRVABC-59 was non-neuroinvasive
and non-neurovirulent at all three ages. Also, we showed marked differences in IFN sensitivity among
the three ZIKVs: In 4-week-old A129 (IFNAR−/−) mice, the three ZIKVs were uniformly neurovirulent
but varied in neuroinvasiveness (rMR-766, neuroinvasive; rP6-740, intermediate; and rPRVABC-59,
almost non-neuroinvasive); however, all three ZIKVs, including rPRVABC-59, were neuroinvasive
in age-matched AG129 (IFNAR−/−/IFNGR−/−) mice. Consistent with previous work, we noted a
greater susceptibility and more severe disease in AG129 mice than in A129 mice [44–49]. In all fatal
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cases, the mortality was related to the productive infection in the brain, coupled with tremors, ataxia,
and hind limb paralysis.
In conclusion, use of our newly developed comparative functional genomics and immunologic
tools, combined with various cell culture and mouse infection model systems, will facilitate further
research leading to ZIKV disease prevention and therapy, as well as an in-depth understanding of
ZIKV biology.
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Abstract: Heme oxygenase-1 (HO-1), a rate-limiting enzyme involved in the degradation of heme,
is induced in response to a wide range of stress conditions. HO-1 exerts antiviral activity against
a broad range of viruses, including the Hepatitis C virus, the human immunodeficiency virus,
and the dengue virus by inhibiting viral growth. It has been reported that HO-1 displays antiviral
activity against the Zika virus (ZIKV) but the mechanisms of viral inhibition remain largely unknown.
Using a ZIKV RNA replicon with the Green Fluorescent Protein (GFP) as a reporter protein, we were
able to show that HO-1 expression resulted in the inhibition of viral RNA replication. Conversely,
we observed a decrease in HO-1 expression in cells replicating the ZIKV RNA replicon. The study
of human cells infected with ZIKV showed that the HO-1 expression level was significantly lower
once viral replication was established, thereby limiting the antiviral effect of HO-1. Our work
highlights the capacity of ZIKV to thwart the anti-replicative activity of HO-1 in human cells.
Therefore, the modulation of HO-1 as a novel therapeutic strategy against ZIKV infection may
display limited effect.
Keywords: antiviral; heme-oxygenase 1; Zika virus; viral replication
1. Introduction
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus (family Flaviviridae), which has
become a major medical problem worldwide. In 2007, the first documented outbreak of ZIKV occurred
on Yap Island, affecting more than 70% of the population. Subsequently, ZIKV continued to spread in
the South Pacific Islands and has largely emerged in the Americas since 2015 [1]. Phylogenetic analysis
of viral sequences has identified two main virus lineages, African and Asian, the latter being the main
cause of large, current epidemics with millions of cases of infection [2,3].
Classically, the human disease known as Zika fever is characterized by mild flu-like symptoms
with fever, maculopapular rash, headache and sometimes conjunctivitis, arthralgia, and myalgia.
Epidemiological studies from the recent epidemics have shown that infection due to ZIKV can also
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cause serious complications in humans such as microcephaly in newborns or Guillain–Barré Syndrome
(GBS) in adults [4,5]. Once ZIKV has entered the human body, most commonly through the bite of
a mosquito, it targets many types of cells, such as epithelial cells, in order to replicate and produce a viral
progeny. Similar to other flaviviruses, the life cycle of ZIKV leads to the release of its single-strand positive
sense genomic RNA in the cell cytoplasm where it is translated into a single polyprotein. The polyprotein
is cleaved by host and viral proteases into three structural proteins (C, prM/M and E), and seven
nonstructural proteins (NS) (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) [6]. The NS proteins initiate
the replication process. The viral cycle continues with the production and maturation of envelope proteins,
encapsidation, budding, and the release of the virions by exocytosis.
HO-1 is an ubiquitously expressed, stress-inducible enzyme that catabolizes heme into biliverdin,
carbon monoxide, and ferrous iron [7]. These products contribute to the cytoprotective effect of HO-1
by acting as anti-oxidant, anti-inflammatory, and immunomodulatory molecules [7]. In addition, it has
been shown that HO-1 can display antiviral activity. The upregulation of HO-1 was shown to limit
infection by Hepatitis C and B virus (HCV and HBV), Ebola virus (EBOV), human immunodeficiency
virus (HIV), and Dengue virus (DENV) [8].
Even if no therapeutic ZIKV control strategy is available to date, it has been previously proposed
that the FDA approved drug Hemin could be used for its anti-viral activity, based on its action on
HO-1 [9]. However, the direct effect of HO-1 on ZIKV replication has not yet been demonstrated. Here,
using cells expressing a molecular ZIKV replicon, we provide evidence that cobalt protoporphyrin
(CoPP), an inducer of HO-1, or direct overexpression of HO-1 inhibits ZIKV replication. Unexpectedly,
we observe that ZIKV is able to downregulate HO-1 expression as a result of its own replication.
Based on these observations, we conclude that the induction of HO-1 to limit ZIKV infection is likely
to be ineffective as a therapeutic strategy.
2. Materials and Methods
2.1. Virus and Cell Lines
The clinical isolate PF-25013-18 (PF13) of ZIKV has been previously described [10]. Cell lines
used in this study included the A549-Dual™cell line (InvivoGen, a549d-nfis), referred to hereafter
as “A549 cells”, and the HEK-Blue™ IFN-α/β cell line (InvivoGen, San Diego, CA, USA) which
possesses the HEK-293A backbone and is referred to hereafter as “HEK-293A cells”. Both cell lines
were cultured at 37 ◦C with 5% CO2 in MEM Eagle medium, supplemented with 10% heat inactivated
fetal bovine serum and 2 mmol·L−1 L-Glutamine, 1 mmol·L−1 sodium pyruvate, 100 U·mL−1 of
penicillin, 0.1 mg·mL−1 of streptomycin and 0.5 μg·mL−1 of fungizone (PAN Biotech, Aidenbach,
Germany). Additionally, A549 cellular growth medium was supplemented with 10 μg·mL−1 blasticidin
and 100 μg·mL−1 zeocin (InvivoGen) and HEK-293A cell growth medium was supplemented with
30 μg·mL−1 blasticidin and 100 μg·mL−1 zeocin (InvivoGen). Cells were harvested and stored as
frozen pellets for further protein or mRNA analysis.
2.2. Generation of ZIKV Replicon by the ISA Method
The production of a ZIKV RNA replicon with GFP as a reporter protein, named ZIKV replicon
in the study, was based on the sequence of ZIKV strain MR766 Uganda 47-NIID (Genbank access
# LC002520) using the ISA (Infectious Subgenomic Amplicons) method [11]. The design of the
viral genome, without the structural protein region, into four viral genomic fragments Z1-PURO,
Z2, Z3, and Z4-IRES-eGFP (Figure 1A) was chosen to mimic those used to construct the molecular
clone MR766MC [11]. Compared to the conventional method based on the in vitro transcription from
a T7 promoter, our construction was designed to allow the in cellulo transcription of recombinant
DNA obtained from the four viral genomic fragments Z, by replacing the T7 promoter with
a CytoMegaloVirus (CMV) promoter [12]. The fragment Z1-PURO contains the CMV promoter
immediately adjacent to the 5′ non-coding region of MR766 followed by the puromycin resistance
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(PAC) cassette fused in frame to the first 33 amino acids of the ZIKV C protein. It is ended by the
porcine teschovirus-1 2A protease and the nucleotide sequence coding for the last 95 C-terminal amino
acids of the E protein. The fragments Z2, Z3, and Z4 have been previously described [11]. The fragment
Z4-IRES-eGFP contains a cassette containing the Interne Ribosomal Entry Site IRES2 sequence from
Clontech followed by the eGFP sequence between the NS5 gene and the 3′NTR from Z4. HEK-293A
cells were electroporated with the four fragments Z1-PURO to Z4-IRES-eGFP, using a gene pulser II
according to manufacturer protocol (BioRad, Hercules, CA, USA). Cells harboring the ZIKV replicon
were selected with puromycin (1 μg·mL−1) for at least five days (Figure 1A). The selected cells were
kept in culture throughout the experiment (passage 1 to 5). GFP expression was checked periodically
by RT-PCR (Figure 1B), cytometry (Figure 1C), as well as by microscopy (Figure 1D). The replicon
maintenance was followed by RT-PCR (Figure 1B) and the immunodetection of double-stranded RNA
(Figure 1D). Viral protein expression was verified during the different passages by immunodetection
(Supplemental Figure S1).
Figure 1. Generation and validation of ZIKA Virus (ZIKV) replicon in HEK-293A cells. (A) Schematic
representation of overlapping fragments Z1 to Z4 covering of ZIKV replicon. Below, the flow chart
representing the design of the experiment. (B) GFP, ZIKV NS3, ZIKV NS1 and RNA pol-II mRNA
expression assessed by RT-PCR in ZIKV-infected A549 cells, ZIKV replicon cells and HEK 293A
cells. (C) Cytometry monitoring of GFP after ribavirin treatment. (D) Fluorescence microscopy
images of ZIKV replicon cells (GFP positive) after immunostaining of dsRNA with J2 antibody (red).
(E) ISRE/SEAP activity evaluated in HEK 293A cells and ZIKV replicon cells. As positive control,
cells were treated for 24 h with recombinant IFN-β (10,000 UI·mL−1). ** p < 0.01.
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2.3. RNA Isolation and RT-PCR
Total RNA was extracted from cells seeded in 60 mm Petri dishes with the RNeasy Mini
Kit (Qiagen, Venlo, Netherlands). RT-PCR was performed using M-MLV Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) using 500 ng of total RNA and the GoTaq®enzyme (Promega,
Madison, WI, USA) according to manufacturer’s recommended procedures [13]. The primers used for
RT-PCR were GFP F: 5′-AAGGCTACGTCCAGGAGCGC-3′, R: 5′-CTTGTGCCCCAGGATGTTGC-3′;
NS1: F 5′-AGAGGACCATCTCTGAGATC-3′, R 5′-GGCCTTATCTCCATTCCATACC-3′; NS3:
F 5′-ATGC ACACTGGCTTGAAGC-3′, R 5′-CAGATGCAACCTGATAGGC-3′; RNA PolII:
F 5′-GCACCACGTCCAATG-3′, R 5′-GTGCGGCTGCTTCCA-3′; GAPDH: F 5′-GGGAGCCAAAAG
GGTCATCA-3′ , R 5′-TGATGGCATGGACTGTGGTC-3′ . RT-PCR products were visualized by
agarose gel electrophoresis. qPCR was performed using the GoTaq® qPCR Master Mix (Promega).
All steps were conducted according to the manufacturer’s instructions. The qPCR data were analyzed
using the ΔΔCt method and results were normalized to GAPDH, which was used as an internal control.
2.4. Western Blot Analysis
Cells seeded in 6-well plates were harvested after two washes with Phosphate buffered saline
(PBS) containing phosphatase and protease inhibitors (Thermo Fischer Scientific, Waltham, MA, USA)
and lyzed with RIPA lysis Buffer (Sigma-Aldrich, St. Louis, MS, USA). Proteins were separated
by 12% SDS-PAGE and transferred onto nitrocellulose membranes [14]. The membranes were
first blocked with 5% milk in TBS-Tween for 1 h, then incubated with appropriate dilutions of
primary antibody at 1:1000 for 2 h. Anti-rabbit immunoglobulin-horseradish peroxidase and
anti-mouse immunoglobulin-horseradish peroxidase conjugates were used as secondary antibodies
(dilution 1:2000, Vectors). The membranes were incubated with Amersham ECL Select or prime
Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA) and exposed to a film or
on an Amersham imager 600 (GE Healthcare) or GeneGnome imager (Syngene, Cambridge, UK).
Horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies were purchased from
Vector Labs. The mouse anti-pan flavivirus envelope E protein mAb 4G2 was produced by RD
Biotech. Mouse antibody against HO-1was from Abcam and the mouse antibody against α-tubulin,
β-tubulin and M2 FLAG were from Sigma–Aldrich. All Western-blot data are representative of three
independent experiments.
2.5. ISRE/SEAP Activity Quantification
Interferon-sensitive response element (ISRE) promoter activation was evaluated in supernatant of
HEK-293A cells expressing the ZIKV replicon using the substrate Quanti-blue (Invivogen) according
to the manufacturer’s recommendations to measured secreted embryonic alkaline phosphatase (SEAP)
activity. As a positive control, HEK-293A cells were treated for 24 h with recombinant IFN-β
(10,000 UI·mL−1, Peprotech).
2.6. Flow Cytometry Assay
To detect GFP-expressing cells, cells were harvest after trypsinization and fixed with 3.7% PFA in
PBS at room temperature for 10 min. Fixed cells were subjected to a flow cytometric analysis using
FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The percentage of GFP-positive
cells was determined using the FlowJo software package.
2.7. Cell Immunofluorescence Staining
HEK-293A cells expressing the ZIKV replicon were grown on glass coverslips, fixed and
permeabilized for further incubation in monoclonal mouse anti-double-stranded RNA, clone J2
(English & Scientific Consulting Kft, Szirák, Hungary, J2-1104) (1:200) in 1% PBS-BSA and then
with Alexa594-conjugated anti-mouse Ig (1:1000). Nuclei were revealed by DAPI staining (final
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concentration 100 ng/mL). Coverslips were mounted in Vectashield (Vector Labs; Clinisciences,
Nanterre, France), and fluorescence was observed using a Nikon Eclipse E2000-U microscope (Nikon,
Tokyo, Japan). Images were obtained using the Nikon Digital sight PS-U1 camera system and the
imaging software NIS-Element AR (Nikon).
2.8. HO-1 Overexpression
HEK-293A cells expressing the ZIKV replicon were seeded on 6-well plates and transfected
with the expression plasmid pcDNA3.1-Neo or pcDNA3.1-HO-1-Flag-Neo encoding the human
HO-1 protein using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions.
Transfected cells were cultivated in media with G418 to enforce the expression of HO-1. For preparation
of pcDNA3.1-HO-1-Flag-Neo, the human HO-1 open reading frame was synthesized and cloned
between the KpnI and XhoI restriction sites of the pcDNA3.1-Neo plasmid (Invitrogen) by GeneCust
(Ellange, Luxembourg).
2.9. Crystal Violet Assay
To assess cell viability, we used the crystal violet staining assay (adapted from Saotome et al. [15]).
Briefly, cells seeded in 6-well plates were washed with PBS and then stained with 0.1% crystal violet in
PBS for 15 min. The plates were carefully washed with water. Then, 500 μL of 1% sodium dodecyl
sulfate was added to each well to solubilize the stain and absorbance was read at 590 nm.
2.10. Statistical Analysis
All values are expressed as mean ± SD and represent at least three independent experiments.
Comparisons between different treatments were analyzed using a one-way ANOVA test. Values of
p < 0.05 were considered statistically significant for a post-hoc Tukey–Kramer test in order to compare
treated versus non-treated. RT-qPCR statistical analysis was carried out by the Student’s t-test.
All statistical tests were performed using the software Graph-Pad Prism version 5.01 (San Diego,
CA, USA). Degrees of significance are indicated in the figure captions as follow: * p < 0.05; ** p < 0.01;
*** p < 0.001, ns = not significant.
3. Results
3.1. Generation of a ZIKV Replicon in HEK-293A Cells by the ISA Method.
For enveloped viruses, most antiviral therapies consist of drugs which target a specific viral
protein or cellular cofactor that mediates important steps in the viral life cycle, including viral entry,
fusion, replication or egress. Antiviral activity of HO-1 against flaviviruses results in the inhibition of
replication [9,16]. To address the effect of HO-1 on ZIKV replication in epithelial cells, independently
of other steps in the viral life cycle, we produced HEK-293A cells stably expressing and replicating
an RNA molecule acting as a ZIKV replication reporter, i.e., a ZIKV replicon (Figure 1A).
To validate the maintenance of a ZIKV replicon in the puromycin selected cells, we checked the
presence of RNA molecules encoding for NS1, NS3 and the GFP reporter gene by RT-PCR (Figure 1B).
These observations were further supported by the expression of NS1 protein (Supplemental Figure S1).
The presence of the GFP reporter gene in the construct allowed us to follow the ZIKV replicon
expressing cells by flow cytometry. To ensure that the replicon was maintained in cells, we used
Ribavirin, a synthetic nucleoside that inhibits RNA virus replication and blocks their nucleic acid
synthesis [17]. The decrease of the GFP signal observed with ribavirin likely corresponds to the
effect on self-replication of the replicon (Figure 1C) and has been used elsewhere as direct evidence
previously used to validate the function of viral replicons [12,18]. We then confirmed the presence
of double-stranded RNA (dsRNA), which corresponds to the active replication of the ZIKV replicon,
by immunodetection with the J2 antibody (Figure 1D). Cells expressing the GFP reporter gene were
also positive for the J2 staining. Lastly, the presence of dsRNA should trigger an antiviral response
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through type I interferon production. Since ZIKV replicon cells provide a reporter gene with an ISRE
fused to secreted embryonic alkaline phosphatase (SEAP), we were able to confirm the IFN-β response
by the measure of SEAP activity in the cell media (Figure 1E). This is additional evidence that the
self-replicating system specific to the viral replicon is maintained. The ZIKV replicon was able to
assemble and replicate autonomously in the ZIKV replicon cells.
3.2. HO-1 Reduces ZIKV RNA Replication
To investigate the effect of HO-1 on ZIKV replication, we first treated HEK-293A cells
expressing ZIKV replicon with CoPP, an inducer of HO-1. We verified the upregulation of HO-1 in
a dose-dependent manner with increasing concentrations of CoPP (Figure 2A). Under these conditions,
no cytotoxic effects were observed using neutral red assay (data not shown).
We then assessed the replication efficiency of the ZIKV replicon by measuring the percentage of
GFP-positive cells by flow cytometry analysis (Figure 2B). We found that CoPP treatment significantly
reduced the percentage of GFP-expressing cells at all tested doses and noted that CoPP was able to
inhibit ZIKV replicon replication as efficiently as ribavirin.
CoPP is known to upregulate the expression of genes that are under the control of the Antioxidant
Response Element (ARE-driven gene) including HO-1 and NQO1 [19]. To investigate a direct
involvement of HO-1 in the CoPP-induced inhibition of ZIKV replicon, we quantified the effect
of an overexpression of HO-1 in our system. HEK-293A cells with ZIKV replicon were transfected with
a plasmid pcDNA3.1-HO-1-Flag-Neo and checked for HO-1 overexpression (Figure 2C). As previously
seen with CoPP treatment, the percentage of GFP-positive cells decreased upon HO-1 overexpression
(Figure 2D).
Given that the system used to generate the replicon requires the use of the CMV promoter and
since it cannot be excluded that the initial DNA fragments may provide constitutive expression of the
GFP, we verified that the effect of HO-1 was specific to the replicon and could not be exerted on a CMV
dependent transcription. To support an effect of HO-1 induction or overexpression on the replicon and
not on such a phenomenon, we confirmed that there was no change in the constitutive expression of
GFP under CMV promoter (Supplemental Figure S2A and S2B).
To further characterize the effect of HO-1 on the ZIKV replicon, the transfected cells were
continuously cultured in media containing G418 and puromycin for 7 days to enforce the expression
of HO-1 and ZIKV replicon, respectively. The puromycin N-acetyltransferase (PAC) expression is
directly linked to replication of ZIKV replicon. If HO-1 had a negative effect on the upkeep of the ZIKV
replicon, we expected a progressive reduction of the puromycin resistance, leading to a growth defect
(Figure 2E). Using the crystal violet assay, we observed a massive cell death in the HO-1 overexpressing
cell, which is related to a capacity of the enzyme to downregulate the replication of the ZIKV replicon
(Figure 2F). Notably, co-expression of a plasmid carrying the PAC gene (pSilencer-puro) and the
plasmid pcDNA3.1-HO-1-Flag-Neo does not induce cell death upon selection with puromycin and
G418 (Supplemental Figure S2C).
The results are consistent with available data on the protective effect of HO-1 on ZIKV [9]. In order
to be sure that HO-1 was also able to reduce the ZIKV RNA replication during infection in the same
assay system as the ZIKV-replicon, i.e., the HEK-293A cells. These backbone cells overexpressing HO-1
were infected with the recombinant ZIKV-GFP [11]. We did notice a reduction in the number of infected
cells and a similar reduction was observed in cells treated with CoPP (Supplemental Figure S2D).
Taken together, all of these observations support the inhibition of ZIKV replication by the action
of HO-1.
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Figure 2. ZIKV replicon expression is inhibited by HO-1 induction or overexpression. (A) HO-1 protein
expression was assessed by Western blot in HEK-293A cells expressing ZIKV replicon after treatment
with several doses of CoPP for 20 h. Antibody against α-tubulin served as the protein loading control.
(B) The percentage of GFP-expressing cells was analyzed by flow cytometry assay in ZIKV replicon
cells after treatment with different concentrations of CoPP for 20 h. As positive control, cells were
treated for 24 h with 40 μg·mL−1 (164 μM) of ribavirin. *** p < 0.001. (C) Overexpression of HO-1 in
ZIKV replicon cells transfected with pcDNA3.1-HO-1-FLAG-Neo was assessed by Western blot using
the anti-FLAG M2 and antibody against HO-1. Antibody against β-tubulin served as protein loading
control. (D) The percentage of GFP-expressing cells was analyzed by flow cytometry assay in ZIKV
replicon cells after transfection with pcDNA3.1-HO-1-FLAG encoding the human HO-1 protein or with
pcDNA3.1. ** p < 0.01. In (E) and (F), cell viability was observed by optical microscopy or crystal violet
staining respectively in ZIKV replicon cells transfected with pcDNA3.1 or pcDNA3.1-HO-1-FLAG after
7 days of treatment with G418 and puromycin to respectively allow the expression of HO-1 and the
expression of ZIKV replicon. *** p < 0.001.
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3.3. ZIKV Inhibits HO-1 Expression
HO-1 is known to be rapidly induced for cellular protection under various stresses, including
many types of viral infection. Classical swine fever virus (CSFV) or human cytomegalovirus (HMCV)
induces an increase in HO-1 expression [20,21]. Conversely, HIV, HCV and Bovine viral diarrhea
virus infections are associated with a down-regulation in HO-1 expression [19,22,23]. To determine
whether ZIKV interferes with the expression of HO-1, we analyzed whether the level of HO-1 protein
was modulated in HEK-293A cells expressing the ZIKV replicon. We found that HO-1 was no
longer detectable at the protein level (Figure 3A) and was reduced at the mRNA level (Figure 3B).
qPCR values indicate approximately a halving in the number of transcripts (Figure 3C). This suggests
that the regulation of HO-1 expression may take place at both transcriptional and post-transcriptional
levels upon replication of the ZIKV replicon and/or expression of NS proteins. To confirm that the
observed deregulation of HO-1 was indeed a property of ZIKV, A549 cells that are more susceptible to
ZIKV than HEK 293A were chosen to be infected with a clinical isolate of ZIKV (ZIKV-PF13) [10] and
assessed for HO-1 expression at different times post-infection. HO-1 protein was markedly reduced
24 h post-infection (Figure 3D). It should be noted that molecular clones representing viruses of the
African ancestral strain (MR766) or the Brazilian epidemic strain (BR15) were also able to decrease
HO-1 expression in another cell line model (Supplemental Figure S3). In addition, we could confirm
a slight significant decrease in HO-1 expression at the level of quantified transcripts in ZIKV-infected
A549 cells (Figure 3E,F).
Figure 3. ZIKV replication and ZIKV infection decrease HO-1 protein and mRNA levels. (A) Western
blot analysis of HO-1 protein expression in HEK 293A cells and ZIKV replicon cells using anti-HO-1.
(B) RT-PCR analysis of HO-1, ZIKV NS1 and GAPDH mRNA expression in HEK 293A cells and ZIKV
replicon cells. (C) RT-qPCR analysis of HO-1 expression in HEK 293A cells and ZIKV replicon cells.
A549 cells were infected with ZIKV-PF13 at multiplicity of infection (MOI) of 5. In (D), HO-1 and
ZIKV-E protein expression were analyzed by Western blot using anti-HO-1 and anti-ZIKV-E 4G2
antibody. Antibody against β-tubulin served as protein loading control. In (E), HO-1, ZIKV NS1 and
GAPDH mRNA expression were analyzed by RT-PCR 24-h post infection. In (F) RT-qPCR analysis of
HO-1 expression in A549 cells infected with ZIKV-PF13 24-h post-infection. * p < 0.05.
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3.4. Inhibition of HO-1 Induction During ZIKV Infection
The inhibiting effect of ZIKV on HO-1 expression may be a limitation in the use of an HO-1
inducer for antiviral purposes [9]. We first tested whether HO-1-induction by CoPP was able to inhibit
viral growth of the epidemic ZIKV-PF13 strain. The effect of HO-1 induction by CoPP on viral growth
was followed by adding CoPP 2-h post-infection with ZIKV-PF13 at multiplicity of infection (MOI) of
0.1 or 1 (Supplemental Figure S4). In this experiment, induction of HO-1 with CoPP only decreased the
viral progeny production of ZIKV-PF13 at lower MOI. This observation and the down-regulation of
HO-1 upon ZIKV infection observed above suggest that the inhibition of HO-1-induction depends on
the viral load. To test this hypothesis, we evaluated whether ZIKV was able to counteract the induction
of HO-1 by CoPP. We infected A549 cells for 2 h with ZIKV-PF13 at different MOIs and then induced
HO-1 expression with CoPP for an additional 16 h. We can see that, despite the presence of CoPP,
ZIKV inhibited HO-1 protein level in an MOI-dependent manner (Figure 4A). The ability of ZIKV
to inhibit HO-1 induction in response to CoPP at the protein level was not correlated to a significant
decreased in HO-1 at the mRNA level (Figure 4B,C). Indeed, ZIKV induces a more robust translational
or post-translational downregulation of HO-1 than a transcriptional or post-transcriptional regulation
of HO-1 expression.
Figure 4. ZIKV infection decreases HO-1 induction mediated by CoPP at the protein and the mRNA
levels. A549 cells were infected with ZIKV-PF13 at several multiplicity of infection (MOI) and then
treated 2 h post-infection with CoPP for 16 h. In (A), HO-1 and ZIKV-E protein expression were
analyzed by Western blot using anti-HO-1 and anti-ZIKV-E 4G2 antibody. Antibody against α-tubulin
served as protein loading control. Quantification was done with the ImageJ software. In (B), HO-1,
ZIKV NS1 and GAPDH mRNA expression were analyzed by RT-PCR. In (C) RT-qPCR analysis of HO-1
expression. ns = not significant.
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4. Discussion and Conclusions
In the recent years, HO-1 has gained increasing interest as a potential “super cytoprotective
agent”. Much work has been done to provide a therapeutic value for HO-1 and to find ways to
activate or modulate its expression and activity. Research in this field shows a strong interest in
molecules capable of inducing HO-1, including various natural substances such as curcumin [24,25].
Numerous observations have also supported a major role of HO-1 in the control of viral infections,
notably through the direct inhibition of viral replication. A role of HO-1 has been described in the
case of Dengue after induction by lucidone, a plant extract [26], and the use of HO-1 induction by
Hemin has been proposed as a novel modality for developing new therapeutic strategies against ZIKV
infection [9].
In the present study we provide evidence that HO-1 induction by CoPP or its direct overexpression
is able to inhibit ZIKV replication (Figure 2, Figure S2C and S2D). Our results, therefore, support
a beneficial effect of HO-1 in the context of ZIKA pathology which would justify renewed efforts to
find effective HO-1 inducers for therapeutic purposes. The modulation of ZIKV growth by HO-1 is
related to an effect on replication (Figure 2). It has been previously shown that biliverdin, a product of
heme degradation by HO-1, is able to inhibit DENV replication through an interaction with NS2B/NS3
protease activity [16]. This mechanism can be conserved during ZIKV infection and needs to be
confirmed by an in vitro assay of ZIKV NS2B/NS3 protease activity.
To our knowledge, this is the first report showing that ZIKV infection modulates HO-1 expression
(Figures 3 and 4) in order to limit the antiviral effect of this cytoprotective protein (Figure 5). This result
appears to be inconsistent with the effect recently observed with the FDA-approved formulation of
Hemin which, by inducing HO-1, inhibits viral growth during ZIKV infection [9]. However, in this
report, the formulation of Hemin was added at 100 μM, 24 h before the infection with ZIKV at low
MOI (0.01). We therefore assume that under these drastic conditions the virus is not able to counteract
the effect of HO-1 by blocking its translation or post-translational regulations. These differences would
rather suggest that HO-1 targeting can only work in a preventive but not curative way for the control
of ZIKV infection.
Figure 5. The model of the crosstalk between HO-1 and ZIKV. HO-1 induction inhibits ZIKV at the
replication level. ZIKV growth downregulates HO-1 level through its own replication.
While our study confirms that HO-1 induction could be an effective cell-based strategy to control
ZIKV infection, it highlights the ability of the virus to target and counteract this antiviral response
(Figure 5). Therefore, if HO-1 induction is to be maintained as a promising strategy in the fight
against ZIKV infection, it will be necessary to understand at what level ZIKV interferes with HO-1
expression. Nrf2 (the nuclear factor erythroid-related factor 2) is an important transcription factor
that activates HO-1 expression through ARE elements located in the HO-1 promoter gene [27].
HO-1 down-regulation during ZIKV replication could occur through the modulation of Nrf2
transcription factor activity or expression. To the best of our knowledge, several viruses (HBV, HCV,
DENV, HIV, Respiratory syncytial virus, Marburg virus) induce Nrf2 activation and the subsequent
upregulation of the antioxidant responses genes such as NQO1, GSPT2 and HO-1 [28]. The control of
HO-1 expression by ZIKV seems quite outstanding and therefore necessitates an understanding of
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its mechanism of action for the inhibition of the Nrf2/ARE pathway, which results in decreased host
defenses against viral infection. This may be extremely important in the case of viruses’ co-circulation
(such as DENV during ZIKV outbreak in Brazil in 2015), as ZIKA virus infection may lower cell
antiviral defense resulting in exacerbated viremia of the second infecting virus.
In addition, during the induction of HO-1, the effect of ZIKV on HO-1 expression is more
pronounced on the level of the protein than of mRNA. This last point therefore suggests that the
virus may interfere with the translation of the HO-1 messenger or the degradation of the the HO-1
protein. As it has been previously shown that ZIKV infection can trigger Endoplasmic-Reticulum
stress (ER stress) [29] and that HO-1 can be degraded through the Endoplasmic-Reticulum-Associated
protein Degradation (ERAD), a proteasome pathway induced during ER stress [30,31], it will be of
interest to test if ZIKV downregulation of HO-1 is a combination of the ERAD pathway during ZIKV
infection and an interference of ZIKV with Nrf2 transactivation of ARE elements in the HO-1 promoter.
While many unanswered questions remain, these observations suggest that a better understanding
of ZIKV pathogenicity (such as that associated with the Brazilian epidemic in 2015) may be achieved
through a mechanistic understanding of HO-1 inhibition. Here we have established a cellular system
to conduct such studies and have observed a crosstalk between HO-1 expression and ZIKV replication
(Figure 5), suggesting that HO-1 targeting treatments may be of limited therapeutic efficacy against
ZIKV infection.
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Abstract: Zika virus (ZIKV) is a neuropathic virus that causes serious neurological abnormalities
such as Guillain-Barre syndrome in adults and congenital Zika syndrome (CZS) in fetuses, which
makes it an important concern for global human health. A catalogue of cells that support ZIKV
replication, pathogenesis, and/or the persistence of the virus still remains unknown. Here, we
studied the behavior of the virus in human placenta (JEG-3) and human microglia (HMC3) cell lines
in order to better understand how different host tissues respond during infection. We quantified the
host transcriptional response to ZIKV infection in both types of cells at 24 and 72 h post-infection.
A panel of 84 genes that are involved in the innate or adaptive immune responses was used to
quantify differential expression in both cell lines. HMC3 cells showed a unique set of significant
differentially expressed genes (DEGs) compared with JEG-3 cells at both time points. Subsequent
analysis of these data using modern pathway analysis methods revealed that the TLR7/8 pathway
was strongly inhibited in HMC3 cells, while it was activated in JEG-3 cells during virus infection.
The disruption of these pathways was subsequently confirmed with specific small interfering RNA
(siRNA) experiments that characterize their role in the viral life cycle, and may partially explain why
ZIKV infection in placental tissue contributes to extreme neurological problems in a developing fetus.
Keywords: zika virus; placenta cells; microglia cells; siRNA; TLR7/8
1. Introduction
Zika virus (ZIKV) is an enveloped positive-sense, single-stranded RNA virus that belongs to
the Flavivirus genus of the Flaviviridae family. Viruses belonging to this taxon include several human
pathogens, such as yellow fever (YFV), dengue (DENV), Japanese encephalitis (JEV), tick-borne
encephalitis (TBEV), and West Nile (WNV) viruses. ZIKV is transmitted mainly by Aedes spp.
mosquitoes, and was originally discovered in 1947 in the blood of a febrile Rhesus monkey in Uganda’s
Zika forest [1].
Most ZIKV infections were associated with mild symptoms characterized by fever, rash, joint pain,
and conjunctivitis. However, the recent worldwide epidemic has demonstrated that ZIKV can exhibit
neurotropism that causes serious neurological abnormalities in humans. Specifically, Guillain-Barre
syndrome has been observed in adults after infection, and congenital Zika syndrome (CZS) has been
observed in the fetuses of infected mothers, with microcephaly being one of the most devastating
consequences of this infection [2,3]. After a surge in microcephaly cases was associated with the recent
severe Zika virus outbreak in Brazil [4], the World Health Organization declared ZIKV to be a Public
Health Emergency of International Concern on 1 February 2016.
A marked difference between Zika and other flaviviruses is that ZIKV can be sexually
transmitted [5–8] and is part of the “TORCH” pathogens, which include Toxoplasma gondii, Listeria
monocytogenes, human immunodeficiency virus (HIV), varicella zoster virus, and other infectious
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Viruses 2018, 10, 649
agents that are associated with congenital anomalies [9]. The most recent studies have demonstrated
that ZIKV is highly neurotropic; it infects and crosses the placenta in pregnant women, can be vertically
transmitted from the infected mother to the fetus, and can produce CZS [10].
Despite a large effort by researchers, the molecular mechanism(s) of the vertical transmission
of infection across the placenta barrier is still unknown [10]. Various cell types in the placenta are
susceptible to infection with Zika virus [11]. Specifically, observations of hydropic and hyperplastic
chorionic villi, as well as the proliferation of Hofbauer cells, have been reported during infection with
Zika virus [12]. However, these cellular effects have not been shown to significantly impact placental
function [12,13]. It is difficult to establish accurate laboratory models, since there are substantial
anatomical differences between the placenta in humans versus other animals. Although human cell
lines cannot currently replicate all of the gestational stages or the inherent structure of the human
placenta, they are a useful initial tool to better understand the mechanism of action of teratogenic
pathogens. Recognizing both the practicality and the limitations of these cell lines will help researchers
better interpret experimental results.
Recent studies have described the cellular innate immune response against ZIKV infection,
specifically, the role of Toll-like receptors [14,15], as well as specific molecules involved in this response
such as STAT2 [16,17]. In this work, we better characterize the role of the intracellular immune response
during Zika virus infection. To do so, we infected either human placenta or human microglia cell
lines with ZIKV, and studied their innate immune response against ZIKV infection across multiple
time points. Specifically, we studied the role of TLR7, TLR8, and STAT2 during ZIKV infection, since
they are key molecules in the cellular antiviral and IFN-mediated responses. This work improves
our understanding of how the virus is able to cross the placental barrier and the role of microglia
cells during infection of the fetal brain. We demonstrate that the intracellular response of specific
immunological pathways against ZIKV infection differs depending on the type of cells being infected.
2. Materials and Methods
2.1. Cells and Virus
Microglia HMC3 (CRL-3344), epithelial placenta JEG-3 (HTB-36), and epithelial Vero (CCL-81)
cells were purchased from the American Type Culture Collection (ATCC, Bethesda, MD, USA) and
maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM), containing 10% fetal
bovine serum (FBS; HyClone Laboratories, South Logan, UT, USA) and 1% penicillin/streptomycin at
37 ◦C in a 5% CO2 incubator. ZIKV Puerto Rican strain (PRVABC59) was obtained through Biodefense
and Emerging Infections (BEI) research resources (Zika Virus, PRVABC59, NR-50240).
2.2. Cell Infection
Cells were plated one day prior to infection in complete DMEM at 37 ◦C in a 5% CO2 incubation
chamber. ZIKV stock was diluted in DMEM with 2% FBS to obtain an inoculum with a multiplicity
of infection (MOI) of 0.01, which was then incubated with the cells at 37 ◦C in a 5% CO2 incubation
chamber for one hour and rocked every 15 min. The inoculum was removed after one hour, complete
DMEM was added, and cells were incubated at 37 ◦C in a 5% CO2 incubation chamber until the
collection time point.
2.3. LIVE/DEAD Cellular Assay
The cytopathic effects (CPE) of ZIKV infection on the different cells was measured by using the
LIVE/DEAD Cell Imaging Kit (ThermoFisher, R37601, Waltham, MA, USA), based on a cell-permeable
dye for staining live cells and a cell-impermeable dye for staining dead and dying cells, which are
characterized by compromised cell membranes. For this assay, cells were plated and ZIKV-infected at a
MOI of 0.01 and incubated for five days. Supernatants were collected at each time point and saved for
viral titering. In parallel, cells were exposed to the staining reagent included in the LIVE/DEAD Cell
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Imaging Kit for 15 min. The image data were captured using a Celigo Imaging Cytometer (Nexcelom
Bioscience, Lawrence, MA, USA) at different times of infection, identifying healthy cells in green and
damaged cells in red.
2.4. RNA Extraction, cDNA, RT-qPCR, qPCR Arrays, and Standard Curve
RNA from mock or ZIKV-infected cells was extracted from samples using the RNeasy mini kit
from Qiagen (Hilden, Germany). Subsequent cDNA synthesis was performed with the SuperScript™
III First-Strand Synthesis SuperMix (ThermoFisher 18080400, Waltham, MA, USA). RT-qPCR was
performed using specific primers for gene expression experiments (IDT; Supplementary Table S1)
and PowerUp™ SYBR® Green Master Mix (ThermoFisher A25778, Waltham, MA, USA). The RT2
Profiler PCR Array Human Innate and Adaptive Immune Responses (Qiagen, Hilden, Germany)
was used following the manufacturer’s protocol (Supplementary Table S2) for pathway-focused gene
expression analysis.
The ZIKV standard curve was established using custom TaqMan Primers and Probe (IDT;
Supplementary Table S3). Briefly, 10-fold serial dilutions of ZIKV genetic material from BEI resources
(NR-50244) were used to establish the correlation between the cycle threshold (Ct) value and the
number of molecules/μL of viral RNA. The RNA copy number (number of molecules/μL) was
calculated as: [RNA concentration (g/mL)]/[RNA transcript length (nucleotides) × molecular weight
of a nucleotide (330 g/mol) × Avogadro’s number (6.023 × 1023). In the same way, RNA from ZIKV
stock (BEI, NR-50240) was serially diluted to establish the correlation between Ct and PFU/mL.
Separate primers and probes were designed for the Asian and African lineages, with the African
lineage used as a negative control in these sets of experiments. Specifically, bioinformatics analysis
was performed to identify the best sequences for primers and probes. This workflow consisted of: (1)
collecting available Asian and African ZIKV complete genomes from the Virus Pathogen Resource
(ViPR) database [18], (2) generating a multiple sequence alignment with MAFFT [19], (3) performing
a statistical analysis to identify nucleotide positions that significantly differed between Asian and
African lineages [20], and (4) confirming the specificity of the reagents using BLAST [21].
2.5. Plaque Assays
Viral titers were determined by plaque assay on Vero cells, which were plated one day before the
assay at 90% of confluency in complete DMEM at 37 ◦C in a 5% CO2 incubation chamber. Supernatants
collected at various time points after infection were serially diluted and inoculated on the cells for one
hour, with rocking every 15 min, at 37 ◦C in a 5% CO2 incubation chamber. After that, a 1:1 mixture
of 0.6% agarose and DMEM with 2% FBS was added and incubated at 37 ◦C in a 5% CO2 incubation
chamber. The overlay was removed after three days, cells were washed with phosphate-buffered saline
(PBS), and stained and fixed with a crystal violet solution (2 g crystal violet + 60 mL 100% Ethanol
+ 40 mL 37% Formaldehyde + 100 mL PBS) for 30 min at room temperature in the dark. The excess
crystal violet solution was removed by washing with water. After the plates were dry, plaques were
visualized, and the number of plaque-forming units (PFU)/mL was determined. All of the experiments
were performed in triplicate.
2.6. siRNA Experiments
ON-TARGET plus SMARTpool siRNA for human TLR7, TLR8, and STAT2 together
with positive and negative controls were purchased from Dharmacon (51284, 51311,6773,
D-001830-10-05, D-001810-10-05 respectively) and transfected into the cells with the transfection
reagent Lipofectamine™ RNAiMAX (ThermoFisher 13778030, Waltham, MA, USA) following the
manufacturer’s protocol. Cells were infected with virus eight hours after transfection, once the
effect of the siRNA was corroborated. Efficiency controls for the siRNA experiments were included
(Supplementary Figure S1), and were used as the negative control to normalize the gene expression
data. Supernatants from cell cultures were collected for viral titering at one day or three days
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post-transfection in each cell type, and at one day or three days post-transfection and subsequent
viral infection in each cell type. Cells were washed with PBS and collected at the same time points for
RNA extraction.
2.7. Signaling Pathway Analysis
The R implementation of the signaling pathway impact analysis algorithm (SPIA) was used
to predict activated or inhibited pathways. Specifically, pathway data from five publicly available
databases were used to generate a null distribution of the genes in each signal cascade pathway
(1000 bootstrap replicates) and calculate a Bonferroni-corrected p-value in order to account for multiple
hypothesis testing. The total net accumulated perturbation in each pathway was calculated by using
the differential expression values and pathway topology. Positive perturbation values indicate pathway
activation, while negative values represent pathway inhibition. Pathways that contained a statistically
significant number of detected differentially expressed genes in the different cell types at each time
point were categorized as either “activated” or “inhibited” in the algorithm output and subsequently
ranked by p-value [22].
2.8. Statistical Analysis
Data analysis was performed using Prism (GraphPad Software, La Jolla, CA, USA) for statistical
analysis. All of the experiments were carried out in triplicate, and values were presented as means
± SEM. p-values of these experiments were calculated with a non-paired Student’s t-test. Statistical
significance was accepted at p < 0.05.
3. Results
3.1. ZIKV Production, Titer, Cell Infection, and Cytopathic Effects (CPE)
After infecting different cell lines with ZIKV at 0.01 MOI, we showed that ZIKV was able to
replicate in both cell lines (HMC3, JEG-3) as well as in the control cells (VERO), increasing its replication
along the time of infection (Figure 1A). A standard curve was generated to establish the correlation
between Ct values and the number of molecules/μL of viral RNA (Figure 1A upper panel) using
a ZIKV-specific TaqMan probe. It is of note that the rate of ZIKV replication was at least 10-fold
lower in placenta cells than in microglia or VERO cells when quantified by qPCR (Figure 1A lower
panel) as well as through plaque assays (Figure 1B, lower panel). When we performed a live/dead
assay, we observed CPE in ZIKV-infected placenta and microglia cells starting to appear at four days
post-infection. Compared with the mock-infected cells, the images captured immediately after the
assay showed a steady number of healthy cells (green) over time in mock-infected samples, and a
decrease in the number of cells in ZIKV-infected samples (Figure 1B). This decrease is due to the
increased detachment and loss of dead cells, as well as an increase in damaged cells (red) (Figure 1B,
upper panel). In order to quantify the levels of infection in each time point, we performed plaque
assays to determine the viral particles released to the media along the time (Figure 1B, lower panel).
Based on these initial results, we chose one day post-infection (dpi) and three dpi as the optimal time
points for further experiments, with the aim of studying the kinetics of the intracellular transcriptional
response during viral infection before transcription associated with the cytopathic effects overcomes
the virus-specific transcriptional signal.
190
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Figure 1. Quantification of Zika virus (ZIKV) titer, replication, and cytopathic effects (CPE) over time.
(A) RT-qPCR standard curve to measure the number of virus genomes (upper panels); RT-qPCR to
quantify ZIKV molecules in VERO, HMC3 and JEG-3 cells after one, two, and three days of infection.
(B) CPE induced by ZIKV infection in HMC3 and JEG-3 cells at one, three, four, and five days
post-infection, with the green stain representing healthy cells and the red stain indicating unhealthy
and/or dying cells and the scale bar representing 100 micrometers. The lower panel shows the results
from plaque assays performed in triplicate to quantify the ZIKV particles released to the media at each
time point. Error bars represent standard deviation.
3.2. Host Intracellular Innate Immune Response and Differentially Affected Signaling Pathways
ZIKV is able to cross the placenta in pregnant women and infect the fetal brain; however, the
mechanism by which this occurs has not been fully elucidated. To better understand the intracellular
transcriptional response in placenta and microglia cell lines during ZIKV infection, we used RT-qPCR
to evaluate an unbiased panel of 84 genes involved in the human innate and adaptive immune response
(Supplementary Table S2). The results of this analysis are shown in Figure 2, where each dot or square
represents a single transcript. When we compared the differentially expressed transcripts at one dpi
versus three dpi (Figure 2A), there was a significant difference in the transcriptional regulation in
infected cells compared with uninfected cells in microglia cells, but there was not a difference in
placenta cells. Also, when we checked infected (I) cells versus uninfected (UI), a significant difference
in differentially expressed genes from microglia cells compared with placenta cells at both time points
one dpi and three dpi was observed (Figure 2B).
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Figure 2. Results from an intracellular innate immune response RT-qPCR array. Each circle or
square represents an individual gene that was either upregulated (black) or downregulated (blue).
(A) Differentially expressed genes at one dpi versus three dpi in human microglia and placenta cells.
(B) Differentially expressed genes of ZIKV-infected (I) samples versus time-matched mock-infected (UI)
samples at 24 h and three days post infection with ZIKV. The numerical values on the Y-axis have been
collapsed in regions that had no differentially expressed genes in order to improve visibility.
The significant differences observed in the RT-qPCR data led us to hypothesize that genes
in specific signaling pathways were differently affected in each cell type within three days after
ZIKV infection. Therefore, we analyzed these data using the signaling pathway impact analysis
algorithm (SPIA) to identify the signaling pathways (i.e., networks of genes flowing from receptors
to transcription factors) that were either significantly activated or inhibited in the different cells and
at the different time points (Table 1). The summarized results from this analysis displayed several
pathways that consistently differed between both cells lines. The predicted results for the TLR7/8
cascade appeared interesting, since they showed opposite phenotypes (e.g., activation or inhibition) in
each cell line. Specifically, these pathways were predicted to be inhibited in infected microglia cells
(blue), but activated in infected placenta cells (orange) when comparing the three dpi and one dpi time
points in ZIKV-infected cells. This pattern was repeated in all of the pathways involving TLR7/8.
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3.3. Effect of siRNA against TLR7, TLR8, or Both
We then tested the role of TLR7 and TLR8 in the host–pathogen interaction network. To do
so, we used pools of siRNAs that specifically target these receptors, and measured the impact on
viral replication (Figure 3) and the level of expression of a group of well-known genes involved in
intracellular antiviral and innate immune responses (toll-like receptors, transcription factors, and
interferon-stimulated genes) (Figures 4 and 5).
3.3.1. Viral Replication
We quantified viral replication by measuring the number of whole infectious viral particles
released to the media through plaque assays after knocking down TLR7 and/or TLR8 (Figure 3A).
We compared these numbers to the Ct values that were obtained from ZIKV RT-qPCR, and saw that
they corresponded with each other (Figure 3B). We observed that siRNA against TLR7 and/or TLR8
had no effect on viral replication three dpi when compared with the siRNA control in microglia cells
(HMC3). However, when the same transcripts were knocked down in placenta cells (JEG-3), ZIKV
replication was significantly increased three dpi compared with the control. These assays confirmed
the previous results in each of our selected cell lines.





































































Figure 3. Viral and transcriptional effects of siRNAs targeting TLR7, TLR8, or TLR7 + TLR8 on
ZIKV virus replication in different cell types over time. (A) Plaque-forming units (PFU) per mL of
supernatant were measured to quantify infectious virus production at each time point in each cell
type. (B) The number of ZIKV RNA molecules from the same samples was measured with RT-qPCR to
quantify viral genome replication at both time points in each cell type (* p < 0.05). Error bars represent
standard deviation.
3.3.2. Innate Immune Response in Microglia and Placenta Cells
In order to determine whether other intracellular factors contributed to ZIKV replication, we
quantified the level of expression of other components in the innate immune system. Specifically,
we evaluated: transcription factors STAT1, STAT2, IRF3, IRF7, and IRF9; as well as the
interferon-stimulated genes (ISGs) CXCL10, IFIT1, and MX1 in mock-infected (UI) and ZIKV-infected
(I) placenta cells (Figure 4, left panel) and microglia cells (Figure 4, right panel). Placenta cells showed
a strong induction of the ISGs at two and three days after Zika infection, but no noticeable induction
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of the remaining studied genes. Conversely, the microglial cells showed induction of almost the entire
panel of transcripts three days after infection.
Figure 4. Fold induction values for genes involved in the innate immune response of time-matched
mock-infected (UI) versus ZIKV-infected (I) HMC3 and JEG-3 cells at 24 h post infection (hpi), 48 hpi,
and three dpi. Values were determined by calculating the fold induction (FI) using the delta-delta cycle
threshold (ΔΔCt) method for each gene, normalizing the values for each gene to the UI results.
We next wanted to understand how the differential expression of these transcripts was affected
after blocking TLR7, TLR8, or both (Figure 5, Supplementary Figure S2). In microglia cells (Figure 5A),
after siRNA transfections, there was an initial response from some of the transcription factors at day
one and three. However, that induction returned to normal when the transfection was followed by
ZIKV infection. At three dpi, the ZIKV-infected microglia cells showed sporadic induction compared
with uninfected cells (Figure 4), but not with cells that were ZIKV-infected and previously transfected
with the specific siRNAs (Figure 5A, right lower plot). Similar results were observed in placenta
cells (Figure 5B), where cells transfected with siRNAs against TLR7 and/or TLR8 showed a strong
upregulation of a subset of genes (Figure 5B, left plots) that mostly disappeared when these cells were
transfected and infected with ZIKV (Figure 5B, right plots). In addition, the observed upregulation
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of cytokines in infected placenta and microglia cells (Figure 4) was not as strong when the cells were
transfected with siRNAs, or transfected and infected.
Figure 5. A comparison of the effects of a panel of siRNAs including TLR7, TLR8, TLR7 + TLR8, or
scramble (control) on the expression of selected innate immune response factors. (A) HMC3 cells
transfected with siRNA and either time-matched mock-infected (UI) or infected with ZIKV (I) at one
dpi and three dpi. (B) JEG3 cells transfected with siRNA and either time-matched mock-infected (UI) or
infected with ZIKV (I) at one dpi and three dpi. The horizontal black line marks the two-fold induction
(FI) threshold in each plot.
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3.4. Role of STAT2 in Host Intracellular Response after ZIKV Infection
We next decided to study the role of STAT2 in the intracellular transcriptional response after
ZIKV infection. This decision was partially dependent on the results from the previous experiments
performed in this study, and also based on previous reports that showed that ZIKV can degrade STAT2
in specific cells [16]. We first observed a significant upregulation of STAT2 after three days of infection
in microglia cells; however, this upregulation was absent in placenta cells (Figure 6A). Transfecting
cells with pools of STAT2-specific siRNAs to knockdown STAT2 transcript levels resulted in a dramatic
reduction in the expression levels for genes involved in the intracellular innate immune response
in both cell lines at both time points. The only exception to this trend was found for CXCL10 in
placenta cells, which was upregulated after STAT2 knockdown; however, this upregulation decreased
somewhat after ZIKV infection (Figure 6B). We then quantified the number of ZIKV RNA molecules in
each cell type as a measure of viral replication after STAT2 knockdown. This experiment showed an
increase in the ZIKV RNA molecules in microglia cells compared to the siRNA control, but no changes
were observed in placenta cells (Figure 6C).
Figure 6. Role of STAT2 in ZIKV replication and in the intracellular response to infection. (A) STAT2
expression in time-matched mock-infected (UI) and ZIKV-infected (I) HMC3 and JEG-3 cells at one
dpi and three dpi. (B) Effect of STAT2 knockdown on selected innate immune genes in time-matched
mock-infected (UI) and infected (I) HMC3 and JEG-3 cells at one dpi and three dpi. The horizontal black
line represents the two-fold induction (FI) threshold in each plot. (C) Number of ZIKV RNA molecules
detected from the total RNA collected from cells treated with siRNAs against STAT2. (* p < 0.05).
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3.5. Role of Viral Receptor AXL in Microglia and Placenta Cells
The AXL gene encodes a tyrosine protein kinase receptor that has been shown to be a cellular
receptor used by the Zika virus to gain entry into host cells [23]. When we studied this receptor, AXL
showed a significantly higher expression one day after infection in placenta cells when compared to
uninfected cells; however, those expression levels returned to normal within three days after infection.
In contrast, there was no differential-expression of AXL in infected microglia cells when compared
to the uninfected cells (Figure 7A). Therefore, we wanted to test the effect of siRNAs against STAT2,
TLR7, and/or TLR8 on AXL expression in these two cell lines. We observed that AXL maintained
relatively normal levels of expression in microglia cells after blocking TLR7, TLR8, TLR7/8, and STAT2.
However, in placenta cells, we saw that siRNA against TLR8 significantly decreased AXL expression
after three days, with a similar downregulation also observed after TLR7 knockdown three days
after infection. In contrast, siRNA against STAT2 in infected placenta cells significantly induced AXL
expression after three days of infection when compared to control cells (Figure 7B).



































































































































































Figure 7. Role of AXL in ZIKV infection. (A) AXL fold induction ZIKV-infected (I) relative to
time-matched mock-infected (UI) HMC3 and JEG-3 cells at one dpi and three dpi. (B) Effect of siRNAs
targeting TLR7, TLR8, TLR7 + TLR8, or STAT2 on AXL expression in time-matched mock-infected (UI)
and ZIKV-infected (I) HMC3 and JEG-3 cells at one dpi and three dpi. (* p < 0.05). Error bars represent
standard deviation.
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4. Discussion
Defining the mechanisms by which ZIKV causes neuropathic effects is critical to predict future
risks as well as establish control measures against the disease. In this study, we evaluated the behavior
of ZIKV in two target cell lines, placenta and microglia, with the aim of understanding how the virus
counteracts the intracellular antiviral response in these two cell lines during infection. Several studies
have demonstrated that ZIKV infection can result in different interferon (IFN) responses depending
on the cell type [24–27]. In concordance with these studies, we first demonstrated that Zika is able to
replicate in both cell lines, placenta (JEG-3) and microglia (HMC3), causing cytopathic effects after
four days of infection. Interestingly, the host intracellular response to ZIKV infection was different in
each of the cell lines that we tested. Not only did we identify sets of significant differentially expressed
genes that are involved in the intracellular innate immune response when we compared the two cell
types, but we also observed differences in the activation and/or inhibition of immunological signaling
pathways. Due to the different function of each cell type, we expected to observe a higher immune
activation in microglia cells, which are known as the “macrophages of the brain”, to fight against any
pathogen that could compromise this tissue. In contrast, the placenta cells function as a barrier to
protect the fetus from any disturbance such as inflammation or immune activation that could affect its
stability and development, which led us to expect an active but more subdued antiviral response.
Assuming these functional differences and based on immunological pathways analysis results, we
demonstrated that knocking down the expression of TLR7 and/or TLR8 had different consequences
for viral replication in each cell line. We demonstrated that TLR7/8 inhibits viral replication in placenta
cells but not in microglia, as this pathway is already inhibited by the virus. Prior studies carried out
with the TLR7/8 agonist R848 demonstrated that this molecule blocks ZIKV replication in monocytes
and macrophages by inducing the antiviral protein Viperin [15]. Follow-up experiments will be
needed to test whether Viperin is also involved in the inhibition of virus replication in placenta cells.
The stronger inhibitory response after ZIKV infection on a selected group of genes when the TLR7/8
signaling pathway was blocked in both cell lines demonstrates its role in the intracellular innate
immune response. It has been recently shown that the inhibition of TLR8 in ZIKV-infected trophoblasts
abrogated the inflammatory cytokine responses, which is in accordance with our findings [14].
Previous investigations to determine the mechanism causing a reduction in the intracellular IFN
response showed that the ZIKV NS5 protein is able to degrade STAT2, which is an IFN pathway
precursor molecule [16]. However, this mechanism is not expanded to other cell types such as
dendritic cells, where ZIKV is able to antagonize IFN type I response by impeding STAT1 and STAT2
phosphorylation [28]. In this study, we demonstrate that STAT2 is significantly upregulated in infected
microglia cells when compared with uninfected cells, but its levels do not change during the infection
of placenta cells. We validated that the virus behaves differently in each cell line to counteract the
unique intracellular antiviral response, which likely reflects the functions of their respective tissues.
In addition, ZIKV showed a significantly higher replication rate when STAT2 was knocked down
in microglia cells compared with the control; however, no significant differences were observed in
placenta cells under similar conditions. As observed when we knocked down TLR7/8, after reducing
STAT2 transcript abundance, we observed a stronger inhibition of the set of genes involved in the
intracellular innate immune response. These data justify performing more in-depth studies into the
pathogenic mechanism(s) of Zika virus in these and other cell types that are susceptible to ZIKV
infection. We expect that such experiments would greatly contribute to the discovery of specific targets
for antiviral drug development.
Another controversial molecule in ZIKV infection is the cellular receptor AXL. While in some
cell types it acts as a ZIKV viral entry receptor [24,29], it has been demonstrated that AXL does not
always perform this role during ZIKV infection [30,31]. In accordance with these publications, our
study demonstrates that AXL gene expression is different in these two cell lines. Interestingly, AXL
is associated with viral infection, TLR7/8 transcript abundance, and STAT2 transcript abundance
in placenta cells, since their levels vary both when these cells are infected as well as when TLR7/8
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or STAT2 are knocked down. Global transcriptomic methods, such as RNAseq could be used in
future experiments in order to decipher this relationship during ZIKV infection and its implications in
viral pathogenesis. Such an approach would give us much more information about host–pathogen
interactions and the relevant molecules and pathways involved in ZIKV pathogenesis in placenta,
microglia, and/or other cells. Confirmation of these findings at the protein level will also be important
to better define the mechanism of action of Zika pathogenesis and neurotropism in different cell types.
In this manuscript, we have demonstrated that the antiviral response during ZIKV infection is
highly dependent on the type of host cell being infected. Based on the results presented here, we
propose a Zika virus–host cell interaction molecular model for placenta and microglia cells involving
TLR7/8, STAT2, and AXL (Figure 8). This model will enable better understanding of the mechanism of
action of the virus and as well as the design and development of specific antiviral drugs.
Figure 8. A potential schematic molecular model depicting the differing relationships between the
expression of STAT2, TLR7, TLR8, and AXL during ZIKV infection in human placenta (JEG-3) and
microglia (HMC3) cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/11/649/
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Abstract: Aedes aegypti (L.) is the primary vector of many emerging arboviruses. Insecticide resistance
among mosquito populations is a consequence of the application of insecticides for mosquito control.
We used RNA-sequencing to compare transcriptomes between permethrin resistant and susceptible
strains of Florida Ae. aegypti in response to Zika virus infection. A total of 2459 transcripts were
expressed at significantly different levels between resistant and susceptible Ae. aegypti. Gene ontology
analysis placed these genes into seven categories of biological processes. The 863 transcripts were
expressed at significantly different levels between the two mosquito strains (up/down regulated)
more than 2-fold. Quantitative real-time PCR analysis was used to validate the Zika-infection
response. Our results suggested a highly overexpressed P450, with AAEL014617 and AAEL006798
as potential candidates for the molecular mechanism of permethrin resistance in Ae. aegypti. Our
findings indicated that most detoxification enzymes and immune system enzymes altered their gene
expression between the two strains of Ae. aegypti in response to Zika virus infection. Understanding
the interactions of arboviruses with resistant mosquito vectors at the molecular level allows for the
possible development of new approaches in mitigating arbovirus transmission. This information
sheds light on Zika-induced changes in insecticide resistant Ae. aegypti with implications for mosquito
control strategies.
Keywords: Aedes aegypti; RNA-seq; insecticide resistance; Zika virus; detoxification and immune
system responses
1. Introduction
Aedes aegypti (L.) is the primary vector of emergent mosquito-borne viruses, including yellow
fever, dengue, chikungunya, and Zika [1,2]. Zika fever is an emerging viral disease (family Flaviviridae,
genus Flavivirus) that is transmitted to humans by infected female mosquitoes, primarily Ae. aegypti
and Ae. albopictus. Zika virus (ZIKV) consists of three lineages, one from Asia and two from Africa [3].
Molecular analyses indicate that ZIKV originated in Uganda and spread to Central and West Africa
through two introductions occurring in 1935 and 1940 [3]. Zika spread eastward to Asia around
1945 [3]. The Asian lineage of ZIKV was responsible for the first epidemic on Yap Island, Micronesia
in 2007 followed by another outbreak in French Polynesia during 2013 [4]. Zika was detected in
northeastern Brazil in early 2015 resulting in 1.5 million human cases [5,6]. Since the arrival of Zika
in Brazil, the mosquito-borne pathogen has spread throughout the Americas and local transmission
in the U.S. is a major public health risk among parts of the Gulf Coast. Symptoms associated with
Zika infection are only observed in 20% of cases, and symptoms are often mild including fever, rash,
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joint pain, conjunctivitis, headache, and muscle pain. However, ZIKV is strongly associated with more
severe outcomes including birth defects, such as microcephaly [7], and neurological complications,
such as Guillain–Barré syndrome [8].
Recurrent use of insecticides in mosquito control and agricultural pest control has selected for
insecticide resistance in mosquito populations [9–15]. Permethrin resistance is widespread in Ae. aegypti
which compromises mosquito control and disease prevention efforts [11,13]. There are several modes
that mosquito populations have become resistant to insecticides in nature. Insecticide resistance
mechanisms can be divided into penetration resistance, behavioral resistance, target-site insensitivity,
and metabolic detoxification of insecticides [16,17]. Penetration resistance occurs when insects absorb
an insecticide more slowly than susceptible insects attributable to cuticle barriers. Behavioral resistance
occurs when insects recognize and alter their behavior (feeding and movement) in the presence of an
insecticide. Target-site insensitivity results from modifications (e.g., point mutations in genes encoding
target proteins) to sites where the insecticide binds to reduce the detrimental effects of an insecticide.
Metabolic detoxification of insecticides results when resistant insects detoxify or destroy insecticides
more effectively than susceptible insects. Metabolic detoxification of insecticides is one of the most
common mechanisms of resistance. Detoxification of insecticides in mosquitoes include three major
gene families: Cytochrome P450s, esterases, and glutathion S-transferases (GSTs) [18,19].
Pyrethroid/permethrin resistant mosquitoes exhibit insecticide resistance through elevated
levels of multiple detoxification enzymes, including GSTs [14,20–22], ATP-binding cassette (ABC)
transporters [21,23], carboxylesterase [14,24,25], and cytochrome P450 [14,26–33]. Penetration
resistance occurs through modifications in cuticular proteins [14,34]; metabolic resistance occurs
by detoxification enzymes and G-protein-coupled receptor [26], UDP glucuronosyltransferase, and
glucosyl/glucuronosyl transferase [32,35]; and target site insensitivity is mediated by changes in the
voltage-gated sodium channel gene [11,15,36,37], and transcription factor Maf-S [38].
Multigene expression in response to arbovirus infection has been reported in Ae. aegypti and
other species of mosquitoes [39–43]. Many genes are involved in the mosquito’s antiviral immunity,
such as antimicrobial peptide (AMP)-coding genes [44]. Immune responses and several arthropod
immunity pathways such as Toll, Imd, JAK/STAT, and RNAi also play important roles during mosquito
arboviral infection [39,41,42,45]. In addition to antiviral responses, several studies have reported
changes in expression levels of multiple categories of biological processes in response to ingestion of
arbovirus infected blood. An infection study showed that trypsins, metalloproteinases, and serine-type
endopeptidases were significantly upregulated in mosquitoes following ingestion of chikungunya virus
infected blood [39]. Along the same lines, another study reported that dengue virus infection induced
upregulation of gene expression associated with lipogenesis, lipolysis and fatty acid β-oxidation, and
lipid metabolism [46].
The unprecedented global spread of ZIKV has created a need to improve our understanding
of host–microbe interactions in this mosquito–arbovirus system [43,45,47,48]. Understanding the
mechanism(s) of insecticide resistance may provide insight into novel molecular strategies that may be
used to improve control of Zika vector. To understand mechanisms by which pyrethroid/permethrin
resistant Ae. aegypti populations alter their gene expression in response to ZIKV infection, we used
RNA-sequencing (RNA-seq) and functional analysis to explore the difference between a permethrin
resistant Ae. aegypti population (Key West, FL, USA) and a permethrin susceptible population
(Orlando, FL, USA). Zika infection activated metabolic pathways (e.g., drug metabolism) in which
some transcripts were putatively linked to insecticide resistance. Our observations provide a global
picture of gene expression associated with metabolic detoxification among permethrin resistant and
susceptible populations of Ae. aegypti, including antiviral responses following ingestion of ZIKV. This
study aims to improve our understanding of the entomological components of ZIKV epidemiology
in context of insecticide-based control through a combination of traditional genetic and biochemical
approaches to address issues related to mosquito vector control.
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2. Materials and Methods
2.1. Mosquito Strains
Ae. aegypti larvae were collected from Key West (24.55◦ N, 81.78◦ W), Florida, USA and maintained
at the Florida Medical Entomological Laboratory (FMEL) in Vero Beach, FL since 2011. The parental
collection of Ae. aegypti from the field was initially tested for permethrin resistance, then subjected
to permethrin selection for 15 generations (see below) and again assayed for resistance (referred to
as the resistant strain). Assays for resistance followed WHO protocols for mortality thresholds using
the permethrin CDC bottle bioassay with a diagnostic dose and mortality rate (>90%) in laboratory
bioassays using modified WHO bottle bioassay (WHO 2016). Bottles used in the assays were coated
with a known amount of permethrin (diagnostic dose, 47 μg/bottle), after which adult Ae. aegypti
mosquitoes were placed in the bottle and observed for 2 h and mortality was recorded.
The Orlando strain of Ae. aegypti was collected from Orlando (28.53◦ N, 81.37◦ W), Florida, USA
and reared in the Mosquito and Fly Research Unit, Center for Medical, Agricultural and Veterinary
Entomology, ARS-USDA in Gainesville, FL since 1952. The Orlando strain is recognized as a permethrin
susceptible strain of Ae. aegypti [9].
2.2. Zika Virus Infection
Four-day-old female adults were fed defibrinated bovine blood containing either ZIKV (treatment)
or blood lacking virus (control). The method utilized in this study was as previously described by
Zhao et al. [48]. Mosquitoes were deprived of sucrose, but not water, 24 h before blood feeding
trials performed in a biosafety level-3 laboratory at the FMEL. Isolates of the Asian lineage of ZIKV
(strain PRVABC59, GenBank accession # KU501215.1) from Puerto Rico were prepared in African
green monkey (Vero) cells and used in the mosquito infection study. Monolayers of Vero cells were
inoculated with 500 μL of diluted stock virus (multiplicity of infection, 0.1) and incubated for 1 h at
37 ◦C and 5% CO2 atmosphere, after which 24 mL media (M199 medium supplemented with 10% fetal
bovine serum, penicillin/streptomycin, and mycostatin) were added to each tissue culture flask and
incubated for six days for propagation of ZIKV. Freshly harvested media from infected cell cultures
were combined with defibrinated bovine blood and ATP (0.005 M) and presented to mosquitoes using
a membrane feeding system (Hemotek, Lancashire, UK) for one hour feeding trials. Control blood
meals were prepared similarly except that monolayers of Vero cells were inoculated with media only.
Samples of infected blood were collected at the time of the feedings and stored at −80 ◦C for later
determination of virus titer. Mosquitoes were fed 6.4 log10 plaque forming units (pfu)/mL of ZIKV
(Table 1). The experiments were replicated three times. The ZIKV infected and control mosquitoes from
two Ae. aegypti strains were harvested for a time course study. Individual mosquitoes were dissected
into body and legs and tested to confirm susceptibility to infection and disseminated infection rates,
respectively. Ten mosquitoes (12 h and 7 days post ZIKV infection) were pooled for each sample for
RNA sequencing.
Table 1. Transcription profiles of detoxification enzymes associated with permethrin resistance. (A)
Genes related to detoxification significant upregulated in the Zika infection in the permethrin resistant
(KW) strain compared with susceptible (OR) strain Aedes aegypti 7-days post infection. (B) Detoxification
related gene significant upregulated/downregulated in the Control in the permethrin resistant (KW)
strain compared with the susceptible (OR) strain Aedes aegypti 7-days post injection.
Gene ID logFC p-adj Gene Description Gene Name Publications
A
AAEL012457 2.2934 3.09 × 10−10 alcohol dehydrogenase Faucon et al., 2015 [32]
AAEL009044 2.5174 4.04 × 10−11 amine oxidase Faucon et al., 2015 [32]
AAEL002385 2.0902 2.33 × 10−3 Carboxy/choline esterase CCEAE3B Dusfour, 2015 [49]
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Table 1. Cont.
Gene ID logFC p-adj Gene Description Gene Name Publications
A
AAEL001960 2.1283 7.7 × 10−7 cytochrome P450 CYP6M9 Faucon et al., 2015 [32]
AAEL002031 1.837 1.37 × 10−19 cytochrome P450 CYP12F7 Faucon et al., 2015 [32]
AAEL006798 2.8656 8.05 × 10−3 cytochrome P450 CYPJ10 Faucon et al., 2017 [31]
AAEL006805 2.6907 6.0 × 10−18 cytochrome P450 CYP9J2 Faucon et al., 2015 [32]
AAEL006815 2.4201 6.0 × 10−17 cytochrome P450 CYP9J16 Faucon et al., [31,32]
AAEL007473 2.1909 5.5 × 10−15 cytochrome P450 CYP6AH1 Faucon et al., 2015 [32]
AAEL009018 2.5349 4.5 × 10−8 cytochrome P450 CYP6CB1 Faucon et al., 2015 [32]
AAEL009123 2.4747 7.8 × 10−9 cytochrome P450 CYP6Z6 Faucon et al., 2017 [31]
AAEL009125 2.6551 7.0 × 10−13 cytochrome P450 CYP6M10 Faucon et al., 2017 [31]
AAEL009129 2.4377 2.6 × 10−34 cytochrome P450 CYP6Z9 Faucon et al., 2017 [31]
AAEL014603 2.4789 2.24 × 10−3 cytochrome P450 CYP9J30 Faucon et al., [31,32]
AAEL014607 2.1961 4.6 × 10−4 cytochrome P450 CYP9J? Faucon et al., 2015 [32]
AAEL014608 1.9517 8.2 × 10−3 cytochrome P450 CYP9J? Faucon et al., 2017 [31]
AAEL014609 2.4159 1.1 × 10−12 cytochrome P450 CYP9J26 Faucon et al., [31,32]
AAEL014614 3.9363 4.1 × 10−8 cytochrome P450 CYP9J? Faucon et al., 2015 [32]
AAEL014617 2.3975 5.7 × 10−4 cytochrome P450 CYP9J28 Faucon et al., 2015 [32]
AAEL014893 2.2053 2.1 × 10−8 cytochrome P450 CYP6BB2 Faucon et al., 2015 [32]
AAEL015663 4.0198 9.0 × 10−6 cytochrome P450 CYP25? Faucon et al., 2015 [32]
AAEL017297 3.2113 1.7 × 10−6 cytochrome P450 CYP6M9 Faucon et al., [31,32]
AAEL003099 3.0651 1.4 × 10−4 glucosyl/glucuronosyl transferases Faucon et al., 2015 [32]
B
AAEL001312 2.0651 2.5 × 10−4 cytochrome P450 CYP9M6 Faucon et al., 2017 [31]
AAEL006798 3.6029 5.1 × 10−4 cytochrome P450 CYP9J10 Faucon et al., 2015 [32]
AAEL006811 2.5971 2.37 × 10−3 cytochrome P450 CYP9J8 Faucon et al., [31,32]
AAEL014606 1.9372 1.49 × 10−6 cytochrome P450 CYPJ7 Faucon et al., 2015 [32]
AAEL014617 2.2615 3.35 × 10−3 cytochrome P450 CYPJ28 Faucon et al., 2015 [32]
AAEL014891 −2.8122 3.8 × 10−4 cytochrome P450 CYP6P12 Faucon et al., 2017 [31]
AAEL007947 2.5390 8.31 × 10−32 glutathione transferase GSTE Faucon et al., 2017 [31]
2.3. RNA Extraction
All samples (10 mosquitoes per pool) were homogenized with a plastic pestle in the 1 mL TRIzol
reagent (Ambion, Life Technologies, Carlsbad, CA, USA). Total RNAs were isolated using TRIzol
reagent according to the manufacturer’s instruction and followed a standard protocol (Ambion, Life
Technologies). To avoid genomic DNA contamination, the RNA samples were processed by DNase
I (RNase-free) following the manufacturer’s instructions (Thermo Scientific, Wilmington, DE, USA).
The RNA samples were quantitated by NANODROP 2000 Spectrophotometer (Thermo Scientific,
Wilmington, DE, USA).
2.4. RNA-Seq Library Preparation and Sequencing
Preparation and sequencing libraries were carried out in the Interdisciplinary Center for
Biotechnology Research (ICBR), at the University of Florida following the manufacturer’s protocol
(Illumina, Inc., San Diego, CA, USA). The TruSeq DNA Library Preparation Kit (Illumina, Inc.,
San Diego, CA, USA) was used to prepare DNA libraries with insert sizes from 300–500 bp for
high-throughput sequencing. For the Illumina NextSeq 500 run, the NCS v1.2 control software was
used. The libraries were pooled at equimolar concentrations to yield a 4 nM stock solution, containing
0.33 nM of each library. The library pool was prepared for sequencing following the manufacturer
protocol. The Illumina® NextSeq® 500 sequencing platform was used to create paired-end reads using
Illumina’s sequencing-by-synthesis approach (Illumina®, San Diego, CA, USA) using 2 × 150 cycles.
2.5. Data Mining and RNA-Seq Analysis
Reads acquired from the sequencing platform were cleaned up with the Cutadapt program
(Martin 2011) to trim off sequencing adaptors, low quality bases, and potential errors introduced during
sequencing or library preparation. Reads with a quality phred-like score <20 and read length <40 bases
were excluded from RNA-seq analysis.
The transcripts of Ae. aegypti (18,840 sequences) were retrieved from the VectorBase (https:
//www.vectorbase.org/organisms/aedes-aegypti/liverpool) and used as reference sequences for
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RNA-seq analysis. The cleaned reads of each sample were mapped independently to the reference
sequences using the bowtie2 mapper (version. 2.2.3) with a “3 mismatches a read” allowance [50]. The
mapping results were processed with the samtools and scripts developed in house at ICBR to remove
potential PCR duplicates and to choose uniquely mapped reads for gene expression analysis. Gene
expression was assessed by counting the number of mapped reads for each transcript [51]. Significant
up- and downregulated genes were selected using the adjusted p-value (p-adj), log2 fold-change
(log2FC), or both for the analysis. The RNA-seq data have been deposited to NCBI (Accession number:
GSE118858, https://www.ncbi.nlm.nih.gov/gds/?term=GSE118858).
2.6. Assignments of Gene Ontology (GO) Terms and Pathway Analyses
All genes with p-adj ≤ 0.01 were selected for the GO enrichment analysis (http://amigo.
geneontology.org/amigo). The GO terms of Ae. aegypti genes were retrieved from the VectorBase and
assigned to GO hierarchies and functional groups. The genes matched to the functional categories of
immune system process (GO:0002376), response to stimulus (GO:0050896), developmental process
(GO:0032502), cellular process (GO:0009987), signal transducer activity (GO:0004871), biological
regulation (GO:0065007), electron carrier activity (GO:0009055), transporter activity (GO:0005215),
catalytic activity (GO:0003824), and metabolic process (GO:0008152) were divided into two pools:
the downregulated and upregulated gene pools based on the log2 transformed-fold-change of the
RNA-seq results. The selected genes that were not assigned GO terms or categorized to other functional
groups were treated as the unknown group.
2.7. C-DNA Synthesized and qPCR Amplification
C-DNA synthesis was performed using methods described by Zhao 2017 et al. [48]. The qPCR
assay for confirming genes in Ae. aegypti was performed using Platinum® SYBR® Green qPCR
SuperMix-UDG with ROX (Invitrogen, Carlsbad, CA, USA) in a volume of 15 μL on a BIO-RAD C1000
Touch Thermal Cycler, CFX 96™ Real-Time System (“Bio-Rad”). The primers were designed using
Primer3 program https://sourceforge.net/projects/primer3 (Table S1).
3. Results
3.1. Global Changes in Transcriptome of the Aedes Aegypti Female Adult in Response to ZIKV Infection
To understand the molecular interactions of the arbovirus with permethrin resistant Ae. aegypti
from Florida, RNA-seq was conducted to explore the global changes in the Ae. aegypti (Key West
and Orlando strains) transcriptome in response to oral ingestion of ZIKV infected blood and ZIKV
infection. In this study, four-day-old female Ae. aegypti adults were fed a blood meal containing
6.4 log10 pfu/mL of ZIKV (Figure 1). Fresh fed mosquitoes ingested 4.2 to 4.3 log10 pfu/mL of
ZIKV. By 7 days post infection (dpi), ZIKV titer in mosquito bodies were 4.1 ± 1.7 log10 pfu/mL and
3.6 ± 1.2 log10 pfu/mL for the permethrin resistant and susceptible strains of Ae. aegypti, respectively.
A two-tailed t-test showed no significant differences in ZIKV titer in the bodies of the two strains
of Ae. aegypti (t17 = 0.77, p = 0.44). By 10 dpi, ZIKV titer in permethrin resistant strain mosquito
bodies were 6.5 ± 0.05 log10 pfu/mL, which was 100-fold higher (t4 = 8.12, p = 0.001) than the titer of
the susceptible strain (4.5 ± 0.34 log10 pfu/mL). This result demonstrated that the ZIKV replication
rates were higher at this point in the infection process for the permethrin resistant strain than the
susceptible strain.
Twelve hours post infection and 7 dpi, RNAs from female Ae. aegypti were extracted. A total of 24
RNA-seq libraries were created from Ae. aegypti infected by ZIKV (12 h and 7 dpi) and control (fed
uninfected blood, 12 h and 7 dpi). Three replicates of each group were prepared and sequenced. A total
of 706,051,842 raw reads were generated from the permethrin resistant and susceptible strains. The
cleanup resulted in 705,983,440 cleaned reads, which mapped to 18,840 transcripts of Ae. aegypti (Table
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S2). The qPCR of the selected 13 genes showed significantly different expression levels between the
two Ae. aegypti strains in response to ZIKV at 7 dpi, supporting the RNA seq data analysis (Figure 2).
Figure 1. Zika virus titers in infectious blood meals and blood fed mosquitoes for permethrin resistant
(KW) and susceptible (OR) strains of Aedes aegypti, including initial dose in bloodmeal, freshly fed,
7 days post infection (7 dpi), and 10 days post infection (10 dpi). Zika virus (strain PRVABC59, GenBank
accession # KU501215.1) isolated from a human infected in Puerto Rico in 2015.
Figure 2. Validation of the expression of transcripts between the permethrin resistant (KW) and
susceptible (OR) strains of Aedes aegypti by qRT-PCR. * p < 0.05. ** p < 0.01.
3.1.1. Expression Profiles of Differentially Expressed (DE) Transcripts in Response to Blood Feeding
(Control) between Two Aedes aegypti Strains, Resistant Versus Susceptible Strains
Functional analysis based on Gene Ontology were conducted on the significant differentially
expressed (DE) transcripts between the permethrin resistant and susceptible strains of Ae. aegypti.
Comparison of the transcriptome profiles showed a relatively low number of DE transcripts 12 h after
blood-feeding. There were 90 DE transcripts at 12 h post blood-feeding (p-adj ≤ 0.01), of which 35 were
upregulated and 55 were downregulated (Figure 3A and Figure S1A). The largest proportion of total
number of DE genes (38.9%) had unknown functions (Figure 3A and Figure S1A). Other DE transcripts
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mainly belonged to the functional categories of Binding (23.3%), Catalytic activity (14.4%), Cellular
process (12.2%), Response to stimulus (5.6%), and Transporter activity (4.4%). All other categories were
less than 1%. After 7-days post blood-feeding, 631 DE genes were significantly different, (p-adj ≤ 0.01;
291 upregulated and 340 downregulated) (Figure 3E and Figure S1E). Of those 631 transcripts, 36.8%
of those genes were assigned to an unknown function (Figure 3E and Figure S1E). Other DE genes
were mainly placed in functional categories of Binding (20.0%), Catalytic activity (13.9%), Cellular
process (14.1%), Response to stimulus (7.9%), and Transporter activity (4.8%).
Figure 3. Overview of the functional categories of differentially expressed (DE) transcripts in response
to ZIKV infection and between the permethrin resistant (KW) and susceptible (OR) strains of Aedes
aegypti blood-feeding control. DE transcripts were determined based on statistical analysis by DESeq
package. The total number of DE transcripts for each comparison is shown in parentheses in each
figure. Gene ontology analysis of DE genes was performed based on the database of AmiGO 2
(http://amigo.geneontology.org/amigo), and pie charts were generated using Excel. Up, upregulated
DE genes; Down, downregulated DE genes. Please also notice the details in the Supplementary Figure
S1. GO analyses for RNA-seq data. (A) 12 h post injection KW-Control compared with OR-Control;
(B) 12 h post infection, KW-ZIKV compared with OR-ZIKV; (C) 7 dpi, KW-ZIKV compared with
KW-Control; (D) 7 dpi, OR-ZIKV compared with OR-Control; (E) 7 dpi, KW-Control compared with
OR-Control; (F) 7 dpi, KW-ZIKV compared with OR-ZIKV.
3.1.2. Expression Profiles of DE Transcripts in Aedes Aegypti, Resistant and Susceptible Strains, in
Response to ZIKV
Analysis of mRNA expression profiles of Ae. aegypti mosquitoes at different time points of ZIKV
infection revealed a relatively low number of DE transcripts 12-h after blood-feeding. Only five DE
transcripts were identified in the susceptible strain and none in the resistant strain. However, there
209
Viruses 2018, 10, 470
were 932 DE genes (p-adj ≤ 0.01; 540 upregulated and 392 downregulated) in the resistant strain of Ae.
aegypti at 7 dpi with ZIKV (Figure 3C and Figure S1C). Most of these transcripts (36.2% in the total:
35.0% in the Up; 37.8% in the Down) had unknown functions. The remaining of the DE transcripts
matched to the functional categories of Binding (19.5% in the total: 22.0% in the Up; 16.1% in the
Down), Catalytic activity (15.0% in the total: 15.7% in the Up; 14.1% in the Down), Cellular process
(14.95 in the total: 14.3% in the Up; 15.8% in the Down), Response to stimulus (7.5% in the total: 7.0%
in the Up; 8.2% in the Down), and Transporter activity (4.4% in the total: 4.1% in the Up; 4.8% in the
Down). All other categories were lower than 1%. About 57.9% of 932 DE transcripts were upregulated
in the Ae. aegypti resistant strain in response to the ZIKV infection at 7 dpi.
Functional analysis based on the significant DE transcripts between the ZIKV exposed susceptible
strain and control susceptible at 7 dpi showed that most of the transcripts were downregulated (p-adj
≤ 0.01; 26 upregulated and 327 downregulated) (Figure 3D and Figure S1D). Approximately 36.8%
of the DE transcripts (42.3% in the Up; 36.4% in the Down) had unknown functions. The other DE
transcripts were categorized into the functional groups of Binding (16.4% in the total: 7.7% in the
Up; 16.5% in the Down), Catalytic activity (18.1% in the total: 19.2% in the Up; 18.0% in the Down),
Cellular process (15.3% in the total: 19.2% in the Up; 15.0% in the Down), Response to stimulus (4.2%
in the total: 3.8% in the Up; 4.3% in the Down), and Transporter activity (5.6% in the total: 7.7% in the
Up; 5.5% in the Down). All other categories were lower than 1%. Most of the DE transcripts (92.6%
of 353 transcripts) were downregulated in the susceptible strain in response to the ZIKV infection at
7 dpi.
3.1.3. Expression Profiles of DE Transcripts in Response to ZIKV Infection between Two Strains
Aedes Aegypti, Resistant Versus Susceptible Strains
Analysis and comparison of mRNA expression profiles of Ae. aegypti at different strains following
ZIKV infection revealed that ZIKV induced a relatively low number of DE transcripts 12 h after
blood-feeding. We observed 77 DE transcripts (p-adj ≤ 0.01), of which 28 were upregulated and 49
were downregulated (Figure 3B and Figure S1B) at 12 h post infection. Among those DE transcripts,
46.8% in total (42.9% in the UP; 49% in the Down) had unknown functions. The other DE transcripts
mainly belonged to the functional categories of Binding (18.2% in the total: 14.3% in the Up; 20.4% in
the Down), Catalytic activity (14.2% in the total: 17.9% in the Up; 12.2% in the Down), Cellular process
(5.2% in the total: 0% in the Up; 8.2% in the Down), and Transporter activity (10.4% in the total: 17.9%
in the Up; 6.1% in the Down). All other categories were lower than 1%. Most of the DE genes (63.6%)
were downregulated in the Ae. aegypti resistant strain compared to the susceptible strain at the 12 h
post infection.
Comparison of the transcriptome profiles of two Ae. aegypti strains in response to ZIKV 7 dpi
revealed 2459 DE transcripts (p-adj ≤ 0.01; 1936 upregulated and 523 downregulated, Figure 3F and
Figure S1F). Most of those DE transcripts (35.5% in the total) had unknown functions (Figure 3F and
Figure S1F). Of the DE transcripts that were up regulated in the resistant strain, 36.6% had unknown
functions; while 31.7% of the downregulated DE transcripts were of unknown function. The remaining
DE transcripts matched the functional categories of Catalytic activity (18.2% in the total: 19.8% in the
Up; 12.0% in the Down), Cellular process (15.0% in the total: 13.7% in the Up; 22.0% in the Down),
Response to stimulus (5.0% in the total: 5.1% in the Up; 4.5% in the Down), and Transporter activity
(5.5% in the total: 6.6% in the Up; 1.3% in the Down). All other categories were lower than 1%. Most
of the DE transcripts (78.7%) were upregulated in the Ae. aegypti resistant strain compared to the
susceptible strain at the 7 dpi. The data showed global changes in the two strains of Ae. aegypti female
adult transcriptome in response to ZIKV infection.
3.1.4. DE Transcripts Related to Immunity in Response to ZIKV Infection
When Ae. aegypti were infected with ZIKV at 7 dpi, a total of 863 transcripts had 2-fold or
more changes (p-adj ≤ 0.01; log2 fold change > ±2.0). Seventy-one immunity-related DE transcripts
210
Viruses 2018, 10, 470
were significantly upregulated in response to ZIKV 7 dpi between the two strains. These results
suggest that ingestion of ZIKV can induce an immune response in the permethrin resistant Key West
strain (Table S3A). These upregulated immunity related genes encoded two allergens, one caspase-1,
eleven Clip-domain serine protease family B and D, four C-type lectins, two C-type lysozymes, one
cysteine-rich protein, one cysteine-rich venom protein (AAEL005098, 5.77 log2 fold change), one
environmental stress-induced protein, five fibrinogen and fibronectins, two Gram-negative binding
proteins (GNBP), one granzyme A precursor, one lachesin, thirteen leucine-rich immune proteins, one
M protein, one neuroendocrine protein, one p37NB protein, one peptidoglycan recognition protein
(AAEL012380), one prophenoloxidase (AAEL011763), one rh antigen, SEC14, SEC15, SEC16, one
thioester-containing protein (tep2), one toll protein and four Toll-like receptors, eight trypsins, and
three venom allergens (Table S3A).
Compared with the control group, more immune related enzymes at 7 dpi infected with ZIKV
were detected and most of them were upregulated significantly (Table S3A,B). The comparison
between Ae. aegypti infected with ZIKV and the control at the 7-dpi in the resistant strain revealed
that 318 transcripts had changes of 2-fold or more in either direction. Fifteen DE transcripts
related to immunity were significantly dysregulated more than 2-fold (seven upregulated and
eight downregulated, Table S3C). These transcripts encoded two Class C Scavenger Receptors,
two Clip-domain serine proteases family B, two C-type lectins, one cysteine-rich venom protein
(AAEL005098, 2.71 log2 fold change), one Gram-negative binding protein, one lachesin, three
leucine-rich transmembrane proteins, a shoc2, one venom allergen, and one Wnt10a protein (Table
S3C). In the Orlando strains infected with ZIKV at 7 dpi, a total 128 transcripts had changes of 2-fold or
more, but only one was upregulated. All 14 DE transcripts related to immunity between ZIKV infected
and the control group at 7 dpi were significantly downregulated (Table S3D). These transcripts encoded
six Clip-domain serine proteases family B, one C-type lectin, five leucine-rich immune proteins, one
Trypsin 3A1 precursor, and one tyrosine kinase receptor (Table S3D). Both the Ae. aegypti resistant and
susceptible strains infected with ZIKV at the 7 dpi shown regulated with Clip-domain serine protease
family B, C-type lectin, and some leucine-rich proteins.
Some important immunity transcripts were significantly upregulated (more than 4-fold) in the
permethrin resistant than the susceptible strains, such as prophenoloxidase and M protein. The
prophenoloxidase (AAEL011763) is a modified form of the complement response found in insects,
and a major innate defense system in invertebrates that controls the melanization of pathogens and
damaged tissues [52]. M protein (AAEL011747), a strongly antiphagocytic and a major virulence factor
in viruses, parasites, and bacteria aids in entering by counteracting the mosquito’s defenses [53,54]. In
addition, two lachesins, a novel immunoglobulin superfamily protein required for morphogenesis of
the Drosophila tracheal system, were also significantly upregulated [55]. The peptidoglycan recognition
protein (AAEL012380), an important role in the innate immune response, was correspondingly
upregulated significantly in the Key West strain [56].
3.1.5. DE Transcripts Related to Detoxification in Response to ZIKV Infection
The RNAseq study between two Ae. aegypti strains infected with ZIKV at 7 dpi showed that 62
DE transcripts related to detoxifications were upregulated more than 2-fold in response to ZIKV. These
transcripts encoded one alcohol dehydrogenase, two aldehyde oxidases, one aldo-keto reductase, two
Carboxy/choline esterases, one core 1 UDP-galactose galactosyltransferase, 33 cytochrome P450, one
d-amino acid oxidase, one epoxide hydrolase, seven glucosyl/glucuronosyl transferases, one glutamate
semialdehyde dehydrogenase, three n-acetylgalactosaminyltransferases, one prophenoloxidase, four
short-chain dehydrogenases, one sterol desaturase, and one thioredoxin peroxidase (Table S4A).
Four cytochrome P450 (AAEL009018, AAEL014609, AAEL014617, and AAEL014893) were
reported as associated with insecticide resistance in several populations of Ae. aegypti [31,32,57].
Compared with the control, between the Key West strain and the Orlando strain at 7 dpi infected with
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ZIKV, more detoxification enzymes were detected and most of them were upregulated significantly
more than 2-fold (Table S4A,B), suggesting those genes might associate with insecticide resistance.
Comparing the Key West Ae. aegypti infected with ZIKV with the Key West control at the
7 dpi, 19 DE transcripts related to detoxification were significantly regulated (11 upregulated and
eight downregulated, Table S4C). Nevertheless, all 14 DE transcripts related to detoxification were
significantly downregulated between the Orlando Ae. aegypti infected with ZIKV and the Orlando
control at the 7 dpi (Table S4D).
According to previous studies [31,32,57], 23 transcriptions of detoxification enzymes associated
with permethrin resistance were significantly upregulated at 7 dpi between the Key West
strain and the Orlando strain in response to ZIKV infection (Table 1A). They encoded an
alcohol dehydrogenase (AAEL012457), an amine oxidase (AAEL009044), Carboxy/choline esterase
(AAEL002385), 19 Cytochrome P450, and a glucosyl/glucuronosyl transferase (AAEL003099). In
the control at 7 dpi, we observed six cytochromes and a glutathione transferase (AAEL007964) that
were significantly expressed between the Key West and Orlando Controls fed uninfected blood
(Table 1B). Nineteen Cytochrome P450 included, CYP6CB1 (AAEL009018), CYP9M10 (AAEL009125),
and P450s of the CYP9J subfamily such as CYP9J10 (AAEL006798) and CYP9J28 (AAEL014617),
from which several members were shown to contribute to deltamethrin metabolism [31,32,58,59].
The glucosyl/glucuronosyl transferases (AAEL003099) were reported as differentially expressed in
pyrethroid resistant populations relative to the susceptible strain [32,59].
3.1.6. DE Transcripts Likely Related to Permethrin resistance in Response to ZIKV Infection
Except detoxification enzymes, many other enzymes related to insecticide resistance have been
reported. We analyzed the DE transcripts possible related to permethrin resistance in response to
ZIKV infection. Most of the fifty-five DE transcripts likely related to permethrin resistance were
upregulated in response to ZIKV 7 dpi in the Key West strain compared with the Orlando strain, but
only one zinc finger protein (AAEL002388) was downregulated (Table S5A). These transcripts encoded
one acetylcholine receptor, two adenylate cyclases, four alkaline phosphatases, one ATP-binding
cassette transporter, three ATP-dependent bile acid permeases, two brain chitinase and chias, two
bumetanide-sensitive Na-K-Cl cotransport proteins, two cgmp-dependent protein kinases, one
glutamate decarboxylase, three glutamate receptors, one glutamate transporter, one glutamate-gated
chloride channel, five GPCR related genes, two guanine nucleotide-binding proteins, two matrix
metalloproteinases, one metalloproteinase, two prolylcarboxypeptidases, eight protease m1 zinc
metalloproteases, two voltage-gated potassium channels, five zinc carboxypeptidases, four zinc finger
proteins, and one zinc metalloprotease (Table S5A).
Nineteen DE transcripts likely related to permethrin resistance, except some detoxification
enzymes, were regulated (14 upregulated and five downregulated) in response blood feeding control
in the Key West strain compared with the Orlando strain (Table S5B). The voltage-gated sodium
channel (AAEL006019) was only upregulated 1.4-fold, which may play an important role in the Key
West Ae. aegypti strain. Between Key West Ae. aegypti infected with ZIKV and the Key West control
at the 7 dpi, 14 DE transcripts possibly related to permethrin resistance were significantly regulated
(six upregulated and eight downregulated) in response to ZIKV infection (Table S5C). Nonetheless,
all 16 DE transcripts related to detoxification were significantly downregulated between the Orlando
Ae. aegypti infected with ZIKV and the Orlando control at the 7 dpi (Table S5D).
3.1.7. DE Transcripts Related to Cytoskeleton in Response to ZIKV Infection
A cytoskeleton with multitude of functions is present in all cells of all domains of life, including
archaea, bacteria, and eukaryotes. The cytoskeleton assists the cell move in its environment and
controls the movement of the cell’s interior workings. Our RNAseq study of two strains of Ae. aegypti
following ZIKV infection at 7 dpi revealed that all 56 DE transcripts related to the cytoskeleton were
upregulated in response to ZIKV 7 dpi in the Key West strain compared with the Orlando strain
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(Table S6A). These genes encoded four actin, one ca-activated cl channel protein, one cadherin, one
calcium-binding protein, two calcium-transporting ATPases, one calmin, two calponin/transgelins, one
calsyntenin-1 precursor, one coronin, one dynein heavy chain, one flagellar radial spoke protein, one
gelsolin precursor, one gliotactin, three innexins, one integrin alpha-ps, one jnk interacting protein, one
laminin, one leucokinins precursor, one mitogen activated protein kinase, one muscle lim protein, one
myo inositol monophosphatase, one myoinositol oxygenase, nine myosins, one myosin regulatory light
chain, one nuclear lamin L1 alpha, one nucleosome assembly protein, one otopetrin, one paramyosin,
one pyrokinin, one talin, one testisin precursor, one titin protein, one tropomyosin invertebrate, five
troponins, one unconventional myosin 95e isoform, and one vesamicol binding protein (Table S6A).
According to RNA-seq analysis, 21 cytoskeletons related to DE transcripts were significantly
regulated (12 upregulated and nine downregulated) in response to blood feeding control in the Key
West strain compared with the Orlando strain (Table S6B). Nineteen DE cytoskeleton transcripts were
regulated (nine upregulated and 10 downregulated) in the ZIKV infected group of the Key West strain
at the 7 dpi (Table S6C). However, all six DE transcripts related to the cytoskeleton were significantly
downregulated in the ZIKV infected group of the Orlando strain at the 7 dpi (Table S6D).
We found that most genes were downregulated in the Ae. aegypti Orlando susceptible strain at
7 dpi following ZIKV infection. In contract, most genes were upregulated in the Ae. aegypti Key West
permethrin resistant strain (Tables S3–S6). Compared with the Ae. aegypti Orlando susceptible strain
at 7 dpi following ZIKV infection, Ae. aegypti Key West permethrin resistant strain showed a global
upregulation of endogenous genes, many of which encode proteins specifically involved in immunity,
detoxification, pesticide resistance, and cytoskeleton movement related genes.
4. Discussion
Arbovirus–mosquito interactions alter global gene expression in Ae. aegypti and other
mosquitoes [39,40,43,48,60,61]. Although Zika infection had been reported to change transcript levels
in Ae. aegypti [43], the mechanism(s) of insecticide resistance in Ae. aegypti-ZIKV remains unknown.
Since insecticide-resistance monitoring is the key to controlling arboviruses, we need to improve our
understanding of mosquito–virus interactions in both resistant and susceptible strains to facilitate
surveillance and monitoring of Zika vector populations under control.
Many reports have been shown that the upregulated genes contained multiple detoxification
genes and several immune-related genes in insecticide resistant mosquitoes, including Ae. aegypti,
Anopheles gambiae, An. sinesis, An. stephensi, and Culex quinquefasciatus [23,31,33,62–65]. To the best of
our knowledge, this is one of the first documentations showing an association between insecticide
resistance and altered mosquito–arbovirus interactions. However, we are unable to rule out the
possibility that inherent genetic differences between the two strains of Ae. aegypti, in part, contribute
to differences in ZIKV infection. Although the mechanism(s) responsible for altered interactions
between mosquitoes and pathogens is not fully understood, changes in oxidative stress and vector
immunity have been proposed as potential sources [66]. Our observed results are consistent with Alout
et al. 2013 [67] showing higher Plasmodium falciparum prevalence at both the oocyst and sporozoite
stages, in Anopheles gambiae s.s. resistant to pyrethroids and DDT than in a susceptible strain. In
contrast, insecticide-resistant (organophosphate) Culex quinquefasciatus mosquitoes were less capable of
transmitting the filarial parasite Wuchereria bancrofti than insecticide-susceptible conspecifics, mediated
by disrupted development of the parasite [68,69]. It is likely that the biological processes in response to
mosquito infection of arboviruses differs from that of parasites such as filarial worms and Plasmodium.
Regardless, taken together, these observations suggest a connection between insecticide resistance
and altered physiology that translates to changes in interactions between mosquitoes and the disease
agents they transmit.
To obtain a global view of changes in gene expression between Ae. aegypti Key West permethrin
resistant strain and Ae. aegypti Orlando susceptible strains, we analyzed RNA-seq data and identified
at least 23 detoxification enzymes linked to insecticide resistance that were significantly upregulated in
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response to ZIKV infection [31,32]. Our current study showed that the Ae. aegypti Key West permethrin
resistant strain and the Ae. aegypti Orlando susceptible strain differentially altered their gene expression
in response to ZIKV infection.
To survive in a world full of pathogens, insects have developed a powerful defense mechanism
that recognizes and removes microbial threats [70]. Insects depend on innate immunity for their
survival. The immune system accommodates host colonization by the virus, maintains virus–host
homeostasis and defends against pathogens. Viral infections are detected by innate antiviral
responses [71]. Pathogen receptors in the innate immune system play a role in the detection of
viral nucleic acids in different ways [71]. Toll-like receptors detected viral DNA or RNA in endosomal
compartments in immune cells [45,72], while retinoic acid inducible gene-I-like receptors recognized
viral RNA in the cytoplasm and DNA sensors detected cytoplasmic viral DNA [71]. The Toll pathways
have previously been shown to suppress arbovirus infection in Ae. aegypti midgut tissue [45].
Peptidoglycan recognition proteins, conserved from insects to mammals, are pattern recognition
molecules that recognize microbes and their unique cell wall component, peptidoglycan [73]. Our
transcriptomic study revealed that five Toll-like receptors and three peptidoglycan recognition proteins
were significantly upregulated in the Key West permethrin resistant strain Ae. aegypti at 7 dpi following
ZIKV infection compared with the Orlando susceptible Ae. aegypti (Table S3A,B). Clip-domain
serine proteases are the essential components of extracellular signaling cascades in various biological
processes and function in developmental processes and innate immune responses [74,75]. Twelve
Clip-domain serine proteases were upregulated between the Key West permethrin resistant and
the Orlando susceptible strains of Ae. aegypti. CLIP proteases are found in insect hemolymph and
participate in cascade pathways that activate prophenoloxidase in the melanization response and
synthesis of antimicrobial peptides [74], including immune signaling in Ae. aegypti [76,77].
Other immune related enzymes, such as cecropin antimicrobial peptide, Class B scavenger
receptor, defensin antimicrobial peptide, fibrinogen and fibronectin, and leucine-rich immune proteins
were also upregulated between the Key West permethrin resistant strain Ae. aegypti and the Orlando
susceptible Ae. aegypti. Cysteine-rich venom proteins, found in the fluids of animal venoms, inhibit both
smooth muscle contraction and cyclic nucleotide-gated ion channels [78]. Previous studies displayed
that cysteine-rich venom proteins were changed in yellow fever and ZIKV-infected mosquitoes and
silencing the gene led to an increase in replication of dengue viruses, which indicated their possible
importance in replication of these viruses [43,79]. The current study showed that cysteine-rich venom
proteins (AAEL005098) were upregulated 2.71 log2 fold change in the Key West strain ZIKV compared
with Key West control, and upregulated 5.77 log2 fold change when compared with the Orlando strain
Ae. aegypti in response to ZIKV. Further studies may need to demonstrate the role of cysteine-rich
venom proteins play in response to Zika infection. These data indicated the permethrin resistant Key
West Ae. aegypti mosquitoes altered immune system in response to ZIKV infection, differently from the
susceptible Orlando Ae. aegypti strain.
The activation of multiple signaling pathways following virus infection, the detoxification genes
implicated in the establishment of the antiviral state, and the strategies used by viruses and their specific
viral products to antagonize and evade the host antiviral response. Recent studies have utilized [31]
deep targeted DNA sequencing for identification of increases in gene copy number in the genome
associated with pyrethroid resistance in populations of Ae. aegypti and subsequently identified novel
genomic resistance markers potentially associated with their cis-regulation and modifications of their
protein structure confirmation [31,32]. The current RNA-seq study also confirmed 23 over expression
of detoxification enzymes associated with insecticide resistance in Key West Ae. aegypti in response
to ZIKV 7 dpi compared with Orlando Ae. aegypti susceptible strain. CYP6CB1-like AAEL009018,
considerably favor the binding of an HNF-3 element and overexpression of this gene in resistant
populations has frequently been associated with the regulation of drug-metabolizing P450s [31,49].
CYP9M10, AAEL009125, was not only demonstrated in the Ae. aegypti mosquito but also reported in the
resistant strain of Culex quinquefasciatus [31,80,81]. The current study also confirmed that detoxification
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enzymes, such as carboxy/choline esterase and glucosyl/glucuronosyl transferases, were associated
with resistance mosquitoes in response to ZIKV infection [31,32,82,83]. The mechanisms for regulation
of detoxification enzymes in response to ZIKV and their relevance to insecticide resistance are unclear.
It has been proposed that regulation in some metabolic detoxification genes may result from responses
to various endogenous and exogenous compounds, or to pathophysiological signals [33,63,64,84,85].
The actin and microtubule cytoskeleton play important roles in the life cycle of viruses. Viruses
succeed as intracellular parasites and interact with the actin cytoskeleton at various stages of the host
cell throughout their life cycles to facilitate the infection process [86,87]. Many animal viruses interact
with cytoskeleton elements inside infected cells at different stages of replication and cytoskeleton
involvement in virus budding [88]. The microfilament signal pathway is involved in DENV infection
through regulation of actin reorganization in EAhy926 cells [89]. Viral interaction with the host
microtubule (MT) cytoskeleton is critical to infection by many viruses, with modifying MT dynamics
and functions that affect processes beyond virion transport [90]. Myosin protein enforced track
selection on the microtubule and actin networks in vitro, depending on the active transport of diverse
intracellular cargo on the ubiquitous actin and microtubule networks [91]. Some studies showed that
the manipulation of host actin cytoskeleton is essential for viral pathogens to invade the host cells [92].
Our current data show that 56 DE transcripts related to cytoskeleton, including four actin and 10
myosin proteins, were significantly upregulated in the Zika infected Key West strain compared with
the Orlando strain Ae. aegypti 7-day post infection. The overexpression of actin cytoskeleton genes in
the permethrin resistance strain of Ae. aegypti might be associated with higher viral loads later during
the infection process, although the precise functional importance of these interactions and their roles
in pathogenesis remain largely unresolved.
Our observations provide an overview of gene expression associated with metabolic detoxification
among permethrin resistant and susceptible populations of Ae. aegypti, including antiviral responses
following ingestion of ZIKV. Our understanding of host–virus interactions in mosquito systems
combining traditional genetic and biochemical approaches with ”omics” based approaches in both
laboratory and natural environmental studies is key to improving the surveillance and monitoring of
Zika vector populations under control. One of the limitations of this approach is that it falls short of
providing an in-depth analysis of any one specific mechanism, or collection of mechanisms. Rather,
our broad approach is aimed at providing a global view to identify candidate genes and functional
categories for subsequent studies using other methods (e.g., reverse genetics) that target candidate
genes for elucidating molecular mechanisms of insecticide resistance and the development of novel
molecular mechanisms to circumvent resistance.
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Abstract: Zika virus (ZIKV) infections have caused a wide spectrum of neurological diseases, such as
Guillain-Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective
therapies currently exist for treating patients infected with ZIKV. MicroRNAs (miRNAs) are a
group of small RNAs involved in the regulation of a wide variety of cellular and physiological
processes. In this study, we analyzed digital miRNA and mRNA profiles in ZIKV-infected primary
mouse neurons using the nCounter technology. A total of 599 miRNAs and 770 mRNAs were
examined. We demonstrate that ZIKV infection causes global downregulation of miRNAs with
only few upregulated miRNAs. ZIKV-modulated miRNAs including miR-155, miR-203, miR-29a,
and miR-124-3p are known to play critical role in flavivirus infection, anti-viral immunity and brain
injury. ZIKV infection also results in downregulation of miRNA processing enzymes. In contrast,
ZIKV infection induces dramatic upregulation of anti-viral, inflammatory and apoptotic genes.
Furthermore, our data demonstrate an inverse correlation between ZIKV-modulated miRNAs and
target host mRNAs induced by ZIKV. Biofunctional analysis revealed that ZIKV-modulated miRNAs
and mRNAs regulate the pathways related to neurological development and neuroinflammatory
responses. Functional studies targeting specific miRNA are warranted to develop therapeutics for
the management of ZIKV neurological disease.
Keywords: Zika virus; flavivirus; microRNAs; neurons; neuroinflammation; anti-viral immunity
1. Introduction
Zika virus (ZIKV) is an emerging mosquito-borne pathogen that is part of the Spondweni
serocomplex of the genus Flavivirus, family Flaviviridae. ZIKV is closely related to other pathogens
of public health importance including yellow fever virus (YFV), dengue virus (DENV), Japanese
encephalitis virus (JEV), and West Nile virus (WNV). The ZIKV genome is comprised of a
single-stranded, positive-sense 11-kb RNA that contains three structural and seven nonstructural
genes [1,2]. ZIKV is highly neurotropic in human fetal infections and has been linked to
the development of severe fetal abnormalities that include spontaneous abortion, stillbirth,
hydranencephaly, microcephaly, and placental insufficiency that may cause intrauterine growth
restriction [1]. An increased incidence of Guillain-Barré syndrome (GBS), neuropathy of the peripheral
nervous system, has also been reported in ZIKV-infected patients [3]. No effective therapies currently
exist for treating patients infected with ZIKV.
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ZIKV has been shown to replicate and induce cell death in neuronal cells of fetal mice as well
as in human neural progenitor cells and brain organoids, a mechanism thought to play an important
role in the pathogenesis of ZIKV neurological disease [4–7]. It is known that immunocompetent
adult mice are resistant to subcutaneous or intraperitoneal inoculation of ZIKV [8,9]. However, it has
been demonstrated that intracerebral inoculation of ZIKV in adult immunocompetent mice results in
neurological disease [10]. Additionally, several studies have reported that neonatal immunocompetent
mice inoculated with ZIKV via subcutaneously or intracerebral route develop ZIKV disease, and ZIKV
infection can be detected in the neurons [11–13]. It has also been demonstrated that ZIKV infection
during the period of maximal brain growth causes microcephaly and corticospinal neuron apoptosis in
wild-type mice [14]. However, to date the effect of ZIKV infection on microRNAs (miRNAs) expression
in primary mouse neurons has not been examined.
miRNAs are a group of small RNAs involved in the regulation of a wide variety of cellular and
physiological processes. miRNAs are considered novel diagnostic and interventional candidates due
to their biochemical structure [15]. They function by directly binding to the 3’ untranslated regions
(3’UTRs) of specific target mRNA, causing a block of translation or degradation of the target mRNA.
miRNAs have been demonstrated to play a crucial regulatory role in neurodegenerative diseases
such as Alzheimer and Parkinson [16]. miRNAs also play a critical role in the regulation of immune
response; including differentiation, proliferation, cell fate determination, function of immune cells,
and inflammatory mediator release as well as the intracellular signaling pathways [17,18].
miRNAs of infected cells can influence the ability of a virus to replicate or spread. It is known
that endogenous miRNAs inhibit replication of a number of RNA viruses including HIV-1, Ebola virus
and vesicular stomatitis virus [19–23]. For example, miR-28, miR-125b, miR-150, miR- 223, miR-198,
and miR-382 inhibit HIV replication in CD4 T cells by directly targeting HIV RNA or by modulating
cellular factors responsible for its replication [24]. Furthermore, miR-122 supports HCV replication
by enhancing colony formation efficiency of HCV [25], whereas miR-196 and miR-296 substantially
attenuate virus replication through type I interferon (IFN)-associated pathways in liver cells [26].
Over-expression of miRNA-30e, let-7c, and miRNA-126-5p inhibits DENV replication [27–29]. Cellular
miR-532-5p inhibits WNV replication via suppression of host genes SESTD1 and TAB3 required for
virus replication [30]. miRNA HS_154 contributes to WNV-mediated apoptosis in vitro in the human
neuronal cell line, SK-N-MC [31]. Moreover, incorporation of a target sequence for cellular microRNAs
expressed in the central nervous system (CNS) into the flavivirus genome alters the neurovirulence of
the virus and prevents the development of lethal encephalitis in mice [32].
We have previously demonstrated the role of cellular miRNAs in the pathogenesis of WNV
encephalitis [33,34]. In this study, we analyzed miRNA and mRNA profiles in ZIKV-infected
neurons using the nCounter system. Unlike other platforms (such as microarray and next generation
sequencing), the nCounter platform enables high throughput, sensitive, quantitative, and reproducible
gene expression analysis without the need of enzymatic target amplification. This technology utilizes
100 nucleotide molecular bar codes which measure gene quantities without an amplification step [35].
To our knowledge, this is the first study to evaluate the modulation of miRNAs following ZIKV
infection using relevant cells, primary neurons.
2. Materials and Methods
2.1. Neuronal Cultures
Mouse cortical neuron cultures were prepared from one-day old pups of either gender
(approximately equivalent numbers) obtained from established colonies of wild-type C57BL/6J mice
as described previously [36]. The neurons were plated onto poly-D-lysine-coated 6-well or 24-well
plates in serum Neurobasal A medium. The cultures were maintained in serum-free Neurobasal A
medium supplemented with B27 for seven days prior to infection [36,37]. This study was carried out
in accordance with the recommendations of the National Institutes of Health and the Institutional
222
Viruses 2019, 11, 162
Animal Care and Use Committee (IACUC). The protocol was approved by the University of Hawaii
IACUC (protocol number 17-2721) and Georgia State University (protocol number A19005).
2.2. ZIKV Infection and Plaque Assay
In this study, we used a low cell-culture-passaged and sequence-verified ZIKV strain, PRVABC59
(BEI Resources, NR-50240). Virus strain was amplified once in Vero E6 cells and had titers of 5 × 106
plaque-forming units (PFU)/mL. Cells were infected with ZIKV or PBS (Mock) at multiplicity of
infection (MOI)-1 and supernatants and cell lysates were harvested at 12, 24, 48, and 72 h after
infection [38]. ZIKV titers were measured in cell supernatants using plaque assay [38,39]. Experiments
were repeated to obtain four biological replicates of mock- and ZIKV-infected neurons at each time
point for the NanoString analysis (n = 4 per group per time point).
2.3. Indirect-Immunofluorescence Microscopy
Neuronal cell monolayers were grown on coverslips in 24-well plates and infected with ZIKV
or PBS at MOI-1. Cells were fixed in 4% paraformaldehyde (PFA) and immunostained using mouse
anti-dsRNA (1:1000) antibody followed by secondary antibody conjugated with Alexa Fluor 555
(Millipore, Burlington, MA, USA) as described previously [40].
2.4. NanoString nCounter® Gene Expression
Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden, Germany) as described
previously [33]. Genomic DNA contamination was eliminated by digesting the RNA with RNase-free
DNase (Ambion, Cambridge, MA, USA). RNA was quantitated using Nanodrop (Thermo Scientific,
Waltham, MA, USA), and the 28S/18S RNA ratios of all RNA samples were between 1.8 and
2.0. RNA quality was analyzed using the Bioanalyzer [33,41]. For miRNA analysis, we used the
nCounter® Mouse miRNA Expression Panel (NanoString, Seattle, WA, USA, Cat: CSO-MMIR15-12).
Raw data was normalized using the geometric mean values of the top 100 expressed miRNA in each
sample using the nSolver Analysis Software (NanoString), according to the manufacturer’s guidelines.
For mRNA analysis, we utilized the nCounter® Mouse PanCancer Immune Profiling Panel to count
770 immune-related genes (NanoString, Cat: XT-CSO-MIP1-12). Raw data was normalized with a set
of housekeeping genes and analyzed using the nSolver Analysis Software (NanoString), according to
the manufacturer’s guidelines.
2.5. qRT-PCR
Total RNA was isolated using miRNeasy Mini Kit, and cDNA prepared using a miScript II
RT Kit (Qiagen) [33,34]. qRT-PCR was performed using specific miRNA primer (Qiagen), and the
miScript SYBR green PCR kit (containing Universal reverse primer) [33]. For mRNA analysis, cDNA
was prepared using iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA), and qRT-PCR was
conducted as described previously [41,42]. The primer sequences used for qRT-PCR are listed in
Table 1.
Table 1. Primer sequences used for qRT-PCR.
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Table 1. Cont.






























2.6. Measurement of Cytokines and Chemokines
The levels of cytokines and chemokines were measured in the cell supernatants by multiplex
immunoassay using MILLIPLEX MAP mouse Cytokine/Chemokine magnetic panel as per
manufacturer’s instructions (Millipore) [43,44].
2.7. Ingenuity Pathways Analysis (IPA)
Target prediction and pathway analysis were conducted using IPA (Ingenuity Systems Inc.,
Redwood City, CA, USA) as described previously [33,34,41]. Fisher’s exact test, using IPA, was used
to calculate the cut-off point of significance. p < 0.05 is considered significant. We also conducted
correlation pairing with mRNA expression data and significantly modulated miRNAs using IPA.
For multiplex immunoassay analysis, unpaired Student’s t-test using Graph Pad was used to calculate
p values.
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3. Results
3.1. ZIKV Can Infect Primary Mouse Cortical Neurons
ZIKV infection of neuronal cells plays an important role in the pathogenesis of ZIKV neurological
disease. Therefore, we used primary neurons for our experiments. We first determined ZIKV infection
and replication kinetics in primary mouse cortical neurons by plaque assay. Mouse cortical neuron
cultures were infected with ZIKV (PRVABC59 strain) or PBS (Mock) at MOI-1 and supernatants were
collected at 12, 24, 48, and 72 h after infection. High ZIKV replication was observed as early as 12 h
after infection. Viral titers peaked at 48 h (log 7–8 PFU/mL) followed by a slight decline at 72 h after
infection (Figure 1A). Immunofluorescence staining of ZIKV-infected neurons demonstrated robust
dsRNA staining in the cytoplasm. Based on a total of 5,000 cells counted in 10 independent fields,
dsRNA was detected in approximately 60% of cells at 48 h after infection (Figure 1B,C).
 
Figure 1. Zika virus (ZIKV) infection of the primary mouse neurons. Mouse cortical neuron cultures
were prepared from one-day old pups. Neurons were infected with ZIKV (PRVABC59 strain) or PBS
(Mock) at multiplicity of infection (MOI)-1. (A) ZIKV titers in culture supernatant were determined
by plaque assay. Viral titers are expressed as plaque forming units (PFU)/mL of supernatant. Data
represents the mean ± SEM. Neurons grown and fixed on coverslips at 48 h after infection were
stained with anti-dsRNA antibody (red) and counterstained with DAPI (blue). (B) Mock-infected
cells. 20× magnification. (C) ZIKV-infected cells demonstrate robust virus staining in the cytoplasm.
20× magnification.
3.2. ZIKV Infection Modulates Cellular miRNA Expression
Neurons were infected with ZIKV (PRVABC59 strain) or PBS (Mock) at MOI-1 and cell lysates
were harvested at 24 and 48 h after infection. We used nCounter® Technology (NanoString) to evaluate
the global miRNA expression profiles in the mock-and ZIKV-infected neurons at 24 and 48 h after
infection (n = 4 per group per time point). Among 599 miRNAs present on the array, 67 and 45
miRNAs were significantly modulated at 24 and 48 h, respectively. miRNAs that were altered at least
2-fold were considered significant. While 62 miRNAs were significantly downregulated (between 2- to
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4-fold), only five miRNAs were upregulated (between 2 to 18-fold) in ZIKV-infected neurons when
compared to mock-infected neurons at 24 h (Tables 2 and 3). Similarly, 40 miRNAs were significantly
downregulated (between 2- to 6-fold), and only five were upregulated (between 2 to 10-fold) at 48 h
(Tables 2 and 4). As depicted in the Venn diagram (Figure 2A), three upregulated and 26 downregulated
miRNAs were common in both 24 and 48 h-infected neurons. Among upregulated miRNAs; miR-155,
miR-29a, and miR-29b were induced at both 24 and 48 h. miR-3471 and miR-2145 were upregulated
only at 24 h, and miR-203 and miR-1902 were upregulated only at 48 h. The miRNAs with the highest
induction during the course of infection were miR-155 (18.2-fold), miR-3471 (4.9-fold), and miR-203
(4.6-fold) (Table 2). Among downregulated miRNAs, miR-124-3p was the highest downregulated
miRNA at both 24 (4-fold) and 48 (6.6-fold) h. Other miRNAs with high downregulation were
miR-883a-3p (3.9-fold) and miR-2137 (2.9-fold). We also conducted qRT-PCR to confirm the expression
changes of a selected number of differentially expressed miRNAs. Similar to the NanoString data,
miR-155, miR-29a, and miR-203 were significantly upregulated, and miR-124-3p was downregulated
in ZIKV-infected neurons (Figure 2B).
 
Figure 2. ZIKV infection of the primary mouse neurons causes changes in cellular miRNA expression.
Neurons were infected with ZIKV (PRVABC59 strain) or PBS (Mock) at MOI-1. (A) Venn diagram
showing the number of differentially expressed miRNAs at 24 and 48 h after infection. Sets of
upregulated miRNAs are represented by upward red arrows and sets of downregulated miRNAs are
represented by downward green arrows. Pairs of arrows in the intersection refer to the number of
miRNAs upregulated (double red arrows) or down regulated (double green arrows) at both 24 and 48 h
after infection. (B) qRT-PCR was conducted on RNA extracted from mock and ZIKV-infected neurons
to determine fold-change in miR-155, miR-203, miR-29a, and miR-124-3p expression. Changes in the
levels of each miRNA were first normalized to the snoRNA and then the fold-change in ZIKV-infected
cells was calculated in comparison to corresponding mock-infected cells. Data represents the mean
± SEM. (C) qRT-PCR was conducted on RNA extracted from mock and ZIKV-infected neurons to
determine fold-change in Dicer-1, Drosha, DGCR8, AGO1, and AGO2 expression. Changes in the levels
of each mRNA were first normalized to the β-actin and then the fold-change in ZIKV-infected cells
was calculated in comparison to corresponding mock-infected cells. Data represents the mean ± SEM.
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Table 2. Upregulated miRNAs in Zika virus (ZIKV)-infected neurons at 24 h and 48 h.
miRNA Fold-change (24 h) miRNA Fold-change (48 h)
miR-155 18.29 miR-155 10.61
miR-3471 4.96 miR-203 4.61
miR-2145 2.33 miR-1902 2.95
miR-29a 2.09 miR-29b 2.1
miR-29b 2.05 miR-29a 2.08
Table 3. Downregulated miRNAs at 24 h.
miRNA Fold-change miRNA Fold-change
miR-124-3p −4.02 miR-144 −2.15
miR-M1-1 −2.97 miR-201 −2.15
miR-1892 −2.85 miR-764-5p −2.15
miR-883a-3p −2.7 miR-1895 −2.13
miR-879 −2.69 miR-871 −2.12
miR-669g −2.65 miR-m108-1 −2.12
miR-654-3p −2.62 miR-1928 −2.11
miR-339-3p −2.52 miR-1941-5p −2.11
miR-1960 −2.51 miR-759 −2.11
miR-207 −2.51 miR-1187 −2.1
miR-2861 −2.51 miR-666-3p −2.1
miR-412 −2.48 miR-1966 −2.09
miR-741 −2.47 miR-1942 −2.08
miR-770-5p −2.41 miR-1946a −2.08
miR-673-5p −2.38 miR-1967 −2.08
miR-1941-3p −2.37 miR-m01-1 −2.07
miR-493 −2.33 miR-383 −2.06
miR-465a-3p −2.31 miR-186 −2.05
miR-1956 −2.26 miR-323-5p −2.05
miR-1194 −2.25 miR-M1-3 −2.05
miR-709 −2.25 miR-433 −2.04
miR-m107-1-5p −2.25 miR-767 −2.04
miR-877 −2.23 miR-1188 −2.03
miR-331-5p −2.22 miR-694 −2.03
miR-483 −2.22 miR-665 −2.02
miR-675-5p −2.2 miR-2139 −2.02
miR-1957 −2.19 miR-883a-5p −2.02
miR-M23-1-3p −2.19 miR-1943 −2
miR-1898 −2.18 miR-346 −2
miR-1940 −2.17 miR-764-3p −2
miR-1894-5p −2.16 miR-710 −2
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Table 4. Downregulated miRNAs at 48 h.
miRNA Fold-change miRNA Fold-change
miR-124-3p −6.68 miR-m21-1 −2.15
miR-883a-3p −3.93 miR-335-3p −2.14
miR-2137 −2.92 miR-1957 −2.12
miR-2133 −2.74 miR-764-5p −2.11
miR-714 −2.56 miR-1194 −2.08
miR-669g −2.54 miR-683 −2.08
miR-467g −2.5 miR-509-5p −2.07
miR-1188 −2.41 miR-463 −2.06
miR-879 −2.33 miR-741 −2.06
miR-760 −2.25 miR-761 −2.05
miR-298 −2.21 miR-710 −2.03
miR-m01-3 −2.21 miR-346 −2.01
miR-764-3p −-2.2 miR-882 −2.01
miR-370 −2.18 miR-1898 −2.01
miR-1892 −2.16 miR-759 −2
miR-m01-2 −2.16 miR-433 −2
miR-133b −2.15 miR-709 −2
miR-1894-5p −2.15 miR-1956 −2
miR-666-3p −2.15 miR-483 −2
miR-877 −2.15 miR-1941-5p −2
3.3. ZIKV Infection Results in Downregulation of miRNA Processing Enzymes
Flaviviruses have been shown to induce downregulation in the expression of cellular miRNAs by
targeting miRNA processing enzymes [45–48]. Our data also demonstrated a trend toward decrease
in miRNA expression in ZIKA-infected cells. Therefore, we next evaluated the expression of miRNA
processing enzymes in ZIKV-infected neurons. mRNA expression levels of Dicer-1, Drosha, AGO1,
and AGO2 were downregulated in ZIKV-infected neurons as compared to mock-infected neurons at
both 24 and 48 h (Figure 2C). mRNA expression of DGCR8 increased slightly at 24 h followed by a
decrease in the expression at 48 h.
3.4. Functional Analysis of ZIKV-Modulated miRNAs and Their Predicted Targets
Biofunctional analysis of ZIKV-modulated miRNAs and their targets revealed organismal injury
and abnormalities, immunological disease, inflammatory response, neurological disease, and nervous
system development and function as the top pathways in signaling pathways category (Table 5).
Since ZIKV infection is associated with a wide spectrum of neurological and immunological diseases,
these miRNAs may play an important role in the development of brain abnormalities following
ZIKV infection.
Table 5. Top biological functions regulated by significantly modulated miRNAs.
Biological Process/Pathway p-Value Number of miRNAs
Cancer 4.02 × 10−10 18
Organismal Injury and Abnormalities 4.02 × 10−10 23
Reproductive System Disease 4.02 × 10−10 18
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Table 5. Cont.
Biological Process/Pathway p-Value Number of miRNAs
Immunological Disease 6.98 × 10−10 13
Inflammatory Disease 6.98 × 10−10 13
Inflammatory Response 6.98 × 10−10 11
Neurological Disease 6.98 × 10−10 10
Connective Tissue Disorders 1.46 × 10−8 10
Respiratory Disease 1.46 × 10−8 7
Nervous System Development and Function 7.20 × 10−7 6
3.5. ZIKV Infection Induces Dramatic Upregulation of Anti-Viral, Inflammatory, and Apoptotic Genes
in Neurons
We next analyzed the mRNA expression of key anti-viral, inflammatory, and apoptotic genes
in the ZIKV-infected neurons to examine whether differentially expressed miRNAs could regulate
their target mRNAs. Mouse cortical neuron cultures were infected with ZIKV (PRVABC59 strain) or
PBS (Mock) at MOI-1 and cell lysates were harvested at 24 h and 48 h after infection. We utilized the
nCounter® Mouse PanCancer Immune Profiling Panel to count 770 immune-related genes. mRNA
expression profiles for ZIKV-infected neurons were compared with mock-infected neurons. Only
mRNAs that were altered at least 2-fold were considered significant. Figure 3A demonstrates total
numbers of up- and downregulated differentially expressed mRNAs in ZIKV-infected neurons at 24
and 48 h. The number of differentially expressed mRNAs was higher at 48 h after infection, which
correlates with significantly higher viral load observed at 48 h as compared to 24 h (Figure 1A). At 24 h,
65 mRNAs were upregulated with fold change values ranging from 2.0 to 26 (Table 6). mRNAs
were not downregulated at 24 h. At 48 h, 116 mRNAs were upregulated with fold change values
ranging from 2.0 to 244 (Tables 6 and 7) and 12 mRNAs were downregulated (Table 8). 62 upregulated
mRNAs were common in both 24 and 48 h- infected neurons (Table 6). MMP9, SOCS3 and IFI27 were
upregulated only at 24 h. 54 mRNAs were upregulated only at 48 h (Table 7).
 
Figure 3. ZIKV infection of the primary mouse neurons causes changes in cellular mRNA expression.
Neurons were infected with ZIKV (PRVABC59 strain) or PBS (Mock) at MOI-1. (A) Venn diagram
showing the number of differentially expressed mRNAs at 24 and 48 h after infection. Sets of
upregulated mRNAs are represented by upward red arrows and sets of downregulated mRNAs
are represented by downward green arrows. Pairs of arrows in the intersection refer to the number
of mRNAs upregulated (double red arrows) or down regulated (double green arrows) at both 24 and
48 h after infection. (B) qRT-PCR was conducted on RNA extracted from mock and ZIKV-infected
neurons to determine fold-change in IFIT1, IFIT3, IL6, and Caspase1 expression. Changes in the levels
of each mRNA were first normalized to the β-actin and then the fold-change in ZIKV-infected cells
was calculated in comparison to corresponding mock-infected cells. Data represents the mean ± SEM.
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Rsad2 26.44 244.24 Ccl2 3.91 14.32
Cxcl10 22.31 113.73 Ifna4 2.85 14.02
Ifit3 21.63 103.85 Nlrc5 3.42 13.39
Ifi44 18.36 103.12 Psmb10 3.13 12.78
Irf7 12.53 96.42 Stat2 5.55 12.37
Ifit1 24.52 75.06 H2-K1 2 12.34
Isg15 20.58 69.08 Cfb 2.04 12.04
Lcn2 27.07 68.88 Ifi35 4.05 11.3
Zbp1 13.57 55.1 Ddx58 3.84 10.56
Gbp5 12.51 44.43 Psmb9 2.4 10.03
Ifit2 2.53 41.91 Tap1 2.77 9.85
Ccl5 24.11 37.65 C3 3.29 9.22
Oas2 10.64 37.13 Casp1 2.76 7.63
Oasl1 5.15 34.55 Socs1 2.13 6.63
Usp18 9.7 32.04 H2-Ab1 2.21 5.82
Isg20 5.57 30.07 Cxcl1 3.49 5.5
H2-T23 3.61 28.33 Ifitm1 3.94 5.39
Ifih1 6.11 25.37 Ccl12 3.68 5.38
Ddx60 7.87 23.88 Pml 2 5.38
Stat1 6.92 21.99 Vcam1 2.23 5.24
Bst2 4.92 21.62 Myd88 2.38 4.87
Mx2 7.55 20.85 Cxcl9 2.83 4.7
Psmb8 4.31 20.39 Il6 2.07 3.63
Ccl7 2.71 19.98 Ptgs2 2.02 3.32
Cd274 4.02 19.34 Cxcl2 2.68 3.27
Cmpk2 4.01 18.95 Sbno2 3.05 2.86
Xaf1 8.02 18.06 Ccl4 2.52 2.84
Herc6 3.68 17.33 Lif 2.75 2.47
Ifnb1 2.97 16.75 Il13ra1 2.01 2.33
Tlr3 3.84 16.4 Runx1 2 2.15
Irgm2 6.29 15.13 Litaf 2 2.01
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Table 7. Upregulated mRNAs in ZIKV-infected neurons at 48 h only.
mRNA Fold-Change mRNA Fold-Change
Cxcl11 17.69 Slamf7 2.81
C2 9.88 Tnfrsf14 2.76
Tnfsf10 9.53 Fcgr4 2.6
Cxcl13 9.29 Mill2 2.59
Cd74 8.49 Ptprc 2.59
C1ra 7.96 H2-Dma 2.57
H2-D1 7.64 Nfkbia 2.52
H2-Aa 7.35 Tnfaip3 2.51
Tap2 6.53 Cxcl5 2.47
Ccl11 5.49 A2m 2.46
Fcgr1 5.32 Ifna1 2.38
H2-M3 5.25 Il3ra 2.36
Ccrl2 4.9 Ctss 2.34
Cd47 4.2 Ripk2 2.34
Tapbp 3.97 H2-DMb1 2.28
C4b 3.96 Lck 2.27
Ifna2 3.96 Cd80 2.26
Irf1 3.88 Cxcl16 2.19
Tlr2 3.87 Cybb 2.19
C1s1 3.56 Icosl 2.18
Lbp 3.44 Cfi 2.14
Il7 3.3 Irf2 2.1
Irf5 3.03 Nod1 2.02
Cd69 2.99 Atm 2
Serping1 2.91 Axl 2
Flt3l 2.87 H2-Eb1 2
Bid 2.85 Relb 2
Table 8. Downregulated mRNAs in ZIKV-infected neurons.
mRNA Fold-Change (48 h) mRNA Fold-Change (48 h)
Cd36 −2 Cd207 −2.19
Elane −2 Timd4 −2.22
Il17f −2 Xcl1 −2.31
Ticam2 −2 Card9 −2.65
Pax5 −2.02 Sh2d1b1 −2.76
Il1rapl2 −2.15 Mpped1 −2.87
Genes associated with virus sensing and type 1 IFN signaling were the most upregulated genes
after ZIKV infection. ZIKV infection also induced a strong upregulation of multiple cytokines and
chemokines in the neurons. Most of the chemokines and cytokines were significantly upregulated
after ZIKV infection, including CXCL10, CCL5, CCL7, CCL2, CXCL1, CCL12, CXCL9, CXCL2, CCL4,
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CXCL11, CXCL13, CCL11, CXCL5, IL6, IL7, PTGS2, and LIF. Several genes involved in cell death
(CASP1, TNFSF10, RIPK2, and BID) were also activated upon ZIKV infection (Tables 6 and 7). We also
validated the expression of selected upregulated mRNAs using qRT-PCR. Similar to the NanoString
data, IFIT1, IFIT3, IL6, and Caspase1 were significantly upregulated in the ZIKV-infected neurons as
compared to mock-infected neurons at both 24 and 48 h (Figure 3B). To examine that this increase in
mRNA expression also lead to increased protein levels, we measured protein levels of key chemokines
and cytokines in the cell culture supernatants using multiplex immunoassay. Similar to the mRNA
expression, protein levels of the key chemokines such as CCL2, CCL4, CCL5, CCL11, CXCL1, CXCL2,
CXCL9, and CXCL10, and cytokines such as IL6 and LIF were significantly increased in ZIKV-infected
neurons as compared to mock-infected neurons (Figure 4).
 
Figure 4. Enhanced production of cytokines and chemokines in ZIKV-infected neurons. Mouse cortical
neuron cultures were infected with ZIKV (PRVABC59 strain) or PBS (Mock) at MOI-1 and supernatants
were collected at 24 and 48 h after infection. Levels of chemokines and cytokines as noted in the figure
were measured in cell supernatants using multiplex immunoassay and are expressed as the mean
concentration (pg/mL) ± SEM. *p < 0.05, **p < 0.001.
3.6. Functional Analysis of ZIKV-Modulated mRNAs
To investigate the biological interactions of differentially expressed mRNAs and identify important
functional networks, significantly modulated mRNAs were imported into the IPA tool. The highest
activated networks (high z-score) were identified using IPA. Figure 5 depicts the top 10 activated
canonical pathways after ZIKV infection. The topmost activated canonical pathway after ZIKV
infection was ‘Neuroinflammation Signaling’. In addition, key players in inflammation and innate
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immunity, such as ‘Activation of IRFs by Cytosolic Pattern Recognition Receptors (PRR)’, ‘Role of PRR
in Recognition of Viruses and Bacteria’, and ‘IFN Signaling’ were also highly activated (positive z-score).
To further understand the role of these differentially activated canonical pathways, we generated the
network maps of ‘PRR in Recognition of Viruses and Bacteria’ and ‘IFN Signaling’.
 
Figure 5. Core functional pathway analysis of ZIKV-modulated mRNAs using IPA. Top canonical
signaling pathways regulated by significantly modulated mRNAs. Threshold bar indicates cut-off
point of significance p < 0.05, using Fisher’s exact test. Range of activation z-score is also depicted in
the figure. The color of the bars indicates predicted pathway activation based on z-score (orange =
activation; blue = inhibition; gray = no prediction can be made; white = z-score close to 0). Orange line
represents the ratio = number of genes in dataset/total number of genes that compose that pathway.
3.6.1. Pattern Recognition Receptors
Our data demonstrate that ZIKV infection induces the expression of all three major PRR;
retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLR), toll-like receptors (TLR), and the nucleotide
oligomerization domain (Nod)-like receptors (NLR) (Figure 6A). The RLR are a family of cytosolic
RNA helicase proteins comprised of three members: RIG-I, myeloma differentiation antigen 5 (MDA5),
and LGP2 [49]. Both RIG-I and MDA5 were upregulated after ZIKV infection. The importance of
the RLR signaling pathway in protection against flaviviruses has been validated by several studies
in vivo [49–51]. The TLR family is composed of more than 10 members, with each acting as a sensor of
conserved microbial component, that drive the induction of immune response [52]. Our data show that
ZIKV infection induces the expression of TLR2, TLR3, and adaptor molecule MYD88. NLR are soluble
or cytosolic receptors in the mammalian cell cytoplasm [53]. Activation of NOD1 and NLRC5 was
observed following ZIKV infection. In addition to RLR, TLR, and NLR; PKR and OAS are classes of
IFN-inducible PRR that can recognize dsRNA and restrict a number of viruses. Our data demonstrate
the activation of OAS after infection with ZIKV. Furthermore, we observed increased levels of type 1
interferons and several pro-inflammatory mediators after ZIKV infection in neurons, which correlate
with PRR activation in these cells.
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Figure 6. Pathway analysis for PRR and IFN signaling. Genes associated with (A) PRR and (B) IFN
signaling activated by ZIKV infection are shown. Differentially expressed mRNAs are highlighted in
color. Color intensity indicates the degree of upregulation (red) relative to the mock-infected neurons.
Solid lines represent direct interactions and dashed lines indirect interactions. Shading intensity
indicates the degree that each mRNA was upregulated.
3.6.2. IFN Signaling
ZIKV infection induced strong upregulation of genes associated with IFN signaling such as
IFNα, IFNβ, STAT1, and STAT2 (Figure 6B). Interferon-stimulated genes (ISG) such as MX2, IFIT1,
IFIT3, IFITM1, IFI35, and RSAD2 (Viperin) were significantly upregulated after ZIKV infection.
The IFN response is central to the innate defense mechanisms of the host against flavivirus infection.
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The paracrine and autocrine secretion of IFN creates an anti-viral state by inducing several genes
including ISG [49,54].
3.7. Network Analysis of Expression of miRNAs and mRNAs From ZIKV-Infected Neurons
We next sought to determine whether mRNA expression changes might be influenced by the
differential expression of cellular miRNAs during ZIKV infection. To analyze the direct and indirect
miRNA–mRNA interactions, we conducted IPA expression pairing analysis with mRNA expression
data and significantly modulated miRNAs. Several miRNAs were found to directly or indirectly
target multiple mRNAs analyzed in our study and demonstrated an inverse correlation with mRNA
expression induced by ZIKV. These targets are predicted by TargetScan. miR-124-3p was the highest
downregulated miRNA. Our data demonstrated increased expression of all the predicted targets of
miR-124-3p including IL7, CCL2, LITAF, IRF1, and SBNO2 in ZIKV-infected neurons (Figure 7A). Other
known targets of miR-124 includes SOCS5, TLR6, STAT3, TNF, and NF-kB [55]. Similarly, miR-654-3p
was downregulated and its predicted targets—CD69, FLT3LG, IFIT1, TLR2, ZBP1, LITAF—were
upregulated in ZIKV-infected neurons (Figure 7B). These targets involve genes belonging to anti-viral
and inflammatory response signaling pathways. Furthermore, downregulation of miR-331-5p and
miR-509-5p was inversely correlated to their predicted targets IL7, CD274, HLA-DRB5, XAF1, IL13RA1,
TAP1, and CD80 (Figure 7C,D). Our data further indicate that miR-335-3p may play an important role
in regulating inflammatory and apoptotic genes in the neurons following ZIKV infection. miR-335-3p
targets Caspase1, CCL5, CXCL3, PTPRC, and GBP5. These genes play significant roles in mediating
inflammation and cell death (Figure 7E). We also show an increase in the protein levels of the target
genes such as CCL2, CCL5, and CXCL10 (Figure 4). It is interesting to see the correlation between
ZIKV-modulated miRNAs and target genes at both mRNA and protein level, which is consistent with
the miRNA–mRNA–protein triad and demonstrate the functional importance of our results.
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Figure 7. Networks of the interactions of the miRNA target genes. IPA tool was used to
generate the miRNA-mRNA interaction network of (A) miR-124-3p, (B) miR-654-3p, (C) miR-331-5p,
(D) miR-509-5p, and (E) miR-335-3p and mRNAs significantly modulated in neurons after ZIKV
infection. Red (increased expression) and green (decreased expression).
4. Discussion
In this study, we used nCounter technology to identify miRNAs and mRNAs modulated by
ZIKV infection in neurons. Our data demonstrate that ZIKV infection causes global downregulation
of miRNAs with only few upregulated miRNAs. ZIKV infection also results in downregulation of
miRNA processing enzymes. Upregulated miRNAs including miR-155, miR-203, and miR-29a have
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been previously shown to play critical role in flavivirus infection and anti-viral immunity [22,56–60].
ZIKV infection in the neurons significantly induced the expression of anti-viral, inflammatory and
apoptotic genes. Biofunctional analysis revealed that ZIKV-modulated miRNAs and their target
genes regulate the pathways related to neurological development and neuroinflammatory responses.
Furthermore, our data show an inverse correlation between ZIKV-modulated miRNAs and target host
immune mRNAs induced by ZIKV infection.
Flaviviruses have been shown to induce downregulation in the expression of cellular miRNAs by
targeting miRNA processing enzymes [33,45–48,61]. It has been reported that depletion of Dicer and
Drosha by siRNA-mediated silencing results in increase in flavivirus replication [46,47,61]. We also
observed a trend towards decrease in miRNAs expression in ZIKA-infected cells. Similar to our
data, ZIKV infection in human astrocytes induces global downregulation of miRNAs [62]. It has
been demonstrated that ZIKV infection in Aedes aegypti mosquitoes downregulates expression of host
miRNAs [63]. In this study, we also show that ZIKV infection results in downregulation of miRNA
processing enzymes. Downregulation of genes involved in miRNA processing enzymes including
Dicer-1 was also reported in ZIKV-infected astrocytes [62]. Similarly, ZIKV infection in HepG2 cells led
to a decrease in DGCR8, Ago1, and Ago3 expression [64]. It is known that non-coding, subgenomic
RNA (sfRNA) of WNV and DENV can interfere with miRNA biogenesis pathway. WNV sfRNA is
processed by Dicer and suppresses RNAi [33,45–48,61]. Future experiments are warranted to elucidate
whether this sfRNA function holds for all flaviviruses including ZIKV. Since miRNAs negatively
regulate mRNA expression, decrease in cellular miRNA expression results in increase in apoptotic and
inflammatory genes associated with flavivirus infection [27,30,31,33,41]. Our data also demonstrate
that ZIKV infection is associated with dramatic upregulation of several anti-viral, apoptotic and
inflammatory genes.
We observed significant upregulation of miR-155, miR-203, miR-29a, and miR-29b in
ZIKV-infected neurons. These miRNAs have been shown to play an important role in viral
infection [19–21,65,66]. miR-155 is multifunctional and widely reported to modulate different
stages of innate immune response during inflammation and infection [21,22,56]. miR-155 not only
modulates TLR-mediated innate immune response, but also targets complement regulatory proteins
and facilitate complement activation [56,57]. This phenomenon is critical to eliminate the virus
from infected cells. Several published studies have demonstrated the essential role of miR-155 in
viral infections caused by Epstein–Barr, Borna disease, and reticuloendotheliosis viruses [19,20,56,65].
For example, overexpression of miR-155 significantly suppressed human HIV infection in activated
macrophages [21]. Similarly, miR-155 suppresses JEV replication in microglial cells and regulates
JEV-induced inflammatory response in mice brain [22,67]. Studies have shown that miR-203 is also
involved in regulating the anti-viral immune response [59,60]. It has been demonstrated that miR-29b
regulates JEV-induced neuroinflammation [58]. Since these miRNAs are known to have a role in
anti-viral immunity, upregulation of these miRNAs might play a role in controlling ZIKV infection
and associated neurotoxicity. A recent study identified upregulation of miR-30e-3p, miR-30e-5p, and
miR-17-5p in ZIKV infection of human astrocytes [62]. However, we did not observe upregulation of
these miRNAs in ZIKV-infected mouse neurons. This could be due to the difference in the neural cell
type and species studied.
In our study, miRNAs with the highest downregulation were miR-124-3p, miR-883a-5p and
miR-2137. miR-124 is the most abundant miRNA in the brain and affects a broad spectrum of
biological functions in the CNS [55,68–70]. miR-124 has been reported to participate in chronic
stress, neurodegeneration, alcohol/cocaine neuroadaptation, synapse morphology, neurotransmission,
long-term potentiation, neurodevelopment, myeloid cell function, and hematopoiesis. In mammalian
neurons, miR-124 suppresses the levels of many non-neural genes, which contributes to the acquisition
and maintenance of neuronal identity [69]. Furthermore, when miR-124 is aberrantly expressed,
it contributes to pathological conditions involving the CNS [68–70]. It has also been shown to be
useful as a diagnostic and prognostic indicator of CNS disorders, such as brain tumors and stroke [68].
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miR-883a has been demonstrated to be involved in inflammatory pathways, and target genes belonging
to the TLR signaling pathway as well as the VEGF and chemokine signaling pathways [71]. miR-2137
is involved in the pathogenesis of traumatic brain injury [72]. IPA analysis also revealed that individual
miRNA including miR-124a-3p, miR-654-3p, miR-331-5p, miR-335-3p, and miR-509-5p can modulate
multiple upstream regulatory genes. There was an inverse correlation between these miRNAs and
target host immune mRNAs induced by ZIKV infection. Since these miRNAs are known to have a
role in brain injury and inflammatory responses, downregulation of these miRNAs following ZIKV
infection possibly resulted in upregulation of neuroinflammatory and apoptotic genes. However,
further experiments are required to validate their biological functions in ZIKV infection.
This study has few limitations. First, we only analyzed the mRNA expression of genes primarily
involved in immune response, which introduce a bias in the analysis towards anti-viral response.
Second, additional experimental studies are warranted to validate the interplay between miRNA,
mRNA, and ZIKV replication, which includes knockdown of individual miRNA and its effect on the
expression levels of its target mRNAs and virus titers.
In conclusion, this is the first study to evaluate the modulation of miRNAs following ZIKV
infection in neurons. ZIKV-modulated miRNAs in neurons are also known to play a role in the
pathogenesis of other flaviviruses and anti-viral immune response. In this study, the utility of the
nCounter system enabling rapid miRNA and mRNA expression analysis was also demonstrated.
Collectively, these data suggest that miRNAs regulate downstream gene expression, important in ZIKV
disease pathogenesis, and can be targeted in the future to develop therapeutics for the management of
ZIKV neurological disease.
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Abstract: Arthropod-borne viruses (arboviruses) are resurging across the globe. Zika virus (ZIKV)
has caused significant concern in recent years because it can lead to congenital malformations in
babies and Guillain-Barré syndrome in adults. Unlike other arboviruses, ZIKV can be sexually
transmitted and may persist in the male reproductive tract. There is limited information regarding
the impact of ZIKV on male reproductive health and fertility. Understanding the mechanisms that
underlie persistent ZIKV infections in men is critical to developing effective vaccines and therapies.
Mouse and macaque models have begun to unravel the pathogenesis of ZIKV infection in the male
reproductive tract, with the testes and prostate gland implicated as potential reservoirs for persistent
ZIKV infection. Here, we summarize current knowledge regarding the pathogenesis of ZIKV in
the male reproductive tract, the development of animal models to study ZIKV infection at this site,
and prospects for vaccines and therapeutics against persistent ZIKV infection.
Keywords: flavivirus; arbovirus; Zika; sexual transmission; testis; prostate
1. Emergence of Zika Virus
Zika virus (ZIKV), a previously obscure and scientifically neglected virus, became a serious
public health concern in 2015 due to an association with microcephaly (refer to Glossary) in Brazil [1].
ZIKV is a positive-sense, nonsegmented, enveloped, single-stranded RNA virus that belongs to the
flavivirus genus within the Flaviviridae family [2,3]. The genus also includes other medically important
flaviviruses such as dengue, yellow fever, West Nile, and Japanese encephalitis viruses [2,4]. The virion
is spherical with an icosahedral symmetry and approximately 50 nm in diameter [2,3]. The C protein
comprises the viral capsid which is surrounded by a lipid bilayer derived from the host, and the M and
E proteins are anchored in the outer surface membrane. The 10.8 Kb ssRNA genome comprises a 5′
untranslated region (UTR), a single open reading frame, and a 3′ UTR. The open reading frame encodes
a single polyprotein which is cleaved into the structural (C, prM and E) and nonstructural (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5) proteins [2,3]. ZIKV is an arthropod-borne virus (arbovirus) that
is mainly transmitted to humans through the bite of mosquitoes [5,6], specifically Aedes aegypti and
Aedes albopictus species [4]. ZIKV was first isolated from sentinel monkeys in Uganda in 1947 [7],
and thereafter several ZIKV isolates were sampled from Aedes africanus mosquitoes [5]. Since the first
reported human cases in 1952 [8], ZIKV has been sporadically detected in equatorial Africa and Asia
over the next five decades [9,10]. Prior to 2007, only 14 human cases had ever been reported and ZIKV
had been regarded as an arbovirus with mild clinical symptoms and inconsequential sequelae [11,12]
that typically involved headache, fever, rash, conjunctivitis, arthralgia, and myalgia [2,11,13]. Fifty to
80% of infections remain asymptomatic [11,14,15]. Three genotypes of the virus have been identified:
East African, West African, and Asian [13].
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The first large outbreaks of ZIKV occurred in 2007 on the island of Yap in Micronesia, as the
virus moved from Asia to the Pacific. The Yap outbreak is estimated to have affected ~73% of Yap
residents older than three years of age [11,13]. The Yap outbreak was followed by a second large
outbreak, this time in French Polynesia, during 2013–2014 [16,17]. During the French Polynesian
outbreak, Guillain-Barré syndrome (GBS) was linked to ZIKV infection for the first time [18]. In May
2015, the World Health Organization (WHO) received the first reports of locally-transmitted ZIKV in
Brazil [19]. In February 2016, due to the rapid expansion of ZIKV and a suspected causal relationship
between the virus and microcephaly in Brazil, the WHO declared ZIKV a public health emergency
of international concern. The epidemics in the Pacific and the Americas have seen increased rates
of congenital neural abnormalities such as microcephaly, malformations of cortical development,
brain calcifications, and hearing and vision loss [1,17,20–22], with infection often resulting in fetal
demise during pregnancy [22,23]. Retrospective investigations of the 2013–2014 French Polynesian
outbreak have linked microcephaly in newborns to ZIKV [17]. In adults, infection may lead to
GBS [24,25], encephalitis [26], thrombocytopenia [27], and ocular and auditory disturbances [28].
To date, 84 countries have been affected, with almost one million cases, and at least 23 countries have
reported a surge in the incidence of GBS (WHO, 10 March 2017).
2. Sexual Transmission of ZIKV
Probable sexual transmission of ZIKV was first reported in 2011 when a scientist, who had
contracted the virus while working in Senegal in 2008, infected his wife after returning home [29]. This
was the first report of sexual transmission for any arbovirus to date. Since then, at least 14 countries
outside the endemic range of ZIKV have reported person-to-person transmission of the virus (Figure 1).
Both Asian and African genotypes of ZIKV have been reported to be sexually transmitted [29,30],
suggesting that this mode of transmission appeared early in the evolution of the virus and prior to the
divergence of genotypes [31]. Male-to-male [32], female-to-male [33], and male-to-female [29,30,34,35]
cases of sexual transmission have been documented, with the latter being the most common [36].
Sexual transmission from men with no obvious symptoms has also been reported [37,38], although
the prevalence is unclear since asymptomatic cases are inherently difficult to identify. Mathematical
models predict the contribution of sexual transmission to the spread of ZIKV to be 3–4.8% [39,40].
However, one recent study suggests the risk of sustained sexual transmission may be much higher [41].
Differences in the age- and sex-specific attack rates of ZIKV have been observed, with women of
childbearing age having the highest incidence of infection [36,42]. However, reporting bias may
partially account for this pattern, as more women than men may have sought diagnosis due to
increased fear of infection during pregnancy [39]. Although sexual transmission is unlikely to lead
to sustained cycles of infection in areas without mosquito vectors, it could increase the likelihood of
outbreaks occurring, and the size and duration of epidemics [39–41,43,44].
Figure 1. Countries outside of the endemic range of ZIKV that have reported cases of sexual transmission,
2011–2018 (shown in green).
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3. Persistent Shedding of ZIKV in Semen
ZIKV RNA has been detected in the semen of symptomatically [35,45–49] and
asymptomatically-infected [50,51] men, sometimes for many months post onset of infection.
Very high concentrations of ZIKV RNA can be found in semen during the clinically symptomatic phase
of the infection [30]. One study has shown that up to 73% of infected men have detectable ZIKV RNA
in their semen over the short term [48]. ZIKV has also been found attached to sperm [48,49,52,53],
in particular to the mid-piece of mature spermatozoa [53], suggesting this could be a route of infection
in addition to semen. The infectivity and longevity of ZIKV in semen varies [51]. The risk of sexual
transmission by men is particularly high in the first few weeks of infection [54], with the median time
between sexual contact and onset of symptoms in women estimated to be 9.5 days [43]. Persistent
viral replication and shedding of infectious virus could, however, prolong this risk. Viral RNA and
infectious virus have been detected in semen for up to 6 months [47] and 69 days [51,54] post-infection,
respectively. Most studies have reported the presence of viral RNA in semen rather than infectious
titers, possibly due to the difficulty of culturing viable virus from this fluid. How long infectious
ZIKV persists in semen is therefore unclear. Nonetheless, the longevity of infectious ZIKV in semen,
compared to vaginal fluids [55], indicates viral seeding and local replication occur in the genital organs
and cells of the male reproductive tract (MRT). Persistently infected males may therefore be acting
as potential reservoirs of ZIKV, which could account for some of the observed asymmetry in sexual
transmission [36,41].
4. The MRT and Immune Privilege
Persistent viral replication and shedding of infectious virus from organs of the male reproductive
tract (Figure 2A) could prolong the risk of sexual transmission [56]. Some regions of the MRT offer
an immune-privileged environment that may lead to lowered fertility if disrupted by infection.
Maintenance of immune privilege in the testis, the major organ where sperm are produced and
androgens synthesized, is essential for healthy spermatogenesis. Within the testis, developing sperm
are also protected from autoimmune attack by a physical blood-testis-barrier (BTB) formed by tight
junctions between adjacent Sertoli cells that prevent immunoglobulin entry into the lumen (Figure 2B).
An immune-privileged environment is also achieved through the suppression of normal immune
responses that could lead to inflammation [57–60]. During male adolescence and throughout adult
life, germ cells in the testes divide and differentiate to produce spermatogonia that are released into
the lumen of the seminiferous tubules (Figure 2B). Immature sperm then travel to the epididymis and
vas deferens where they mature and remain until ejaculation. Spermatozoa in the testes and regions
of the epididymis are isolated from the host adaptive immune system to prevent the development
of anti-sperm lymphocytes and, importantly, the production of anti-sperm antibodies (ASA). This
immunosuppressive environment is enabled by the sequestration of antigens in phagocytosing Sertoli
cells and testicular macrophages, downregulation of antigen presentation by macrophages and
dendritic cells in the draining lymphatics, and the tight barrier formation between adjacent Sertoli cells
preventing permeability of immunoglobulin [60]. Disruption of key cells involved in spermatogenesis,
such as Sertoli and Leydig cells (Figure 2B), through infection and loss of immune privilege, could
lead to autoimmune attack of spermatozoa and development of ASA, thereby lowering fertility.
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Figure 2. (A) Schematic representation of the male reproductive tract indicating potential ZIKV
reservoirs. (B) Cross section of a portion of the seminiferous tubule within the testis. The seminiferous
tubules contain the developing sperm cells and their supporting Sertoli cells. Sertoli cells form the
lumen of the seminiferous tubules for release and transport of spermatozoa into the epididymis.
Surrounding the seminiferous tubules are one or more continuous layers of peritubular myoid cells
that function in the expulsion of spermatozoa out of the tubules and into the epididymis. The basement
membranes of the seminiferous tubules are linked by tight junctions that, coupled with the myoid
cells, form the blood-testis barrier (BTB). The interstitial compartment located between the tubules
contains the Leydig cells, which are also essential for normal sperm development, maintenance of the
blood-testis barrier, immune privilege, and Sertoli-germ cell junction assembly and disassembly.
5. ZIKV in the Testis and Prostate Gland
Prostatitis, hematospermia, and microhematospermia have been reported in ZIKV-infected
men [29,34,61,62], as well as the presence of leukocytes in semen that is suggestive of inflammation
in the MRT [62]. ZIKV may be breaching the BTB, disrupting immune privilege in the testes and
replicating at these sites. ZIKV-infected human Sertoli cells show enhanced expression of cytokines
and cell-adhesion molecules, increasing the adhesion of leukocytes and permeability of the BTB [63].
Inflammatory mediators released by ZIKV-infected testicular macrophages could also compromise
the integrity of the BTB [63]. Low sperm counts have been observed in ZIKV-infected men [48,49,62],
indicating that infection in the testis may be affecting sperm production. The lack of a correlation
between the highest ZIKV loads in semen and serum [64] suggests that localized ZIKV replication
occurs in the testicles and/or seminal glands [49]. The receptors used by ZIKV to enter the different
cell types present in the MRT remain to be elucidated. However, the tyrosin kinase Axl is a major
candidate entry receptor for ZIKV [65–68] and is expressed throughout the MRT, including the testes
(particularly in Sertoli cells), the epididymis, and the prostate [69]. Axl is also an essential regulator
in spermatogenesis [69]. Imaging of ZIKV-infected semen samples found that the virus colocalized
to the Tyro3 receptor expressed at the mid-piece of mature spermatozoa, suggesting a role in ZIKV
binding and entry [53]. Interestingly, Tyro3 receptors serve as entry ligands for Ebola and Marburg
viruses [70], which have also been isolated from human semen and can be sexually transmitted [71].
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Other as yet unidentified cell surface receptors may exist that could account for the tropism and sexual
transmission of ZIKV.
The immunochemical detection of ZIKV inside the spermatozoa of a patient [49], as well as
virus detection, isolation, and sexual transmission in the absence of spermatozoa [38,72,73], indicate
that ZIKV could be present in semen as free virus particles or associated with cells. In the latter
case, ZIKV could be transmitted to sperm by infected Sertoli cells, or virus particles could adsorb or
penetrate spermatozoa during epididymal transit. The length of time required for sperm development
in the seminiferous tubule (~2 months), relative to sperm maturation in the epididymis (~2 weeks),
suggests most infectious virus could be acquired during the latter phase. However, additional studies
are needed to determine the exact fate of ZIKV virions in the MRT.
Virus may also be present in semen as a result of viral replication in the male accessory glands [71].
Sexual transmission of ZIKV from a vasectomized male to his female partner has recently been
reported [72]. The presence of ZIKV in the semen of vasectomized men [72,73] has strongly implicated
the prostate and seminal vesicles as potential reservoirs facilitating sexual transmission. Recently,
in vitro infection of human prostate stromal, epithelial cells, and organoids demonstrated that ZIKV,
but not dengue virus, actively infects and replicates in these cells, producing infectious virus in
significant quantities [74]. The prostate is a strong candidate organ for prolonged viral shedding
because it can host chronic infections with a variety of pathogens [56] and contributes a large proportion
of seminal fluid during ejaculation [75].
6. Mouse Models of ZIKV in the MRT
Mice have proved the most tractable model to investigate ZIKV in the MRT, with a plethora
of recent studies (Table 1) [31,52,76–90]. However, as ZIKV does not naturally replicate and cause
disease in wild-type mice, studies of ZIKV pathogenesis have primarily utilized immunodeficient mice
(Table 1). In such mouse models, the antiviral immune response is impaired, allowing replication and
dissemination of ZIKV into different organs and tissues. Mouse models of sexual transmission have
indicated the presence of infectious virus in 60–70% of ejaculates [31,79,84], and male-to-female
sexual transmission in 50% of all matings [84]. Additionally, sexual transmission resulted in
significantly greater morbidity and mortality and higher ZIKV titers in the female reproductive
tract than subcutaneous or intravaginal inoculation [91]. A study using vasectomized mice showed
that sexual transmission of ZIKV still occurred, despite semen containing significantly lower levels of
infectious virus [84]. Overall, studies of pathogenesis in the MRT of mice have detected ZIKV in the
testes [31,52,76–86,88–90] of all animals tested and the epididymis [31,52,76–78,80,84,86–89] of most
mice (Table 1). ZIKV was also detected in the seminal fluid inside the lumen of the vas deferens [80]
and the seminal vesicles [31,84,89] of some infected mice (Table 1). Although most studies did not
investigate prostate tissues, one team reported negative results for ZIKV in the prostate [77], whereas
two others did detect virus in this gland [88,89].
Androgen levels were altered in infected mice [79], concordant with ZIKV-induced reproductive
hormone changes reported in men [48]. Inhibin B [76] and testosterone levels [76–78] were significantly
decreased in mice, likely due to Leydig cell infection and apoptosis [76,78]. Furthermore, mouse
ZIKV infection typically results in disruption of the BTB [77,86], breakdown of the epithelium
and seminiferous tubules [76,77,79,86–88,90], inflammation and tissue injury to the epididymis and
testis [76,77,80,83,84,87,89], and testicular atrophy [31,76–78,81,82,87]. Cytokine production within the
testis, as well as infiltration of inflammatory cells, immune cells, and macrophages into this organ,
seminiferous and epididymal tubules were observed [76,77,84,86–88]. ZIKV infection in mouse models
also resulted in altered sperm morphology and motility, an absence of spermatozoa or reduction in
total sperm counts, and a measurable reduction in fertility [52,76–79,81,87].
Testicular cells contribute much of the infectious virus shed in the seminal fluid of mice [84],
however, mouse studies offer conflicting evidence regarding which exact cell types are targeted.
In agreement with reports that human primary Sertoli cells support persistent ZIKV replication for
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at least six weeks [63,68], some mouse studies report Sertoli cells to be the major targets for ZIKV
in testes [76,79,87,89,92]. Other studies report Leydig and myoid cells to be completely destroyed,
resulting in the reduction in testosterone production and testicular atrophy in mice [77,78]. Virions
attached to developing and mature sperm in the testes and epididymis, respectively, have been
observed by transmission electron microscopy [52]. Some mouse models suggest that ZIKV infected
cells are likely to be germinal spermatogonia or primary spermatocytes [76,77,83,84]. However,
the detection of virus in epididymal spermatozoa 7 days post-infection strongly suggests that ZIKV
directly infects spermatozoa in the epididymal lumen [76]. Sperm may therefore serve as a vehicle to
transmit ZIKV in addition to semen.
The observed difference in disease manifestation and severity between different mouse models
could, in part, be explained by the use of varying mouse strains and ages at infection [89], ZIKV
genotype, and virus dose and inoculation routes [76,85,86]. Although some of the key phenotypes
observed in humans are recapitulated in immunodeficient mice, there are inherent limitations to using
mouse models for the study of persistent ZIKV infection in the MRT. Compared to ZIKV-infected
men [48,49], the injury to the MRT observed in mice is much more severe, and spermatogenesis more
drastically affected [76,77]. Furthermore, the role of human immunity in ZIKV pathogenesis cannot be
fully captured in immunodeficient mouse models. Using nonlethal mouse models [80,89] that allow
for the long-term study of ZIKV infection kinetics and pathological progression, with an antibody
response similar to macaques [85], could offer a way forward.
7. Primate Models of ZIKV Pathogenesis in the MRT
Rhesus, cynomolgus, and pig-tailed macaques have been shown to be susceptible to a variety
of ZIKV strains [93–98] and have been used to study ZIKV tropism and test ZIKV vaccine
platforms [44,94,97–99]. Macaque models have been suggested as an alternative to mice because
they develop clinical symptoms, viremia, widespread tissue infection, and a robust adaptive immune
response comparable to human infection [93,95,98,100,101]. Clinical symptoms in infected macaques
are generally mild [93,98,102], with plasma viremia peaking 2 to 6 days after infection and resolving
within 10 to 14 days [93,95,97,102]. Infected rhesus macaques developed ZIKV-specific humoral
and cell-mediated immune responses [93–95,102], protecting them from re-challenge with either
homologous or heterologous ZIKV strains [97,102]. Both vector [93,95–97] and sexual [44] transmission
routes have been studied in macaques. Asymmetry in ZIKV infectivity between males and females has
also been observed in macaques [44]. Using in situ hybridization and quantitative reverse transcription
PCR (RT-PCR) analysis to detect viral RNA, ZIKV dissemination into many tissues has been observed
in macaques, including to the urogenital tract and shedding into mucosal secretions [94,95,98,100].
ZIKV persistence in the testes [95,100] and shedding of infectious virus in the semen [95] have been
demonstrated. Importantly, the high viral load present in the testes of macaques, long after the systemic
viral load has resolved [95,100], indicates that virus might be replicating at these anatomical sites.
Immunohistochemistry of infected testes has shown virus localizing to Sertoli cells [95]. In addition,
ZIKV has been detected in the seminal vesicles and prostate of rhesus and cynomolgus macaques for
up to 35 days post infection [95,98]. However, not all studies using rhesus macaques have been able to
detect ZIKV RNA in the testes [98], epididymis, and prostate [94]. Interestingly, pathogenesis studies
have also detected ZIKV RNA in the kidney, bladder and urine [95,98], suggesting that ZIKV may
also seed into semen from the urethra. The impact of ZIKV infection seems much less pronounced
in immunocompetent macaque models versus mice. Although none of these macaque studies report
the impact of ZIKV infection on testis structure and integrity and fertility, they clearly show that viral
shedding continues unabated in the MRT.
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8. Implications for the Development of Therapeutics and Vaccines
Reservoirs of persistent infection in the MRT could complicate the development of vaccines,
antivirals, and/or other therapeutics for ZIKV. Proposed interventions and vaccines [103] need to be
evaluated in their ability to clear persistent infection in the immune-privileged sites such as the male
gonad. Evidence from HIV suggests that the testes may represent a distinctive virus sanctuary site in
patients receiving suppressive antiviral therapy, with lingering virus detected in the testicles despite
the virus been cleared from the bloodstream [104]. In this regard, although the antiviral Ribavirin was
recently shown to suppress viremia in ZIKV-infected STAT1-deficient mice [105], it failed to suppress
viral load in the brain, another immune-privileged site. Several compounds have shown promise
as ZIKV prophylactic and therapeutic agents in vitro [66,68]. The antibiotic azithromycin has been
shown to reduce ZIKV proliferation and cytopathic effects in vitro in glial cell lines, human astrocytes,
and Sertoli cells [66,68]. Further studies are needed to investigate their effectiveness in vivo. Recently,
the basic fibroblast growth factor (FGF2) was shown to be significantly upregulated in ZIKV-infected
human Sertoli cells and to enhance viral replication and persistence [68]. Pre-treatment of Sertoli
cells with either a neutralizing antibody to FGF2 or a FGF receptor inhibitor significantly inhibited
ZIKV replication without affecting cell viability [68], thus indicating the therapeutic potential of FGF
receptor antagonists.
A successful vaccine must provoke a subclass of immunoglobulin (IgG) inside the seminiferous
tubules, as it has been proposed that only certain subclasses of IgG (i.e., IgG4) can cross the
BTB [53]. Antibody treatments have shown promise in providing protection against persistent
ZIKV infection. Human antibodies to the dengue virus E-dimer epitope (EDE1-B10), in addition
to their inhibitory effects against dengue virus, have shown therapeutic potential against ZIKV [106].
EDE1-B10 treatment administered 1 to 3 days post infection was able to reduce viral persistence in
the brain and testis, protect against ZIKV-induced inflammation, and damage to the seminiferous
tubules, and preserve sperm counts [106]. The treatment, however, failed when administered 5 days
after ZIKV infection. Polyclonal antibody treatment given 1 day prior to challenge [82], as well
as live-attenuated and DNA-based vaccines [81,87], have protected mice against testicular atrophy
and damage. In addition, DNA-based vaccines have been shown to induce sterilizing immunity
against ZIKV challenge [99,107,108]. A vaccinia-based single vector construct, multi-pathogen vaccine,
which encodes the structural polyprotein cassettes of both Zika and chikungunya (CHIKV) viruses,
has recently been developed [90]. A single vaccination of Ifnar1−/− mice induced neutralizing
antibodies to both viruses and protected mice from CHIKV and ZIKV infection and disease, including
testicular infection and pathology in males [90]. Vaccination resulted in complete clearance of ZIKV
RNA in the testes from challenged male Ifnar1−/− mice [90]. Initial murine studies have rapidly
translated to clinical trials and have demonstrated that humans also develop neutralizing antibodies
to the vaccine, which can provide passive immunity to mice during lethal ZIKV challenge [109].
Whilst a prophylactic ZIKV vaccine is achievable, the efficacy of current candidates as a therapeutic
vaccine for chronically infected males remains unknown. The limited amount of immunoglobulin and
lymphocytic infiltrate in the testes during infection may impede the success of current approaches.
9. Concluding Remarks and Future Prospects
Numerous questions regarding ZIKV infection in the MRT remain as yet unanswered (Box 1).
The long-term effects of persistent ZIKV infection on male reproductive function, as well as
on sperm production and fertility, including those exposed in utero, remain to be investigated.
Of note, cryptorchidia, hypospadias, and micropenis have been described in newborns from infected
mothers [110], but their prevalence is unknown. Although questions regarding pathogenesis can be
answered using functional studies in animals, any effect of ZIKV infection on male fertility will only be
detected with long-term epidemiological studies. Asymptomatic, persistent ZIKV replication in men
and cryptic sexual transmission remain a risk to conception, given the large number of ZIKV infections
that are silent. ZIKV-infected reproductive tissue (e.g., infected sperm) could pose a threat to patients
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seeking fertility services. Prospective studies of infected men are starting to reveal how long travelers
from ZIKV-endemic areas should wait before trying to conceive naturally, donate gametes, or proceed
with fertility treatments. Such data will aid in formulating appropriate public health guidelines to
mitigate the risk of ZIKV infection through sexual transmission.
Box 1. Key questions remaining to be answered regarding ZIKV in the MRT.
• What are the cellular and molecular mechanisms of ZIKV persistence in the MRT?
• What is the origin of ZIKV in semen?
• What is the ZIKV entry receptor in the MRT?
• Which cells in the MRT are primarily infected following ZIKV attachment and entry?
• What are the viral and host characteristics that influence the infectivity and longevity of ZIKV in semen?
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Glossary
Arthralgia Non-inflammatory joint pain.
Blood-testis-barrier
Physical barrier between blood vessels and the Sertoli cells of the seminiferous tubules in the
mammalian testes.
Conjunctivitis Inflammation of the outer layer of the eye and inside of the eyelid that causes the eye to turn pink.
Cryptorchidia Condition in which one or both of the testes fail to descend from the abdomen into the scrotum.
Encephalitis Inflammation of the brain.
Epididymis Highly convoluted duct behind the testis, along which sperm passes to the vas deferens.
Guillain-Barré
syndrome (GBS)
Autoimmune disease where antibodies and lymphocytes attack and damage the peripheral nerves
causing weakness/paralysis and/or abnormal sensations and pain.
Hematospermia Blood in the semen.
Hypospadias




Interferon alpha, beta and gamma receptor deficient mice on a 129 background.
Ifnar1−/− mice Interferon alpha and beta receptor deficient mice.
Immune-privileged site
Sites that are able to tolerate the introduction of antigens without eliciting an inflammatory
immune response. Immune-privileged sites include the central nervous system, the brain, the eye,
and regions of the male reproductive tract.
Irf3−/− × Irf7−/− mice Interferon 3 and 7 double knockout mice.
Leydig cells
Testosterone-producing cells located in the connective tissue surrounding the seminiferous tubules
in the testicle.
Male accessory glands In humans, these are the seminal vesicles, prostate gland, and the bulbourethral glands.
Microcephaly
Medical condition in which the brain does not develop properly resulting in a smaller than normal
head.
Microhematospermia
Hematospermia not evident by macroscopic examinations of the semen, but detected by tests for
occult blood.
Micropenis An unusually small penis.
Myalgia Pain in a muscle or group of muscles.
Organoids Three-dimensional cell cultures that incorporate some of the key features of the represented organ.
Prostatitis Inflammation of the prostate gland.
Rag1−/− mice Recombination activating gene 1 (Rag1) deficient mice.
Seminal glands
Accessory glands of the MRT, located between the bladder and the rectum that contribute
approximately 60–70% of the ejaculate.
Seminiferous tubules The site of the germination, maturation, and transportation of the sperm cells within the male testis.
Sertoli cells
Somatic cells of the testis that are part of a seminiferous tubule and facilitate the nourishment and
progression of germ cells to spermatozoa.
Spermatocytes Diploid cells formed through the process of spermatogenesis.
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Spermatogenesis The origin and development of the sperm cells within the male reproductive organs.
Spermatogonia
Undifferentiated male germ cell, formed in the wall of a seminiferous tubule and giving rise by
mitosis to spermatocytes.
Spermatozoa The mature motile male sex cell.
Testicular atrophy Medical condition in which the testes diminish in size and may be accompanied by loss of function.
Testicular macrophages
Antigen-presenting cells, the most prevalent cell type in the testicular interstitium. They are in
close morphological association and functional interaction with Leydig cells.
The male reproductive
tract (MRT)
The male gonads, associated ducts and glands, and external genitalia that function
during procreation.
Thrombocytopenia
Condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the
blood. This causes bleeding into the tissues, bruising, and slow blood clotting after injury.
Vas deferens Tiny muscular tube in the MRT that carries sperm from the epididymis to the ejaculatory duct.
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Abstract: Despite flaviviruses remaining the leading cause of systemic human infections worldwide,
ocular manifestations of these mosquito-transmitted viruses are considered relatively uncommon
in part due to under-reporting. However, recent outbreaks of Zika virus (ZIKV) implicated in
causing multiple ocular abnormalities, such as conjunctivitis, retinal hemorrhages, chorioretinal
atrophy, posterior uveitis, optic neuritis, and maculopathies, has rejuvenated a significant interest
in understanding the pathogenesis of flaviviruses, including ZIKV, in the eye. In this review, first,
we summarize the current knowledge of the major flaviviruses (Dengue, West Nile, Yellow Fever, and
Japanese Encephalitis) reported to cause ocular manifestations in humans with emphasis on recent
ZIKV outbreaks. Second, being an immune privilege organ, the eye is protected from systemic
infections by the presence of blood-retinal barriers (BRB). Hence, we discuss how flaviviruses
modulate retinal innate response and breach the protective BRB to cause ocular or retinal pathology.
Finally, we describe recently identified infection signatures of ZIKV and discuss whether these system
biology-predicted genes or signaling pathways (e.g., cellular metabolism) could contribute to the
pathogenesis of ocular manifestations and assist in the development of ocular antiviral therapies
against ZIKV and other flaviviruses.
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1. Introduction
Flaviviruses consist of more than 90 RNA-enveloped viruses out of which 30 can cause severe
disease in humans and animals. Most members of the family are arthropod-borne and are transmitted
to the host by mosquitos or ticks [1]. The genus flavivirus contains several members which continue to be
of global concern such as mosquito-borne Dengue virus (DENV 1–4), West Nile Virus (WNV), Japanese
Encephalitis virus (JEV), Yellow fever virus (YFV), Zika virus (ZIKV), Murray Valley Encephalitis
Virus (MVEV), Kyasanur Forest Disease virus (KFDV), St. Louis Encephalitis Virus (SLEV) (Fenner’s
Veterinary Virology, 5th ed, 2017) along with Tick-borne Encephalitis Virus (TBEV). Interestingly,
despite sharing a similar genomic organization and replication mechanisms, phylogenetically closely
related flaviviruses can induce a spectrum of diseases. Broadly, the genus flavivirus is known to cause
hemorrhage and vascular leakage (e.g., DENV and YFV), encephalitis (e.g., WNV and JEV) and, more
recently, known to cause microcephaly and Guillain-Barre syndrome (ZIKV) [2,3].
Apart from causing systemic infections, these pathogens have been documented to cause multiple
ocular complications (Figure 1) with the most common being conjunctivitis, uveitis, and diseases in
the posterior segment of the eye (e.g., choroiditis, chorioretinal atrophy, retinitis) [4] (Table 1).
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Figure 1. Eye anatomy and ocular complications caused by flaviviruses. Various components of the
human eye are labelled in black. The flaviviruses responsible for causing ocular manifestations are
shown in green whereas specific ocular tissue pathology is highlighted in red.
Table 1. Comparison of the major ocular findings among the different flaviviruses.
Ocular Complication ZIKV DENV JEV WNV YFV KFDV
Conjunctivitis/keratitis + + − − − +
Macular mottling + + − − − −
Chorioretinal atrophy
+
focal pigmentary clumping + − − − +
Optic nerve abnormalities + + − + + −
Cataract Hypoplasia, cupping, pallor − − − − −
Microphthalmia + − − − − −
Iris coloboma + − − − − −
Uveitis + + − + − +
Chorioretinitis + + − − − +
Retinal hemorrhage + + + − − +
ZIKV—Zika virus; DENV—Dengue virus; JEV—Japanese Encephalitis virus; WNV—West Nile virus; YFV—Yellow
Fever virus; KDFV—Kyasanur Forest Disease virus.
In the following sections, we provide an overview of ocular complications resulting from flavivirus
infections in humans worldwide and elaborate on their main features, systemic complications, and
ocular involvement. These viruses have evolved specific mechanisms to counteract the antiviral
response from the host and exploit various metabolic pathways to cause disease. Moreover, we discuss
probable interactions of viruses and their encoded proteins with ocular cells and the BRB to infect the
eye and cause ophthalmic anomalies.
Molecular Pathogenesis of Flaviviruses
Flaviviruses are a family of lipid-enveloped viruses with a single-stranded ~10.5 kb positive-sense
RNA genome. They encode only ten proteins which exploit host machinery to complete their infectious
replication cycles. Most viral proteins have been shown to associate with host cellular functions and
metabolic pathways but their biological consequence in most of these communications are not yet
clearly understood [2]. The virus is introduced into the host by an infected vector (e.g., mosquito)
during its blood meal. Flaviruses enter cells by receptor-mediated endocytosis [2], where they bind with
host endosomes in an acidic environment triggering conformational modifications to their envelope (E)
glycoprotein. Conformational changes lead to fusion of the host and viral membrane, facilitating the
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release of the viral genomic RNA. The polypeptide is co- and post-translationally processed by host
signalases and virus encoded serine proteases to translate into the ten viral proteins: three structural
proteins (Envelope (E), Capsid (C), Pre-Membrane (PrM)) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5) [1].
The non-structural proteins are involved in viral genome replication, budding, and deploying
the host cell machinery. Following translation, the RNA-dependent RNA polymerase (RdRp), NS5,
creates a negative-strand from genomic RNA, which then becomes a template for a new positive strand
to be made. In the rough Endoplasmic Reticulum (ER), viral proteins begin to assemble, and viral
RNA is packaged with structural proteins—C, E, and prM. Viral particles are then transported to the
trans-Golgi network, where prM is cleaved into M, and the mature virus is then released from the host
via exocytosis into the extracellular space (Figure 2).
 
Figure 2. Flavivirus replication cycle and genome structure. (A) The flavivirus enters the host cell
by attaching to specific receptors (1) which then leads to its endocytosis (2) followed by fusion to a
lysosome into an acidic environment (3). The genome is released from the endolysosome (4) which
is then translated on the Endoplasmic reticulum membrane (5) and post translational processing is
done in the Golgi apparatus (6). The mature virus then buds off from the Golgi network (7) to the
extracellular space via exocytosis (8, 9). (B) The genome consists of three structural proteins (Envelope
(E), Capsid (C) and pre-membrane (prM)) and seven non-structural proteins (NS1, NS2A, NS2B, NS3,
NS4A, NSB, and NS5).
2. Flaviviruses and Ocular Complications
Despite the plethora of studies on host–virus interactions to understand their pathogenesis
in humans, studies of flaviviruses and their role in ocular diseases are limited. Our knowledge
is incomplete regarding properties which confer an ocular tropism to particular flaviviruses and
underlying molecular mechanisms which allow the breach of blood-retinal barrier (BRB) for ocular
exposure. To appropriately control and treat diseases presenting with ocular complications, a more
rigorous understanding of ocular symptoms is needed that can range from maculopathy to retinal
hemorrhage and vision loss (Table 2).
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Table 2. Flaviviruses known to cause ocular disease in humans and their symptoms.
Virus General Symptoms Ocular Disease in Humans References
West Nile Virus
headache, photophobia, back pain, confusion,
fever, encephalitis, meningoencephalitis, acute
flaccid paralysis—poliomyelitis-like,
Guillain–Barré syndrome
chorioretinitis, anterior uveitis, retinal





fever, chills, malaise, headache, lower back
pain, generalized myalgia, nausea, and
dizziness, vomiting, epigastric pain,
prostration, and dehydration, petechiae,
ecchymoses, epistaxis (bleeding of the gums),
and the characteristic “black vomit”
(gastrointestinal bleeding)
loss of vision, optic neuritis [9–11]
Japanese
Encephalitis Virus
Fever, headache, vomiting, fits, encephalitis,
and coma




Frontal headache, fever, hemorrhagic
pneumonitis, hepatomegaly and
parenchymatic degeneration, nephrosis,
characteristic reticulo-endothelial cells in
spleen and liver along with leucopenia,
thrombocytopenia, reduced red blood cells,
bradycardia, meningoencephalitis,
hemorrhagic fever manifestations, coma,
mental disturbance, giddiness, stiff neck,
abnormality of reflexes
hemorrhages in the conjunctiva, vitreous




Fever, retro-orbital pain, myalgia,
thrombocytopenia, severe abdominal pain,
persistent vomiting, bleeding gums,
restlessness
maculopathy, blurred vision, scotoma, floaters,
subconjunctival hemorrhage, uveitis, vitritis,
retinal hemorrhaging, retinal venular widening,
higher retinal vascular dimension, retinal
vascular sheathing, RPE mottling, tortuous
vessels, acute macular neuroretinopathy,
intraretinal macular, retinal edema, cotton wool
spots, Roth’s spot, retinal detachment,
retinochoroiditis, neuroretinitis, choroidal
effusions, choroidal neovascularization, optic
disc swelling and optic disc neuropathy,
oculomotor nerve palsy, and panophthalmitis
[25–35]
Zika Virus
fever, rash, headache, joint pain, conjunctivitis,
muscle pain, and may result in Guillain-Barre
syndrome, microcephaly, hearing loss, seizures,
impaired joint movement, facial deformities
gross macular pigment mottling, foveal reflex
loss, and macular neuroretinal atrophy,
chorioretinal atrophy, optic neuritis, retinal
hemorrhaging, retinal mottling, iris coloboma,
lens subluxation, gross macular pigment
mottling, optic nerve hyperplasia, macular
chorioretinal atrophy, anterior uveitis, and
non-purulent conjunctivitis
[36–43]
2.1. Yellow Fever Virus (YFV)
Yellow fever (YF) has been a major threat to human health from the 18th to 20th century with
repeated epidemics in North America, Europe, and the Caribbean. Described as “the original viral
hemorrhagic fever (VHF),” severe YF is pan-systemic viral sepsis with viremia, fever, prostration,
hepatic, renal and myocardial injury, hemorrhage, shock and lethality up to 20–50% [44]. There is
an abrupt onset of severe symptoms after 3 to 6 days of fever. Patients may experience fever, chills,
malaise, headache, lower back pain, generalized myalgia, nausea, and dizziness, often manifesting
Faget’s sign (increasing temperature with decreasing pulse rate). Infections in humans range from
unapparent abortive infection to a fatal, fulminating disease with high fever, vomiting, epigastric
pain, prostration, and dehydration. Hepatic-induced coagulopathy produces severe hemorrhagic
manifestations including petechiae, ecchymosis, epistaxis (bleeding of the gums), and the characteristic
“black vomit” (hematemesis; gastrointestinal hemorrhage) [10]. The infection rate of YFV has rapidly
declined due to the successful development of two attenuated vaccines during the 1930–1940s [9].
Currently, YFV is majorly persevered in jungle environments with sporadic human outbreaks in South
America and sub-Saharan Africa. The present risk of emergence and transmission of the disease is
being primarily controlled by wide coverage of vulnerable populations with vaccinations [45,46].
Among reported studies in virus-induced ocular complications, there is only a single case study
on a 21-year old woman traveler to Africa who suffered from irreversible loss of vision along with optic
neuritis and encephalitis upon receiving vaccinations for yellow fever, hepatitis A, and B. The causal
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factor among the multiple vaccines could not be resolved during the investigation [11]. To our
knowledge, there have been no further reports of eye infections, and therefore, the involvement
of YFV in causing ocular complications is still not clear.
2.2. Japanese Encephalitis Virus (JEV)
JEV is the causal agent for Japanese Encephalitis, which can lead to severe neurological
damage [47] and is known to cause 30,000 to 50,000 cases each year in the Pacific and Asia. Symptoms
depend on the affected part of the nervous system and include early symptoms, such as non-specific
febrile illness, diarrhea and rigor, followed by reduced levels of consciousness, seizures, headache,
photophobia, and vomiting [13]. Late symptoms could include poliomyelitis-like flaccid paralysis [12]
and parkinsonian syndrome. Patients exhibit the classic description of Japanese encephalitis-dull, flat,
mask-like face with wide, unblinking eyes, tremor, generalized hypertonia, cogwheel rigidity, and
other complications in locomotion [13]. The frequency of seizures increase with the severity of the
disease [14]. In fatal cases of JEV, pathological changes are polymorphic and diffuse, involving different
parts of the nervous system where the brain shows a severe degree of congestion in vasculature,
microglial proliferation, and gliomesenchymal nodules formation, cystic necrosis in focal or confluent
areas, cerebral edema, and trans-compartmental shift which can also lead to acute coma [15,16].
There has been a drastic reduction in the occurrence of JEV induced encephalitis cases since the use
of a live attenuated vaccine (LAV) for humans [48]. There has been only a single case study published
on a 53-year old woman infected with JEV leading to blurred vision with retinal hemorrhage and a
clinical presentation of ocular fundus [17]. In vitro studies on JEV have shown that virus infection
leads to the production of a macrophage-derived neutrophil chemotactic factor, which alters the
blood-retinal barrier and thereby might have been a cause for the observed retinal hemorrhage [17,18].
2.3. Kyasanur Forest Disease Virus (KFDV)
KFDV was first reported in 1957 from Kyasanur forest in Karnataka, India and is prevalent in South
Asia. It is transmitted to humans and animals by the bite of infected ticks (Haemophysalis spinigera) [49].
It causes biphasic illness composed of acute and convalescent phase [50]. Chief pathological
features include hemorrhagic pneumonitis, hepatomegaly and parenchymatic degeneration, nephrosis,
characteristic reticuloendothelial cells in spleen and liver [19] along with leucopenia, thrombocytopenia,
reduced red blood cells and elevated levels of liver enzymes [20]. The second non-viremic phase
may include bradycardia, meningoencephalitis, hemorrhagic fever manifestations, conjunctival
inflammation, coma and neurological complications such as mental disturbance, light-headedness, stiff
neck, abnormality of reflexes, confusion, and tremors [19,21]. KFDV has been classified as a risk group
4 pathogens and NIAID (National Institute of Allergy and Infectious Diseases) Category C priority
pathogen due to its extreme pathogenicity and lack of US FDA approved vaccines and drugs [21].
There are around 400–500 cases reported annually during the past five decades, and the
ophthalmic presentation of KFDV includes hemorrhages in the conjunctiva, vitreous humor, and retina,
mild iritis, the opacity of lens and keratitis [20,22–24]. KFDV has only been reported from India,
and there have been no further studies to understand the ocular anomalies and the reason behind the
complications. Currently, there are no experimental models to study its pathogenesis.
2.4. West Nile Virus (WNV)
Smithburn et al. first isolated WNV, a neuro-invasive flavivirus, from the West Nile
district of Uganda in 1937 [51]. The disease has gained recent global attention due to its
reported multiple outbreaks in Africa, Asia, Europe, and the United States. The incubation
period for the infection in humans range from 3 to 14 days along with three different systemic
disease presentations: asymptomatic, fever and meningoencephalitis. Severe, potentially lethal,
involvement of neurological complications (encephalitis, meningoencephalitis, acute flaccid
paralysis—poliomyelitis-like, Guillain–Barré syndrome and optic neuritis) had been limited to 1%
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in the past, but with time, WNV has increased its severity. WNV meningoencephalitis may be
characterized by a headache, photophobia, back pain, confusion, and fever.
The ocular involvement following WNV infection was first reported during 2002–2003 with
chorioretinitis, anterior uveitis, retinal vasculitis, optic neuritis, and congenital chorioretinal scarring [6].
Around 80% of the WNV infected patients with neurological complications suffered from multifocal
chorioretinitis without any ocular symptoms or vaguely reduced vision. The multifocal pattern has
been regarded as an early diagnostic marker for WNV infection with meningoencephalitis. Currently,
there are no vaccines or antivirals against WNV infection. Clinical cases usually recover within a week
and upon administration of steroids [52].
A prospective case study in India revealed that 70% of positive cases with WNV infection reported
additional ocular complications apart from what was initially reported. The fundus examination
revealed discrete superficial white retinitis, arteritis, phlebitis, and retinal hemorrhages with or without
a macular star [5]. Moreover, areas of retinal inflammation with unclear borders, vascular and optic
disc leakage, vessel wall staining, or capillary non-perfusion were also observed. One of the patients
with diabetes exhibited choroidal inflammation.
Other various ocular complications reported in the past are iridocyclitis in the absence of
chorioretinitis, retinitis, retinal hemorrhages, focal or diffuse vascular sheathing, vascular leakage,
macular edema, occlusive vasculitis, and segmental wedge-shaped zones of atrophy and mottling
of the retinal pigment epithelium [53–56]. WNV-associated optic nerve involvement may occur,
including optic neuritis, neuroretinitis, optic disc swelling. WNV infection has been rarely associated
with Opsoclonus-myoclonus syndrome (OMS), also known as the dancing eye syndrome in patients
with rapid, involuntary, multifactorial, conjugated fast eye movements persisting during sleep [7,8].
The exact mechanisms related to optic neuropathy related to WNV are still unknown.
2.5. Dengue Virus (DENV)
DENV has been involved in causing epidemics throughout the tropics and subtropics since the
1950s, with over one-third of the world’s population living at risk of infection. The transmission of
DENV occurs between humans and Aedes mosquitoes, with incubation periods between 3 to 10 days
and symptoms lasting from 3 to 7 days [57–59]. There are four serotypes of DENV reported, DENV-1,
DENV-2, DENV-3, and DENV-4 [60], that can cause dengue fever (DF) as well as severe forms of
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
The symptoms during dengue fever usually include high fever, severe headache, retro-orbital
pain, arthralgia, myalgia, nausea, vomiting, and rash. A severe form of dengue may be lethal to
individuals with symptoms including bleeding gums, restlessness, fatigue, blood in vomit, and
thrombocytopenia [25]. Severe forms of DENV infection mostly occur due to antibody-dependent
enhancement (ADE), where pre-existing antibodies from a primary infection bind to an infecting DENV
particle during secondary infection with a different DENV serotype [61]. While only 5% develop severe,
life-threating infections, most dengue infections are asymptomatic. Recently, DENV NS1 protein has
also been shown to be responsible for causing vascular leakage in both in vitro and in vivo models
and is being used as a marker to detect DENV infection in DHF patients [62–64]. The viral NS1 protein
is secreted from the cells and stays in the blood circulation of patients even after the fever and viral
nucleic acid subside. At the time when severe dengue hemorrhage begins, NS1 protein levels correlate
well with the degree of thrombocytopenia [65].
Traditionally, ocular pathology in dengue fever was thought to be uncommon; however,
its involvement of ocular complications is now being recognized increasingly as it leads to permanent
visual impairment in certain cases. Clinical studies have not seen any disease correlation with age, sex
or ethnicity as risk factors [26]. Factors which have been postulated in the pathogenesis of dengue
ocular diseases include viral virulence, serotypes, mutations, host susceptibility and geographic factor.
Dengue eye disease can be unilateral or bilateral and the onset of ocular symptoms range from 2 to
5 days after the onset of fever and most ocular symptoms have been noted within one day after the
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peak of thrombocytopenia [27]. One study reported that 10% of 160 DENV seropositive hospitalized
patients had maculopathy [26]. The main ocular complaints are eye pain, retro-ocular pain, blurring
of vision, diplopia, foreign body sensation, photopsia, floaters, and metamorphopsia. In addition
to this, other ocular symptoms include blurred vision floaters, subconjunctival hemorrhage, uveitis,
and vitritis etc. (Table 2) [26–35]. Significant predictors of ocular symptoms included leukopenia and
hypoalbuminemia, which could predispose patients to an opportunistic infection of ocular tissues and
hyper permeability [66].
Dengue maculopathy is well recognized and studied more than other ocular manifestations, and
it has been seen to be serotype and geography-related. There have been very few studies to understand
the mechanism behind dengue-induced ocular implications which limit our understanding of the
disease pathology. There is only one study relating maculopathy to be serotype specific with DENV-1
epidemic causing 10% incidence while there were no cases during DENV-2 epidemic [67]. Macular
edema and macular hemorrhage were common findings in symptomatic patients with maculopathy.
While cellular and molecular mechanisms to understand systemic dengue has been extensively
studied, there has been no studies of DENV in vitro as well as in vivo to understand the disease
pathology, risk factors of eye disease and preventive measures. The serious threat to vision is dengue
retinopathy, including retinal vasculopathy and macular edema. The mechanism of retinopathy is
not clearly understood, but observations in patients implicate the involvement of retinal pigment
epithelium (RPE) and endothelial cells. Smith et al. 2017 have recently shown that retinal epithelial
and endothelial cells are susceptible to DENV infection with cytopathic effects in epithelial cells.
The infection decreased the epithelial barrier integrity while the endothelial junctions were intact
which correlated with the clinically observed loss of RPE in DENV infected patients [68].
Research on DENV vaccine has been a challenging path because there are four known serotypes
and the associated complications of partial immunity leading to increase disease severity due to ADE.
Live attenuated vaccines based on recombinant attenuated DENV serotypes (NIH) or recombinant
yellow fever virus (Sanofi) or DENV-2 (Takeda) constructs expressing prM and Envelope genes from
four serotypes, are currently in phase 3 or 4 clinical trials. The leading candidate, Dengvaxia, developed
by Sanofi Pasteur, has been approved for use in individuals above the age of 9 years in Brazil, Mexico
and the Philippines [69–71].
2.6. Zika Virus (ZIKV)
Zika virus was first isolated from a rhesus macaque from the Zika forest in Uganda, 1947 [72],
with its first human detection in 1952 [72,73]. ZIKV then spread throughout parts of Africa and Asia,
and in 2007 a ZIKV epidemic on Yap Island in Micronesia had 49 confirmed cases [74]. Over the last
2 years, it has raised a global alarm as it infected people in more than 70 countries causing severe
deformities in newborns and neurological diseases in adults [75]. Apart from being transmitted by
the vector (mosquitoes), ZIKV is capable of vertical transmission in humans during pregnancy or
delivery, through sexual contact, or through contaminated blood transfusions. The incubation period
for ZIKV ranges from 3 to 14 days while the symptoms last from 3 to 7 days. The risk of transmission
of infection is escalated because 80% of infected adults remain asymptomatic. The usually visible signs
of infection are mild and include fever, rash, headache, joint pain, conjunctivitis, muscle pain, and may
result in Guillain-Barre syndrome. Congenitally contracted ZIKV causes birth defects in newborns
such as microcephaly, impaired brain development, hearing loss, seizures, impaired joint movement,
facial deformities, and vision problems [76].
In the eyes of adults, ZIKV presents most commonly as non-purulent conjunctivitis; however,
more serious findings, such as the disruption of the RPE and iridocyclitis, have been reported in healthy
and immunocompromised patients [42,77,78]. The first report on Congenital Zika Syndrome (CZS) had
originated from Brazil describing ophthalmologic findings in three children with microcephaly caused
by presumed ZIKV infection. There has been a steep increase in reported cases in the pathology of
ocular complication in CZS, thereafter. Children present with gross macular pigment mottling, foveal
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reflex loss, macular neuroretinal atrophy, and fundoscopic alterations in the macular regions [79].
There have also been reports of chorioretinal atrophy, optic neuritis, retinal hemorrhaging, retinal
mottling, iris coloboma, lens subluxation, gross macular pigment mottling, optic nerve hyperplasia,
macular chorioretinal atrophy in other reported CZS cases [36–40]. Retinal abnormalities were also
reported without microcephaly indicating the capability of ZIKV to cause ocular complications by
direct infection [37]. The first study to reveal the ocular histopathologic findings of ocular tissue
samples from deceased CZS fetuses by Fernandez et al., 2017 revealed pupillary membranes, immature
anterior chamber angles, loss of pigment and thinning of the retinal pigment epithelium, choroidal
thinning, undifferentiated nuclear layers of the retina, and a perivascular inflammatory infiltrate
within the choroid. The viral antigen could be detected in iris, neural retina, choroid and the optic
nerve [80].
Currently, the long-term effects of these infections are unknown, but a report in an
immunocompromised patient indicates that lesions can be persistent [77]. ZIKV has been isolated
from conjunctival swabs of infected patients which indicates its ability to infect the peri-ocular tissues
and transmit through ocular secretions [81]. To date, there are thirteen open clinical trials at different
phases, testing various concepts of ZIKV ranging from DNA vaccines, mRNA vaccines, Purified
Inactivated Virus (PIV) vaccines and viral-vector-based vaccines [82,83].
3. Experimental Models of Ocular ZIKV Complications
To alleviate the disease burden associated with ocular viral infections, it is necessary to focus
today’s research on disease control and therapeutic strategies. An animal model for a disease would
prove to be a valuable tool to shed light on the pathophysiology of infection and facilitate the
assessment of therapeutics and vaccines in the offing.
3.1. In Vivo Models
There have been several animal models used to mimic the ZIKV infection. The wild-type C57BL/6,
BALB/c, and CD-1 mice are resistant to flavivirus infections [84–86]. Most of the studies used
immunocompromised mice, both type I and type II interferon knockout mice (AG129), for efficient
infection and viral replication to mimic human symptoms [86–91]. The first model of ocular
complication during ZIKV infection in mice was described by Miner et al., where subcutaneous
injection of the virus in IFNAR−/− mice caused panuveitis and shedding of viral RNA in tears,
but there was complete absence of live virus in ocular tissues and retina, as seen in humans [88].
There were no histological abnormalities evident in the eyes of congenitally infected IFNAR+/− fetuses
from C57BL/6 IFNAR1−/− dams [88]. Direct inoculation of the virus in the organ/tissue of interest
has been another approach used by various groups [92,93]. Singh et al. have developed a new model
of ocular ZIKV infection to mimic human disease conditions by injecting the ZIKV intravitreally in the
eyes of immunocompetent C57BL/6 mice or ISG15 knockout mice [94]. This model could show the
observed pathological findings of retinal pigment epithelium atrophy and pigment clumping/mottling
in humans. Another successful mouse model showed ocular infections mimicking humans upon
subcutaneous injection of ZIKV in 1 day old pups (p1) [75]. The model showed presence of virus in
the ocular tissues till 30 days pi while the inflammation subsided by 60 dpi. Therefore, these models
could be used to study ocular complications in ZIKV as well as other viral infections to understand the
viral pathogenesis in the ocular tissue.
In mouse models, ZIKV has been shown to infect multiple ocular cell types and that ZIKV
inoculated mice developed conjunctivitis, pan-uveitis, infection of the cornea, iris, optic nerve, retina,
as well as the detection of viral RNA in tears [88,94]. These studies exhibit the ability of ZIKV to infect
previously unexplored cell types of the eye, and the need for research investigating these relationships
is of paramount importance. The studies indicate the spread of the virus via two modes: hematogenic
or axonal which is also supported by Fernandez et al. [80]. The virus could reach the fetal circulation
from the placenta and infect the RPE, retinal endothelial cells, and the retina [94]. The other possible
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pathway would be through axonal transport into the eye along the optic nerve [95,96], leading to
ganglion cell layer (GCL) loss, foveal maldevelopment, and central chorioretinal abnormalities [97].
How ZIKV and other flaviviruses enter the eye in vivo remains to be determined.
3.2. In Vitro Models
Since wild-type mice are not susceptible to ZIKV, most in vitro studies have used primary human
cells or established cell lines. For example, Singh et al. have recently reported that retinal cell types
lining the BRB are susceptible to ZIKV infection and cause cell death by activating Caspase 3 [94]. Zhao
et al. and Aleman et al. have independently shown the Muller glia cells to be the primary target of
ZIKV infection leading to decreased neurotropic functions and increased pro-inflammatory cytokines
post infection with the help of murine models [96,98]. ZIKV infection in RPE was shown to disrupt
its cell to cell adhesion and barrier properties [99]. Similarly, ZIKV was found to infect human fetal
retinal pigment epithelial cells (FRPE), iPSC-derived retinal stem cells (iRSCs), and retinal cup (RC)
organoids [100]. The underlying mechanisms and detailed sketch of the breach of BRB to cause the
ocular pathology has not been addressed till now. Currently, the field of ZIKV research has been
undecided on the role of the protein tyrosine kinase TAM receptors—TYRO3, AXL, and MER—in
ZIKV entry into cells. The TAM receptors have been shown to be upregulated in the retinal epithelial
and endothelial primary cells during ZIKV infection but their roles are still under debate [94].
4. Interaction with Blood-Retinal Barrier (BRB)
The BRB forms as an extension of the blood-brain barrier (BBB), which aids in the separation of
the internal environment of the eye from the systemic vascular system. The BRB has two modules:
an inner barrier, formed by retinal endothelial cells, and an outer barrier, formed by the RPE layer
along with Bruch’s membrane and choriocapillaries [94]. The outer BRB shields the neuroretina from
blood-borne pathogens including viruses. Therefore, disruption of the RPE could create a route of
entry for virus present in fenestrated choroidal capillaries to enter the tissues of the eye. The BRB is
limited internally by tight junctions between the endothelial cells underlining the retinal capillaries
whereas the outer barrier is formed of tight junctions between the cells of RPE, separating the choroid
system from the sensory retina [101].
The development and maintenance of the BRB is needed for healthy vision and the loss of the
BRB leads to the pathology of a variety of retinal diseases. A balance of the vascular endothelial and
epithelial mechanisms of the BRB supports the specialized neural retina environment. The vascular
endothelium and the pigment epithelium layer of the retina possess a highly developed complex of
inter cellular junction complexes including the adherens and tight junctions [102,103]. These junctions
impart a high degree of barrier permeability to the solute and fluid across the retina. An understanding
of BRB regulation during viral infection will allow the development of therapies aimed at restoring the
compromised barrier or manipulating the barrier for specific transport of therapies.
ZIKV is permissive to all cell types comprising the different layers of the eye except the
photoreceptor cells and causes similar pathological findings as in human patients with chorioretinal
atrophy, pigment mottling/clumping [94]. There are two models proposed for the infection and entry
of ZIKV into the eye: (a) cell death caused by ZIKV infection in the outer BRB might form the portal of
entry of the virus into the eye and infect the inner layers, thereby causing inflammation and vision loss
in severe infected cases [94]; (b) ZIKV could possibly enter via the retinal arteries (inner BRB) which
leads to infection of the retinal endothelial cells and pericytes and the virus enters the outer BRB via
the choroid capillaries [104].
4.1. Modulation of Retinal Innate and Adaptive Immunity
RPE cells are multi-functional and help in transport of nutrients and waste from the retina across
the choroid and impart adhesive properties to the retina (Bok, 1995, 1993). It forms the first line of
defense against pathogens in the retina and has a role in innate as well as adaptive immunity [105].
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These cells have been identified as an ideal target for infectious agents such as Cytomegalovirus,
Toxoplasma gondii, Coronavirus, Zika virus [94,105]. They produce a variety of cytokines (IL6, IL8,
MCP-1), chemokines, growth factors, and act as Antigen Presenting Cells (APC) in the retina upon a
pathogen assault [106–108]. Few immune cells reside within the ocular tissues [41,109]. Upon infection,
the peripheral immune cells can gain access to the eye leading to local inflammation [110]. Despite
the upsurge of interest in the RPE cell and its critical role in retinal health and disease, the exact
mechanisms of how the RPE cells participate in the regulation of the blood-retinal barrier remain
largely unknown. The retina also contains specialized myeloid cells (microglia), similar to brain
microglia and the central and peripheral rims of the retina contain a small population of DCIR+ MHC
Class IIhi DCs, as does the corneal periphery [111]. In addition to neurons, retina contains glial cells
(microglia and Muller glia) and astrocytes which not only provide structural support but play an
important role in evoking retinal innate responses to injury or infectious stimuli. How these retinal
residential glial cells regulate innate immunity is an active area of investigation in our laboratory.
Similarly, cells lining the BRB, also contribute to retinal immune response to microbial infections.
ZIKV infection of RPE, Muller glia and the retinal endothelial cells leads to an increase in the
markers of innate immune response along with interferon and interferon stimulated gene response in
a time dependent manner and causes chorioretinal atrophy, RPE mottling and cell death in in vitro
as well as in vivo models [75,94,112]. ZIKV induces the expression of AXL in all the retinal cell types
except the photoreceptor cells and the TAM receptor seems to be the dominant receptor used for the
infection of the retinal cell types. ZIKV infection leads to an increase in innate immune response with
an increase in TLR3 expression along with an increase in the expression of other viral recognition
receptors—MDA5, RIG-I. There is an increase in ocular pathology due to the inflammation caused
by significant production of RANTES and an increase in the expression of inflammatory genes TNFA,
IL1B, CXCL10, CCL5 leading to ocular inflammation [94,104]. The infection also leads to elevated levels
of granzyme B, perforin, IFN and IFN stimulated genes—OAS2, ISG15, and MX1 [75,94].
Recently, Manangeeswaran et al., 2018 reported that subcutaneous infection can also lead to
symptomatic posterior uveitis that could replicate the infection in the patients by employing wild-type
B6 mouse model [75]. The model demonstrated the preferential infection of cornea and retina causing
chorioretinal lesions upon ZIKV infection. The infection elicits an inflammatory response characterized
by increased local chemokine expression, infiltration of neutrophils, APCs, natural killer cells and
CD4 and CD8 cells in the later stage. The infection subsides by 30 dpi while the cytotoxic T cells
remained in the eyes along with the expression of several chemokines. The study also showed that
the cornea and retina had higher levels of chemokines associated with the infiltration of CD45+ cells
along with biomarkers for APCs (CD86, B2m, H2-EB1) and T-cell infiltration (CD3, CD4, GITR, CD40L,
Fas-L) causing increased cytotoxicity in the infected tissues. This new model of study could prove
to be very helpful in dissecting the mechanism of the breach of BRB during ZIKV infection and the
various alterations occurring in the ocular tissues as it mimics vector bite followed by infection and
inflammation in the eye similar to symptoms in human.
During ZIKV infection, ISG15 acts as a key player in confining viral replication in the retina/eye
mostly by positive loop regulation of interferon signaling. The backfire of the antiviral immunity in the
infected host leads to a huge amount of tissue inflammation and tissue damage leading to vision loss
and further complications which has also been evident during the fetus development [113]. Another
parallel study on primary Muller glia cells demonstrated their high susceptibility to ZIKV infection
and induce a robust inflammatory response. They activate several intracellular pathways, including
ERK, p38MAPK, NF-kB, STAT3 and ER stress, thereby influencing the differential expression of growth
and inflammatory factors. The p38MAPK has been shown to be strongly controlling the expression
of inflammatory pathways and has been proven to be highly potent during many viral infections,
including ZIKV [112].
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4.2. Modulation of Cellular Metabolism
As viruses are non-living entities and do not possess their individual metabolism, they alter
host cellular metabolic pathways for their optimal replication. The flaviviruses are known to subvert
cholesterol homeostasis using multiple mechanisms to transform lipid droplets into their replication
complexes with host membranes. To identify unique molecular signature of ZIKV infection in RPE,
Singh et al., performed meta-analysis of ZIKV infected RPE cells and other related flaviviruses, DENV,
JEV, WNV [114]. This led to the identification of a 43 genes signature referred to as core signature genes
which are dysregulated upon ZIKV infection and not by the other flaviviruses tested. The validation of
some of the identified genes in the signature revealed that ZIKV modulated (upregulation) their
expression at relatively higher levels than DENV. Interestingly, the pathway analysis revealed
that ZIKV alters cellular metabolism involving SH3/SH2 adaptor activity, lipid metabolism and
ceramide metabolism. The SH2B3 gene may help in evading the immune system by attenuating
the inflammatory response and the infiltration of innate immune cells to the site of infection [114].
The reduction in ALDH5A1 enzyme activity would lead to an increase in the endogenous levels of GHB
(gamma-Hydroxybutyric acid) and GABA (gamma-aminobutyric acid) levels, leading to neurological
manifestations of ZIKV infection such as microcephaly and Guillain-Barre Syndrome in adults.
ZIKV capsid protein has been recently shown to hijack host lipid metabolism for efficient viral
replication and interact with nucleolar proteins to facilitate replication [115]. Among the highly altered
genes, ABCG1 and ABCA1, membrane transporters involved in cholesterol efflux and innate immune
response, are among the top candidates. Moreover, inhibition of ABCG1 resulted in reduced ZIKV
replication in RPE cells [114]. As host cell lipids and cholesterol play an essential role in various
stages of viral replication, including entry, uncoating, genome replication, assembly, and release,
it is important to understand the molecules exploited by the virus and exploit the drug targets for
therapeutic purposes. Recently studied global interactomics revealed the hijack of lipid metabolism
machinery by the ZIKV Capsid protein and the interaction of NS2A and other ZIKV proteins with
peroxisome-associated polypeptides that govern the lipid trafficking and innate immune regulation in
host cells for the efficient replication of the virus [115]. The lipid metabolism machinery is centrally
controlled by AMPK (5’ AMP activated protein kinase), one of the master regulators of various cellular
metabolic pathways. AMPK has a prominent role during bacterial endophthalmitis with its activation
by pharmacological drugs leading to a significant decrease in bacterial load in the infected eyes [116].
AMPK is known to be altered during flavivirus infection and has pro- as well as antiviral activity upon
activation for different viruses [117]. Its role in ZIKV infection and ocular pathology has not been
studied till now. Studies are ongoing in our laboratory to understand its role in viral replication and
the breach of BRB by altering the intercellular junction machinery [118,119].
5. Conclusions
Ocular complications caused by flaviviruses and other viruses will have long-term economic,
psychological and health implications. Therefore, a deeper understanding of the host–virus interaction
and the viral pathogenesis in the eye will help in the discovery or re-purposing of therapeutic drugs to
protect against viral-borne ocular abnormalities. As there are no known effective antiviral treatments
or vaccines against emerging flaviviruses, infected patients can only be provided with palliative care
upon diagnosis. The incidence of flavivirus infections can be reduced with supervised vector control
and prevention of bites with vectors. A therapeutic approach to decrease viral load combined with
a regulation of immune cascade response in the eye could save patients from detrimental ocular
consequences in the future. Investigations in both immune-deficient and immune-competent mouse
models of ZIKV infection may help to identify key host-pathogen factors and devise novel therapies
to restrain the systemic and local inflammatory responses associated with ZIKV infection in the eye.
The severity of ocular complications due to viral infections presents additional stress and challenges
to communities that have already been devastated by the loss of life, community, and infrastructure.
Flavivirus infections are seen increasingly in the endemic and non-endemic regions as the result of an
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increase in international travel, and therefore, ophthalmologists should have the requisite knowledge
to diagnose and manage such patients and keep a track of the patient’s history for exposure to viral
infections for early diagnosis of viral-related ocular complications.
6. Future Directions
Viral infection epidemics pose significant challenges for healthcare and the world economy.
Flavivirus infections causing ocular diseases will have significant long-term economic, psychological
and health implications. Vision-related complications may be an underreported effect of flavivirus
infection which has been a reason of global concern for many years. ZIKV infection and other related
ocular complications in the recent epidemic in Brazil emphasizes the urgency to understand the virus
pathogenesis in the eye and develop strategies to prevent potential vision loss due to viral infections.
Viral infections may linger in immune privilege tissue/organs such as the central nervous system or
the eye. The recent description of a patient recovering from Ebola, where the blood and urine tests
were negative but ocular inflammation including anterior uveitis and vitritis continued, calls attention
to the long-term effects of ocular infections and understand the role they might play in the replication
cycle [120]. The precise pathogenesis of the ocular complications, development of specific antiviral
therapy and vaccinations against these threatening flaviviruses are fields that require further research.
There could be various possible theories to explain the factors involved in the breach of the
blood-retinal barrier and the transmission of the Zika virus to the eye. In this section, we are trying to
hypothesize some of the probable ones to understand the ZIKV disease model and the increase in the
severity of the disease caused and their transmission route to the ocular tissues (Figure 3).
Figure 3. Probable mechanisms for the breach of blood-retinal barriers by ZIKV. Upon infection and
peak viremia, there is an increased circulation of Zika virus, ZIKV NS1 protein, and immune cells in
the blood (1). The virus in the retinal blood capillaries infect the endothelial lining (2) and the immune
cells reach the site of infection/inflammation by diapedesis through the capillaries (3). It is followed by
infection of RPE, the cell lining the outer BRB, resulting in chorioretinal atrophy. The viral infections
might cause a BRB weakening by decreasing intercellular junction integrity. Being a neurotrophic virus,
at later stages ZIKV can infect retinal Muller glia or neurons inside of the eye (4). The complications
are worsened with the involvement of immune cells which get activated upon infection and release a
“cytokine storm” as an antiviral response which damages the host cells by altering the barrier integrity
(5). The virus along with the circulating immune cells can cross the inner BRB (retinal blood vessels) and
infect neuronal cells such as ganglion cells (6, 7). The Image has been created with BioRender software.
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6.1. Possible Involvement of ADE
Since the transmission system of flaviviruses overlap, there is a high probability that many
patients who have ZIKV infection have also had a previous exposure to at least one of the DENV
serotypes. Likewise, many patients now exposed to ZIKV are highly likely to be exposed to at least
one of the DENV serotypes in the future. There have been reports of an increase in the severity of
ZIKV infection in individuals who have been infected with DENV in the recent past via a mechanism
similar to ADE [121–123]. Therefore, pre-existing immunity against one flavivirus can affect clinical
outcomes and diagnosis of the disease produced by infection with a heterologous flavivirus.
6.2. Possible Role of Secreted ZIKV NS1 Protein
Secreted DENV NS1 protein, a marker for DENV infection in patients, has been shown to be
a causal factor for severe dengue and hemorrhage in cell culture and in vivo studies [63,64,124].
Zika virus, being a closely related member of the same family, may also share similar antigenic roles
for secreted NS1 protein and may be a potential candidate in causing retinal hemorrhage and ocular
complications by being a possible mediator in breaching the blood-retinal barrier.
6.3. Involvement of Immune Response and Cytokine Storm
The ocular complications are usually the outcome of a robust immune response from the host
following an infection. During DENV infection, hemorrhage caused in tissues is mostly due to
the cytokine storm from invading immune cells into tissues, thereby increasing severity of the
disease [125–127]. The invading immune cells in the eye could also be exacerbating the severity
of the complications and damaging the retina and blood vessels due to their response to control the
infection. The inflammation and infiltrating cells may play a key role in clearing the virus but may
also contribute to the development of lesions. Understanding the role of the immune response in
the generation and persistence of the retinal lesions may enlighten the helpfulness of using immune
suppressors, such as corticoids, during the later stages in the disease.
6.4. Involvement of the Altered Host Machinery
Flaviviruses employ the host lipid metabolism machinery for its replication which makes it
a potent target for therapeutic purpose [2,128,129]. Flaviviruses have been shown to impair the
intercellular junction integrity via different cellular intermediates and cause a breach in the barrier
via tight junction and adherens junction protein alteration and degradation. Little research has
been conducted to understand the pathogenesis of ZIKV and how it breaches the blood-retinal
barrier to cause ocular complications. Our recent study using a transcriptomic approach on retinal
epithelial cells, a major component of the outer blood-retinal barrier, indicates the involvement of
cholesterol metabolism in viral replication [114]. Targeting host cellular metabolism could alleviate
ocular complications due to ZIKV infection.
Therefore, a deeper understanding of the ocular pathogenesis of viral diseases and their interaction
with the various cell types involved in the blood-retinal barrier can etch a path towards the invention or
re-purposing of therapeutic drugs to prevent vision loss in infected patients. The ocular complications
during viral infections have been under-reported mostly due to the late or ignored investigation by
ophthalmologists. Ophthalmologists have a crucial role to help in decreasing ocular complications by
being aware of changing symptoms during flavivirus infections and having a complete patient history
of their previous exposure to viral infections to rule out secondary infection complications.
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Glossary
Chorioretinitis Inflammation of the choroid and retina of the eye. It is a form of posterior uveitis
Keratitis Inflammation of the cornea
Iritis Inflammation of the iris
Chorioretinal
atrophy
A condition of the eye where both the choroid and retina are damaged. This causes them
to wither away and stop working
Maculopathy
Any pathological condition of the macula, an area at the center of the retina that is
associated with highly sensitive, accurate vision
Conjunctivitis Inflammation of the conjunctiva of the eye
Uveitis Inflammation of the uvea
Vitritis Inflammation of the vitreous body
Optic neuritis
Inflammation that damages the optic nerve, a bundle of nerve fibers that transmits visual
information from your eye to the brain
RPE Retinal pigment epithelium cells
ADE Antibody-Dependent enhancement
Scotoma A partial loss of vision or a blind spot in an otherwise normal visual field
cotton wool spots
Fluffy white patches on the retina. They are caused by damage to nerve fibers and are a
result of accumulations of axoplasmic material within the nerve fiber layer
Roth’s spot Retinal hemorrhages with white or pale centers
Panophthalmitis Inflammation of all coats of the eye including intraocular structures
iris coloboma A hole in the iris
BRB Blood-retinal barrier
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Abstract: The recent emergence of Zika virus (ZIKV) in Brazil was associated with an increased
number of fetal brain infections that resulted in a spectrum of congenital neurological complications
known as congenital Zika syndrome (CZS). Herein, we generated de novo from sequence data an
early Asian lineage ZIKV isolate (ZIKV-MY; Malaysia, 1966) not associated with microcephaly
and compared the in vitro replication kinetics and fetal brain infection in interferon α/β receptor
1 knockout (IFNAR1−/−) dams of this isolate and of a Brazilian isolate (ZIKV-Natal; Natal, 2015)
unequivocally associated with microcephaly. The replication efficiencies of ZIKV-MY and ZIKV-Natal
in A549 and Vero cells were similar, while ZIKV-MY replicated more efficiently in wild-type (WT) and
IFNAR−/− mouse embryonic fibroblasts. Viremias in IFNAR1−/− dams were similar after infection
with ZIKV-MY or ZIKV-Natal, and importantly, infection of fetal brains was also not significantly
different. Thus, fetal brain infection does not appear to be a unique feature of Brazilian ZIKV isolates.
Keywords: Zika virus; pregnancy; fetal infection; congenital Zika syndrome; Asian lineage
1. Introduction
Zika virus (ZIKV) belongs to the genus Flavivirus of the Flaviviridae family [1], which includes
yellow fever virus, dengue virus, West Nile virus, Japanese encephalitis virus, and tick-borne
encephalitis virus. First isolated in Uganda in 1947, ZIKV has since spread across continents,
emerging as a medically significant pathogen associated with Guillain–Barré syndrome in adults
and, following infection of pregnant women, with a spectrum of congenital neurological complications
known as congenital Zika syndrome (CZS) that manifests in the newborns [2]. ZIKV is an enveloped
virus with a single-stranded positive-strand RNA genome of approximately 11 kb in length. Like all
flaviviruses, the ZIKV genome encodes a single open reading frame translated into a single polyprotein
that is cleaved post-translationally by cellular and viral proteases into three structural proteins, i.e.,
capsid (C), precursor membrane (prM), envelope (E), and seven non-structural (NS) proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5) [3].
Phylogenetically, ZIKV strains are categorized into either African or Asian lineages [4], with most
epidemic-associated ZIKV strains belonging to the Asian lineage [4–8]. Several epidemiological
and bioinformatics studies investigating the etiology of ZIKV emergence in the Americas have
independently suggested that amino acid changes within the Asian lineage viruses were likely to have
contributed to enhanced infectivity and pathogenicity, which resulted in the unprecedented increase in
Viruses 2018, 10, 541; doi:10.3390/v10100541 www.mdpi.com/journal/viruses278
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CZS that was primarily associated with the Brazilian outbreak [8–12]. The ability to infect a developing
fetus and cause CZS, including microcephaly [13,14], is the most distressing feature of ZIKV. In the 2015
Brazilian outbreak, microcephaly in newborns was reported to be 20 times higher than the background
incidence [15], with a retrospective analysis of the 2013 outbreak in French Polynesia also showing an
increased risk of microcephaly associated with ZIKV infection [16].
A central question associated with the ZIKV epidemic in Brazil (and in French Polynesia) is whether
the virus strains involved had acquired mutations that enhanced their ability to cause CZS [17,18].
Several studies have supported this notion [19,20], whereas others have argued that all ZIKV strains may
be similarly neurotropic [21,22].
We previously generated the contemporary Asian lineage isolate ZIKV-Natal from sequence
data obtained directly from the brain tissue of an aborted ZIKV-infected human fetus during
the 2015 Brazilian outbreak [14,23]. Using a pregnant IFNAR1−/− mouse model, we previously
demonstrated that the Brazilian isolate (ZIKV-Natal) was capable of causing fetal infection and
congenital malformations [23,24]. Herein, we sought to determine whether fetal infection is a
newly acquired characteristic of Asian lineage strains of ZIKV by comparing ZIKV-Natal to the
P6-740 Malaysian 1966 ZIKV isolate (ZIKV-MY). ZIKV-MY was chosen because it represents the
earliest documented Asian lineage ZIKV strain, with no reported association with human congenital
disease [25]. We show that ZIKV-MY and ZIKV-Natal produced similar viremias in pregnant interferon
α/β receptor 1 knockout (IFNAR1−/−) dams and were both capable of causing fetal brain infections.
2. Materials and Methods
2.1. Generation of ZIKV-MY and Chimeric Virus Using Circular Polymerase Extension Reaction (CPER)
The ZIKV-MY (strain P6-740) isolate whose sequence was used in this study was reported to
be passaged six times in suckling mouse brains, once in baby hamster kidney (BHK) cells, once in
C6/36 cells, twice in Vero cells, and five times in Vero E6 cells (GenBank accession number KX694533).
Six dsDNA fragments covering the entire viral sequence (Figure 1a) were purchased from Integrated
DNA Technologies (Baulkham Hills, NSW, Australia) as gBlocks, and each cloned into a pUC19
vector to produce six plasmids. The plasmids were sequenced to confirm the correct viral sequence.
The fragments used for CPER (see Figure 1a) were then amplified from individual pUC19 plasmids
using corresponding pairs of primers (Table 1). CPER assembly and recovery of WT ZIKV-MY virus
by transfection into Vero cells were performed as previously described [23]. The WT ZIKV-Natal virus
was generated previously [23]. The ZIKV-Natal/MY-prME chimeric virus was generated using CPER
by replacing the ZIKV-Natal fragments 1 and part of fragment 2 encompassing E gene (Figure 1a)
with those of ZIKV-MY. Chimeric primers (Table 1) were used for polymerase chain reaction (PCR)
amplification of amplicons to generate chimeric virus.
Table 1. Primers used for generation of cDNA amplicons of parental P6-740 Malaysian 1966 Zika virus
isolate (ZIKV-MY) and ZIKV-Natal (Brazilian isolate)/MY chimeric virus.
WT ZIKV-MY Primers Primer Sequence (5′ to 3′)
Fragment 1 Forward AGTTGTTGATCTGTGTGAATCAGAC
Fragment 1 Reverse GTGAACGCCGCGGTACATAAGGAGTATG
Fragment 2 Forward CATACTCCTTATGTACCGCGGCGTTCAC
Fragment 2 Reverse GATGAAAGAGACCAGCAACGCGGG
Fragment 3 Forward CCCGCGTTGCTGGTCTCTTTCATC
Fragment 3 Reverse CAGCAGCGACAACCCTGGTTGGAG
Fragment 4 Forward CTCCAACCAGGGTTGTCGCTGCTG
Fragment 4 Reverse GTACATGTAGTGCGCCACGAGCAGAATG
Fragment 5 Forward CATTCTGCTCGTGGCGCACTACATGTAC
Fragment 5 Reverse CTCCTGGTGTGCGGCTCATTTCTTC
Fragment 6 Forward GAAGAAATGAGCCGCACACCAGGAG
Fragment 6 Reverse AGACCCATGGATTTCCCCACACCG
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Table 1. Cont.
WT ZIKV-MY Primers Primer Sequence (5′ to 3′)
Chimeric primers Primer sequence (5′ to 3′)
Natal 5′C (MY1966) R CTCCCACGTCTGGTGACCTCCACTGCCATAGCTGTGGTCAGCAG
MY1966prM_F GTGGAGGTCACCAGACGTG
MY1966E_R AGCAGAGACGGCTGTAGATAGG
Natal NS1-junc2 (MY1966) F CTTCCTATCTACAGCCGTCTCTGCTGATGTGGGGTGCTCGGTG
2.2. Growth Kinetics
Vero (CCL-81), A549 (ATCC CCL-185), wild-type mouse embryonic fibroblasts (MEFs),
and IFNAR−/− MEFs (44) were infected with passage 1 of C6/36-derived stock of ZIKV-MY,
ZIKV-Natal, or ZIKV-Natal/MY-prME viruses at the indicated multiplicity of infection (MOI),
and 200 μL of culture supernatant was collected from each sample well at the indicated times
post-infection. Three independent experiments were conducted for each cell line. Viral titers were
determined by standard plaque assay on Vero cells, as previously described [23].
2.3. Mice and ZIKV Infection
IFNAR1−/− mice on a C57BL/6J background were provided by Dr P Hertzog (Monash University,
VIC, Australia) [26] and bred in-house at the Queensland Institute of Medical Research (QIMR)
Berghofer Medical Research Institute. Pregnant female IFNAR1−/− mice (between 10–20 weeks old)
were infected s.c. at the base of the tail with 100 μL of medium at a dose of 104 CCID50 as described [24].
Mating was verified by the presence of a vaginal plug. Pregnancy was monitored by weight gain.
In older (>10 weeks) IFNAR1−/− mice, infection with either ZIKA-MY or ZIKV-Natal did not result in
any overt morbidity. Mice were euthanized with CO2.
2.4. Ethics Statement
All mouse work was conducted in accordance with the “Australian code for the care and use of
animals for scientific purposes”, as defined by the National Health and Medical Research Council of
Australia. Animal experiments and associated statistical treatments were reviewed and approved by
the QIMR Berghofer Medical Research Institute animal ethics committee (P2195, A1604-611M).
2.5. ZIKV CCID50 Assays
ZIKV cell culture infectious dose, 50% endpoint (CCID50) assays for viremia and tissue titers
were undertaken as described [27,28], with minor modifications. Briefly, serum or supernatants from
tissues (bead-macerated in medium) were collected and titrated in quadruplicates in five-fold serial
dilutions on low-passage C6/36 cells (ATCC CRL-1660). After five days, 25 μL of the supernatants were
individually transferred onto parallel plates (i.e., A1 to A1, A2 to A2 . . . H12 to H12, etc.) containing
Vero E6 cells (ATCC CRL1586). After seven more days, the plates were stained with crystal violet to
visualize cytopathic effects (CPE). The titers were calculated using the Reed and Münch method.
2.6. Statistics
Statistical analysis of experimental data was performed using IBM SPSS Statistics for Windows,
Version 19.0. Two-sample comparison using t-test was performed when the difference in variances was
<4, skewness was >−2, and kurtosis was <2. Non-parametric data with difference in variances of <4 was
analyzed using Mann–Whitney U-test; if the difference of variances was >4, the Kolmogorov–Smirnov
test was employed.
280
Viruses 2018, 10, 541
3. Results
3.1. De Novo Generation and Characterization of ZIKV-MY
To generate ZIKV-MY, six synthetic gBlock DNA fragments covering the full genome of
ZIKV-MY (GenBank: KX694533) were purchased from Integrated DNA Technologies (Figure 1a).
The first 28 nucleotides of the 5′-UTR were missing from the published sequence, and, therefore,
a fully conserved sequence of this region from four complete genomes of Asian lineage ZIKV
(AGTTGTTGATCTGTGTGAATCAGACTGC, GenBank: KU527068, KU501215, KU681081, KU681082)
was used instead. The gBlock fragments were individually cloned into pUC19 plasmids for archival
purposes and then re-amplified for assembly by CPER, with the addition of the UTR-linker fragment,
as described previously [23]. The CPER DNA was transfected into Vero cells, the culture media
collected at six days post-transfection, and the presence of the virus was confirmed by plaque assay
method as previously described [23] (Figure 1b).
Analysis of replication efficiencies in different cell lines showed that ZIKV-MY and ZIKV-Natal
replicated with similar efficiencies in Vero and A549 cells (Figure 1c,d). As reported previously [23],
ZIKV-Natal was unable to replicate in wild-type (WT) mouse embryonic fibroblasts (MEFs), while, here,
we show that ZIKV-MY replicated to a detectable, albeit still relatively low, level (~2.57 × 103 pfu/mL)
(Figure 1e). Even in MEFs deficient in the type I IFN response (interferon α/β receptor-deficient
MEF; IFNAR−/− MEF), ZIKV-MY replicated more efficiently than ZIKV-Natal (Figure 1f). To ascertain
whether the structural proteins of ZIKV-MY contributed to improved replication in murine cells,
a chimeric virus with ZIKV-MY prME proteins and ZIKV-Natal non-structural proteins was constructed
(ZIKV-Natal/MY-prME) (Figure S1a). In both WT and IFNAR−/− MEFs, the chimeric virus expressing
ZIKV-MY prME did not show enhanced replication compared to ZIKV-Natal (Figure S1b,c). The better
replication of ZIKV-MY in MEFs is clearly unrelated to the type I IFN response and would appear to
be imparted by non-structural proteins.
Figure 1. De novo generation and characterization of ZIKV-MY. (a) Schematic of Circular Polymerase
Extension Reaction (CPER) fragments used for recovering ZIKV-MY. All fragments, except for the
UTR-linker, are drawn to scale; (b) Plaque morphology on a Vero cell monolayer of ZIKV-MY recovered
from the culture supernatant of CPER-transfected Vero cells, compared to ZIKV-Natal;
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Growth kinetics of ZIKV-MY versus ZIKV-Natal was performed on (c) Vero, (d) A549, (e) WT MEF, and
(f) IFNAR−/− MEF cells at their indicated multiplicity of infection (MOI), and culture supernatants
were harvested at the indicated time points post-infection and titered by plaque assay. The dashed
lines represent the limit of detection of the assay. Means and ± SE are shown. Statistical analyses were
performed using t-tests (n = three biological replicates); statistically significant are differences shown in
panel (f) **—p = 0.008, ***—p < 0.001.
3.2. ZIKV-MY and ZIKV-Natal Both Infect IFNAR1−/− Mice and Produce Similar Viraemia and Viral Titres
in Different Organs
IFNAR1−/− mice were infected with ZIKV-MY or ZIKV-Natal at E12.5 of gestation, and viremias
were determined daily for five days post-infection. No statistically significant differences in mean
viremias were observed after infection with the two viruses in either pregnant or non-pregnant mice
(Figure 2a). Viremia in the non-pregnant mice were measured up to day 7 post-infection and showed
that the virus was cleared by 7 days post-infection (Figure 2a). The pregnant mice were euthanized on
day 5 post-infection (E17.5), and a panel of organs was harvested (spleens, spinal cords, muscles, liver,
kidneys, eyes, brains) to determine the viral titres. No statistically significant differences in viral titres
for any organs were observed between ZIKV-MY and ZIKV-Natal infections (Figure 2b–h).
Figure 2. ZIKV-MY and ZIKV-Natal replicate to similar levels in vivo. (a) Interferon α/β receptor 1
knockout (IFNAR1−/−) C57BL/6 female mice were infected with ZIKV-MY or ZIKV-Natal. Pregnant
mice were infected at E12.5 of gestation. Viremia was determined daily for five days post-infection.
Pregnant mice were euthanized at E17.5, and their (b) spleen, (c) spinal cord, (d) muscle, (e) liver,
(f) kidney, (g) eye, and (h) brain samples were processed to determine the viral titers by the
CCID50 assay.
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3.3. ZIKV-MY and ZIKV-Natal Infection of Placenta and Foetal Heads in Pregnant IFNAR1−/− Mice
Groups of pregnant mice were infected with ZIKV-MY or ZIKV-Natal at E12.5 of gestation and
euthanized at E17.5, with fetuses and placentas collected. The viral tissue titres in fetal heads
obtained from dams infected with ZIKV-MY or ZIKV-Natal were not significantly different (Figure 3a,
p = 0.077 Kolmogorov–Smirnov test). Placental titers were about 0.8 logs higher for ZIKV-MY than for
ZIKV-Natal infection (p = 0.002, Kolmogorov–Smirnov test). Following ZIKV infection, placenta and
fetuses often form highly deformed indistinguishable masses, as described previously [23]. Viral titers
in these masses were ≈2 logs higher (p = 0.045, Kolmogorov–Smirnov test) in ZIKV-MY- than in
ZIKV-Natal-infected dams (Figure 3c). These data provide no support for the notion that ZIKV-Natal
(unequivocally associated with microcephaly) has acquired elevated capacity to infect fetal brains.
Figure 3. Fetal and placental virus titers after infection with ZIKV-MY or ZIKV-Natal. IFNAR1−/−
C57BL/6 pregnant mice were infected with ZIKV-MY or ZIKV-Natal at E12.5 and were euthanized at
E17.5 of gestation. (a) Fetal heads, (b) placenta, and (c) deformed fetal–placental masses were collected,
and tissue viral titers determined by the CCID50 assay. *—p = 0.002; **—p = 0.045.
4. Discussion
Herein, a 1966 Malaysian isolate of ZIKV was generated de novo directly from a published sequence
and was shown to cause fetal brain infection in pregnant IFNAR1−/− mice, with similar efficiency to
the 2015 Natal isolate from Brazil. Both ZIKV-MY and ZIKV-Natal also generated indistinguishable
viremia and viral loads in a panel of organs tested. Thus, the propensity for congenital infection does
not appear to be a unique feature of contemporary Brazilian ZIKV strains.
The use of mice as a ZIKV animal model remains the main practical approach for in vivo
characterization of ZIKV virulence. Because of the inability of ZIKV to degrade murine STAT2 [29],
IFN response-deficient mice are required, and previously we have validated the use of IFNAR1−/−
C57BL/6 as a congenital infection model [23]. In other studies that investigated fetal infection by
ZIKV in a mouse model [18,30–34], direct comparisons between pre-outbreak versus outbreak ZIKV
strains were not performed. Although one study [35] did compare the pre-outbreak 1966 Malaysian
strain to an outbreak Puerto Rico 2015 strain of Asian lineage, viral pathogenesis was examined only
in the context of an infection in non-pregnant adult mice, rather than investigating fetal infection in
pregnant dams. Here, we have directly compared the infection of pregnant dams and their fetuses
after subcutaneous infection with Malaysian and Brazilian isolates and show that both strains are
capable of infecting fetal brains.
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A potential limitation of our study is that the Malaysian isolate generated herein was derived from
the sequence of an isolate that had undergone six passages in suckling mouse brain (Table 2). Potentially,
such passaging may have resulted in the selection of a virus with increased ability to mediate congenital
infections in mouse models. However, on the basis of the amino acid alignment, only two amino acids
in ZIKV-MY (NS4B I180 and NS5 Y720) are found in one of two other mouse-adapted isolates (Table 2),
and the rest of the amino acid changes are either found in non-mouse-adapted isolates or not found in
any other isolates (Table 2). NS4B I180 and NS5 Y720 are also unlikely to be associated with congenital
ZIKV syndrome [9].
































1 A A V A A A
17 S S S S N N
21 K K K K E E
31 V V V V M M
E
154–156 NDT Deleted NDI NDT NDT NDT
393 D D D D E E
473 V V V V M M
487 T T T T M M
NS1
146 E K K K E K
188 V V A V V V
233 T T T T A T
264 V V V V M M
349 M M M M V M
NS2A
117 A A V A A A
143 A A A A V V
NS3
400 N N N N H H
472 M M M M L L
584 Y Y Y Y H H
NS4B
14 A A G A S S
26 M V M M I I
49 L L L L F F
98 M M M M I I
180 I A I V V V
184 V V V V I I
186 L L L L S S
240 T T T T I T
NS5
115 M M T M V V
140 P P S P P P
230 I I I I T T
268 A A A A V V
276 M M L M M M
283 I I V I I I
377 N N N N S S
527 A A T A I I
531 K K K K R R
588 G G R G K K
643 P P P P S S
648 R R S R N N
704 S S S S D D
714 H H Y H H H
720 Y H Y H H H
868 D D D D N N
Accession numbers: ZIKV-MY (KX694533), ZIKV-Natal (KU527068), MR766 (HQ234498), Nigeria (HQ234500)
DakAr41525 (KU955591), Suriname (KU312312). SM—suckling mouse brain.
In conclusion, our results argue that ZIKV has an intrinsic ability to cause congenital infection,
irrespective of the sequence evolution that has been documented in recent years.
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Abstract: The establishment of a well characterized non-human primate model of Zika virus (ZIKV)
infection is critical for the development of medical interventions. In this study, challenging Indian
rhesus macaques (IRMs) with ZIKV strains of the Asian lineage resulted in dose-dependent peak viral
loads between days 2 and 5 post infection and a robust immune response which protected the animals
from homologous and heterologous re-challenge. In contrast, viremia in IRMs challenged with an
African lineage strain was below the assay’s lower limit of quantitation, and the immune response
was insufficient to protect from re-challenge. These results corroborate previous observations but
are contrary to reports using other African strains, obviating the need for additional studies to
elucidate the variables contributing to the disparities. Nonetheless, the utility of an Asian lineage
ZIKV IRM model for countermeasure development was verified by vaccinating animals with a
formalin inactivated reference vaccine and demonstrating sterilizing immunity against a subsequent
subcutaneous challenge.
Keywords: Zika virus; ZIKV; rhesus macaques; Non-human primates; NHP; infection; natural history;
Asian-lineage; African-lineage
1. Introduction
Since its introduction into the Americas, Zika virus (ZIKV) has been the subject of a widespread
outbreak linked to a number of different fetal abnormalities including congenital microcephaly [1–6]
and neurological disorders such as Guillain-Barre syndrome (GBS) [7]. Previously, human infections
with ZIKV were infrequent or underreported and associated with only mild symptoms including
headache, myalgia, rash and a self-limiting fever; thus, no vaccines or therapeutics have been
developed against ZIKV despite the fact that the virus has been known since 1947 [8]. Given the
magnitude of the recent outbreak and association with significant clinical manifestations, there is a
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heightened need for medical interventions to prevent or treat ZIKV infections in humans. Concomitant
with the need for new vaccines and therapeutics is the need for appropriate animal models which can
be used to support pre-clinical efficacy studies.
ZIKV is a mosquito-borne virus belonging to the Flavivirus genus of the Flaviviridae family and
was first isolated in the Zika forest region of Uganda from the blood of a sentinel rhesus macaque [9].
Since that time, the virus has spread from Africa into Asia with little incidence until 2007 when it
was associated with an outbreak characterized by rash, conjunctivitis, and arthralgia on the Island
of Yap in the Federal States of Micronesia [10]. This outbreak was followed by an epidemic of ZIKV
infection in French Polynesia in 2013 and 2014 that was correlated retrospectively with a 20-fold
higher incidence rate of GBS [11,12]. A retrospective case-control study confirmed the association of
ZIKV with increased incidence of GBS [13], and a second study identified an increased incidence of
congenital cerebral malformations in fetuses and newborns associated with ZIKV infection during this
time [14]. Subsequent ZIKV outbreaks were reported from numerous islands in the Pacific prior to
its emergence in Brazil in March of 2015 [15,16]. As of March 2017, the World Health Organization
Situation Report identified 84 countries, territories and subnational areas with evidence of vector-borne
ZIKV transmission; 31 countries or territories who have reported microcephaly and other central
nervous system malformations possibly associated with ZIKV infection; and 33 countries or territories
who have reported and increased incidence of GBS potentially associated with ZIKV infection [17].
Prior to 2015, animal models of ZIKV infection were limited. However, with the increased
magnitude of the recent ZIKV outbreaks and severity of clinical disease in both adults and in
the developing fetus, there has been a heightened interest in developing animal models to better
understand the pathogenesis of different geographic and temporal ZIKV isolates [18]. Recent research
efforts with mice have focused predominantly on the use of immunocompromised strains which lack
receptors for type I interferon (IFN α/β), type II interferon (IFN γ) or which lack other components
of the innate antiviral response [19–23]. Infection of immunocompromised mice with ZIKV is
frequently lethal depending on the specific immune deficiency; however, most of these studies used
different ZIKV strains, doses, and routes of administration, making it difficult to draw conclusions.
While a lethal challenge model provides a definite endpoint for efficacy studies, a central tenant
to animal model development under the animal rule (21 CFR Parts 314.600–314.650 and 21 CFR
Parts 601.90–601.95) is that disease progression in the model recapitulates that observed in humans.
The immunocompromised nature of these models also limits their utility for vaccine efficacy studies.
Although no overt disease is observed in wild-type immunocompetent mice challenged with ZIKV,
viral RNA in addition to infectious viruses can be detected in serum and tissues depending on the
ZIKV isolate and the route of inoculation, and these models have been used for vaccine efficacy
studies [19,23–25].
Non-human primates (NHP’s) have also been studied extensively following the emergence of
ZIKV in the America’s, and rhesus macaques are an obvious first choice given the fact that the virus was
originally isolated from this species in 1947 [9]. Consequently, several different groups have evaluated
ZIKV pathogenesis in rhesus macaques and the resultant model has been used for vaccine efficacy
studies [26–31]. Cynomolgus macaques and pigtail macaques have also been evaluated [28,32,33]
and all species have been found to be similarly susceptible and affectively recapitulate the human
condition; however, each of these studies utilized different ZIKV isolates of either African or Asian
lineages, different routes of inoculation, and different challenge doses, again making it difficult to
make comparisons. The objective of this study is to provide a definitive evaluation of ZIKV natural
history utilizing highly characterized virus stocks of African and Asian lineages to establish an Indian
rhesus macaque (IRM) model for product evaluation under the animal rule. In the process, significant
differences in the infectivity of IRMs to ZIKV strains of Asian and African lineages were noted and are
contrary to previous reports with other strains of the African lineage [34]. The implications of these
differences are discussed below.
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2. Materials and Methods
2.1. Care and Use of Animals
This study was designed to use the fewest number of animals possible, consistent with the
objective of the study, the scientific needs, contemporary scientific standards, and in consideration
of applicable regulatory requirements. The study design was reviewed by the Institutional Animal
Care and Use Committee (IACUC) at Southern Research (ACUP#16-08-037F, approved 13 October
2016). Animals were socially housed during the quarantine and pre-study phases, then single housed
following challenge phases of the study. Animals were housed in stainless steel cages that meet
requirements as set forth in the Animal Welfare Act (Public Law 99–198) and the Guide for the
Care and Use of Laboratory Animals (8th Edition, Institute of Animal Resources, Commission on Life
Sciences, National Research Council; National Academy Press; Washington, DC, USA; 2011). Animals
were housed in an environmentally monitored and ventilated room. Fluorescent lighting provided
illumination approximately 12 h per day to simulate the natural diurnal lighting and minimize
housing-associated stress.
2.2. Viruses, Cell Culture
Vero cells were grown in Dulbecco’s Minimal Essential Medium (DMEM, Lonza, Walkersville,
MD, USA), supplemented with 10% Fetal Bovine Serum (FBS), NEAA and L-Glutamine according
to standard culture conditions. ZIKV strain PRVABC59 was isolated in 2015 from human serum
collected in Puerto Rico and obtained from the Centers for Disease Control and Prevention (Division
of Vector-borne Infectious Diseases, CDC, Fort Collins, CO, USA). The PLCal_ZV strain (NR-50234)
was isolated from a human who had traveled to Thailand in 2013 and was obtained through the
Biodefense and Emerging Infections Research Resources Repository (BEI Resources, Manassas, VA,
USA), National Institute of Allergy and Infectious Diseases (NIAD), of the National Institute of Health
(NIH). ZIKV, IbH_30656, NR-50066 was obtained through BEI Resources, NIAID, NIH, as part of the
WRCEVA program and was isolated from human blood collected in Nigeria in 1968. Master and
working stocks of each virus strain were amplified in Vero cells (with minimal passages after receiving
them in house from the primary source) and quantified using standard plaque assay on Vero cells to
determine the plaque forming unit (PFU) titer. All stocks were determined to be free of mycoplasma
using a MycoAlert Mycoplasma Detection Kit (Lonza, LT07-118). Endotoxin levels for stocks were
determined by a QCL-1000 kit (Lonza, 50-647U) and found to be <0.1 EU/mL. Sterility was also
verified by both blood agar and potato dextrose slant cultures for at least 14 days.
2.3. Natural History Study
A total of 36 IRM’s seronegative by ELISA for Dengue, West Nile and ZIKV were subdivided into
nine groups, each group containing 2 males and 2 females assigned randomly based on body weight.
Animals weighed between 3.0 to 7.5 kg and 2–5 years age at the study start.
For the initial challenge, animals were inoculated subcutaneously (SC) with a ZIKV isolate from
either the Asian-lineage (PRVABC59 or PLCal_ZV) or the African-lineage (IbH_30656) at the indicated
doses (Table 1). Biological fluid samples (blood, urine, and saliva) were collected between days 0–30
post initial challenge (Figure 1). Following a 2-week resting period, the 12 animals originally challenged
with each isolate in Phase 1 were distributed into two groups composed of one male and one female
from each low, medium and high dosing group and re-challenged at a dose of 1 × 106 PFU/animal
using either the identical strain they were previously exposed to or a different strain as indicated in
Table 2. Serum collection during the re-challenge phase paralleled the periodicity of the collection time
points of the initial challenge phase, between days 45–75 as per Figure 1.
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Table 1. Animal groupings of (36) Indian Rhesus Macaques subdivided into 9 groups for initial
challenge with the ZKV isolate at the dose indicated.
Group Number Animal Number Isolate Target Dose (PFU/Animal) Delivered Dose (PFU/Animal)
1 4 (2M/2F) PRVABC59 1 × 104 5.5 × 103
2 4 (2M/2F) PRVABC59 1 × 105 9.1 × 104
3 4 (2M/2F) PRVABC59 1 × 106 7.6 × 105
4 4 (2M/2F) PLCal_ZV 1 × 104 3.0 × 103
5 4 (2M/2F) PLCal_ZV 1 × 105 9.0 × 104
6 4 (2M/2F) PLCal_ZV 1 × 106 6.5 × 105
7 4 (2M/2F) IbH_30656 1 × 104 2.8 × 103
8 4 (2M/2F) IbH_30656 1 × 105 3.4 × 104
9 4 (2M/2F) IbH_30656 1 × 106 3.9 × 105
Table 2. Animal groupings of (36) Indian Rhesus Macaques for the re-challenge phase resulting in
some animals being re-challenged with the identical geographical isolate or cross challenged with a
ZKV isolate from a different geographical location at the dose indicated.









1 6 (3M/3F) PRVABC59 PRVABC59 1 × 106 5.9 × 105
2 6 (3M/3F) PRVABC59 PLCal_ZV 1 × 106 1.4 × 106
3 6 (3M/3F) PLCal_ZV PLCal_ZV 1 × 106 1.4 × 106
4 6 (3M/3F) PLCal_ZV PRVABC59 1 × 106 5.9 × 105
5 6 (3M/3F) IbH_30656 IbH_30656 1 × 106 1.0 × 106
6 6 (3M/3F) IbH_30656 PRVABC59 1 × 106 5.9 × 105
Figure 1. Key Study Challenge and Sample Collection Time Points. Challenge Phase I animals were
subdivided into cohorts and inoculated on day 0 with a primary challenge ZIKV isolate. After the
primary challenge and a resting period, animals were regrouped and challenged on day 45 with either
the same isolate or cross-challenged with an isolate of different geographic origin. Blood, saliva and
urine samples were collected as indicated for viral load analysis by qRT-PCR or plaque assay.
2.4. Primers and Probes
PCR primers and probes were designed to the viral Envelope region of each ZIKV
genome, proximal to those described in [35] utilizing modified sequences optimizing
primer/probe binding for strains PRVABC59 (Genbank Accession KU501215.1), PLCal_ZV
(Genbank Accession KX694532.1) and IbH_30656 (Genbank Accession HQ234500.1). All genomic
ZIKV strain analysis used for primer and probe design for PRVABC59 and IbH_30656
were as previously described [36]. For the PLCal_ZV strain, we used the previously
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described primers Zika Dual-For and Zika Dual-Rev [36] and a sequence optimized probe
(5′6FAM-TGC-CCA-ACA/ZEN/CAA-GGC-GAA-GCC-TAC-CT-3′IABkFQ). The probe contains a
5’-6FAM reporter, an internal ZEN quencher and a 3′ IBFQ Iowa Black quencher. All primers and
probes were synthesized by Integrated DNA Technologies (IDT, Coralville, IA, USA). Primer and
probe combinations were fully characterized for compatible melting temperatures (Tm), self-dimer
and hairpin potential as previously described [32]. Primers and protocols used for the generation of
the RNA template used for the standard curve for absolute quantitation were as described in [36].
2.5. Biological Sample Collection
Biological fluid samples (serum, urine and saliva) were collected from anesthetized IRM at
multiple times after the initial challenge on days 0–30 and re-challenge on days 45–79 (Figure 1).
Briefly, for the initial challenge (day 0), blood was collected daily (day 0–10) and then on days 15, 20,
25 and 30. After the re-challenge on day 45, blood was collected daily from days 45–55 and thereafter
on days 60, 65, 70 and 75. Collected blood samples were immediately processed to serum using serum
separator tubes (SST) with brief centrifugation and stored at or below −70 ◦C. Urine was collected by
either cystocentesis (needle) or catheter. Saliva (or drool) was collected directly; if saliva could not be
collected, oral cavity swabs were taken and immersed in 1 mL DPBS without Calcium and Magnesium
(Cat. # 17-512F, Lonza Walkersville, MD, USA). Both urine and saliva collections occurred on the same
schedule, post initial challenge on days 5, 10, 15, 20, 25, and 30 and post re-challenge on days 50, 55, 60,
65, 70 and 75. Upon collection and the preparation of small aliquots, urine and saliva were frozen at or
below −70 ◦C.
2.6. Viral Load by qRT-PCR
Viral RNA was extracted from collected biological fluids to quantify viral load. Briefly, using
the QIAmp Viral RNA Mini kit, (Qiagen, 52906, Germantown, MD, USA) total RNA was extracted
and purified from a biological sample volume of 140 μL (as per the manufacturer) and eluted into
60 μL of nuclease-free water (Ambion, AM9939). Five μL of purified RNA from each test article
was used in a 20 μL qRT-PCR reaction consisting of Fast Virus 4× Master Mix (Applied Biosystems,
4444436, Foster City, CA, USA) containing 500 nM forward and reverse primers with a 200 nM probe.
Cycling parameters for the QuantStudio Flex 6 instrument include: an initial reverse transcription
(RT) step for 5 min at 53 ◦C, followed by 1 min at 95 ◦C and 45 cycles of 2-step cycling at 95 ◦C
for 5 s and 60 ◦C for 50 s. A standard curve for absolute quantitation using a positive control RNA
template was established over the dynamic range of 6-logs (1 × 106–1 × 101) with each dilution in
triplicate of test samples. As reported in [32] the Ct values obtained for each of the 6-log dilutions
for each strain specific primer/probe combination performed consistently (within 1 Ct) with each
other. NCBI Sequence alignment was used for the development of primers and probes that would
work specifically with IbH_30656 and other strains used in this study. Additionally, the lower limit
of quantitative detection (LLOQ) is approximately 10 copies/20 μL PCR reaction. Depending on the
volume/weight of the extracted test sample and the elution volumes, the resulting dilution factor is
typically between 80 and 100 fold, thus the LLOQ for this assay is recorded as 500 copies/mL.
2.7. Viral Load by Plaque Assay
The 3 serum samples from each primary and secondary challenge containing the highest viral
load as determined by qRT-PCR were further assessed by plaque assay on Vero cells. Briefly, Vero cells
were cultured in 6-well plates to approximately 90–100% confluent monolayers and cells were exposed
to 200 μL of 4-fold serially diluted samples. Three dilutions of each sample were tested in duplicate.
Plates were incubated at 37 ◦C and 5% CO2 for 1 h before the addition of an overlay media consisting
of EMEM and 0.5% agarose. Plates were incubated for 3 to 5 days until discernable plaques were
formed then fixed and stained with crystal violet.
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2.8. Indirect ELISA
Purified African lineage ZIKV lysate (The Native Antigen Company, Oxfordshire, UK) was
diluted to 0.5 μg/mL in carbonate-bicarbonate buffer (Thermo Fisher Scientific, Waltham, MA, USA).
Lysate was generated by culturing virus in Vero cells, clarified, concentrated via sucrose gradient
ultracentrifugation, then lysed in Triton X-100, and heat-inactivated. Use of a whole virus lysate
provides magnitudes of additional linear epitopes, when compared to use of a single viral protein
(Env or NS1 only). This allows for increased epitope presentation, presumably including targets
present on both African and Asian lineages.
High binding MAXISORP™ 96-well plates (Thermo Fisher Scientific) were coated with 100 μL
of diluted antigen and refrigerated at 2–8 ◦C overnight. Plates were washed five times with 0.05%
Tween 20 in PBS, then blocked for 30 min at 37 ◦C using 5% dry milk (Quality Biological, Gathersburg,
MD, USA). Plates were washed five times then incubated for 1 h at 37 ◦C with serially diluted sera
samples. Signal was detected using goat anti-human HRP conjugated IgG (SeraCare, Milford, MA,
USA) diluted 1:2000 in 5% milk. Following washing, 100 μL of ABTS 1-component peroxidase substrate
(SeraCare, Milford, MA, USA) was added to each well under low light. Plates were covered and
incubated at room temperature for fifteen to twenty minutes, then 100 μL of 1% sodium dodecyl sulfate
(Fisher Scientific) was added to stop the reaction. Absorbance optical density (OD) was read at 405
nm on a SpectraMax i3 using Softmax Pro software (Version 6.3 GxP, Sunnyvale, CA, USA). Averaged
OD values were plotted against the log of the reciprocal of their dilution (ex. Log10100, Log1012800).
A four-parameter non-linear regression method (GraphPad Prism 5 software, La Jolla, CA, USA) was
used for data analysis. Using the formula from curve fitting, data points between each dilution step
were extrapolated, expanding the data from eight to one thousand OD values. The log of the reciprocal
dilution that corresponded to the extrapolated OD value at a cut-point was identified. The antilog of
each identified value at the cut-point was calculated. This value is the reciprocal of the lowest serum
dilution capable of producing a positive result for anti-ZIKV IgG antibodies.
An endpoint cut-off was defined as follows: more than twenty IRM serum samples were tested
using commercially available kits for ZIKV (XpressBio, Frederick, MD, USA) and Dengue Virus
(Calbiotech, El Cajon, CA, USA and Abcam, Cambridge, MA, USA). Sera testing negative for both
viruses on all kits were run on the above ELISA, with the exception that samples were diluted 1:100
only. Naive sera averaged an OD value of 0.064. The cut point OD value (0.148) was calculated by
adding two times the standard deviation of the OD values to the average OD value.
2.9. Focus Reduction Neutralization Test (FRNT)
The FRNT assay for ZIKV was performed on serum samples collected at the time points indicated.
Briefly, Vero cells seeded at a concentration of approximately 1 × 105 to 2 × 105 cells/mL in a 96-well
plate were incubated for approximately 24 h. On the day of the assay, input virus and serially diluted
serum samples were mixed and incubated for 1 h at 37 ◦C ± 1 ◦C in the dilution plate. The supernatant
was decanted from cell-seeded 96-well plates and then 100 μL of virus/serum mixture was transferred
from the dilution plate and added to the cells. After adsorption for 1 h, overlay medium was added to
the plate and incubated at 5% CO2 overnight. The following day, the plates were stained using broad
spectrum pan-flavivirus antibody (MAB10216, Millipore, Burlington, MA, USA) and Goat anti-mouse
IgG (H + L) HRP-conjugated secondary antibody (5220-0341, SeraCare Life Sciences, Milford, MA,
USA). TrueBlue Peroxidase Substrate (5510-0030, SeraCare Life Sciences, Milford, MA, USA) was
added to the plates and spots were analyzed by BioSpot scanner. Each dilution of sera was tested in
triplicate. Neutralizing antibody titers were reported as the inverse of the serum dilution estimated to
reduce the number of input virus by 50% (FRNT50). The percent neutralization at each dilution was
calculated by the ratio of average foci counts of the replicates to the average foci of the input virus
wells. FRNT50 titers were estimated by point-to-point linear regression between the two dilutions that
spanned 50% neutralization.
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2.10. Efficacy and Immunogenicity Testing of Inactivated Vaccine
Formalin Inactivated PRVABC59 Vaccine (lot number 2016) [37], with a concentration of
5 μg/0.5 mL, obtained from Walter Reed Army Institute of Research (WRAIR, Springfield, MD, USA)
was used for the study. Prior to Study day 0, four (4) IRMs were randomized into two groups
(2 animals/group) according to gender/weight using Provantis Software. On days 0 and 28, all animals
were anesthetized and inoculated intramuscularly (IM) with inactivated-PRVABC59 vaccine (Group 1)
or SC with Minimal Essential Medium supplemented with 1% FBS as a vehicle control (Group 2).
On day 56, all macaques were anesthetized and challenged SC with 0.5 mL of ZIKV strain PRVABC59
with a target challenge dose of 1 × 105 PFU per animal. Blood samples were collected on day 0 (prior to
immunization), day 14, day 28 (prior to boost) and day 56 (prior to challenge) to determine anti-ZIKV
neutralizing antibody (Nab) titer’s by FRNT. Viral load was assessed by qRT-PCR on serum samples
collected daily between days 56 and 66 and again on day 85.
3. Results
3.1. Clinical Observations
All of the animals were monitored twice daily during the challenge and re-challenge phases.
With the exception of some mild erythema, described below, none of the animals showed overt signs
of clinical manifestations associated with ZIKV infection throughout the study. On day 1, ZIKV
challenge-associated mild erythema at the injection site was observed in 5 animals; however, there
was no correlation with challenge dose or strain, and lesions resolved by day 2. Mild erythema
at the inguinal region was also observed in one animal challenged with PLCal_ZV at 1 × 106
PFU on day 6 and another challenged with the PRVABC59 strain at 1 × 105 PFU on day 21.
Mild erythema was detectable for only one day and lesions were barely perceptible in these monkeys.
ZIKV re-challenge-associated mild erythema at the injection site was observed in a total of 13 animals
distributed throughout the study groups on day 46 and one animal on day 47, but resolved afterwards
without progressing further. Overall, mild erythema detected post primary and secondary challenge
was mostly limited to the local injection site and completely resolved without desquamation.
3.2. Virus Detection Following Primary Infection
Following the challenge, the dose preparations were back titered via plaque assay, and targeted
doses were confirmed for all but the high, medium and low dose groups for IbH_30656 and the low
dose group for PLCal_ZV, which were slightly more than 0.5 logs below the targeted dose (Table 1).
Serum, saliva and urine samples collected at the time points indicated in Figure 1 were tested by
qRT-PCR to estimate the relative level of virus replication in each animal. Analysis of the serum viral
RNA load (Figure 2) showed that animals challenged with PRVABC59 developed peak concentrations
on day 2 in the mid and high dose groups as compared to day 3 in the low dose group (Figure 2A).
Regardless of the dose concentration, viral RNA fell below the LLOQ after day 4 in serum from animals
challenged with PRVABC59. Animals challenged with PLCal_ZV demonstrated similar serum viral
RNA kinetics to PRVABC59 at the mid and high dose levels, but peak RNA concentration was delayed
until day 4 and persisted until after day 6 in the low dose group (Figure 2B). Animals challenged with
the IbH_30656 (African) strain demonstrated only low levels of viral RNA in serum samples collected
throughout the study that were generally at or below the LLOQ (Figure 2C). Only the highest dose
group produced an average viral RNA concentration above the LLOQ on day 2 that was transient.
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Figure 2. Serum viral RNA copies in IRMs infected with different ZIKV isolates: Serum viral RNA
copies in the IRM’s (N = 4 per dose group) infected with different doses of ZIKV isolates as indicated
in the figures. (A) PRVABC59 (B) PLCal_ZV (C) IbH_30656. Viral RNA is reported as copies/mL
from serum purified from blood collected at multiple time points post challenge between days 0–30.
Lower Limit of Quantitation (LLOQ) is shown by the dotted line.
Serum samples with high viral RNA concentrations in the qRT-PCR assay (above the LLOQ)
were selected for testing by standard plaque assay to quantify infectious virus particles present in
serum, and the comparative results are presented in Tables S1 and S2. Based on these criteria, the viral
plaque assay was only performed on samples from IRMs challenged with PRVABC59 and PLCal_ZV.
Infectious virus particles were detected in most samples confirming viremia; however, viral PFU titers
were generally 2 to 3 logs lower as compared to viral genome levels. In some cases, no plaque titers
were detected despite RNA copy numbers as high as 1.12 × 105/mL; thus, there was no consistent
correlation between RNA copy number and plaque titer, and qRT-PCR analysis was confirmed to be a
more reliable method for the detection of the virus in serum.
Detectable levels of viral RNA were also observed in urine and saliva samples collected
throughout the study from animals challenged with the PRVABC59 and PLCal_ZV strains.
However, RNA detection from individual animals was sporadic and independent of dose concentration
as demonstrated in Figure 3 for animals challenged with PRVABC59. In this case, low levels of viral
RNA (5.3 to 69 copies/mL on average) were detected in urine samples up to day 30 (Figure 3A),
yet only one animal challenged with the lowest dose had RNA levels above the LLOQ on day 10
post infection. Viral RNA ranging from 3.9 to 970 copies/mL on average was also observed in saliva
samples up to day 25, but again only two samples from animals in the medium dose group had
detectable RNA above the LLOQ on days 5 and 10 post-infection (Figure 3B). Results were similar for
samples collected from animals challenged with PLCal_ZV; however, viral RNA was only detected
in 4 urine samples from animals challenged with IbH_30656 collected over the course of this study
while none of the saliva samples had detectable RNA levels [38]. The most notable observation from
the analysis of urine and saliva samples from animals challenged with Asian lineage viruses is that
viral RNA is most reliably detected (though below the LLOQ) in saliva samples collected 5 days post
infection as demonstrated for PRVABC59 in Figure 3.
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Figure 3. Viral RNA shedding in PRVABC59 infected IRM: Urine and saliva were collected at multiple
time points post challenge between days 0–30 from IRM infected with ZIKV PRVABC59 and subjected to
qRT-PCR assay. ZIKV RNA concentrations (copies/mL) in the urine (A) and saliva (B). Circles represent
data from single animals in the 1 × 104 dose group, squares represent the 1 × 105 dose group,
and triangles represent the 1 × 106 dose group. Urine could not be collected from one IRM on day 5
(dose 1 × 104) and day 25 (dose 1 × 105). Lower Limit of Quantitation (LLOQ) is shown by the
dotted line.
3.3. Immune Response Following Primary Infection
Anti-ZIKV antibodies induced following challenge with varying doses of ZIKV are illustrated
in Figure 4 and Table S3. IgG antibodies were measured using an in-house quantitative ZIKV ELISA
against a purified African lineage ZIKV lysate and enumerated using four-point non-linear regression
analysis. Following the challenge, a dose-dependent anti-ZIKV immune response was detected by
day 10 in all groups though higher levels of IgG were observed in IRMs challenged with Asian
lineage strains (PRVABC59 and PLCal_ZV) as compared to the African lineage strain (IbH_30656).
Antibody titers were weak for IbH_30656-infected animals presumably due to very low infection
of the animals. The highest average IgG titers on day 10 were observed in the high dose groups
challenged with PLCal_ZV, followed by PRVABC59 and IbH_30656. By day 15, antibody titers in the
high dose groups of each isolate increased; however, by day 30, average IgG antibody titers from
IRMs challenged with PLCal_ZV and IbH_30656 began to decrease while PRVABC59 continued to
increase. IRMs challenged with PLCal_ZV and PRVABC59 at the median dose level had averaged
titers of 732 and 1026, respectively, on day 10 as compared to an average titer of 226 in those challenged
with IbH_30656. Titers peaked at this dose level in all groups on day 15. By day 30, PLCal_ZV titers
in the median dose group were retained, while PRVABC59 and IbH_30656 titers decreased. In the
lowest dose groups, only one of four animals challenged with IbH_30656 and three of four animals
challenged with PLCal_ZV had an IgG Antibody titer above the LLOQ, whereas all animals challenged
with PRVABC59 at this dose on this day had a detectable titer. By day 15, the average IgG titers
increased in IRMs challenged with PRVABC59 and PLCal_ZV and titers continued to increase on
day 30. IgG antibody titers in IRMs challenged with the low dose of IbH_30656 also increased on
day 15 but fell on day 30.
Figure 4. Anti-ZIKV IgG production after initial challenge with ZIKV. Animals were challenged
with 1 × 104 PFU, 1 × 105 PFU, or 1 × 106 PFU with either ZIKV (A) PRVABC59, (B) PLCal_ZV or
(C) IbH_30656 and anti-ZIKV IgG was detected in serum by ELISA. Bars with no fill 1 × 104 PFU,
hatched lines 1 × 105 PFU, or horizontal lines 1 × 106 PFU.
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3.4. Virus Detection Following Secondary Challenge
After primary challenge and the conclusion of the natural history study, animals were regrouped
as described in the materials and methods section and were challenged on day 45 either with the same
isolate they were previously exposed to or cross-challenged with an isolate of different geographic
origin (Table 2). The targeted dose of 2 × 106 PFU/mL was confirmed by plaque assay (Table 2),
and serum was collected to assess viral load and immunological responses as before (Figure 1).
In animals previously challenged with PRVABC59, viral RNA that was below the LLOQ was detected
in only 4 samples following re-challenge with PRVABC59 and two samples from animals challenged
with PCal_ZV (Figure 5). Following homologous challenge, no viral RNA was detected in serum
samples from IRMs previously challenged with PLCal_ZV; however, RNA that was below the LLOQ
was detected in at least one animal at various times when challenged with the heterologous PRVABC59.
Re-challenging IRMs with IbH_30656 resulted in detectable levels of RNA in multiple samples that
were similar to the levels seen following primary challenge but again below the LLOQ. In contrast,
challenging IRMs with PRVABC59 following a primary challenge with IbH_30656 resulted in detectable
levels of viral RNA that were attenuated by only two logs as compared to naïve animals challenged
with PRVABC59 (Figure 5 vs. Figure 2A). In this case, peak concentrations of viral RNA were achieved
between days 2 and 3 post challenge and persisted to day 5 before falling below the LLOQ (Figure 4).
Figure 5. Serum viral RNA copies post rechallenge in IRMs: Serum viral RNA copies were determined
by qRT-PCR in IRMs (N = 6 per group) previously infected and re-challenged with either PRVABC59,
PLCal_ZV, or IbH_30656 at a dose of 1 × 106 PFU/IRM. Viral RNA is reported as copies/mL of
serum purified from blood collected at multiple time points post re-challenge between days 45–50.
Note, for the IbH_30656:IbH_30656 group day (50) viral RNA copies were determined from N = 3.
Lower Limit of Quantitation (LLOQ) is shown by the dotted line.
3.5. Immune Response Following Secondary Challenge
Figure 6 and Table S4 illustrate the anti-ZIKV immune response at 5 and 30 days post-secondary
challenge (Study days 50 and 75, respectively) with homologous and heterologous ZIKV challenge.
Average IgG antibody titers ranged between 10,141 and 12,099 on day 50 when IRMs received
homologous or heterologous secondary challenges with high doses of PRVABC59 or PLCal_ZV.
IgG concentrations remained high on day 75 for IRMs that received a secondary challenge
with PLCal_ZV (Figure 6A,B), while titers of animals re-challenged with PRVABC59 decreased.
Re-challenging IRMs with IbH_30656 did not increase the average IgG immune response on days 50
or 75; however, challenging IRMs with PRVABC59 following an initial exposure to IbH_30656 resulted
in increased IgG concentrations on day 75 of 10,456 on average as shown in Figure 6C.
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Figure 6. Anti-ZIKV IgG production after secondary challenge with ZIKV. Antibody titers on Study
days 50 and 75 during Phase II. Animals from each group in Phase I were reassigned based on previous
challenge strain and titer, then re-challenged with 1 × 106 PFU of PRVABC59, PLCal_ZV, or IbH_30656.
(A) Primary challenge with PRVABC59 followed by secondary challenge with PRVABC59 (No fill) or
PLCal_ZV (Hatched lines); (B) Primary challenge with PLCal_ZV followed by secondary challenge
with PLCal_ZV (No fill) or PRVABC59 (Hatched lines); and (C) Primary challenge with IbH_30656
followed by secondary challenge with IbH_30656 (No fill) or PRVABC59 (Hatched lines).
3.6. Immunogenicity and Efficacy of Inactivated ZIKV Vaccine
To demonstrate the utility of the resultant model, groups of 2 IRMs were immunized twice
(day 0 and 28) with inactivated PRVABC59 vaccine (Group 1) or vehicle alone (Group 2) followed
by SC challenge with PRVABC59 virus on day 56. Immunogenicity of the inactivated vaccine was
evaluated by measuring Nab’s as shown in Figure 7A. FRNTs in sera collected on day 14 demonstrated
seroconversion in both animals in the vaccinated group with an average FRNT50 titer of 294. By day 28,
prior to boost, FRNT50 titers had decreased to 127 on average; however, following the boost and
prior to challenge on day 56, FRNT50 titers averaged 3270 in the two vaccinated animals. In contrast,
ZIKV neutralizing antibodies were not observed in the vehicle control animals.
Efficacy of the vaccine was evaluated by assessing serum viral loads in the vaccinated and control
animals via qRT-PCR as shown in Figure 7B. Viremia was below the LLOQ in vaccinated animals
throughout the study, whereas control animals showed significant viremia starting on day 57 and
peaking on day 58. Individual peak viral titers in the unvaccinated animals ranged from 6.2 × 104
to 2.8 × 105 GE/mL and viral titers fell below the LLOQ by day 62, 6 days post challenge, similar to
what was observed in preliminary studies.
Figure 7. Immunogenicity (A) and Efficacy (B) of Formalin-inactivated ZIKV vaccine in the IRM
model: IRMs were vaccinated with formalin-inactivated ZIKV vaccine or the sham control on day 0,
followed by challenge with 1 × 105 PFU of PRVABC59 per IRM on day 54. Serum viral RNA copies
after the challenge and FRNT50 titers after vaccination were measured by using qRT-PCR assay
and ZIKV neutralization assay as described in the method section. Triangles—Vaccinated animals,
Circles—Vehicle control.
4. Discussion
In 2016, more than 40,000 symptomatic Zika disease cases, not including congenital disease cases,
were reported in the United States and its territories alone (https://www.cdc.gov/zika/reporting).
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In 2017, the number decreased to less than 1000; however, the global incidence remained high
with as many as 84 countries, territories or subnational areas reporting evidence of vector-borne
ZIKV transmission [17]. In the same report, at least 13 countries have also reported evidence of
person-to-person transmission, underscoring the need to better understand the factors contributing to
the epidemiology and pathogenesis of ZIKV and to develop new vaccines and therapies to prevent or
treat disease in humans. Paramount to addressing these needs are animal models which recapitulate
the human condition, and NHPs have arguably proven to be the most appropriate model to fulfill
these requirements. The rhesus macaque in particular has been the most extensively utilized to study
the pathogenesis of multiple different ZIKV isolates from the Asian-lineage following SC exposure;
however, only one isolate of the African-lineage, MR766, has been evaluated via this route to this
point [34]. MR766 represents the prototype ZIKV strain originally isolated from rhesus macaques in
Uganda in 1947 and was passaged at least 149 times in suckling mouse brains [9]. IRMs challenged with
ZIKV strain MR766 via the SC route resulted in plasma viral loads that were similar to those seen in
IRMs challenged with a French Polynesian strain (H/FP/2013) isolated in 2013 [34]. Primary infection
of IRMs with the MR766 strain also resulted in a robust immune response, which protected the
animals from subsequent challenge with H/FP/2013. In a separate study, cynomolgus macaques were
demonstrated to be refractory to infection with the IbH_30656 strain of ZIKV which was isolated in
Nigeria in 1968 [32]. The IbH_30656 strain falls under the West African subclade of the African-lineage
ZIKV isolates as compared to MR766 which falls under the East African subclade [39,40]; thus, it is
unclear if the disparity in these results is related to the phylogenetic differences, the extensive passage
history of MR766 in mouse brains, or the genetic background of the NHPs. In yet another study,
both rhesus macaques and cynomolgus macaques developed detectable viremia following intravaginal
(IVAG) and intrarectal (IR) challenge with a ZIKV strain isolated from mosquitoes collected in Senegal
in 1984 [29]. This strain (ArD 41525) is also of the West African subclade and closely related to
IbH_30656 [39,40], further complicating the interpretation of these results. The IbH_30656 strain was
chosen for this comparative study because it is a historical African isolate but unlike MR766 was not
passaged in animals with the intent of increasing virulence. The objective of this study was not to
provide an exhaustive comparison of Asian and African lineage viruses but to verify previous data
with the IbH_30656 strain in cynomolgus macaques and to challenge the dogma from a single study
with MR766 that African lineage isolates are equally pathogenic to Asian lineage isolates in rhesus and
that an immune response generated to the African-lineage isolates is protective against Asian-lineage
viruses. The ultimate goal of these studies was to perform a definitive analysis of ZIKV isolates from
Asian and African-lineage using qualified virus stocks and to establish an NHP model of ZIKV suitable
for vaccine and antiviral evaluation.
To this end, master and working stocks of ZIKV isolates PRVABC59, PLCal_ZV, and IbH_30656
were prepared in a qualified bank of Vero cells and were confirmed for purity, quantity, mycoplasma
contamination, and endotoxin levels. All stocks met the acceptance criteria prior to use in the study.
Comparison of the genome copies (as measured by qRT-PCR) and PFU data suggested that generally
the genome copies were about 2–3 log higher than the PFU levels. These differences are most
likely due to the sensitivities of the assays which are much greater for qRT-PCR that will detect
all viral RNA as compared to the plaque assays, which will only detect viable virus able to infect
cells in culture. IRMs determined to be naïve to flavivirus exposure were challenged with ZIKV via
the SC route and at doses between 1 × 104 and 1 × 106 PFU as has been done previously [27] to
most closely mimic the natural route of vector-borne transmission and at theoretical concentrations
reported for West Nile Virus in mosquito saliva [41]. More recent studies suggest that the maximum
concentration of ZIKV in mosquito saliva is closer to 1 × 103 PFU and that replication kinetics
are delayed when ZIKV is delivered via mosquito bite as compared to the SC route at a dose of
1 × 104 PFU [42]. However, the number of mosquitoes feeding on any given animal was not controlled
in that study, adding variability to the actual challenge dose, and other aspects of ZIKV infection
including tissue distribution were not significantly altered, justifying the dose and route used in these
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studies. Following the challenge, a transient rash was observed in some IRMs similar to previous
reports [34,43]. Previous reports have also reported mild weight loss after infection of IRMs with the
French Polynesian strain H/FP/2013 [27] and elevations in body temperatures [26,28]. In contrast,
no significant changes in body weight or temperatures were observed in these experiments.
Similar to previously published IRM studies with Asian lineage ZIKV strains and
MR766 [27,28,34,44,45], serum RNA levels in PRVABC59 and PLCal_ZV infected NHPs peaked at day 2
to 3 depending on the dose and persisted until day 6). Virus shedding in urine and saliva that persisted
to day 30 and day 25, respectively, was also observed similar to previous reports [26,27,43] but at
significantly reduced concentrations (1 × 102–1 × 103 genome copies/mL here versus 1 × 104–1 × 106
genome copies/mL in other reports). Differences in virus shedding in urine and saliva might be
due to the ZIKV strain used, the method by which the sample was collected, or differences in the
sensitivities and detection limits of the qRT-PCR assays, and highlight the need to standardize these
methods between laboratories so that accurate comparisons can be made. Regardless, the sporadic
nature of virus shedding in urine and saliva reported here and elsewhere limits the utility of these
specimens for assessing clinical progression of ZIKV and efficacy of medical interventions as compared
to viremia. The immune response to ZIKV PRVABC59 and PLCal_ZV as measured by IgG response
was also similar to previous reports [43,44]. All animals challenged with these strains had detectable
IgG titers by day 10 that peaked at day 15 or day 30 depending on the challenge dose. Higher IgG titers
were generally observed in IRMs challenged with PLCal_ZV as compared with PRVABC59; however,
the immune response following exposure to either PLCal_ZV or PRVABC59 was sufficient to protect
IRMs from homologous and heterologous re-challenge as demonstrated by serum viral RNA titers
that were below the LLOQ.
In contrast to IRMs challenged with PRVABC59 and PLCal_ZV, viremia following primary
challenge with ZIKV strain IbH_30656 was below the LLOQ consistent with what was observed
previously in cynomolgus macaques [32]. Consistent with the low level infectivity, the immune
response to challenge with the IbH_30656 isolate was also low, and although detectable serum
IgG responses were observed in all animals by day 15, they were insufficient to protect IRMs from
heterologous challenge with the PRVABC59 strain. While these results appear contrary to what was
reported previously in IRMs challenged with the MR766 strain, it is most likely that this failure to
protect is due to the low level immune response as opposed to the failure of the antibodies to cross
protect [34].
These results serve to rule out the genetic background of the NHP model as a factor contributing to
the differential infectivity of African-lineage ZIKV strains; however, it is yet to be determined what viral
genetic factors contribute to the disparity. Both the IbH_30656 and MR766 isolates have been subject to
multiple laboratory passages since their initial isolation more than 50 years ago. Sequence comparisons
performed in 2012 demonstrated that MR766 and IbH_30656 differ by 7% at the nucleotide level and
2.2% at the amino acid level, whereas the ArD 41519 strain which was isolated more recently and also
productively infected IRMs via the IVAG and IR routes differs from MR766 by 1.7% at the amino acid
level despite a 7% nucleotide divergence [40]. These results serve to narrow the amino acid changes to
be assessed in future studies aimed at discerning the viral genetic factors that contribute to differential
pathologies of ZIKV strains from the African-lineage and should aid in determining the changes that
have contributed to recently emerging pathologies associated with Asian-lineage strains.
Until then, the results presented here and elsewhere support the use of IRMs and the ZIKV
PRVABC59 strain as a model of Asian-lineage ZIKV infection for the evaluation of new vaccines and
therapeutics. The PRVABC59 strain represents a human clinical isolate of low passage which is a
prerequisite for animal model development under the animal rule. Additionally, infection of IRMs
with as little as 1 × 104 PFU of virus results in detectable viremia that can be assessed by qRT-PCR.
Vaccinating IRMs with an inactivated PRVABC59 vaccine resulted in Nab’s of similar titers and kinetics
to those reported previously [31], and vaccinated animals were protected from challenge with 1 × 105
PFU of live ZIKV PRVABC59 as determined by the absence of viremia as compared to sham vaccinated
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animals. This model utilizing qualified master and working virus banks will serve as a valuable
resource suitable for submission of preclinical efficacy data on new ZIKV vaccines and therapeutics to
the FDA.
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Abstract: Maternal infection with Zika virus (ZIKV) during pregnancy can result in neonatal
abnormalities, including neurological dysfunction and microcephaly. Experimental models of congenital
Zika syndrome identified neural progenitor cells as a target of viral infection. Neural progenitor
cells are responsible for populating the developing central nervous system with neurons and glia.
Neural progenitor dysfunction can lead to severe birth defects, namely, lissencephaly, microcephaly,
and cognitive deficits. For this study, the consequences of ZIKV infection in human pluripotent stem
cell-derived neural progenitor (hNP) cells and neurons were evaluated. ZIKV isolates from Asian and
African lineages displayed lineage-specific replication kinetics, cytopathic effects, and impacts on hNP
function and neuronal differentiation. The currently circulating ZIKV isolates exhibit a unique profile of
virulence, cytopathic effect, and impaired cellular functions that likely contribute to the pathological
mechanism of congenital Zika syndrome. The authors found that infection with Asian-lineage ZIKV
isolates impaired the proliferation and migration of hNP cells, and neuron maturation. In contrast,
the African-lineage infections resulted in abrupt and extensive cell death. This work furthers the
understanding of ZIKV-induced brain pathology.
Keywords: Zika virus; neural progenitor cells; neurons
1. Introduction
Zika virus (ZIKV) was recognized in the 1950s as an arbovirus that could infect humans, though it
garnered little attention until the substantial outbreaks in French Polynesia and other South Pacific
islands were reported in 2013–2014 [1,2]. ZIKV causes mild febrile illness, joint pain, and conjunctivitis
when symptomatic, yet remains asymptomatic in 80% of infected individuals [3]. Beginning in 2016,
an epidemic of ZIKV in Brazil established an evidentiary link between congenital infection and placental
insufficiency, spontaneous abortion, ocular defects, and microcephaly [4–7]. However, these severe clinical
manifestations of congenital ZIKV infection had not been previously reported in areas where ZIKV
was endemic. A phylogenetic comparison of ZIKV isolates demonstrated a distinction between older
African-lineage isolates of the virus and contemporary Asian-lineage isolates [8]. Further characterization
of ZIKV isolates that are directly associated with congenital abnormalities suggests that genetic mutations
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distinguishing African-lineage and Asian-lineage ZIKV isolates may be responsible for the unique
pathologies observed in Latin America.
Efforts to understand the pathological mechanism of congenital ZIKV infection were initiated using
in vitro and in vivo model systems. Murine models of vector-borne, vertical, and sexual transmission
were established [9–13]. Both vertically transmitted infections and direct infection of the developing
mouse brain highlighted the susceptibility of human neural progenitor (hNP) cells and immature
neurons to ZIKV infection [13–15]. This neurotropism was confirmed using in vitro organoid and
2D-cultures of hNP cells derived from pluripotent stem cells [16–21]. Experimental models of congenital
ZIKV syndrome prompted the current hypothesis that ZIKV infects and damages the developing
central nervous system (CNS) and, to a lesser extent, the peripheral nervous system (PNS) [20,22–24].
Initial studies suggest that African-lineage ZIKV isolates cause more profound cell death in hNP cells
and neurons than Asian-lineage ZIKV [25].
To further address the lineage-specific effects of ZIKV infection, the authors employed a representative
in vitro model of CNS development to directly evaluate the effects of ZIKV infection using both
African-lineage and Asian-lineage isolates of ZIKV. Previously, the authors demonstrated that hNP cells
could yield mature neurons in a predictable and well-defined manner representative of in vivo human
development [26–28]. In vitro culture of hNP cells and hNP-derived neurons enabled the evaluation of
viral replication and cytopathic effect of both Asian and African lineages of ZIKV. Although African isolates
displayed more rapid viral replication and detriment to cell viability, the Asian isolates disrupted key
functional aspects of hNP cells and hNP-derived neurons including proliferation, migration, and neurite
outgrowth. The authors surmised that the less dramatic cell death allowed for a population of functionally
damaged neurons to remain. Deficient neural maturation caused by the Asian lineages correlates to
pronounced effects on in vivo human neural development. The defects in hNP maturation due to
Asian-lineage infections increase the understanding of the underlying mechanisms of CNS malformation
resulting from congenital ZIKV infection.
2. Materials and Methods
2.1. Culture and In Vitro Differentiation of hNP Cells
hPSC line WA09 (WiCell 0062, Madison, WI, USA) was used to derive hNP cells (hNP1TM 00001)
as previously described and was obtained from ArunA Biomedical, Inc. (Athens, GA, USA) [29].
hNP cells were thawed in proliferation medium containing AB2TM basal medium supplemented with
ANSTM neural supplement (both from ArunA Biomedical Inc.), 2 mM L-glutamine (Gibco, Waltham,
MA, USA), 2 U/mL penicillin (Gibco), 2 μg/mL streptomycin (Gibco), 20 ng/mL fibroblast growth
factor 2 (FGF2) (R&D Systems Inc. Inc., Minneapolis, MN, USA), and 10 ng/mL leukemia inhibitory
factor (LIF) (Millipore, Billerica, MA, USA) and subsequently plated on cell culture dishes coated with
Matrigel 1:100 (B&D Biosciences, Bedford, MA, USA). Differentiation of hNP cultures was induced
by substituting the proliferation medium with differentiation medium (the proliferation medium
lacking FGF2). Cultures were maintained for up to 28 days in vitro (DIV) with the fresh differentiation
medium applied every two or three days. All cell cultures were maintained at 37 ◦C in a humidified
incubator with a 5% CO2 atmosphere.
2.2. ZIKV Stock Production
ZIKV stocks were grown in Vero cells. Cell supernatant was collected when cells showed >80%
cytopathic effect. Supernatants were cleared of cell debris (5000× g, 5 min, 4 ◦C), aliquoted into
cryovials, and frozen at −80 ◦C for one week before titers were determined. The amount of infectious
virus was quantified by either TCID50 or plaque assays. African isolate MR766 was derived from
the original ZIKV isolation and underwent extensive passaging in both mice and tissue culture cells.
African isolate IbH 30656 (VR-1829™, ATCC) was also extensively passaged in cell culture before it was
obtained. The IbH stock was obtained from ATCC. Asian isolate MEX1-44 was isolated from a mosquito
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in Chiapas, Mexico, and the virus was obtained after being passaged four times. The lab passaged
the virus three additional times in Vero cells before completing these studies. Asian isolate SPH was
isolated from a male ZIKV patient in Brazil. The virus was passaged two times in Vero cells before
the stock was received, and the virus was passaged three times in Vero cells before performing the
experiments. Prior to experimentation, all ZIKV isolates tested negative for Mycoplasma contamination
(MycoSensor PCR Assay Kit, Agilent, West Cedar Creek, TX, USA).
2.3. ZIKV Infection of hNP Cells and Neurons
hNP cells, 14 DIV nascent neurons, or 28 DIV mature neurons were seeded into 12-well tissue
culture treated dishes for viral replication assays at a density of 400,000 cells/well or Costar® 96-well
cell culture plates for viability and proliferation assays at a density of 30,000 cells/well. In all cases,
wells were treated with Matrigel 1:200 (B&D) for one hour and rinsed with phosphate buffered saline
(PBS) prior to plating. Cells adhered to the plate prior to ZIKV infection (12 h). Cells were infected by
multiplicity of infection (MOI) ranging from 0.1 to 10. Viral inoculum was removed 12 h following
infection. The cells were washed once with PBS and restored with the respective culture medium.
2.4. Virus Quantification
ZIKV isolates MR766, IbH, and MEX1-44 produced easily discernable plaques on Vero cells and
therefore titers were determined using plaque assays. The differential plaque morphologies may
be a result of the variation of amino acid deletions in the E protein glycosylation sites, which have
been previously noted [30]. For plaque assays, Vero cells were infected with 10-fold serial dilutions
of sample for 1–2 h. The inoculum was then removed, replaced with 1.5% semi-solid agar overlay,
and the cells were incubated for 4–5 days at 37 ◦C, 5% CO2. The cells were fixed in 4% formalin in PBS
and stained with crystal violet, and the number of viral plaques was enumerated. ZIKV-SPH stocks
titers were determined by 50% tissue culture infectious dose (TCID50) titration on Vero cells according
to the Spearmann–Karber method and scored 6–7 days later.
2.5. Cell Viability Assay
Cell viability was measured either two or six days following infection with CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, Fitchburg, WA, USA) according to manufacturer
specifications. Briefly, cells were lysed in CellTiter-Glo® Reagent. After a 15-min incubation, luminescence
was measured with a GloMax-96 Microplate Luminometer (Promega).
2.6. Immunocytochemistry to Assess Viral Infection or Proliferation
hNP, neurons, or Vero cells were fixed with 4% paraformaldehyde 48 h following infection by
applying 100 μL of warm (37 ◦C) 8% paraformaldehyde solution to wells containing 100 μL of medium
and incubated at room temperature for 20 min [31]. Following fixation, cells were washed three times
with PBS. The following steps were performed with the epMotion® 5073l liquid handling station
(Eppendorf, Hauppauge, NY, USA). Cells were permeabilized with 0.5% saponin in PBS and blocked
for 1 h in 0.1% saponin in PBS containing 2% bovine serum albumin (BSA). Anti-Ki67 antibody
(ab15580) (ABCAM, Cambridge, MA, USA) or mouse anti-flavivirus group antigen monoclonal
antibody (MAB10216) (Millipore, Temecula, CA, USA) were diluted 1:1000 or 1:400 respectively,
in 0.1% saponin containing 2% BSA and incubated with cells for 2 h. Following incubation with these
primary antibodies, cells were washed three times with 0.1% saponin containing 2% BSA and incubated
with a 1:1000 dilution DyLight® 488-conjugated donkey anti-rabbit IgG secondary antibody in 0.1%
saponin containing 2% BSA for 1 h at room temperature while protected from light. Cells were then
incubated in 0.1% Hoechst 33342 dye in 0.1% saponin containing 2% BSA for 20 min, then washed three
times with PBS, and stored at 4 ◦C. Images and quantifications were done with the Thermo Scientific
ArrayScanVTI HCS Reader (Thermo Fisher Scientific/Cellomics, Waltham, MA, USA). A minimum of
eight wells per treatment group and three biological replicates were analyzed.
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2.7. ORISTM Cell Migration Assay
60,000 hNP cells were seeded onto Oris Cell Migration Assay plates with seeding stoppers.
After 12 h, wells were infected with ZIKV at an MOI of 10, 1, or 0.1. At 12 h post-infection, the seeding
stoppers were removed, cells were washed once with PBS, and fresh differentiation medium was
applied to all wells. Cells were allowed to migrate into the exclusion zone for 48 h and were then fixed
and stained following the method previously stated to assess cellular proliferation. The migration
assay was quantified with the attachment of the OrisTM detection mask and the Thermo Scientific
ArrayScanVTI HCS Reader (Thermo Fisher Scientific/Cellomics).
2.8. Neurite Outgrowth Assay
The neurite outgrowth assay was conducted as previously described [32]. Briefly, 28 DIV neurons
were seeded onto Costar® 96-well cell culture plates at a density of 15,000 cells per well. Cells were
infected with ZIKV 12 h after plating, then the culture medium was washed and refreshed after
an additional 12 h. At 48 h following infection, cells were fixed and stained with Anti-MAP2 antibody
(5622) (Millipore, Temecula, CA, USA) at a dilution of 1:200. Following incubation in primary antibodies,
DyLight® 488-conjugated donkey anti-rabbit IgG secondary antibody and 0.1% Hoechst 33,342 dye
were used following an identical method as the one used for the hNP immunocytochemistry assays
reported in this study.
2.9. Statistics
All analyses were conducted in R [33]. All measurements were compared by ANOVA and Tukey
honest significant difference (HSD) test. A p-value of <0.05 indicated statistically significant differences
between groups.
3. Results
3.1. Isolate-Specific ZIKV Growth and Cytotoxicity in Human Neural Progenitor Cells
Proliferating naïve hNP and differentiating hNP cells were infected with multiple isolates of ZIKV.
As previously demonstrated, hNP cells self-renew when the culture medium contains FGF2 and LIF
(Figure 1A) and neuronal differentiation is induced by the removal of FGF2 [34]. Two prototypical
isolates of African-lineage ZIKV, MR766 and IbH [35], were juxtaposed against two contemporary
ZIKV isolates of the Asian lineage, MEX1-44 and SPH [30]. Infection with African and Asian isolates
resulted in differential temporal dynamics and peak titers. African isolates (MR766 and IbH) produced
high viral titers within four days of initial infection and subsequently diminished (Figures 1B and
S1A). Asian isolates (MEX1-44 and SPH) demonstrated delayed growth, but ultimately achieved equal
or greater peak titers compared to African isolates (Figures 1B and S1A). In addition to robust virion
production, both African and Asian isolates significantly reduced hNP and differentiating hNP viability
six days post-infection compared to uninfected control cells (Figures 1C,E and S1B,D). African stains
were significantly more cytopathic than Asian isolates at comparable MOIs (Supplementary Tables S1
and S2). This result complemented the observed decrease in viral titers over time in the African-lineage
infections. Cumulatively, ZIKV infection has an isolate-specific impact on viral replication and viability
in both hNP and differentiating hNP cells.
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Figure 1. Zika virus (ZIKV) isolate-specific growth and cytotoxicity in human pluripotent stem
cell-derived neural progenitor (hNP) cells at six days post-infection. (A) hNP cells are maintained
as a proliferating population in media with fibroblast growth factor (FGF) and leukemia inhibitory
factor (LIF). Withdrawal of FGF and LIF from the media leads to differentiation and a population
of immature neurons after 14 DIV, then post-mitotic neurons exclusively emerge after 28 DIV.
(B–E) African-lineage ZIKV isolate (IbH) grew robustly and induced cell death in undifferentiated hNP
cells and differentiating hNP cells, while Asian isolate (SPH) replicated more slowly with less extensive
cell death. * demonstrates p < 0.05.
3.2. Isolate-Specific Cell Death and Growth in hNP-Derived Neurons
The differentiation process from hNP to highly enriched mature neurons requires 28 days (28 DIV),
whereas nascent neurons are evident halfway through the process (14 DIV). The authors, using their
well-characterized hNP to neuron differentiation process, could characterize the pathogenic effects of
ZIKV infection on populations of both immature and mature neurons. After 14 DIV in the absence of
FGF2, hNP cell cultures presented a neuronal phenotype with reduced SOX1 expression and a portion
of HuC/HuD+ and βIII-tubulin+ cells, indicative of maturing neurons (Figure 1A) [28]. The full 28 DIV
of differentiation in vitro resulted in a highly homogeneous population of post-mitotic and mature
neurons characterized by microtubule-associated protein 2 (MAP2) expression (Figure 1A) [34,36].
One African Zika isolate, IbH, and one Asian isolate, SPH, were selected to evaluate the isolate-specific
effects of ZIKV on 14 DIV and 28 DIV neurons. The phenotypic differences between ZIKV lineages
were again apparent when immature neurons were infected with African and Asian ZIKV. The African
isolate, IbH, quickly reached peak viral production four days following infection. Peak IbH titers
were followed by a marked reduction in viral production caused by virus-induced death of the cell
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population (Figure 2A,B). In contrast, cells infected with SPH continued to produce virions, resulting
in higher viral titers peaking six or eight days post-infection. SPH-induced cell death was less apparent
than with IbH, resulting in more viable immature neurons six days post-infection (Figure 2A,B).
Mature neurons infected with SPH produced similar phenotypes to the nascent 14 DIV neurons
(Figure 2C,D). Altogether, both isolates of the ZIKV effectively replicated in immature and mature
neurons, although the Asian lineage produced higher viral titers while inducing less cell death.
Figure 2. ZIKV isolate-specific growth and cytotoxicity in human neurons. (A,B) Viral replication
and viability of hNP-derived nascent neurons (14 DIV) and (C,D) mature neurons (28 DIV) six days
post-infection. * demonstrates p < 0.05.
3.3. ZIKV Infects Neural Progenitor Cells and Mature Neurons
The differences observed in cell viability between the ZIKV lineages may be influenced by the
isolates’ abilities to initially infect the cells. A previous study found that African isolates were able to
infect significantly more hNP cells than an Asian isolate [37,38]. To evaluate the ability of two prototypical
Asian and African ZIKV isolates to infect hNP cells and mature neurons, the number of hNP cell or
neurons containing ZIKV E protein was compared to infected Vero cells 12 h after infection. Vero cells
readily produced viral proteins, and pervasive infection was observed independent of the ZIKV isolate
(Figure 3A,D). hNP cells and 28 DIV mature neurons displayed lower susceptibility/permissivity relative
to Vero cells. Only a fraction of the hNP cells and 28 DIV neurons expressed ZIKV E protein, and lineage-
specific susceptibility was observed in these cell lines. The high MOI infection (MOI 10) of hNP cells
resulted in 13% of the IbH-infected cells expressing ZIKV E protein after 48 h, whereas only 7% of hNPs
and 28 DIV neurons were infected by Asian isolate SPH (Figure 3B–D).
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Figure 3. Isolate-dependent ability of ZIKV to infect hNP cells and mature neurons. (A) ZIKV
isolates IbH and SPH readily infect Vero cells within 48 h. (B) hNP cells are more susceptible to
IbH infection than SPH infection, however neither isolate infected more than 13% of the population.
(C) Mature neurons (28 DIV) were similarly more susceptible to ZIKV IbH infection than SPH infection.
(D) Non-infected (0 MOI) did not demonstrate ZIKV E protein’s presence, but infected (SPH 10 MOI)
cells after 48 h did contain ZIKV E protein in all three cell types.
3.4. Neural Progenitor Cell Proliferation and Migration Decreases after ZIKV Infection
Proper hNP cell proliferation and migration are two fundamental cellular activities needed to
construct the human cerebral cortex [26]. The impact of ZIKV infection on hNP cell function was
evaluated 48 h after infection. At this time point, hNP cells infected with both IbH and SPH exhibited
significant viral replication, yet minimal impact on cell viability (Figures 1B and 4A). Proliferation of
hNP cells diminished when infected with African and Asian ZIKV isolates, indicated by a decrease
in the number of Ki67 positive cells (Figure 4B). However, infection with SPH decreased hNP cell
proliferation without impacting cell viability (Figure 4A,B). hNP cell motility was evaluated by
enumerating the cells migrating into the exclusion zone. hNP cells infected with either IbH or SPH
exhibited a reduced ability to migrate compared to non-infected hNP cells (Figure 4C). IbH-infected
populations had significantly fewer mobile hNP cells at all MOIs. In contrast, SPH-infected hNP cells
only significantly impaired migration when infected at a high MOI (Figure 4C). Overall, ZIKV infection
impacted the proliferation and migration of hNP cells, and these impacts occurred prior to reduced
cell viability resulting from ZIKV infection.
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Figure 4. ZIKV infection decreased hNP cell proliferation and migration. (A) Only infection with
MOI 10 of African-lineage ZIKV demonstrated a significant impact on cell viability after 48 h,
whereas infection with SPH did not decrease viability. (B) The proliferation of hNP cells after ZIKV
infection was significantly decreased following infection with SPH as determined by quantification
of Ki67 expression. (C) The migration of hNP cells was disrupted by both IbH and SPH infections.
IbH infection severely inhibited migration at MOI 10 to such an extent that no acceptable data were
collected (shown as ND). * demonstrates p < 0.05 significance between IbH and SPH and # demonstrates
p < 0.05 significance difference from non-infected control.
3.5. Neuronal Maturation is Hindered by ZIKV Infection
Neurite outgrowth of cortical neurons is a critical step near the conclusion of neural maturation,
and pathological perturbation of neurite outgrowth contributes to defects in cognitive function [39].
The impact of ZIKV infection on neurite outgrowth was assessed prior to significant viral-induced
cell death. Both IbH and SPH Zika isolates actively produced virus in mature 28 DIV neurons 48 h
after initial infection despite a relatively small proportion of the cell population exhibiting an active
infection (Figures 3C and 2C). The acute infection with IbH, but not SPH, induced significant cell
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death at high MOI (Figure 5A,C). Infection of 28 DIV neurons with SPH significantly diminished
the number of neurites, attenuated the neurite length, and decreased the number of branch points
(Figure 5B–F). The total number of neurites extending from neurons infected with IbH was unaltered,
but the length and number of branch points were decreased. Infection with Asian isolate SPH did
not impact cell viability but altered the neurite outgrowth. Collectively, Asian isolate ZIKV infection
impacted neurite outgrowth prior to decreased viability of the infected 28 DIV neurons. This result
suggested an exceptional ability of the Asian isolates to functionally damage populations of neurons
differently than African isolates.
Figure 5. ZIKV infection perturbs neurite outgrowth in human neural progenitor cell-derived neurons.
(A) At 48 h post-infection, both African (IbH) and Asian (SPH) isolates had minimal impact on neuron
viability. (B) Representative images of neurite outgrowth quantification. Hoechst stain labels nuclei of
neurons and MAP2 identifies neurites. Both images contribute to the enumeration and quantification
of neurite outgrowth characteristics. Scale bar = 50 micrometers (C–F). Infection with Asian-lineage
ZIKV (SPH) did not reduce the number of valid neurons observed, yet infection with SPH (MOI 10)
proved detrimental to neurite outgrowth by decreasing the quantity, length, and number of branch
points per neuron. * demonstrates p < 0.05 significance between IbH and SPH and # demonstrates
p < 0.05 significance difference from non-infected control.
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4. Discussion
hNP cells and hNP-derived neurons are advantageous when assessing developmental
malformations and provide a platform to examine the effects toxins and pathogens exert in a controlled,
homogenous, and reproducible setting [39]. In vitro assays designed to evaluate critical functions of
hNP and hNP-derived neurons provide critical insight into how environmental stresses and pathogens
can alter normal functions including cell migration and neurite outgrowth [28,39,40]. In order to
evaluate the impact of Asian and African isolates of ZIKV on human neural cell development,
both undifferentiated hNP cells and hNP-derived neurons were infected to observe ZIKV-induced
changes in differentiation, proliferation, migration, and neurite outgrowth.
Initially, the authors compared African and Asian isolates’ abilities to infect, replicate, and induce
cell death in hNP cells and neurons. Genetic divergence between African and Asian isolates of ZIKV
has been implicated in differential infection phenotypes [8,35,38]. Embryonic mice infected with
African ZIKV isolates exhibited more pronounced apoptosis and a larger decrease in progenitor
cell proliferation than mice infected with an Asian isolate [25]. African isolates of ZIKV induced
higher chicken embryo mortality than Asian isolates [30]. These observations were confirmed with
in vitro model systems using hNP cells and other cell types within the developing brain derived from
pluripotent stem cells. However, the possibility remains that pluripotent stem cell-derived hNP cells
and neurons could respond differently than cells of primary origins [16–20,41]. The observation of
viral replication in hNP cells and hNP-derived neurons in this study provides further evidence that
African and Asian isolates generate distinct differences in neural developmental processes.
Both isolates displayed infection in the hNP cells and neurons compared to the Vero cells.
Adding equivalent volumes of ZIKV resulted in nearly 100% of the Vero cells infected with ZIKV,
whereas only a fraction of hNP cells and neurons produced viral protein E (Figure 3). The relatively
poor rates of infection in hNPs and neurons compared to Vero cells may be due to a functional interferon
response in the CNS lines compared to the interferon deficient Vero cells [42,43]. The African-lineage
virus was able to infect twice as many hNPs and mature neurons compared to Asian isolates (Figure 3).
The African isolates used in this study were extensively cultured in fetal mouse brains for several
decades, which may have created viral isolates more adept at infecting the primordial mammalian
CNS [44]. Conversely, Asian isolates infected fewer neural cells initially, yet were able to remain in the
population longer by inducing only modest cell death (Figures 1–3). Perhaps this trait is an indication
of the Asian ZIKV isolate’s ability to more effectively evade host anti-viral defenses [45].
The authors suspect that the African-lineage isolates produced lower viral titers because of
virus-induced cell death. Only a small percentage of the hNP or neuron populations contained the ZIKV
E protein, but the viability of the neural populations dramatically decreased. This result suggested
that some of the cell death could be due to bystander killing rather than primary ZIKV infection
(Figure 3) [46]. This hypothesis of bystander effects of ZIKV infection altering the proliferation of
infected cells and the paracrine stimulation of hNP cells could trigger apoptotic pathways independent
of infection [41,47]. Mutations could enable the Asian-lineage isolates to prevent cell death pathways
or decrease bystander cell death. Such changes may allow Asian-lineage ZIKV to persist in the prenatal
or neonatal CNS without fatal consequences [48].
Beyond evaluating ZIKV growth and viral-induced cell death, the authors tested how ZIKV
infection disturbed the functional attributes of hNP cells and hNP-derived neurons. Neural progenitor
cell function is critical for CNS growth and maturation [26]. Previous in vitro models reported that
ZIKV caused perturbation of the cell cycle and transcription of neurodevelopmental pathways in hNP
cells [17,49]. Murine experimental models and autopsies of newborns with congenital Zika syndrome
exhibited altered neural cell proliferation and migration after ZIKV infection [14,15,50]. This study’s
data demonstrated that SPH uniquely inhibited proliferation prior to any detrimental effect on cell
viability (Figure 4A,B), suggesting the in vitro infection model could be used in further examining the
mechanisms of ZIKV-induced microcephaly.
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hNP cell migration is the culmination of intracellular processes and interactions with the extracellular
matrix [51]. Monitoring hNP cell migration after ZIKV infection indicated that both IbH and SPH could
subvert normal cell mobility prior to the cytotoxic effects of ZIKV. Deficiencies in the cell motility likely
contributed to the observation of CNS malformation in mouse models when exposed to either African- or
Asian-lineage viruses [11,52]. This study’s results suggested that Asian ZIKV isolates caused diminished
proliferation and migration of hNP cells while avoiding significant cell death. In combination, these events
likely contribute to how ZIKV infection leads to congenital brain malformations.
The architecture of the cortex is established by the proliferation and migration of hNP cells [53].
Later, neurons mature within the cortex by extending neurites and synaptogenesis [54]. The integrity of
neurite structure is critical for CNS function, and the precise organization of the cytoskeleton, microtubule
dynamics, and neurite outgrowth can be pathologically disrupted [55]. The impact of ZIKV infection
in neurons was evaluated by measuring the degree of neurite outgrowth and branching. High MOI
infections with Asian isolate SPH caused significant loss in the number of neurites, the length of the
neurites, and the number of branch points. Clinical reports from congenital ZIKV infection included
ocular defects and seizures [56]. The attenuated proliferation, migration, and neurite outgrowth reported
in this study appears to resemble other pathologies leading to seizures and cognitive defects [53,57].
5. Conclusions
In conclusion, the authors’ use of well-defined cell types and assays allowed them to evaluate the
functional consequences of ZIKV infection in cells of the developing brain. The direct comparison of
African and Asian isolates of the ZIKV revealed the ability of the Asian ZIKV isolate, SPH, to disturb
hNP and neuronal cell function. The diminished hNP cell proliferation, migration, and altered neurite
outgrowth in neurons suggested that Asian-lineage ZIKV infection altered cellular function in the
developing CNS while slowly inducing cytopathic effects, which could result in congenital Zika
syndrome. The evidence indicates that ZIKV isolates of Asian origin may have a unique ability to alter
critical cellular processes. Further work comparing viral evolutionary changes should provide evidence
of how Asian isolates of the ZIKV are capable of altering cells of the developing brain without inducing
extensive cell death and will help elucidate the mechanism behind ZIKV congenital syndrome.
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Abstract: The recent outbreaks of Zika virus (ZIKV), its association with Guillain–Barré syndrome
and fetal abnormalities, and the lack of approved vaccines and antivirals, highlight the importance of
developing countermeasures to combat ZIKV disease. In this respect, infectious clones constitute
excellent tools to accomplish these goals. However, flavivirus infectious clones are often difficult to
work with due to the toxicity of some flavivirus sequences in bacteria. To bypass this problem, several
alternative approaches have been applied for the generation of ZIKV clones including, among others,
in vitro ligation, insertions of introns and using infectious subgenomic amplicons. Here, we report
a simple and novel DNA-launched approach based on the use of a bacterial artificial chromosome
(BAC) to generate a cDNA clone of Rio Grande do Norte Natal ZIKV strain. The sequence was
identified from the brain tissue of an aborted fetus with microcephaly. The BAC clone was fully
stable in bacteria and the infectious virus was efficiently recovered in Vero cells through direct
delivery of the cDNA clone. The rescued virus yielded high titers in Vero cells and was pathogenic in
a validated mouse model (A129 mice) of ZIKV infection. Furthermore, using this infectious clone
we have generated a mutant ZIKV containing a single amino acid substitution (A175V) in the NS2A
protein that presented reduced viral RNA synthesis in cell cultures, was highly attenuated in vivo and
induced fully protection against a lethal challenge with ZIKV wild-type. This BAC approach provides
a stable and reliable reverse genetic system for ZIKV that will help to identify viral determinants of
virulence and facilitate the development of vaccine and therapeutic strategies.
Keywords: Zika virus; Full-length cDNA infectious clones; Bacterial artificial chromosome;
NS2A protein
1. Introduction
Zika virus (ZIKV) is a recently emerged mosquito-borne member of the family Flaviviridae,
which was declared by the Word Health Organization (WHO) as a global public health emergency on
February 2016 [1,2]. Like other flaviviruses, the viral particle is constituted by an inner nucleocapsid
composed of the capsid (C) protein associated with the viral genomic RNA (gRNA), surrounded by
a lipid bilayer that contains the structural membrane (M) and envelope (E) proteins, which are arranged
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with icosahedral symmetry on the surface [3]. The viral genome consists in a positive single-stranded
RNA molecule of about 10.8 kb that, similarly to cellular mRNAs, contains a cap structure at the 5’ end
and a single open reading frame (ORF) flanked by 5’ and 3’ untranslated regions (UTRs). The ORF
encodes a large polyprotein of approximately 3423 amino acids, which is co- and post-translationally
processed by viral and cellular proteases into three structural proteins (C, pre-membrane (prM) and E)
and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The structural
proteins are essential components of the virion and are involved in viral entry, fusion, and assembly.
The NS proteins are required for viral RNA synthesis, virion assembly and evasion of the host antiviral
responses [4,5].
Human illness caused by ZIKV infection was first recognized in Nigeria in 1953 [6] and only a few
cases of ZIKV infections across Africa and Asia were reported over 50 years. Historically, ZIKV was
considered as a modest public health concern, causing a mild febrile illness with similar symptoms
to those of dengue (DENV) and chikungunya (CHIKV) viruses, hampering differential diagnosis [7].
In general, over 80% of ZIKV cases are asymptomatic, while the remaining cases typically exhibit
mild fever, maculopapular rash, and joint pain for a period of several days to a week [8]. However,
the recent large outbreaks in the Island of Yap in 2007 [9], French Polynesia in 2013 [10], and the massive
epidemic that emerge from Brazil in 2015 to rapidly spread throughout South and Central America,
the Caribbean, and more recently the United States [1,11–13], have changed the historic perspective
of ZIKV infection due its association with Guillain–Barré syndrome (a debilitating neuronal disease
in adults) and severe congenital abnormalities such us stillbirth, hydrocephaly and microcephaly,
which are collectively known as congenital ZIKV syndrome (CZVS) [14–19]. Human health concerns
posed by ZIKV are further aggravated due to the non-vector-borne transmission of ZIKV. The virus is
spread to people primarily through the bite of infected mosquitoes of the genus Aedes [20,21], however,
at difference to most other flaviviruses, ZIKV can also be transmitted from mother to child during
pregnancy or spread through sexual contact, breastfeeding, blood transfusion, and non-human primate
bites [1,22,23]. Due to the recent emergence of ZIKV as an important human pathogen, there are not
currently approved vaccines or antivirals available to combat ZIKV infection. The only available
disease prevention measures consist in protection from mosquito bites, excluding pregnant females
from travelling to ZIKV-endemic areas, and practicing safe sex.
The significance of ZIKV in human health, together with the lack of prophylactic and therapeutic
interventions to combat ZIKV infection, highlight the importance of developing safe and effective
countermeasures to control or prevent ZIKV disease in humans. In this sense, the development of
ZIKV reverse genetic systems constitute an essential tool for basic research and development of
vaccine and antiviral strategies. Likewise other flaviviruses, construction of ZIKV infectious clones
has been hampered due to the toxicity of some flavivirus sequences during its propagation in bacteria
using standard high copy number plasmids, which can be attributed to the leaky expression of toxic
viral proteins from cryptic bacterial promoters (CBPs) encoded in the viral genome [24–26]. Recently,
this toxicity problem was overcome using non-traditional approaches based on in vitro ligation of
cDNA fragments [27,28], low-copy plasmids [29,30], intron insertion in the toxic region [31–33],
Gibson assembly method [34], infectious subgenomic amplicons (ISA) [35,36], in silico prediction and
mutational silencing of CBPs present in the viral genome [37], and the use of circular polymerase
extension reaction (CPER) [38]. All these systems are valuable tools to study viral pathogenesis,
vector transmission and for the development of attenuated forms of ZIKV for their implementation as
safe vaccines or for the identification of therapeutics.
In the present study, we report a different and efficient ZIKV reverse genetic approach, based on
the use of a bacterial artificial chromosome (BAC), that overcomes the toxicity problems and allows
the generation of ZIKV cDNA clones on single bacterial plasmid. Following a similar strategy to
that used for DENV [39], the full-length cDNA copy of the viral genome of ZIKV Rio Grande
do Norte Natal (RGN) was assembled in a BAC under the control of the cytomegalovirus (CMV)
immediate-early promoter. This DNA-launched system couples expression of the viral RNA in the
320
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nucleus from the CMV promoter with a second amplification step in the cytoplasm driven by the
viral polymerase. The recombinant virus rescued from the BAC clone was fully infectious in vitro and
in vivo. The ZIKV-RGN infectious clone was further used to evaluate the effect of a single amino acid
change (alanine to valine) at residue 175 of the NS2A protein on viral RNA synthesis and pathogenesis
in vivo. We found that this unique single amino acid substitution impairs viral RNA synthesis in
cell culture and results in viral attenuation in A129 mice. Remarkably, a single dose of the mutant
virus was sufficient to induce protection against challenge with the parental wild-type (WT) ZIKV.
These results demonstrate the reliability and potential of our BAC approach to study ZIKV biology
and to facilitate the development of vaccine and antiviral strategies.
2. Materials and Methods
2.1. Cell Culture and Virus Infection
Vero (a kidney epithelial cell line from an African green monkey) and A549 (an human
adenocarcinomic alveolar epithelial cell line) cells were purchased from the American Type Culture
Collection (ATCC, CCL-81) and were grown and maintained at 37 ◦C and 5% CO2 in growth medium,
consisting in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine
serum (FBS) (HyClone, ThermoFisher Scientific, Madrid, Spain), 2 mM L-glutamine (Sigma-Aldrich,
Madrid, Spain), 1% nonessential amino acids (Sigma-Aldrich), 100 U/mL penicillin (Sigma-Aldrich)
and 100 μg/mL streptomycin (Sigma-Aldrich).
The recombinant ZIKV-RGN WT (rZIKV-RGN) or NS2A mutant (rZIKV-RGN-mNS2A) viruses
were propagated in Vero cells with virus growth medium (DMEM supplemented with 2% FBS, 2 mM
L-glutamine, 1% nonessential amino acids, 100 U/mL penicillin and 100 μg/mL streptomycin) at
37 ◦C and 5% CO2. For virus stocks preparation, 80 to 90% confluent monolayers of Vero cells were
infected with a multiplicity of infection (MOI) of 0.1 plaque forming units (PFU) per cell in virus
growth medium and incubated at 37 ◦C under 5% CO2. After 3–4 days of infection, the tissue culture
supernatants were collected, clarified by centrifugation at 6000× g for 5 min, and stored in small
aliquots at −80 ◦C.
2.2. Plasmids and Bacteria Strains
The BAC plasmid pBeloBAC11 [40], kindly provided by H. Shizuya (California Institute
of Technology, Pasadena, CA, USA), was used to assemble the ZIKV-RGN infectious cDNA
clone. This plasmid is a synthetic low-copy-number plasmid (one copy per cell) based on the
Escherichia coli (E. coli) F-factor [41] that minimize the toxicity problems in the bacteria of exogenous
sequences. E. coli DH10B cells (Invitrogen, ThermoFisher Scientific) were used to amplify the BAC
plasmids. Electrocompetent DH10B cells (Invitrogen, ThermoFisher Scientific) were transformed by
electroporation using a MicroPulser unit (Bio-Rad, Madrid, Spain), according to the manufacturer’s
instructions. BAC-based plasmids were isolated and purified using the Large-Construct kit (Qiagen,
Hilden, Germany), following the manufacturer’s specifications.
2.3. Construction of ZIKV-RGN Infectious cDNA Clone
We have assembled a ZIKV infectious cDNA clone in the BAC plasmid pBeloBAC11, based on
the data of the full-length sequence of the ZIKV clinical strain RGN [19] deposited in the GenBanK
(accession number KU527068). This strain was selected because the full-length sequence was obtained
directly from the virus-infected brain tissue of an aborted fetus with microcephaly in Brazil in 2015
and therefore represents a good candidate to study ZIKV pathogenesis. The first step for the assembly
of the full-length cDNA clone was the selection of the restriction sites PmlI, AfeI, and BstBI (genomic
positions 3347, 5969 and 9127, respectively), which are unique in the viral genome (Figure 1A).
After that, four overlapping DNA fragments covering the entire viral genome (ZIKV 1 to ZIKV 4)
and flanked by the appropriate restriction sites, were generated by chemical synthesis (Bio Basic,
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Inc., Toronto, Canada) (Figure 1B). ZIKV 1 fragment contained the CMV promoter precisely fused
to the first 3350 nucleotides of the viral genome flanked at the 5’-end by ApaLI and AscI (absent in
the viral genome) sites and at the 3’-end by a multiple-cloning site containing the selected restriction
sites (PmlI, AfeI and BstBI) followed by MluI (absent in the viral genome) and BamHI. Fragments
ZIKV 2 (flanked by PmlI and AfeI) and ZIKV 3 (flanked by AfeI and BstBI) covered the genomic
regions 3346–5972 and 5967–9131, respectively. ZIKV 4 fragment contained the restriction site BstBI,
the last 1683 nucleotides of the viral genome, the hepatitis delta virus (HDV) ribozyme, the bovine
growth hormone (BGH) termination and polyadenylation sequences, and the MluI restriction site.
The infectious clone was assembled into pBeloBAC11 by sequential cloning of these four overlapping
DNA fragments. Briefly, fragment ZIKV 1 was digested with ApaLI and BamHI and cloned into
pBeloBAC11−AfeI (a pBeloBAC11 without the AfeI restriction site) digested with the same enzymes,
to generate the intermediate plasmid pBAC-ZIKV1. Then, this plasmid was used as the backbone
for the sequential cloning of the remaining overlapping DNA fragments (ZIKV 2 to ZIKV 4) into
the multicloning site of the intermediate plasmid (contains the restriction sites selected, PmlI, AfeI,
BstBI and MluI) to generate the full-length cDNA clone pBAC-ZIKV-RGN (Figure 1B). The genetic
integrity of the cDNA clone was verified throughout the assembly process by extensive restriction
analysis and sequencing. In all cases, the bacterial strain DH10B (Invitrogen, ThermoFisher Scientific)
was used as the E. coli host for all the cloning steps and the propagation of the BAC cDNA clone.
2.4. Recovery of Infectious Virus from the BAC cDNA Clones
To recover the infectious virus, Vero cells on 6-well plates were grown to 90% confluence in
growth medium without antibiotics, and transfected with 4 μg of the BAC cDNA clone using 12 μL of
Lipofectamine 2000 (Invitrogen, ThermoFisher Scientific), following the manufacturer’s specifications.
After 6 h of incubation at 37 ◦C, the transfection medium was replaced with fresh growth medium
and the cells incubated at 37 ◦C. Aliquots of the culture supernatants were collected at 24 h intervals
for virus titer determination by plaque assay on Vero cells. After five to seven days of transfection,
when the cytopathic effect (CPE) was clear, cell culture supernatants were harvested and the recovered
virus was cloned by three rounds of plaque purification.
2.5. Sequencing of Viral RNA
To determine the complete genome sequence of the rescued viruses, virions from supernatant
of infected Vero cells (MOI of 0.01 PFU/cell) were purified through a 20% (w/v) sucrose cushion.
Viral RNA was isolate from the purified virus with the QIAamp viral RNA minikit (Qiagen) following
the manufacturer’s instructions and deep-sequenced at the University of Rochester Genomics Research
Center using Illumina MiSeq (Illumina, San Diego, CA, USA). Briefly, 0.5 μg of total viral RNA
was fragmented by controlled sonication and a DNA library was generated using the NEBNext
mRNA library prep master mix set for Illumina (New England Biolabs, Ipswich, MA, USA), according
to the manufacturer’s instructions. After analyzing the library for size and quality (Bio-Analyzer;
Agilent Technologies, Inc., Santa Clara, CA, USA), deep-sequencing was performed using MiSeq
(Illumina) and the raw sequencing reads analyzed using SWARM custom software. The genomic 5’-
and 3’-terminal sequences were determined by the rapid amplification of cDNA ends (RACE) using
the 5’/3’ RACE second generation kit (Roche, Basilea, Switzerland) with a polyA-tail added to the
cDNA prior to the 3’ RACE reaction using polyA polymerase (New England Biolabs), following the
manufacturer’s instructions.
To analyze the genetic stability of the recombinant ZIKV harboring the point mutation A175V
in the coding region of the NS2A protein (rZIKV-RGN-mNS2A), total RNA was purified from Vero
cells infected with viruses from passage 1 (P1) to passage 5 (P5) using the RNeasy minikit (Qiagen),
according to the manufacturer’s specifications. Purified RNA (600 ng) was reverse transcribed (RT)
with random hexamer primers using the High-Capacity cDNA Transcription kit (Life Technologies,
ThermoFisher Scientific), and the cDNA was amplified by PCR with the forward primer ZIKV-3414VS
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(5’-GAGGAATGGTGCTGCAGG-3’), spanning nucleotides 3414 to 3431 of the viral genome, and the
reverse primer ZIKV-4817RS (5’-GCTTGACATCTCCCCAG-3’), complementary to nucleotides 4817 to
4833 of the viral genome. Finally, the amplicons generated covering the region encoding NS2A and
NS2B proteins (genomic region 3414–4833) were sequenced by Sanger sequencing (Macrogen Europe,
Amsterdam, Netherlands) using specific oligonucleotides.
2.6. Virus Titrations
Vero cells seeded into 12-well plates at 80–90% of confluence were infected with 150 μL of serial
10-fold dilutions of the virus in virus growth medium without FBS for 1 h at 37 ◦C. After viral
absorption, the viral inoculum was removed and the cells overlaid with 2 mL of virus growth medium
containing 1% DEAE-Dextran (Sigma-Aldrich) and 0.6% Agar Noble (Difco, ThermoFisher Scientific).
After 3–4 days of incubation at 37 ◦C under 5% CO2, the cells were fixed with 4% formaldehyde for 1 h
at room temperature, the overlaid removed, and the viral plaques visualized by staining with 0.1%
crystal violet in 20% methanol or by immunostaining with 1 μg/mL of the pan-flavivirus E protein
monoclonal antibody (mAb) 4G2 (BEI Resources; NR-50327) using the Vectastain ABC kit (Vector
Laboratories Inc., Burlingame, CA, USA). Visible plaques were counted and virus titers were calculated
as PFU/mL.
2.7. Virus Growth Kinetics
Vero and A549 cells seeded into 24-well plates at 90% of confluence were infected with the
indicated viruses diluted in virus growth medium without FBS at the specified MOIs. After 1 h of
absorption at 37 ◦C in 5% CO2, the virus inoculum was removed, the cell monolayers washed twice
with PBS, and 0.5 mL of fresh virus growth medium was added to each well. Cells were incubated at
37 ◦C under 5% CO2 and at selected time points, aliquots of tissue culture supernatants were collected
and virus titers determined by plaque assay in Vero cells as described above.
2.8. Analysis of Viral RNA Synthesis
Viral RNA synthesis was evaluated by quantitative RT-PCR (RT-qPCR). Total intracellular RNA
from uninfected or infected Vero cells was purified using the RNeasy minikit (Qiagen) and total
cDNA was synthetized from 100 ng of purified RNA using random hexamer primers and the
High-Capacity cDNA Transcription kit (Life Technologies, ThermoFisher Scientific), following the
manufacturer’s specifications. Using this cDNA, the level of viral RNA was further quantified by qPCR
using a custom TaqMan assay specific for ZIKV-RGN RNA. This TaqMan assay is constituted by the
forward primer 5’-GAAGAGCATCCAGCCAGAGAA-3’ (spanning nucleotides 1358 to 1378 of the viral
genome), the reverse primer 5’-CTGGGAGCCATGAACTGACA-3’ (complementary to nucleotides
1399 to 1418 of the viral genome), and the probe 5’-FAM-TGGAGTACCGGATAATG-3IABKFQ-3’
(covering nucleotides 1381 to 1397 of the viral genome). To normalize for differences in RNA sampling,
the expression of the histone H2B (reference housekeeping gene) was analyzed using a specific TaqMan
gene expression assay (Rh04253068_s1; Life Technologies, ThermoFisher Scientific). Data were acquired
with a 7500 real-time PCR system (Life Technologies, ThermoFisher Scientific) and analyzed with ABI
PRISM 7500 software v2.0.6. The relative quantifications were performed using the cycle threshold
(2−ΔΔCT) method [42]. All experiments and data analysis were MIQE (Minimum Information for
Publication of Quantitative Real-Time PCR Experiments) compliant [43].
2.9. Indirect Immunofluorescence Assay
The expression of ZIKV E protein was analyzed by indirect immunofluorescence assay (IFA).
Vero cells grown on coverslips in 24-well plates at 80–90% of confluence were infected with the
rescued rZIKVs at the indicated MOIs. At selected time points post-infection, cells were fixed with 4%
paraformaldehyde in 250 mM Hepes pH 7.4 during 20 min at room temperature and then permeabilized
with 0.5% Triton X-100 in PBS for 10 min. After that, cells were treated for 1 h at room temperature
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with blocking solution (10% FBS in PBS) and incubated with 1 μg/mL of the pan-flavivirus E protein
mAb 4G2 (BEI Resources; NR-50327) in blocking solution for 2 h at room temperature. After three
washed with PBS, cells were incubated at room temperature for 1 h with donkey anti-mouse antibody
conjugated to Alexa Fluor 488 (Invitrogen, ThermoFisher Scientific) diluted 1:500 in blocking solution,
extensively washed with PBS, and incubated for 10 min with DAPI (4’,6’-diamidino-2-phenylindole)
(Sigma-Aldrich) diluted 1:200 in PBS for nuclear staining. Finally, coverslips were mounted in ProLong
Gold antifade reagent (Invitrogen, ThermoFisher Scientific) and analyzed on a Leica SP5 confocal
microscope. Immunofluorescence acquired images were processed and analyzed with ImageJ 1.52b
software [44].
2.10. Enzyme-Linked Immunosorbent Assay
For the evaluation of the virus-specific antibodies levels present in the sera of vaccinated
mice, enzyme-linked immunosorbent assays (ELISAs) were performed as previously described [45].
Briefly, 96-well plates were coated with cell lysates from mock- or ZIKV-infected Vero cells and
incubated overnight at 4 ◦C. The coated wells were washed with PBS, blocked with 1% BSA in PBS,
and then incubated with two-fold dilutions (starting dilution of 1:50) of mice sera for 1 h at 37 ◦C.
After that, plates were washed with water and incubated with HRP-conjugated goat anti-mouse
IgG (1:2000; Southern Biotech, Birmingham, AL, USA) for 1 h at 37 ◦C. Reactions were developed
with tetramethylbenzidine (TMB) substrate (BioLegend, San Diego, CA, USA) for 10 min at room
temperature, quenched with 2 N H2SO4, and read at 450 nm in a Vmax Kinetic microplate reader
(Molecular devices, San Jose, CA, USA).
2.11. Mice Experiments
The in vivo studies were performed in type-I interferon (IFN) receptor deficient (IFNR-/-) A129
mice (The Jackson Laboratory, Bar Harbor, ME, USA) maintained in the animal care facility at the
University of Rochester under specific pathogen-free conditions. In this animal model, subcutaneous
(s.c.) or intraperitoneal (i.p.) infection with ZIKV induces neurological disease and the animals
succumb to viral infection, with high viral load in blood, brain, spin cord, and testes, consistent with
manifestations of ZIKV infection in humans. Although deficient in innate IFN responses, A129 mice
retain their adaptive immunity and have been successfully used as a suitable model for testing
antivirals and vaccines [46–48].
To evaluate virus pathogenicity, female 4-to-6-week-old A129 mice (n = 5) were first anesthetized
i.p. with a mixture of ketamine (100 μg per gram of body weight) and xylazine (20 μg per gram of
body weight), and then mock-infected (PBS) or infected s.c. in the footpad with the indicated doses of
rZIKV-RGN or rZIKV-RGN-mNS2A diluted in PBS in a final volume of 50 μL. After viral infection,
animals were monitored daily for morbidity (body weight loss and disease signs, including hunching,
ruffling and hind limb paralysis) and mortality (survival) over 14 days. Mice showing more than 20%
of body weight loss or severe paralysis were considered to have reached the experimental endpoint
and were humanely euthanized. To correlate development of clinical symptoms and death with
virus replication, 4-to-6-week-old mice (n = 6) were infected as described above and the viral titers in
serum were determined at days 2 (n = 3) and 4 (n = 3) by plaque assay and immunostaining using the
pan-flavivirus E protein mAb 4G2 as indicated before.
To evaluate the protection efficacy of the rZIKV-RGN-mNS2A, female 4-to-6-week-old A129
mice (n = 5) were first anesthetized i.p. as indicated above, and then mock-immunized (PBS) or
immunized s.c. in the footpad with 105 PFU of rZIKV-RGN-mNS2A diluted in PBS in a final volume
of 50 μL. At 20 days post-immunization, mouse sera were collected by submandibular bleeding and
the presence of total antibodies against ZIKV-RGN was evaluated by ELISA. Twenty-four hours after
bleeding, mice were challenged s.c. in the footpad with 105 PFU of rZIKV-RGN and their morbidity and
mortality monitored over 14 days as previously described. To determine viral replication, challenged
4-to-6-week-old A129 mice (n = 6) were bleeding at days 2 (n = 3) and 4 (n = 3) post-challenge and
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ZIKV viremia was determined by plaque assay and immunostaining using the pan-flavivirus E protein
mAb 4G2 as previously described.
2.12. Statistical Analysis
For quantitative analyses, a two-tailed, unpaired Student t test was used to analyze differences in
mean values between groups. All results were expressed as mean ± standard deviations of the means.
P values of <0.05 were considered significant. For mice experiments, the Meier Log-Rank test was used
to compare survival data and the Reed and Muench method to determine the mouse lethal dose 50
(MLD50). GraphPad Prism v7.0 software was used for all statistical analysis.
2.13. Ethics Statement
All animal protocols were approved by the University of Rochester Committee of Animal
Resources (Protocol number: UCAR-2017-005/101851; approval date: 05/05/2017) and complied
with the recommendations in the Guide for the Care and Use of Laboratory animals of the National
Research Council [49].
3. Results
3.1. Development of a ZIKV-RGN Reverse Genetic System Using a BAC
To overcome the toxicity problems associated to several flavivirus sequences during its
propagation in bacteria, we used the BAC plasmid pBeloBAC11 (a single-copy plasmid derived from
the E. coli F-factor) [40] to assemble a ZIKV infectious cDNA clone, based on the genome sequence of
the RGN strain of ZIKV (GenBank accession number KU527068) [19] (Figure 1). This ZIKV-RGN strain
was selected because it has no laboratory passage history and the full-length genome sequence was
obtained from a ZIKV-infected fetus with microcephaly in 2015 [19], constituting a good candidate to
further study ZIKV pathogenesis.
After appropriate selection of unique restriction sites in the ZIKV-RGN genome (Figure 1A),
four overlapping DNA fragments (ZIKV 1 to ZIKV 4), spanning the full-length viral genome and
flanked for the selected restriction sites, were chemically synthesized, and sequentially cloned into
pBeloBAC11 to generate the infectious cDNA clone pBAC-ZIKV-RGN (Figure 1B). Fragment ZIKV 1
contained the CMV immediate-early promoter to allow the expression of the viral RNA in the nucleus
by the cellular RNA polymerase II [50] and fragment ZIKV 4 was flanked at the 3’-end by the HDV
ribozyme followed by the BGH termination and polyadenylation sequences to produce synthetic RNAs
bearing authentic 3’-ends of the viral genome. This DNA-lunched system ensures capping of the viral
RNA and allows the recovery of infectious virus from the transfected cDNA clone without the need of
an in vitro transcription step. Once assembled, the full-length sequence of the ZIKV-RGN BAC clone
was determined and no changes were detected to that reported for the ZIKV-RGN strain (GenBank
accession number KU527068). Finally, to confirm the stability of this synthetic infectious cDNA clone
in bacteria, the BAC clone was passaged in E. coli DH10B cells for more than two hundred generations
and the genetic integrity of the passaged infectious clone analyzed by restriction endonuclease analysis
and sequencing. No differences were detected, demonstrating that the ZIKV-RGN BAC clone was
fully stable in bacteria and that the BAC approach is a reliable and simple method to generate ZIKV
infectious cDNA clones.
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Figure 1. Assembly of a Zika Virus-Rio Grande do Norte Natal (ZIKV-RGN) infectious cDNA clone
as a bacterial artificial chromosome (BAC). (A) Genetic structure of the ZIKV-RGN strain genome.
The coding region from the structural (C, prM and E) and NS (NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS5) proteins are illustrated by colored boxes. Relevant unique restriction sites in the viral genome used
for the assembly of the infectious clone and their genomic positions (in brackets) are indicated. 5’ and
3’ UTR: 5’ and 3’ untranslated regions; cap: cap structure. (B) Strategy to assemble the ZIKV-RGN
infectious cDNA clone. Four overlapping DNA fragments (ZIKV 1 to ZIKV 4, left to right), covering the
entire viral genome and flanked by the indicated restriction sites, were generated by chemical synthesis
and sequentially cloned into the BAC plasmid pBeloBAC11 to generate the infectious BAC clone
pBAC-ZIKV-RGN. The full-length cDNA was assembled under the control of the cytomegalovirus
(CMV) immediate-early promoter and flanked at the 3’-end by the hepatitis delta virus (HDV) ribozyme
(Rz) followed by the bovine growth hormone (BGH) termination and polyadenylation sequences.
Acronyms for coding regions and regulatory elements are as described in panel A.
3.2. Rescue and In Vitro Characterization of rZIKV-RGN
To recover the infectious virus (Figure 2), Vero cells were transiently transfected with the BAC
cDNA clone using Lipofectamine 2000 and virus production analyzed during seven days. In contrast
to mock-transfected cells, increasing amounts of infectious virus were detected in the tissue culture
supernatant of cells transfected with the infectious clone, with peak titers around 107 PFU/mL on
day five (Figure 2A). To further confirm the identity of the rescued virus, Vero cells were infected
with an MOI of 0.5 PFU/cell of the rescue virus and monitored for CPE induction and viral E protein
expression by IFA using the pan-flavivirus E protein mAb 4G2 (Figure 2B). The rescued virus induced
a clear CPE, characterized by the presence of rounded and birefringent cells, and high levels of E
protein expression were detected in the perinuclear region of infected cells. These results demonstrated
that the ZIKV-RGN infectious BAC cDNA clone produces high titers of rZIKV-RGN directly after
transfection of susceptible Vero cells.
Once the identity of the rescued virus was confirmed, it was cloned by three round of plaque
purification, and its phenotypic and genotypic properties were determined. Analysis of the growth
kinetics revealed that the rZIKV-RGN replicated efficiently in both Vero and A549 cells, reaching
peak titers of approximately 107 and 106 PFU/mL at 48 hpi, respectively (Figure 3A). In addition,
the rescued virus generated homogeneous plaques of about 2 mm in size after four days of infection
in Vero cells (Figure 3B). Finally, the genetic identity of the virus was analyzed by deep-sequencing
of two independent clones. Full-genome sequencing of both viral clones revealed that both clones
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presented the same sequence that the cDNA clone. Overall, these results demonstrate the feasibility of
generating infectious rZIKVs using a BAC-based approach.
Figure 2. Recovery of infectious rZIKV-RGN from the BAC cDNA clone. (A) Virus rescue. Vero cells at
90% of confluence (6-well plate format; triplicates) were mock-transfected (Mock) or transfected
with 4 μg/well of the ZIKV BAC cDNA clone (pBAC-ZIKV-RGN) and at the indicated times
post-transfection, virus titers in the tissue culture supernatant of transfected cells were determined
by plaque assay. Error bars represent standard deviations of the means from three experiments.
(B) Analysis of the cytopathic effect (CPE) induction and ZIKV E protein expression. Vero cells were
mock-infected (left) or infected (right) with 0.5 PFU/cell of the rescued virus (rZIKV-RGN) and at 48 h
post-infection (hpi) analyzed for the induction of CPE by light microscopy (top) and for viral E protein
expression by immunofluorescence assay (IFA) using the pan-flavivirus E protein mAb 4G2 (bottom).
Bars, 20 μm.
 
Figure 3. Viral growth kinetics and plaque phenotype of rZIKV-RGN. (A) Growth kinetics. Vero and
A549 cells at 90% confluence (24-well plate format; triplicates) were infected at a multiplicity of
infection (MOI) of 1 PFU/cell and at the indicated hpi, virus titers in the tissue culture supernatants
were determined by plaque assay on Vero cells. Error bars represent standard deviations of the mean
from three experiments. (B) Plaque morphology. Vero cells at 90% confluence (6-well plate format) were
infected with 50 PFU of rZIKV-RGN and at four days post-infection viral plaques were visualized by
staining with crystal violet (left) or immunostaining (right) using the pan-flavivirus E protein mAb 4G2.
3.3. Pathogenesis of rZIKV-RGN in Mice
To determine whether the rescued rZIKV-RGN was pathogenic in vivo (Figure 4), groups of five
female 4-to-6-week-old A129 mice (IFNR-/-) were inoculated s.c. in the footpad with PBS (as negative
control) or with different doses of rZIKV-RGN (103, 104 and 105 PFU per animal) and the morbidity
(body weight loss and disease signs) and survival were monitored daily over 14 days (Figure 4A).
As expected, weight loss and survival correlated with the inoculated dose. Mice infected with 103 PFU
did not show disease symptoms, only a slight reduction in body weight was detected on days 8 to 12,
and all of them survived. In the case of mice infected with 104 PFU, they presented some symptoms of
327
Viruses 2018, 10, 547
disease (hunching and reduced mobility) and weight loss from days seven to nine (with a maximum of
10% on day nine), but all of them recovered the initial body weight and survived. In contrast, animals
infected with 105 PFU showed hind limb paralysis, rapidly lost weight, and all of them succumbed to
viral infection between days seven and eight post-infection (Figure 4A). Using the Reed & Muench
method we determined that the MLD50 of rZIKV-RGN was approximately 5 × 104 PFU. To further
analyze whether the virulence observed correlated with viral replication, viral titers in mouse sera
were analyzed at days two and four post-infection (Figure 4B). As expected, the viremia in the infected
animals was dose dependent, reaching the highest titers at day two after inoculation. At day four
post-inoculation a significant reduction of the viral titers was observed. In the case of animals infected
with 103 or 104 PFU, viremia was not detected or only detected in one of the three infected mice,
respectively (Figure 4B). Overall, these results indicated that the rZIKV-RGN recovered from the
infectious clone is virulent in mice but only at high (105 PFU) dose.
Figure 4. Pathogenesis of rZIKV-RGN in A129 mice. (A) Weight loss and mortality. Female 4-to-6-
week-old A129 mice (five mice per group) were mock-infected (PBS) or infected s.c. in the footpad
with the indicated PFU of rZIKV-RGN, and body weight loss (expressed as the percentage of starting
weight, left panel) and survival (right panel) were monitored daily during 14 days. Mice that lost more
than 20% of their initial body weight or presented hind limb paralysis were humanely euthanized.
Error bars represent standard deviations of the mean for each group of mice. Asterisks indicate that
the differences between viral doses of 103 and 104 are statistically significant when data are compared
using the unpaired t test (*, P < 0.05; **, P < 0.01). (B) Viral titers in mice sera. Female 4-to-6-week-old
A129 mice (six mice per group) were infected with the indicated PFU of rZIKV-RGN as described
above, and viral titers in sera were determined at days two and four after infection (three animals per
time point) by plaque assay and immunostaining using the pan-flavivirus E protein mAb 4G2. Symbols
represent data from individual mice and bars the geometric means of viral titers. Asterisks indicate
that the differences in viral titers between experimental samples are statistically significant when data
are compared using the unpaired t test (**, P < 0.01; ***, P < 0.001). &: virus not detected in two mice;
ND: virus not detected. The detection limit of the assay (200 PFU/mL) is indicate as a dashed line.
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3.4. Rescue and In Vitro Charazterization of a rZIKV-RGN Harboring a Point Mutation in the NS2A Protein
During the assembly of the pBAC-ZIKV-RGN infectious clone, we detected the presence of a point
mutation in the NS2A protein, which was introduced during the chemical synthesis of fragment
ZIKV 2. This mutation consists in a cytosine-to-thymidine substitution at genomic position 4069,
resulting in an alanine-to-valine change in the residue 175 of the NS2A protein (A175V). Because
this mutation consists of a conservative amino acid change, we decided to explore the possibility of
using this mutation as a genetic marker. To this end, the infectious clone pBAC-ZIKV-RGN-mNS2A
was generated by replacing the ZIKV 2 WT fragment for that containing the NS2A A175V mutation.
This infectious clone was fully stable in bacteria and no additional mutations were observed after
sequencing the full-length clone. After that, Vero cells were transfected with the mutant infectious
clone and the recovery efficiency of the rZIKV-RGN-mNS2A mutant virus was compared to that
of the parental rZIKV-RGN virus (Figure 5). Although the infectious virus was recovered in both
cases, virus production was one logarithm lower in the case of the mutant rZIKV-RGN-mNS2A,
reaching maximum titers of 106 PFU/mL at seven days post-transfection (Figure 5A). When the plaque
phenotype was analyzed, we found that the plaque size of the mutant rZIKV-RGN-mNS2A was
smaller (more than a 5-fold reduction) than that of the parental rZIKV-RGN (Figure 5B), indicating
that the A175V mutation, despite of being a conservative substitution, caused reduction in plaque size
and virus production. In addition, an in silico analysis was performed to evaluate the frequency of
amino acid residues 175 of the NS2A protein in more than 700 ZIKV strains sequences deposited in the
database [51] (https://www.viprbrc.org/brc/home.spg?decorator=flavi). This analysis indicated that
amino acid A175 is highly conserved, since the 100% of the analyzed ZIKV sequences contained an
alanine residue at this position.
Figure 5. Cont.
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Figure 5. Rescue and growth properties of rZIKV-RGN-mNS2A in Vero cells. (A) Virus rescue. Vero cells
at 90% of confluence (6-well plate format; triplicates) were transiently transfected with 4 μg/well
of the infectious clones pBAC-ZIKV-RGN or pBAC-ZIKV-RGN-mNS2A, and at the indicated times
post-transfection, virus titers in tissue culture supernatants were determined by plaque assay. Error bars
represent standard deviations of the means from three experiments. (B) Plaque morphology. Vero cells at
90% confluence (6-well plate format) were infected with 25 PFU of rZIKV-RGN or rZIKV-RGN-mNS2A
and at four days post-infection the viral plaques were visualized by immunostaining using the
pan-flavivirus E protein mAb 4G2. (C) Growth kinetics. Vero cells at 90% confluence (24-well plate
format; triplicates) were infected with rZIKV-RGN or rZIKV-RGN-mNS2A at high (2 PFU/cell, left)
or low (0.05 PFU/cell, right) MOI, and at the indicated hpi virus titers were determined by plaque
assay. Error bars represent standard deviations of the mean from three experiments. (D) Analysis
of viral RNA synthesis. Vero cells at 90% confluence (12-well plate format; triplicates) were infected
(MOI of 0.5 PFU/cell) with rZIKV-RGN or rZIKV-RGN-mNS2A and at the indicated hpi, viral RNA
levels were quantified by RT-qPCR. Error bars represent standard deviations of the mean from three
experiments. (E) Analysis of viral E protein expression. Vero cells were infected (MOI of 0.5 PFU/cell)
with rZIKV-RGN or rZIKV-RGN-mNS2A and at the indicated hpi, viral E protein expression was
analyzed by IFA using the pan-flavivirus E protein mAb 4G2. Bars, 20 μm. Asterisks in panels A,
C, and D indicate that the differences between rZIKV-RGN and rZIKV-RGN-mNS2A are statistically
significant when data are compared using the unpaired t test (***, P < 0.001).
To further confirm the effect of the NS2A A175V mutation on virus production, the growth kinetics
at high (2 PFU/cell) and low (0.05 PFU/cell) MOI of the mutant virus were compared to those of the
parental virus (Figure 5C). Again, a reduction of about one logarithmic unit in virus production was
detected in Vero cells infected with the mutant virus both at high and low MOI (Figure 5C). Taken into
consideration that flavivirus NS2A protein is involved in regulation of RNA replication and virus
assembly [5], we further analyzed whether the reduction in plaque size and virus production of the
mutant virus was associated with reduced viral RNA synthesis. To this end, the production of viral
RNA in Vero cells infected with either the parental or mutant viruses at an MOI of 0.5 PFU/cell was
analyzed at 24 and 36 hpi by RT-qPCR using a custom TaqMan assay specific for ZIKV-RGN genome
(Figure 5D). At both times, a 5-fold reduction in the levels of viral RNA was observed in cells infected
with the mutant virus (Figure 5D), confirming that NS2A A175V mutation at least impairs viral RNA
synthesis. In agreement with these data, a reduction in the expression levels of ZIKV E protein was
observed by IFA in Vero cells infected with the mutant virus in comparison to cells infected with the
parental virus (Figure 5E). Finally, to discard the presence of other undesired mutations, the full-length
sequence of the mutant virus was determined by deep-sequencing, and no mutations other than NS2A
A175V were detected. Collectively, these results indicated that NS2A A175V mutation alone affected
ZIKV growth in Vero cells at least by impairing viral RNA synthesis.
3.5. Pathogenesis of rZIKV-RGN-mNS2A in Mice
To investigate whether the reduced RNA synthesis of rZIKV-RGN-mNS2A in Vero cells could
result in viral attenuation in vivo, the ability of the mutant virus to induce pathogenesis was analyzed
in A129 mice and compared with that of the parental rZIKV-RGN (Figure 6). To that end, groups of
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five female 4-to-6-week-old A129 mice were inoculated s.c. in the footpad with 105 PFU of either
rZIKV-RGN or rZIKV-RGN-mNS2A, or with PBS as a negative control, and the body weight loss
and survival were monitored daily over 14 days. In contrast to mice infected with rZIKV-RGN that
quickly lost weight and all of them died at day eight after infection, mice infected with the mutant
rZIKV-RGN-mNS2A did not presented any clinical signs of infection or weight loss and all of them
survived to viral infection (Figure 6A). To further analyze the correlation of the attenuation of the
mutant virus with viral replication, presence of the virus in mice sera was analyzed at days two
and four post-infection. In agreement with the pathogenicity data, mice infected with the mutant
virus presented lower viremia than mice infected with the parental virus (Figure 6B). The mutant
virus was only detected at day two after infection and at lower titers (approximately 1.5 logarithms
lower) than the parental virus. As an internal control of the experiment, the plaque phenotype of the
viruses recovered from the blood of infected mice were analyzed. As expected, rZIKV-RGN formed
big plaques while the mutant rZIKV-RGN-mNS2A formed small plaques (Figure 6C). These results
indicated that rZIKV-RGN-mNS2A was highly attenuated in mice, as compared to rZIKV-RGN,
and that this attenuation may be due to a lower replication of the rZIKV-RGN-mNS2A mutant virus.
Figure 6. Pathogenesis of rZIKV-RGN-mNS2A in A129 mice. (A) Weight loss and mortality. Female
4-to-6-week-old A129 mice (five mice per group) were mock-infected (PBS) or infected s.c. in the
footpad with 105 PFU of rZIKV-RGN or rZIKV-RGN-mNS2A, and body weight loss (expressed as
the percentage of starting weight, left panel) and survival (right panel) were monitored daily during
14 days. Mice that lost more than 20% of their initial body weight or presented hind limb paralysis were
humanely euthanized. Error bars represent standard deviations of the mean for each group of mice.
(B) Viral titers in mice sera. Female 4-to-6-week-old A129 mice (six mice per group) were infected with
105 PFU of rZIKV-RGN (WT) or rZIKV-RGN-mNS2A (MUT) as described above, and viral titers in sera
were determined at days two and four after infection (three animals per time point) by plaque assay and
immunostaining using the pan-flavivirus E protein mAb 4G2. Symbols represent data from individual
mice and bars the geometric means of viral titers. Asterisks indicate that the differences between
rZIKV-RGN and rZIKV-RGN-mNS2A are statistically significant when data are compared using the
unpaired t test (***, P < 0.001). ND: virus not detected. The detection limit of the assay (200 PFU/mL)
is indicate as a dashed line. (C) Plaque phenotype. Vero cells at 90% confluence (6-well plate format)
were infected with 25 PFU of rZIKV-RGN (left) or rZIKV-RGN-mNS2A (right) recovered from infected
mice at day two post-infection and the plaque size evaluated by plaque assay and immunostaining
using the pan-flavivirus E protein mAb 4G2.
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3.6. Analysis of the Protection Efficacy in Mice of rZIKV-RGN-mNS2A
After elucidating that rZIKV-RGN-mNS2A was attenuated in vivo, its ability to induce protection
against a challenge with the parental rZIKV-RGN was analyzed (Figure 7). To that end, groups of
five female 4-to-6-week-old A129 mice were vaccinated s.c. in the footpad with 105 PFU of
rZIKV-RGN-mNS2A or mock-vaccinated with PBS. Twenty days after vaccination, blood samples
were collected to evaluate the humoral response. One day later, mice were challenged with a lethal
dose (105 PFU) of rZIKV-RGN and the body weight loss and survival were analyzed daily over
14 days. As expected, mice vaccinated with PBS lost weight rapidly, showed clear symptoms of
disease, and all of them succumbed to challenge with rZIKV-RGN. In contrast, mice vaccinated with
rZIKV-RGN-mNS2A did not lose weight and all of them survived the challenge with rZIKV-RGN
(Figure 7A), indicating that a single immunization dose with rZIKV-RGN-mNS2A is enough to induce
full protection against ZIKV-RGN. In agreement with these data, a strong humoral response against
ZIKV-RGN was observed in mice vaccinated with rZIKV-RGN-mNS2A (Figure 7B) and no viremia
was detected in sera samples of vaccinated mice at days two and four after challenge (Figure 7C).
Figure 7. Protection efficacy of rZIKV-RGN-mNS2A. (A) Weight loss and mortality. Female 4-to-6-
week-old A129 mice (five mice per group) were mock-vaccinated (PBS) or vaccinated s.c. in the footpad
with 105 PFU of rZIKV-RGN-mNS2A. At 21 days after vaccination, mice were challenged with 105 PFU
of rZIKV-RGN and the body weight loss (expressed as the percentage of starting weight, left panel)
and survival (right panel) were monitored daily during 14 days. Mice that lost more than 20% of their
initial body weight or presented hind limb paralysis were humanely euthanized. Error bars represent
standard deviations of the mean for each group of mice. (B) Induction of humoral response. One day
before challenge with rZIKV-RGN, sera samples were collected from mock-vaccinated (PBS) and
rZIKV-RGN-mNS2A vaccinated mice, and total IgG antibodies against ZIKV-RGN were evaluated by
ELISA. OD, optical density. Error bars represent standard deviations of the mean for each group of mice.
(C) Viral titers in mice sera. Female 4-to-6-week-old A129 mice (six mice per group) mock-vaccinated
(PBS) or vaccinated with 105 PFU of rZIKV-RGN-mNS2A (MUT) were challenged with 105 PFU of
rZIKV-RGN as described above, and viral titers in sera were determined at days two and four after
challenge (three animals per time point) by plaque assay and immunostaining using the pan-flavivirus
E protein mAb 4G2. Symbols represent data from individual mice and bars the geometric means of
viral titers. †: virus not detected in one mouse; ND: virus not detected. The limit of detection of the
assay (200 PFU/mL) is indicate as a dashed line.
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3.7. Genetic Stability of rZIKV-RGN-mNS2A In Vero Cells
Once confirmed that rZIKV-RGN-mNS2A was attenuated in vivo and induces protection against
ZIKV-RGN in mice, the genetic stability of the mutant virus was analyzed in Vero cells, in order to test
the possible use of this mutant virus as a base for the development of a live-attenuated ZIKV vaccine
(Figure 8). To this end, both mutant (rZIKV-RGN-mNS2A) and parental (rZIKV-RGN) viruses were
passaged five times in Vero cells (P1 to P5) and the virus plaque phenotype, growth kinetics and the
sequence of NS2A were analyzed for each passage.
Figure 8. Stability of rZIKV-RGN-mNS2A in cultured cells. Vero cells growth in 6-well plates at
90% of confluence were infected with 0.1 PFU/cell of rZIKV-RGN or rZIKV-RGN-mNS2A. At 72 hpi,
cell culture supernatants were collected and used to infect fresh Vero cells. This process was repeated
four more times and virus stocks of passages 1 to 5 (P1 to P5) were generated. (A) Plaque size. Vero cells
were infected with the different passages (P1 to P5) of rZIKV-RGN or rZIKV-RGN-mNS2A, and at four
days post-infection the viral plaques were visualized by immunostaining using the pan-flavivirus E
protein mAb 4G2. (B) Growth kinetics. Vero cells at 90% confluence (24-well plate format; triplicates)
were infected (MOI of 1 PFU/cell) with P1 and P5 of rZIKV-RGN or rZIKV-RGN-mNS2A and at the
indicated hpi, virus titers were determined by plaque assay. Error bars represent standard deviations of
the mean from three experiments. Asterisks indicate that the differences between rZIKV-RGN-mNS2A
P1 and the experimental samples, rZIKV-RGN P1, rZIKV-RGN P5 and rZIKV-RGN-mNS2A P5,
are statistically significant when data are compared using the unpaired t test (***, P < 0.001).
Analysis of the plaque phenotype showed that the parental virus presented the expected plaque
size throughout all passaging. In contrast, for the mutant virus a reversion to parental plaque phenotype
was observed. This reversion started at P2 (2% of big plaques), clearly increased at P3 (45% of big
plaques) and was complete at P4 (Figure 8A). After that, we analyzed whether this plaque size reversion
of the mutant rZIKV-RGN-mNS2A correlated with an increase in virus replication to levels of that of
the parental virus. To that end, the growth kinetics (MOI of 1 PFU/cell) of the mutant virus from P1 and
P5 were compared to those of the parental virus. Growth curve analysis showed that in contrast to the
mutant virus from P1, the virus from P5 replicated to the same levels as the parental virus (Figure 8B),
suggesting that the mutant virus reverted to the WT sequence during its propagation in Vero cells.
To confirm these observations, the NS2A coding region of mutant viruses from P1 to P5 was amplified
by RT-PCR and sequenced. Sequence analysis confirmed the reversion of the A175V mutation to
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the WT sequence. Although the instability and reversion of the mutant virus to the WT sequence
during its propagation in Vero cells limits the use of this mutant for vaccine development, these data
further support the importance of this NS2A residue for virus replication. Moreover, these data also
suggest that ZIKV NS2A protein represents a good target for the development of antivirals against
ZIKV infection.
4. Discussion
The significance of ZIKV to public health due its association with Guillain–Barré syndrome
and fetal abnormalities [14–19], together with the lack of approved antiviral agents or vaccines,
have triggered a global effort to study this flavivirus in order to develop effective strategies to prevent
and control ZIKV infection in humans. In this respect, the development and implementation of
reverse genetic approaches for ZIKV provide investigators with a novel and powerful experimental
tool to study both the biology and pathogenesis of ZIKV as well as the development of attenuated
forms of ZIKV for their implementation as live-attenuated vaccines. However, as described for other
flaviviruses, the generation of ZIKV infectious clones using traditional approaches are very difficult
due to the toxicity and instability of some viral sequences when they were propagated as cloned
cDNA in bacteria [24–26]. In the past two years, several approaches that overcomes this toxicity
problem have been applied for the successfully generation of ZIKV infectious clones. These include the
use of low-copy plasmids [29,30], insertion of introns to disrupt toxic sequences [31–33], mutational
silencing of CBPs present in the viral genome [37], in vitro ligation of cDNA fragments [27,28,34],
the ISA method [35,36], and the CPER approach [38]. Although very useful, some of these approaches
are laborious, time consuming and present several disadvantages. For instance, most of them need
in vitro ligation and transcription steps that complicate the assembly and reduce the recovery efficiency.
Moreover, these low recovery efficiencies increase the presence of undesired mutations that could
result in in vitro and/or in vivo attenuation, limiting the use of these infectious clones for certain
studies. Others, such as the mutational silencing of CBPs, in which a high number of silent mutations
have to be introduced, could affect viral fitness. Finally, the use of low-copy plasmids has been shown
to be effective for several ZIKV strains but not for others, probably due the different degrees of toxicity
of RNA sequences of different strains [28,32,34,36].
Here, we describe a powerful approach for the generation of an infectious cDNA clone of the
ZIKV-RGN strain in a single plasmid, based on the use of a combination of synthetic biology and BACs.
The full-length cDNA copy of the ZIKV-RGN strain was generated from four synthetic DNA fragments
and cloned in the BAC plasmid pBeloBAC11 [40] under the control of the CMV promoter, which allows
the expression of the viral RNA in the nucleus [50], and flanked at the 3’-end by the HDV ribozyme and
the BGH polyadenylation and termination sequences to produce synthetic RNAs bearing authentic
3’-ends of the viral genome. The BAC cDNA clone was fully stable during its propagation in bacteria
and the functional infectious virus was rescued after direct transfection of susceptible Vero cells that
was pathogenic in A129 mice. A ZIKV-RGN infectious clone generated using the CPER approach has
been recently reported [38]. However, in contrast to our results, the rescued virus was asymptomatic
and nonlethal in female 8-to-12-week-old A129 mice infected with doses of 103 to 106 CCID50 (50%
cell culture infective doses) via the s.c. route. Whether the differences in pathogenicity among this
rZIKV-RGN and ours are related to the experimental approach (CPER versus BAC), the age of the
mice (8-to-12-week-old versus 4-to-6-week-old) or the MOI used to infect the mice (103–106 CCID50
versus 105 PFU) remain to be evaluated.
Although other ZIKV reverse genetic systems have been reported (discussed above), the BAC
approach constitutes an useful alternative that presents important advantages: (i) The BAC plasmids
present a strictly controlled replication leading to only one plasmid per cell and therefore minimize
the toxicity associated with several flavivirus sequences when amplified in bacteria [41]. This allows
the easy and direct manipulation of the viral genome for molecular studies; (ii) Similarly to other
approaches using polII-driven promoters, the BAC approach results in intracellular expression of
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the viral RNA [32,33,35,36,38], allowing the capping of the viral RNA and the recovery of infectious
virus without the need of an in vitro transcription step. Although some splicing events could occur
during the nuclear expression of the viral genome, mainly due to the presence of donor and acceptor
putative sequences in the viral genome, the efficiency of this phenomenon is very low and does not
affect the recovery of infectious viruses [52]; (iii) Like other systems based on transfection of DNA
constructs [32,33,35,36,38], BAC cDNA clones present a higher efficiency of transfection than RNA
transcripts in mammalian cells. This allows higher efficiencies of virus recovery, reducing the passages
in cell culture to get a viral stock and therefore, the possibility of introducing undesired mutations by
cell culture adaptation; (iv) The manipulation of BAC cDNA clones is relatively easy and similar to
that of conventional plasmids with slight modifications due to the presence of only one plasmid copy
per cell. In addition to standard protocols, the BAC cDNA clones could also be efficiently modified into
E. coli by homologous recombination using a two-step approach that combine the Red recombination
system and counterselection with the homing endonuclease I-SceI [53–56]; and (v) The BAC approach
has been successfully used to engineer infectious clones of other flaviviruses, including DENV [39],
and several coronaviruses that contain the largest viral RNA genome known and similar toxicity
problems to those described for flaviviruses [52,57–60]. These data highlight the potential of the BAC
approach for the rapid and reliable construction of stable infectious clones of emerging flavivirus and
other similar RNA viruses with unstable viral genomes when amplified as cDNAs in bacteria.
The ZIKV reverse genetic system described in this article was further used to study the effect
of a single amino acid substitution (A175V) in the viral NS2A protein on virus growth in cultured
cells and pathogenesis in vivo. Our results suggested that this single amino acid change impaired
viral RNA synthesis and virus production in cell culture and highly attenuated the virus in mice.
However, we cannot discard that this mutation in the NS2A protein could affect other steps in the
replication cycle of the virus. Flavivirus NS2A protein is a 22-kDa hydrophobic protein associated
with the endoplasmic reticulum that contains eight transmembrane domains. It is a multifunctional
protein that has been involved in viral RNA synthesis [61,62], virus assembly [63,64], membrane
rearrangement [64], and immunomodulation of innate immune response [65–67]. By homology with
the DENV NS2A topology, the ZIKV NS2A A175V mutation maps in the last transmembrane domain,
for which no specific function has been reported. Therefore, our data constitute the first evidence of
a role of this NS2A domain in viral RNA synthesis. On the other hand, it is important to note that the
NS2A A175V mutation promoted a 5-fold reduction in viral RNA synthesis and more than 10-fold
reduction in virus production. This reduced virus production could be a consequence of the RNA
synthesis impairment. However, since the reduction in virus production is higher than that observed
in RNA synthesis and that flavivirus NS2A protein is also involved in virus assembly, we cannot
discard an additional effect of A175V mutation in ZIKV assembly. In addition, we have found that the
mutant virus was attenuated in A129 mice. This attenuation could be explained as a consequence of
the lower RNA synthesis of the mutant virus. However, an additional effect of the A175V mutation
on the putative immunomodulatory role of NS2A protein [65–67], leading to virulence attenuation,
cannot be discarded. Future studies will be required to determine whether this mutation affects only
viral RNA synthesis or also virus assembly and immunomodulation of the host defenses.
Importantly, we have shown that immunization with a single dose of 105 PFU of the mutant
rZIKV-RGN-mNS2A induced protection against a lethal challenge with the parental rZIKV-RGN,
suggesting the potential implementation of this NS2A mutant as the base of a live-attenuated vaccine.
Unfortunately, the mutant rZIKV-RGN-mNS2A was instable and reverted to the WT sequence during
its propagation in Vero cells, limiting the use of this mutation alone for vaccine development. However,
this instability and the high conservation of the amino acid A175 of the NS2A protein among ZIKV
strains highlights the importance of this NS2A residue for virus replication, and therefore the potential
use of NS2A protein as a good target for antiviral development against ZIKV infection.
In summary, we have developed a powerful ZIKV reverse genetic system based on the use of
BACs that has allowed us to identify a single point mutation in the NS2A protein that attenuates
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the virus in vitro and in vivo. This infectious clone system provides a valuable tool to the research
community to explore ZIKV molecular biology, viral determinants of ZIKV pathogenesis, virus-host
interactions, and vaccine and antivirals developments.
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Abstract: The Zika virus (ZIKV) was first isolated in Africa in 1947. It was shown to be a mild virus
that had limited threat to humans. However, the resurgence of the ZIKV in the most recent Brazil
outbreak surprised us because it causes severe human congenital and neurologic disorders including
microcephaly in newborns and Guillain-Barré syndrome in adults. Studies showed that the epidemic
ZIKV strains are phenotypically different from the historic strains, suggesting that the epidemic
ZIKV has acquired mutations associated with the altered viral pathogenicity. However, what genetic
changes are responsible for the changed viral pathogenicity remains largely unknown. One of our
early studies suggested that the ZIKV structural proteins contribute in part to the observed virologic
differences. The objectives of this study were to compare the historic African MR766 ZIKV strain
with two epidemic Brazilian strains (BR15 and ICD) for their abilities to initiate viral infection and to
confer neurocytopathic effects in the human brain’s SNB-19 glial cells, and further to determine which
part of the ZIKV structural proteins are responsible for the observed differences. Our results show
that the historic African (MR766) and epidemic Brazilian (BR15 and ICD) ZIKV strains are different
in viral attachment to host neuronal cells, viral permissiveness and replication, as well as in the
induction of cytopathic effects. The analysis of chimeric viruses, generated between the MR766 and
BR15 molecular clones, suggests that the ZIKV E protein correlates with the viral attachment, and the
C-prM region contributes to the permissiveness and ZIKV-induced cytopathic effects. The expression
of adenoviruses, expressing prM and its processed protein products, shows that the prM protein and
its cleaved Pr product, but not the mature M protein, induces apoptotic cell death in the SNB-19 cells.
We found that the Pr region, which resides on the N-terminal side of prM protein, is responsible for
prM-induced apoptotic cell death. Mutational analysis further identified four amino-acid residues
that have an impact on the ability of prM to induce apoptosis. Together, the results of this study show
that the difference of ZIKV-mediated viral pathogenicity, between the historic and epidemic strains,
contributed in part the functions of the structural prM-E proteins.
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1. Introduction
The 2015 Zika virus (ZIKV) outbreak in South America has a tremendous impact on public health.
It was estimated that it left more than three thousand babies who were born with microcephaly, due to
ZIKV infection in Brazil alone [1]. Monitoring those babies after birth continue to show various
developmental and neurologic disorders that are now known as the congenital ZIKV syndrome [2,3].
Even though the causal relationship between ZIKV infection and ZIKV-induced microcephaly and
other neurologic disorders have been firmly established [4–6], the reason for the sudden ZIKV virulence,
and resulting neurologic disorders in humans, remain largely unknown.
ZIKV was originally isolated in 1947 from caged monkeys in the Zika forest of Uganda, Africa [7].
It was thought to be a mild virus that causes mild flu-like symptoms [7,8] and having a limited threat
to humans [9,10]. A number of small-scale ZIKV outbreaks, with increasing number of individuals
affected, took place in Asia and in Pacific Islands in past years [11,12] until it reached the Americas in
a large-scale outbreak in 2015 [1]. In the most recent ZIKV outbreak, the virus spread to eighty-four
countries, territories, or sub-national areas, with an estimate of over 1.5 million affected individuals [13].
Brazil was the most affected country, with an estimated 440,000 to 1.3 million cases reported [14].
The fact that the epidemic ZIKV causes severe human congenital and neurologic disorders, suggests
that the epidemic ZIKV must have acquired enhanced viral pathogenicity through adaptive viral
gene mutations.
ZIKV is a member of the flaviviruses (the family of Flaviviridae), which include a number of
well-known human pathogens such as Dengue Virus (DENV), West Nile Virus (WNV), and Japanese
Encephalitis Virus (JEV). It is a single-stranded, positive-sense RNA virus with a viral genome of
approximately 10.7 kilobases (kb). The ZIKV genome encodes a single large open reading frame that
produces a polyprotein, which is subsequently processed by viral and host proteases to produce a
total of fourteen immature proteins, mature proteins, and small peptides [10,15]. A total of ten mature
viral proteins, i.e., three structural proteins and seven non-structural proteins are produced after viral
processing [16,17]. The structural proteins consist of an anchor capsid (anaC) protein, a precursor
membrane (prM) protein, and an envelope (E) protein. In non-infectious and immature viral particles,
the prM protein forms a heterodimer with the E protein [18,19]. The E protein, composed of the
majority of the virion surface, is involved in binding to the host cell surface and triggering subsequent
membrane fusion and endocytosis [10,20,21]. For virus maturation, the mature capsid (C) protein
is produced by the proteolytic cleavage of the anaC protein in a post-Golgi compartment, which in
turn triggers the cleavage of the prM protein by a host protease furin to produce a mature membrane
(M) protein (75 a.a) and a Pr protein product (93 a.a) [15,22,23]. The transition of prM to M by furin
cleavage results in mature and infectious particles [19,24]. Thus, one of our research interests here was
to examine the effect of prM and its processed proteins, the mature M protein and a cleaved Pr protein
product, on ZIKV-mediated cytopathic effect.
Based on phylogenetic analysis, ZIKV can be classified into two viral lineages, i.e., the African lineage,
that includes ZIKV strains from Africa; and the Asian lineage that includes both Asian strains and those
ZIKV strains that were isolated from the Americas, such as the Brazilian strains [25,26]. Comparative
studies of the African and Asian ZIKV strains in vivo, ex vivo, and in animal models suggest that
these two ZIKV lineages are intrinsically different in their pathogenicity and virulence [10,25,27,28].
Those virologic differences could potentially explain why the Brazilian ZIKV, which belongs to the
Asian lineage, has acquired the epidemic potential and become highly virulent in humans. Conceivably,
those epidemic and virologic potentials to cause the observed congenital ZIKV syndromes could be
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acquired through evolution by adaptive viral gene mutations [10,28,29]. Nevertheless, which viral
gene(s) is responsible for the observed phenotypic transition, and what type of viral gene mutations
were adapted for this transition remain elusive.
Potential virologic differences between the African and Asian ZIKV lineages could be elucidated
by exchanging different components of the ZIKV genome between the two viral lineages by generating
chimeric viruses. Through such analysis of chimeric viral infection, any virologic changes, due to the
swapping alteration would allow us to correlate a virologic change with a specific domain or gene of
the ZIKV genome. By using this strategy and comparative analysis of a historic African ZIKV MR766
strain and an epidemic Brazilian BR15 strain in human host cells, we discovered in our earlier study
that the structural proteins of the BR15 and MR766 ZIKV strains differ in their ability to initiate viral
infection [30]. In line with our findings, an earlier comparative study of the ZIKV protein evolution
from the pre-epidemic to the epidemic ZIKV, suggested that some of the amino acid (a.a.) sites in the
E protein were negatively selected during ZIKV evolution, indicating possible functional alterations
might have occurred during evolution [29]. In addition, another evolutionary study suggested that the
S139N substitution in the prM protein was positively selected for in the pre-epidemic to the epidemic
transition, and this single mutation alone led to more severe microcephaly than the pre-epidemic
ZIKV strain [31]. The objectives of this study were (1) to further compare the historic African MR766
ZIKV strain with two epidemic Brazilian strains (molecular clones of BR15 and ICD) for their abilities
to initiate viral infection and to confer neurocytopathic effects in human brain SNB-19 glial cells,
and (2) to evaluate the contribution of prM-E proteins in the susceptibility of human brain glial cells to
ZIKV infection.
2. Materials and Methods
2.1. Cell Culture
The SNB-19 (RRID:CVCL_0535), provided by Dr. HL Tang [32], is a human astrocytoma cell line,
which was maintained in Corning RPMI 1640 medium (Product number: 10-040-CV, Mediatech, Inc.,
Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS) and 100 units/mL penicillin plus
100 μg/mL streptomycin. Vero76 cell is a derivative of the original Vero cells, which were originally
isolated from the kidney of a normal adult African green monkey. Vero76 cells (ATCC-CRL-1587,
Manassas, VA) were grown in Dulbecco’s Modified Eagle Medium (DMEM) medium (Product number:
10-017-CV, Mediatech, Inc., Manassas, VA, USA), supplemented with 10% FBS and 100 units/mL
penicillin, plus 100 μg/mL streptomycin.
2.2. Zika Virus Molecular Clones and Infection
The MR766 ZIKV strain was the first documented Zika strain that was isolated from caged
monkey in the Zika forest in Uganda in 1947 [9]. Hence, it is called the historical strain. This viral
strain has been passaged countless times in new-born mouse brains. The molecular clone of ZIKV-
ZIKV-MR766-NIID was generated, based on the sequence of ZIKV strain MR766 Uganda 47-NIID
(Genbank access # LC002520), using the infectious sub-genomic amplicon (ISA) method as described
previously [33]. The BR15 ZIKV strain (BeH819015) was isolated from a blood sample of a patient and
sequenced after one passage in mosquito C6/36 cells. It was one of the earliest Zika viral sequences
that was isolated from one of the Northern states of Brazil (Pará) in July 2015 from a large clade [34,35].
The molecular clone of BR15 was generated, based on the BeH819015 sequence (Genbank Accession
number: KU365778), using the same strategy as that of the ZIKV-MR766-NIID [30,33]. BR15 is available
to BEI resources (Manssas, VA, USA) under the catalog number NR-51129. The ZIKV Paraíba_01/2015
strain (Genbank Accession number: KX280026) was originally isolated from the northeast state of
Paraíba (Brazil) in 2015 from a serum sample of a febrile female. The virus was passed twice in Vero
cells, and a molecular clone (ZIKV-ICD aka 674v4) was generated as described [36].
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For viral infection, the cells were seeded in culture plates and incubated at 37 ◦C/5% CO2
overnight to allow the cells to attach to the wells. The second day, ZIKV was added to the cells with
the multiplicity of infection (MOI) of 1.0, unless specifically indicated. The cells were incubated for
2 h at 37 ◦C, with gentle agitation every 30 min. Next, the inoculum was removed, and the cells were
washed twice with PBS. The culture medium was added to each well, and the cells were incubated at
37 ◦C/5% CO2 for the duration of the experiment.
2.3. Generation and Production of the Chimeric Viruses
Two chimeric ZIKV molecular clones were generated. The M/B chimeric virus consisted of the
C-prM viral sequence of MR766, with the rest of the viral genome replaced with the counterpart
sequence of BR15 ZIKV molecular clone. Conversely, the B/M chimeric virus consists of the C-prM
viral sequence of BR15 with the rest of the viral genome replaced with the counterpart sequence of
MR766 ZIKV molecular clone. The general approach used for the construction of chimeric molecular
clones was previously described [30,33]. To generate the M/B or B/M chimeric molecular clones,
the respective C-prM regions from the MR766 or from the BR15 were extracted from the Z1 fragment.
It was then introduced into the BR15 or the MR766 backbone respectively, by using the following
shared primers: 5′-GCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGC-3′ and
5′-GCCGGGGCAATCAGCAGTATCATGACCAAGTATATGACTTTTTGGC-3′.
The procedure to generate and produce chimeric ZIKV viruses was essentially the same
as described [30,33]. Briefly, the purified PCR fragments were electroporated into Vero76 cells.
After 5 days, cell supernatants were recovered, usually in absence of cytopathic effects and were
used to infect fresh Vero76 cells (DMEM with 2% FBS) in a first round of amplification (P1). Viral clones
M/B or B/M were recovered 3–7 days later until cytopathic effect was observed under microscope
and amplified for another 2 days on Vero76 cells to produce working P2 stocks of the viruses that
were used for all studies. The viral titers were determined using the standard plaque-forming assay,
as described previously, and expressed as plaque-forming units per mL (PFU/mL) [30]. The sequences
of all the viruses and plasmid used in the study are available from the authors upon request.
2.4. Adenoviral Constructs and Cell Transduction
All of the Adenoviral (Adv) constructs, that were used in this study, were custom-made by ViGene
(Rockville, MD, USA). The viral titers were determined using an ELISA Adeno-X rapid titer kit (Cat#:
631028, Clontech, Mountain View, CA, USA), which detects the Adenoviral Hexon surface antigen.
For Adv transduction, SNB-19 cells in the concentration of 1 × 104/well in 96 well plate were seeded
and incubated at 37 ◦C/5% CO2 overnight to allow the cells to attach to the wells. The second day,
the SNB-19 cells were transduced with Adv with the MOI of 1000. The Adv transduced cells were
incubated at 37 ◦C/5% CO2 and the cells were collected at indicated times for analyses.
2.5. Viral Binding Assay
SNB-19 cells were cultured at sub-confluent density in 60 mm dishes. Cell monolayers
were washed in cold PBS and cooled at 4 ◦C for at least 20 min in the presence of RPMI
1640, supplemented with 2% FBS. Pre-chilled cells were then incubated at 4 ◦C with ZIKV
at MOI of 1.0 in 1.5 mL of RPMI 1640 medium supplemented with 2% FBS. After 1 h of
incubation, the virus inputs were removed, and the cells were washed with RPMI 1640 medium,
supplemented with 2% FBS. Total cellular RNA was extracted using TRIzol reagent (Life technologies,
Carlsbad, CA, USA). The RT-qPCR analysis on viral RNA was performed using the primers
amplifying a conserved ZIKV region between the NS5 and 3’UTR. The nucleotide sequences
of these primer pairs are ZIKV-F: 5′-AGGATCATAGGTGATGAAGAAAAGT-3′ and ZIKV-R:
5′-CCTGACAACACTAAGATTG-GTGC-3′. For viral binding assay in A549 cells, the RT-qPCR
analysis on viral RNA was performed using the primers amplifying a region of the E protein,
as described [30]. ZIKV E primers were designed to match both MR766-NIID and BeH819015
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sequences. A house-keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as
an endogenous control for the measurement of viral bindings.
2.6. Immunofluorescence Staining
The immunostaining method was used to determine ZIKV infectivity and induction of apoptosis,
as described in [32]. Briefly, SNB-19 cells were infected with ZIKV, as described above. ZIKV-infected
cells were fixed at 48 h post-infection (p.i.) with 3.7% paraformaldehyde in PBS for 1 h at room
temperature on Labtek II slides. After washing three times for 5 min in PBS, the cells were blocked
and permeabilized for 30 min in blocking buffer (10% FBS, 0.25% Triton X-100 in PBS). To determine
viral infectivity, i.e., the percent of cells infected with ZIKV with MOI of 1.0, cells were first incubated
with mouse anti-Flaviviridae group antigen (clone name: D1-4G2-15, Cat# MAB10216, MilliporeSigma,
Burlington, MA) primary antibody with proper dilutions in the incubation buffer (1% BSA in PBS)
for 2 h at 37 ◦C. After washing, cells were incubated with Texas Red-conjugated goat anti-mouse
IgG secondary antibody (Cat# T-862, ThermoFisher, Waltham, MA, USA) at suggested concentration
in the incubation buffer for 1 h at room temperature. After washing, cells were stained with DAPI
for 5 min and washed again. Cells were then mounted with mounting medium and visualized
on a Leica DM4500B microscope (Leica Microsystems, Buffalo Grove, IL) with Openlab software
(Improvision, Lexington, MA, USA). ZIKV-induced caspase-3 cleavage, a hallmark of cellular apoptosis,
was measured, by using the same immunostaining method, as described except cells was tested at 72 h
p.i., and the primary antibody used was Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb (Cat#9664,
Cell Signaling, Danvers, MA, USA). The secondary antibody used was the FITC-conjugated goat
anti-rabbit IgG secondary antibody (Cat# 31635, ThermoFisher, Waltham, MA, USA).
2.7. Measurement of ZIKV Viral Replication
ZIKV viral replication was measured over time, by using real-time reverse transcription
polymerase chain reaction (RT-PCR) analysis, essentially as described previously [37]. Briefly, the total
RNA was extracted from SNB-19 cells using TRIzol reagent (Life technologies, Carlsbad, CA, USA)
according to the manufacturer’s protocol. The RNA pellet was re-suspended in RNase-free distilled
water and stored at −80 ◦C. Five hundred nanograms of RNA was used for real-time RT-PCR
analysis, using iTaq universal SYBR Green one-step kit (BioRad, Hercules, CA, USA), according
to the manufacturer’s instruction. The primer sequences used here are the same conserved ZIKV
region between the NS5 and 3’UTR as that described in the Section 2.5. The amplification in BioRad
CFX96 real-time PCR system involved a reverse transcription reaction at 50 ◦C for 10 min, activation
and DNA denaturation at 95 ◦C for 1 min, followed by 40 amplification cycles of 95 ◦C for 15 s and
60 ◦C for 30 s. The mRNA expression (fold-induction) was quantified by calculating the 2−ΔCT value,
with GAPDH mRNA as an endogenous control.
Besides the RT-PCR, the conventional plaque forming assay was also used to measure viral
replication. Viral titers were determined by a standard plaque-forming assay, as previously described,
with minor modifications [38]. Briefly, Vero76 cells, grown in 48-well culture plate, were infected with
tenfold dilutions of virus samples for 2 h at 37 ◦C and then incubated with 0.8% carboxymethylcellulose
(CMC) for 4 days. CMC was removed from plate. The cells were washed two times with PBS and fixed
by 3.7% FA in PBS and stained with 0.5% crystal violet in 20% ethanol. Viral titers were expressed as
PFU/mL.
2.8. MTT Assay
The MTT assay was used to measure cell proliferation and viability as described previously [39].
SNB-19 cells were plated in 100 μL media in 96-well plate, with 10,000 cells per well, and incubated
at 37 ◦C/5% CO2 overnight to allow the cells to attach to the wells. At the indicated time intervals
post-treatment, 10 μL of MTT solution (Thiazolyl Blue Tetrazolium Bromide, 5mg/mL in PBS) was
added to each well, thoroughly mixed and incubated at 37 ◦C for 4 h to allow the MTT to be
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metabolized. Then the media was removed and resuspended in 100 μL DMSO to solubilize formazan
(the MTT metabolized product). After shaking at 150 rpm for 5 min, the plate was subjected to optical
density measurement at 562 nm by a SYNERGY-H1 microplate reader (BioTek Instruments, Winooski,
VT, USA).
2.9. Measurement of Cellular Necrosis and Apoptosis
Cellular necrosis and apoptosis were measured by a RealTime-Glo™ Annexin V Apoptosis and
Necrosis Assay kit (Promega, Madison, WI, USA) according to manufacturer’s instruction. Briefly,
1 × 104 SNB-19 cells/well were seeded into a 96-well plate (Costar 3610, Corning, NY, USA) and
cultured at 37 ◦C/5% CO2 overnight. The cells were transduced with adenovirus, and 2x detection
reagent (which included Annexin V NanoBiT®substrate, CaCl2, Necrosis Detection Reagent, Annexin
V-SmBiT and Annexin V-LgBiT) was added into each tested well of 96-well plate. The plates were
incubated at 37 ◦C/5%, followed by measurements of luminance (RLU) for apoptosis, and fluorescence
(RFU, 485 nmEx/520–30 nmEm) for necrosis at the indicated time intervals post infection using a
SYNERGY-H1 microplate reader.
2.10. Statistical Analysis
Unless indicated, two-tailed and paired student t-test was used for a pair-wise comparison of
data, using Microsoft Excel software. Two-way ANOVA analysis was used to analyze results generated
for Figure 1B, Figure 2A, Figure 3C, Figure 4A, Figure 5B,C and Figure 6C,D, respectively using Prism
7 (GraphPad Software, San Diego, CA, USA). A difference is considered statistically significant if
p ≤ 0.1 (*), p ≤ 0.05 (**) or p ≤ 0.01 (***) according to conventional definitions.
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Figure 1. Different infectivity between the epidemic Brazilian Zika virus (BR15 and ICD) molecular
clones and the historical African MR766 molecular clone in human brain glial SNB-19 cells. (A) Viral
binding to SNB-19 cells was measured by presence of cell-associated vRNA one-hour post-infection
(p.i.). A housekeeping gene GAPDH was used as an endogenous control for the measurement of viral
bindings. (B) Zika virus (ZIKV) replication was measured by quantitative RT-PCR with timeframe
as indicated. SNB-19 cells were infected by Zika viruses with multiplicity of infection (MOI) 1.0.
Results represent average and standard deviation (X ± SD) of four independent experiments. (C) Viral
infectivity measured by anti-E mAb 4G2 at 48 h p.i. (D) Viral infectivity is shown as an average of three
different experiments, each carried out in triplicates. Average cell number counted was about 100–200.
Results represent average and standard deviation (X ± SD). Levels of statistical significance were
calculated by two-tailed and paired t-test for (A), and Two-way ANOVA was used for (B). **, p < 0.05;
***, p < 0.01.
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Figure 2. Different neuro-cytopathic effects of epidemic and historical molecular clones of Zika viruses
on human brain glial SNB-19 cells. (A) Cellular survival was measured by the MTT assay. The graph is
plotted as the relative growth in relevance to mock infected SNB19 cells. Statistic t-test shows that the
differences among three viruses are not statistically significant. (B) ZIKV-induced cell death as measured
by the Trypan blue assay. **, p < 0.05 for BR15 and ***, p < 0.01 for ICD. Three different experiments
were carried out. Average cell number counted was about 100–200. (C) ZIKV-induced apoptosis was
measured by caspase-3 cleavages using immunostaining as reported previously [32]. Cells were collected
at 72 h p.i. Two experiments were conducted and cells showing caspase-3 cleavages were counted at
10 different areas with an average number of cells counted at 25–75. All results represent average and
standard deviation (X + SD). Levels of statistical significance were calculated by Two-way ANOVA for (A).
The difference between MR766 and BR15 is highly significant with p < 0.01 (***).
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Figure 3. Correlation of the ZIKV C-prM with viral attachment and viral infection. (A) Generation of
chimeric ZIKV molecular clones are shown along with their parental clones. The chimeric viruses were
made between the MR766 and the BR15 ZIKV molecular clones. The viral genome exchange is at the
junction of prM and E protein. (B) Viral binding was measured by presence of cell-associated vRNA
1 h p.i. A housekeeping gene GAPDH was used as an endogenous control for the measurement of viral
bindings. Results represent average and standard deviation (X ± SD) of four independent experiments.
(C) ZIKV viral replication was measured by RT-qPCR with timeframe as indicated. (D) Viral infection
was measured by anti-E mAb 4G2 at 48 h p.i. (E) Quantification of the results shown in (D). SNB-19
cells were infected with Zika viruses with MOI of 1.0. Three different experiments were carried out in
triplicates. Average cell number counted was about 100–200. All quantitative results represent average
and standard deviation (X ± SD). Levels of statistical significance were calculated by two-tailed and
paired t-test for (B), and Two-way ANOVA was used for (C). **, p < 0.05; ***, p < 0.01.
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Figure 4. Correlation of the C-prM with ZIKV-induced growth restriction and apoptotic cell death.
(A) Cell proliferation was measured by the MTT assay. Statistic t-test shows the differences shown
among three viruses are not significant. (B) ZIKV-induced cell death was measured by the Trypan
blue assay 72 h p.i. Two different experiments were carried out. Average number of cells counted
was about 100-200. Differences between MR766 vs. BR15, and MR766 vs. B/M were both high
significant with p ≤ 0.05 (**) for both comparisons. The difference between MR766 and M/B was not
significant with p = 0.11. (C) ZIKV-induced apoptosis was measured by cleavage of caspase-3. Cells
were collected at 72 h p.i. All results represent average and standard deviation (X ± SD). Levels of
statistical significance were calculated by Two-way ANOVA for (A). The difference between MR766
and BR15 is highly significant with p < 0.01 (***).
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Figure 5. Effect of prM protein processing on ZIKV-induced neurocytotoxicity. (A) Cell proliferation
and viability was measured overtime by the MTT assay. The graph is plotted as the relative growth
in relevance to mock infected SNB-19 cells. The differences shown were highly significant with
p < 0.05 (**). (B) Measurement of apoptosis by Annexin V over time. The difference between Adv-prM
and Adv-M was highly significant with p < 0.01 (***), but the difference between Adv-prM and Adv-Pr
was not significant with p = 0.84. (C) Measurement of cellular necrosis over time. Two-way ANOVA
was used to calculate the difference between Adv-prM and Adv-M for (B) and (C). The differences
between Adv-prM and Adv-M were highly significant with p < 0.01 (***). More than two different
experiments were conducted to evaluate apoptosis and necrosis. All results represent average and
standard deviation (X ± SD).
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Figure 6. Mutational analysis of the Pr region of the prM protein. (A) Mutagenesis of the Pr protein.
Four amino acids mutations (A148P, V153M, H157Y and V158I) were generated as shown by “*” on the
top of the prM sequence alignments between MR766 (top) and BR15 (bottom). The resulting mutant
adenoviral construct is labeled as Adv-Pr*MR766. The site of the reverse N139S mutation is shown
by “†” on the top of the prM sequence. The corresponding mutant adenoviral construct is labeled as
Adv-Pr†BR15. (B) Cell proliferation and viability by the MTT assay. Only Adv-prM showed significant
differences overtime with p < 0.05 (**). Adv-Pr-induced cell death was measured by (C) apoptosis,
and (D) necrosis over time. The underlined RSRR sequence indicates the putative furin cleavage site
on the prM protein, based on its consensus target site Arg-X-Lys/Arg-Arg↓, where the arrow indicates
the location of furin cleavage site. Two-way ANOVA was used to calculate the differences between
Adv-prM and Adv-M for (C) and (D). The differences between Adv-Pr MR766 and Adv-Pr* MR766
were highly significant with p < 0.01 (***). However, the difference between Adv-Pr BR15 and Adv-Pr†
BR15 was not significant with p > 0.99 for both apoptosis and necrosis. All quantitative results represent
average and standard deviation (X ± SD).
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3. Results
3.1. Comparison of Viral Infectivity Between the Historical African Zika Virus and the Epidemic Brazilian Zika
Viruses in Human Brain Glial SNB-19 Cells
Viral infectivity is defined as the ability of the ZIKV to bind, enter, and to replicate in host cells
over time [40]. The goal of this experiment was to compare the viral infectivity between the epidemic
Brazilian ZIKV molecular clones (BR15 and ICD) and the historical African ZIKV molecular clone
(MR766). We first compared the viral attachment between molecular clones derived from epidemic
Brazilian ZIKV strains (BR15 and ICD) and from the historical African ZIKV strain (MR766). All three
ZIKV molecular clones have been reported previously [30,36]. The historical MR766 ZIKV strain is
the first documented Zika strain that was isolated from caged monkey in the Zika forest in Uganda
in 1947 [9]. Two epidemic ZIKV strains, BR15 (BeH819015) and ICD (Paraiba_01/2015) were isolated
from Brazil in 2015 during the ZIKV epidemic [34,36]. A human brain glial cell line SNB-19 was used
in this study because it is highly permissive to ZIKV infection [32].
The SNB-19 cells were infected with these three ZIKV molecular clones at the MOI of 1.0. After 1 h
of incubation on ice, the free viruses were removed by washing the infected cells with cold RPMI 1640
medium supplemented with 2% FBS. Cell-associated viral RNA (vRNA), which represents the viruses
attached to the cell surface, was isolated and quantified by real-time RT-PCR. A housekeeping gene,
GAPDH, was used as an endogenous control for the measurement of viral bindings. As shown in
Figure 1A, statistically significant differences in the virus binding to the SNB-19 cells were observed.
Specifically, the numbers of ZIKV ICD or BR15 viral particles, that bound to the cells were about 4.2- to
9.5-fold lower, compared to the MR766 molecular clone.
We next monitored ZIKV viral replication over a time period of 3 days by real-time RT-PCR analysis
(Figure 1B). The infection of the MR766 results, in consistently high viral RNA levels, were about 30-fold
higher than that of BR15 or ICD over time. Both MR766 and BR15 displayed comparable replication
kinetics, with a replication rate of 5.9 ± 0.71 fold-increase, and 4.4 ± 0.47 fold-increase, from 24 h, to 48 h
p.i., respectively. The rate of vRNA decreased thereafter, presumably due to cytotoxicity. Notably, the vRNA
in the ICD-infected cells was relatively stable over time, with an average replication rate of 1.3 ± 0.27
fold-increase, from 24 h to 48 h p.i.
Since there were clearly differences in the levels of viral bindings and the rates of vRNA production
between the two types of molecular clones, we tested whether they were due to the viral permissiveness
to SNB-19 cells, which typically represents the result of viral circumvention to host antiviral responses.
The percentage of cells producing ZIKV particles was measured at 48 h p.i. Cells were immune-stained
using the monoclonal antibody 4G2, which is directed against the flavivirus E protein [32]. The results
of the immunostaining are shown in (Figure 1C), and the percentages of infected cells with each
molecular clone are shown in (Figure 1D). Infection with the MR766 molecular clone resulted in
statistically higher percentages of infected cells, with an average of 81.9% than the two Brazilian
molecular clones, that displayed 57.8% for BR15 and 46.1% for ICD.
Together, these data indicate that the historical African strain MR766 showed a higher rate vRNA
production and better infectivity in SNB-19 cells than that of the epidemic Brazilian ZIKV molecular
clones (BR15 and ICD) presumably due to, at least in part, higher level of virus binding.
3.2. Comparison of the Historical Zika Virus with the Brazilian Epidemic Zika Viruses in Their Abilities to
Induce Cytotoxicity
We next tested ZIKV-mediated cytotoxicity of the three ZIKV molecular clones. The SNB-19 cells
were infected with the three molecular clones separately, as described in the Materials and Methods
section. The MTT assay, which measures cell proliferation and viability [39], was used to measure the
impacts of ZIKV infection on cellular metabolic activities. As shown in Figure 2A, cell proliferation and
viability decreased rather rapidly in the MR766-infected cells between 24 h to 72 h p.i., whereas BR15-
and ICD-infected cells were less affected. Even though the trend was clear, the differences are not
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statistically significant. ZIKV-mediated cell death was then measured over the same period of time by
Trypan blue staining that specifically detects dead cells. Time-dependent cell death was observed in
cells infected with all three molecular clones. ZIKV-induced cell death was the most pronounced at
72 h p.i., in which the rate of MR766-induced cell death was significantly increased with 49.0 ± 5.0% of
Trypan blue-positive cells than that of BR15 or ICD both with 25.3 ± 2.1%, and 27.9 ± 4.4% of dead
cells, respectively (Figure 2B; two-tailed t-test). To further assess whether ZIKV-induced cell death
in the SNB-19 cells was caused by apoptosis, we carried out an immunostaining assay to measure in
situ Caspase-3 (Casp-3) cleavages, a hallmark of apoptosis [30,32]. In mock-infected cells, little or no
cells showed background staining (Supplemental Figure S1A); whereas ZIKV-infected cells showed
Casp-3 cleavages, and MR766-infected cells showed significantly higher percentage of apoptotic cells
(Figure 2C; two-tailed t-test, p ≤ 0.001). These data show that the historical MR766 molecular clone is
more apoptotic than the two Brazilian molecular clones (BR15 and ICD), suggesting that mutations
within the epidemic strains might contribute to the reduced cytotoxicity.
3.3. Effects of the C-prM Region on Viral Infectivity
Since there were clear differences in viral infectivity between the historic and epidemic ZIKV
strains in SNB-19 cells (Figure 1), we were interested in identifying which part of the ZIKV genome is
responsible for the observed differences. Hereafter, we only focused on MR766 and BR15 molecular
clones, as BR15 and ICD were very similar. Our previous study showed that the structural protein
region (C-prM-E) of the ZIKV genome contributed to initiation of viral infection [30]. In this study,
we decided to generate chimeric viruses, by separating the C-prM region from the E region of the
structural proteins, using the ISA method [33]. In this way, we were able to differentiate the possible
contribution of the C-prM region to viral infectivity or cytotoxicity from that of the E region. Specifically,
the C-prM region of the MR766 was exchanged with that of the BR15 molecular clone, or vice versa.
The two resulting new chimeric viruses were designated as M/B or B/M, in which the chimeric M/B
virus carries the C-prM region of the MR766 with the rest of viral genome from the BR15; conversely,
the chimeric B/M virus carries the BR15 C-prM region and the rest of the genomic structure is from
MR766 (Figure 3A). These two chimeric viral genomes were assembled separately in Vero 76 cells,
as previously described [30]. The viruses were recovered from cell supernatants, and were then
amplified twice in Vero76 cells. The final viral titers were determined using the plaque-forming
assay [38].
The ability of the two chimeric viruses to bind SNB-19 cells was firstly evaluated (Figure 3B).
As the E protein is responsible for viral attachment to cells [10,21], the levels of cell attachment indeed
corresponded to which ZIKV strain the E region originated from. For example, as we previously
demonstrated [30], significantly high levels of cell-attached vRNA were observed with ZIKV clones
harboring the MR766 structural proteins. Similar levels of cell-associated vRNA were detected with
the B/M virus, in which the MR766-derived E protein is presented. In contrast, both the BR15 and
the M/B viruses were less efficient in attaching to SNB-19 cells. The same viral binding test was also
conducted in a different cell line A549, and similar results were observed (Supplemental Figure S2A).
These results confirm the link between the E protein and cell attachment, and demonstrate that C-prM
region is not directly involved in viral attachment to the host-cells. In addition, the initial levels of
ZIKV viral replication as measured by RT-PCR correlated with the levels of virus attachment to SNB-19
cells (Figure 3C). MR766 and B/M showed significantly higher levels of vRNA over time than BR15
and M/B, with similar kinetics. Consistently, the conventional plaque-forming assay was also used
to test viral infectivity of newly generated chimeric viruses in A549 cells. The test results showed a
strong correlation between 4G2-positive cell percentages and viral progeny productions (Supplemental
Figure S2B).
We next analyzed the percentages of SNB-19 cells infected with these two chimeric viruses and
their parental controls. As shown in (Figure 3D,E), both chimeric viruses were able to infect the
SNB-19 cells. Interestingly, an opposite correlation was observed between the chimeric viruses and
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the parental viruses in the percentages of viral infection to the SNB-19 cells. Statistical two-tailed and
paired t-test analyses showed that the differences between MR766 vs. BR15, and MR766 vs. B/M were
highly significant with p ≤ 0.01 (***) for both comparisons; whereas the difference between MR766 and
M/B was not significant with p = 0.64. Thus, the levels of infected cells, with a given chimeric virus,
correlated with the C-prM region of its parental virus, not the E region. Indeed, in the cells infected by
the M/B chimeric virus, the percentage of infected cells was significantly higher than that of BR15,
but it was comparable with that of MR766 (p = 0.64, two-tailed and paired t-test). A similar correlative
relationship was also observed between the B/M chimeric virus and the BR15 virus (Figure 3E).
These results confirm that ZIKV E region correlates with viral attachment to the host cells,
and suggest that ZIKV C-prM region contributes to the permissiveness of viral infection.
3.4. Contribution of the ZIKV C-prM Region to ZIKV-Induced Growth Restriction and Apoptotic Cell Death
The data shown in Figure 3D,E were unexpected. It is believed that if the virus has high binding
efficiency to the host cells, it should result in higher percentage of viral infected cells. Since ZIKV
induces cytotoxicity, we reasoned that the C-prM region could contribute to ZIKV-induced cytotoxicity,
which affects the outcome of the measured levels of viral infection. To test this possibility, we measured the
effects of chimeric viruses on cell proliferation and viability. As shown in Figure 4A, genetic determinant(s)
of cell viability was associated with of the C-prM region of the viral genome. For instance, both MR766
and M/B showed similar cell growth pattern, which was clearly distinguishable from that of BR15 and
B/M. Nevertheless, a statistical t-test showed those differences were not statistically significant. However
and consistent with the trend shown in Figure 4A, a similar but statistically significant correlation was
detected in ZIKV-induced cell death (Figure 4B), and in apoptosis, as shown by the casp-3 cleavages
(Figure 4C). Together, these data supported the idea that the C-prM domain of African ZIKV molecular
clone contributes to ZIKV-induced growth restriction and apoptotic cell death.
3.5. Effect of prM Protein and Its Processed Protein Products (M and Pr) on ZIKV-Induced Cytotoxicity
Considering the association of the C-prM region of ZIKV genome with virus-induced cytotoxicity,
it was interesting to evaluate whether the proteolytic processing of the C-prM protein precursor relates
to cytotoxicity. Here, we focused on testing prM protein and its processed protein products (M and Pr).
The C protein was studied separately. The proteolytic cleavage of prM by furin protease generates
two proteins: a virion-associated M protein of 75 a.a. and an extracellularly released Pr polypeptide of
99 a.a. The M protein is only found in mature and fully infectious virus particles [10,41].
The SNB-19 cells were transduced with MOI of 1000 by Adv-prM, Adv-Pr or Adv-M, that were
derived from MR766. They represent the precursor prM and a processed mature M protein and a Pr
protein product, respectively. Mock-transduced cells were used as a background control. Cell viability
was first measured at day 3 and day 5 p.i. as shown in Figure 5A. Both the prM and the Pr caused
approximately 50% reduction of the cell viability while no clear change in cell viability was observed
in the Adv-M-transduced cells. The prM effect on cell viability was further confirmed in different
cell lines including human brain microvascular endothelial cells (HBMEC) and a neuronal cell line
SH-SY5Y (Supplemental Figure S3A). Time-dependent measurements of cellular necrosis (Figure 5B)
and apoptosis (Figure 5C), by real-time Annexin V Apoptosis and Necrosis assays, showed comparable
results, in total agreement with the MTT assay at end of the time course. Note that the differences
among the three Adv constructs were relatively small at early time points and only became significant
at 120 h p.i.
Overall, our data indicated that ZIKV prM protein and its cleaved Pr protein product, but not the
matured M protein, induced apoptotic cell death in SNB-19 cells.
3.6. Mutational Analysis of the Pr Region of the prM Protein and Their Effects on ZIKV-Induced Cytotoxicity
In Figure 2, we showed that the MR766 was more cytotoxic than the BR15. Our data further
showed that the MR766 prM, and its cleaved product, Pr protein contributed to ZIKV-induced
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cytotoxicity, suggesting that the Pr region of the prM protein might be the source of prM-mediated
cytotoxicity (Figure 5). However, we did not know whether Pr-induced apoptosis is ZIKV
strain-specific. There is a total of 10 known divergent a.a. mutations of prM protein between MR766
and BR15 (Figure 6A) [31]. Seven of those mutations are within the Pr region. Thus, we tested whether
the Pr-induced cell death is only restricted to MR766, or whether we could alter the Pr-induced cell
death by introducing divergent genetic mutations, that are present in the Pr protein of the BR15
molecular clone into the MR766 Pr protein. The residue 139 was first selected for reverse genetic
analysis because the pre-epidemic to epidemic mutational transition from S to N at the residue 139
(S139N) of the Pr region was reported to be a crucial site for ZIKV-induced microcephaly [31]. Here,
we reversed this mutational transition by generating the N139S mutation on the backbone of the
BR15 Pr nucleotide sequence (Adv-PrBR15) to generate the Pr mutant (Adv-Pr†BR15). Another four
additional a.a. mutational sites (A148P, V153M, H157Y and V158I) were selected for the forward genetic
mutagenesis. This region was of particular interest because the A148P mutation could have a major
impact on protein folding. We decided to replace the entire cluster 148->158 as adjacent mutations
could support putative structure changes associated with A148P mutation. The wildtype MR766 Pr
nucleotide sequence (Adv-PrMR766) was used to generate the MR766 Pr mutant clone (Adv-Pr*MR766),
that carries the four selected mutants to represent forward genetic mutations.
The effect of Adv-Pr†BR15 or Adv-Pr*MR766 on the SNB-19 cell viability was measured by the MTT
assay and compared to the wild type Adv-PrBR15 or the Adv-PrMR766. The expression of Adv-PrBR15
showed comparable proliferation and viability at day 3 and day 5 p.i., suggesting that the BR15 Pr is
not as cytotoxic as the MR766 (Figure 6B). Next, we analyzed the effect of the N139S reverse mutation
in the BR15 Pr protein. The introduction of the N139S substitution into the BR15 Pr protein showed
little or no significant changes of BR15 Pr-induced growth restriction and cell death. In contrast and
similar to what we showed in Figure 5A, about 50% decrease of cellular growth was observed in cells
transduced with the wildtype Adv-PrMR766 at 5 days p.i. (Figure 6B). However, cells infected with
the mutant Adv-Pr*MR766 displayed no viability decrease in cellular growth, in marked contrast with
cells transduced with the wildtype Adv-PrMR766 at 5 days p.i. (Figure 6B). Similarly, the induction of
necrosis (Figure 6C) and apoptosis (Figure 6D) by Adv-PrMR766 was completely blocked by the four
a.a. mutations generated in the Pr region.
These data suggest that the Pr region of the MR766 prM protein is indeed responsible for
prM-induced cytotoxicity. By introducing the four epidemic and divergent a.a. variants (A148,
V153, H157 and V158) to the MR766 Pr region of the prM protein, by forward mutagenesis, alleviated
MR766 Pr-induced apoptotic cell killing. This suggests that the acquisition of these four a.a. in BR15
could be responsible for its attenuated cytotoxic phenotype. However, reverse genetic mutation at the
residue 139 (N139S) did not improve Adv-PrBR15-induced cytotoxicity, indicating the N139S mutation
does not seem to play a role in prM-induced cytotoxicity.
4. Discussion
In this study, we showed that the historic African MR766 ZIKV strain displays different
characteristics from that of the epidemic Brazilian strains BR15 and ICD. Those differences include the
levels of virus attachment to the human brain glial SNB-19 cells, viral infection and replication overtime
(Figure 1), as well as cytotoxicity, as measured by cell proliferation and apoptotic cell death (Figure 2).
Since our early study showed that the structural protein region is responsible for the initiation of viral
infection, in this study, we further examined the contribution of ZIKV structural prM-E proteins to
viral infectivity and cytopathic effects. This was accomplished by generating chimeric viruses (M/B
and B/M) that swap the C-prM and E regions of the structural proteins between the MR766 and
the BR15 viral genomes. We showed that the E protein is associated with viral attachment to host
cells (Figure 3B,C) and the C-prM region is correlated with viral permissiveness and ZIKV-induced
cytotoxicity (Figure 3D,E; Figure 4). Further analysis of the prM and its processed protein product,
the mature M protein and the Pr protein, indicated that the Pr region of the prM is responsible for
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the prM-induced cytopathic effects (Figure 5). To further pinpoint where exactly the specific changes
occurred in the Pr region of the prM protein, which contributes to the differences observed between
MR766 and BR15, we carried out genetic mutagenesis (Figure 6A) to test whether we could reverse
or mimic the respective effects observed in MR766 or BR15. As a result, we showed that the forward
genetic mutation at four a.a. changes (A148P, V153M, H157Y and V158I) reversed MR766 Pr-induced
cytopathic effects (Figure 6B–D). However, the reverse genetic mutation at the residue of 139 (S139N)
did not show any clear effect (Figure 6B–D).
Differences between the historic African MR766 strain and the epidemic Brazilian ZIKV strains have
been reported previously [for reviews, see [27,28]]. Although the specific causes of those differences
are currently unknown, it is possible that the neurological defects caused by the epidemic Brazilian
ZIKV in humans were attributed by subtle but important changes. Those newly adapted changes could
include the alteration of viral infection patterns to human brain cells, the ability to establish replication
in host cells, and the induction of neuropathic damages that lead to those observed ZIKV-associated
neurological disorders [27]. Overall, the historic African MR766 strain has been shown to be more virulent
and to cause more severe brain damage than that of the epidemic Asian lineages, including the Brazilian
strains [25,42–44]. Indeed, the results of our comparative studies, described here between the historic
African MR766 and the epidemic Brazilian BR15 and ICD molecular clones, supported this general notion
that MR766 strain is more pathogenic than Brazilian strains.
One of our earlier studies suggested that the structural proteins contribute in part to the differences
we observed between historical MR766 and epidemic BR15 strains of Zika viruses [30]. Following that
lead, we further dissected the structural proteins of those two ZIKV molecular clones and evaluated
the effect of separating the C-prM proteins from the E protein in viral infectivity and induction of
cytotoxicity. This objective was achieved by swapping the C-prM region of the viral genome between
the two viruses (Figure 3A). Our results suggested that the E protein is likely associated with viral
attachment to host cells (Figure 3B,C) whilst the C-prM region is responsible for ZIKV permissiveness
and ZIKV-induced cytopathic effects (Figure 3D,E; Figure 4). The finding that, E protein is linked to
viral attachment to host cells, is expected because E protein is a major viral surface protein that is
responsible for the viral entry. It is a crucial that the viral determinant for initiating the ZIKV-host
interaction and for determining viral pathogenesis, and further investigations are needed [10,21].
Our study also suggests a possible relationship between ZIKV permissiveness and ZIKV-induced
apoptosis, which would be based on the Pr, a processed protein product by furin cleavage of the prM
protein. It would be interesting to clarify the exact contribution of the Pr protein in this relationship.
Here, we provide evidences showing that the function of the prM protein is linked to
ZIKV-induced cytotoxicity that could affect the outcome of viral infection (Figure 3D,E; Figure 4).
This finding is consistent with our previous reporting showing that the prM protein induces cytopathic
effects in fission yeast cells [15]. The dissection analysis of the prM processing further indicated
that the functional domain of the prM-mediated cytotoxicity resides within the Pr region of the
protein (Figure 5). Most interestingly, reverse genetic analysis by converting asparagine (N) at
residue 139 of the BR15 molecular clone to serine (S) of the MR766 molecular clone (N139S) did
not significantly alter the cytopathic effects of BR15 Pr (Figure 6B–D). In contrast, forward genetic
mutation analysis completely reversed the MR766 Pr-induced cell growth restriction and apoptotic cell
death (Figure 6B–D), by replacing four divergent a.a. at residues 148, 153, 157 and 158 presented in
MR766, with that of BR15 (A148P, V153M, H157Y and V158I). Note that, ideally, a reciprocal mutant
construct should also be generated using BR15 backbone to test whether the opposite effect can be
observed. However, the presence of additional divergent amino acids in the Pr protein (Fig. 6A) could
contribute to the observed phenotypes that will complicate the interpretation of the experimental
results using reciprocal constructs. Similarly, to confirm the mutant effect of Pr during viral infection,
it would be desirable to generate a MR766 mutant molecular clone that contains the four described
a.a. and test their mutant effect in the context of viral infection. This is not possible because, besides
the prM, the ZIKV-induced apoptotic phenotype is also contributed by other viral proteins, such as
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non-structural proteins during viral infection. For these reasons, we decided not to generate this
reciprocal adenoviral mutant construct or the mutant viral molecular clones.
It should be mentioned that an early study indicates that the pre-epidemic to epidemic
mutational transition (S139N) of the prM protein is a crucial site for ZIKV-induced microcephaly [31].
This forward genetic substitution in the viral polyprotein of a presumably less neurovirulent
Cambodian ZIKVFSS13025 strain [45], substantially increased ZIKV infectivity in both human and
mouse neuronal cells, that led to more severe microcephaly in the mouse fetus, as well as higher
mortality rates in neonatal mice [31]. The results of this study suggested an important contribution
of prM to fetal microcephaly. However, the molecular mechanism in which prM contributes to
microcephaly, and the functional impact of S139N mutation on the prM function in human host cells,
are presently unknown. It is intriguing to note that residue 139 is located in the Pr region of the
prM protein. Since neither prM nor Pr are present in the mature and infectious viral particles [24,46],
it would be interesting to test whether the N139S substitution in the MR766 strain or the four divergent
mutations in the BR15 strain will have any effects on their abilities to infect human brain cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/2/157/s1,
Figure S1: Representative pictures of the immunostaining assay to measure caspase 3 cleavages (A) as shown
in Figure 2C; Figure S2: Correlation of viral attachment and viral infection between chimeric viruses and their
parental viruses in A549 cells; Figure S3: Effect of Adv-prM expression on ZIKV-induced cell viability in different
cell lines.
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Abstract: Zika virus (ZIKV) is an emerging pathogen member of the Flaviviridae family. ZIKV has
spread rapidly in the Latin American region, causing hundreds of thousands of cases of ZIKV disease,
as well as microcephaly in congenital infections. Detailed studies on the pattern of evolution of ZIKV
strains have been extremely important to our understanding of viral survival, fitness, and evasion of
the host’s immune system. For these reasons, we performed a comprehensive phylogenetic analysis
of ZIKV strains recently isolated in the Americas. The results of these studies revealed evidence of
diversification of ZIKV strains circulating in the Latin American region into at least five different
genetic clusters. This diversification was also reflected in the different trends in dinucleotide bias
and codon usage variation. Amino acid substitutions were found in E and prM proteins of the
ZIKV strains isolated in this region, revealing the presence of novel genetic variants circulating in
Latin America.
Keywords: Zika; viral evolution; genetic variability; Bayesian analyses
1. Introduction
Zika virus (ZIKV) is an emerging pathogen member of the Flaviviridae family, naturally
transmitted between Aedes spp. mosquito vectors and human/non-human primates, which
serve as amplifying hosts in urban and sylvatic cycles, respectively [1]. The ZIKV genome
consists of a single-stranded positive sense RNA molecule of about 10.7 kb with two flanking
non-coding regions (5′ and 3′NCR), and a single long open reading frame encoding a polyprotein:
5′-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3′. This polyprotein is cleaved into capsid (C),
precursor of membrane (prM), envelope (E), and seven non-structural proteins (NS) [2]. ZIKV was
isolated for the first time in 1947, from the blood of a sentinel Rhesus monkey stationed in the
Zika forest, Uganda [3]. Although ZIKV enzootic activity was reported in diverse countries within
Africa and Asia, only a few human cases were reported until 2007, when an epidemic occurred in
Micronesia [4]. A large ZIKV outbreak took place in French Polynesia during 2013–2014, and then
spread to other Pacific Islands [5]. In early 2015, a ZIKV epidemic outbreak took place in Brazil,
estimated at 440,000–1,300,000 cases [6]. By January 2016, locally transmitted ZIKV cases were reported
by most countries and territories of the American region to the Pan American Health Organization [7].
ZIKV has spread rapidly across the Americas, causing hundreds of thousands of cases of
ZIKV disease in this region, as well as microcephaly associated with congenital infection and other
neurological disorders [8]. To date, ZIKV has been classified into two major genetic lineages, namely
African and Asian. The African lineage is comprised of two groups: The West African (Nigerian
Viruses 2018, 10, 698; doi:10.3390/v10120698 www.mdpi.com/journal/viruses361
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cluster) and East African (MR766 prototype cluster) [9,10]. Previous studies have shown that the Asian
genetic lineage is responsible for the Pacific Islands and American outbreaks [11,12].
The two viral envelope proteins, prM/M and E, have been used as major targets for vaccine
development against ZIKV infections [13], since they are the main determinants for the high stability
of ZIKV, and where epitopes for CD4+ and CD8+ T-cell adaptive immune responses and neutralizing
antibodies are located [13,14]. The most promising vaccines currently in trials are the ones that use a
combination of both prM and E proteins [13]. A detailed characterization of prM and E proteins of
ZIKV strains circulating in all regions of the world are very important for our understanding of the
antigenicity and pathogenesis of ZIKV, as well as for the development of suitable ZIKV vaccines.
For all these reasons, a detailed analysis on the molecular evolution of ZIKV populations is
of extreme importance to understand the relation among viruses and hosts, viral survival, fitness,
and evasion from the host’s immune system [15,16]. In order to gain insight into these matters,
we performed a comprehensive phylogenetic analysis of recently isolated ZIKV strains in the Latin
American region. Five different genetic clades were observed revealing a process of diversification
among the ZIKV strains circulating in this region. Besides, these genetic clades displayed distinct
compositional properties. Amino acid substitutions were found in E and prM proteins of the ZIKV
strains isolated, revealing the presence of novel genetic variants circulating in the American region.
2. Materials and Methods
2.1. Sequences
Complete coding sequences of 61 available and comparable ZIKV strains, isolated from humans
in the Latin American region, from December 2014 through to August 2017, as well as comparable
10 ZIKV strains isolated in the south region of the USA were obtained from GenBank (available at
http://www.ncbi.nlm.nih.gov). For strains, accession numbers, geographic location, and date of
isolation, see Supplementary Material Table S1. Only strains for which the day, month, and year of
isolation was known were included. Sequences were aligned using MUSCLE [17].
2.2. Recombination Analysis
GARD program was used to detect any possible recombination event [18]. There was no evidence
of recombination in the dataset.
2.3. Bayesian Coalescent Markov Chain Monte Carlo (MCMC) Analysis
To investigate the evolutionary rate and patterns of ZIKV strains circulating in the Latin American
region, we used a Bayesian Markov Chain Monte Carlo (MCMC) approach as implemented in the
BEAST package v.1.8.0 [19]. We started by identifying the evolutionary model that best fit our
sequence dataset by using the FindModel software (available at http://hiv.lanl.gov/content/sequence/
findmodel/findmodel.html). Bayesian Information Criterion (BIC), Akaike Information Criterion
(AIC), and the log of the likelihood (LnL), indicated that the Tamura-Nei (TN93) + Γ model was the most
suitable model (BIC = 41,048.518; AIC = 39,356.515; and LnL = −19,531.228). Importantly, the strict and
the relaxed molecular clock models were implemented to test different models (constant population
size, exponential population growth, expansion population growth, logistic population growth, and
Bayesian Skyline). Statistical uncertainty in the data was reflected by the 95% highest posterior density
(HPD) values. By using the TRACER program v1.6 (available at http://beast.bio.ed.ac.uk/Tracer) we
assessed the results. Fourty-million generations were needed to obtain convergence, after a burn-in of
4 million steps, which were enough to acquire a suitable sample for the posterior, assessed by effective
sample sizes (ESS) with values over 200. The comparison of models was done by measuring AIC
in a Bayesian Monte Carlo (AICM) from the posterior output of each of the models using TRACER
v1.6 program. Lower AICM values indicated better model fit. The Bayesian Skyline model was the
best model to analyze the data (see Appendix A). Through the Tree Annotator program, maximum
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clade credibility trees were generated, and then visualized in the FigTree program v1.4.2 (available at
http://tree.bio.ed.ac.uk).
2.4. Compositional Analyses
For each ZIKV, we determined for the whole polyprotein: Dinucleotide observed/expected ratios
(dinucleotide bias), relative synonymous codon usage (RSCU) values for each degenerate codon (all
triplets excluding AUG, UGG, and stop codons), and amino acid frequencies; as was described in
previous work on the genus Flavivirus [20]. These compositional analyses were performed using the R
package seqinr [21], with count, rho, and AAstat functions. The relationship between compositional
variables and samples was obtained using multivariate statistical analyses; principal component
analysis (PCA) is a type of multivariate analysis that allows a dimensionality reduction. Compositional
properties of each strain included in this study were obtained, and the distribution of these strains
in the plane defined by the first two principal axes of a PCA (PC1 and PC2) examined. Major trends
within a dataset were determined using measures of relative inertia and sequences ordered according
to their position along the different axes, and correlation between the axes and original variables.
For the values obtained from the compositional analyses, see Table S2.
2.5. Prediction of Exposed Residues and Structural Regions of E and prM Proteins
To identify exposed residues and coiled regions of E and prM ZIKV proteins, we used the
BepiPred approach [22]. BepiPred uses hidden Markov algorithms in combination with propensity
scale methods to predict epitopes in protein sequences. From a FASTA file as input, the method outputs
a GFF file with prediction scores and classifications, given a threshold. We used the BepiPred online
server (available at http://www.cbs.dtu.dk/services/BepiPred) with 0.5 as threshold.
3. Results
3.1. Bayesian Coalescent Analysis of ZIKV Strains Recently Isolated in the Latin American Region
To address the degree of genetic variability and mode of evolution of the ZIKV strains recently
isolated in the Latin American region, a Bayesian MCMC approach was employed [17]. The results
shown in Table A1 were the outcome of 40 million steps of the MCMC, using the Tamura-Ney (TN93)
+ Γ model, a relaxed molecular clock, and the Bayesian Skyline model. The date of the most common
ancestor to all ZIKV strains isolated in Latin America was estimated to be in early 2014 (95% HPD
October 2013 to December 2014), in agreement with recent results [23–25]. A mean rate of evolution of
1.21 × 10−3 substitutions per site per year (s/s/y) was found for the ZIKV sequences included in these
studies (95% HPD 7.55 × 10−4 to 1.66 × 10−3). This was also in agreement with recent estimations of
1.15 × 10−3 s/s/y [23].
The phylogenetic relationships among ZIKV strains recently isolated in the Latin American region
were explored and summarized in a maximum clade credibility tree shown in Figure 1. ZIKV strains
isolated in the Latin American region from 2014 to 2017 clustered in at least five different genetic
groups, revealing a significant local genetic diversification of the ZIKV strains isolated in this region.
Co-circulation of different genetic lineages was observed in several countries in the region (see for
instance the ZIKV strains recently isolated in Cuba in 2017).
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Figure 1. Bayesian maximum clade credibility tree representing the time-scale of ZIKV, obtained by
the analysis of 61 complete coding sequences using the Tamura-Ney (TN93) + Γ model, the Bayesian
Skyline model, and a relaxed exponential clock. The tree is rooted to the Most Recent Common
Ancestor (MRCA) of strains included. The scale at the bottom is in units of evolutionary time and
represents the years before the last sampling date. Strains in the tree are shown by their accession
number, geographical location, and year of isolation expressed in decimal format. Clades are indicated
in blue, red, green, violet, and black.
3.2. Trends in Compositional Properties Across ZIKV Strains Isolated in the Latin American Region
Principal component analysis (PCA) has shown different patterns among the genetic clusters
examined (Figure 2; also see Supplementary Material Figure S1 for the loadings of the compositional
variables). The phylogenetic clusters of the Zika strains presented in Figure 1 displayed a similar
behavior for each compositional property analyzed (i.e., dinucleotide bias, RSCU, and amino
acid frequencies).
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Figure 2. Positions of the ZIKV strains for the first two major axes of principal component analysis of
the (a) dinucleotide observed/expected ratios, (b) relative synonymous codon usage, and (c) amino
acid frequencies. The proportion of variance explained by each axis is displayed, placed between
parentheses. Strains in the plot are colored according to their clade assignment depicted in Figure 1
(i.e., in blue, red, green, violet, and black).
Dinucleotide biases account for the dinucleotides over- and/or under-represented in a genome.
For these Zika strains, the first axis (PC1) generated by the PCA accounted for 28% of the total variation,
while the second axis (PC2) accounted for 18%. The results of this study are shown in Figure 2a. PC1
tended to separate the majority of clade red sequences from the rest; this axis had strong positive
correlations with dinucleotides ApC and GpG, and correlated negatively with UpC and ApG. The other
axis tended to distinguish blue and green clades; PC2 correlated positively with UpA and negatively
with both UpG and GpU.
The redundancy of the genetic code confers the possibility to tune the efficiency and accuracy
of protein production to various levels, while maintaining the same amino acid sequences [26].
The relation of codon usage among viruses and their host’s is expected to affect viral survival, fitness,
evasion from the host’s immune system, and evolution [27]. PC1 accounted for 16% of the total
variation, while the PC2 accounted for 14% (Figure 2b). PC1 discriminated the red clade from the
green clade; this axis was explained by relatively high usage of CUC, AAU, UAC, and AUC codons,
and relatively low usage of GUC, AAC, CUU, and UAU (towards the positive values of the PC1; the
opposite towards the negative ones).
Amino acid frequencies vary as a result of non-synonymous mutations across a coding sequence.
PC1 and PC2 accounted for 23% and 12% of the total variation, respectively (Figure 2c). PC1 separated
the green clade from the other clades, due to a relative enrichment in cysteine and leucine, based on
the highest correlations of this axis with the amino acid frequencies. Finally, PC2 was associated with
glutamic acid and tryptophan.
3.3. Mapping of Amino Acid Substitutions in the ZIKV E Protein
ZIKV enters the host cell by receptor-mediated endocytosis. Importantly, the E protein has been
associated with attachment and endosomal membrane fusion. Thus, the action of E-binding antibodies
can impair receptor interaction and/or membrane fusion, making this protein the main target for
virus-neutralizing antibodies [28]. Three domains constitute the ZIKV E protein: A central β-barrel
domain (DI), an extended dimerization domain (DII), and an immunoglobulin-like segment (DIII) [29].
A fusion loop (FL) is located at the distal end of DII. This loop is inserted directly into the endosomal
membrane of the host cell and then triggers fusion thanks to pH-dependent conformational changes.
Furthermore, antiparallel dimers are packed in the E protein in a herringbone pattern that lies against
the lipid envelope [30].
To investigate if the genetic variability observed among America´s ZIKV strains was associated
with antigenic changes displayed by their E protein sequences, we explored their inferred amino acid
substitutions. From the 61 strains isolated in this region, amino acid substitutions were found in only
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eight ZIKV strains with respect to the H/PF/2013 strain of the Asian genotype (accession number
KJ776791; Table A2). Intriguingly, three substitutions were found at the DIII domain (V330L, T335A,
and T369I) of E proteins from strains isolated in Latin America with respect to the H/PF/2013 strain
(Figure 3).
Figure 3. An amino acid sequence alignment of the DIII domain of ZIKV E proteins. Strains are shown
by accession number, geographic location, and year of isolation. Identity of the strain H/PF/2013 from
the Asian genotype (accession number KJ776791) is shown by a dash. Sequence position relative to
the E protein of that strain is shown on the top of the figure. Predicted coiled regions of the protein
are indicated by a blue arrow on top of the alignment. Predicted exposed residues are indicated by an
asterisk on the upper part of the alignment. Previously described conformational epitopes ABDE, C-C’,
and LR [30] are shown in green, blue, and magenta.
3.4. Mapping Amino Acid Substitutions in the ZIKV prM Protein
ZIKV virion assembly involves the interaction among prM and E proteins in the endoplasmic
reticulum, the encapsulation of the RNA genome with C protein, and the coverage of a lipid bilayer
containing a prM-E protein complex to form immature virions. Then, the cleavage of prM to M protein
by furin or furin-like proteases in the trans-Golgi network will permit the release of mature virions [31].
Therefore, due to the important function of prM in the ZIKV life cycle, we studied the amino acid
substitutions found in the ZIKV strains isolated in the American region. From the 61 strains isolated in
this region, only four strains had amino acid substitutions in the prM protein, by comparison with the
H/PF/2013 strain of the Asian genotype (Figure 4). All Latin American strains revealed an asparagine
(N) at position 139; previous studies revealed that a serine to asparagine amino acid substitution at this
position (S139N) of the ZIKV prM protein exhibited the greatest neurovirulence in neonatal mice [32].
Moreover, recent studies revealed that when pre-epidemic strains were compared with epidemic
strains, several amino acid substitutions were found among pre-epidemic and epidemic ZIKV prM
proteins [11,33]. Interestingly, two new substitutions were found in strains isolated in 2017 in Cuba, in
positions where differences among pre-epidemic and epidemic strains were previously reported [11,33]:
MF438286 had a lysine at position 143 only observed in pre-epidemic strains (substitution E143K), and
MH063264 had a threonine at position 266 (substitution A266T).
Figure 4. An amino acid sequence alignment of ZIKV prM proteins. Strains are shown by accession
number, geographic location, and year of isolation. Identity of the strain H/PF/2013 from the Asian
genotype (accession number KJ776791) is shown by a dash. Sequence position relative to the prM
protein of that strain is shown on the top of the figure. Predicted coiled regions of the protein are
indicated by a blue arrow on top of the alignment. Predicted exposed residues are indicated by an
asterisk on the upper part of the alignment. Positions where amino acid substitutions were found
between pre-epidemic and epidemic strains are highlighted in green. Position 139 is shown in red.
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4. Discussion
Studying the degree of genetic variability and evolution of ZIKV strains would be crucial for
diagnostics, vaccine development, and disease management [9]. Previous studies have shown that
ZIKV strains from the Asian genotype have evolved and spread to geographically distinct continents
since approximately 1960 [34]. These studies also suggest that the strain H/PF/2013 (KJ776791)
is likely the ancestor of ZIKV strains of the Asian genotype currently circulating in the American
region [12,34,35]. The shape of the tree, near the root, suggested rapid early spread of the outbreak,
consistent with the introduction of a new virus to an immunologically naive population. This is also in
agreement with recent results [23]. ZIKV genomes from strains isolated in the Latin American region
and included in these studies fell into five different genetic lineages (Figure 1). This result highlighted
an important degree of diversification in the ZIKV strains in this region, in agreement with previous
studies done in America [23,25].
ZIKV strains belonging to distinct genetic clades were placed at different sides in the plane
formed by axes 1 and 2 of each PCA (Figure 2). The patterns shown in these figures revealed that
the emergence and diversification of ZIKV in this region of the world were also reflected by their
dinucleotide biases and codon usage, because the clustering in these PCA plots was comparable to the
topology presented in the phylogenetic tree. Previous studies have suggested that ZIKV has evolved
host- and vector-specific codon usage patterns to maintain successful replication and transmission
chains within multiple hosts and vectors [36], and ZIKV strains are in the process of evolutionary
fine-tuning their codon usage [37]. Moreover, selection pressure from Homo sapiens on the ZIKV RSCU
patterns was found to be dominant compared to Ae. aegypti and Ae. albopictus vectors [38]. Recent
reports identified RNA-editing by the double-stranded RNA-specific adenosine deaminase ADAR as a
mechanism that may have contributed to the mutational pressure on the ZIKV genome [39], suggesting
that the lower amount of areas associated with ADAR-editing in the RNA minus strand of the Asian
ZIKV lineage could be the major cause behind the rise in the number of outbreaks in past decade.
Furthermore, the pattern shown by the use of amino acids (Figure 2c) reflected poorly their
phylogeny. The green clade, interestingly, presented a singular behavior in their protein composition
that couldn’t be explained solely by the divergence assessed in Figure 1. More studies are needed to
take into account the extent of selective pressures on the ZIKV polyprotein, or in some subproducts.
Importantly, E protein is a primary antigenic target for neutralizing antibodies, which bind
epitopes in all three structural domains, with many type-specific protective antibodies recognizing
determinants in the DIII domain [30]. Recent studies identified the ZIKV DIII domain as a potential
target for neutralizing antibodies and thus a possible immunogen for vaccines [30]. DIII has been used
previously in the context of different flavivirus vaccines [40,41]. In order to discern if the diversification
observed among the ZIKV strains isolated in the Latin American region may affect the antigenic
structure of E proteins, we mapped the substitutions found in the E protein of ZIKV strains isolated
in this region by comparison with the ZIKV strain H/PF/2013 E protein, representative of the Asian
genotype [31]. Interestingly, substitutions were observed in the DIII domain of E proteins from strains
isolated in this region (Figure 3). Substitution T335A mapped to a previously described DIII LR
conformational epitope [30], and two of the three substitutions found mapped to exposed amino
acid residues (Figure 3). More studies will be needed to address the biological relevance of these
substitutions in ZIKV biology.
ZIKV has a similar structure to other known flaviviruses [42], and prM protein studies revealed
that this protein is critical for viral assembly [43]. Therefore, studying the degree of genetic
variability and evolution of the prM may contribute to our understanding of ZIKV infectivity and
pathogenicity [13]. ZIKV prM, together with E proteins, are being used in most ZIKV vaccines currently
undergoing clinical trials [44].
Among several amino acid substitutions found in ZIKV proteins, a serine to asparagine amino
acid substitution (S139N) in the ZIKV prM protein, which is observed in most human epidemic strains,
exhibited the greatest neurovirulence in neonatal mice [32]. These findings suggested that this serine
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to asparagine amino acid substitution in prM proteins of epidemic strains may have contributed
to the recently observed congenital birth defects associated with ZIKV outbreaks in the American
region [8]. Nevertheless, the contributions of other prM substitutions to ZIKV neurovirulence remain
to be established.
When pre-epidemic and epidemic strains were compared, amino acid substitutions were identified
in ZIKV prM proteins [11,33]. This genomic variability may have been driven by the adaptation of
ZIKV to an urban-based transmission cycle targeting humans as hosts instead of the original sylvatic
mode of transmission, as recently suggested [36]. Whether the two amino acid substitutions found
in these studies at positions 21 and 140 of the prM protein may be related to these facts remains to
be studied.
The relative contributions of prM amino acid substitutions to E protein structural biology are
not yet well understood. However, amino acid changes may affect prM protein structure and induce
structural changes in the E protein since its assembly is dependent on prM protein expression [45].
5. Conclusions
Altogether, these studies showed patterns of diversification of ZIKV strains circulating in the
Latin American region in five different genetic groups. Moreover, different trends in dinucleotide bias
and in codon usage variation among distinct genetic linages were observed, probably as a result of this
diversification. Amino acid substitutions were found in E and prM proteins of ZIKV strains isolated in
this region, revealing the presence of novel genetic variants circulating in the American region.
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Appendix A
Table A1. Bayesian coalescent inference of ZIKV strains.
Parameter Value a HPD b ESS c
Log likelihood −21,802.85 −21,852.01 to −21,744.02 3179.90
Clock rate d 1.21 × 10−3 7.55 × 10−4 to 1.66 × 10−3 4823.21
tMRCA e All 4.20 3.70 to 5.03 291.75
29/6/2013 3/10/2012 to 2/13/2014
tMRCA e Latin American clade 3.37 2.87 to 6.33
3/27/2014 10/24/2013 to 11/13/2014
a In all cases, the mean values are shown; b HPD, highest posterior density values; c ESS, effective sample size;
d clock rate was calculated in substitutions/site/year; e tMRCA, time of the most common recent ancestor is shown
in years. The date estimated is indicated in bold.
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Appendix B
Table A2. Mapping of amino acid substitutions in E proteins of ZIKV strains isolated in Latin America.
Strain a
Amino Acid Position b









a Strains are shown by accession number, geographic location, and date of isolation; b amino acid positions are
relative to strain H/PF/2013 (KJ776791) of the Asian genotype.
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Abstract: The recent outbreaks of Zika virus (ZIKV) infections and associated microcephaly in newborns
has resulted in an unprecedented effort by researchers to target this virus. Significant advances have
been made in developing vaccine candidates, treatment strategies and diagnostic assays in a relatively
short period of time. Being a preventable disease, the first line of defense against ZIKV would be to
vaccinate the highly susceptible target population, especially pregnant women. Along those lines,
several vaccine candidates including purified inactivated virus (PIV), live attenuated virus (LAV),
virus like particles (VLP), DNA, modified RNA, viral vectors and subunit vaccines have been in
the pipeline with several advancing to clinical trials. As the primary objective of Zika vaccination
is the prevention of vertical transmission of the virus to the unborn fetus, the safety and efficacy
requirements for this vaccine remain unique when compared to other diseases. This review will
discuss these recent advances in the field of Zika vaccine development.
Keywords: Zika virus; flaviviruses; vaccines; virus like particles; clinical trials; ZIKV
1. Introduction
Zika virus (ZIKV) is a flavivirus that was first isolated in 1947 form a sentinel rhesus monkey
in Uganda [1]. Since the identification of this new member of the Flaviviridae family, the virus has
been implicated in several localized outbreaks. Currently, this mosquito borne flavivirus has been
reported to be circulating in 26 countries and territories in Latin America and the Caribbean [2,3].
The natural transmission cycle of the virus involves vectors mainly from the Aedes genus, with monkeys
as intermediate hosts and humans as occasional hosts [2]. Clinical symptoms of ZIKV infection include
asymptomatic cases to an influenza like syndrome with fever, headache, malaise and cutaneous
rash [4,5]. However recently, more cases of ZIKV in pregnant women with fetal microcephaly, a range
of disorders referred to as congenital Zika syndrome (CZS), and other neurological disorders such
as the Guillain–Barre syndrome have been described [6]. The sudden appearance of fetal defects
associated with the current outbreaks has drawn international attention, with the primary objective of
developing effective vaccines and therapeutics to combat the virus.
2. ZIKV Genomic Organization
The ZIKV genome consists of a single stranded positive sense RNA of 10.749 Kb. The genome
consists of a single open reading frame encoding a polyprotein 5′-C-PrM-E-NS1-NS2A-NS2B-NS3-
NS4A-NS4B-NS5-3′ [7,8] (Figure 1). This polyprotein is then cleaved into capsid (C), precursor of
membrane (prM), envelope (E) and seven non-structural proteins. The E protein (~53 Kd) is the
major surface protein involved in the virus binding to the cell surface and membrane fusion [8,9].
As the E protein is the primary target for neutralizing antibodies, it is the preferred antigen in most
vaccine platforms. Expression of the structural proteins (prME) of most flaviviruses is sufficient
for the formation of sub-viral particles (SVPs) which makes these proteins prime candidates for
vaccine development [10–13]. SVPs share several properties with wild-type viruses, such as fusogenic
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activity [14] and the induction of a neutralizing antibody response [12,13]. The flaviviral capsid protein
is important for encapsidation of the viral genome along with interactions with lipids for particle
formation [15]. While presence of the capsid protein is not required for the generation of sub-viral
particles, inclusion of the protein has proven to be beneficial for vaccine purposes, for a better cell
mediated immune response [16]. The flaviviral nonstructural proteins are important for several key
aspects of virus replication. With regards to virus assembly, NS3 is the key protein that cleaves the
terminal capsid and prME via its N terminal region in conjunction with NS2B, known as NS2B3 [10].
The non-structural proteins also help in evasion of the host’s innate immune response by inhibiting
production of anti-viral molecules, like the interferons [17].
Figure 1. Zika virus genome. The viral genome comprises of a positive sense RNA that encodes a
polyprotein that is processed by viral and host cell proteases. The amino terminus of the genome
encodes the structural proteins (C-prM-E) essential for virion morphogenesis. The non-structural
proteins NS1–NS5 are important for virus replication, polyprotein processing and invoking a cell
mediated immune response, along with immune evasion.
3. Zika Disease Outbreak and Pathogenesis
The recent outbreaks of ZIKV were highly concerning due to the devastating outcome of
microcephaly and other birth defects in the unborn fetus. Although identified in 1947, ZIKV remained
obscure, circulating in certain African and Asian countries with limited number of reported cases.
The 2007 outbreak in the Yap island, Micronesia, was the first outbreak beyond Africa and Asia followed
by the 2013 outbreak in the French Polynesia with 11% of the population seeking medical attention.
Soon thereafter, Brazil saw one of the worst outbreaks of ZIKV in 2015 with some areas reporting
sero-positivity as high as 60% [18]. While the recent virus outbreaks have clearly been associated
with marked fetal defects and congenital Zika syndrome, the reason for the sudden appearance
of these defects, particularly with the current outbreak, remains unknown. Several theories have
been proposed for the phenomenon including infection of neuronal progenitor stem cells during
pregnancy [19], enhancement of infection due to pre-existing antibodies to Dengue virus (DENV)
and/or West Nile virus (WNV) [20], presence of mutations in the envelope glycoprotein of the Asian
lineage [21], environmental factors, etc. The incidence of microcephaly during the 2015 ZIKV outbreak
was ~100 fold higher than the baseline microcephaly cases in the US, providing the first evidence of a
link between Zika infection and birth defects. [22]. Furthermore, the isolation of ZIKV from placental
tissue and infected fetuses directly linked the virus to the birth defects, although it remains uncertain
if the virus alone is sufficient to induce congenital brain defects [23]. A recent study by Reynolds et al.,
found that in the United States, 15% of pregnant women with confirmed ZIKV infection in the first
trimester had babies with Zika-associated birth defects [22].
4. Need for a Vaccine
Currently there are no ZIKV specific antivirals approved for clinical use, making prophylactic
vaccination the best approach to combat the disease. As of now, control of mosquito vectors,
prophylaxis against mosquito bites and prevention of pregnancy in endemic areas are the only feasible
prophylaxis measures available to reduce the risk of fetal transmission. Although the mortality rate for
ZIKV infections is low, the incidence of Guillain Barré syndrome following ZIKV infection warrants
vaccination in endemic areas. More importantly, the high incidence of ZIKV induced fetal development
disorders like microcephaly in pregnant women suggests an urgent need for an effective vaccine.
Although the WHO has declared that the ZIKV outbreak is no longer a Public Health Emergency of
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International Concern (PHEIC), due to a decline in the number of cases seen in 2018, the risk of a new
outbreak in the near or distant future cannot be ignored. As per the WHO Target Product Profile (TPP)
for ZIKV vaccines, the immunization of women of reproductive age, including pregnant women, is
the highest priority. Various models have suggested that prioritizing ZIKV vaccination in women of
child bearing age is likely to control ZIKV mediated prenatal infections and Congenital Zika Syndrome
(CZS) [24]. A ZIKV vaccine that is safe for use in pregnant women is needed not only to combat
an outbreak like the recent one in Brazil, but also for routine vaccination in endemic areas [25] that
propagate/sustain the mosquito vectors imperative for virus transmission.
5. Characteristics of a Zika Vaccine
Experience from vaccines against other flaviviruses like Japanese Encephalitis Virus (JEV) and
Yellow Fever Virus (YFV), suggest that a vaccine against ZIKV will need to fulfill unique criteria. As per
Centers for Disease Control (CDC) guidelines, the Purified Inactivated Virus (PIV) vaccine against JEV
and the live attenuated vaccine against YFV are largely contraindicated, in pregnant women unless the
benefits outweigh the risk. As the target population of the ZIKV vaccine is largely women who are or
may become pregnant, the vaccine will need to meet high safety standards. While safety remains a
top priority, the efficacy of the ZIKV vaccine also needs to be high as vertical transmission of virus
during pregnancy is associated with CZS. Although sterilizing immunity is unlikely to be achieved by
a flaviviral vaccine, candidates that elicit a strong enough immune response to prevent trans-placental
transfer of the virus to the fetus would be desirable. However, it is unclear what titer of neutralizing
antibodies will achieve this, although results from vaccine studies in mouse model show promising
results [26]. As ZIKV infections are spreading largely in developing and under developed countries,
the cost of vaccination will also be a key consideration point for mass vaccination campaigns. Thus,
it would be safe to say that any platform for a ZIKV vaccine must overcome the safety, efficacy and
economical barriers to be successful.
6. Zika Vaccine Development
The response by the research community to the recent Zika outbreak has been unprecedented.
In less than three years, multiple vaccine candidates have gone through preclinical testing and
several have made it to clinical trials (Table 1). The vaccine candidates currently being pursued
are discussed below.
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6.1. DNA Vaccines
DNA vaccines against ZIKV were amongst the first platform to be developed concurrently by
several groups [26]. All of these approaches utilize the expression of prME proteins from ZIKV,
as expression of these proteins in mammalian cells leads to assembly of sub-viral particles that are
non-infectious, but retain structure and antigenicity similar to native virions. Larocca et al. were the
first to demonstrate that a DNA vaccine expressing codon optimized prME from Brazil (BeH815744
strain, Accession # KU365780) was immunogenic and protected mice against a virus challenge [27].
Similarly, Dowd et al. developed a DNA vaccine incorporating the prME proteins (French Polynesian
strain H/PF/2013, Accession # KJ776791) which was immunogenic and provided protection against
viremia in mice, as well as non-human primates [28]. Similar studies were conducted by Muthumani
et al. who also showed that a DNA vaccine generated via a synthetic prME construct was protective
in mice and non-human primates [29]. Additionally, in this study IFNAR−/− mice that were highly
susceptible to Zika infection, were protected after DNA vaccination. These vaccine platforms have now
progressed to clinical trials (Table 1) and preliminary safety data shows that the DNA vaccines are safe
and effective. Gaudinski et al. [30] tested the safety and efficacy of two DNA vaccines; VRC 5288 that
expresses a chimeric E protein containing Zika and Japanese encephalitis sequences, and VRC 5283
that expresses the wild type Zika E protein. In both vaccines, the prM signal sequence comprised of
the JEV signal to improve particle secretion. In phase 1 clinical trials, the neutralizing response to VRC
5283 was superior to VRC 5288 with 100% of the participants showing neutralizing antibodies in the
split needle-free dose group, making it a better candidate to progress to phase 2 clinical trials. Similarly,
Tebas et al. [31] tested the efficacy of a Zika DNA vaccine (GLS5700) expressing prME regions of ZIKV
from a synthetic construct derived from a consensus sequence. The vaccine showed development
of neutralizing antibodies in 63% of the participants. Other DNA platforms have also progressed to
clinical trials and are listed in Table 1. Although DNA vaccines provide many advantages like ease of
production and rapid adaptation to new and emerging infectious agents, a head to head comparison
of DNA vaccine with Purified Inactivated Virus (PIV) vaccine showed that PIV vaccines fare better in
terms of immunogenicity, at least in the rhesus monkeys [32].
6.2. Purified Inactivated Virus (PIV) Vaccines
Larocca et al. described the use of a PIV ZIKV vaccine in June 2016, immediately after the
2015 outbreaks [27]. They used the Puerto Rican strain (PRVABC59) for the vaccine candidate that
was passaged in Vero cells followed by inactivation with formalin. The alum adjuvanated vaccine
provided complete protection in mice after a single immunization followed by challenge with ZIKV-BR
(Brazil ZKV2015). Interestingly, higher antibody titers were achieved in the intramuscular versus
subcutaneous immunized mice that also correlated with better protection after challenge. In the
same study, the authors also compared a DNA based prME vaccine which protected mice completely
against ZIKV challenge, after a single immunization. Simultaneously, in September 2016, the same
group [32] evaluated the efficacy of the PIV vaccine platform against ZIKV in rhesus monkeys which
provided complete protection against virus challenge. The PRVABC59 isolate was used in two doses
(weeks 0 and 4) in conjunction with alum and protected monkeys against challenge with the Brazilian
and Puerto Rico ZIKV isolate. Moreover, passive transfer of antibodies from immunized monkeys
protected both mice and monkeys from ZIKV challenge, in a dose dependent manner. Two doses of
the formalin inactivated PRVABC59 vaccine provided protection in monkeys even when challenged a
year after immunization [33]. This was superior to two immunizations with a DNA counterpart that
conferred protection early at the peak of antibody titers, but efficacy against challenge declined after
a year.
The Walter Reed Army Institute conducted three phase 1 trials [34] of the above PIV vaccine
using alum adjuvant (N = 55) and placebo controls (N = 12). The objective was to test the safety and
efficacy of the PIV candidate in humans. Healthy participants were administered two doses of the PIV
vaccine 29 days apart which was well tolerated with minimal side effects like pain, tenderness at the
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injection site or generalized fatigue. The neutralizing antibody titers obtained were ≥1:10 at day 43
and adoptive transfer of purified IgG from immunized recipients into Balb/c mice offered protection
after challenge evident by reduced viral loads. Sumathy et al. developed a PIV vaccine using the
African ZIKV isolate (MR766) and formalin inactivation [35]. Two doses of the vaccine provided 100%
protection against the homotypic and heterotypic (FSS 13025, Accession #KU955593) ZIKV strains in
AG129 mice. Moreover, passive transfer of immune sera generated in rabbits protected Balb/c mice
against live virus challenge. On a related note, Yang et al. [36] described a cDNA clone of PRVABC59
with mutations in the NS1 (K265E) prME (H83R) and NS3 (S356F) proteins that increased virus yield
by more than 25 fold when compared to the WT clone. This would not only facilitate high titer virus
yield for PIV production in less time, but also minimize the introduction of unwanted mutations upon
continuous virus passage.
6.3. Live Attenuated Virus (LAV) Vaccines
Experience from vaccination studies with other flaviviruses like YFV and JEV suggest that
live attenuated vaccines (LAV) for ZIKV are likely to be effective. The most widely used LAV
for YFV is derived from the 17D strain that has been in use since 1937, and shows significant
protection [37]. Similarly, the JEV vaccine based on the attenuated SA14-14-2 strain has been extensively
used in endemic areas [38]. With regards to ZIKV, Shan et al. [39] developed a LAV vaccine by
deleting 10 nucleotides in the 3′ untranslated region (UTR) of a Cambodian strain of ZIKV (FSS
13025, Accession #KU955593). This attenuated virus provided sterilizing immunity with saturating
neutralizing antibody titers in WT adult mice, and did not induce pathology after intracranial injection
in 1 day old immunocompetent mice. A single dose of the vaccine also protected rhesus macaques
against viremia upon challenge. Further analysis of this LAV vaccine showed that a single dose
significantly reduced vertical transmission of Zika in pregnant mice, and prevented testicular damage
in male mice [40]. Zou et al. [41] developed a DNA launched version of the LAV vaccine with a
20 bp deletion in the 3′-UTR, and demonstrated the efficacy of the vaccine at extremely low doses
(0.5 μg), compared to other DNA vaccines. Besides the direct attenuation of ZIKV, other approaches
like chimeric viruses have been used for making attenuated vaccines. Xie et al. [42] showed that a
chimeric virus containing Zika prME in a DENV-2 backbone was highly attenuated in A129 mice
and provided protective immunity against Zika challenge. Similarly Li et al. [43] used the attenuated
JEV strain SA14-14-2 as the backbone to introduce the Zika prME region of an Asian ZIKV strain FSS
13025. When administered as a single dose, this vaccine provided protection against placental and fetal
damage in pregnant mice and protected the offspring against intracranial virus challenge. A single
vaccine dose was also protective in rhesus monkeys that were challenged with the virus.
6.4. Virus like Particles (VLP) Vaccines
In case of flaviviruses, expression of the structural proteins (prME or CprME) gives rise to
non-infectious virus like particles that resemble infectious virions. This provides a method for
presentation of viral antigens in a highly native conformation. Thus, VLP vaccines often surpass the
elicited immune response when compared to subunit vaccines that are comprised of single proteins [44].
Moreover, VLPs present antigens in their native conformation in a repetitive manner that is recognized
effectively by B cells leading to their activation and production of high titers of specific antibodies.
Another advantage of VLP vaccines is their ease of production and scalability providing an economic
platform, especially by generation of stable cell lines. Due to their non-infectious nature, VLPs are safe
for administration in immunocompromised adults, children and pregnant women.
Surprisingly, with regards to ZIKV, the description of VLP platforms came much later than the
PIV, DNA and mRNA counterparts. Garg et al. [45] reported the development of prME and CprME
VLPs (Suriname 2015, Accession # KU312312.1) and compared them to their DNA counterparts in
efficacy studies in mice. Immunization with CprME VLPs generated higher neutralizing antibody
titers than prME VLPs. DNA vaccination with prME was less effective than VLPs with CprME
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DNA, failing to generate neutralizing antibodies in mice. An advantage of the approach by Garg
et al. was the generation of stable cell line secreting the prME VLPs, thereby eliminating the need
for routine transfections and DNA amplification for large scale VLP production. This study also
brought forth the advantage of incorporating the capsid protein in the VLPs for an enhanced immune
response. In a similar study, Boigard et al. [46] compared CprME VLPs (Strain H/PF/2013, Accession #
KJ776791.1) with formalin inactivated ZIKV (PIV) and found superior antibody generation with CprME
VLPs, versus inactivated virus. While using a transient transfection protocol for VLP generation,
their study emphasized the deleterious effects of chemical inactivation on neutralizing epitopes for
vaccine production.
Thereafter, a number of studies described the use of different VLP platforms for ZIKV.
Yang et al [47] developed a VLP displaying the EIII domain of ZIKV (PRVABC59 (amino acids 1–403,
Accession # AMC13911)) on the Hepatitis B core antigen. The advantage of this system was the easy
production and purification from Nicotiana plants. The vaccine elicited a strong neutralizing and
cellular immune response against different ZIKV strains, and the elicited antibodies did not cause
enhancement of Dengue virus infection in cells expressing the Fcγ receptor. Espinoza et al. [48] also
developed a prME VLP vaccine ((prM sequence from the African MR766 strain (Accession # KU955594);
the E ectodomain from the Brazilian SPH2015 strain (Accession # KU321639) and the stem-anchor from
the African MR766 strain (Accession # KU955594)) containing a heterologous IL-2 signal sequence and
found that the immune sera generated in WT CB6F1 mice was protective of ZIKV infection in AG129
mice. Basu et al. [49] displayed highly immunogenic potential B cell epitopes from the E protein of
ZIKV (strain MR-766) on bacteriophage particles, and saw moderate protection in challenge studies in
Balb/c mice. Baculovirus expressed Zika VLPs [50] displaying the prME proteins (strain SZ-WIV01)
elicited a potent neutralizing and T cell response in immunized mice. Salvo et al. [51] used the Zika
CPrME (strain H/PF/2013, Accession # KJ776791) VLPs to immunize Balb/c and AG129 mice followed
by challenge studies and observed decreased viremia or increased survival in respective models.
6.5. Modified mRNA Vaccines
mRNA technology has recently gained popularity in the field of vaccination as mRNA’s
pose minimal risk of integration into the host genome making them safer than DNA vaccines.
mRNA vaccines make use of the host cell processes to translate viral proteins and generally encode
the protein of interest, untranslated regions at the 5′ and 3′ end give stability in cells and replacement
of uridine residues in the sequence with other natural modifications, prevent indiscriminate innate
immune activation [52,53]. Moreover, encapsulation of naked mRNA into lipids not only increases
stability, but also helps in high protein expression by aiding in intramuscular delivery. After the
2015 ZIKV outbreaks, one of the first vaccine strategies to be described was the use of modified
mRNA to protect against ZIKV infection in two simultaneous reports published in March 2017 [54,55].
Richner et al. developed a modified RNA with a type-1 cap, a signal sequence from human IgE or JEV,
and the prME genes of ZIKV Asian strain (Micronesia 2007, Accession # EU545988). The modified
RNA was encapsulated in lipid nanoparticles to aid in intramuscular delivery and showed excellent
protection in WT C57BL/6 and AG129 mice upon virus challenge leading to sterilizing immunity.
The authors also tested the role of Antibody dependent enhancement (ADE) inducing epitopes in the
DII region of the flavivirus E protein by generating modified mRNA vaccines containing mutations
in the E-DII-FL region. Interestingly, they showed that mutations of the DII-Fusion loop epitope
diminished generation of antibodies that would enhance Dengue virus infection. The same group [56]
also showed protection against “ZIKV induced congenital disease”, after vaccination of pregnant
dams with the lipid nanoparticle vaccine, containing the modified mRNA followed by virus challenge.
Similarly, Pardi et al. [54] simultaneously demonstrated that immunization with a modified mRNA
encoding the prME of ZIKV (H/PF/2013, Accession # KJ776791) encapsulated into lipid nanoparticles
was able to confer potent B and T cell responses in mice and strong ZIKV specific neutralizing antibody
titers in non-human primates, after a single immunization. Moreover, low doses of the vaccine (30 μg
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in mice and 50 μg in non-human primates) was sufficient to protect the animals against live virus
challenge. Thereafter Chahal et al. [57] developed a modified dendrimer nanoparticle (MDNP)-RNA
vaccine that expressed the prME proteins of ZIKV (Accession # KU312312, Asian lineage virus isolated
from a patient in Suriname in 2015) cloned into an RNA replicon vector. Their approach identified a
9 amino acid long highly conserved MHC-1 restricted epitope in the E protein capable of inducing a
CD8 specific T cell response in mice.
Soon after the reports of ZIKV mRNA vaccines, Moderna therapeutics in collaboration with
Biomedical Advanced Research and Development Authority (BARDA) initiated clinical trials of the
vaccine in 2016. The objective was to “evaluate the safety and immunogenicity of mRNA 1325 Zika
vaccine in healthy adults in a non-endemic Zika region”, via a phase 1, randomized, and placebo
controlled trial. The study is set to complete in February 2019, enrolling 90 participants to assess any
adverse events and seroconversion when compared to placebo controls. The Phase 1 study was funded
by BARDA with $8 million, which will pave way for Phase 2 and 3 clinical studies with $117 million,
along with supporting large scale manufacturing of the vaccine for worldwide dissemination.
6.6. Subunit Vaccines
As the E protein of flaviviruses is the major antigen for generation of neutralizing response,
this protein has been used in various forms as a subunit vaccine candidate for DENV [58] and
WNV [59]. Building on the same premise, To et al. [60] expressed and purified soluble ZIKV E
protein produced in Drosophila melanogaster cells. The expression vector contained an insect cell
optimized synthetic gene, expressing the entire prM and amino acids 1–408 of the E protein from the
French Polynesian strain (Accession # KJ776791). Immunization of mice with purified recombinant
E protein in combination with adjuvant resulted in neutralizing antibody titers that were protective
against viremia in immunocompetent mice. Tai et al. [61] fused the ZIKV E domain III region to the C
terminal Fc region of human IgG, to generate a recombinant immunogen. This recombinant E protein
contained amino acids 298–409 of ZIKV E (ZIKV SPH2015 Accession # KU321639.1) and was found to
be highly immunogenic, resulting in neutralizing antibody generation and protection of mice in various
models. Yang et al. [62] developed a subunit vaccine derived from the EIII domain of strain PRVABC59
produced as E. coli inclusion bodies. The vaccine evoked a high titer neutralizing antibody response
that did not enhance DENV infection in vitro, along with production of Th1 and Th2 cytokines by
splenocytes. The same group [63] also described a plant produced subunit E vaccine that was found to
be highly immunogenic, as seen via neutralizing antibody and T cell responses. Qu et al [64] described
ZIKV subunit vaccines produced in insect cells and comprised of the domain III or the 80% N terminal
region of the E protein (Accession # KU312312). Both vaccines generated antibody and T cell specific
responses with the domain III vaccine being superior. Recently, Zhu et al [65] described a subunit
vaccine comprising of the N terminus (450 amino acids) of the E glycoprotein that was capable of
inducing long term protection in mice. Immunization of pregnant dams with the subunit vaccine also
protected the fetal brains in utero and neonates against microcephaly.
6.7. Viral Vectors
Using viral vectors to deliver antigens for the purpose of developing immunity is a new and
emerging field. Adenoviruses and vaccinia virus are perhaps the most well studied and widely used
platforms for vaccine development. Replication deficient versions of these viruses are safe and potent
inducers of immunity against antigens of choice. Abbink et al. [32] used rhesus Adenovirus 52 (RhAd52)
as vector expressing ZIKV prME in rhesus monkeys. In the same study they compared multiple vaccine
platforms and found that a RhAd52-prME vaccine generated neutralizing antibodies, and complete
protection from challenge in rhesus monkeys after a single immunization. Xu et al. [66] developed a
recombinant chimpanzee adenovirus type 7 (AdC7) expressing ZIKV M and E proteins from the Asian
linage of ZIKV FSS13025 (Accession # MH158236), isolated in Cambodia. In mouse models of ZIKV,
a single immunization protected the mice against ZIKV viremia and testicular damage after challenge.
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Similarly, Cox et al [67] developed an Adenovirus serotype 26 (Ad26) based vaccine containing the ME
region of ZIKV strain BeH815744 (Accession # KU365780.1). Single immunization with this adenoviral
vaccine provided protection against challenge in both mice and Non-human primates (NHP) models.
To improve upon the antigenicity of ZIKV adenoviral vaccines, Lopez-Camacho et al. [68] modified
the prME region (consensus sequence) by deleting the transmembrane (TM) region of Envelope (Env).
This prMEΔTM region in a chimpanzee adenoviral vector (ChAdOx1) provided better neutralizing
response than the full length prME, suggesting that modification of antigen membrane anchor can
enhance immunogenicity. Liu et al. [69] recently included the NS1 gene of ZIKV along with prME
(isolate 1_0080_PF, Accession # KX447521) in an Adenovirus serotype 2 vector system to generate
Ad2-prME-NS1 vector. The Ad2-prME-NS1 vector resulted in both Env as well as NS1 specific
antibodies, and protected pups born to immunized dams against Zika induced pathology.
Recently, Prow et al. [70] incorporated ZIKV prME (Brazilian isolate SPH2015, Accession #
KU321639) as well as a Chikungunya virus (CHIKV) structural protein cassette into a vaccinia derived
Sementis Copenhagen Vector (SCV) system. This multi pathogen vaccine provided protection against
both ZIKV and CHIKV in wild type and IFNAR−/− mice. Development of a similar multivalent
vaccine against arboviruses that circulate in the same geographical region may have added advantages.
Betancourt et al [71] were the first group to use the recombinant Vesicular stomatitis virus (VSV)
platform to express either Zika Env or Zika prME proteins from a SPH2015 isolate (Accession #
KU321639). Two immunizations with these vectors resulted in an anti Zika antibody response that
protected newborn mice born to vaccinated mothers against lethal Zika challenge. Emanuel et al. [72]
recently used a recombinant VSV that expressed the codon optimized prME (Accession # KU681081.3)
region of Zika along with an Ebola GP protein. This vector was built upon the previous Ebola vaccine
vector, VSV-EBOV vaccine [73,74]. The vector was tested in IFNAR−/− mice and provided protection
from lethal challenge after a single immunization as late as 3 days prior to ZIKV challenge. However,
the replicating nature of the recombinant VSV vectors make them less likely to be used in vulnerable
populations like pregnant mothers. The rapid nature of protection makes them ideal for controlling
outbreaks in certain geographical regions.
7. Conclusions
There is no doubt that the response from the research community with respect to a Zika vaccine
has been unprecedented. With the tremendous progress made in this field, a viable vaccine for ZIKV is
both possible and closer than expected. However, the lack of new Zika cases in 2018 has dampened
the enthusiasm as well as urgency for the vaccine. Moreover, lack of uniformity in the assays being
used to determine vaccine efficacies makes comparison of different candidates difficult. The reduction
in Zika cases also makes it difficult to study the efficacy of the vaccine in clinical trials. Moreover,
conducting placebo control trials in pregnant women in Zika endemic areas has serious ethical issues.
Nevertheless, a safe effective and economical vaccine for Zika should be developed in order to prepare
for a subsequent outbreak which remains a real possibility. This lesson has already been learned from
the overwhelming 2015 outbreaks, more than 50 years after the identification of the virus.
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Abstract: Zika virus recently re-emerged and caused global outbreaks mainly in Central Africa,
Southeast Asia, the Pacific Islands and in Central and South America. Even though there is a
declining trend, the virus continues to spread throughout different geographical regions of the world.
Since its re-emergence in 2015, massive advances have been made regarding our understanding of
clinical manifestations, epidemiology, genetic diversity, genomic structure and potential therapeutic
intervention strategies. Nevertheless, treatment remains a challenge as there is no licensed effective
therapy available. This review focuses on the recent advances regarding research models, as well as
available experimental tools that can be used for the identification and characterization of potential
antiviral targets and therapeutic intervention strategies.
Keywords: Zika virus; antivirals; therapeutics; research models and tools
1. Introduction
Zika virus (ZIKV) was first isolated in 1947 in the Zika forest in Uganda from an infected rhesus
macaque monkey [1]. Since its discovery, the virus has been detected in different species of Aedes
mosquitos followed by the identification of the first infected human case in Uganda in 1962 [2–5].
Since then, human infections had only been sporadically reported in Africa and Asia [6] before the
first major outbreak occurred in 2007 in Micronesia [6,7]. After this, the virus continued to spread
and caused another major outbreak in 2013–2014 in French Polynesia [8], which was retrospectively
associated with an unusual high frequency of newborns with microcephaly, a cerebral congenital
anomaly, and an increase in the number of cases of Guillain-Barré syndrome (GBS) in adults [9]. ZIKV
received global attention in 2015, following its emergence in Brazil due to its association with several
thousand cases of microcephaly in newborn children [10–12]. Since then, the virus has spread further,
with a total of 86 countries reporting evidence of Zika infection (WHO 2018). Mosquito bites present
the major route of transmission of ZIKV, after which viral replication is believed to occur in skin
fibroblasts/keratinocytes and skin-associated dendritic cells (DCs) with subsequent dissemination
to lymph nodes and the bloodstream [13]. In addition, sporadic non-vector borne human-to-human
transmissions have been described. ZIKV has been reported to be transmitted perinatally (reviewed
in [14]), sexually [15] and via blood transfusion products [16,17]. Recently, the virus was suspected
to transmit through breastfeeding [18]. Furthermore, viral RNA, as well as in some cases infectious
virus, has been isolated from various body fluids (reviewed in [14]) including saliva, urine, vaginal
secretions, breast milk, semen and conjunctival fluid [19].
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ZIKV infection is in most cases asymptomatic or can lead to mild, self-limiting symptoms
including rash, fever, joint pain, as well as conjunctivitis [20]. Infrequently, severe neurological
conditions such as GBS [21], meningoencephalitis [22] and acute myelitis [23] have been reported
in association with ZIKV infection. However, exposure to ZIKV during pregnancy can have
severe consequences for the fetus including several fetal malformations such as microcephaly and
hydrocephaly, as well as spontaneous abortion, stillbirth and placental insufficiency [20,24]. In addition,
it is becoming clear that the long-term neurological defects in affected children are not yet fully
elucidated. Up to date, there is still no protective vaccine available. Mosquito control practices are the
primary measures to impede further spread and transmission of the virus. Even though much progress
was made regarding potential treatment options, no specific antiviral has been licensed against ZIKV,
emphasizing the need for the development of effective therapeutics.
2. Replication Cycle and Potential Intervention Strategies
2.1. Genomic Organization
ZIKV belongs to the genus flavivirus within the Flaviviridae family. It has a positive-sense
single-stranded RNA genome of 10.8 kb, containing a single open reading frame, flanked by a 5′ and 3′
untranslated region (UTR), encoding for three structural and seven nonstructural proteins, which are
co- and post-translationally processed by viral and host proteases [25]. The three structural proteins,
the envelope protein (E), the membrane protein (M), which is expressed in the immature virion as
precursor preM, as well as the capsid (C) form the mature virion. The nonstructural (NS) proteins
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral replication and assembly and
participate in the evasion of the host immune system [26].
2.2. Replication Cycle
After binding to specific receptors on the host cell, the virus is internalized by clathrin-mediated
endocytosis. The low pH within the endosomes triggers viral uncoating and release of the viral genome
into the cytosol [27]. The genomic RNA is translated, resulting in the synthesis of a polyprotein that is
co- and post-translationally processed; the RNA-dependent RNA polymerase (RdRp) NS5 replicates
viral RNA in close association with cell-derived membranes [28]. Immature virions containing newly
synthesized RNA assemble through budding within the endoplasmatic reticulum (ER), followed by
transition from the ER through the trans-Golgi network (TGN) to the cell surface, upon which protease-
and pH-dependent maturation occurs, and subsequent budding and release of mature virus particles
through the secretory pathway [29].
2.3. Intervention Strategies
Several therapeutic approaches that target the different steps of the viral replication cycle (Figure 1)
have been developed (reviewed in [30–32]). In general, drug candidates can be classified according to
their mode of action, either directed against viral targets (direct-acting antivirals) or acting against
cellular targets (host-targeting antivirals). To inhibit the binding of a virus particle to a target cell,
strategies include, among others, blocking of the receptor-virus interactions via various compounds [33,
34], direct interaction with the viral lipid envelop [35], targeting of the viral surface by structurally
mimicking cellular receptors, binding to carbohydrates that interact directly with the glycosylated
viral envelope proteins or binding to other peptide regions of the viral envelope (reviewed in [32]).
Another antiviral strategy is to target endocytosis and subsequent pH-dependent endosomal fusion and
uncoating of the viral particle. This includes, e.g., drugs that alter host-cell membrane properties [36] or
blocking of endosomal pH acidification [37–41]. Interference with translation of the viral polyprotein
and polyprotein processing via host and viral proteases also represents an attractive target for antiviral
drugs. Especially, interference with the viral NS2B-NS3 protease, which post-translationally cleaves
the polyprotein, has been extensively evaluated (reviewed in [30–32]). Next to its protease activity,
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NS3 displays a nucleoside-tri-phosphatase (NTPase) and RNA helicase activity that is crucial for
viral replication. However, there are only a few studies investigating NS3 helicase inhibitors so
far [42]. This might be due to some difficulties, e.g., limited access to the active site of the NS3
helicase-RNA complex as described for Dengue virus (DENV) [43]. NS5offers a very attractive target
for intervention with the viral replication complex, which is one of the most conserved among the NS
proteins. NS5 contains the RdRp at the C-terminus, which is required for RNA synthesis, and there are
several drugs described to interfere with its function (reviewed in [30–32]). Next to its polymerase
function, NS5 encodes an N-terminal methyltransferase (MTase) domain, which is required for mRNA
capping and stabilization to facilitate the translation process, to escape detection of the viral mRNA by
the host innate immune sensors, as well as for cap-independent methylation [44]. Interference with
the MTase domain offers an additional therapeutic target [42,45–48]. Furthermore, interference with
other viral proteins that are crucial for viral RNA replication, e.g., NS4B, which has been shown to be a
therapeutic target for other flaviviruses [49–52] or NS1 [53], could be attractive for the development of
new antivirals. In addition, host proteins could be targeted to inhibit viral replication. These include
host cell nucleoside biosynthesis inhibitors, host cell lipid biosynthesis inhibitors and host kinase
inhibitors (reviewed in [53]). To inhibit viral assembly, maturation and budding, interference with
the host metabolism by targeting proteins involved in protein synthesis, folding and degradation can
be employed (reviewed in [30]). Furthermore, targeting of intracellular membrane trafficking can
inhibit several steps of the viral replication cycle, including entry, assembly and release of infectious
particles [54]. Compounds that presumably directly interfere with glycosylation and maturation of
ZIKV during its trafficking through the secretory pathway can also inhibit the release of infectious
particles [55]. Finally, the capsid protein could be targeted by antivirals. The protein has multiple
functions during the viral replication cycle, and studies with other flaviviruses have shown an effect of
specific capsid inhibitors on viral assembly and/or release and entry of infectious particles [56–58].
In conclusion, several strategies have been employed for interfering with the viral replication cycle
(Figure 1). However, to avoid the surge of resistance mutation, several strategies could and should be
used in combination to treat an acute ZIKV infection.
 
Figure 1. Intervention strategies to interfere with the different stages of the viral replication cycle.
(*) direct-acting antivirals; (**) host-targeting antiviral intervention strategies. RdRp: RNA-dependent
RNA polymerase, MT: methyltransferase.
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3. In Vitro Models and Screening Approaches
The first prerequisite with respect to the development of antiviral compounds is the availability
of in vitro systems including virus isolates and/or recombinant constructs and robust in vitro cellular
models (Figure 2).
Figure 2. In vitro systems and screening approaches used for antiviral compound development
against ZIKV. The text highlighted in green and red indicates advantages and limitations, respectively.
PSCs: pluripotent stem cells, HTS: high-throughput screening, VYR: virus yield reduction, CPE:
cytopathic effect.
3.1. Viruses
3.1.1. Clinical Viral Isolates
Clinical viral isolates are the best representatives of the currently circulating ZIKV strains. Among
ZIKV strains, there are two distinct lineages described, the African and the Asian lineages [59].
Phylogenetic analysis revealed that the currently circulating and pathogenic ZIKV strains most likely
descended from the Asian lineage [60]. The “historical” ZIKV strain from Uganda (MR766) has been
most consistently used in several in vitro and in vivo studies. Even though it has been passaged over
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147 times in different culture models, there seems to be only a low number of nucleotide changes
compared to some primary ancient African lineage isolates [61]. Interestingly, of all the ZIKV genomes
isolated so far, all African strains have been recovered from mosquitos or non-human primates (NHPs),
whereas the Asian strains have been isolated from mosquitos or humans [62]. Phylogenetic analysis
revealed that the virus has changed significantly since its initial isolation, with regard to both the
nucleotide sequences and amino acid composition with several lineage-specific differences between
the African and Asian isolates [59,63,64]. These changes can have a substantial impact on pathogenesis,
viral fitness, transmissibility and replication kinetics. Indeed, there are several studies that have
analyzed the lineage-dependent properties in animal and cell culture models and found differences
between the African and the Asian lineages with respect to plaque phenotype, infectivity, replication
kinetics and virulence, with most studies showing that the African lineages display faster replication
kinetics, high viral titers, as well as higher virulence in mice [64–68]. On the other hand, there is a
significant number of studies with primary human cells and mouse models suggesting that the strains
from the African lineage are also neurovirulent and sometimes even more than the contemporary
Asian strains [64,69–73]. Thus, there is currently no definitive evidence that the rise in microcephaly
cases is exclusively caused by the Asian lineage viruses [74,75]. Of note, all these results have to be
interpreted with care as variations including viral strain passage number, cell culture system used and
utilization of different mouse background strains can have an impact on the observed phenotypes. For
instance, it has been speculated that a high passage number of some ZIKV isolates has resulted in a
distinct loss of glycosylation sites, which could have an impact on ZIKV-associated pathogenesis [61].
Nevertheless, for the development and characterization of antivirals, it is important to take into account
potential differences between viral isolates, as well as culture systems, since variations in infectivity
and replication kinetics can have a significant influence on drug efficacy.
3.1.2. Full-Length Infectious Clones
Next to clinical isolates, reverse genetic systems for the generation of recombinant ZIKV are of
great advantage to study virus properties, including virulence/attenuation, replication, host range
and tropism. Especially with respect to the identification and development of antivirals, molecular
infectious clones are crucial for the understanding of the molecular mechanisms of viral replication
and consequently development of potential intervention strategies. To generate an infectious clone,
a complementary DNA (cDNA) copy of an RNA virus is usually stably incorporated into a plasmid
vector and amplified in Escherichia coli. This cDNA can be modified and manipulated as required before
genomic RNA is obtained via in vitro transcription and subsequent virus recovery upon transfection
of suitable cells [76]. Generation of a ZIKV infectious clone has not been that simple to establish as
flavivirus sequences are often not compatible with growth in E. coli and may contain viral proteins
with bacterial toxicity expressed through cryptic bacterial promoters, which hamper the propagation
of the viral cDNA via bacterial plasmids (reviewed in [76,77]). Nevertheless, several strategies have
been reported to generate ZIKV molecular clones (Table 1). These include the insertion of a synthetic
intron into the molecular construct, which is later removed upon splicing in mammalian cells [78,79],
or the separation of the viral genome and generation of subgenomic fragments. Several approaches
have been used to circumvent toxicity in bacteria including usage of low copy plasmids [80], usage
of bacterial artificial chromosomes [81] and separation of the genome to disrupt toxic regions [82,83].
Furthermore, a more elaborated approach using a bacterium-free reverse genetic method called ISA
(infectious subgenomic-amplicons) [84] based on the in vitro generation of overlapping subgenomic
amplicons covering the ZIKV genome, subsequent transfection into susceptible host cells and recovery
of recombinant virus by “in cellulo” recombination was applied [85–87]. Furthermore, a circular
polymerase extension cloning (CPEC) protocol [88] based on the polymerase extension mechanism to
join overlapping DNA fragments into a double-stranded circular form has been used [89,90]. Another
recent approach used mutational inactivation of several cryptic E. coli promoters [91]. All these efforts
have resulted in the construction of several molecular clones encompassing various viral strains,
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with or without the presence of reporter proteins for easier detection. These proteins can easily be
manipulated to study molecular functions and to identify potential targets for therapeutic intervention
(Table 1). Furthermore, the appearance of possible resistance mutations can be studied upon repeated
passaging of the virus in the presence of a compound of interest, thereby anticipating possible viral
counter mechanisms. Nevertheless, it is important to keep in mind that, due to a high mutation rate of
viral RNA polymerases, it is believed that RNA viruses exist not as a homogeneous entity, but rather
as quasispecies of genomes that are centered around a consensus sequence, which facilitates a higher
robustness of a viral population [92,93], features that are not recapitulated in molecular clones. This
leads, for most ZIKV clones described so far, to an attenuation in cell lines in comparison to the parental
strains. Furthermore, reporter-protein expression can additionally attenuate viral replication and/or
can show low genomic stability limited to few passage numbers.
3.1.3. Replicons
Compared to full-length infectious clones, ZIKV replicons offer an alternative for the identification
and characterization of antiviral compounds. Subgenomic replicons contain the genetic elements
crucial for viral replication, but lacking the structural genes required for assembly and release of
infectious progeny virus [94]. This renders the replicon system non-infectious, thereby reducing
possible biosafety concerns, an issue to consider when used for large screening approaches of
compound libraries. In general, flavivirus replicons encompass an in-frame deletion in the structural
genes; however, the first 20 codons of the C protein, as well as the 3′ end of the E gene need to
be retained as they contain important elements for replication, as well as the signal peptide for the
downstream NS1 protein, respectively [94]. Incorporation of a reporter protein, either luminescence-
or fluorescence-based, allows for easy detection of viral replication. Stable replicon cell lines can
be generated by introducing resistance genes and thus facilitate large-scale antiviral screenings [94].
Several approaches have been described to generate and use ZIKV replicons for the characterization of
antivirals [95,96]. Future studies using this molecular tool might facilitate the characterization and
development of new therapeutic strategies to inhibit ZIKV replication.
3.2. Cell Culture Systems
Cell culture models are crucial tools to study the molecular mechanisms of ZIKV life cycle and
to develop and identify therapeutics. ZIKV has been shown to display a broad tissue tropism with
several cell surface receptors facilitating ZIKV entry. These include receptor tyrosine kinase family
members like AXL and Tyro-3, as well as the innate immune receptor DC-SIGN and the receptor
TIM-1, also known as hepatitis A virus cellular receptor 1 (HAVcr-1) (reviewed in [97]). However,
none of these receptors seems to be unique for ZIKV. Genetic ablations of, e.g., the AXL receptor,
which has been discussed as a crucial attachment factor for ZIKV, could not confer resistance to ZIKV
infection in vitro and in vivo [98]. This might indicate that ZIKV either concordantly uses several
receptors as attachment factors or that receptor usage differs between different cell types and tissues.
In accordance with its clinical manifestation, the virus infects several brain cells including cortical
neurons, neuronal progenitor cells (NPCs), as well as glial cells, astrocytes and microglia. Furthermore,
given its classical route of transmission, skin cells with dermal fibroblasts and epidermal keratinocytes,
as well as skin-associated immune cells, including DCs, have also been described to be susceptible.
Other susceptible tissues include testis, with Sertoli cells suspected to act as a ZIKV reservoir, and
placenta with Hofbauer cells, trophoblasts and placental endothelial cells being susceptible to ZIKV
infection (reviewed in [97]). A comprehensive list of the currently identified susceptible human primary
cells to ZIKV infection is presented in Table 2.
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Table 2. Susceptible human primary cells to ZIKV infection.
Primary Cell Type Tissue/Source Reference
Dermal fibroblasts Skin [99,100]
Epidermal keratinocytes Skin [99]
Blood dendritic cells Peripheral blood [101]
Monocyte-derived dendritic cells Peripheral blood [73,99,102,103]
Monocyte-derived macrophages Peripheral blood [104,105]




Endothelial cells Brain [113]
Hofbauer cells Placenta [114–117]
Trophoblasts Placenta [114,116,118–120]
Fibroblasts Placenta [116]
Endothelial cells Placenta [116]
Fibroblasts Uterus [34,114]
Mesenchymal stem cells Umbilical cord [114]
Epithelial cells Vagina and cervix [121]
Sertoli cells Testis [122–124]
Spermatozoa Testis [125]
Germ cells Testis [126,127]
Retinal endothelial cells Eye [128]
Retinal pericytes Eye [128]
Retinal pigmented cells Eye [128]
3.2.1. Human and Animal Cell Lines
Cell lines can be used as a platform to produce high-titer ZIKV stocks, but also to study various
aspects of virus replication, including replication kinetics, susceptibility and, to a certain extent,
immune response. Especially for the identification and initial characterization of antivirals, they offer
a solid basis and have been used to test several approaches. One of the most commonly-used cell lines
in ZIKV research is the Vero cell line derived from epithelial kidney cells from African green monkeys.
These cells are deficient in type I interferon (IFN) production, making them suitable to yield high virus
titers [129]. Other cell lines that have been shown to be susceptible and support ZIKV replication
include human kidney, skin, liver, muscle, retina, placental and lung epithelial cell lines, as well as
human and murine neuronal cell lines. Interestingly, even though ZIKV was able to replicate efficiently
in various cell lines, the amount of intracellular infectious particles, as well as virus release and extent
of cytopathic effect varied among the cell lines tested [87,113,130–132]. Furthermore, it was shown
that next to human, NHPs and murine cells, ZIKV is able to replicate within a wide range of animal
cell lines, expanding the variety of cell lines that can be used to study ZIKV infections [81,130,133].
Given their usefulness regarding availability, cost and handling, cell lines offer a powerful tool for the
identification and characterization of antivirals. However, cell line-specific differences with respect to
viral kinetics, observed phenotypes, genetic manipulation, as well as innate immune defects should be
considered when interpreting results.
3.2.2. Human Primary Cell Cultures
In contrast to cell lines which often differ genetically and phenotypically from their parental
tissue, primary cells have a low population doubling level and therefore more closely recapitulate
the physiological conditions observed in vivo (Table 2). Primary cells are characterized by their
high degree of specialization, are often fully differentiated and thus require optimal defined culture
conditions in order to preserve their original phenotype. This means that the use of serum-free specific
formulated media is required in order to prevent undesired differentiation or promote the growth
of contaminating cells, typically fibroblasts. A large majority of the studies for searching/screening
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potential therapeutics against ZIKV infection focused on a specific in vitro system often based on cell
lines. Considering the wide tissue and cellular tropism of ZIKV and the different possible routes of
transmission, broader approaches are mandatory. Thus, when evaluating a potential antiviral approach
against ZIKV infection, the selection of the appropriate in vitro system is of central importance,
particularly when evaluating compounds targeting cellular host factors involved in viral life cycle. For
instance, when the experimental paradigm is to pharmacologically modulate host factors to interfere
with vector-borne transmission, the primary cellular targets of ZIKV infection should be selected
for therapeutics screening, including skin fibroblasts, epidermal keratinocytes or skin-associated
immune cells such as DCs. On the other hand, when screening for therapeutics in the context of
vertical transmission, placental, amniotic and/or fetal primary cultures are a more appropriate in vitro
system and have already been used by some investigators for the screening of antivirals [34,116,134].
Furthermore, the ability of ZIKV to be transmitted sexually and to persist in the genital tract led
to the use of human primary vaginal/cervical epithelial and male germ cells to test the efficacy of
anti-ZIKV compounds [121,127]. Although primary cell cultures are relevant biological systems for
the identification of potential anti-ZIKV therapeutics, there are technical difficulties limiting their use.
Depending on the tissue of interest, obtaining a pure population of primary cells can be laborious,
and phenotypic variability is commonly observed between donors. Furthermore, the vast majority of
isolated primary cells have a limited shelf life and eventually undergo cellular senescence after a short
number of passages. Finally, yet importantly, work with human-derived primary cells from native
tissue requires patient-approved consent and the evaluation by an institutional ethical review board.
3.2.3. Human Pluripotent Stem Cell-Derived Cultures
When screening for anti-ZIKV therapeutics targeting host factors with a protective effect on
the human neuronal tissue, the use of primary human cell-based systems is challenging for ethical
and technical reasons. In addition, in the context of congenital neurotropic ZIKV infection, there is
currently no robust in vivo system modelling early human brain development. These obstacles can be
bypassed using elaborated in vitro systems exploiting the possibilities offered by human embryonic
stem cells (ESCs) and/or human induced pluripotent stem cells (iPSCs) (collectively PSCs) (Table 2).
PSCs proliferate extensively and retain multi-lineage activity allowing one to generate virtually any cell
type of the body, making them a precious source of primary cells. While ESCs are isolated from surplus
human embryos for in vitro fertilization, iPSCs are obtained by reprogramming somatic cells and can
be used as a replacement of ESCs to generate distinct brain cells, including cortical neurons, NPCs, glial
cells and complex cerebral three-dimensional (3D) cultures termed organoids [135,136]. In the fetal
brain, ZIKV targets NPCs, and several investigators used PSC-derived NPCs to investigate the efficacy
of antivirals and their ability to prevent microcephaly in vitro [137,138]. Furthermore, there are now
established methods to generate primary glial cultures, astrocytes and microglia from PSCs ([139–141].
Additionally, a more advanced in vitro system generated from PSCs, namely 3D cerebral organoids,
is to date the only available in vitro system modelling early human brain development [142]. Contrary
to NPCs and glial cultures, the cerebral organoid approach allows the screening for therapeutics
using an in vitro system mimicking the cellular and architectural complexity of the brain tissue and
is thus more predictive of how a potential treatment responds in vivo. This advanced in vitro model
helped to unravel the link between microcephaly and ZIKV infection during pregnancy [143,144].
Given the neurotropism of ZIKV, brain organoids have already been used to validate anti-ZIKV
compounds [38,138,145]. Although the cerebral organoid technology is currently the most relevant
model of the developing human brain, this system has some limitations such as PSCs’ line-to-line and
organoid batch-to-batch variability, leading to some level of variability and in general to a limited
degree of standardization.
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3.3. Screening Approaches
In addition to testing specific compounds that have been described to inhibit related viruses
or have been shown to possess a known antiviral activity, unbiased screening approaches offer an
alternative to identify new antiviral compounds based on libraries containing hundreds of bioactive
molecules. Several of these libraries contain FDA-approved drugs and clinical investigational agents,
which have shown good safety and pharmacokinetics in vivo, thereby facilitating drug-repurposing
strategies. Drug repurposing plays a very important role, given that a considerable risk of an
infection exists during pregnancy, which can complicate medical intervention. Identification of
antiviral drugs that are already approved during pregnancy could greatly accelerate the availability of
therapeutic interventions.
3.3.1. In Vitro Screening Approaches
Different in vitro screening approaches exist, which are usually based on an automated readout,
mostly microscopy- or luminescence-based. This readout can be either based on virus yield reduction
(VYR) or on cytopathic effect (CPE) reduction [30]. VYR assays include luciferase reporter activity
assays, where the reduction in reporter signal correlates to VYR, which in the case of ZIKV has
been described either upon usage of replicon cell lines [95,96], pseudo-viruses [146], full-length
infectious clones [80,83,91], assays based on immuno-labeling of viral proteins and/or cell proliferation
markers and fluorescent or histochemical microscopic analysis [34,134,138,147] and assays based on
quantification of viral RNA via quantitative PCR [148]. CPE reduction assays generally monitor the
ability of the compound to reduce or inhibit virus-mediated CPE, thereby monitoring cell viability [30].
In the case of ZIKV, several assays have been utilized including colorimetric or luminometric cell death
assays [149–151], bright-field microscopy-based phenotypic assays analyzing the percentage of cells
undergoing ZIKV-induced morphology changes detected by automated image analysis software [152],
viral plaque forming assays [153] and assays measuring caspase-3 activity, which precedes cell death in
ZIKV-infected human NPCs [38]. However, CPE reduction assays lack some specificity as alterations
in the cellular morphology or viability based on the compound treatment can sometimes not be
distinguished from the effects mediated by a reduced CPE due to reduced virus replication and
should therefore be interpreted carefully. An alternative approach is to utilize purified recombinant
ZIKV proteins, e.g., the NS2-NS3 protease or the NS5 RdRp, and to monitor their enzymatic
activity upon compound treatment [154,155] or utilization of a split luciferase complementation
assay for the identification of orthosteric inhibitors, which block specific viral protein interactions (e.g.,
NS2B-NS3) [156].
3.3.2. In Silico Screening Approaches
Computational in silico approaches have proven to be powerful tools in predicting drug targets
and the evaluation of treatment strategies. In general, these in silico systems use computational models
to describe macromolecule–ligand interactions. Structure-based approaches mimic the binding of the
putatively active ligand within the relevant binding site and are therefore frequently able to facilitate
further chemical optimization of the compound [157]. Structure-based drug discovery approaches
include in silico homology modeling, which predicts the tertiary structure of an amino acid sequence
based on a homologous experimentally-determined structure [158]. Homology modeling techniques
and molecular docking analyses, which essentially reflect the ligand-receptor binding process of a
virtual library of compounds, can be utilized to identify compounds that can target directly viral
proteins and have been applied to ZIKV protease [42,159], methyltransferase [42] and RdRp [42,160].
Furthermore, homology models have been designed to predict the ability of potential compounds
to inhibit allosterically the binding of viral envelope proteins to cellular glycoproteins [161]. As an
alternative to homology modeling, consensus scoring can be used if the target 3D structure is known.
This method involves the comparison of two or more methods of docking process, thereby enhancing
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the performance of virtual screening by improving the rates at which potential hit compounds
are reached, which improves the prediction of bound conformations and poses [162]. As ZIKV
proteins have been crystalized and ZIKV virions have been studied by electron microscopy [163–165],
this method could be used to identify potential hit compounds that have good binding affinities for a
real matured ZIKV protein structure obtained with cryo-electron microscopy [166]. A complementary
approach to that of molecular docking analysis is to use pharmacophore searching algorithms to find
ligands similar to one of known activity and chemical features (such as hydrogen bonds, charges,
lipophilic areas) [167,168], which has recently been utilized to identify potent inhibitors of ZIKV
NS2B-NS3 [169]. Next to structure-based drug discovery approaches, mathematical analysis of viral
replication dynamics and antiviral treatment strategies have been performed for several viruses,
including human immunodeficiency virus, hepatitis C virus, influenza A virus, Ebola virus, DENV
and ZIKV [170]. A recent study predicted ZIKV replication dynamics in an NHP model including the
potential effects of antiviral treatments, data that can be used to optimize and evaluate in silico the
impact of antiviral strategies [171]. In conclusion, in silico screening approaches accelerate the drug
development process combined with low costs.
4. In Vivo Models
In vitro models greatly facilitate the initial screening and identification of new antivirals. However,
they do not fully reflect the complexity and physiology of living organisms. To this end, several in vivo
models have been developed to study virus pathogenesis and to test new drugs and vaccines (Figure 3).
 
Figure 3. Overview of the currently available in vivo models for the study of ZIKV pathogenesis and
for possible antiviral approaches. The text highlighted in green and red indicates advantages and
limitations, respectively.
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4.1. Mouse Models
Mouse models are widely used to study various aspects of virus infection in vivo, such as
pathogenesis and transmission. Several mouse models have been developed to study ZIKV infection
(Table 3). Very early studies have shown that mice are susceptible to ZIKV infection, with intracranial
inoculation causing neurological symptoms in suckling mice, whereas consistent disease in adult
white mice was not clearly manifested ([172–174]. It has been shown that peripheral inoculation of
most wildtype (WT) mice results in poor replication, as well as a rapid clearance of infection with
no disease development [70,175,176]. One major obstacle appears to be innate immune responses,
namely the murine IFN system [177,178]. Similarly to other WT mouse strains, ZIKV infection of the
Balb/c mouse model does not result in a fatal outcome; however, it seems to support ZIKV replication
more efficiently compared to C57BL/6 WT mice and leads to viremia that is comparable to human
in its magnitude and duration [179]. Furthermore, neonatal mouse models have been shown to be
susceptible to ZIKV and to develop symptoms and even lead to fetal death depending on the age and
virus dose [180–183]. Another exception seems to be the WT SJL mouse model, which supports ZIKV
replication and results after intravenous ZIKV inoculation of pregnant mice in growth restriction of
developing fetuses, cortical malformations and ocular defects [144,179]. However, SJL mice have been
described to have impaired IFN signaling and several immunological defects, rendering them not
fully immunocompetent, which might explain the observed susceptibility and fetal pathogenesis [178,
184,185]. To overcome these limitations, immunocompromised mouse systems have been developed.
Especially, interference with the type I IFN signaling pathway has been proven to be useful to facilitate
viral replication [186]. Genetically modified mice lacking either the type I IFN receptor ifnar1 gene
(Ifnar1−/−) or the transcription factors Irf3, Irf5 and Irf7 (Irf3−/−, Irf5−/−, Irf7−/− triple knockout) in
129 (A129) or C57BL/6 background have been shown to be highly susceptible to ZIKV infection and
to develop severe diseases following peripheral inoculation, including development of neurological
disease and death [70,175,176,180,187–190]. Severity of ZIKV infection in these immunocompromised
mice seems to be age dependent, with older mice (>11 weeks-old) being less susceptible to infection
than younger mice (3–5 weeks-old) [175,176]. Double knockout mice, lacking both the type I IFN
receptor and type II IFN receptor (AG129), displayed even greater susceptibility and more severe
disease following ZIKV infection compared to Ifnar1−/−-deficient A129 mice [175,191]. Furthermore,
in an attempt to better model vertical ZIKV transmission, it could be shown that crossing of female
immunocompromised mice with WT males produced heterozygous, IFN competent (Ifnar+/−) fetuses,
which better resembled the immune status of human fetuses, with ZIKV maternal inoculation resulting
in fetal demise that was associated with ZIKV infection of the placenta and fetal brain [192]. Besides
directly targeting the IFN receptors, blockage of type I and type III IFN signaling via interference
with STAT signaling in Stat1−/−- or Stat2−/−-deficient mice has also been shown to facilitate ZIKV
infection and spreading [70,193]. Furthermore, blockage of type I IFN signaling upon administration
of a monoclonal antibody (Mab) targeting the Ifnar1 receptor has been tested as a means to only
temporally block IFN signaling in an otherwise immunocompetent mouse and has been shown to
increase susceptibility to ZIKV infections [176,194–196]. Increased susceptibility to ZIKV infection
has also been demonstrated by pretreatment of mice with dexamethasone, resulting in temporal
immunocompromised animals, rendering them susceptible to ZIKV infections [197]. Recently, a
transgenic immunocompetent mouse model has been described in which murine Stat2 was replaced
with human STAT2, thereby allowing evasion of IFN signaling cascades in infected cells. This model
was combined with the generation of a mouse-adapted strain of ZIKV containing a key mutation
in the viral NS4B gene and resulted in reduced induction of IFN-β and greater replication in the
brain. This approach of establishing an immunocompetent mouse model of ZIKV infection allowed
analyses on virus replication, trans-placental transmission, as well as fetal infection [196]. Mouse
models can be very well suited to analyze pharmacokinetics of drug candidates, including stability
and in vivo retention, as well as the protective efficacy of antivirals and new therapeutics in vivo.
There are several studies showing that infection of immunocompromised AG129 (IFN type I and
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II receptors deficiency), A129 (IFN type I receptor deficiency) or Stat1−/− mice with ZIKV and
subsequent treatment with potential antiviral compounds can lead to decreased viral burden in
various tissues, reduced pathology, as well as reduced or delayed morbidity and mortality [156,193,
198–203]. Furthermore, dexamethasone-immunosuppressed mice have been used to evaluate the
therapeutic potential of antivirals [159], and in addition, immunocompetent or neonatal mouse models
have been shown to be useful to evaluate the efficacy of potential antiviral candidates to reduce
viremia [40,204–207]. Even though mouse models can give important insights into viral transmission
and pathogenesis and can be used for the initial characterization of therapeutics, it is important to
keep in mind that they differ significantly from humans, with respect to several features including
placental anatomy and gestation period, as well as disease manifestation, rendering more complex
animal models necessary to study specific aspects of ZIKV infection.
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4.2. Non-Human Primate Models
NHPs seem to be natural hosts for ZIKV and are believed to represent the major animal
reservoir [209]. ZIKV was first isolated from a rhesus macaque [2], and several monkey species
in forests were found to be seropositive for ZIKV [210]. Given their close relatedness to humans,
they offer great potential as surrogate models to study specific aspects of ZIKV infection and
pathogenesis. It has been shown that macaques are susceptible to infection by both African and
Asian ZIKV lineages and that infection results in similar patterns comparable to human infections
regarding transmission, cellular tropism, immune responses and viral replication. Infection with
ZIKV resulted in viremia that peaked around 2–6 days post-infection, followed by viral clearance.
Importantly, viral RNA could be detected in various body fluids including urine, saliva, seminal
fluid, vaginal secretions and cerebrospinal fluid, indicating similar dissemination patterns compared
to humans [211–217]. Furthermore, mucosal viral inoculation (vaginal or rectal) was shown to lead
to productive infection in macaques, mimicking the anogenital transmission route in humans [218].
Importantly, in contrast to mice, NHPs display similarities in gestation, placental barrier and fetal
development to humans, rendering them suitable to model ZIKV infections physiologically during
pregnancy in humans [219,220]. Indeed, subcutaneous ZIKV inoculation of pregnant macaques with
an Asian lineage ZIKV resulted in vertical maternal-fetal ZIKV transmission and reduced growth of
the fetal brain, as well as substantial pathology to the central nervous system [216,221]. Even though
NHPs offer a more physiological animal model for the study of ZIKV, there are several limitations
including ethical issues, high costs, availability and low throughput. These limitations have so far
hampered the usage of NHPs for the development and characterization of vaccines and antiviral
approaches [214,222–225].
4.3. Alternative Animal Models
Several other animal models have been investigated for the study of ZIKV infections, including
guinea pigs, cotton-rats and rabbits, all of which failed to show clinical signs of infection after
intracerebral inoculation with the prototype African ZIKV strain MR766 [172]. However, recent studies
described the susceptibility of guinea pigs to infection with Asian strains of ZIKV and the development
of various clinical features, immune activation and viral kinetics, similar to what has been observed
in humans [226]. In addition to subcutaneous infection, other infection routes including intranasal
infection and contact transmission of Zika virus could be demonstrated using the guinea pig model,
highlighting its suitability to study transmission pathways [227]. However, not all clinical aspects
can be reproduced, as circulating ZIKV strains seemed not to be pathogenic during the pregnancy of
immunocompetent guinea pigs and did not interfere with offspring development [228]. Nevertheless,
in contrast to other small animal models, the guinea pig model is physiologically and immunologically
more similar to humans [229]. Especially in the context of ZIKV infection, the similarity of the guinea
pig’s reproductive physiology, placentation and estrous cycle to humans, as well as the fact that
pups are born with a mature central nervous system can be of great advantage for the study of ZIKV
pathogenesis and transmission [229–231]. Next to guinea pigs, Syrian golden hamsters have recently
also been shown to be to some extent susceptible to certain ZIKV isolates and dependent on the
route of inoculation, development of viremia and appearance of virus neutralizing antibodies, and in
some cases, mild disease manifestations were observed, rendering them an interesting model to study
phenotypic variations between ZIKV strains [232].
These studies show that the host range of ZIKV might be broader than originally anticipated, and
different animal models might be useful for the study of different aspects of ZIKV infections. However,
the value of these alternative animal models for the characterization and development of antivirals
and therapeutics still needs to be fully explored.
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5. Concluding Remarks
In recent years, significant advances were made regarding our understanding of ZIKV-associated
morbidity in human. Consequently, significant progress was achieved regarding the availability
of research models and new experimental tools for the identification of therapeutic and antiviral
strategies against ZIKV. However, treatment remains a challenge. Given that treatment needs to
be safe and efficient especially in the context of pregnancy further complicates drug development.
In addition, a declining trend in ZIKV infections could limit clinical trials. As there is no licensed
effective therapy available yet, further efforts are required in order to find potential drug candidates
with ideally a wide spectrum of action against flaviviruses found in similar geographical regions with
often overlapping symptoms. Furthermore, assuming the broad cellular tropism and the different
routes of ZIKV transmission of ZIKV, a variety of models should be applied in order to validate a
promising drug. Ultimately, beyond the potential clinical benefits, the knowledge derived from the
screening of anti-ZIKV drugs using relevant models will reveal new insights into the understanding
of the molecular mechanisms of ZIKV-associated morbidity and greatly contribute to increase our
knowledge on flavivirus biology.
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Abstract: Zika virus (ZIKV), a mosquito-borne flavivirus, was an almost neglected pathogen until its
introduction in the Americas in 2015, where it has been responsible for a threat to global health, causing
a great social and sanitary alarm due to its increased virulence, rapid spread, and an association with severe
neurological and ophthalmological complications. Currently, no specific antiviral therapy against ZIKV is
available, and treatments are palliative and mainly directed toward the relief of symptoms, such as fever
and rash, by administering antipyretics, anti-histamines, and fluids for dehydration. Nevertheless, lately,
search for antivirals has been a major aim in ZIKV investigations. To do so, screening of libraries from
different sources, testing of natural compounds, and repurposing of drugs with known antiviral activity
have allowed the identification of several antiviral candidates directed to both viral (structural proteins
and enzymes) and cellular elements. Here, we present an updated review of current knowledge about
anti-ZIKV strategies, focusing on host-directed antivirals as a realistic alternative to combat ZIKV infection.
Keywords: flavivirus; Zika virus; therapy; host-directed antivirals
1. Introduction
Since the beginning of the 21st century, a number of infectious disease threats have emerged
that demand a global response. Among them, severe acute respiratory syndrome virus, avian
influenza in humans, pandemic influenza A (H1N1), Middle East respiratory syndrome coronavirus,
chikungunya virus, and Ebola virus have been the most threatening ones. Nonetheless, the emergency
of a vector-borne virus, Zika virus (ZIKV), which is responsible for congenital malformations and
other neurological and ophthalmological disorders, was hard to predict.
ZIKV is a mosquito-borne virus belonging to the Spondweni serocomplex in the genus Flavivirus of
the family Flaviviridae [1]. The virus has been isolated from various mosquito species, although it seems
that the natural transmission vectors are mosquitoes of the genus Aedes [2,3]. Besides mosquito bites, viral
direct human-to-human transmission can occur perinatally, sexually, and through breastfeeding and blood
transfusion [4]. The ZIKV genome is a single-stranded RNA molecule (≈10.7 kb) of positive polarity
encoding a single open reading frame (ORF) flanked by two untranslated regions at the 5′ and 3′ ends [5].
ZIKV was first isolated from the serum of a monkey in 1947, and one year later from Aedes africanus
mosquitoes caught in the same area, the Zika forest [6]. Until it was detected in Asia in the 1980s,
the virus had been confined to Africa. Later on, human outbreaks were reported in the Pacific
islands, Micronesia in 2007 and, then, in French Polynesia in 2013 [4]. The natural course of ZIKV
infection was usually asymptomatic or produce a relatively mild illness and an uneventful recovery [7],
hence, the virus was considered an almost neglected pathogen until its recent introduction into the
Americas in 2015, when it became a threat to global health, showing increased virulence, rapid spread,
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and an association with severe neurological complications such as an unexpected rise of microcephaly
cases in fetuses and newborns and a remarkable increase in Guillain-Barré syndrome (GBS) cases [8].
This drove the World Health Organization (WHO) to declare a public health emergency of international
concern (PHEIC) in 2016 [9].
ZIKV is a neurotropic virus with a wide tissue tropism [10–12], including reproductive tissues
and organs. In males, ZIKV can infect testes, the prostate, and seminal vesicles [12,13], and in females
it can infect the vagina, uterus, vaginal epithelium, uterine fibroblasts, Hofbauer cells, trophoblasts,
and endothelial cells from the placenta [12,14]. ZIKV has also been detected in the cornea, neurosensory
retina, optic nerve, aqueous humor, and tears [15]. Because of this, ZIKV infection can lead to severe
neurological and ophthalmological disorders.
Lack of effective prophylactics, vaccines, or therapeutics hampers the fight against ZIKV.
Consequently, inactivated viruses, live vector-based, and nucleic acid (DNA or RNA)-based candidates,
subunit elements, virus-like particles, and recombinant viruses are been rehearsed, some of them
already in clinical trials [16]. Likewise, many different compounds are being tested as possible
therapeutic agents against ZIKV that target either viral or cellular components.
The present review discusses recent advances in the design and development of antivirals and
therapeutics for ZIKV infection, focusing in those directed against host factors needed for the viral life
cycle as a realistic alternative for the treatment of ZIKV infection.
2. Therapeutic Approaches
Since the recent outbreak in 2015 in the Americas, a quite high number of possible antiviral
candidates are being tested in vitro and in vivo. However, until now, no specific therapy has been
approved against any flavivirus [17], including ZIKV [18], and, thus, current treatments are mainly
directed toward the relief of symptoms, such as fever and rash, by administering antipyretics,
anti-histamines, and fluids for dehydration [15]. Nevertheless, it should be noted that some commonly
used drugs, such as acetylsalicylic acid, are contraindicated in ZIKV-infected patients, since they
increase the risk of internal bleeding, and other arboviruses (dengue or chikungunya viruses) that can
co-infect the patients may produce hemorrhages [3].
Due to the natural course of ZIKV infection, which is usually asymptomatic or produce
a relatively mild illness and an uneventful recovery, when facing anti-ZIKV strategies, a very
important point to take into account is the main target population that would benefit from it, namely
immunocompromised patients and pregnant women and their fetuses [4]. In this sense, only for
some of the tested drugs their safety profiles are known [19]. However, in cases of Food and Drug
Administration (FDA) (https://www.drugs.com/) category B compounds (animal reproduction studies
have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant
women), or even in those of category C (animal reproduction studies have shown an adverse effect on the
fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use
of the drug in pregnant women despite potential risks), or D (there is positive evidence of human fetal risk
based on adverse reaction data from investigational or marketing experience or studies in humans, but potential
benefits may warrant use of the drug in pregnant women despite potential risks), their use in pregnancy can be
contemplated if the potential benefit outweighs the risks. Even more, some of the assayed compounds
cross the placenta and, thus, can also benefit the fetus. Nonetheless, if used, this should be done in
an individualized way, conditioning dosage and timings, and always under a clinician’s control where
the patient is informed of the pros and cons.
Current search for ZIKV antivirals is being conducted with different approaches: by screening
of compounds libraries; by the repurposing of drugs of known active efficacy against other diseases
now in use in clinical practice, many of which display broad-spectrum activity; and by testing natural
products. Two different strategies can be applied when pursuing for antivirals, those searching
for compounds directed to viral targets (direct-acting antivirals) and those aimed to target cellular
components needed for the viral life cycle (host-directed antivirals).
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3. Direct-Acting Antivirals
Among the virus-directed drugs tested [18,20] are those acting against the viral RNA-dependent
RNA polymerase (non-structural protein 5 (NS5)) catalytic domain, including nucleoside analogs and
polymerase inhibitors; the methyltransferase catalytic domain of the NS5 responsible for transferring
the mRNA cap; the NS2B-NS3 trypsin-like serine protease needed for proper processing of the
viral polyprotein; and the NS3 helicase. The crystal structures of all these proteins have already
been resolved and will certainly help to find new antivirals [21–32]. In the same way, structures
from other viral proteins are also available that could help to design ZIKV therapeutic alternatives,
such as those of the capsid C protein [33], whose destabilization may impair ZIKV multiplication,
the NS1 [34,35], an immuno-modulator, or the envelope glycoprotein [36–38], which mediates cell
binding and endosomal fusion, constitutes a major target for neutralizing antibodies, and could be
also the target for virucidal compounds [39].
On the other hand, it has also been reported that passive transfer of neutralizing antibodies to
pregnant mice suppresses ZIKV multiplication, inhibits cell death, reduces the number of progenitor
neuronal cells, and prevents microcephaly [40,41]. Likewise, administration of monoclonal antibodies
(MAbs) recognizing the domain III of the ZIKV-E protein protect mice of lethal ZIKV challenge [42,43]
and other MAbs are able to bind and neutralize ZIKV, including those directed against the E dimer
epitope [44]. Human polyclonal antibodies produced in transchromosomal bovines also protect
mice from ZIKV lethal infection, eliminated ZIKV induced tissue damage in the brain and testes,
and protected against testicular atrophy [45]. Thus, administration of therapeutic antibodies seems
to also be a potential strategy against ZIKV. Nevertheless, it should be noted that, although still
controvertial in the case of ZIKV infection [46], the well-known antibody dependent enhancement
effect (ADE) [47], of which dengue virus (DENV) is the prototypic model, may potentiate the risk of
disease exacerbation.
4. Host-Acting Antivirals
Flaviviruses have small RNA genomes (around 10.7 kb in length) and thus require many host
factors and co-option of cellular metabolic pathways to successfully infect host cells and propagate
efficiently [48]. This offers an opportunity to search for host targets as therapeutic tools that, in many
instances, as they are shared by different members of the Flaviviridae family, can be envisaged as
pan-flaviviral antivirals [48–50]. This strategy can be directed to host factors implicated in infection,
pathogenesis, and in the immune response, as it has been shown for DENV and the West Nile virus
(WNV) [51]. In addition, their effect would be less prone to the emergence of mutants that will
escape their action, as often occurs with drugs targeting viral components. Consequently, this kind of
approach could ideally lead to the discovery of broad spectrum antivirals that could provide low cost
but effective tools for the control of flaviviral threats.
Different approaches are being used to identify potential host factors as therapeutic targets
against flaviviruses including the analyses of transcript levels (e.g., next generation RNA sequencing)
for altered expression patterns during infection, proteome changes, kinases activities variations,
and protein-RNA interactions (e.g., two-hybrid screenings and affinity chromatography). Likewise,
functional analysis can be applied by overexpressing cDNAs or by RNAi-mediated loss of function
screens using dsRNA, siRNA, or shRNA libraries, although it should be noted that in some cases
downregulation is inefficient and some genes have redundant functions [51]. Replicons may also be
used to specifically assay replication activity [52,53].
Theoretically, host-acting antivirals can be directed to any molecule or pathway implicated in the
different steps of the viral life cycle, from early events (binding, entry, and fusion), to the formation of
the replication complex, and the viral maturation and egress.
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4.1. Early Steps: Binding, Entry, and Endosomal Fusion
The first step of ZIKV infection is its binding to the cellular receptor (Figure 1). Several molecules
have been proposed as a ZIKV receptor (members of the Tyro3/Axl/Mer (TAM) family of receptor tyrosine
kinases, T-cell immunoglobulin and mucin domain (TIM) and dendritic cell-specific intercellular adhesion
molecule 3-grabbing nonintegrin (DC-SIGN)) that are expressed in different neuronal and non-neuronal
permissive cell types. These molecules are also receptors for other viruses, including flaviviruses such as
DENV and WNV, regulate several cellular activities (adhesion, migration, proliferation, and survival, release
of inflammatory cytokines, antigen uptake, and signaling), and play important roles in the host’s response to
infection [54]. However, elimination of a known receptor does not necessarily result in complete protection
from viral infection, since flaviviruses use different receptors and, thus, there is always redundancy and
alternatives. For instances, inhibiting, downregulating, knocking-down, or ablating AXL, although in some
cases they reduce ZIKV infection, they do not completely abolish it, pointing to the use of different cell
surface receptors on different cell types [55–58].
Figure 1. Life cycle of Zika virus (ZIKV) and drugs targeting cellular components. Drugs targeting:
attachment (1); entry (2); endosomal fusion (3); translation/transcription (4); replication (5) by
affecting the endoplasmic reticulum (ER) (5.1), the lipid metabolism (5.2), the pyrimidine and the
purine biosynthesis (5.3); assembly or maturation of the virions (6); or innate immune response
(7). Drugs effective for ZIKV infection side effects (8). Drugs with unknown mechanism (9).
MYD1: AXL decoy receptor; 25HC: 25-hydroxycholesterol; CQ: chloroquine; FAC: iron salt ferric
ammonium citrate; DFMO: difluoromethylornithine; NGI-1: N-linked Glycosylation Inhibitor-1; NDGA:
nordihydroguaiaretic acid; M4N: terameprocol; MPA: mycophenolic acid; IFNs: interferons; IFITM:
interferon-induced transmembrane proteins; AVC: (1-(2-fluorophenyl)-2-(5-isopropyl-1,3,4-thiadiazol-
2-yl)-1,2-ihydrochromeno[2,3-c]pyrrole-3,9-dione; HH: hippeastrine hydrobromide; AQ: amodiaquine
dihydrochloride dehydrate.
4.1.1. Binding/Entry
Different molecules have been shown to inhibit ZIKV infection at the entry step (Figure 1).
R448 (an AXL kinase inhibitor) and MYD1 (an AXL decoy receptor) compromises, but do not
completely abolish, ZIKV infection of glial cells [57]. R448, as well as cabozantinib, an inhibitor of
AXL phosphorylation, that are currently in clinical trials for anticancer activities, significantly impairs
ZIKV infection of human endothelial cells in a dose-dependent manner by affecting a post-binding
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step [59]. Likewise, curcumin, a widely used food additive and herbal supplement, reduces ZIKV
infection in cell culture inhibiting cell binding while maintaining viral RNA integrity [60], as does
suramin, an anti-parasitic that interferes with attachment to host cells and with virion biogenesis by
affecting glycosylation and maturation [61,62].
4.1.2. Endosomal Fusion
Once ZIKV binds to the cell receptor, like other flaviviruses, it is internalized through
clathrin-mediated endocytosis and transported to the endosomes with the involvement of cellular
actin and microtubules to establish a productive infection (Figure 1) [57]. After internalization,
to start translation and replication, the viral genome is released inside the cytoplasm by fusing
the viral envelope with the membranes of the cellular endosomes, a process triggered by acidic
pH inside them [63,64]. Nanchangmycin, an insecticide and antibacterial polyether, inhibits ZIKV
multiplication and, although the exact mechanism of action has not been completely elucidated,
it probably targets AXL and blocks clathrin-mediated endocytosis [65]. Acid endosomal pH triggers
rapid conformational changes on viral envelope protein that result in its fusion with endosomal
membrane in a pH-dependent manner, thus allowing nucleocapsid release to the cytoplasm for genome
uncoating (Figure 1). The optimal pH for conformational rearrangements and viral fusion is 6.3–6.4,
and these processes are likely dependent on the presence of cholesterol and specific lipids in the target
membrane [66]. These processes can be potentially druggable, and in fact, arbidol, a broad-spectrum
antiviral and immunomodulatory use for human influenza A and B infections, inhibits ZIKV
multiplication in cell culture probably because it intercalates into membrane lipids leading to the
inhibition of membrane fusion between virus particles and plasma membranes, and between virus
particles and the membranes of endosomes [67]. Chlorpromazine, an antipsychotic drug that also
inhibits clathrin-mediated endocytosis, reduced ZIKV infection, confirming the requirement for
clathrin-mediated endocytosis of ZIKV [68]. In addition, 25-hydroxycholesterol (25HC) is increased
in ZIKV-infected human embryonic cells and brain organoids, and reduces viremia and viral loads
without affecting viral binding, but blocking internalization and suppressing viral and cell membranes
fusion [69]. Even more, 25HC reduces mortality and prevents microcephaly in ZIKV-infected mice,
and also decreases viral loads in the urine and serum of treated non-human infected primates [69].
Daptomycin, a lipopeptide antibiotic that inserts into cell membranes rich in phosphatidylglycerol,
which suggests an effect on late endosomal membranes enriched in this lipid, has also been described
as a ZIKV inhibitor [70].
The dependence on endosomal acidification for ZIKV infection also provides a host target suitable
for antiviral intervention. For instance, Obatoclax (or GX15-070), an anti-neoplastic and pro-apoptotic
inhibitor of the Bcl-2 that targets cellular Mcl-1, impairs ZIKV endocytic uptake by reducing the
pH of the endosomal vesicles in cell culture, and thereby most likely inhibits viral fusion [71,72].
However, Obatoclax, which presents a low solubility, has not produced satisfactory results in clinical
trials for hematological and myeloid diseases. Saliphenylhalamide (SaliPhe), which targets vacuolar
adenosine triphosphatase enzyme (ATPase) and blocks the acidification of endosomes, inhibits
ZIKV multiplication in human retinal pigment epithelial cells [71] that are natural targets for ZIKV
infection [12]. Similar results were found by Adcock et al. (2017) with SaliPhe using a different
screening [73]; however, they reported that, contrary to that described by others [65], other compounds
that interfere with the endocytic pathway, such as dynasore, that blocks clathrin-mediated endocytosis,
or monensin, a cation transporter, were either toxic for the cells used or did not show any anti-ZIKV
activity, as neither did chloroquine (CQ). These contradictory results are probably explained by the
different methodologies, cell types, and, to a lower extent, viral strains used to analyze the antiviral
activities of the compounds and suggest that compounds showing different activities should be
carefully evaluated before going further with investigations. In this line, and contrary to above
mentioned report [73], CQ, an FDA-approved anti-inflammatory 4-aminoquinoline and an autophagy
inhibitor widely used as an anti-malaria drug that is administered to pregnant women at risk of
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exposure to Plasmodium parasites, was shown to have anti-ZIKV activity in different cell types
(Vero cells, human brain microvascular endothelial cells (hBMECs), and human neural stem cells
(NSCs)), affecting early stages of the viral life cycle, possibly by raising the endosomal pH and
inhibiting the fusion of the envelope protein to the endosomal membrane [74,75]. CQ has been shown
to reduce placental and fetal ZIKV infection [76], and also attenuate ZIKV-associated morbidity and
mortality in mice and protect the fetus from microcephaly [77]. Even more, CQ attenuated vertical
transmission in ZIKV-infected pregnant interferon signaling-competent Swiss Jim Lambert (SJL) mice,
significantly reducing fetal brain viral loads [78]. Similarly, CQ, and other lysosomotropic agents
(ammonium chloride, bafilomycin A1, quinacrine, mefloquine, and N-tert-Butyl Isoquine (GSK369796))
that neutralize the acidic pH of endosomal compartments, block infection of a human fibroblast cell
line and Vero cells [68,75].
Additionally, by medicinal chemistry-driven approaches, a series of new 2,8-bis(trifluoromethyl)quinoline
and N-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives have been proved to inhibit
ZIKV replication in vitro with a higher potency than chloroquine or mefloquine [79,80]. More recently,
by screening FDA-approved drugs using a cell-based assay, it has been shown that amodiaquine,
another antimalarial drug, also has anti-ZIKV activity in cell culture by targeting early events of
the viral replication cycle [81]. Niclosamide, a category B antihelmintic drug approved by FDA,
was capable of inhibiting ZIKV infection, and although its antiflaviviral effect has been associated to
its ability to neutralize endolysosomal pH and interfere with pH-dependent membrane fusion, in the
case of ZIKV, it seems that it was affecting other post-entry steps [82]. In addition, recently, it has been
reported that niclosamide decreases ZIKV production, partially restores differentiation, and prevents
apoptosis in human induced NSCs; even more, it can partially rescue ZIKV-induced microcephaly
and attenuate infection in a developed humanized ZIKV-infected embryo model in vivo [83]. Likewise,
tenovin-1, which represses cell growth and induces apoptosis in cells expressing p53 by inhibiting
the protein-deacetylating activities of SirT1 and SirT2 and, thus, affects endosome functions, potently
inhibits ZIKV infection in primary placental fibroblast cells [65]. Iron salt ferric ammonium citrate (FAC)
also inhibits ZIKV infection through inducing viral fusion and blocking endosomal viral release by
promoting liposome aggregation and intracellular vesicle fusion [84]. Overall, these studies evidence
the potential of targeting viral entry to combat ZIKV.
4.2. Translation/Transcription
Once ZIKV-RNA is released from the endosomes in the cytoplasm, it acts as mRNA to
synthesize the negative-strand viral RNA that directs positive-strand RNA synthesis (Figure 1) [4].
Silvestrol, a natural compound isolated from the plant Aglaia foveolata that it is known to inhibit
the Asp-Glu-Ala-Asp (DEAD)-box RNA helicase eukaryotic initiation factor-4A (eIF4A) required to
unwind structured 5′-untranslated regions and thus impairing RNA translation, exerts a significant
inhibition of ZIKV replication in A549 cells and primary human hepatocytes [85]. N-(4-hydroxyphenyl)
retinamide (fenretinide or 4-HPR), an activator of retinoid receptors that inhibits the proliferation
of cancer cells and can induce apoptosis, inhibits ZIKV in cell culture and significantly reduces
both serum viremia and brain viral burden in mice by decreasing the rate of viral RNA synthesis,
though not via direct inhibition of the activity of the viral replicase [86]. ZIKV relies on polyamines for
both translation and transcription [87], so that, drugs targeting the polyamine biosynthetic pathway,
such as difluoromethylornithine (DFMO or eflornithine), an FDA-approved drug that is used to treat
trypanosomiasis, hirsutism, and some cancers, as well as diethylnorspermine (DENSpm) limit viral
replication in BHK-21 cells [88].
4.3. Replication, Assembly, and Maturation
ZIKV replication and particle morphogenesis take place associated with a virus-induced
organelle-like structure derived from the membrane of the endoplasmic reticulum (ER) (Figure 1) [4].
De novo synthesized positive strand-RNA, once packaged, form enveloped immature virions in the ER,
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enter the secretory pathway and, then, in the trans-Golgi network, the prM is cleaved before the virus
is released from the infected cell (Figure 1) [89,90].
ER-membrane multiprotein complexes, such as the oligosaccharyltransferase (OST) complex,
have been reported to be critical host factors for flavivirus multiplication. In this regard, it has
been shown that the N-linked Glycosylation Inhibitor-1 (NGI-1) chemical modulator of the OST
complex blocks ZIKV-RNA replication in different cell types [91]. Similarly, the host ER-associated
signal peptidase (SPase) is an essential, membrane-bound serine protease complex involved in
cleavage of the signal peptides of newly synthesized secretory and membrane proteins at the ER
and also for processing of the flavivirus prM and E structural proteins [92]. It has also been reported
that cavinafungin, an alaninal-containing lipopeptide of fungal origin, potently inhibits growth of
ZIKV-infected cells [93]. Nitazoxanide, a broad-spectrum antiviral agent approved by the FDA
as an antiprotozoan and with potential activity against several viruses in clinical trials (rotavirus
and norovirus gastroenteritis, chronic hepatitis B, chronic hepatitis C, and influenza), also inhibits
virus infection targeting a post-attachment step, most likely virus genome replication [94]. Likewise,
Brefeldin A, a Penicillium sp. product that inhibits protein transport from the ER to the Golgi apparatus,
inhibits ZIKV multiplication [95], as does Emetine, an anti-protozoal agent that inhibits both ZIKV
NS5 polymerase activity and disrupts lysosomal function [96].
ZIKV infection leads to cell-death by inducing host caspase-3 and neuronal apoptosis during its
propagation [97]. Thereby, bithionol, a caspase inhibitor, inhibits ZIKV strains of different geographical
origin in Vero cells and human astrocytes [98]. Similarly, by using a drug repurposing screening of over
6000 molecules, it was found that emricasan, a pan-caspase inhibitor that restrains ZIKV-induced increases in
caspase-3 activity and is currently in phase 2 clinical trials in chronic hepatitis C virus (HCV)-infected patients,
protected human cortical neural progenitor cells (NPC) in both monolayer and three-dimensional organoid
cultures, showing neuroprotective activity without suppression of viral replication [82]. Additionally,
bortezomib, a dipeptide boronate proteasome inhibitor approved for treatment of multiple myeloma
and mantle cell non-Hodgkin’s lymphoma that regulates the Bcl-2 family of proteins, has also been
described as a ZIKV inhibitor [70]. Similarly, different cyclin-dependent kinase (CDK) inhibitors, such as
(alphaS)-4-(Acetylamino)-alpha-methyl-N-(5-(1-methylethyl)-2-thiazolyl)benzeneacetamide (PHA-690509),
reduced ZIKV-infection and propagation [82]. However, CDK inhibitors should not be suitable for the
treatment of pregnant women but could be useful for the treatment of other non-pregnant patients,
preventing the complications associated with ZIKV infection.
4.3.1. Lipid Metabolism Modulators
The need for specific host lipids for flavivirus replication and particle envelopment make lipid
metabolism a potential target for an antiviral search [66,99], and, even though manipulating a major
metabolic pathway such as lipid biosynthesis can be envisaged as a dangerous antiviral approach due
to the undesirable effects that could be detrimental for the host, current use of drugs such as ibuprofen
and aspirin (cyclooxygenase-2 (COX-2) inhibitors) or statins (3-hidroxi-3-metil-glutaril-CoA (HMG-CoA)
reductase inhibitors) highlights the feasibility of lipid-based therapeutics [100,101]. Accordingly, inhibition
of key enzymes involved in fatty acid synthesis, such as acetyl-CoA carboxylase (ACC) [102], and fatty
acid synthase (FASN) [103–105], are potential targets for anti-ZIKV therapy. In this line, we have reported
that nordihydroguaiaretic acid (NDGA) and its derivative tetra-O-methyl nordihydroguaiaretic (M4N or
terameprocol), two compounds that disturb the lipid metabolism probably by interfering with the sterol
regulatory element-binding proteins (SREBP) pathway, inhibit the infection of ZIKV and WNV, likely
by impairing viral replication, as did other structurally unrelated inhibitors of the SREBP pathway,
such as 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinyl-benzamide
dihydrochloride (PF-429242) and fatostatin [106]. In the same way, the dependence on cholesterol
for different processes during flavivirus infection also provides a suitable target for antiviral strategies.
As mentioned above, 25HC reduces viremia and viral loads in vitro, and also reduces mortality and
prevent microcephaly in mice, and decreases viral loads in the urine and serum in non-human infected
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primates [69]. Lovastatin and mevastatin are hypolipidemic agents (HMG-CoA inhibitors) belonging to
the family of statins that are widely used for lowering cholesterol in patients with hypercholesterolemia
and have been previously shown to present antiviral activity against dengue and hepatitis C viruses.
Both agents have been proposed as therapeutic candidates against ZIKV [107]. In fact, lovastatin attenuates
nervous injury in animal models of GBS [108]. Likewise, imipramine, an FDA-approved antidepressant,
inhibits ZIKV-RNA replication and virion production in human skin fibroblasts, probably by interfering
with intracellular cholesterol transport [109]. Regarding sphingolipid metabolism, which has been
involved in flavivirus infection [66], treatment with the neutral sphingomyelinase inhibitor GW4869
reduced ZIKV production by affecting viral morphogenesis [110] as described for other flaviviruses [111].
Finally, since adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of lipid
metabolism, its activation by PF-06409577 or metformin reduced ZIKV infection by impairing viral
replication [112,113]. Thus, targeting lipid metabolism could provide therapeutic alternatives for the
discovery of host-directed antivirals against ZIKV.
4.3.2. Nucleosides Biosynthesis Inhibitors
The NS5 protein is the viral RNA-dependent RNA polymerase responsible for the RNA synthesis
that also inhibits interferon (IFN) signaling by acting over the signal transducer and activator of
transcription 2 (STAT2) protein [114], being, thus, a major target for antiviral design. Besides the
proven antiviral activities of different nucleosides analogs and inhibitors of the ZIKV-NS5 [18], several
inhibitors of the biosynthesis of nucleosides (purines and pyrimidines) also impair ZIKV replication
(Figure 1). Ribavirin is an inhibitor of the inosine monophosphate dehydrogenase (IMPDH) with
antiviral activity to several RNA viruses [115], but its mechanism of action is not entirely clear. It may
act as a guanosine synthesis inhibitor, a viral cap synthesis inhibitor, a viral RNA mutagen, and as
an inducer of lethal mutagenesis [116–118]. By using a cell-based assay, no antiviral activity of the
drug was initially observed [73] but, later on, it was reported that although no activity against ZIKV
was detected in Vero cells, the drug did inhibit virus multiplication in human cell lines, including liver
Huh-7 and rhabdomyosarcoma (RD) cells [119]. Further studies have confirmed an inhibitory activity
of ribavirin against ZIKV strains of different geographical origin in various types of cells, such as human
neural progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma
cells (A549), and even in Vero cells [120–122]. Still more, the drug was shown to abrogate viremia in
ZIKV-infected STAT-1-deficient mice [121], which lack type I IFN signaling, are highly sensitive to
ZIKV infection, and exhibit a lethal outcome. Two other inhibitors of IMPDH, merimepodib (MMPD or
VX-497) [123] and mycophenolic acid (MPA) [65,70,124] also inhibit ZIKV-RNA replication in different
cell types, including Huh-7 cells, human cervical placental cells, and neural stem and primary amnion
cells. However, other authors [73] have described that MPA have little effect on ZIKV replication and
showed significant cell toxicity. Likewise, azathioprine, another inhibitor of purine synthesis and
immunosuppressant, impaired ZIKV replication in HeLa and JEG3 cells [70]; nonetheless, its use in
pregnant women is not recommended. The above described contradictory results stress again the
differences that drug treatments may have as a consequence of the different viral strains, cell types,
and methodologies used to assess them.
As with the inhibitors of purine biosynthesis, compounds inhibiting the synthesis of pyrimidines
have also effect on ZIKV replication (Figure 1). So that, the virus was highly susceptible to brequinar
and CID 91632869 treatments in cell culture [73]. However, it should be noted that it has been reported
that brequinar, as well as DD264, antiviral activity may not be due to pyrimidine deprivation, but rather
to the induction of the cellular immune response [125,126]. Similarly, other inhibitors of the pyrimidine
synthesis, such as gemcitabine, an activator of cellular caspases [65,71], and, although with a lower
efficiency probably due to its lower solubility, 6-azauridine and finasteride, a 4-azasteroid analog
of testosterone that inhibit type II and type III 5α-reductase and is being tested for benign prostatic
hyperplasia and male pattern baldness, reduce ZIKV replication [73,107].
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4.3.3. Unknown Mechanisms
Several other compounds have been shown to have anti-ZIKV activity by inhibiting viral entry
and/or RNA synthesis, although their mechanisms of action have not yet been fully elucidated.
Among them are antiparasitics such as ivermectin (used mainly against worms infections) and
pyrimethamine (a folic acid antagonist that inhibits the dihydrofolate reductase and, thus, DNA and
RNA synthesis, is classified as a pregnancy category C, and was initially used to treat malaria and now
toxoplasmosis and cystoisosporiasis) [70]; antibiotics such as azithromycin that prevents infection, replication,
and virus-mediated cell dead [55], and kitasamycin (a natural product from Streptomyces narbonensis that
inhibits protein biosynthesis) [107]; drugs used to prevent chemotherapy-induced nausea and vomiting as
palonosetron (a FDA-approved 5-HT3 antagonist) [107]; antidepressants like sertraline (a selective serotonin
reuptake inhibitor) [107] and cyclosporine (that is also use for rheumatoid arthritis, psoriasis, Crohn’s
disease, nephrotic syndrome, and in organ transplants, is believed to lower the activity of T-cells, and
is currently in clinical trials for tis possible use in ameliorate neuronal cellular damage) [70]. Similarly,
after chemical screening, it was found that hippeastrine hydrobromide (HH), an active component of
traditional Chinese medicine, and amodiaquine dihydrochloride dihydrate (AQ), an FDA-approved drug
for treatment of malaria, inhibit ZIKV infection of human pluripotent stem cell-derived cortical NPCs and
in adult mouse brain in vivo even when the infection was already ongoing but, again, their mechanisms of
action are not known [127].
5. Drugs Preventing ZIKV Infection Side Effects
Besides drugs that act against host targets directly implicated in the viral cycle, there are
compounds that can prevent undesirable effects of ZIKV infection. In this regard, ZIKV infection leads
to massive neuronal damage, especially of neural progenitor cells, and neurodegeneration [128–130],
via both direct replication in neuronal cells and possibly through increased excitotoxicity via over
activation of N-methyl-D-aspartate receptor (NMDAR)-dependent neuronal excitotoxicity in nearby
cells. Memantine, a pregnancy category B FDA-approved drug widely used to treat patients with
Alzheimer’s disease, as well as other NMDAR blockers (dizocilpine, agmatine sulfate, or ifenprodil),
prevents neuronal damage and death and intraocular pressure increase induced by ZIKV infection
in infected mice, but it does not affect virus replication, pointing to its possible use to prevent
or minimize ZIKV-related microcephaly during pregnancy [131]. Ebselen (EBS), an antioxidant
that reduces oxidative stress and improves histopathological features in a testicular injury study
model and is currently in clinical trials for various diseases, showed minor effects in reducing ZIKV
progeny production and viral E protein expression and on overall survival and viremia level of
challenged AG129 mice; however, it should be noted that EBS reduced some ZIKV-induced effects,
such as testicular oxidative stress, leucocyte infiltration, and production of pro-inflammatory response,
whereas, in a model of male-to-female mouse sperm transfer, the drug improved testicular pathology
and prevented the sexual transmission of ZIKV [132].
6. Innate Immunity Modulation
IFNs play a key role in the elimination of pathogens and they are release upon the activation
of the innate immune response by infecting viruses. In this way, ZIKV infection induces IFN
signaling pathways and further activates cytoplasmic retinoic acid inducible gene 1 protein (RIG1)-like
receptors (RLRs) and several type I and III IFN-stimulated genes, driving to the subsequent
activation of the Janus kinase (JAK)/STAT innate immune pathway that confer resistance to ZIKV
infection [54]. Different studies showed that IFN-α, IFN-β, and IFN-γ inhibit ZIKV replication
in cell culture [124,133,134], and that treatment of pregnant mice with IFN-λ reduced ZIKV
infection [135]. In addition, IFITM1 and IFITM3, which are interferon-induced transmembrane
proteins, impair early stages of ZIKV infection. Even more, IFITM3 prevents ZIKV-induced
cell death [136]. Likewise, it has been reported that an interferon-activating small molecule
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(1-(2-fluorophenyl)-2-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1,2-ihydrochromeno[2,3-c]pyrrole-3,9-dione
(AVC) strongly inhibits replication of ZIKV in cell culture [137]. However, it is also known that
the virus is capable of evading type I IFN responses by acting over the JAK/STAT signaling
pathway [114,138–140], and that type I IFNs might be mediators of pregnancy complications, including
spontaneous abortions and growth restriction [141]. In any case, use of IFN against ZIKV, alone or in
combination with other antivirals, deserve further studies.
By screening a library of known human microRNAs (miRNAs), small, noncoding RNAs
(sncRNAs) that modulate gene expression post-transcriptionally and regulate a broad range of cellular
processes, several miRNAs were found to inhibit ZIKV by increasing the capability of infected cells to
respond to infection through the interferon-based innate immune pathway [142]. Another alternative
is intervening over epigenetic regulation by using epigenetics modulators. For instance, histone
H3K27 methyltransferases (EZH1 and EZH2) suppress gene transcription and it has been shown
that inhibitors such as 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-
6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide (GSK-126) reduce ZIKV multiplication in cell
culture through the activation of cellular antiviral and immune responses [143]. In any case, further
studies are needed to evaluate the potential therapeutic capability of these immunomodulators against
ZIKV infection.
7. Conclusions
A great effort is being lately made to find compounds to fight ZIKV infection by applying different
approaches, from repurposing of drugs with known antiviral activity to the screening of bioactive
molecules from different libraries, as well as natural products. However, most of the already tested
drugs have been found to inhibit viral replication in vitro, and only a few have been tested in vivo.
Hence, since, in many instances, the results will be difficult to extrapolate to humans, it would be hard
for most of the tested antivirals to complete the entire drug development pipeline. In addition, it should
be remarked that many drugs could have untoward effects and, thus, careful evaluation should be
conducted before using them in clinical practice, as the main target populations for anti-ZIKV therapy
will be pregnant women and patients with other medical complications.
Many of the already tested drugs are directed against viral structural and enzymatic proteins,
including, for instance, anticancer and anti-inflammatory molecules, antibiotics, and antiparasitics;
however, it is well known that this approach can easily lead to the appearance of resistance.
Since flaviviruses require many host factors and co-option of cellular metabolic pathways to
successfully infect host cells and propagate efficiently, this offers an opportunity to search for host
targets as therapeutic tools that, in many instances, can be broad spectrum agents, and which effect
would be less prone to the emergence of mutants that will escape their action. Because of that, and even
though manipulating host metabolic pathways can be seen as dangerous due to the undesirable effects
that could be detrimental for the host, its success for other diseases make of them a realistic option for
the treatment of ZIKV infection.
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Abstract: The Zika virus (ZIKV) outbreak in 2016 in South America with specific pathogenic outcomes
highlighted the need for new antiviral substances with broad-spectrum activities to react quickly to
unexpected outbreaks of emerging viral pathogens. Very recently, the natural compound silvestrol
isolated from the plant Aglaia foveolata was found to have very potent antiviral effects against the
(−)-strand RNA-virus Ebola virus as well as against Corona- and Picornaviruses with a (+)-strand
RNA-genome. This antiviral activity is based on the impaired translation of viral RNA by the
inhibition of the DEAD-box RNA helicase eukaryotic initiation factor-4A (eIF4A) which is required
to unwind structured 5´-untranslated regions (5′-UTRs) of several proto-oncogenes and thereby
facilitate their translation. Zika virus is a flavivirus with a positive-stranded RNA-genome harboring
a 5′-capped UTR with distinct secondary structure elements. Therefore, we investigated the effects of
silvestrol on ZIKV replication in A549 cells and primary human hepatocytes. Two different ZIKV
strains were used. In both infected A549 cells and primary human hepatocytes, silvestrol has the
potential to exert a significant inhibition of ZIKV replication for both analyzed strains, even though
the ancestor strain from Uganda is less sensitive to silvestrol. Our data might contribute to identify
host factors involved in the control of ZIKV infection and help to develop antiviral concepts that
can be used to treat a variety of viral infections without the risk of resistances because a host
protein is targeted.
Keywords: Ziks virus; silvestrol; antiviral; eIF4A; hepatocytes
1. Introduction
The Zika virus (ZIKV) is an emerging mosquito-borne virus of the genus Flavivirus within the
Flaviviridae family. It is closely related to other flaviviruses like dengue virus, West Nile virus, and
yellow fewer virus, which are all transmitted by mosquitos and can cause severe pathological effects
in infected individuals. The ZIKV genome is a (+)-strand ssRNA of about 11 kb with highly structured
untranslated regions (UTRs) on the 5′- and 3′-ends, which are predicted to form hairpin structures and
are essential for viral replication and translation [1–3]. The genome acts as a viral mRNA with a single
open reading frame that is directly translated into a polyprotein of 3419 or 3410 amino acids for the
Africa and French Polynesia strains, respectively [4,5]. This polyprotein is then co- and posttranslational
processed by viral and host proteases into three structural proteins (capsid, premembrane, envelope)
and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) [4]. The viral
RNA-dependent RNA polymerase NS5 possesses an additional methyltransferase domain which
introduces an essential 5′-cap on the viral RNA [6].
The recent outbreak of ZIKV in Brazil, which was associated with severe neurological effects like
Guillain-Barré syndrome and microcephaly of newborns if ZIKV infection occurred during pregnancy,
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prompted the WHO to consider ZIKV infection as a “public health emergency of international concern
(PHEIC)”. This highlights the need for efficient and well-tolerated antiviral therapies for emerging
infectious diseases [7,8]. Such severe pathological effects were not present in patients infected with
the original isolate from Uganda but firstly appeared in an outbreak in French Polynesia. The high
mutation rate of RNA-viruses like ZIKV offers them the chance to develop escape mutant strains that
are resistant to drugs targeting viral proteins. Therefore, a promising strategy is to target host proteins
which are essential for the viral life cycle but do not underlie the high viral mutation rate.
Silvestrol is a natural compound of the rocaglate family that can be isolated from the plant
Aglaia foveolata [9]. It has been identified as a specific inhibitor of the DEAD-box RNA helicase
eukaryotic initiation factor-4A (eIF4A), which is part of the heterotrimeric translation initiation
complex eIF4F together with the cap binding protein eIF4E and the scaffolding protein eIF4G [10,11].
The complex eIF4F regulates translation by recruiting ribosomes to the 5′-UTR of many mRNAs
through binding to m7GpppN cap structures [12]. The helicase eIF4A unwinds RNA secondary
structures to create a binding platform for the 43S preinitiation complex. Silvestrol selectively
binds eIF4A, resulting in its depletion from the eIF4F complex due to an increased affinity
of eIF4A to its bound mRNA substrate and thus abolishes translation [13]. Silvestrol exhibits
anti-tumor activity in many pre-clinical models without showing major toxic side effects [11,14–16].
The proposed mechanism of silvestrol is to inhibit the eIF4A-dependent translation of short-lived
key proto-oncogenes such as c-MYC and PIM1, whose mRNA 5′-UTRs are extended and include
regions of stable RNA secondary structures that require unwinding by eIF4A to create a binding
platform for the 43S preinitiation complex [17]. Moreover, silvestrol leads to an increased survival
rate in several xenograft mouse models and thus was described as a potential novel anticancer
drug [14,15,18,19]. In addition, in two recent studies antiviral effects of silvestrol against Ebola, Corona-,
and Picornaviruses have been reported. In these systems, silvestrol inhibits the eIF4A-dependent
translation of viral mRNAs with extended and structured 5′-UTRs [20–22]. While Ebola virus and
Coronavirus are 5′-cap dependently translated, Picornavirus is translated via an eIF4A-dependent
internal ribosomal entry site (IRES) [21].
Given the facts that the rocaglate silvestrol inhibits the eIF4A-dependent translation of capped
mRNAs with extended 5′-UTRs and the ZIKV genome represents an RNA with these features,
this study aims to investigate the effect of silvestrol on the translation and replication of two
ZIKV strains.
2. Materials and Methods
2.1. Cell Culture
Human A549 cells were cultured in DMEM supplemented with 4.5 g/L glucose, 10% fectal calf
serum (FCS), 2 mM L-Glutamine, 0.1 U/mL Penicillin, and 100 μg/mL Streptomycin. The cells were
seeded in a multi-well plate and 6 h later infected with ZIKV strain 976 Uganda (U) (kindly provided
by the European Virus Archive) or ZIKV PF13/251013-18 from French Polynesia (FP) (kindly provided
by Prof. Didier Musso Institute Louis in Papeete, Malardé, Tahiti) with an multiplicity of infection
(MOI) of 0.1. The substances silvestrol (Medchemexpress LLc; purity > 98%) and DMSO (Genaxxon
bioscience; purity > 99%) were present in the respective dilutions in the inoculum. The cells were
washed once with warm PBS 16 h, 40 h, and 64 h p.i., and covered with fresh DMEM supplemented
with the respective substances in the same concentrations to ensure presence of silvestrol during
the whole time course. At 24 h, 48 h, or 72 h p.i. the cells were washed with PBS and harvested in
peqGOLD TriFast (peqlab Biotechnologie GmbH, Erlangen, Germany) for RNA isolation or RIPA-buffer
for protein isolation. The supernatant was harvested for the determination of extracellular viral RNA
and particles.
Primary human hepatocytes (PHHs) were isolated and cultivated as described [23,24]. Infection
and treatment of the PHHs were performed in accordance with the A549 experiments.
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2.2. RNA-Isolation
The intracellular RNA was isolated using peqGOLD Trifast (peqlab Biotechnologie GmbH)
according to the manufacturer’s instructions.
The extracellular RNA was isolated from the cell culture supernatant after 5 min of centrifugation
at 1000× g with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions.
2.3. RT-qPCR
Extracellular ZIKV RNA was quantified in a LightCycler480 (Roche) using the Zika Virus detection
kit (TIB Molbiol, Berlin, Germany) together with the LightCycler Multiplex RNA Virus Mastermix
(Roche, Basel, Switzerland) according to the manufacturer’s protocol.
Reverse transcription of the intracellular RNA was performed as described [25]. The cDNA
was quantified in a LightCycler480 (Roche) using the SYBR Green Mastermix (Thermo Fisher
Scientific, Waltham, MA, USA) and the following primers: ZIKV-fwd (AGATCCCGGCTGAAACACTG),
ZIKV_rev (TTGCAAGGTCCATCTGTCCC), hRPL27_fw (AAAGCTGTCATCGTGAAGAAC), hRPL27_rv
(GCTGCTACTTTGCGGGGGTAG).
The amount of ZIKV RNA was normalized to the amount of RPL27 transcripts.
2.4. Cell Viability and Cytotoxicity Assays
Cell viability was assessed using the PrestoBlue Cell viability reagent (Thermo Fisher Scientific)
as described [26]. In addition, lactate dehydrogenase (LDH)-release was quantified with the LDH
Cytotoxicity Detection Kit (Clontech, Mountain View, CA, USA) according to the manufacturer’s
protocol. LDH-release-assay was performed in DMEM with a reduced amount of FCS (1%) to lower the
measurement background. The LDH activity in the supernatant of cells treated with 1% Triton X-100
served as control and reference for normalization. Viability of PHHs was assessed by ALT (alanine
aminotransferase) activity measurement of the cell culture supernatant with the Reflotron Plus (Roche)
and the respective GPT (ALT) test strips according to the manufacturer’s protocol.
2.5. Western Blot
RIPA-Lysates were used to perform SDS-PAGE and Western blot analysis as described [27]. A specific
antibody was used to detect the protein NS1 (Biofront technologies, 1225-36, Tallahassee, FL, USA) in the
dilution 1:1000. Detection of β-actin with a specific antibody (Sigma Aldrich, A5316, St. Louis, MO, USA)
in the dilution 1:10,000 served as loading control. Specific antibodies were used for the detection of PIM1
(Santa Cruz, 12H8), MVP (LRP 1014, Santa Cruz Biotechnology, Heidelberg, Germany), NS3 (8G-2, abcam),
and NS5A (described in Reference [28]) Densitometry scans of the membranes with IRDye-coupled
secondary antibodies (dilution 1:10,000) were quantified with the software Image Studio (both from Licor,
Lincoln, NE, USA).
2.6. Plaque Assay
For titer determination of cell culture supernatants, plaque assays were performed. For this,
Vero cells were seeded in a 6-well plate (3 × 105 cells/well) and infected 6 h later with cell culture
supernatant in a serial dilution in DMEM. At 2 h p.i. the cells were washed once with PBS and covered
with 37 ◦C pre-warmed DMEM containing 0.4% agarose. After 15 min at room temperature the plates
were incubated for 96 h at 37 ◦C. To visualize the plaques the agarose was removed, cells were fixed
with 4% formaldehyde in PBS for 20 min at room temperature, and then stained for 15 min with
0.1% crystal violet in 20% ethanol. Then the cells were washed once with water and the titer (PFU/mL)
was determined by counting the plaques in the well with the respective dilution.
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2.7. Immunofluorescence Microscopy
The cells were grown on cover slides and fixed with 4% formaldehyde in PBS for 20 min at
room temperature. Then the cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min on
room temperature. After blocking with 1% BSA in PBS for 15 min at room temperature, the cells
were stained with the anti-NS1 antibody (Biofront technologies, 1225-36) in the dilution 1:200 and
afterwards with the secondary antibody anti-mouse-AlexaFluor488 (Thermo Fisher Scientific) for
1 h at room temperature in a humid chamber. The secondary antibody dilution was supplemented
with DAPI to visualize the nuclei. Finally, the cells were mounted with Mowiol on microscope
slides. Immunofluorescence staining was analyzed using a confocal laser scanning microscope
(CLSM 510 Meta) with Zen 2009 Software (both from Carl Zeiss, Oberkochen, Germany) and
a Cytation5 with the Gen5 Software (both from Biotek, Winooski, VT, USA). For each condition
the amount of ZIKV positive cells in at least four fields of view of three experiments were quantified.
2.8. Statistical Analysis
Results are presented as means ± standard errors of the means (SEMs) from at least
three independent experiments. The significance of the results was analyzed by unpaired
two-tailed Student’s t test, using GraphPad Prism, version 6.07 for Windows (GraphPad Software,
San Diego, CA, USA). In all figures the statistical significance is compared to the DMSO control group.
Statistical significance is represented in figures as follows:
ns = not significant = p > 0.05; * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001.
3. Results
3.1. Silvestrol Shows a Cytostatic rather than a Cytotoxic Effect in A549 Cells
In a previous study, silvestrol was used for treatment of Ebola virus (EBOV)-infected HuH7-cells
in concentrations of 5, 10, and 50 nM [20]. To determine the working concentration of silvestrol in
A549 cells, we first analyzed the metabolic activity of these cells treated with different concentrations
of silvestrol for 24, 48, and 72 h by PrestoBlue assays. Silvestrol exhibits a concentration-dependent
inhibition of the cells metabolism starting with a concentration as low as 5 nM (Figure 1A). To rule
out a cytotoxic effect of silvestrol, an LDH release assay was performed to quantify the activity of
LDH in the supernatant released from dead cells. For none of the three tested silvestrol concentrations
was a cytotoxic effect reflected by an increase in the LDH activity detected after 24 h. After 48 h,
no cytotoxic effect was observed for the 5 nM and 10 nM concentrations, while in case of the cells
treated with 50 nM silvestrol an increase in the LDH activity was detected. In case of the incubation
period for 72 h a weak cytotoxic effect was detectable for the lower concentrations of silvestrol
(5 nM and 10 nM), while treatment with 50 nM silvestrol was associated with cytotoxicity (Figure 1B),
although there were still a high number of viable intact cells, as reflected by the intact nuclei in the
DAPI staining (Figure 2A).
These data demonstrate that silvestrol affects the cellular metabolism in the cancer cell line A549
in a time- and dose-dependent manner and exerts a moderate cytotoxic effect in higher concentrations
after 48 h and 72 h.
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Figure 1. Cytostatic effect of silvestrol in A549 cells. (A) Time- and concentration-dependent decrease
of cellular metabolic activity after silvestrol treatment in A549 cells determined by the PrestoBlue assay.
Cycloheximid (CHX) served as positive control in a concentration of 35 μM to inhibit cell proliferation;
(B) Lactate dehydrogenase (LDH) release assay with the supernatants of silvestrol treated A549 cells
did not show an increased cell death. Treatment with 1% Triton X-100 served as positive control for
complete cell death. LDH activity in the samples was normalized to the LDH activity in the supernatant
of Triton X-100 treated cells. ns = not significant = p > 0.05; * = p ≤ 0.05; **** = p ≤ 0.0001.
Figure 2. Silvestrol treatment reduces the number of Zika virus (ZIKV) positive cells. (A) A549 cells were
infected with ZIKV French Polynesia isolate (FP) and treated with the indicated amount of silvestrol.
Cells were fixed on the indicated time points and nuclei were stained with DAPI (blue) and NS1 was
stained with a specific antibody in green, scale bar = 200 μm; (B) Ratio of NS1-positive cells in at least four
fields of view of the respective samples exemplary shown in (A); (C) A549 cells were infected with ZIKV
Uganda isolate (U) and treated with the indicated amount of silvestrol. Cells were fixed on the indicated
time points and nuclei were stained with DAPI (blue) and NS1 was stained with a specific antibody in
green, scale bar = 200 μm; (D) Ratio of NS1-positive cells in at least four fields of view of the respective
samples exemplary shown in (C). * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001.
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3.2. Silvestrol Impairs ZIKV Infection in A549 Cells
To investigate the potential antiviral effect of silvestrol on ZIKV life cycle, A549 cells were infected
with two ZIKV strains with an MOI of 0.1 and subsequently treated with silvestrol for 24, 48, and 72 h.
The ZIKV strain 976 Uganda (ZIKV U), which did not show neuropathological effects in patients,
was compared to the ZIKV strain PF13/251013-18 (ZIKV FP) from French Polynesia, which was the
first strain associated with microcephaly. Based on the data from the cytotoxicity and viability assays
and in accordance to a previous study, silvestrol was used in concentrations of 5, 10, and 50 nM [20].
The impact on viral life cycle was analyzed by immunofluorescence microscopy using an NS1-specific
antiserum (Figure 2A,C). The quantification of the immunofluorescence microscopy reveals for the
ZIKV strain French Polynesia a decrease in the number of ZIKV-positive cells and fluorescence intensity
as evidenced by the NS1-specific staining after treatment with silvestrol for 48 h and 72 h (Figure 2B).
No significant effect could be observed for the ZIKV Uganda strain, except for 5 nM silvestrol at
48 h (Figure 2D).
These data indicate that silvestrol exerts an inhibitory effect on the spread of ZIKV infection in
A549 cells.
3.3. Inhibition of ZIKV Replication by Silvestrol
For a more detailed analysis of the effect of silvestrol on the ZIKV life cycle, the amount of intra-
and extracellular ZIKV-specific RNA was determined by real-time PCR (RT-qPCR). For both isolates
(Uganda isolate (U) and French Polynesia isolate (FP)) a strong decrease of the intra- and extracellular
amount of ZIKV-genomes was observed for infected cells that were incubated with 5 nM or 50 nM at all
three analyzed points in time (24 h, 48 h, and 72 h). Interestingly, there was no strict dose-effect relation
since a weaker (for the intracellular viral RNA, see Figure 3A,B) or almost no effect (for the extracellular
viral RNA, see Figure 3C,D) was observed if silvestrol was applied in a 10 nM concentration.
As viral genomes do not directly correspond to infectious viral particles, the impact of silvestrol
treatment on the number of released viral particles was determined by plaque assay on Vero cells.
Again, for both isolates there was no strict dose-effect relation. In case of cells infected with the French
Polynesia isolate for 5 nM and 50 nM silvestrol as compared to the control (DMSO-treated cells),
a decrease in the number of released viral particles was observed at 24 and 48 h. Treatment for 72 h
with 5 nM silvestrol very efficiently decreased the titer, but no significant effect was observed with
50 nM silvestrol. A similar picture was observed in the case of cells infected with the Uganda strain,
but the 72-h treatment did not lead to a reduction in the amount of released viral particles (Figure 3E,F).
The observed lack of a strict dose-effect relation might reflect the equilibrium of silvestrol actions
on the one hand directly affecting ZIKV life cycle/replication and on the other hand affecting the
antiviral defense mechanisms of the host cell. In this context, it should be considered that silvestrol,
as an inhibitor of eIF4A, affects on the one hand the translation of the viral RNA and on the other hand
the translation of a variety of host factors. These factors could include RNases, proteasomal, lysosomal,
or autophagosomal proteins. If such activities triggering the degradation of viral genomes or viral
proteins are impaired, a stabilization of i.e., viral genomes is the consequence that could compensate
for the inhibitory effects of silvestrol on other parts of the viral life cycle.
Taken together, these data show that the silvestrol-dependent effects on the ZIKV life cycle do
not follow a strict dose-effect relation in A549 cells. While 5 nM and 50 nM silvestrol exerted a strong
inhibition of ZIKV replication as reflected by a significantly reduced amount of intra- and extracellular
ZIKV genomes, 10 nM silvestrol failed to impair ZIKV replication most likely due to secondary effects
in the infected host cell.
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Figure 3. Significant reduction of intra- and extracellular ZIKV RNA levels and released virions.
(A) Quantification of intracellular ZIKV RNA of A549 cells infected with ZIKV FP and treated with
the indicated concentrations of silvestrol. ZIKV RNA was quantified by RT-qPCR and normalized
to the amount of RPL27 transcripts; (B) Quantification of intracellular ZIKV RNA of A549 cells
infected with ZIKV U and treated with the indicated concentrations of silvestrol. ZIKV RNA was
quantified by RT-qPCR and normalized to the amount of RPL27 transcripts; (C) RT-qPCR quantification
of extracellular ZIKV RNA of A549 cells infected with ZIKV FP and treated with the indicated
concentrations of silvestrol; (D) RT-qPCR quantification of extracellular ZIKV RNA of A549 cells
infected with ZIKV U and treated with the indicated concentrations of silvestrol; (E) Relative
extracellular titers of A549 cells infected with ZIKV FP and treated with the indicated concentrations
of silvestrol. Titers were quantified by plaque assay in Vero cells; (F) Relative extracellular titers
of A549 cells infected with ZIKV U and treated with the indicated concentrations of silvestrol.
Titers were quantified by plaque assay in Vero cells. $: only two experiments were performed.
ns = not significant = p > 0.05; * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001.
3.4. Silvestrol Inhibits ZIKV Translation by Inhibition of eIF4A
To pinpoint whether silvestrol exerts its direct antiviral effect on the translation of viral proteins
due to specific inhibition of the DEAD-box RNA helicase eIF4A, a Western blot analysis of infected
and silvestrol-treated A549 cells was performed. The ZIKV protein NS1 was detected with a specific
antibody and referred to the β-actin signal. In case of the lowest concentration (5 nM) there was,
for both isolates—ZIKV-U and ZIKV-FP—after 24 h, no significant reduction detectable. This may be
because only 2% of the cell culture was infected with ZIKV after 24 h (see Figure 2), so the detection of
NS1 by Western blot showed only moderate signals, resulting in increased SEM for this time point.
However, after 48 h and 72 h a significant reduction in the amount of NS1 was found. This comes
along with a dose-dependent reduction of the oncogene PIM1, which is known to be translated in an
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eIF4A-dependent manner (Figure S1). In case of 50 nM silvestrol, for both isolates a strong reduction
in the amount of NS1 was found at all three investigated time points. As described above, again there
was no strict dose-effect relation. Thus, for both isolates treated with 10 nM almost no reduction in
the amount of NS1 was detectable (Figure 4). This is in accordance to the data described above that
show that 10 nM silvestrol leads to a slight increase in the amount of ZIKV-specific RNA. These results
indicate that the antiviral effect of silvestrol observed in A549 cells for concentrations of 5 nM and
50 nM is associated with a decreased amount of ZIKV proteins, as shown here by a NS1-specific
Western blot.
As a loss in viral protein could also be related to an inhibition of reinfections or the viral replication
rather than the translation, according to similar experiments that were performed with a high MOI
(MOI = 1). Even higher MOIs would not be beneficial in this system because of the cytopathic effect of
ZIKV. Silvestrol is able to decrease the amount of ZIKV RNA and proteins in the same concentration
range also at this high MOI, confirming the eIF4A-dependent mechanism of silvestrol (Figure S4).
To test whether this effect is specific to cap-dependent viral translation the effect of silvestrol on
hepatitis C virus (HCV), which uses an eIF4A-independent IRES for translation was tested. Indeed,
the treatment of HCV-positive Huh7.5 cells did not result in a decrease of the viral proteins (Figure S3).
This data confirms the specificity of silvestrol on eIF4A-dependent viral translation.
Figure 4. Silvestrol treatment reduces the amount of intracellular NS1 protein. (A) A549 cells were infected
with ZIKV U and treated with the indicated amount of silvestrol. Cell lysates of the indicated time points
were analyzed by Western blot with specific antibodies against NS1 and β-actin; (B) Quantification of
densitometry scans examples are shown in (A); (C) A549 cells were infected with ZIKV FP and treated
with the indicated amount of silvestrol. Cell lysates of the indicated time points were analyzed by Western
blot with specific antibodies against NS1 and β-actin; (D) Quantification of densitometry scans examples
are shown in (C). ns = not significant = p > 0.05; * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001.
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3.5. Silvestrol Inhibits ZIKV Replication in Infected Primary Human Hepatocytes
Initially, silvestrol was described as a potential anti-cancer drug due to its inhibitory effect on
the proliferation of a variety of cancer cells [11,14,16]. As A549 cells originate from a human lung
carcinoma primary, non-transformed cells were used to study the antiviral effect of silvestrol on the
ZIKV life cycle to exclude any side effects that are due to the anti-cancer effect of silvestrol. For
this purpose, primary human hepatocytes (PHHs) of two different donors were infected with ZIKV
FP and subsequently treated with silvestrol. Even though the physiological host cells of ZIKV are
thought to be keratinocytes and neurons, in a recent study we found that ZIKV efficiently replicates
in hepatocytes [29]. As the isolation and cultivation of primary human hepatocytes (PHHs) is
well-established in our lab, we decided to use these cell culture model for human primary cells.
Supernatants were harvested after 24 h, 48 h, and 72 h. As primary human hepatocytes are much more
resistant to silvestrol [20,30,31], 100 nM silvestrol was tested as the highest concentration. The amount
of viral genomes was quantified by RT-qPCR, and the number of infectious viral particles was
quantified by plaque assays. The results analyzed after 24 h show that none of the investigated
concentrations of silvestrol (5 nM, 10 nM and 100 nM) exhibited a significant reduction in the amount
of viral genomes. However, after 48 h and 72 h a strong and significant reduction of the number of
released viral genomes was observed (Figure 5A–C).
Figure 5. Silvestrol exerts an anti-ZIKV effect also in primary cells. Primary human hepatocytes were
infected with ZIKV FP and treated with the indicated concentrations of silvestrol. The extracellular
ZIKV RNA was quantified by RT-qPCR after 24 (A), 48 (B), and 72 h (C); (D) Extracellular titers of
infected and treated primary human hepatocytes (PHHs) after 48 and 72 h. Shown are titers from
just one PHH donor quantified by plaque assay in Vero cells; (E) ALT activity in PHH supernatants.
ns = not significant = p > 0.05; * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001.
441
Viruses 2018, 10, 149
Quantification of the number of infectious viral particles in the supernatant confirmed this. For all
three investigated time points, the number of infectious ZIKV particles was strongly decreased and
in some cases even below the detection limit, reflecting a strong inhibitory potential (Figure 5D).
Interestingly, as observed for the A549 cells, there was no strict dose-effect relation as in case of
the cells treated with 10 nM silvestrol. ZIKV particles were detectable in the supernatant but in a
strongly reduced amount as compared to the control. The ALT activity in the supernatants of the
PHHs, as a measure of cytotoxicity, was below the detection limit of 5 U/L in most samples and only
slightly increased in case of 100 nM silvestrol (Figure 5E). However, sera of male humans with ALT
activities above 41 U/L are considered to represent liver damage, hence the obtained ALT activities of
about 7 U/L do not correspond to cytotoxicity. To address the toxicity of silvestrol on primary cells
in more detail, brightfield imaging and PrestoBlue assays were performed with treated cells as well.
Both readouts confirmed the toxic effect of 100 nM silvestrol on the PHHs at 48 h and 72 h of treatment
(Figure S2). However, the lower concentrations are not toxic to the cells but show a remarkably
reduction of the viral load.
These data confirm that the specific inhibition of eIF4A-dependent translation affects ZIKV
replication in a complex interplay between direct inhibition of the viral life cycle on the one hand and
interference with cellular antiviral mechanisms on the other hand.
4. Discussion
The Zika viral genome is a (+)-strand ssRNA and therefore serves directly as a template for
protein biosynthesis by the cellular translation machinery. As the ZIKV genome has an exposed and
structured 5′-UTR and its translation depends on the 5′-cap introduced by the viral NS5 protein, eIF4A
is expected to be required to initiate the translation of the viral polyprotein by unwinding the RNA
secondary structures [6,21,32]. For EBOV, a (−)-strand ssRNA virus, a significant antiviral effect of
silvestrol was observed. In the EBOV system, silvestrol inhibits the eIF4A-dependent translation of
viral mRNAs with extended and structured 5′-UTRs [20].
Indeed, the natural compound silvestrol, if used in 5 nM and 50 nM concentrations, exerts
a significant antiviral effect on ZIKV-infected A549 cells. This effect was observed for both analyzed
Zika virus strains (ZIKV-U and ZIKV-FP). As silvestrol is well characterized to inhibit eIF4A-dependent
protein synthesis, these data suggest that translation of the ZIKV genome is eIF4A-dependent and
can be blocked by silvestrol [13]. To prove the inhibitory effect of silvestrol on eIF4A-dependent
translation in the used system, the amount of the oncogene PIM1 was determined by Western blot,
which decreases in a concentration-dependent manner by silvestrol treatment (Figure S1). Futhermore,
the lack of an inhibitory effect of silvestrol on the IRES-dependent translation of HCV underlines the
proposed eIF4A-dependent antiviral mechanism of silvestrol in the case of ZIKV (Figure S3).
Both ZIKV strains possess a stable and long stem-loop structure in their 5′-UTR, but the secondary
structure of the Uganda strain seems to be much more stable, as predictions with several online tools
show [1]. This higher stability would imply a higher dependency of the helicase activity of eIF4A to
initiate the translation of the Uganda strain genome. Hence, a stronger antiviral effect of silvestrol
would be expected. In general, we did not observe a different effectivity of silvestrol on the ZIKV
Uganda strain, except in the quantification of the infectious titer. Concerning the number of positive
cells, silvestrol seems even to be less effective as mentioned before. This could be partially explained
by the fact that ZIKV-U represents a very early isolate that might have acquired cell culture adaptive
mutations and therefore might have better replication efficiency [33]. The ZIKV strain PF13/251013-1
was isolated in 2007 and therefore is not as well adapted to cell cultures as the ancestor virus from
Uganda [34]. Furthermore, the unwinding of 5′-UTR with higher stability may require additional
helicase activities such as DDX3, so inhibiting eIF4A alone might not be sufficient to inhibit the
translation of these RNAs. Uncovering the detailed features of a silvestrol-sensitive 5′-UTR structure
will be of future interest. However, the more sensitive readout via RT-qPCR clearly shows a significant
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antiviral effect of silvestrol on ZIKV U, which suggests that viral translation is also inhibited in
this strain.
To investigate the specificity of the observed effects, cell viability and toxicity assays were
performed. In the cell viability assay (PrestoBlue assay), which measures metabolic activity of the cells,
a time- and concentration-dependent decrease of the metabolic activity was observed by silvestrol
(Figure 1A). This is in accordance with former publications as well as the microscopic images in this
study (Figure 2), which show a decreased proliferation of tumor cell lines by silvestrol [14]. However,
no cytotoxicity was observed by silvestrol treatment in the LDH-release assay for the 24-h and 48-h
incubation periods (Figure 1B). This was expected, as the inhibition of eIF4A by different substances
did not show a cytotoxic effect in previous studies [35]. Therefore, the antiviral effect of silvestrol
on the Zika virus at these time points is not based on cytotoxicity and can also not be explained by
a minor cytostatic effect. Moreover, the amount of the NS1 protein and the ZIKV genomes were
normalized on the housekeepers β-actin and RPL27, respectively, to rule out possible secondary effects.
The specificity of silvestrol on the ZIKV translation is further underlined by using primary human
hepatocytes infected with the French Polynesia strain (Figure 5). These cells are not based on tumor
cell lines and therefore show no growth inhibition by silvestrol. No increased ALT activity and no
morphological effect were observed due to silvestrol treatment (Figure 5E). Remarkably, 100 nM
silvestrol showed a toxic effect on PHHs of some donors, which could be explained by a oncogenic
predisposition of these cells as donors suffered from hepatocellular carcinomas (Figure S2). The strong
effect of silvestrol on ZIKV is even more pronounced in these cells.
Of course, on first glance the lack of a clear dose-effect relation is surprising. However, it should
be considered that silvestrol, as an inhibitor of eIF4A, affects on the one hand the translation of the viral
RNA and on the other hand the translation of cellular mRNAs, and thus the expression of a variety
of host factors. From the mass spectrometry data of cellular lysates of A549 cells, the cellular major
vault protein (MVP) was identified to be downregulated by silvestrol treatment (submitted). This was
confirmed by Western blot and immunofluorescence analysis, which showed a decreased amount
of MVP and a translocation from the cytoplasm to the perinuclear region (Figure S5). As MVP is
supposed to exert its antiviral effect by affecting IRF7 and interferon type I cytoplasmic signaling,
a decreased amount of the protein and a withdrawal of MVP from the cytoplasm would affect the its
capacity to deregulate these cytoplasmic antiviral signaling cascades. As MVP is part of an antiviral
interferon-cascade, a decreased amount of this protein in the cytoplasm could explain the partial
recovery of ZIKV at 10 nM silvestrol [36]. However further experiments have to be performed to
characterize the potential antiviral effect of MVP on ZIKV and to study the impact of MVP on the
ZIKV life cycle in detail.
Surprisingly, there was a concentration-dependent effect of silvestrol in A549 cells infected with
a comparably high MOI of 1 (Figure S4). This might indicate that in low MOI infections, the antiviral
effect (of e.g., MVP) inhibits the spread of the virus which cannot be seen with a high MOI, because
reinfections are rare.
Interestingly MVP could not be detected in HCV-positive Huh7.5 cells (Figure S3). This is not
surprising, since Huh7.5 cells bear mutations in the antiviral interferon-pathway (e.g., RIG-I) which
confers the susceptibility of those cells to HCV. In line with this, no increase of viral proteins was
observed with silvestrol treatment because cellular antiviral proteins cannot be affected.
In light of the complex interplay of silvestrol in inhibiting the pathogenic and host translation
of some antiviral proteins, a direct application of silvestrol in clinics might be difficult. However,
this study identified eIF4A as a cellular factor that can be targeted to inhibit ZIKV spread.
A comparison of the antiviral effects of cells treated with 5 nM or 50 nM to the effects observed for
cells treated with 10 nM silvestrol showed the lack of a dose-effect relation. This atypical course reflects
a complex interplay between direct effects on ZIKV translation and the translation of anti-viral factors.
There is a variety of host factors triggering an antiviral response, such as RNases, and proteasomal,
lysosomal, or autophagosomal proteins. If the translation of these antiviral activities involved i.e.,
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in the degradation of viral genomes or viral proteins is impaired, a stabilization of viral genomes is the
consequence. This increased stability leads to elevated genome levels and thereby could compensate
for the inhibitory effects of silvestrol in other parts of the viral life cycle, such as impaired translation.
5. Conclusions
Taken together, this study gives evidence that silvestrol has the potential to exert a potent antiviral
effect on the pathogenic ZIKV. It might contribute to identify host factors involved in the control of
ZIKV infection and so might help to develop antiviral concepts that can be used to treat a variety of
viral infections without the risk of resistances as a host protein is targeted.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/4/149/s1,
Figure S1. Silvestrol inhibits eIF4A-dependent translation. A549 cells were treated with the indicated amount of
silvestrol. Cell lysates of the indicated time points were analyzed by Western blot with specific antibodies against
PIM1 and β-actin; Figure S2. Toxic effect of 100 nM silvestrol in primary human hepatocytes. PHHs were treated
with the indicated concentrations of silvestrol. At 24 h, 48 h, and 72 h post treatment, PrestoBlue assay (A) and
brightfield imaging (B) were performed; Figure S3. No inhibiting effect of silvestrol on the IRES-dependent
translation of HCV. Huh7.5 cells were transfected with the full-length HCV genome Jc1 and 72 h post-transfection
treated with the indicated concentrations of silvestrol. (A) Cells lysates of the indicated time points were analyzed
by Western blot with specific antibodies against NS3, NS5A, and β-actin. (B) Quantification of NS3 of densitometry
scans exemplary shown in A). (C) Quantification of NS5A of densitometry scans exemplary shown in (A); Figure S4.
Silvestrol exerts its antiviral effect also with higher MOI. (A) Quantification of intracellular ZIKV RNA of A549 cells
infected with ZIKV FP (MOI = 1) and treated with the indicated concentrations of silvestrol. ZIKV RNA was
quantified by RT-qPCR and normalized to the amount of RPL27 transcripts; (B) Quantification of intracellular ZIKV
RNA of A549 cells infected with ZIKV U (MOI = 1) and treated with the indicated concentrations of silvestrol.
ZIKV RNA was quantified by RT-qPCR and normalized to the amount of RPL27 transcripts; (C) RT-qPCR
quantification of extracellular ZIKV RNA of A549 cells infected with ZIKV FP (MOI = 1) and treated with the
indicated concentrations of silvestrol; (D) RT-qPCR quantification of extracellular ZIKV RNA of A549 cells
infected with ZIKV U (MOI = 1) and treated with the indicated concentrations of silvestrol; (E) Western blot
analysis of A549 cells infected with ZIKV FP (MOI = 1) and treated with the indicated concentrations of silvestrol;
(F) Quantification of NS1 of densitometry scans exemplary shown in (E); (G) Western blot analysis of A549 cells
infected with ZIKV U (MOI = 1) and treated with the indicated concentrations of silvestrol; (H) Quantification of
NS1 of densitometry scans exemplary shown in (G); Figure S5. Silvestrol decreases the amount of the antiviral
protein MVP. A549 cells were treated with the indicated concentrations of silvestrol. (A) Twenty-four hours after
treatment, cells were fixed with ice-cold ethanol. Nuclei were stained with DAPI (blue) and MVP was stained with
an antibody (red); (B) cell lysates were analyzed by Western blot analysis with antibodies against MVP and actin.
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Abstract: Zika virus (ZIKV) is an emerging flavivirus responsible for a major epidemic in the Americas
beginning in 2015. ZIKV associated with maternal infection can lead to neurological disorders in
newborns, including microcephaly. Although there is an abundance of research examining the
neurotropism of ZIKV, we still do not completely understand the mechanism by which ZIKV targets
neural cells or how to limit neural cell infection. Recent research suggests that flaviviruses, including
ZIKV, may hijack the cellular autophagy pathway to benefit their replication. Therefore, we hypothesized
that ZIKV replication would be impacted when infected cells were treated with compounds that target
the autophagy pathway. We screened a library of 94 compounds known to affect autophagy in both
mammalian and insect cell lines. A subset of compounds that inhibited ZIKV replication without affecting
cellular viability were tested for their ability to limit ZIKV replication in human neurons. From this
second screen, we identified one compound, 7-ketocholesterol (7-KC), which inhibited ZIKV replication
in neurons without significantly affecting neuron viability. Interestingly, 7-KC induces autophagy, which
would be hypothesized to increase ZIKV replication, yet it decreased virus production. Time-of-addition
experiments suggest 7-KC inhibits ZIKV replication late in the replication cycle. While 7-KC did
not inhibit RNA replication, it decreased the number of particles in the supernatant and the relative
infectivity of the released particles, suggesting it interferes with particle budding, release from the host
cell, and particle integrity.
Keywords: Zika virus; antiviral compounds; neural cells; viral replication
1. Introduction
Zika virus (ZIKV) is an emerging arbovirus that gained public attention in 2015 when
maternal infection in the Americas was causally associated with congenital birth defects, including
microcephaly [1]. ZIKV belongs to the Flaviviridae family and is related to other important human
pathogens, including dengue (DENV), yellow fever (YFV) and West Nile (WNV). ZIKV is an enveloped
virus with a positive-sense RNA genome that translates into a single polypeptide, which is later cleaved
into three structural and seven nonstructural viral proteins. Upon binding to host cell receptors,
the cell engulfs virions through clathrin-mediated endocytosis [2]. Low pH in the endosome triggers
viral-cellular membrane fusion, releasing the viral RNA genome into the host cell cytoplasm [2].
Transcription occurs in the cytoplasm and translation of ZIKV proteins occurs on membrane scaffolds
near the endoplasmic reticulum (ER) [3].
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Autophagy is a normal cellular process used to recycle cytoplasmic components in eukaryotic
cells. The autophagy pathway is activated by mTOR [4]. This activation signals the production
of lipid membranes that engulf targeted cytoplasmic components, forming autophagosome vesicles.
Eventually, the autophagosomes fuse with lysosomes to form autophagolysosomes, which degrade cargo
and prepare it to either be recycled or ejected from the cell [4]. Because cells always contain components
that need to be recycled, the autophagy pathway is constantly on at a basal level. Different stimuli or
stresses, such as pathogen infection, can alter basal levels of autophagy. For example, selectively encasing
intercellular bacteria and targeting them for autophagic degradation is part of the innate immune response
pathway for dealing with Salmonella enterica serovar Typhimurium and Mycobacterium tuberculosis [5,6].
While the host can utilize this pathway to rid itself of some pathogens, many flaviviruses, including
Dengue, Hepatitis C, and Zika viruses, hijack this process to benefit their own replication [4,7–9].
The autophagy process mobilizes cellular membranes. Flaviviruses replicate on membranes and appear
to benefit from initiating early cellular autophagy processes [7,10]. Chemical inducers of autophagy,
such as rapamycin, slightly increase levels of viral RNA and infectious particle production [11–13].
In addition, chemical inhibitors of autophagy decrease particle production [12,13]. Some autophagy
inhibitors, such as bafilomycin A, prevent the acidification of autophagolysosomes. Such compounds do
not selectively block acidification of only autophagolysosomes, but also alter the pH of other endosomal
vesicles. Because flavivirus entry requires an acidic endosome environment to trigger membrane fusion,
some of the drugs may be inhibiting initial entry. Therefore, their effects on autophagy may be unrelated to
the flavivirus inhibition. Flavivirus replication appears to be enhanced when the autophagy pathway is
started, but is stalled and autolysosome degradation is blocked [4].
Autophagy also affects other aspects of cell biology that may influence viral pathogenesis,
including induction of the interferon response [14]. However, depending on the location and timing of
infection, autophagy can also be antiviral. For instance, experiments in Drosophila indicate that ZIKV
infection in the brain induces an NF-κB/dSTING (Drosophila stimulator of interferon genes) signaling
pathway, which induces autophagy and protects against ZIKV infection [15]. Therefore, autophagy
can be very consequential to viral replication and may play a role in ZIKV pathogenesis [4].
Since autophagy and ZIKV replication are intertwined, small molecules that induce or inhibit
stages of the autophagy pathway may alter ZIKV production and spread in host cells. To elucidate
these interactions, we screened a library of 94 autophagy inducers or inhibitors in Vero and C6/36 cells
infected with ZIKV. Surprisingly, only about 30% of compounds reduced ZIKV titer by at least one log
compared to control. We performed subsequent experiments in both Vero cells and human neurons
with the compounds that reduce ZIKV replication without inhibiting cell viability. We identified one
compound, 7-ketocholesterol (7-KC), which effectively reduced ZIKV titer in human neurons without
affecting cellular viability. 7-KC blocked late stages of ZIKV replication, suggesting it reduces particle
integrity and budding efficiency from host cells.
2. Materials and Methods
2.1. Cell Lines
Vero cells were maintained in DMEM with 5% fetal bovine serum (FBS) at 37 ◦C, 5% CO2. C6/36
Ae. albopictus cells (ATCC CRL-1660) were maintained in L-15 Leibovitz Medium with L-glutamine and
10% FBS at 28 ◦C. Human neurons were made by differentiating hNP1 cells and were obtained from
ArunA Biomedical, Inc. [16]. Neurons were maintained in medium containing AB2TM basal medium
supplemented with ANSTM neural supplement (both from ArunA Biomedical Inc. Athens, GA,
USA), 2 mM L-glutamine (Gibco, ThermoFisher, Waltham, MA, USA), 2 U/mL penicillin (Gibco,
ThermoFisher, Waltham, MA, USA), 2 μg/mL streptomycin (Gibco, ThermoFisher, Waltham, MA,
USA), and 10 ng/mL leukemia inhibitory factor (LIF) (Millipore, Billerica, MA, USA) and plated on
cell culture dishes coated with Matrigel 1:100 (B&D, Franklin Lakes, NJ, USA).
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2.2. Virus Isolates
ZIKV SPH is a low-passage (<5), Asian-lineage isolate derived from an infected patient in Brazil
in 2015 and obtained from the Oswaldo Cruz Foundation (FIOCRUZ). ZIKV IbH 30656 (ATCC #
VR-182) is a highly-passaged, African-lineage isolate derived from a human patient in Nigeria in 1968.
Following its initial isolation, IbH was extensively passaged in mouse brains.
2.3. Reagents
We used the Enzo Screen-Well Autophagy Library for these experiments (category number:
BML-2837-0100; Lot number: 03181609B; Version 1.5). The compounds came resuspended at 10 mM in
dimethyl sulfoxide (DMSO). To prevent DMSO related toxicity, we diluted the stocks 1:1000 and
screened the compounds at a final concentration of 10 μM. DMSO was included in all of our
untreated controls.
2.4. Autophagy Compound Library Screen
Vero and C6/36 cells were plated at densities of 1.5 × 105 cells/well and 2 × 105 cells/well,
respectively in 24-well plates. The cells were incubated for 2–4 h and then treated with the autophagy
compounds at a final concentration of 10 μM. Immediately after treatment, the cells were infected with
ZIKV (MOI 0.1). Vero cells were incubated for 40 h and the C6/36 cells for 96 h, then supernatants
were collected and titrated by determining the 50% tissue culture infective dose (TCID50) according
to the Spearman-Karber method [17,18]. Results from treated cells were compared to results from
DMSO controls.
2.5. Autophagy Detection
Vero cells were plated at densities of 3 × 105 cells/well in 12-well plates. The cells were
incubated for 2–4 h and then treated with the autophagy compounds at a final concentration of 10 μM.
Twenty-four hours following treatment, the cells were lifted in trypsin, washed in PBS, and stained
with the CYTO-ID Autophagy Detection Kit 2.0 (Enzo, Farmington, NY, USA). The autophagy activity
factor (AAF) [19] was determined by comparing the green mean fluorescence intensities (MFI) of
treated and DMSO control cells using the formula:






Vero and C6/36 cells were plated at densities of 1.5 × 104 cells/well and 2 × 104 cells/well,
respectively in 96-well plates. The cells were incubated for 2–4 h and then treated with the
autophagy compounds at a final concentration of 10 μM. Vero cells were incubated for 40 h and
the C6/36 cells incubated for 96 h. Metabolic activity (ATP abundance), which correlates to cell
viability, was determined with CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI,
USA) and a Glomax plate reader per the manufacturer’s instructions. The experiment was repeated at
least three independent times. Results from treated cells were compared to results from DMSO controls.
2.7. Human Neuron Response to Autophagy Compounds
The human PSC line WA09 (WiCell 0062, Madison, WI, USA) was used to derive human neural
progenitor cells (hNP1TM 00001) as previously described [16]. ArunA Biomedical, Inc. (Athens,
GA, USA) differentiated the hNP1 cells into neurons and we cultured the neurons as previously
described [20]. Before plating neurons, each well was coated with Matrigel (1:100 dilution; (B&D,
Franklin Lakes, NJ, USA) and incubated for at least 30 min at room temperature. After incubation,
the Matrigel was removed and the wells were washed twice with PBS. Neurons were immediately
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plated at densities of 2 × 105 cells/well in 24-well plates and 3 × 104 cells/well in 96-well plates.
The following day cells were treated with 10 μM final concentration of compounds, and the 24-well
plate was infected with ZIKV SPH (MOI 1.0). The infected/compound-treated neurons were incubated
for 4 days then the supernatants were collected and neuron viability was determined as described
above. The compound-treated supernatants were titrated via TCID50.
2.8. 7-Ketocholesterol Dose-Response
Vero cells were plated at 1.5 × 105 cells/well in a 24-well plate and 1.5 × 104 cells/well in a 96-well
plate and incubated for 16 h. Cells were treated with the indicated concentration of 7-KC or DMSO
control. The cells in the 24-well plate were immediately infected with MOI 1 of ZIKV SPH. After 2 h,
the infectious media was removed and replaced with the same concentrations of 7-KC treated media
as indicated. The cell supernatants were collected 24 h following infection and titers were reported in
TCID50 units. ZIKV titers from 7-KC treated cells were compared to those from DMSO-treated controls.
2.9. 7-Ketocholesterol Time-of-Addition
Vero cells at a density of 3 × 105 cells/well in 24-well plates were treated with either 10 μM of
7-KC or 30 mM of ammonium chloride under the following conditions: 2 h prior to ZIKV infection,
at the same time as ZIKV infection, 2 h following ZIKV infection, or 6 h following ZIKV infection.
Regardless of treatment condition, the cells were infected with ZIKV SPH MOI 0.1 for 2 h. After 2 h,
the infectious media was removed and replaced with fresh media. For the cells treated at the same
time as infection, the fresh media was re-treated with the compounds at the same concentrations as
above. The supernatants were collected at 24 hours post infection (hpi) and titers were reported in
TCID50 units. ZIKV titers from treated cells were compared to those from controls, which were treated
with either DMSO or DMEM at the time of infection and retreated after the media change.
2.10. 7-Ketocholesterol and ZIKV Pre-Incubation
Vero cells were plated at 1.5 × 105 cells/well in a 24-well plate and incubated for 18 h. The next
day, ZIKV stock was pre-incubated with 200 μM of 7-KC for 1 h at room temperature. After incubation,
the ZIKV/7-KC mixture was diluted and added to the Vero cells. The dilution resulted in an infection
at MOI 0.1 and final concentration of 7-KC was approximately 0.2 μM (below the active range of 7-KC
as determined by our dose-response curve). The cell supernatants were collected at 40 hpi and titers
were determined. Pre-incubation results were compared to DMSO controls.
2.11. qRT-PCR
Vero cells were infected with ZIKV SPH and treated with compounds in the same manner as the
time-of-addition experiment. Supernatants and cellular lysates were collected at 24 hpi. Viral RNA
was isolated using the ZR Viral RNA kit (Zymo, Irvine, CA, USA) and cellular RNA was isolated
with the RNAeasy Mini kit (Qiagen, Hilden, Germany). Both total and viral RNA samples were
reverse-transcribed (RT) to cDNA (High Capacity RNA-to-cDNA Kit, Applied Biosystems, Foster
City, CA, USA). To quantify the copies of ZIKV genomes we used the cDNA in a quantitative PCR
(qPCR) reaction assay using TaqMan Gene Expression Master Mix (Applied Biosystems, ThermoFisher,
Waltham, MA, USA), primers and probes (F: ZIKV 1086, R: ZIKV 1162c, ZIKV 1107-FAM; TaqMan
MGB Probe; Invitrogen Custom Primers) [21]. Each sample was analyzed in duplicate, and each
plate contained a DNA plasmid standard curve (ZIKV molecular clone), no template, and no primer
controls. ZIKV copy numbers were extrapolated from the generated standard curve using the Applied
Biosystems protocol. The limit of detection was experimentally established to be 30 copies (10−16
g). Final copy numbers were adjusted by back-calculations to the total RNA and cDNA volume and
expressed as copies per sample.
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2.12. Chemical Structures
We created chemical structures using PyMOL version 2.1.1. Structure files were downloaded from
Pubchem (https://pubchem.ncbi.nlm.nih.gov/).
2.13. Statistics
All experiments were performed in at least three independent trials. We assessed variation across
trials using the standard error of the mean. We used the student’s unpaired t-test to test for significance
when comparing data plotted on a linear scale and Welch’s t-test of unequal variance when data is
plotted on a log-scale. Significance values are: * p < 0.05; ** p < 0.01; *** p < 0.001; NS- not significant.
3. Results
3.1. Autophagy Compound Screen in Vero Cells
We tested the ability of the Enzo Screen-Well Autophagy Library (94 compounds listed in Table 1)
to reduce ZIKV titer in mid-logarithmic growth phase (40 h post infection) [22], without negatively
impacting viability compared to controls in Vero cells. These compounds produced a wide range of
effects on ZIKV titer, though only approximately 30% were able to decrease ZIKV titer by at least
one log compared to control (Figure 1A). Similar to previously published data, treatment with the
prototypical autophagy inducer rapamycin increased ZIKV titers whereas the prototypical autophagy
inhibitor hydroxychloroquine decreased titers [11–13]. Of the 94 compounds, three (amiodarone-HCl,
7-ketocholesterol, and licochalcone A) reduced ZIKV titer to below 10% of control while maintaining
cell viability above 80% of control (Figure 1B).
Table 1. Summary of autophagy compound screen.
# a Name Type b
ZIKV SPH Relative
Titer in Vero Cells c
Vero Viability d
ZIKV SPH Relative
Titer in C6/36 Cells c
C6/36 Viability d
1 Bafilomycin A1 H 0.0 ± 0 55.7 ± 9.5 0.0 ± 0 36 ± 6.1
2 Rapamycin D 167.9 ± 44.4 66.0 ± 2.6 75.7 ± 47.7 59 ± 7.3
3 Timosaponin A-III D 0.0 ± 0 38.7 ± 11.9 13.0 ± 5.2 67 ± 3.6
4 3-Methyladenine H 73.4 ± 4.9 90.7 ± 1.8 155.3 ± 41 120 ± 15.6
5 PI-103 D 42.3 ± 20.6 43.7 ± 6.4 46.2 ± 13.3 39 ± 8.9
6 LY294002 H 264.3 ± 182.9 56.0 ± 6 548.4 ± 221 97 ± 17.2
7 Lithium Chloride D 85.4 ± 18.7 87.0 ± 1 167.9 ± 68.4 111 ± 10.7
8 L-690,330 D 40.7 ± 10.6 93.7 ± 3.5 66.8 ± 2.6 87 ± 4.6
9 Wortmannin H 46.9 ± 9 79.0 ± 3.1 190.1 ± 57.8 105 ± 5.5
10 Sodium Valproate D 110.8 ± 80.4 92.7 ± 1.2 111.4 ± 20.7 111 ± 6.2
11 Verapamil·HCl D 92.9 ± 20.8 87.7 ± 0.9 89.0 ± 40.8 71 ± 2.9
12 SP600125 H 26.5 ± 15 66.0 ± 2.1 50.3 ± 19.8 132 ± 9
13 Chloroquine H 109.0 ± 65 89.7 ± 4.4 126.5 ± 44.8 81 ± 17.1
14 Loperamide HCl D 11.7 ± 3.3 66.7 ± 17.4 0.1 ± 0.1 12 ± 6.1
15 Amiodarone HCl D 6.3 ± 3.6 84.0 ± 8.2 2.0 ± 0.5 44 ± 15.3
16 Nimodipine D 32.5 ± 7.3 92.0 ± 1.5 26.9 ± 13.6 41 ± 8.4
17 Nitrendipine D 66.0 ± 27.1 88.7 ± 1.9 219.7 ± 44.4 62 ± 10.5
18 Niguldipine D 0.2 ± 0.1 30.0 ± 14.2 0.0 ± 0 5 ± 2.1
19 Penitrem A D 34.9 ± 10.4 78.3 ± 6.4 29.8 ± 6.4 43 ± 8.1
20 Ionomycin D 0.0 ± 0 27.7 ± 10.4 0.0 ± 0 1 ± 0.3
21 Rotenone D 1.8 ± 0.9 61.3 ± 7.7 0.1 ± 0.1 17 ± 5.8
22 TTFA D 24.4 ± 7.6 90.0 ± 3.5 72.8 ± 9.6 78 ± 19.9
23 Fluspirilene D 2.5 ± 0.6 56.7 ± 16 1.0 ± 0.7 26 ± 10.3
24 Hydroxychloroquine H 14.7 ± 7.3 85.3 ± 8.4 25.1 ± 12.6 35 ± 9.7
25 Norclomipramine HCl H 3.9 ± 0.5 48.7 ± 22.9 13.4 ± 8.7 19 ± 8.9
26 Trifluoperazine·2HCl D 2.8 ± 0.7 51.0 ± 22.1 0.3 ± 0.3 10 ± 3.8
27 Sorafenib tosylate D 5.8 ± 1.8 58.3 ± 9.9 9.4 ± 8.8 23 ± 8.8
28 Niclosamide D 0.1 ± 0 29.7 ± 3.8 0.1 ± 0 2 ± 0.3
29 Rottlerin D 10.3 ± 5 80.7 ± 8.5 30.3 ± 16.9 40 ± 8.4
30 Caffeine D 80.6 ± 20.9 104.7 ± 8.6 138.4 ± 37.7 83 ± 4.6
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Table 1. Cont.
# a Name Type b
ZIKV SPH Relative
Titer in Vero Cells c
Vero Viability d
ZIKV SPH Relative
Titer in C6/36 Cells c
C6/36 Viability d
31 Metformin·HCl D 122.3 ± 41.5 92.3 ± 4.2 75.8 ± 19.2 64 ± 10.3
32 Clonidine·HCl D 65.4 ± 17.3 97.7 ± 2.6 95.9 ± 53.4 69 ± 5.4
33 Rilmenidine D 191.2 ± 49.5 97.0 ± 2 161.0 ± 58.1 79 ± 8.3
34 2′,5′-Dideoxyadenosine D 93.3 ± 31.9 95.0 ± 1.5 317.4 ± 161.9 118 ± 15
35 Suramin·6Na D 107.4 ± 44.8 92.0 ± 1.2 86.6 ± 23.2 86 ± 8.4
36 (±)Bay K8644 H 34.9 ± 15.2 94.0 ± 3 39.4 ± 10.7 53 ± 11.1
37 Forskolin H 139.0 ± 32.1 74.7 ± 3.7 302.5 ± 18.3 94 ± 12
38 Pimozide D 77.9 ± 15.5 90.0 ± 5.7 109.0 ± 22 49 ± 3.6
39 STF-62247 D 45.0 ± 21.4 77.3 ± 11.7 169.8 ± 45.9 49 ± 9.3
40 Spermidine D 115.0 ± 44.9 78.0 ± 17 90.2 ± 57.4 70 ± 3
41 FK-866 D 7.3 ± 6.5 32.7 ± 2.7 92.7 ± 32.4 48 ± 5.5
42 Tamoxifen citrate D 3.3 ± 2.3 60.7 ± 18.4 8.2 ± 7.3 32 ± 11.9
43 Minoxidil D 60.4 ± 27.2 96.3 ± 3.2 145.7 ± 16.6 72 ± 2.6
44 Imiquimod D 228.5 ± 139.8 91.3 ± 1.2 72.5 ± 18.4 37 ± 8.1
45 Imatinib mesylate D 91.2 ± 60 81.0 ± 10.7 5.3 ± 2.2 19 ± 5.4
46 AG112 D 77.7 ± 38.2 96.7 ± 3.7 85.5 ± 21.3 80 ± 5.8
47 SU11652 D 0.1 ± 0 1.0 ± 0 0.0 ± 0 1 ± 0
48 Dibutyryl cAMP·Na H 60.6 ± 36.7 98.3 ± 4.4 142.6 ± 63.9 117 ± 10.7
49 Rolipram H 103.8 ± 26.8 91.0 ± 3.2 215.4 ± 74.8 127 ± 12.1
50 SB202190 D 13.3 ± 4.2 74.3 ± 5.2 25.9 ± 7.4 44 ± 7.9
51 Brefeldin A D 5.4 ± 4.9 17.0 ± 2.1 123.5 ± 25 91 ± 8.4
52 Tunicamycin D 0.5 ± 0.5 56.3 ± 8.7 1.8 ± 0.8 47 ± 7.6
53 Thapsigargin D 0.4 ± 0.4 38.0 ± 10.5 0.0 ± 0 23 ± 3.9
54 A23187 D 0.5 ± 0.5 17.0 ± 6.7 0.0 ± 0 1 ± 0
55 Capsaicin D 76.9 ± 29.6 91.7 ± 2.4 48.1 ± 12 66 ± 7.2
56 Dihydrocapsaicin D 28.7 ± 10.5 92.3 ± 3.8 64.1 ± 16 61 ± 2.2
57 Glucosamine HCl D 51.8 ± 11.8 99.3 ± 1.9 242.1 ± 45.8 88 ± 5.2
58 DTT D 60.2 ± 20.1 93.0 ± 1.5 145.7 ± 16.6 79 ± 4.4
59 Deoxycholate·Na D 76.6 ± 16.6 95.3 ± 2.6 90.6 ± 12.5 83 ± 1
60 8-CPT-cAMP·Na H 107.8 ± 65.3 92.7 ± 0.7 60.1 ± 18.3 75 ± 3.7
61 EHNA·HCl H 81.0 ± 7.6 92.3 ± 2 36.4 ± 9.1 55 ± 4.2
62 ABC294640·HCl D 51.7 ± 29.2 87.7 ± 6.8 26.0 ± 10.8 32 ± 3.5
63 Licochalcone A D 7.2 ± 2.9 100.7 ± 9.4 51.8 ± 28.5 43 ± 2
64 Curcumin D 24.1 ± 11.3 75.3 ± 11.3 0.3 ± 0.2 3 ± 0.7
65 Plumbagin D 0.1 ± 0 2.0 ± 0 21.4 ± 17.5 49 ± 1.5
66 6-Gingerol D 99.9 ± 63.9 100.0 ± 2.5 109.3 ± 9.3 55 ± 11
67 Akt Inhibitor X·HCl D 3.5 ± 3.3 32.3 ± 14.2 0.0 ± 0 7 ± 1.9
68 PMSF D 89.0 ± 7 98.3 ± 2 258.0 ± 145.2 81 ± 6.4
69 MG132 D 0.1 ± 0.1 10.7 ± 2.8 9.5 ± 7.1 31 ± 5.7
70 ALLN D 123.3 ± 27.3 75.0 ± 17.1 41.6 ± 0.6 49 ± 6.6
71 7-Ketocholesterol D 7.5 ± 1.3 93.0 ± 4 9.8 ± 3.3 36 ± 5.1
72 SB-216763 H 41.6 ± 30.6 80.0 ± 9 54.0 ± 21.7 63 ± 3.6
73 Tolazamide H 176.8 ± 50.9 99.0 ± 1.5 120.1 ± 33.7 113 ± 7.3
74 17-AAG D 36.4 ± 20.8 56. 7 ± 11.8 18.2 ± 11.2 79 ± 16.4
75 Geldanamycin D 108.4 ± 39.4 61.3 ± 5.7 25.8 ± 14.5 45 ± 5.8
76 C1 D 119.3 ± 34.4 97.3 ± 2.4 101.2 ± 29.5 55 ± 1.7
77 Z36 D 0.1 ± 0.1 0.7 ± 0.3 0.0 ± 0 0 ± 0
78 Rockout D 169.6 ± 69.3 87.7 ± 3.8 96.2 ± 44.2 76 ± 5.2
79 Go6850 D 1.3 ± 0.9 36.0 ± 9 1.4 ± 1.4 21 ± 0
80 2-Deoxyglucose D 99.7 ± 15.4 98.7 ± 0.9 108.8 ± 61.2 73 ± 1
81 Etoposide D 134.0 ± 34.3 84.0 ± 3.6 736.8 ± 89.3 119 ± 12.5
82 SMER28 D 65.0 ± 5.6 92.7 ± 3.5 38.7 ± 12.2 36 ± 5.3
83 Trehalose D 107.1 ± 16.9 97.7 ± 1.5 245.7 ± 101.3 99 ± 2.9
84 Quinine HCl·2H2O H 180.2 ± 70.4 89.7 ± 2.7 123.0 ± 28 54 ± 4.6
85 AICAR H 112.3 ± 32.3 90.0 ± 11.1 252.0 ± 115 125 ± 16.4
86 C2-dihydroceramide D 36.5 ± 3 101.3 ± 3.7 262.1 ± 51.7 97 ± 5.8
87 Temozolomide D 89.9 ± 17.5 104.7 ± 1.9 218.7 ± 49.8 113 ± 9.2
88 Resveratrol D 67.5 ± 13.2 87.3 ± 2.3 154.6 ± 62 81 ± 7.5
89 Staurosporine D 0.1 ± 0 14.0 ± 1.5 0.0 ± 0 16 ± 5.3
90 PD-98059 H 101.0 ± 23.3 90.7 ± 1.3 197.3 ± 40 93 ± 8.4
91 Anisomycin H 0.0 ± 0 12.7 ± 4.3 0.0 ± 0 7 ± 0.9
92 Cycloheximide H 0.0 ± 0 37.3 ± 6.2 0.0 ± 0 24 ± 3.5
93 Pifithrin-μ H 38.5 ± 12.4 49.0 ± 15 75.3 ± 27.5 72 ± 3.2
94 Nocodazole H 28.4 ± 23.9 56.0 ± 9.6 182.0 ± 39.5 58 ± 2.9
a Compounds are numbered based on the Enzo library and correlate to Figures 1A and 3A. b Autophagy inducers
are labeled D whereas autophagy inhibitors are labeled H; c All values are displayed as percent of untreated control
± the standard error of the mean (SEM) from three independent trials. Viral inhibition is color coded as follows:
compounds resulting in >90% of control are highlighted in red, between 10–90% are in yellow, and compounds that
dropped titers below 10% are in green. d All values are displayed as percent of untreated control ± the standard
error of the mean (SEM) from three independent trials. Cell viability data is color coded as compounds that retained
>80% viability are in blue and compounds with <80% viability are in grey.
452
Viruses 2019, 11, 20
Amiodarone-HCl, 7-ketocholesterol, and licochalcone A are all characterized as autophagy
inducers. Based on previous work, autophagy inducers would be predicted to increase ZIKV titers.
However, amiodarone-HCl, 7-ketocholesterol, and licochalcone A decreased ZIKV titers in our assay.
To confirm that these compounds induced autophagy in the Vero cells, we stained treated cells with
CYTO-ID, a dye that binds to autophagic vesicles [19]. We detected increased fluorescence when cells
were treated with rapamycin as well as with amiodarone-HCl, 7-ketocholesterol, and licochalcone A,
confirming the compounds induce autophagy in Vero cells (Table 2). Amiodarone-HCl treatment in
particular led to a very large increase in fluorescence intensity. While rapamycin and licochalcone A
both induce autophagy through mTOR signaling, amiodarone-HCl induces autophagy through mTOR
independent pathways [23].
Table 2. Autophagy activity factor.
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Figure 1. Autophagy compound screen in Vero cells. (A) ZIKV SPH growth in compound-treated
Vero cells as a percent of ZIKV titer in untreated Vero cells. Red symbols represent compounds that
increased ZIKV titer compared to the untreated control, yellow symbols represent compounds that
reduced titer between 10 and 99% of control, and green symbols represent compounds that reduced
ZIKV titer below 10% of control (at least 1 log of viral growth). Error bars represent the standard
error of the mean (SEM) from three independent trials. The compounds are numbered according to
Table 1. (B) ZIKV growth in Vero cells versus viability of compound-treated Vero cells. The shaded box
represents the zone in which ZIKV titer is reduced to 10% or lower than the untreated control and cell
viability is at least 80% of control. Compounds that meet these criteria are in green and labeled with
their names.
3.2. Autophagy Compound Screen in Vero Cells Infected with ZIKV IbH
There are two genetic lineages of ZIKV [24], and isolates from these different lineages can produce
distinct phenotypes in infected cells [20,22,25,26]. Therefore, we tested the ability of a subset of
22 autophagy compounds to inhibit African lineage ZIKV IbH in Vero cells (Figure 2). We chose
this subset based on our results with SPH; one third of the compounds decreased SPH titer below
10%, one third decreased SPH titer between 10 and 99%, and the final one third increased SPH titer
compared to control. These compounds affected African-lineage IbH replication in a manner similar to
the effects on ZIKV-SPH (Figure S1). Thus, the compounds effect on ZIKV replication is not lineage
specific. While amiodarone-HCl, 7-ketocholesterol, and licochalcone A all reduced ZIKV IbH titers,
only 7-KC dropped titers more than a log compared to control. Because we did not identify major
differences in ZIKV titer across lineages, we continued with Asian-lineage ZIKV SPH for the remainder
of our experiments.
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Figure 2. African- lineage ZIKV IbH growth in compound-treated Vero cells as a percent of ZIKV titer in
untreated Vero cells (A). The color-codes are the same as in Figure 1A. (B) ZIKV IbH growth in Vero cells
versus viability of compound-treated Vero cells. The shaded box represents the zone in which ZIKV titer is
reduced to 10% or lower than the untreated control and cell viability is at least 80% of control.
3.3. Autophagy Compound Screen in C6/36 Cells
ZIKV is transmitted primarily by Aedes mosquitoes and the virus must infect and replicate in
mosquito cells to be transmitted. To determine if the autophagy compound panel altered ZIKV
replication in mosquito cells in a similar manner to mammalian cells, we performed the screen in
C6/36 Aedes albopictus cells. Because mosquito cells have a slower metabolic rate, cellular viability and
viral titers were examined 96 h post-infection/treatment [22]. Once again, the autophagy compounds
produced a wide range of effects on SPH titer (Figure 3A). However, unlike in Vero cells, we did
not identify any compounds that reduced ZIKV titer to below 10% of control while maintaining
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viability above 80% of control (Figure 3B). Some compounds did not produce the expected results.
For example, rapamycin which increase particle production in Vero cells, slightly decreased titers
in C6/36 cells. Interestingly, more compounds increased SPH titer in C6/36 cells compared to Vero
cells (Figures 2A and 3A, Figure S2, Table 1). While 27 compounds in Vero cells produced virus >90%
of control, 38 compounds behaved similarly in C6/36 cells. The insect and mammalian autophagy
pathways are highly conserved [27] and many of the autophagy altering compounds affected ZIKV
replication in Vero and C6/36 cells in a similar fashion (Figure S2). However we found opposing effects
with some compounds. Cell type specific cytotoxicity may explain many of the differences observed.
For example, brefeldin A was toxic in Vero cells, resulting in little virus production, yet brefeldin
A did not alter viral titers or cell viability in C6/36 cells. While amiodarone HCl, licochalcone A,
and 7-ketocholesterol (7-KC) inhibited ZIKV replication in both Vero and C6/36 cells, they were more
toxic to the C6/36 cells. Many compounds resulted in significant cell death in the C6/36 cells and may
be related to the increased time period the cells were exposed to the compounds. We did not identify
any compounds that inhibited viral replication without significantly affecting cell viability.
Figure 3. Autophagy compound screen in C6/36 cells. (A) ZIKV growth in compound-treated C6/36 cells
as a percent of ZIKV titer in untreated C6/36 cells. The labels and color-codes are the same as in Figure 1A.
(B) ZIKV growth in C6/36 cells versus viability of compound-treated C6/36 cells. As in Figure 1, the shaded
box represents the zone in which ZIKV titer is reduced to 10% or lower than the untreated control and cell
viability is at least 80% of control. No compounds fit these criteria in C6/36 cells.
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3.4. Autophagy Compound Screen in Human Neurons
The three compounds that reduced ZIKV titer without impacting Vero cell viability were further
characterized to determine these compounds’ abilities to inhibit ZIKV replication in human neurons,
a cell line more relevant to clinical ZIKV infection. We performed this screen with neurons derived
from human neural progenitor cells, which have been characterized in previous ZIKV experiments [20].
Of these three compounds, only 7-ketocholesterol (7-KC) reduced ZIKV titer without significantly
decreasing neuron viability (Figure 4A,B). Structurally, 7-KC is very similar to cholesterol, a major
component of cellular membranes; the only difference between the two compounds is an extra oxygen
molecule on 7-KC compared to cholesterol (Figure 4C). The addition of a cholesterol-like molecule could
alter cellular membrane composition, which could block one of the many stages in ZIKV replication
that relies on membranes, including entry, genome replication, or budding from the host cell.
Figure 4. Autophagy compound screen in human neurons. (A) Impact of autophagy compounds on
ZIKV replication in neurons and (B) neuron viability. (C) Chemical structure of cholesterol (PubChem
CID 5997) versus 7-ketocholesterol (PubChem CID 91474). Carbon atoms are shaded in purple,
hydrogen atoms are shaded in grey, and oxygen atoms are shaded in red.
3.5. 7-Ketocholesterol Dose-Response
We generated a dose-response curve to determine the IC50 and range of activity of 7-KC in Vero
cells (Figure 5). The IC50 of 7-KC for ZIKV SPH is 4.064 μM, and Vero cells remained more than 80%
viable at all 7-KC concentrations tested (0–27 μM). Because of the high cell viability, we were not able
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to generate a full viability curve over the range of active 7-KC doses, suggesting there is a large range
of activity between cell viability and viral inhibition.
Figure 5. Dose-response curve and viability of Vero cells treated with varying doses (0–27 μM) of
7-ketocholesterol. The curves were generated by GraphPad Prism version 7.04 using the log (inhibitor)
vs. normalized response variable slope regression. The regression curve estimates the IC50 at 4.064 μM
(R2 = 0.9078). The cell viability did not drop below 80% preventing us from determining the EC50.
3.6. 7-Ketocholesterol Time-of-Addition
To help elucidate the mechanism by which 7-KC inhibits ZIKV replication, we performed a
time-of-addition experiment to determine when 7-KC was most effective at inhibiting ZIKV replication.
First, we determined if 7-KC directly impacts ZIKV infectivity through a virucidal effect. ZIKV stock
was preincubated with a high concentration (200 μM) of 7-KC for 1 h. This mixture was then diluted
onto Vero cells so that the 7-KC concentration was below the active range as determined by the
dose-response curve (Figure 5). Therefore, any viral inhibition would be caused by 7-KC virucidal
effect and not by 7-KC activity within the host cell. As shown in Figure 6A, 7-KC preincubation with
ZIKV SPH did not reduce viral titers compared to controls suggesting 7-KC modifies the infected host
cell in a way that limits ZIKV replication.
Cells were treated with 7-KC or ammonium chloride 2 h before infection, at the time of infection,
and 2, 6, 12, and 18 h following infection. Ammonium chloride raises lysosomal pH, preventing
flavivirus entry [28] and was used as an entry inhibitor control. Ammonium chloride treatment 2 h
prior to infection and at the time of infection inhibited ZIKV replication, but it was less inhibitory
when added later in infection. Interestingly, pre-treating cells with 7-KC 2 h before infection did not
reduce viral titers, yet treatment with 7-KC at the time of infection, at 2 hpi, or at 6 hpi all decreased
ZIKV titers by 90% (Figure 6B). ZIKV inhibition continued even 12 h after infection, while 18 h after
infection only showed a slight decrease in titer. It may take some time for 7-KC treatment to take effect,
and adding the drug at 18 hpi (only 6 h before virus was collected) may allow some virions to be
produced before the drug was added. These results suggest that 7-KC does not inhibit ZIKV entry and
instead inhibits a downstream step in the replication pathways such as viral replication or budding.
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Figure 6. Analysis of 7-ketocholesterol inhibition of ZIKV SPH replication. (A) ZIKV SPH preincubation
with 200 μM of 7-KC before Vero cell infection. (B) 7-KC versus ammonium chloride time-of-addition
assay in Vero cells. Error bars represent the SEM. *, p < 0.05; **, p < 0.01.
3.7. 7-Ketocholesterol qRT-PCR
Time-of-addition experiments demonstrate that 7-KC is able to reduce virus production even
when added 6 h following infection, suggesting that the compound most likely affects ZIKV production
late in the infection cycle. To examine the levels of viral RNA production, we isolated total RNA
from infected cells and quantified the number of viral genome copies present. The levels of ZIKV
RNA were not significantly altered in the presence of 7-KC (Figure 7A), suggesting 7-KC does not
alter RNA production. Although the levels of RNA found in the cells were not significantly different,
the number of viral genome copies in the supernatant was reduced, suggesting a budding or release
defect. When we compared the number of genomes in the supernatant to the amount in the cells, 7-KC
treatment decreases budding/release efficiency to approximately 30% of untreated cells (Figure 7B).
While this defect could account for a slight decrease in virion production, it alone could not cause
the greater than 90% decrease in infectious virions. Therefore, we hypothesized that the particles
budding from the 7-KC treated cells may be less infectious than ZIKV produced from untreated cells.
We determined the specific infectivity of the particles by comparing the infectious titer to the number
of genome copies in the supernatant samples (Figure 7C). Particles produced in cells treated with 7-KC
were significantly less infectious than the DMSO control. Only 1 in approxiamately 9000 genomes
were infectious when 7-KC was present compared to 1 in 1200 of control.
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Figure 7. 7-KC reduced ZIKV budding efficiency and infectious virion production. (A) ZIKV infection
was inhibited by adding 7-KC at the indicated time points following infection. Twenty-four hours post
infection (hpi), total cellular RNA was harvested and ZIKV genomes were quantified using q-RT-PCR.
7-KC did not significantly alter the level of ZIKV genomes in the cells. (B) ZIKV genome copies present
in the supernatants were also quantified. To determine the budding/release efficiency we compared the
number of genomes present in the supernatant to cell associated genomes and determined the budding
efficiency based on DMSO control. (C) ZIKV produced in the presence of 7-KC is less infectious than
virus grown in DMSO control cells. The specific infectivity of the virions was determined by comparing
the titer to the number of genome copies found in the supernatant (×1000). Each RNA sample was run
in triplicate during each trial for a total of 3 trials. *, p < 0.05; **, p < 0.01.
4. Discussion
To further our understanding of how ZIKV replication interacts with the autophagy
pathway, we examined ZIKV replication in the presence of 94 autophagy inducers and inhibitors.
Most compounds did not affect ZIKV replication or substantially reduce cell viability, preventing us
from assessing the compounds’ effect on replication. When comparing the effects of the compounds
in the mammalian and mosquito cell lines, we observed a similar pattern of inhibition for the most
part (Figure S2). Some compounds had cell-type specific cytotoxicity which frequently explained any
differences in trends. The number of compounds that did not significantly alter ZIKV replication
surprised us. While all the compounds in the library have been shown to alter the autophagy
pathway, some of the compounds effects may be indirect. Rapamycin, the prototypical autophagy
inducer increased ZIKV production in Vero cells, yet slightly decreased production in C6/36 cells.
Hydroxychloroquine blocked ZIKV spread in a mouse model [12] and we found it decreased titers in
both Vero and C6/36 cells. While trehalose, an autophagy inducer, has been suggested to block ZIKV
transmission [29], it was not able to reduce ZIKV titers in Vero or C6/36 cells.
Three compounds, amiodarone-HCl, 7-ketocholesterol, and licochalcone A, inhibited ZIKV
replication in Vero cells without reducing cell viability, but neurons only remained viable when
treated with 7-KC. 7-KC was also the only compound that reduced ZIKV IbH by more than 90% of
control. 7-KC is an oxysterol formed by oxidation of cholesterol [30] and is a major component of
oxidized lipoprotein found in atherosclerotic plaque [31]. 7-KC is a biomarker for oxidative stress and
elevated levels are observed in blood samples of cancer patients and patients with inflammation [32–34].
Although the mechanism remains unclear, sub-toxic levels of 7-KC activates PI3K/mTOR signaling,
inducing autophagy [35]. 7-KC has also been linked to enhancing intracellular hydrogen peroxide
levels, triggering autophagy [36]. While low concentrations of 7-KC are associated with autophagy
induction, high concentrations are cytotoxic and induce apoptosis [36]. Most of the existing research
on this compound focuses on it association with atherosclerosis [37], a condition characterized
by hardened, plaque-filled arterial walls caused by oxysterol buildup over time [31]. 7-KC also
induces inflammation through TLR4 signaling [38]. Currently there is no literature examining
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7-KC and antiviral activity against enveloped viruses, however one study examining oxysterols
and non-enveloped viruses found 7-KC had no activity against human papillomavirus and human
rotavirus with minor activity for human rhinovirus [39].
7-KC will incorporate into cellular lipids and disrupt normal lipid order [40,41], which can
impair phagocytosis [42]. A similar oxidized cholesterol-based compound, 25-hydroxycholesterol
(25-HC), reduced ZIKV titers in vitro and in vivo by inhibiting viral entry [43]. 25-HC may modify
host membranes, preventing efficient fusion [43]. Due to the similar make-up of 25-HC and 7-KC one
might predict it would also decrease viral entry. However, our time-of-addition studies suggests 7-KC
does not block viral entry or RNA production, but a late stage in viral replication such as viral budding
or particle release from the cell. In addition to decreasing the efficiency of particle release, the particles
that are released into the supernatant are less infectious.
Interestingly, 7-KC induces autophagy [36], and because ZIKV replication is enhanced by
autophagy induction, one could suggest that 7-KC should increase ZIKV titers. 7-KC’s role in inducing
autophagy and the antiviral activity we observed may not be related. While 7-KC may increase
autophagy flux through activating PI3K/mTOR, its effects on disrupting lipid order may have more
profound consequences on ZIKV spread. ZIKV replication, budding, maturation, and release all
rely on host lipids and the cellular secretory pathway [44]. Particle infectivity was altered when the
infected cells were treated with 7-KC, but the compound had no virucidal effect on intact particles.
This suggests that the 7-KC may significantly alter the lipid environment in the organelles that are
critical for budding and trafficking of ZIKV.
In conclusion, we identified 7-ketocholesterol as an inhibitor of ZIKV replication in both Vero
cells and human neurons. While antiviral, 7-KC only dropped viral titers by an order of magnitude,
suggesting the compound would not be clinically relevant. However, we believe that 7-KC will be
a useful tool to examine the lipids involved in ZIKV particle production and further explore ZIKV
budding and trafficking mechanisms.
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Figure S1: Comparison of autophagy compounds’ effects on ZIKV SPH and IbH; Figure S2: Comparison of the
autophagy compounds’ effects on ZIKV SPH in Vero and C6/36 cells.
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Abstract: Quality Control for Molecular Diagnostics (QCMD), an international provider for External
Quality Assessment (EQA) programmes, has introduced a programme for molecular diagnostics
of Zika virus (ZIKV) in 2016, which has been continuously offered to interested laboratories
since that time. The EQA schemes provided from 2016 to 2018 revealed that 86.7% (92/106),
82.4% (89/108), and 88.2% (90/102) of the participating laboratories reported correct results for all
samples, respectively in 2016, 2017, and 2018. The review of results indicated a need for improvement
concerning analytical sensitivity and specificity of the test methods. Comparison with the outcomes
of other EQA initiatives briefly summarized here show that continuous quality assurance is important
to improve laboratory performance and to increase preparedness with reliable diagnostic assays for
effective patient management, infection and outbreak control.
Keywords: Zika virus; mosquito-borne flavivirus; emerging arbovirus; outbreak control;
molecular diagnostics; laboratory preparedness; assay standardization; external quality assessment;
EQA; QCMD
1. Introduction
Zika virus (ZIKV) is a mosquito-borne flavivirus which had been considered to have low
pathogenicity, with only very sporadic human cases and outbreaks reported in the past [1]. In 2015,
ZIKV was first detected in patients in Brazil, which was a viral strain of the Asian lineage [2,3].
After introduction into South America, the virus has spread rapidly in over 48 countries and territories
in the Americas, with over 220,000 confirmed autochthonous cases and over 3500 confirmed congenital
cases associated with ZIKV infection [4]. During this rapid emergence, the World Health Organization
(WHO) declared a Public Health Emergency of International Concern (PHEIC) in response to a cluster
of microcephaly cases among newborns and other neurological disorders, like Guillain-Barré syndrome,
in adults [5]. In accordance with the situation, the WHO assigned the development, assessment and
validation of ZIKV diagnostic assays as a priority [6]. The PHEIC declaration ended in November
2016 with a longer-term programmatic approach for control and prevention [7].
Laboratory preparedness with access to reliable diagnostic assays, when facing an outbreak of
arboviral infections and increase of international travel, is a key issue for patient management, infection
and outbreak control worldwide [8–13]. Since the beginning of the ZIKV outbreak many diagnostic
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tests, mostly molecular in-house assays, have been developed [6,14–16]. Molecular methods are
preferred for laboratory diagnosis of acute cases, especially in the early stage of arboviral infection [17].
Specific assays have been published for Asian and African ZIKV strains targeting several genomic
regions including the envelope and NS5 [14,15,17]. Several months after the initial outbreak, there are
also some commercial molecular assays available for ZIKV genome detection which have received
regulatory approval [6,18,19].
Quality Control for Molecular Diagnostics (QCMD) is an international provider for External
Quality Assessment (EQA) programmes covering a comprehensive range of infectious diseases [20].
The aims of QCMD’s EQA programmes are to help monitor and improve laboratory quality by
assessing a laboratory’s use of molecular diagnostic technologies within the routine clinical setting.
Participation in EQA programmes is a requirement for achieving accreditation/certification according
to the International Organization for Standardization (ISO) 15189 (‘Medical laboratories–requirements
for quality and competence’ [21]) or equivalent regulatory requirements. After the declaration of the
PHEIC related to ZIKV in February 2016, QCMD rapidly introduced an EQA programme for molecular
diagnostics of ZIKV in August 2016 to support the laboratory’s requirements and provide appropriate
proficiency testing options from then on. Here we review the results of the EQA schemes performed
from 2016 to 2018 showing need for improvement concerning analytical sensitivity and specificity of
the test methods.
2. The QCMD Zika Virus EQA Programme, 2016–2018
QCMD distributes the EQA programme for molecular diagnostics of ZIKV to registered
laboratories annually. The annual EQA schemes have different panel compositions comprising
eight to 12 lyophilized samples with samples containing cell culture-derived, inactivated African-
and Asian-lineage ZIKV at different concentrations, specificity controls covering a range of related
flaviviruses and other arboviruses, and negative samples with transport medium only. Furthermore,
each QCMD panel includes the first WHO international standard (IS) for ZIKV for molecular assays,
developed by the Paul-Ehrlich-Institut (PEI code number 11468/16 [22]) which allows traceability
of EQA materials and comparability of laboratory performance in order to resolve the lack of assay
standardization [23]. This material was officially established as WHO IS by the WHO Expert Committee
on Biological Standardization in October 2016, however the candidate material had been made available
prior to its establishment as the WHO IS for proficiency testing, assay development and clinical use
because of the urgent need for quality-assured diagnostics [6].
All EQA programme and panel design specifications are defined by QCMD in close collaboration
with Scientific Experts in the field, based on epidemiological, clinical and/or technical aspects.
Participating laboratories are expected to test each panel using their routine molecular assays and
workflows, and to report their results together with information of the applied extraction and
amplification methods through the online reporting system to QCMD [20].
The panel compositions and performances for 2016–2018 are shown in Table 1. Participation
has been relatively high since the introduction of the EQA programme, with 106 (116 datasets),
108 (114 datasets), and 102 (112 datasets) participating laboratories from around 37 countries
worldwide, including those in affected geographical regions (with up to 17% of participating
laboratories from affected countries like Brazil, Mexico, Panama), respectively, in 2016, 2017 and
2018. The results were predominantly generated by commercial assays with 54.3% (2016), 57.0% (2017),
and 52.7% (2018) of the submitted datasets. No remarkable difference in performance between in-house
and commercial assays were observed, however for some specific commercial assays analytical
challenges could be identified concerning sensitivity with lower sample concentrations as well
as specificity issues producing false positive results (data not specified). Please note that these
observations do not allow a solid and statistically assured statement as EQA studies per se are not
appropriate for assay validation.
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In the EQA schemes of 2016–2018, all samples were designated by the QCMD Scientific Experts as
Core proficiency samples, which are expected to be correctly reported by the participating laboratories
within the EQA challenge in order to show an acceptable level of proficiency/successful participation.
The percentage of datasets with All Core samples correctly reported were 86.2% (2016), 82.5% (2017),
and 85.7% (2018) (see Table 1). At the laboratory level, these were 86.7% (92/106), 82.4% (89/108),
and 88.2% (90/102), respectively. Incorrect results (including false positive or not determined) were
reported for the true negative sample containing transport medium only (2.6% in 2016; 3.5% in 2017;
0.0% in 2018), for a specificity negative sample containing a mixture of flaviviruses other than ZIKV
(5.2% in 2016; 1.8% in 2017; 1.8% in 2018), and for a specificity negative sample containing chikungunya
virus (3.4%, only included in 2016).
Review of the three QCMD EQA schemes performed between 2016 and 2018 demonstrate that the
overall qualitative performance of participating laboratories for molecular diagnostics of ZIKV was at
an acceptable level. However, analytical sensitivity and specificity remain a challenge. False positive
results may lead to misdiagnosis and potentially affect clinical decisions. Processes should be reviewed
by laboratories reporting false positive results. The risk of a false negative result was a concern for
a small number of laboratories and may result in failure to detect a ZIKV in low concentration in
infected patients during the acute phase of the disease. Laboratories who were unable to detect the
lower concentrated samples should strive to improve the sensitivity of the ZIKV molecular assay used.
3. Review of Results from Other EQA Initiatives
To date, a further three EQA activities for ZIKV molecular diagnostics performed by different
groups have been identified showing similar observations as mentioned above [26–28].
Fischer et al. [26] conducted an EQA study for Brazilian laboratories in 2017. Fifteen laboratories
participated in this study applying their routine molecular diagnostics for ZIKV on a panel comprising
12 lyophilized samples with inactivated full virus spiked into arbovirus-negative human plasma.
The panel included four ZIKV-positive samples with 103–106 RNA copies/mL (representing the
African and Asian lineage, including the outbreak strain in the Americas) to assess sensitivity, seven
different arbovirus-positive samples (chikungunya virus, CHIKV; dengue viruses, DENV-2 & DENV-4;
Japanese encephalitis virus, JEV; St. Louis encephalitis virus, SLEV; West Nile virus, WNV; yellow
fever virus, YFV) for specificity control, and a negative plasma sample. In addition, the WHO IS [24]
as well as a ZIKV armored RNA standard available at the EVAg portal (European Virus Archive goes
Global) were provided as references for quantification of the ZIKV-positive samples. Only 27.0% (four
of 15 laboratories) reported correct results for all samples, while 73.0% (11/15) had limited sensitivity
(correctly testing only the two samples with the highest ZIKV concentration) and/or specificity
(including false positive results from ZIKV-negative samples).
Abdad et al. [27] pointed out how important it is to continually offer and expand an EQA
initiative for emerging arboviruses which helps to assess the laboratory performance and to increase
the preparedness in a certain region. The WHO Regional Office for the Western Pacific Region (WPR)
started with an EQA pilot for two participating laboratories in 2011, including only dengue virus,
and developed it to a global EQA programme for arbovirus diagnostics (including CHIKV, DENV, YFV,
and ZIKV) with participation of 96 laboratories worldwide (of which 25 were coming from 19 countries
in the WPR) in 2016. In 2016, the panels contained blinded samples with different concentrations
for the four targeted arboviruses and were shipped to the participants between November and
December. For ZIKV, 72.0% (18 of 25 laboratories of the WPR) reported correct results in all samples,
while 28.0% (seven) had at least one false result which was not further specified.
Charrel et al. [28] published an EQA study that was performed by the Emerging Viral Diseases
Expert Laboratory Network (EVD-LabNet, Rotterdam, The Netherlands) in October/November 2016 to
assess and to improve the capability of European reference and expert laboratories for ZIKV molecular
detection. Fifty laboratories (reporting 85 datasets) from 31 countries took part in this study, using
mostly in-house assays (72.0% of the submitted datasets). The panel consisted of 12 lyophilized
467
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samples with inactivated virus spiked into plasma or urine, including six ZIKV-positive samples with
103–109 copies/mL (representing the African and Asian lineage, including the outbreak strain in the
Americas; calibrated using in vitro-transcribed ZIKV RNA), three different arbovirus-positive samples
(CHIKV, YFV, DENV-1), and three negative plasma or urine samples. Based on the submitted results, all
samples were assigned as core samples, having a ZIKV status scored correctly by >50% of the participating
laboratories. The study revealed that only 40.0% of the laboratories (20/50), representing 45.0% of the
countries, achieved a sufficient analytical performance. 60.0% of the laboratories (30/50) had a need to
improve their molecular ZIKV detection in relation with specificity, but more obviously with sensitivity
as only half of the laboratories correctly scored the sample with the lowest concentration.
4. Conclusions
Although the comparison of the recent results from the QCMD Zika Virus EQA Programme done
for 2016–2018 with the briefly summarized outcomes of the other EQA initiatives for ZIKV molecular
diagnostics shows great variations in laboratory performance with 27.0–88.2% of participating
laboratories reporting correct results for all samples, all EQAs indicate that there is a clear need
to improve sensitivity and specificity of ZIKV molecular assays.
The ZIKV molecular diagnostics would benefit greatly from the use of standards and controls
in order to ensure that laboratories would also detect lower viral loads as known from the
literature [17,29,30] to avoid false negative results during acute infection. The continued use of the
WHO IS as included in the QCMD EQA programme for molecular diagnostics of ZIKV will help to
support assay standardization and to improve quality performance of molecular ZIKV diagnostics.
As ZIKV and other arboviruses (e.g., DENV, CHIKV) co-circulate affecting many endemic
countries and at-risk countries globally, being a risk for local populations and international travelers,
it is important that laboratories can accurately detect and differentiate to avoid false positive results,
potentially having serious consequences for patients as exemplified by a dramatic increase in
abortion requests in South America during the 2016 ZIKV outbreak [31]. Regular participation
in EQA schemes by laboratories is important to monitor the improvement in laboratory performance;
also, for laboratories outside endemic regions a regular EQA participation would provide confidence
in tests when positive samples are not routinely seen.
Laboratories should be aware of the limitation of their assays and perform their own validation
and verification in line with ISO 15189 and other requirements. Continually offered EQA programmes
for arbovirus diagnostics are an important tool to improve laboratory performance and to increase
preparedness having quality-assured assays disponible for effective patient management, infection
and outbreak control.
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Abstract: We have developed a generalizable “smart molecular diagnostic” capable of accurate
point-of-care (POC) detection of variable nucleic acid targets. Our isothermal assay relies on
multiplex execution of four loop-mediated isothermal amplification reactions, with primers that are
degenerate and redundant, thereby increasing the breadth of targets while reducing the probability
of amplification failure. An easy-to-read visual answer is computed directly by a multi-input Boolean
OR logic gate (gate output is true if either one or more gate inputs is true) signal transducer that
uses degenerate strand exchange probes to assess any combination of amplicons. We demonstrate
our methodology by using the same assay to detect divergent Asian and African lineages of
the evolving Zika virus (ZIKV), while maintaining selectivity against non-target viruses. Direct
analysis of biological specimens proved possible, with crudely macerated ZIKV-infected Aedes aegypti
mosquitoes being identified with 100% specificity and sensitivity. The ease-of-use with minimal
instrumentation, broad programmability, and built-in fail-safe reliability make our smart molecular
diagnostic attractive for POC use.
Keywords: point-of-care diagnostics; isothermal nucleic acid amplification; nucleic acid computation;
nucleic acid strand exchange; zika virus; mosquito; mosquito surveillance; multiplex nucleic acid
detection; boolean logic-processing nucleic acid probes
1. Introduction
While point-of-care (POC) diagnostic assays can be performed at or near the site of sample
acquisition, they have for the most part been considered to be relatively simplistic tests that provide
relatively little information to a clinician or public health worker. Familiar examples include
electrochemical sensors for glucose [1] or rapid immunoassays for metabolites such as human chorionic
gonadotropin (the canonical pregnancy test) [2], and pathogens, either directly (influenza viruses and
Zika virus) or via immune responses (antibodies against HIV-1/2) [3–5]. The range of conditions and
pathogens that could be tested for could likely be greatly expanded by developing POC diagnostics for
nucleic acids [3] that would have greater sensitivity and accuracy. However, the current gold standard
for molecular diagnostics, the quantitative polymerase chain reaction (qPCR), requires significant
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technical expertise and expensive and cumbersome equipment. Even portable instruments, such
the Cepheid GeneXpert Omni, cost several thousand dollars and rely on expensive qPCR cartridge
consumables for individual tests.
In contrast, isothermal nucleic acid amplification tests (iNAATs) have been developed that rival
PCR in sensitivity, cost far less, and do not necessarily rely on complex instrumentation [6]. To further
the adoption of these assays, we and others have begun to develop “smart molecular diagnostics” that
can integrate information at the molecular level. For example, to increase signal specificity, a variety of
sequence-specific probes, including molecular beacons, nuclease-dependent probes, and fluorescence
resonance energy transfer (FRET) pairs have been adapted to isothermal amplification assays such
as rolling circle amplification (RCA), recombinase polymerase amplification (RPA), or loop-mediated
amplification (LAMP) [7–9]. More recently, RNA-guided CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats) enzymes, such as Cas13a and Cas12a, have been used to signal the presence
of isothermally generated amplicons [10,11].
In our own previous work, we developed oligonucleotide strand displacement (OSD) probes [12] that
were triggered by strand exchange reactions with transiently single-stranded stem-loop sequences [13].
This led to the exquisitely sensitive detection of LAMP amplicons without interference [14]. Loop-
mediated amplification-OSD assays that can work with crude samples are especially appealing for POC
use [15,16]. These assays have been coupled to highly-sensitive and reliable “yes/no” output signals
such as fluorescence, glucose, or hCG (human chorionic gonadotropin) that can be readily read using
off-the-shelf cellphones, glucometers, or pregnancy test strips, respectively [14,15,17–21]. Toehold switch
RNA sensors have also been used to link iNAATs with in vitro reporter protein translation, leading to
colorimetric signals [22].
Even as these iNAAT tests move towards wider adoption, they all still face the same problem
as other POC assays, in that the answers they give are relatively simplistic. However, given that the
strand exchange reactions that underlie OSD probes were originally derived from far more complex
DNA computations [12,23–25], it may be possible to go beyond mere improvements in specificity and
to integrate additional desirable features directly into the molecular diagnostic itself, such that the
reaction helps to “compute” its own outcome. As examples, we have previously developed strand
exchange computation modules that can quantitate inputs to isothermal amplification reactions [26],
or that can integrate multiple molecular signals via Boolean logic operations [19].
We now attempt to take on real-world problems with computations that are embedded in the
smart molecular diagnostics themselves. It is unfortunately a fundamental fact that diagnostic
targets often evolve faster than assays designed to detect them. The resulting target sequence
variations can easily prevent recognition of assay primers and probes, leading to test failure and
false negative readouts, a problem which to date can only be solved via regular (and impractical)
assay updates [27,28]. For instance, primers and probes for all eight published reverse transcription
(RT) qPCR assays (qRT-PCR) for Zika virus (ZIKV) were found to have numerous mismatches with
multiple ZIKV genomes sequenced from recent outbreaks [29]. Although most mismatched alleles
were common among all outbreak samples and had likely appeared prior to entry of ZIKV into the
Americas, new mutations were also found. Most of these were detected in fewer than 10% of samples,
but one new mutation appeared in as many as 29% of the samples [29]. These data suggest that
continuing viral genome evolution could lead to accumulation of mismatches with diagnostic assay
oligonucleotides, which might in turn decrease amplification efficiency and assay sensitivity [30–32].
Limited sensitivity of diagnostic tests combined with relatively low viral loads may cause a significant
number of ZIKV-infected patients to remain undiagnosed [28].
To overcome this problem and increase the overall accuracy of POC nucleic acid testing we
have engineered additional computations into our smart molecular diagnostics that can compute the
presence of almost any ZIKV variant. Strategic degenerate bases in 21 multiplex primers allow the
amplification of multiple ZIKV viral genes and gene variants in four, simultaneous LAMP reactions.
The presence of any positive signal is calculated by multi-input Boolean “OR”-gated logic processors
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in a single reaction that directly analyzes crude biological samples and provides a visual yes/no
readout for any ZIKV variant within 60–90 min. As with previous LAMP-OSD assays, the exquisite
sequence-specificity of oligonucleotide strand exchange probes ensures signal specificity, while the
built-in assay redundancy of the molecular logic processors guards against false negatives.
To demonstrate the utility of this smart molecular diagnostic we detected both Asian and African
lineage ZIKVs, which can differ by as much as 12% [33], and cleanly distinguished them from otherwise
related and often co-circulating dengue virus (DENV) and chikungunya virus (CHIKV). Pilot studies
with un-infected and ZIKV-infected Aedes aegypti mosquitoes suggest that the integrated computations
performed by our smart molecular diagnostic yielded results that are on par with qRT-PCR and
demonstrate 100% specificity and sensitivity.
2. Materials and Methods
2.1. Chemicals and Reagents
All chemicals were of analytical grade and were purchased from Sigma–Aldrich (St. Louis, MO,
USA) unless otherwise indicated. All enzymes and related buffers were purchased from New England
Biolabs (NEB, Ipswich, MA, USA) unless otherwise indicated. All oligonucleotides and gene blocks
(summarized in Supplementary Tables S1–S4) were obtained from Integrated DNA Technologies (IDT,
Coralville, IA, USA). Virus genomic RNA and inactivated virions (Supplementary Table S5) were
obtained from BEI Resources (Manassas, VA, USA).
2.2. Cloning of gBlocks and PCR Amplification of Transcription Templates
The gBlock double stranded DNA surrogates of ZIKV sequences were designed to include a T7
RNA polymerase promoter at their 5’-ends. These gBlocks were cloned into the pCR2.1-TOPO vector
(Fisher Scientific, Hampton, NH, USA) by Gibson assembly (NEB) according to the manufacturer’s
instructions [34]. Cloned plasmids were selected and maintained in an E. coli Top10 strain. Plasmid
minipreps were prepared from these strains using Qiagen miniprep kit (Qiagen, Valencia, CA, USA).
All gBlock inserts were verified by Sanger sequencing at the Institute of Cellular and Molecular Biology
Core DNA Sequencing Facility.
For performing in vitro run-off transcription, ZIKV gene segments cloned in a pCR2.1-TOPO
vector were amplified from sequenced plasmids by PCR using Phusion DNA polymerase. The PCR
products were verified by agarose gel electrophoresis and then purified using the Wizard SV gel and
PCR clean-up system (Promega, Madison, WI, USA), according to the manufacturer’s instructions.
2.3. In Vitro Transcription
Some 1000 ng of purified linear, double-stranded DNA transcription templates were transcribed
using the HiScribe T7 High Yield RNA synthesis kit (NEB) according to the manufacturer’s instructions.
Transcription was allowed to occur at 37 ◦C for 2 h. Subsequently the transcription reactions were
incubated with 2 units of DNase I (NEB) at 37 ◦C for 30 min to degrade the template DNA prior to
RNA gel purification.
2.4. Denaturing Polyacrylamide Gel Electrophoresis and RNA Gel Purification
Denaturing 8% polyacrylamide gels containing 7 M urea were prepared using 40% acrylamide
and bis-acrylamide solution, 19:1 (Bio-Rad) in 1× TBE buffer (89 mM Tris Base, 89 mM
Boric acid, 2 mM EDTA, pH 8.0) containing 0.04% ammonium persulphate and 0.1% TEMED
(N,N,N′,N′-Tetramethylethylenediamine). An equal volume of 2× denaturing dye (7 M urea, 1× TBE,
0.1% bromophenol blue) was added to the RNA samples. These were incubated at 65 ◦C for 3 min
followed by cooling to room temperature before electrophoresis. The RNA bands were demarcated
using UV shadowing. Desired bands were excised from the gel and the RNA was eluted twice into
Tris-EDTA (TE) (10:1, pH 7.5) buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8.0) by incubation
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at 70 ◦C and 1000 rpm for 20 min. Acrylamide traces were removed by filtering eluates through
Ultrafree-MC centrifugal filter units (EMD Millipore, Billerica, MA, USA) followed by precipitation
with 2× volume of 100% ethanol in the presence of both 15 μg GlycoBlue (Thermo Fisher Scientific,
Waltham, MA, USA) and 0.3 M sodium acetate, pH 5.2. RNA pellets were washed once in 70% ethanol.
Dried pellets of purified RNA were resuspended in 0.1 mM EDTA and stored at −80 ◦C.
2.5. LAMP Primer and Strand Exchange Probe Design
Zika virus genomic sequences were analyzed for variation using the National Center for
Biotechnology Information (NCBI) Virus Variation Resource [35]. Zika virus sequences were also
compared to related and co-circulating viruses, such as DENV and CHIKV, using MUSCLE [36,37].
Four relatively conserved genomic regions in ZIKV capsid, NS1, NS3, and NS5 genes were chosen
for primer design. The Primer Explorer v5 LAMP (loop-mediated isothermal amplification) primer
design software (Eiken Chemical Co., Tokyo, Japan) was used for generating LAMP primer sets
composed of the outer primers F3 and B3 and the inner primers FIP (forward inner primer) and BIP
(backward inner primer). Primer design was constrained to include at least a 40 base pair (bp) gap
between the F1 and F2 as well as between the B1 and B2 priming sites. Loop primers and stem primers
were manually designed. Primer specificity for ZIKV isolates and a corresponding lack of significant
cross-reactivity to other nucleic acids of human or pathogenic origin was further assessed using NCBI
BLAST [38,39]. Polymorphic loci in the primers were substituted with degenerate bases, although
some polymorphisms near the 5’-end of F3 or B3 or near the middle of FIP or BIP were ignored to
reduce the degeneracy burden and to ensure efficient amplification [17]. Our previous work had
shown that such mismatches minimally disrupted LAMP primer efficiency [17].
The nucleic acid circuit design software NUPACK [40] was used to design four OSD probes, each
specific to one of the four ZIKV amplicons, according to our previously published design rules [14].
Unique, fluorophore-labeled OSD strands were designed to bind between B1 and B2 sequences of NS5 and
NS3 amplicons and between F1 and F2 sequences of NS1 and capsid amplicons. The quencher-labeled OSD
strands were designed to be partially complementary to the fluorophore-labeled strand. Single-stranded
toeholds at the 3’-end or 5’-end of fluorophore-labeled strands were designed to be 10 or 13 nucleotides
long. All 3’-OH ends were blocked with inverted deoxythymidine (dT) to prevent extension by DNA
polymerase. Polymorphic loci in all four OSD probes were substituted with appropriate degenerate
bases. These degenerate OSD probe strands were then used as a basis for designing the two-input 2GO
and four-input 4GO probes. The web application NUPACK was used to visualize and optimize probe
architecture with variables such as buffer composition, temperature, and oligonucleotide concentrations.
2.6. Assembly of Strand Exchange Probes
The OSD probes were prepared by annealing 1 μM of the fluorophore-labeled OSD strand with
5 μM of the quencher-labeled strand in 1× isothermal buffer (NEB: 20 mM Tris-HCl, 10 mM (NH4)2SO4,
50 mM KCl, 2 mM MgSO4, 0.1% Tween 20, pH 8.8 at 25 ◦C). Annealing was performed by denaturing
the oligonucleotide mix at 95 ◦C for 1 min followed by slow cooling at the rate of 0.1 ◦C/s to 25 ◦C.
Excess annealed probe was stored at −20 ◦C.
The CAN3.2GO probe was assembled by annealing 4 μM of CAN3.2GO.Gate oligonucleotide
with 6 μM of the quencher-labeled CAN3.2GO.Q oligonucleotide and 2 μM of the fluorophore-labeled
CAN3.2GO.FAM oligonucleotide. Similarly, the N1N5.2GO probe was assembled by annealing 6 μM
of N5N1.2GO.Gate oligonucleotide with 8 μM of the quencher-labeled N5N1.2GO.Q oligonucleotide
and 2 μM of the fluorophore-labeled N5N1.2GO.FAM oligonucleotide. The three oligonucleotide
components of each 2GO probe were mixed in 1× isothermal buffer supplemented with 8 mM MgSO4
and incubated for 1 min at 95 ◦C. The mixture was then slowly cooled at the rate of 0.1 ◦C/s to 25 ◦C.
Excess annealed 2GO probes were stored at −20 ◦C.
The 4GO probe was assembled by annealing 4 μM of the 4GO.S1 strand, 1 μM of the fluorophore-
labeled 4GO.S2 strand, 4 μM of the quencher-labeled 4GO.S3 strand, 4 μM of the 4GO.S4 strand, and
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3 μM of the 4GO.S5 strand. All oligonucleotides were mixed in 1× isothermal buffer supplemented
with 8 mM MgSO4 and incubated for 1 min at 95 ◦C. The mixture was then slowly cooled at the rate of
0.1 ◦C/s to 25 ◦C. Excess annealed 4GO probes were stored at −20 ◦C.
2.7. RT-LAMP Assay
All RT-LAMP assays were assembled in 25 μL reactions containing 1× isothermal buffer
supplemented with 1.4 mM deoxyribonucleotides (dNTPs), 0.4 M betaine, 6 mM additional MgSO4,
16 units of Bst 2.0 DNA polymerase (NEB), and 7.5 units of warmstart RTx reverse transcriptase
(NEB). Reactions containing primers for only one target gene were appended with 2.4 μM each of a
single type of FIP and BIP primer (NS5 assay utilized 4.8 μM BIP), 1.2 μM of the corresponding loop
primer, 1.2 μM of the corresponding stem primer (only for the capsid assay), and 0.6 μM each of the
corresponding F3 and B3 primer. Primer-containing multiplex LAMP reactions received 0.6 μM of
each of the four FIP and BIP primers (NS5 BIP primer was added at 1.2 μM concentration), 0.3 μM
of each of the four loop primers, 0.3 μM of the capsid stem primer, and 0.15 μM each of the four F3
and B3 primers. The total primer content of these multiplex assays was similar to individual primer
concentrations used in LAMP reactions for single target genes. Control assays lacking primers received
equivalent volume of TE 10:0.1 buffer (10 mM Tris, pH 7.5, and 0.1 mM EDTA pH 8.0).
Loop-mediated amplification assays read using OSD reporters received 200 nM of the
fluorophore-labeled strand annealed with a five-fold excess of the complementary quencher-labeled
strand (see Section 2.6.). Multiplex LAMP-OSD assays received 50 nM of each of the four fluorophore-
labeled OSD strands pre-annealed individually with five-fold excess of their corresponding
quencher-labeled complementary strands.
Assays analyzed using 2GO probes were supplemented with 50 mM trehalose and 100 nM of the
fluorophore-labeled probe strand pre-annealed with the complementary gate and quencher-labeled
oligonucleotides as described in Section 2.6. Multiplex assays read using the complete bipartite signal
transducer contained 100 nM each of both CAN3.2GO and N1N5.2GO probes. Assays read using 4GO
probes were also supplemented with 50 mM trehalose along with 80 nM of the fluorophore-labeled
strand annealed with the remaining four strands of the 4GO probe as described in Section 2.6.
Real-time measurement of fluorescence accumulation was performed using the LightCycler96
real-time PCR machine (Roche, Basel, Switzerland). Reactions were subjected to isothermal
amplification by programming 45 cycles of 150 sec at 65 ◦C (step 1) followed by 30 sec at 65 ◦C (step 2).
Fluorescence was measured in the FAM (Fluorescein) channel during step 2 of each amplification cycle.
Post-amplification reporter fluorescence was also monitored by programming the LightCycler96 to
hold the assays at 37 ◦C for 40 min.
Loop-mediated amplification-based assays intended for visual readout and smartphone imaging
were assembled in 0.2 mL optically clear thin-walled tubes with low auto-fluorescence (Axygen, Union
City, CA, USA). Following 90–120 min of incubation in a 65 ◦C heat block, the reactions were imaged
at room temperature using an unmodified iPhone 6 and an UltraSlim-LED (light emitting diode)
transilluminator (Syngene, Frederick, MD, USA). In some experiments, our previously described
in-house 3D-printed imaging device [15] was used for fluorescence visualization and smartphone
imaging. Briefly, this device uses Super Bright Blue 5-mm light emitting diodes (LED) (Adafruit,
New York, NY, USA) to excite fluorescence. Two cut-to-fit layers of inexpensive >500 nm bandpass
orange lighting gel sheets (Lee Filters, Burbank, CA, USA) placed on the observation window filter the
fluorescence for observation and imaging.
The following ZIKV templates were analyzed by LAMP-OSD, LAMP-2GO, and LAMP-4GO assays:
(i) zero to several thousands of copies of ZIKV synthetic RNA or genomic RNA in TE 10:0.1 buffer. Zika
virus genomic RNA preparations, obtained from BEI Resources, were contained in a background of
cellular nucleic acid and carrier RNA that were isolated from preparations of cell lysates and supernatants
from Cercopithecus aethiops kidney epithelial cells (Vero 76, clone E6: ATCC ® CRL-1586™) infected with
specific ZIKV (Supplementary Table S5); (ii) ZIKV virions in TE 10:0.1 buffer; (iii) un-infected and
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ZIKV-infected Ae. aegypti mosquitoes (see Section 2.10.). Negative controls included (i) assays without
any templates; (ii) assays with non-specific templates including synthetic RNA, DENV genomic RNA,
and CHIKV genomic RNA; and (iii) assays with non-specific amplicons (generated by substituting with
a non-specific template and its cognate LAMP primer set).
2.8. TaqMan qRT-PCR Analysis
The previously reported ZIKV NS2b-specific TaqMan qRT-PCR assay (Supplementary Table S4) [41]
was performed using either the Evoscript RNA Probes Master (Roche, Basel, Switzerland) or the TaqMan
RNA-to-Ct 1-Step Kit (Thermo Scientific, Waltham MA, USA). Standard curves were prepared using
a ten-fold dilution series of 105 to 10 copies of a synthetic RNA template (Supplementary Table S4).
Reactions without any templates served as negative controls. These templates were subjected to
one-step qRT-PCR in 10 μL reactions containing 800 nM each of forward (Zika4481_F) and reverse
(Zika4552c_R) primers along with 200 nM of the TaqMan probe (Zika4507cTqMFAM). Amplification
was performed by adding either (i) 2 μL of the 5× Evoscript RNA probes Master or (ii) 0.25 μL of the
40X TaqMan RT Enzyme Mix (Thermo Scientific) along with 5 μL of the 2× TaqMan RNA-to-Ct 1-Step
master mix. Reactions were incubated for 30 min at 60 ◦C followed by 10 min at 95 ◦C. Subsequently
45 cycles of 15 sec at 95 ◦C and 30 sec at 55 ◦C were performed. TaqMan fluorescence was measured
during the second step of each cycle. Reactions containing Evoscript RNA Probes Master were analyzed
using the LightCycler96 qPCR machine while TaqMan RNA-to-Ct 1-Step assays were performed on the
StepOnePlus real-time PCR machine (Thermo Scientific).
2.9. Analysis of ZIKV Virions
Heat-inactivated virions of Asian ZIKV strain PRVABC59 (BEI Resources, Manassas, VA, USA)
were used as templates for LAMP-based assays and for one-step qRT-PCR. Virions were diluted in TE
10:0.1 buffer prior to being directly added to LAMP-based and qRT-PCR reactions.
2.10. Rearing and Analysis of ZIKV-Infected Mosquitoes
Aedes aegypti mosquitoes were reared under conventional conditions in the insectary at the
University of Texas medical Branch, Galveston, TX, USA. To obtain ZIKV-infected insects, mosquitoes
were starved for a period of 24 hours and then offered a sheep blood meal (Colorado Serum Company,
Denver, CO, USA) containing 106 virions using a hemotek membrane system (Hemotek). Un-infected
mosquitoes received a blood meal that did not contain virus. After 14 days, mosquitoes were collected
and immediately frozen at −80 ◦C. Prior to molecular testing, each mosquito was heated for 10 min
at 60 ◦C in order to inactivate the Zika virus [42] for compliance with biosafety level 2 requirements.
Each mosquito was then manually crushed in a 1.7 mL microcentrifuge tube using a disposable
micropestle (Fisherbrand™ RNase-Free Disposable Pellet Pestles, Catalog number 12-141-364, Fisher
Scientific, Hampton, NH, USA). Each macerated mosquito was re-suspended in 100 μL water. A 2 μL
aliquot of this mosquito sample was directly assessed by Ae. aegypti coi LAMP-OSD assay in both
primer-containing and primer-free reactions. For ZIKV LAMP-based reactions and qRT-PCR assays,
3 μL mosquito samples were directly used as sources of templates. Both primer-containing and
primer-less LAMP-based assays were operated.
3. Results
3.1. Degenerate LAMP-OSD Assays for Detection of Asian and African Lineage ZIKV
Zika virus has an ~10 kilobase RNA genome encoding a polyprotein that is cleaved into
ten structural and non-structural (NS) proteins: 5’-Capsid (C)-preMembrane (prM)-Envelope
(E)-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3’. Zika virus clusters into two African lineages and
one Asian lineage that includes the current epidemic strains [33]. The Asian and African lineages
of ZIKV show 0.2% to 10.6% intra-lineage and 4.5% to 12.1% inter-lineage nucleotide variation [33].
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The epidemic strains have accumulated additional changes and have potentially undergone multiple
natural recombinations [33,43]. The strains are likely continuing to evolve, presenting a challenging
target for surveillance and diagnostics. Here, we designed four reverse transcription (RT) LAMP
assays to amplify relatively conserved regions in four ZIKV genes—capsid (CA), NS1, NS3, and NS5.
Each individual assay included two inner primers (FIP and BIP), two outer primers (B3 and F3),
and one loop primer (LP). The CA LAMP assay utilized an additional sixth primer, termed stem
primer [44] (SP), complementary to the target region between F1 and B1 priming sites (Figure 1A).
Specific nucleotide positions within these primers were substituted with degenerate nucleobases to
allow pairing with variant ZIKV RNA (Supplementary Table S1). The NS3 LAMP primer set had
the lowest degeneracy with only 10 positions varying between two nucleobases and one position
varying between three nucleobases. Twelve positions in the NS1 LAMP primer set varied between two
nucleobases. The CA LAMP primers had a slightly higher degeneracy with 13 polymorphic positions
varying between two bases. The NS5 primer set was the most degenerate with 15, 6, and 1 positions
varying between two, three, or four bases, respectively.
Figure 1. Schematic depicting (A) loop-mediated isothermal amplification (LAMP) integrated with (B)
one-, (C) two-, or (D) four-input oligonucleotide strand exchange signal transducers. LAMP uses 2 inner
(FIP and BIP) and 2 outer (F3 and B3) primers along with the optional stem (SP) and loop (LP) primers
to prime strand displacement DNA amplification by Bst DNA polymerase. The resulting continuous
amplification (initiated by both new primer-binding and by self-priming) generates double-stranded
concatameric amplicons containing single-stranded loops to which non-priming oligonucleotide strand
exchange signal transducers can hybridize. The one-input OSD signal transducer composed of one
long and one short DNA strand can hybridize to a single LAMP amplicon loop sequence leading to
separation of the fluorophore (F) and quencher (Q). The OR Boolean logic processing two-input strand
exchange transducer, 2GO, is composed of two labeled strands, SI and SII, and a third bridging strand
SIII. Either SI and/or SII can hybridize to their specific LAMP loop sequences resulting in separation
of F and Q. The four-input 4GO probe composed of 5 DNA strands (S1–S5) can hybridize to any
combination of up to four different LAMP amplicon loops and perform an OR Boolean operation to
produce fluorescence signal. The 4GO probe is denoted in terms of lettered domains (a–g), each of
which represents a short fragment of DNA sequence in an otherwise continuous oligonucleotide strand.
Complementarity is denoted by a single prime symbol.
To ensure readout specificity, individual hemiduplex OSD probes [14] were designed for each of
the four ZIKV LAMP amplicons (Figure 1B). To facilitate detection of LAMP amplicons from different
viral lineages, probe nucleotide positions corresponding to polymorphic target loci were substituted
with degenerate bases (Supplementary Table S2). The NS3 OSD probe was the least degenerate with
only two positions in the long and the short probe strands varying between two bases. The capsid
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OSD probe contained two nucleotide variations at four and two positions in the long and the short
strand, respectively. Three positions in both the long and the short strands of the NS5 OSD probe
varied between two bases. The NS1 OSD probes displayed the greatest degeneracy with four positions
in both the long and the short strands varying between two bases.
Performance of these four degenerate reverse transcription LAMP-OSD assays was optimized in
individual amplification reactions containing different amounts of synthetic target RNA derived from
ZIKV genomic sequences (Supplementary Table S3). All four assays could detect a few hundred copies
of synthetic target RNA within 60 min without producing spurious signal (Figure 2). Furthermore, the
high signal amplitude and low noise allowed simple yes/no visual readouts and cellphone imaging of
these assays—target RNA yielded bright visible fluorescence while assays lacking specific templates
remained dark (Figure 2).
Figure 2. Detection of Zika virus capsid, NS1, NS3, and NS5 genes using real-time and visually-read
reverse transcription LAMP-OSD assays. Indicated copies of capsid (A), NS3 (B), NS1 (C), and NS5 (D)
synthetic RNA templates were amplified by degenerate LAMP-OSD assays specific to each template.
OSD fluorescence signals measured in real-time during LAMP amplification are depicted as red (105
template copies), blue (104 template copies), orange (103 template copies), gray (100 template copies),
and black (0 template copies; 106 non-template RNA) traces. The x-axis depicts the duration of LAMP
amplification. OSD fluorescence was also imaged at amplification endpoint using a cellphone (images
depicted at the bottom of each panel). Numbers on each assay tube in these images indicate the RNA
template copies used. Representative results from three replicate experiments are depicted.
To verify that all the four assays could identify both Asian and African lineage ZIKV genomes
we individually challenged NS1, NS3, NS5, and CA LAMP-OSD assays with genomic RNA from
nine Asian ZIKV, and two African ZIKV strains (Supplementary Table S5). Reaction specificity was
assessed by seeding duplicate assays with genomic RNA of related dengue virus (DENV) serotypes 1–4
and chikungunya virus (CHIKV) that often co-circulate with ZIKV [45]. Endpoint OSD fluorescence
in all LAMP assays seeded with Asian or African ZIKV genomes was significantly elevated above
background noise in assays seeded with DENV or CHIKV genomic RNA (Figure 3). These results
478
Viruses 2018, 10, 714
demonstrate that all four degenerate LAMP-OSD assays were capable of lineage-independent ZIKV
detection without cross-reaction with or interference from non-target nucleic acids. In contrast,
LAMP-OSD assays containing non-degenerate versions of the same primers demonstrated reduced
breadth of detection. The capsid and NS3 assays recognized only Asian lineages. The NS1 assay
recognized all Asian lineage and one of the two African lineage ZIKV genomes. Meanwhile, the
NS5 assay recognized both the African lineage genomes while failing to give a signal with any Asian
lineage ZIKV (Supplementary Figure S1).
Figure 3. Detection of Asian and African lineage ZIKV using degenerate reverse transcription
LAMP-OSD assays. Genomic RNA from DENV, CHIKV, or Asian or African lineage ZIKV (indicated
by their GenBank accession numbers) were used as templates for amplification in degenerate
RT-LAMP-OSD assays for Zika virus capsid, NS1, NS3, and NS5 genes. OSD fluorescence signals
measured at amplification endpoint using LightCycler 96 real-time PCR machine are depicted as blue
(capsid), orange (NS1), gray (NS3), and yellow (NS5) bars. Representative results from three replicate
experiments are depicted.
3.2. Multiplex LAMP with Degenerate Primers and OSD Probes
To create a multiplex, internally redundant assay that simultaneously amplifies and detects CA,
NS1, NS3, and NS5 sequences, all 21 LAMP primers and 4 hemi-duplex OSD reporters were combined
in a single reaction (multiplex LAMP-OSD). To verify that each individual reverse transcription
LAMP-OSD reaction was functional in this multiplex environment, replicate multiplex assays were
supplemented with all 21 primers but only a single type of OSD reporter at a time. In the presence of
all four ZIKV synthetic RNA templates, multiplex LAMP-OSD demonstrated exponential fluorescence
accumulation. Despite co-mingling of multiple degenerate primers and OSD probes, no spurious
signals were observed in the absence of specific templates (Figure 4A). As a result, brightly fluorescent
ZIKV-positive assays containing only a few hundred copies of ZIKV templates could be readily
distinguished from dark ZIKV-negative reactions by simple visual examination (Figure 4B). Each
individual LAMP assay was functional in the multiplex assay, as indicated by accumulation of
fluorescence in multiplex LAMP-OSD reactions probed with individual OSD reporters (Figure 4C–F).
The multiplex LAMP-OSD assay could also readily identify the more complex ZIKV genomic RNA
from both Asian and African lineages without cross-reaction with DENV and CHIKV genomic nucleic
acids (Figure 4G).
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Figure 4. Simultaneous detection of four Zika virus genes using multiplex reverse transcription
degenerate LAMP-OSD (multiplex LAMP-OSD) assay. (A) Real-time multiplex LAMP-OSD—synthetic
RNA mixtures containing indicated copies of each of the four ZIKV synthetic RNA templates (CA,
NS1, NS3, and NS5) were amplified using multiplex LAMP-OSD assays containing 21 degenerate
primers and 4 degenerate OSD probes for simultaneous LAMP amplification and sequence-specific
detection of all four ZIKV targets. OSD fluorescence signals measured in real-time during LAMP
amplification are depicted as blue (10,000 copies each of CA, NS1, NS3, and NS5 RNA) and orange
(0 ZIKV RNA; 106 copies of DENV RNA) traces. The x-axis depicts the duration of LAMP amplification.
(B) Endpoint multiplex LAMP-OSD assay with visual detection—synthetic RNA mixtures containing
indicated copies of each of the four ZIKV synthetic RNA templates (CA, NS1, NS3, and NS5) were
amplified using degenerate multiplex LAMP-OSD assays. OSD fluorescence was imaged after 90 min
of amplification using a cellphone. Numbers above each assay tube indicate the RNA template copies
used. The reaction with ‘0’ ZIKV RNA received 106 copies of DENV RNA. (C-F) Performance of
individual assays in the multiplex LAMP-OSD system—synthetic RNA mixtures containing indicated
copies of each of the four ZIKV synthetic RNA templates (CA, NS1, NS3, and NS5) were amplified
using multiplex LAMP-OSD assays containing LAMP primers for all four targets but only one type of
OSD for either capsid (C), NS1 (D), NS3 (E), or NS5 (F) amplicons. OSD fluorescence signals measured
in real-time during LAMP amplification are depicted as blue (10,000 copies each of CA, NS1, NS3,
and NS5 RNA) and orange (0 ZIKV RNA; 106 copies of DENV RNA) traces. The x-axis depicts the
duration of LAMP amplification. (G) Detection of Asian and African lineage ZIKV genomic RNA using
degenerate multiplex LAMP-OSD assays. Genomic RNA from DENV, CHIKV, or Asian or African
lineage ZIKV (indicated by their GenBank accession numbers) were used as templates for amplification.
Real-time OSD fluorescence signals are depicted as blue (Asian), red (African), black (CHIKV), and
green (DENV) traces. The x-axis depicts the duration of LAMP amplification. For all experiments,
representative results from three replicate tests are depicted.
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3.3. Multiplex LAMP with Degenerate Primers and Four-Input Logic-Processing Probes
After functionally verifying the feasibility of multiplex reverse transcription LAMP-OSD using
degenerate primers and OSD probes, we sought to reduce reaction cost and enhance assay versatility
by replacing the four individual OSD probes with a single four-input OR Boolean logic-processing
strand exchange probe (4GO) that would “compute” the presence of ZIKV by simultaneously looking
across CA, NS1, NS3, and NS5 amplicons for similarity to the probe. Unlike four individual OSDs that
required a combination of 8 fluorophore or quencher-labeled oligonucleotides, the three-way junction
4GO probe would need a single fluorophore-quencher pair (Figure 1). If either CA, NS1, NS3, or NS5
amplicon was similar enough to initiate strand exchange, the fluorophore would separate from the
quencher and the 4GO probe would light up.
The 4GO probe was composed of 5 oligonucleotides (S1–S5) with a total of 19 degenerate loci
that varied between two nucleobases (Supplementary Table S2). Oligonucleotides S1–S4, designed
based on validated degenerate OSD sequences, served as strand exchange probes for NS1, NS5,
CA, and NS3 amplicons, respectively. The S5 strand acted as a scaffold for 4GO probe assembly
(Figure 1D). Domain c at the 5’-end of S5 was complementary to domain c’ in S1, while, domain f
at the 3’-end of S5 was complementary to domain f ’ of the S4 strand. The intervening region of S5
contained two short target-independent sequences—domain d complementary to domain d’ at the
fluorophore-labeled 5’-end of S2 and domain e complementary to domain e’ at the quencher-labeled
3’-end of S3. Concomitant hybridization of S2 and S3 to S5 would juxtapose the fluorophore and
quencher leading to loss of signal. However, at temperatures ≥20 ◦C, pairing of S2 and S5 was
contingent upon formation of a three-way junction with S1 via interactions between complementary
S2 domain a’ with S1 domain a and S5 domain c with S1 domain c’. Similarly, stable interaction of S3
and S5 was dependent upon a three-way hybridization with S4. As a result, strand exchange between
the 4GO probe and any one or more of the ZIKV amplicons would separate the fluorophore-bearing S2
from quencher-labeled S3. For example, the NS5 LAMP amplicon loop would directly remove S2 from
the 4GO probe. Meanwhile, by binding S1, the NS1 amplicons would destroy the three-way junction
between S1, S2, and S5. Consequently, the 4GO probe would transduce the presence of one or any
combination of the four ZIKV amplicons into a single-channel endpoint fluorescence that could be
easily read at ambient temperature.
To test 4GO probe function, multiplex reverse transcription LAMP reactions containing all 21
degenerate primers and the degenerate 4GO probe (multiplex LAMP-4GO) were spiked with a single
type or a combination of all four of the ZIKV synthetic RNA templates NS1, NS3, NS5, and CA.
As a control to assess signal specificity, duplicate reactions were assembled using a non-specific RNA
template and its cognate LAMP primers that would lead to generation of non-specific LAMP amplicons.
Following LAMP amplification, 4GO probe fluorescence was found to be elevated in all reactions
containing even a few hundred copies of at least one of the ZIKV templates (Figure 5A–E). This
ZIKV-specific signal remained consistently above noise generated in the absence of specific amplicons.
These results demonstrate that the 4GO probe was able to function specifically in multiplex LAMP to
identify and signal the presence of a few hundred copies of one or all four ZIKV amplicons without
interference from non-specific templates or amplicons.
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Figure 5. Simultaneous detection of four Zika virus genes using degenerate 4GO probes and multiplex
degenerate reverse transcription LAMP (multiplex LAMP-4GO) assays. Indicated copies of capsid,
NS1, NS3, and NS5 synthetic target RNA were amplified either individually (panels A–D, respectively)
or as a mixture (panel E) using multiplex LAMP-4GO assays containing LAMP primers for all four
ZIKV targets and the four-input 4GO probe. 4GO probe fluorescence, measured in real-time at 37 ◦C
after 90 min of LAMP amplification, is depicted as red (10,000 template copies), blue (1,000 template
copies), yellow (100 template copies), and black (non-specific LAMP primers with 105 copies of its
target RNA) traces. The x-axis depicts the duration of endpoint signal measurement. (F) Detection
of Asian and African lineage ZIKV genomic RNA using degenerate multiplex LAMP-4GO assays.
Genomic RNA from DENV, or Asian or African lineage ZIKV (indicated by their GenBank accession
numbers) were used as templates for amplification. 4GO probe fluorescence, measured in real-time
at 37 ◦C after 90 min of LAMP amplification, is depicted as blue (Asian), red (African), and green
(DENV) traces. The x-axis depicts the duration of endpoint signal measurement. (G) Detection of
Asian and African lineage ZIKV genomic RNA using TaqMan qRT-PCR assay specific for Asian lineage
ZIKV NS2b gene. Same amount of viral genomic RNA as was used in panel F were amplified and
real-time measurements of assay fluorescence are depicted as blue (Asian), red (African), and green
(DENV) traces. (H) Detection limit of degenerate multiplex LAMP-4GO assay for ZIKV genomic RNA.
Indicated copies of an Asian lineage ZIKV genome or non-specific DENV genomes were amplified
using multiplex LAMP-4GO assays. 4GO probe fluorescence, measured in real-time at 37 ◦C after
90 min of LAMP amplification, is depicted as blue (Asian) and black (DENV) traces with template
copies indicated by open squares (2000 genomes), open circles (189 genomes), and open diamonds
(2 genomes). The x-axis depicts the duration of endpoint signal measurement. For all experiments,
representative results from three replicate tests are depicted.
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The 4GO probes were also able to specifically identify all nine Asian and both African ZIKV
strains tested without cross reaction with related viruses (Figure 5F). Endpoint fluorescence signals in
all degenerate multiplex LAMP-4GO assays seeded with Asian or African lineage ZIKV genomic RNA
were consistently elevated above background noise in assays containing non-specific DENV genomes.
In contrast, a previously reported Asian ZIKV NS2b gene-specific TaqMan qRT-PCR assay [41] was
able to detect only Asian lineage viral genomes while failing to amplify African lineage genomic RNA
(Figure 5G). Asian genomic RNA copy numbers estimated from this qRT-PCR assay (Supplementary
Figure S2) suggested that multiplex LAMP-4GO assays could readily detect a few hundred copies of
viral genomes (Figure 5H). These results demonstrate that a single assay comprised of 21 degenerate
LAMP primers and a five-stranded degenerate logic processing strand exchange probe could reliably
detect viral variants within a genus and distinguish them from related viruses. Furthermore, by
integrating signals from four separate inputs into one output via a single fluorophore-quencher
pair, the five-stranded 4GO probe could capture the viral diversity at a fraction of the cost of four
individually-labeled OSD probes.
3.4. Multiplex LAMP with Degenerate Primers and Two-Input Logic-Processing Probes
Our results demonstrated that the multiplex LAMP-4GO assay could specifically identify both
Asian and African ZIKV without non-specific signaling. However, a fluorimeter was necessary for
assay readout due to the relatively high background noise of the 4GO probe. Therefore, we sought
to further engineer the logic processing probe in order to achieve a signal-to-noise ratio that could
be visually discriminated and thereby allowed easy “yes/no” assay readout in austere conditions
without complex instruments. We surmised that the fluorophore was insufficiently quenched in the
five-stranded 4GO probe due to its high degeneracy level. To reduce probe degeneracy, we engineered
a bipartite four-input signal processor composed of two OR gated strand exchange modules (2GO)
(Figure 1C). Each 2GO probe was comprised of three degenerate oligonucleotides (SI–SIII) that were
partially complementary to each other. The 5’-ends of both SI strands were labeled with the same
type of fluorophore while the 3’-ends of SII strands were labeled with the corresponding quencher
molecules. Simultaneous hybridization of SI and SII to the unlabeled SIII strand would juxtapose the
fluorophore and quencher resulting in loss of signal. Short single-stranded toeholds at the 3’- and
5’-ends of SI and SII, respectively, could independently initiate strand exchange with their cognate
target sequences resulting in separation of the fluorophore from the quencher and a concomitant
rise in signal. For instance, the CAN3.2GO probe fluorescence would increase if it underwent strand
exchange with either CA or N3 amplicons. Similarly, the N1N5.2GO probe would signal if either or
both NS1 and NS5 amplicons were present.
To functionally verify the bipartite signal processor, reverse transcription LAMP assays containing
the degenerate CAN3.2GO or the NS1NS5.2GO probes were supplemented with primers specific to
either ZIKV NS1, NS3, NS5, or CA genes. At amplification endpoint, fluorescence of CAN3.2GO probe
increased only in assays containing CA or N3 amplicons (Figure 6A). Meanwhile the N1N5.2GO probe
was activated only in the presence of NS1 or NS5 sequences. Both probes remained quenched in the
presence of non-specific LAMP amplicons. Moreover, amplicon-specific 2GO probe fluorescence could
be readily distinguished from non-specific noise simply by direct visual examination of assay tubes or
their cellphone images (Figure 6B).
The complete multiplex assay system (multiplex LAMP-2GO) containing 21 degenerate LAMP
primers and the bipartite signal processor (CAN3.2GO + N1N5.2GO) was tested using different
amounts of a synthetic RNA mixture containing all four ZIKV templates (NS1, NS3, NS5, and CA).
Assays containing only a few hundred copies of ZIKV RNA produced bright fluorescence that
could be readily captured using unmodified smartphone camera (Figure 6C). In contrast, assays
containing non-specific amplicons remained dark thereby allowing easy visual distinction from
ZIKV-positive assays.
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Figure 6. Detection of ZIKV RNA using two-input 2GO probes and degenerate reverse transcription
LAMP. (A) Sequence-dependent activation of 2GO probes—synthetic RNA mixtures of 106 copies of
CA, NS1, NS3, and NS5 RNA were amplified using individual or multiplex (Mx) degenerate LAMP
assays containing either one or both CAN3.2GO and N1N5.2GO probes. 2GO probe fluorescence
signals measured at amplification endpoint using LightCycler 96 real-time PCR machine are depicted
as blue (LAMP with only CAN3.2GO), orange (LAMP with only N1N5.2GO), and gray (LAMP
with both CAN3.2GO and N1N5.2GO) dots. LAMP primer specificities are indicated on the x-axis.
(B) Visual readout of degenerate LAMP-2GO assays. Cellphone image depicts 2GO probe fluorescence
at amplification endpoint in individual or multiplex ZIKV LAMP assays containing both CAN3.2GO
and N1N5.2GO probes and 106 copies of all four synthetic ZIKV RNA and a non-specific LAMP
assay (“Non”) containing its cognate RNA. (C) Detection limit of visually-read degenerate multiplex
LAMP-2GO assays. Cellphone image depicts endpoint 2GO probe fluorescence of multiplex degenerate
RT-LAMP assays containing primers and indicated template RNA copies of all four ZIKV targets.
The reaction without any ZIKV RNA contained a non-specific RNA and its cognate LAMP primers.
For all experiments, representative results from three replicate tests are depicted.
Similar to LAMP-OSD and multiplex LAMP-4GO assays, multiplex LAMP-2GO assays could
also detect all nine Asian and both African ZIKV strains tested while suppressing spurious signal
from dengue viruses (serotypes 1–4) (Figure 7A). Examination of endpoint smartphone images of
multiplex LAMP-2GO assays revealed that as few as 189 copies of a representative Asian ZIKV genomic
RNA (quantified using NS2b-specific TaqMan qRT-PCR) could be reliably identified using simple
yes/no visual readout of presence or absence of fluorescence (Figure 7B and Supplementary Figure S2).
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Similarly, African ZIKV genomic RNA could also be detected using smartphone imaged multiplex
LAMP-2GO assays (Figure 7B).
Figure 7. Detection of Asian and African lineage ZIKV genomes using degenerate multiplex
LAMP-2GO assays. (A) Genomic RNA from DENV, or Asian or African lineage ZIKV (indicated by
their GenBank accession numbers) were used as templates for amplification. 2GO probe fluorescence
signals measured at amplification endpoint using LightCycler 96 real-time PCR machine are depicted
as blue (Asian ZIKV), red (African ZIKV), and black (DENV) markers. (B) Detection limit of degenerate
multiplex LAMP-2GO assay for ZIKV genomic RNA. Indicated copies of an Asian lineage ZIKV
genome (left panel), indicated dilutions of an African ZIKV genome (right panel), and non-specific
DENV genomes (“Non”) were amplified using multiplex LAMP-2GO assays. 2GO probe fluorescence
was imaged at amplification endpoint using a cellphone. For all experiments, representative results
from three replicate tests are depicted.
3.5. Identification of ZIKV-Infected Mosquitoes using Cellphones and Smart Molecular Diagnostics
To evaluate assay performance in natural biological matrices, Ae. aegypti mosquitoes were fed
a blood meal spiked with ZIKV virions and then individually tested for viral nucleic acids after
14 days. Half of these mosquitoes that were exposed to ZIKV generated bright endpoint fluorescence
in both NS1 LAMP-OSD and capsid LAMP-OSD assays as well as in multiplex LAMP-2GO assays
(Figure 8, Supplementary Figure S3). Parallel tests performed in the absence of primers, and hence,
absence of LAMP amplification and concomitant probe activation, revealed negligible signal inflation
due to sample auto-fluorescence, indicating the positive LAMP signal was due to these mosquitoes
developing a viral infection. These mosquitoes also tested positive by ZIKV NS2b TaqMan qRT-PCR
assay and were found to contain ~6 × 103 to 4 × 105 NS2b RNA copies per mosquito (Figure 8).
Since only a 1/33 fraction of each mosquito was used for a LAMP test, these results suggest that the
LAMP-based assays were able to generate a readily discernable bright visible fluorescence starting from
as few as 190 copies of ZIKV genomic material embedded in crude virus-infected mosquito matrix.
Capsid and NS1 LAMP-OSD assays and multiplex LAMP-2GO assays of the remaining half of
the ZIKV-fed mosquitoes remained as dark as primer-less assays (Supplementary Figure S3). Our
LAMP-based assays were in 100% agreement with TaqMan qRT-PCR, which also failed to detect ZIKV
nucleic acids in these ZIKV-fed mosquitoes (Figure 8). These results suggest an absence of detectable
infection in these mosquitoes, which is consistent with previously reported infection rates [46–50].
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Specificity of LAMP-based assays was confirmed by analyzing six additional age-matched Ae. aegypti
mosquitoes that had not received a ZIKV-spiked blood meal and were negative for ZIKV when tested by
qRT-PCR. None of the uninfected mosquitoes triggered a false positive signal; LAMP assays containing
these uninfected mosquitoes remained indistinguishable from primer-less assays (Supplementary
Figure S3).
Figure 8. Detection of Zika virus-infected mosquitoes using individual- and multiplex degenerate
reverse transcription LAMP assays. Zika virus-infected (panels A–D) and uninfected (panels E–H)
Aedes aegypti mosquitoes were directly analyzed using NS1 and capsid LAMP-OSD assays or with
multiplex LAMP-2GO assays. As a positive control, mosquitoes were tested using the A. aegypti
coi LAMP-OSD assay (panels D and H). Smartphone images acquired after 2 h of amplification are
depicted. P: positive control; M+: mosquito analyte with LAMP primers; M-: mosquito analyte without
LAMP primers; N: no template control. Results of NS2b TaqMan qRT-PCR analysis of all mosquitoes
are tabulated.
Absence of signal in ZIKV-uninfected mosquitoes was not due to inhibition of amplification.
Both ZIKV-infected and uninfected mosquitoes generated bright fluorescence when tested using
a LAMP-OSD assay for Ae. aegypti mitochondrial cytochrome oxidase I (coi) gene [16] (Figure 8,
Supplementary Figure S3).
These results indicate that our smart molecular diagnostic assays perform at par with qRT-PCR
for direct analysis of ZIKV virions in infected mosquitoes. Similar to capsid and NS1 LAMP-OSD
assays, the multiplex LAMP-2GO assays operated without discernible inhibition or spurious actuation
in this complex milieu and demonstrated 100% specificity and 100% sensitivity for viral detection.
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4. Discussion
While iNAATs have potential as POC diagnostics, they often lack the versatility and intelligence
to deal with genetically variable and rapidly evolving targets. To fill this need we have created a smart
molecular diagnostic composed of a parallel set of degenerate primers that can readily amplify variant
targets. Degenerate LAMP primers have been successfully used by other groups as well [51–55].
Moreover, the resulting multiplex amplicons are integrated into a single readout via a multiplex
OR-gated strand exchange logic processor that “computes” and returns the presence of a target relative
to even closely related non-target sequences. The fact that multiple, different amplification reactions
can be carried out in parallel, and yet the user need only attend to the final, fluorescent signal, highlights
the power of the diagnostic, and presages the possibility of even more complex integration of molecular
signals. For example, strand exchange nucleic acid computation has allowed (i) analysis of repetitive
DNA targets of greater than 500 nucleotides in length with single nucleotide specificity, using “modular
probes” composed of multiple short oligonucleotides that undergo competitive hybridization [56];
(ii) sensing and imaging of nucleic acids, enzymes, small molecules, proteins, and tumor cells via
hairpin oligonucleotide probes and the hybridization chain reaction (HCR) [57]; and (iii) coupling
nucleic acid detection to translational reporters via amplicon-mediated strand displacement reactions
that couple to reporter protein production in a cell-free translation system [22].
More importantly, integration of strand exchange nucleic acid logic computation in a single tube
with LAMP did not significantly compromise the robustness of LAMP, which has been previously
shown to function in the presence of untreated biological fluids [58,59]. Our smart molecular diagnostic
performed with little or no error in inclement environments, such as with crude preparations of
macerated mosquitoes. The LAMP-based smart molecular assays of ZIKV-infected and un-infected
mosquitoes could be performed with results that were on par with those obtained by qPCR analyses.
As few as 190 copies of ZIKV RNA could be readily identified using multiplex LAMP-2GO assays
without any false positive reactions. These assays were equally adept at identifying both Asian and
African lineages of ZIKV without cross-reaction with related or co-circulating viruses. The assay
thus enhances the programmability and signal processing capability of LAMP-based tests, which like
many other isothermal molecular diagnostics are truly capable of performing in demanding field
conditions. For instance, LAMP has been found to be a field-friendly diagnostic test for diseases such
as malaria [60] and tuberculosis [61]. Similarly, RPA has demonstrated near 100% sensitivity and
specificity in field tests for detection of many viruses, bacteria, and parasites [62–64]. Another iNAAT
termed, isothermal nicking enzyme amplification reaction (NEAR), was automated on the Clinical
Laboratory Improvement Amendments (CLIA)—waived portable device Alere i (Alere, Scarborough,
MA) and is being used for POC diagnosis of infectious agents such as influenza viruses [65].
Overall, though, our envisioned smart molecular diagnostics methodology has much greater
versatility for field use going forward. For instance, most field applications of RPA involve purification
of nucleic acid analytes from clinical specimens. In contrast, our reactions can directly analyze crude
biospecimens without necessitating complicated sample preparation and nucleic acid purification.
Field applications of RPA and NEAR typically employ commercial instruments costing a few thousand
dollars for assay readout [64] whereas our assay requires a simple 3D printed box for visual “yes/no”
score for the presence or absence of visual fluorescence signal at endpoint. We have previously
demonstrated execution of our LAMP-based assays using chemical heat from commercial hand
warmers [15]. Our single temperature assay should also be amenable for incubation in other chemical
heaters for LAMP, such as the NINA (non-instrumented nucleic acid amplification) heater [66], as well
as commercial electrical heat blocks.
Most importantly, existing iNAATs lack design considerations to counter target variability,
a deficiency that may reduce sensitivity [65], and in extreme cases lead to assay failure. For example,
RPA uses a recombinase enzyme to facilitate invasion of double stranded templates by primers,
which are then extended by a strand displacing DNA polymerase resulting in signal amplification [8].
Amplicon detection is typically achieved using fluorophore-labeled probes that are measured using
487
Viruses 2018, 10, 714
fluorimetry or converted to a color readout using lateral flow assays [8,67]. Nicking enzyme
amplification reaction relies on DNA nicking and extension reactions using nicking enzymes and
strand displacing DNA polymerase to achieve exponential amplification of target DNA or RNA [68].
The resulting amplicons are typically converted to a fluorescence signal using cleavage probes.
Neither configuration would be particularly suitable for degenerate priming and/or strand exchange
computations, as opposed to our internally redundant Boolean logic processing assay.
In conclusion, our smart molecular diagnostic overcomes the principal challenges faced by
most iNAATs—non-specific amplification, false negatives, and false positives—while maintaining an
easy-to-use user-interface. This assay methodology should be of greatest utility for the development
of disposable point-of-care devices. Despite performing multi-component analytical operations, the
molecular computations are hidden from the user in a single assay that can both directly receive the
sample and emanate visual results. We have previously demonstrated that strand exchange modules
are compatible with preparation of lyophilized LAMP assay mixes [15]—a common mode of extended
storage and commercial application of LAMP tests [69–73]. These various features should minimize
device intricacies, and in turn reduce cost, especially since only two protein enzymes and a single
fluorophore-quencher pair are required. Most importantly, the molecular probes can be configured to
capture both current and future fast-evolving targets, such as Zika viruses, with both greater breadth
and greater accuracy than existing tests.
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Abstract: Differential diagnosis of the Zika virus (ZIKV) is hampered by cross-reactivity with other
flaviviruses, mainly dengue viruses. The aim of this study was to compare two commercial methods
for detecting ZIKV immunoglobulin M (IgM), an indirect immunofluorescence (IIF) and an enzyme
immunoassay (ELISA), using the non-structural (NS) 1 protein as an antigen, both from EuroImmun,
Germany. In total, 255 serum samples were analyzed, 203 of which showed laboratory markers of
ZIKV infections (PCR-positive in serum and/or in urine and/or positive or indeterminate specific
IgM). When tested with IIF, 163 samples were IgM-positive, while 13 samples were indeterminate and
78 were negative. When IIF-positive samples were tested using ELISA, we found 61 positive results,
14 indeterminate results, and 88 negative results. Among the indeterminate cases tested with IIF,
ELISA analysis found two positive, two indeterminate, and nine negative results. Finally, 74 of the
78 IIF-negative samples proved also to be negative using ELISA. For the calculations, all indeterminate
results were considered to be positive. The agreement, sensitivity, and specificity between ELISA
and IIF were 60.2%, 44.9%, and 94.9%, respectively. Overall, 101 samples showed discrepant results;
these samples were finally classified on the basis of other ZIKV diagnostic approaches (PCR-positive
in serum and/or in urine, IgG determinations using IIF or ELISA, and ZIKV Plaque Reduction
Neutralization test—positive), when available. A final classification of 228 samples was possible;
126 of them were positive and 102 were negative. The corresponding values of agreement, sensitivity,
and specificity of IIF were 86.0%, 96.8%, and 72.5%, respectively. The corresponding figures for
ELISA were 81.1%, 65.9%, and 100%, respectively. The ELISA and IIF methods are both adequate
approaches for detecting ZIKV-specific IgM. However, considering their respective weaknesses (low
sensitivity in ELISA and low specificity in IIF), serological results must be considered jointly with
other laboratory results.
Keywords: Zika virus; dengue viruses; flavivirus; ELISA; indirect immunofluorescence;
plaque reduction neutralization test; polymerase chain reaction; cross-reactions
1. Introduction
The Zika virus (ZIKV) is a mosquito-transmitted virus belonging to the flavivirus genus.
This genus includes other human pathogens, such as the dengue virus (DENV), the West Nile virus,
and the yellow fever virus. ZIKV shares some clinical and microbiological characteristics with DENV,
making its diagnosis difficult.
Firstly, both viruses cause an exanthematic febrile disease, characterized by the presence of arthralgia
and retroocular pain, although there are differential signs or symptoms, such as rash with pruritus,
conjunctivitis, and limb edema (characteristic of ZIKV disease), or leucopenia/thrombocytopenia
(characteristic of dengue) [1,2]. Secondly, they share a vector (mosquitoes of the genus, Aedes) and,
consequently, a distribution area [3]. Thirdly, both viruses, as well as other flaviviruses, share antigenic
reactivity, resolved in serological cross-reactivity when measuring specific antibodies [4]. For these reasons,
it is important to have specific serological assays that can facilitate an adequate differential diagnosis.
Indirect immunofluorescence (IIF) is widely used to detect ZIKV antibodies, using ZIKV-infected
cells to identify class-specific antibodies. However, using this approach, the high degree of cross-reactivity
494
Viruses 2018, 10, 379
between ZIKV and other flaviviruses makes correct serological diagnosis difficult. The ZIKV
non-structural (NS) 1 protein was identified as being largely specific to the virus [5], and, as a consequence,
new ELISA assays were developed. Although some studies evaluated the use of ELISA reagents for
determining immunoglobulin M (IgM) against ZIKV [6–12], no comparisons with IIF are available.
The aim of this study was to evaluate the comparative performance characteristics of an NS1
antigen-based ELISA and an IIF assay for identifying ZIKV-specific IgM. For this purpose we used a
large panel of samples that were well characterized by molecular and serological approaches, including
a real-time molecular assay, IgM and IgG ELISA, and the plaque reduction neutralization test (PRNT).
2. Materials and Methods
2.1. Samples
A total of 255 serum samples received in our laboratory were included in the study. Of these,
239 samples showed markers of ZIKV infection, including 203 cases from 201 adults (66 men,
135 women (30 pregnant)) and two newborns. The samples were received over a period of 18 months
(1 January 2016–31 July 2017). The study was approved by the Ethical Committee of the Institute
of Health Carlos III (code: CEI PI 64_2018). All patients had recently traveled to one or more Latin
American countries. The samples were grouped as described below.
1. Seventy-one paired samples from 35 cases (three samples were available from one case):
(a) Four cases (eight samples) were PCR-positive (using real-time PCR) in serum and urine,
and ZIKV IgM-positive using IIF (five samples).
(b) Five cases (10 samples) had a positive result with PCR in serum (one of them was negative
in urine), and two samples from two cases were ZIKV IgM-positive using IIF.
(c) Nine cases (19 samples) were PCR-positive only in urine (six were negative in serum),
and ZIKV IgM-positive in eight (eight positive and four indeterminate samples).
(d) The remaining 17 cases (34 samples; three with a PCR-negative result in serum and one
in urine) were IgM-positive or indeterminate in at least one sample. Seven of them were
ZIKV IgM-positive in acute and convalescent samples. Three cases showed seroconversion
of ZIKV IgM. Of these, both samples of one case were indeterminate, and in the other case,
the acute sample was indeterminate and the convalescent sample was positive. Finally,
five cases (indeterminate to positive (two cases), positive to indeterminate (one case),
positive to negative (one case), and indeterminate to negative (one case)), showed the
presence of DENV IgM (four cases) or DENV IgG seroconversion (one case).
2. One hundred and sixty-eight samples:
(a) Twenty-three samples were ZIKV IgM-positive, of which PCR was positive in serum and
urine (one case), in serum only (eight cases), or in urine only (14 cases).
(b) One hundred and one samples gave a positive result for ZIKV IgM; PCR was carried out
in serum and urine in 28 of them, all of which gave a negative result.
(c) Forty-four samples were negative for ZIKV IgM using IIF, with a positive PCR result in
serum and urine (six cases), in serum only (15 cases), or in urine only (23 cases).
The remaining 16 samples came from recent dengue infections (nine samples from eight patients),
as diagnosed by IgM detection, or past dengue infections (seven samples), as confirmed by IgG
detection in the absence of IgM. These samples were taken during 2012, before the ZIKV epidemic in
the Americas. The patients reported recent travel to Latin American countries. When tested for ZIKV
IgM using IIF, two samples were positive, another two were indeterminate, and one other gave an
uninterpretable result, with a strong background and no specific fluorescence.
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2.2. Methods
ZIKV-specific IgM and IgG were tested using IIF with commercial reagents (Arbovirus Fever
Mosaic 2, catalog #FR2668-1010-1G and #FR2668-1010-1M for IgG and IgM, respectively, obtained
from EuroImmun, Lübeck, Germany). For testing IgM, samples were pretreated with an anti-human
IgG (RF Absorbent, reference OUCG, Siemens, Marburg, Germany), to remove the interference due
to the presence of rheumatoid factor and specific IgG to avoid false-positive results. Briefly, samples
pretreated with a ten-fold dilution were incubated for 30 min at 37 ◦C in wells of slides containing
ZIKV-infected cells. After washing with phosphate-buffered saline (PBS), pH 7.2, supplemented with
Tween 20 (PBS-Tween), an anti-human IgM (goat)-fluorescein isothiocyanate conjugate was added
to the wells and incubated as before. After the final washing, the slides were mounted in glycerol
buffered with PBS, pH 8.4, and read in an inverted fluorescence microscope (Zeiss Axiovert 25, Jena,
Germany) equipped with a mercury vapor lamp HBO50 (Osram, Munich, Germany), at a magnification
of 200×. Samples showing fine-to-coarse granular cytoplasmic structures and/or net-like fluorescence
with a dense perinuclear reactivity were considered to be positive. The kit included positive and
negative controls. The results obtained using IIF were read by two different people. Samples where
interpretations differed between the two assessors were considered to be indeterminate.
Dengue virus serology was done using commercial ELISA tests. Immunoglobulin M was determined
with the Panbio Dengue IgM Capture ELISA, catalog #01PE20, while DENV IgG was determined with
the Panbio Dengue IgG Indirect ELISA, catalog #01PE30, both obtained from Standard Diagnostics Inc.,
Geonggi-do, South Korea. Dengue virus assays use DENV 1–4 antigens, recombinant in the case of the IgM
assay. Dengue virus IgM was confirmed using a background assay, as described elsewhere [13]. The ZIKV
PRNT was assessed with an in-house test using Vero E6 cells and 100 tissue infective infectious dose
50% of ZIKV (African strain MR-766, isolated from a rhesus monkey in the Zika Forest, Uganda, in 1947,
and maintained in our laboratory in Vero E6 cells). For neutralizing antibodies, samples were tested
following titration in two-fold dilutions from 1/8. Samples were considered positive if neutralization of
viral growth at a dilution greater than 128-fold was observed; samples with titers between eight-fold and
128-fold were considered indeterminate, while samples with a titer less than eight-fold were considered
negative. Zika virus RNA was determined using a commercial assay of real-time PCR (RealStar®Zika
Virus, altona Diagnostics, Hamburg, Germany, catalog number: 774AD-591013) [14].
The assay under evaluation was an ELISA using the NS1 protein (recombinant) from the virus
(ELISA Zika virus IgM, catalog number EI 2668-9601 M, EuroImmun) as the antigen. Briefly, samples
diluted 100-fold in a buffer containing anti-human IgG (goat) were incubated with the immobilized
antigen NS1 for 1 h at 37 ◦C. The plate was washed three times, and an anti-human IgM (goat)
peroxidase conjugate was added. After incubating for 30 min at room temperature and washing
as before, a solution of 3, 3’, 5, 5’ tetramethylbenzidine/H2O2 was added as the enzyme substrate.
The reaction was stopped with 0.5 M H2SO4, and the plate was read at 450 nm. A calibrator containing
ZIKV-specific IgM included in the kit was tested in each run to define the cut-off of the test. Samples
with absorbance/cut-off values greater than 1.1 were considered positive, and values less than 0.8 were
considered negative. All other values were regarded as indeterminate.
All tests using commercial reagents were done strictly following the manufacturer’s instructions.
To establish the comparison, all indeterminate results using either IIF or ELISA were considered
as positive.
3. Results
Overall, in the IIF assay, 163 samples were ZIKV IgM-positive, 13 were indeterminate, and 78 were
negative. The result from the remaining sample could not be interpreted, and was excluded from
the analysis.
The general comparison between IIF and ELISA for detecting ZIKV-specific IgM is illustrated in
Table 1. Excluding the sample with an uninterpretable result, the ELISA test showed 67 samples to be
positive, 16 to be indeterminate, and 171 to be negative.
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Out of 163 positive IIF samples, 61 were positive, 14 were indeterminate, and 88 were negative
with ELISA. Of the 13 indeterminate IIF samples, two were positive, two were indeterminate, and nine
were negative with ELISA. Finally, 74 of the 78 IIF-negative samples were also negative with ELISA,
while four were positive (Table 1).
Table 1. Results of ELISA compared with indirect immunofluorescence (IIF).
Indirect Immunofluorescence
Positive Indeterminate Negative Uninterpretable
ELISA
Positive 61 2 4 0
Indeterminate 14 2 0 0
Negative 88 9 74 1
Considering all indeterminate results to be positive, the comparison of ELISA and IIF provided
values of agreement of 60.2% (95% confidence intervals (CIs): 53.9–66.2%; 153/254), a sensitivity of
44.9% (95% CIs: 37.5–52.5%; 79/176), and a specificity of 94.9% (95% CIs: 86.7–98.3%; 74/78).
All positive and indeterminate results with both IIF and ELISA were considered as true positives,
and the samples showing a negative result with both assays were considered as negative. One hundred
and one samples showed discrepant results with the two assays (listed in Tables 2–4). The samples
were finally classified considering other specific ZIKV diagnostic approaches (PCR-positive in serum
and/or in urine, IgG determinations using IIF or ELISA, and ZIKV PRNT-positive), when available.






#1 POS NEG Acute sample. DENV (NS1 Ag & IgM) Negative (dengue)
#2 IND NEG Acute sample. DENV (NS1 Ag & IgM). PRNT ind (9 dao) Negative (dengue)
#3 POS NEG Follow-up sample. DENV (IgM). PRNT neg (45 dao) Negative
#4 POS NEG Single sample. DENV (NS1 Ag & IgM). PRNT neg Negative (dengue)
#5 POS NEG Single sample. PCR neg (serum & urine), PRNT neg, DENV (IgM) Negative (dengue)
#6 POS NEG Single sample. PCR neg (serum), PRNT neg, DENV (IgM) Negative (dengue)
#7–#9 IND NEG Single sample. DENV (IgM). Sample from 2012 Negative (dengue)
#10 POS NEG Acute sample. DENV (IgM). Sample from 2012 Negative (dengue)
#11, #12 POS NEG Single sample. PCR neg (serum & urine), PRNT neg Negative
#13, #14 POS NEG Single sample. PCR neg (serum) Negative
#15 POS NEG Single sample. PCR neg (urine) Negative
#16–#28 POS NEG Single sample. PRNT neg Negative
* dao: days after onset; PRNT: plaque reduction neutralization test; ind: indeterminate result; pos: positive; neg: negative;
ZIKV: Zika virus; DENV: dengue virus; NS1 Ag: non-structural protein 1 antigen; IgM: immunoglobulin M.






#29 POS NEG Acute sample. PCR pos (serum) (1 dao) Positive
#30 POS NEG Follow-up sample (180 dao) Positive
#31 IND NEG Acute sample. PCR pos (urine) (n dao) Positive
#32 POS NEG Follow-up sample. PRNT pos (n+18 dao) Positive
#33 POS NEG Acute sample. PCR pos (urine) (n dao) Positive
#34 IND NEG Follow-up sample. PRNT pos (n+25 dao) Positive
#35 IND NEG Acute sample. PCR pos (urine) (7 dao) Positive
#36 POS NEG Follow-up sample. PRNT ind (33 dao) Positive
497







#37 POS NEG Acute sample. PRNT pos (n dao) Positive
#38 POS NEG Follow-up sample. PRNT pos (n+12 dao) Positive
#39 POS NEG Acute sample. PRNT pos (50 dao) Positive
#40 IND NEG Follow-up sample. PRNT pos (78 dao) Positive
#41 POS NEG Acute sample. IgG SC (IIF & ELISA) Positive
#42 POS NEG Convalescent sample. PRNT pos. PCR pos (urine) Positive
#43 POS NEG Convalescent sample. PCR neg (serum). Acute sample: IgM pos (IIF & ELISA) Positive
#44 IND NEG Convalescent sample. Acute sample: IgM ind (ELISA) Positive
#45 POS NEG Convalescent sample. Acute sample: IgM ind (IIF); pos (ELISA) Positive
#46 POS NEG Convalescent sample. IgM SC (IIF). PRNT pos. Acute sample: PCR pos (serum & urine) Positive
#47, #48 POS NEG Convalescent sample. IgG SC (ELISA) Positive
#49 IND NEG Acute sample. PCR pos (urine) Positive
#50 POS NEG Single sample. PCR pos (urine & serum) Positive
#51 POS NEG Single sample. PCR pos (serum). PRNT pos Positive
#52–#54 POS NEG Single sample. PCR pos (serum) Positive
#55 POS NEG Single sample. PCR pos (urine). PRNT pos Positive
#56–#59 POS NEG Single sample. PCR pos (urine) Positive
#60–#71 POS NEG Single sample. PRNT pos Positive
#72 NEG POS Convalescent sample. IgG SC (IIF & ELISA). PCR pos (urine) Positive
#73 NEG POS Convalescent sample. Acute sample: IgM ind (IIF); pos (ELISA) Positive
#74, #75 NEG POS Single sample. PCR pos (urine) Positive
* SC: seroconversion.






#76 POS NEG Acute sample. PRNT ind Unclassifiable
#77 POS NEG Follow-up sample. PRNT ind Unclassifiable
#78 POS NEG Single sample. PCR neg (serum& urine), PRNT ind Unclassifiable
#79 POS NEG Single sample. PRNT ind. PCR neg (serum) Unclassifiable
#80–#91 POS NEG Single sample. PRNT ind Unclassifiable
#92–#99 POS NEG Single sample. No more results Unclassifiable
#100 POS NEG Single sample. PCR neg (serum), PRNT pos. DENV (IgM pos, NS1 Ag neg) Unclassifiable
#101 POS NEG Single sample. PRNT ind. DENV (IgM pos) Unclassifiable
Firstly, 28 discrepant samples, all with a positive (25 samples) or indeterminate (3 samples) result
using IIF were finally classified as negative (Table 2). Ten of them (#1 to #10, Table 2) came from dengue
cases, since they showed either DENV IgM and NS1 antigens (samples #1, #2, and #4), or DENV IgM
in a follow-up sample (#3), or DENV IgM with ZIKV PRNT-negative and ZIKV PCR-negative in serum
and urine (#5) or in serum only (#6), or DENV IgM in samples taken in 2012, before the outbreak of
ZIKV in the Americas in 2015 (four samples, #7 to #10). Two additional cases tested negative for ZIKV
PCR in urine and serum, and for ZIKV PRNT (#11, #12), while three more were negative for ZIKV
PCR in serum (#13 and #14) or in urine (#15), and the remaining 13 samples (#16 to #28) were negative
for PRNT.
Secondly, 47 samples with discrepant results were finally classified as positive (Table 3). Of these,
43 were positive (37 samples) or indeterminate (6 samples) using IIF and negative using ELISA,
and four were positive using ELISA and negative using IIF. Of the samples giving a positive or
indeterminate result using IIF, 12 were paired samples (#29 to #40, Table 3) from six cases that were
positive (eight samples, #29, #30, #32, #33, #36, #37, #38, and #39) or indeterminate (four samples,
#31, #34, #35, and #40) using IIF. Of these, four cases gave a positive result for ZIKV PCR three cases
in urine (with a positive PRNT assay result in two of them) and one in serum. Two other paired
samples were ZIKV PRNT-positive in acute and convalescent samples. Sample #41 was an acute
sample whose corresponding convalescent sample showed IgG seroconversion with both ELISA and
IIF. Samples #42 to #48 were convalescent ones, showing either a ZIKV PCR-positive result in urine
and an PRNT-positive result (#42), or a positive or indeterminate result using IIF and/or ELISA in the
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corresponding acute samples (#43, #44, and #45), or seroconversion of IgM (#46) or IgG (#47 and #48).
Sample #49 was an acute sample with a ZIKV PCR-positive result in urine. Samples #50 to #71 were
single samples that were ZIKV PCR-positive in urine and serum (#50), ZIKV PCR-positive in serum
and ZIKV PRNT-positive (#51), ZIKV PCR-positive in serum (#52, #53, and #54), ZIKV PCR-positive in
urine and PRNT-positive (#55), and ZIKV PCR-positive in urine (#56, #57, #58, and #59). Samples #60 to
#71 were single samples for which a single positive result in the ZIKV PRNT assay was demonstrated.
Of the four samples showing a positive result using ELISA but a negative one using IIF, two were
convalescent samples showing a ZIKV PCR-positive result in urine and IgG seroconversion (#72),
or an IgM-positive result using ELISA and an indeterminate result using IIF in the acute sample
(#73). The latter samples were two single samples from cases that were ZIKV PCR-positive in urine
(#74 and #75).
Finally, the other 26 samples showing discrepant results were considered unclassifiable, because
not enough results were available (Table 4).
Thus, a final classification was possible for 228 samples (126 positive and 102 negative; Table 5).
Indirect immunofluorescence showed 86% agreement (95% CIs: 80.6–90.1%; 196/228), 96.8% sensitivity
(95% CIs: 91.6–99.0%; 122/126), and 72.5% specificity (95% CIs: 62.7–80.7%; 74/102). ELISA, on the
other hand, showed 81.1% agreement (95% CIs: 75.3–85.9%; 185/228), 65.9% sensitivity (95% CIs:
56.8–73.9%; 83/126), and 100% specificity (95% CIs: 95.5–100%; 102/102).
Table 5. Performance characteristics of IIF and ELISA after the final classification of samples.
Final Classification









The best definition of a clinical case of ZIKV in areas with concurrent circulation of other
flaviviruses is the presence of a rash with pruritus or conjunctival hyperemia, in the absence of
any other general clinical manifestations [2]. However, there are difficulties in the differential diagnosis
of individual cases with other arboviruses, especially DENV, due to the cross-reactions between the
members of the flavivirus genus, and the chikungunya virus. Thus, the main problem in comparatively
evaluating serological assays for ZIKV assays is the correct classification of cases. In the presented study,
samples giving the same result with the compared methods were considered as true, as was the case in
153 samples (60.2%) of those analyzed, having obtained 101 discrepant results using IIF and ELISA.
For the final classification of the discrepant results, the results of other infection markers (PCR-positive
in urine and serum and/or IgG seroconversion and/or PRNT-positive for ZIKV, and IgM and/or IgG
seroconversion and/or NS1 antigen detection for DENV) were taken into consideration when they
were available. In this way, discrepant samples were finally classified as negative (28 samples; Table 3)
or positive (47 samples; Table 4), while a definitive classification of the remaining 26 samples was not
possible (Table 5). After the final classification of the discrepancies, the NS1-based ELISA showed
excellent specificity when applied to samples that were received by the laboratory for the diagnosis
of ZIKV infection. The high specificity obtained was consistent with that previously reported for the
ELISA assay evaluated here [6–9], as well as for other tests based on the NS1 protein [9,10]. It is of
particular note that the specificity of ELISA is markedly higher than that of IIF (Table 5).
The sensitivity, on the other hand, was lower using ELISA than with the IIF test. The figure
obtained here for ELISA (65.9%) was better than those previously reported in the literature: 20.7% [10];
32% [9]; 54% [8], and 58.8% [7]. The differences in sensitivity could be related to the different approaches
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used to establish the comparisons in the various reports. The lower sensitivity of ELISA in relation to
IIF could be explained by the fact that only one protein (NS1) acted as an antigen in ELISA in contrast
to the whole virus in IIF, or by the kinetics of the antibodies against NS1, which could be delayed in
relation to the antibodies detected against the complete virus, as detected in the IIF assay. In order to
assess this aspect, the dates of bleeding of the paired samples showing discrepant results, and those
which were finally classified as positive (samples #29 to #40, Table 3) were reviewed. Follow-up
samples were taken between 12 days and 180 days after the first sample was taken, and in none of the
six cases was the follow-up sample positive using ELISA. Therefore, it does not seem likely that the
lower sensitivity of ELISA compared with that of IIF is related to a deferred response of the ZIKV IgG
to the NS1 antigen.
The cross-reactivity between ZIKV and DENV, as well as that with other flaviviruses,
as consistently reported [6,12], is of particular note. This issue is of particular interest, since patients
with prior dengue infections were reported to not develop an IgM response against ZIKV NS1 [15].
Of the cases analyzed with a unique IIF-positive result for ZIKV IgM, 12 showed markers of recent
DENV infection, either in samples that were classified as ZIKV-negative (#1 to #10, Table 2) or that
were unclassifiable (#100 and #101, Table 4). All cases produced by DENV, included in Table 2,
were confirmed as false-positive in IIF, since they showed markers of DENV infection, by IgM (all cases)
and, more importantly, by detection of the NS1 antigen of DENV (samples #1, #2, and #4), in the
absence of other markers of ZIKV infection. Also of interest are the IIF-positive results in the samples
showing DENV IgM taken before the epidemic of the virus in the Americas (samples #7 to #10, Table 2).
Nevertheless, ZIKV and DENV double infections cannot be completely ruled out; this seems to be the
case for samples #100 and #101 (Table 4), which were considered as unclassifiable. Thus, the ELISA
technique was confirmed as being more specific than IIF, and appeared not to be affected by the
cross-reaction when analyzing cases of DENV infection, even in the presence of the DENV NS1 antigen.
The specificity of the IIF and ELISA assays should be the subject of a broader study, including not only
cases of DENV and ZIKV, but also, at least, cases of yellow fever.
In conclusion, the ELISA and IIF methods could both be adequate approaches for detecting
ZIKV-specific IgM. However, considering their respective weaknesses (sensitivity in ELISA and
specificity in IIF), serological results must be considered in the context of clinical and epidemiological
data, and of other laboratory results.
Author Contributions: Conceptualization, F.d.O. Investigation, F.d.O., M.P.S.-S., and A.V. Methodology, M.D.M.,
E.S., M.J.M., L.M., and F.J.M. Writing—original draft, F.d.O. Writing—review and editing, F.d.O., M.P.S.-S., and A.V.
Acknowledgments: The study was partially financed by a contract between the ISCIII and Euroimmun
Diagnostics España SLU (MVP216/17), and by ISCIII, project RD16CIII/0003/0003, “Red de Enfermedades
Tropicales”, Subprogram RETICS Plan Estatal de I+D+I 2013-2016, and co-funded by FEDER “Una manera de
hacer Europa” and project PI16CIII/00037.
Conflicts of Interest: The founding sponsors had no role in the design of the study, in the collection, analyses,
or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
References
1. Bachiller-Luque, P.; Dominguez-Gil-González, M.; Alvarez-Manzanares, J.; Vázquez, A.; de Ory, F.;
Sánchez-Seco Fariñas, M.P. First case of Zika virus infection imported to Spain. Enferm. Infecc. Microbiol. Clin.
2016, 34, 243–246. [CrossRef] [PubMed]
2. Braga, J.U.; Bressan, C.; Dalvi, A.P.R.; Calvet, G.A.; Daumas, R.P.; Rodrigues, N.; Wakimoto, M.;
Nogueira, R.M.R.; Nielsen-Saines, K.; Brito, C.; et al. Accuracy of Zika virus disease case definition during
simultaneous Dengue and Chikungunya epidemics. PLoS ONE 2017, 12, e0179725. [CrossRef] [PubMed]
3. Epelboin, Y.; Talaga, S.; Epelboin, L.; Dusfour, I. Zika virus: An updated review of competent or naturally
infected mosquitoes. PLoS Negl. Trop. Dis. 2017, 11, e0005933. [CrossRef] [PubMed]
4. Priyamvada, L.; Hudson, W.; Ahmed, R.; Wrammert, J. Humoral cross-reactivity between Zika and dengue
viruses: Implications for protection and pathology. Emerg. Microbes Infect. 2017, 6, e33. [CrossRef] [PubMed]
500
Viruses 2018, 10, 379
5. Stettler, K.; Beltramello, M.; Espinosa, D.A.; Graham, V.; Cassotta, A.; Bianchi, S.; Vanzetta, F.; Minola, A.;
Jaconi, S.; Mele, F.; et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.
Science 2016, 353, 823–826. [CrossRef] [PubMed]
6. Huzly, D.; Hanselmann, I.; Schmidt-Chanasit, J.; Panning, M. High specificity of a novel Zika virus ELISA in
European patients after exposure to different flaviviruses. Euro. Surveill. 2016, 21. [CrossRef] [PubMed]
7. Steinhagen, K.; Probst, C.; Radzimski, C.; Schmidt-Chanasit, J.; Emmerich, P.; van Esbroeck, M.; Schinkel, J.;
Grobusch, M.P.; Goorhuis, A.; Warnecke, J.M.; et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel
NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: A multicohort study of assay
performance, 2015 to 2016. Euro. Surveill. 2016, 21, 30426. [CrossRef] [PubMed]
8. Kadkhoda, K.; Gretchen, A.; Racano, A. Evaluation of a commercially available Zika virus IgM ELISA:
Specificity in focus. Diagn. Microbiol. Infect. Dis. 2017, 88, 233–235. [CrossRef] [PubMed]
9. Safronetz, D.; Sloan, A.; Stein, D.R.; Mendoza, E.; Barairo, N.; Ranadheera, C.; Scharikow, L.; Holloway, K.;
Robinson, A.; Traykova-Andonova, M.; et al. Evaluation of 5 commercially available Zika virus immunoassays.
Emerg. Infect. Dis. 2017, 23, 1577–1580. [CrossRef] [PubMed]
10. Wong, S.J.; Furuya, A.; Zou, J.; Xie, X.; Dupuis, A.P., II; Kramer, L.D.; Shi, P.Y. A Multiplex Microsphere
Immunoassay for Zika Virus Diagnosis. EBioMedicine 2017, 16, 136–140. [CrossRef] [PubMed]
11. Granger, D.; Hilgart, H.; Misner, L.; Christensen, J.; Bistodeau, S.; Palm, J.; Strain, A.K.; Konstantinovski, M.;
Liu, D.; Tran, A.; et al. Serologic testing for Zika virus: Comparison of three Zika virus IgM-screening
enzyme-linked immunosorbent assays and initial laboratory experiences. J. Clin. Microbiol. 2017, 55,
2127–2136. [CrossRef] [PubMed]
12. Pasquier, C.; Joguet, G.; Mengelle, C.; Chapuy-Regaud, S.; Pavili, L.; Prisant, N.; Izopet, J.; Bujan, L.;
Mansuy, J.M. Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked
immunoassays. Diagn. Microbiol. Infect. Dis. 2018, 90, 26–30. [CrossRef] [PubMed]
13. Domingo, C.; de Ory, F.; Sanz, J.C.; Reyes, N.; Gascón, J.; Wichmann, O.; Puente, S.; Schunk, M.;
López-Vélez, R.; Ruíz, J.; et al. Molecular and serological markers of acute dengue infection in naïve
and flavivirus vaccinated travellers. Diagn. Microbiol. Infect. Dis. 2009, 65, 42–48. [CrossRef] [PubMed]
14. L’Huillier, A.G.; Lombos, E.; Tang, E.; Perusini, S.; Eshaghi, A.; Nagra, S.; Frantz, C.; Olsha, R.; Kristjanson, E.;
Dimitrova, K.; et al. Evaluation of Altona Diagnostics RealStar Zika virus reverse transcription-PCR test kit
for Zika virus PCR testing. J. Clin. Microbiol. 2017, 55, 1576–1584. [CrossRef] [PubMed]
15. Barzon, L.; Percivalle, E.; Pacenti, M.; Rovida, F.; Zavattoni, M.; Del Bravo, P.; Cattelan, A.M.; Palù, G.;
Baldanti, F. Virus and antibody dynamics in travelers with acute Zika virus infection. Clin. Infect. Dis. 2018,
66, 1173–1180. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Development and Characterization of
Double-Antibody Sandwich ELISA for Detection of
Zika Virus Infection
Liding Zhang †, Xuewei Du †, Congjie Chen, Zhixin Chen, Li Zhang, Qinqin Han, Xueshan Xia *,
Yuzhu Song * and Jinyang Zhang *
Faculty of Life Science and Technology, Kunming University of Science and Technology,
727 Jingming South Road, Kunming 650500, China; lidingzhang@aliyun.com (L.Z.); xueweidu@126.com (X.D);
kmustccj@163.com (C.C.); arnoldchen1997@gmail.com (Z.C.); lilizhang7102@foxmail.com (L.Z.);
qqhan10@kmust.edu.cn (Q.H.)
* Correspondence: oliverxia2000@aliyun.com (X.X.); syzzam@126.com (Y.S.); jyzhang@kmust.edu.cn (J.Z.);
Tel./Fax: +86-871-6593-9528 (J.Z.)
† These authors contributed equally to this work.
Received: 26 October 2018; Accepted: 13 November 2018; Published: 15 November 2018 	
Abstract: Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that can cause severe
disease, including congenital birth defect and Guillain−Barré syndrome during pregnancy. Although,
several molecular diagnostic methods have been developed to detect the ZIKV, these methods
pose challenges as they cannot detect early viral infection. Furthermore, these methods require the
extraction of RNA, which is easy to contaminate. Nonstructural protein 1 (NS1) is an important
biomarker for early diagnosis of the virus, and the detection methods associated with the NS1 protein
have recently been reported. The aim of this study was to develop a rapid and sensitive detection
method for the detection of the ZIKV based on the NS1 protein. The sensitivity of this method is
120 ng mL−1 and it detected the ZIKV in the supernatant and lysates of Vero and BHK cells, as well as
the sera of tree shrews infected with the ZIKV. Without the isolation of the virus and the extraction of
the RNA, our method can be used as a primary screening test as opposed to other diagnosis methods
that detect the ZIKV.
Keywords: NS1 protein; Zika virus; diagnosis; monoclonal antibodies; ELISA
1. Introduction
The Zika virus (ZIKV), a new arbovirus, is a member of the Flavivirus genus of the Flaviviridae
family. It was initially isolated from a macaque in 1947 in the Zika Forest of Uganda [1]. With fewer than
20 humans documented infected with the ZIKV, it received almost no attention before 2007. During this
time, the ZIKV silently circulated in many parts of Africa and Asia without causing severe diseases or
large outbreaks [2]. In 2015, an outbreak in Northeast Brazil led to an alarming number of babies born
with microcephalus [3]. During this recent outbreak, many devastating severe diseases, including the
Guillain−Barré syndrome in adults and congenital malformations in the fetuses of infected pregnant
women such as microcephaly and fetal demise, were caused by the ZIKV [2,4,5]. Recently, the ZIKV
has been recognized as a significant threat to global public health [6]. The disease was present in large
parts of the Americas, the Caribbean, and also the Western Pacific region of Southern Asia during
2015 and 2016 [7,8]. Thereafter, the ZIKV spread rapidly and large-scale outbreaks were documented
in other regions of the world [9]. As of April 2016, there were approximately 1.5 million people
confirmed to be infected with the ZIKV. More than 46 countries have reported cases of ZIKV infections.
In China, 13 ZIKV cases have been documented, and the possibility of new outbreaks still exists [10].
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Mosquitoes of the Aedes species represent the main vector of transmission; however, it is possible to
become infected with the ZIKV by exposure to blood, as well as perinatal and sexual contact [11,12].
Currently, there is no cure for ZIKV infection and no vaccine is available. Furthermore, rapid, efficient
and easy-to-use kits are scarce [13]. Therefore, the early diagnosis of the ZIKV infection is the most
effective way to treat patients and to control future outbreaks.
Presently, several studies have reported the methods used to detect the ZIKV. Using specific
primers of viral RNAs for a highly-sensitive and simple experiment, the RT-qPCR assay was considered
as a preferred diagnostic method. However, the false-negative results arising from new strains and the
false-positive results arising from sample contamination still exist [14]. Therefore, other methods are
needed to verify the accuracy of the RT-qPCR assay. Furthermore, there are other serological methods
for detecting either ZIKV antigens (e.g., NS1) or immunoglobulins (e.g., IgG and IgM antibodies (Abs)).
Due to the fact that IgM/IgG Abs, which are produced approximately seven days after the onset of
symptoms, vary from patient to patient [15,16]. Thus, these methods are not suitable for the early
diagnosis of ZIKV infection.
Nonstructural protein 1 (NS1) is an important protein secreted by cells infected with the virus,
and it interacts with the host. It forms the homologous dimers within cells and binds to the type
of adipocyte membrane system that participates in viral replication [17]. Furthermore, NS1 is a
soluble protein that is secreted, suggesting that the virus can escape the immune system to strengthen
interactions with the host [18,19]. More importantly, as the main antigen, NS1 can induce the
production of Abs, which is important in early diagnosis of viral markers [20].
Currently, the early detection of the ZIKV largely depends on the NS1 protein, as several studies
have reported that its level remains elevated up to nine days for Dengue, which is more sensitive
than the other ZIKV proteins [21–24]. The detection of the ZIKV antigen for the development of a
diagnostic method has not yet been reported, so the development of a ZIKV detection kit based on a
specific monoclonal antibody (mAb) is absolutely critical [16].
In this study, we developed a rapid and sensitive method to detect the ZIKV in the supernatants
and lysates of Vero and BHK cells, as well as the sera of tree shrew. Due to the short window for the
detection of the ZIKV, it is presently difficult to diagnose patients with traditional methods [25,26].
Thus, we developed a double-antibody sandwich ELISA (DAS-ELISA) to detect the ZIKV-NS1 protein
in individuals newly infected with the ZIKV and to assist the other screening methods used for
detection. This method can effectively improve the diagnosis accuracy.
2. Materials and Methods
2.1. Expression and Purification of the NS1 Protein
The nucleotide sequence of the ZIKV-NS1 protein (Accession number: MG674719.1)
was used to design the primers for the amplification of NS1. Total RNA was extracted
from the supernatant of ZIKV infected Vero cells using the TIANamp Virus DNA/RNA Kit
(TIANGEN, Beijing, China) and PCR was carried out to amplify the NS1 gene with the specific
primers 5′-GGAATTCGGGATGTTGGGTGTTCAGT-3′ (forward; underlined, EcoR I site) and
5′-CCGCTCGAGTTACGCTGTCACCACAGACCT-3′ (reverse; underlined, Xho I site). The amplified
NS1 gene product was digested with EcoR I and Xho I, and ligated into the pET-32a (+) to generate the
recombinant cloning plasmid pET-32a (+)-NS1. The recombinant NS1 protein was expressed in BL21
(DE3) cells. Nickel-nitrilotriacetic acid (Ni2+-NTA) agarose resin was used to purify the NS1 proteins
from the insoluble fraction of induced E. coli cells.
2.2. Ethics Statement
The animal study was approved by the Kunming University of Science and Technology with
permit number: KMUST2018-0053. All experimental procedures involving mice and rabbits were
performed in accordance with the regulations prescribed by the Administration of Laboratory Animals.
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2.3. Production of Monoclonal and Polyclonal Antibodies Against the ZIKV-NS1 Protein
The production of mAb and polyclonal antibody (pAb) against ZIKV-NS1 protein was performed
as previously described by our laboratory [27,28]. After repeated immunizations in rabbits,
the polyclonal antiserum against the ZIKV-NS1 protein was successfully prepared. After the last
immunization, the spleen cells of mice were collected and fused with SP2/0 cells. The fused
cells were cultured in RPMI 1640 containing 20% FBS (Gbico, Gaithersburg, MD, USA) and
hypoxanthine-aminopterin-thymidine (Sigma, Ronkonkoma, NY, USA) for one to two weeks.
The ELISA and the indirect immunofluorescent assay were used to determine the presence of
ZK-NS1-specific Abs in the hybridoma supernatants. Immunoglobulin G (IgG) from nine mAbs
and the pAb were purified using protein A sepharose (GE Healthcare, Chicago, IL, USA).
2.4. Detection of Recombinant ZIKV-NS1 Protein by the DAS-ELISA
To screen a pair of Abs for the development of the DAS-ELISA, nine mAbs were conjugated
with HRP, respectively. Horse radish peroxidase (HRP) labeled Abs and the pAb R1 were prepared
pairwise combinatorial testing for pre-experiment. The pAb R1 was diluted to a final concentration of
10 μg mL−1 with CBS buffer (CBS; NaHCO3 17.84 mM, Na2CO3 27.64 mM, pH 9.6) and the wells of 96
plate were coated with 100 μL coated for 2 h at 37 ◦C. The wells were blocked with 200 μL blocking
buffer (5% skim milk in PBS-T) for 2 h at 37 ◦C. Thereafter, 2 μg recombinant ZIKV-NS1 protein was
added to each well and incubated for 2 h at 37 ◦C. The wells were washed three times with PBS-T
(PBS-T; KCl 2.7 mM, KH2PO4 2 mM, NaCl 137 mM, Na2HPO4 10 mM, 0.05% Tween−20, pH 7.4),
and then 2A7, 4G6, 3F1, 1F4, 3G12, 2C4, 1G2, 2C9, and 1F12 (all conjugated with HRP) were diluted to
a final concentration of 1.4 μg mL−1 with blocking buffer. Thereafter, 100 μL of each mAb was added
into each well, and the plate was incubated for 1 h at 37 ◦C. The wells were washed three times with
PBS-T, 100 μL of the soluble TMB substrate solution (TIANGEN, Beijing, China) was added into each
well and incubated for 20 min at 37 ◦C. Lastly, 50 μL of stopping buffer (2 M H2SO4) was added to
terminate the reaction, and the optical density of each well was then measured at 450 nm using a
microplate reader (Bio-Rad, Hercules, CA, USA).
2.5. Titer and Binding Affinity of mAb 1F12 and pAb R1 Based on the ELISA
An indirect enzyme-linked immunosorbent assay (ELISA) was used to determine the titer of mAb
1F12 and pAb R1. The wells of a 96-well plate were coated with 1 μg of the recombinant NS1 protein,
and incubated for 2 h at 37 ◦C. The wells were washed three times with PBS-T, and then blocked
with 200 μL of blocking buffer for 2 h at 37 ◦C. Thereafter, 100 μL of mAb 1F12 or pAb R1 at different
dilutions (from 1:100 to 1:409,600) were added into each well, and the plate was incubated for 2 h at
37 ◦C. The wells were washed as described above, and then goat anti-mouse IgG (H + L) HRP or goat
anti-rabbit IgG (H + L) HRP (GenScript, Piscataway, NJ, USA) was diluted to a final concentration of
2 μg mL−1 with blocking buffer. Thereafter, 100 μL of the secondary Ab was added into each well.
The blank control well was incubated with 5% skimmed milk. The optical density of each well was
measured at 450 nm using a microplate reader. The binding affinity of mAb 1F12 and pAb R1 were
determined by the ELISA as described above.
2.6. Western Blot Assay
To characterize the reactivity and specificity of mAb 1F12 and pAb R1, Vero cells infected
and mock-infected with ZIKV were harvested, and the proteins were separated by SDS-PAGE and
transferred to nitrocellulose (NC) membranes. The membranes were blocked with blocking buffer
for 2 h at 37 ◦C. Subsequently, the membranes were probed with mAb 1F12 or pAb R1 diluted to a
final concentration of 1.4 μg mL−1 with blocking buffer and incubated for 2 h at 37 ◦C. Thereafter,
the membranes were incubated with HRP-conjugated secondary Abs (diluted as above) for 1 h at 37 ◦C.
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After each incubation step, the membranes were washed five times with PBS-T. Finally, the EasySee
Western Blot Kit (TransGen, Beijing, China) was used to detect the immunoreactive proteins.
2.7. Indirect Immunofluorescent Assay
For the immunofluorescent assay, ZIKV infected and mock-infected Vero cells were cultured for
48 h and fixed with pre-chilled acetone-methanol (1/1) for 20 min at −20 ◦C. After fixation, the cells
were blocked with blocking buffer for 1 h at 37 ◦C. Subsequently, the cells were incubated with
mAbs 2A7, 4G6, 3F1, 1F4, 3G12, 2C4, 1G2, 2C9, 1F12, or pAb R1 diluted to a final concentration of
1.4 μg mL−1 with blocking buffer, and 100 μL of each primary Ab was added into each well. The plate
was incubated for 2 h at 37 ◦C. Finally, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
immunoglobulin G (Abcam, Cambridge, UK) was diluted to a final concentration of 1 μg mL−1 with
blocking buffer, and 100 μL of the secondary Ab was added into each well. The plate was incubated for
1 h at 37 ◦C. After each incubation step, the cells were washed five times with PBS-T. Lastly, 200 μL of
PBS was added into each well for fluorescent detection at 488 nm using the Leica DMI3000B microscope
(Buffalo Grove, IL, USA).
2.8. Establishment of the DAS-ELISA Based on pAb R1 and mAb 1F12 Probe
To establish the DAS-ELISA, 1 μg of pAb R1 was diluted in CBS buffer and incubated for 2 h
at 37 ◦C. The wells of a 96-well plate were blocked with blocking buffer for 1 h at 37 ◦C. Thereafter,
the ZIKV-NS1 protein was added into each well, and the plate was incubated for 2 h at 37 ◦C. The wells
were washed three times with PBS-T. Thereafter, mAb 1F12-HRP was diluted as described above
and 100 μL of the secondary Ab was added into each well, followed by incubation for 1 h at 37 ◦C.
After washing, 100 μL of TMB was added into each well, and the plate was incubated for 15 min at
37 ◦C. Lastly, 50 μL of stopping buffer (2M H2SO4) was added to terminate the reaction. The optical
density of each well was measured at 450 nm using a microplate reader. A yellow-colored reaction and
a high absorbance reading were indicative of a positive reaction, whereas a clear-colored reaction and
a low absorbance reading were indicative of a negative reaction.
2.9. Specificity and Sensitivity of the DAS-ELISA
The specificity and sensitivity for the ZIKV-NS1 protein were determined based on the calibration
curve of the DAS-ELISA. Vero cells were infected with four similar flavivirus (DEN-1, DEN-2, DEN-3,
and JEV). The natural NS1 protein in cell culture supernatant was used to determine the specificity
of the DAS-ELISA. Four similar flavivirus and the ZIKV were added into each well precoated with
pAb R1, and the plate was incubated for 2 h at 37 ◦C. Thereafter, mAb-HRP probes were added and
recognized with the antigen. After washing the plate three times with PBS-T, 100 μL of TMB was added,
and the plate was incubated at 37 ◦C. Negative and positive samples could be easily distinguished by
the naked eye after 15 min. The optical density of each well was measured using a microplate reader.
The sensitivity of the DAS-ELISA was established using the recombinant ZIKV-NS1 protein serially
diluted in water, for the final concentrations of NS1 protein from 500 μg mL−1 to 0.122 μg mL−1.
The following steps were the same as those previously described.
2.10. Application of the DAS-ELISA for the Detection of ZIKV Infection in Cells and Tree Shrews
The test for the application of the DAS-ELISA, supernatants, and cell lysates from Vero and BHK
cells, as well as sera from three tree shrew infected with ZIKV were used. In brief, Vero and BHK
cells were infected with one multiplicity of infection (MOI) and cultured in the presence of 1% FBS.
The supernatants and cell lysates of infected Vero and BHK cells were collected at different times (12,
24, 36, 48, 60, and 72 h) and used for the DAS-ELISA assay. On the other hand, tree shrews were
subcutaneous inoculated with 1 × 106 PFU of the ZIKV. Tree shrews’ sera were collected at different
infection times (from 1 to 15 days) and used for the DAS-ELISA assay described above.
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3. Results
3.1. Expression and Purification of the ZIKV-NS1 Protein
The ZIKV-NS1 gene was amplified from the cDNA of infected cells and cloned into the pET-32a (+)
expression vector. The pET-32a-NS1 plasmid was transformed into E. coli Rosetta (DE3) cells, and the
transformation was confirmed by PCR (Figure 1A, lane 1). Thereafter, the recombinant NS1 protein
was expressed after induction with 1.0 mM IPTG for 10 h at 20 ◦C (Figure 1B, lane 1). The expressed
NS1 protein was purified using a Ni2+-NTA resin column (Figure 1B, lane 3).
Figure 1. Analysis of the recombinant vector construction and expression of recombinant ZIKV-NS1
protein. (A) Identification of the positive clone of pET-32a-NS1 by bacteria polymerase chain reaction,
lane 1: positive clone; lane 2: blank control. (B) Lane 1: E. coli was induced with IPTG; lane 2: E. coli
before induced; lane 3: the purified ZIKV-NS1 after dialysis.
3.2. Evaluation of the Rabbit Antiserum
The recombinant NS1 protein was used as an immunogen for immunization. After repeated
immunizations in rabbits, the antiserum was produced. The reactivity and specificity of the rabbit
antiserum were evaluated by immunofluorescent and Western blot assays. As shown in Figure 2A,
the anti-ZIKV-NS1 serum (R1) reacted with the native NS1 protein in ZIKV infected cells, and the
negative control was not. The Western blot results showed that the rabbit pAb R1 specifically
recognized the recombinant NS1 protein, as well as the native NS1 protein in cells infected with
the ZIKV (Figure 2C,D).
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Figure 2. Evaluation of the pAb R1 and mAbs against ZIKV-NS1 protein. (A) Indirect immunofluorescent
assay of the mAbs and pAb R1, Scale bar = 100 μm. (B) ELISA test of the mAbs and pAb R1. (C) Western
blot analysis of the pAb R1; lane 1: E. coli Rosetta (DE3) without IPTG; lane 2: E. coli Rosetta (DE3) induced
with IPTG; lane 3: the purified ZIKV-NS1. (D) ZIKV infected (lane 1) and mock-infected Vero cells (lane 2)
were used for Western blot analysis using pAb R1. (E) Mock-infected (lane 1) and ZIKV infected Vero cells
(lane 2) were used for Western blot analysis using mAb 1F12.
3.3. Characterization of the Ascites Against NS1 Protein
Ascites of the nine hybridomas were prepared and purified using protein A Sepharose.
The reactivity and specificity of the nine ascites were determined using an immunofluorescent assay
and an ELISA. All mAbs were further verified by the immunofluorescent assay. The results showed
that all Abs recognized the native NS1 protein in cells infected with the ZIKV, and the negative control
had no fluorescence (Figure 2A). Furthermore, the results of the ELISA assay showed that the nine
mAbs reacted with the recombinant NS1 protein (Figure 2B).
3.4. Establishment of the DAS-ELISA
Several Ab pairs were screened to develop the DAS-ELISA. In brief, the mAbs were labeled
with HRP probe and used for ELISA (Figure 3A). Thereinto, HRP-labeled mAbs (2A7, 4G6, 3F1, 1F4,
3G12, 2C4, 1G2, 2C9, and 1F12) and unlabeled pAb R1 were prepared in different combinations for
the pre-experiment. The absorbance values indicated that R1 and 1F12 were more effective than the
other combinations (Figure 3B). Besides, R1 and 1F12 were titrated by the ELISA (Figure 3C,D). Horse
radish peroxidase (HRP) labeled mAb 1F12 and pAb R1 were used for subsequent specificity and
affinity experiments. The KD values of HRP-labeled mAb 1F12 and pAb R1 were measured using an
affinity test, and the results were analyzed by non-linear regression using software GraphPad Prism
6. Their KD values were calculated as KD = 1.77 ± 0.206 nM for the HRP-labeled mAb 1F12 and
KD = 0.868 ± 0.0816 nM for pAb R1 (Figure 3E). Lastly, pAb R1 and mAb 1F12 were purified, and their
purity was confirmed by SDS-PAGE (Figure 3F). According to Figures 3 and 3, pAb R1 functioned as
the capture Ab and mAb 1F12 functioned as the signal Ab, and they were the best combination for
detecting the ZIKV.
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Figure 3. Characteristics of the key components of the DAS-ELISA. (A) The reactivity of nine mAbs
conjugated with HRP, 5% skimmed milk as the blank control. (B) Nine different groups for DAS-ELISA,
the blank control was 5% skimmed milk. The titer of pAb R1 (C) and mAb 1F12 (D) at different dilution
ratios were determined by ELISA, 5% skimmed milk as the blank control. (E) The saturation curves
for determination of the dissociation constants of mAb 1F12 and pAb R1. (F) SDS-PAGE analysis of
purified mAb 1F12 (lane 1) and pAb R1 (lane 2).
3.5. Optimization Operations
To achieve a high sensitivity, a short detection time, and a low cost, the individual steps of the
DAS-ELISA were optimized. Firstly, a suitable buffer for pAb R1 was identified using three commonly
employed coating buffers (PBS buffer, TBS buffer, and CBS buffer). As shown in Figure 4A, CBS buffer
had the highest coating efficiency. Secondly, the time and temperature for the immobilization of pAb
R1 onto the plate were optimized. Figure 4B showed that the absorbance was higher at 37 ◦C than at
4 ◦C with increasing incubation time from 60 to 120 min. However, there was no significant difference
when the incubation time or temperature was raised. Thirdly, the optimal concentration of pAb R1
and mAb 1F12 was determined when R1 and HRP-1F12 Ab s were serially diluted and incubated with
a fixed amount of the recombinant NS1 protein, respectively. The results showed that the capturing
efficiency of the R1 and HRP-1F12 Ab s increased between 10 μg mL−1 and 15 μg mL−1. There was no
obvious change in the curve at concentrations greater than 10 μg mL−1 and 15 μg mL−1, respectively
(Figure 4C,D). Moreover, we also established the temperature and time of antigen binding for pAb
R1. The results of the ELISA indicated that the antigen was able to be completely bound by R1 at
37 ◦C (Figure 4E). Lastly, the binding of the HRP-1F12 probe to the recombinant NS1 protein was
investigated when pAb R1 was combined with the NS1 protein and the HRP-1F12 antibody were
added into the wells, and incubated at 37 ◦C or 4 ◦C, for different time periods. The results showed
that the suitable time and temperature were 1 h at 37 ◦C (Figure 4F).
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Figure 4. Optimization operations of DAS-ELISA. Optimum coating solution (A), coating temperatures
and times (B) of pAb R1. Optimum working concentration of pAb R1 (C) and HRP-labeled mAb
1F12 (D). (E) Optimum incubating temperatures and times of antigen. (F) Optimum incubating times
and temperatures of mAb 1F12-HRP probe.
3.6. The Specificity and Sensitivity of ZIKV Detection by DAS-ELISA
The specificity of the DAS-ELISA was evaluated with others similar flaviviruses. As shown in
Figure 5A,B, the presence of the ZIKV and the recombinant ZIKV-NS1 protein were defined by the
yellow color and the optical density of the solution, respectively. At the same time, the sensitivity of
the DAS-ELISA was established using the recombinant NS1 protein serially diluted from 500 μg mL−1
to 0.122 μg mL−1. Figure 5C,D clearly show that the color of the solution and the optical density
gradually reduced with decreasing concentrations of the recombinant NS1 protein. Figure 5E shows
a good linear relationship when the concentration of the NS1 protein ranged from 500 μg mL−1 to
0.122 μg mL−1, with a correlation coefficient of 0.9984. Within this range, the DAS-ELISA is useful for
quantitative analysis, with a sensitivity of 0.122 μg mL−1.
Figure 5. Specificity and sensitivity of the DAS-ELISA. (A) Specificity of the DAS-ELISA: well 1
represents the recombinant ZIKV-NS1 protein; well 2 represents the natural NS1 protein in the cell
culture supernatant that infected with ZIKV; well 3−6 represent the natural NS1 protein in the cell
culture supernatant infected with DEN-1, DEN-2, DEN-3, and JEV, respectively; and well 7 represents
the blank control. (B) Optical density for the detection of different viruses. (C) Sensitivity of the
DAS-ELISA: well 1−13 represent the different concentrations of recombinant ZIKV-NS1 proteins
(500 μg mL−1–0.122 μg mL−1), well 14 represents the blank control. (D) Optical density for the
detection of different concentrations of recombinant ZIKV-NS1 protein (500 μg mL−1–0.122 μg mL−1).
(E) The plotted linear curve based on the different concentrations of recombinant ZIKV-NS1 protein.
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3.7. Application of the DAS-ELISA for ZIKV Detection in the Supernatants, Cell Lysates of Cells, and the Sera
of Tree Shrews
To test the application of the DAS-ELISA, supernatants, and lysates from Vero and BHK cells,
as well as sera of tree shrews infected with ZIKV were used. In brief, Vero and BHK cells were infected
with viruses at one multiplicity of infection (MOI). The supernatants of the infected cells were collected
at different infection times and concentrated. Thereafter, 100 μL of the supernatant or cell lysates was
used for DAS-ELISA assay, respectively. The results of the DAS-ELISA showed that the supernatants
and lysates of Vero and BHK cells collected at 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h were detectable
(Figure 6A–D). Furthermore, the ZIKV was used to infect tree shrews. Thereafter, tree shrews’ sera
were collected at different infection times for DAS-ELISA. Figure 6E,F shows that the DAS-ELISA
detected the ZIKV, even at eight days after infection. Moreover, the ZIKV-infected supernatants and
sera were used for RT-qPCR using specific primers and probes (Table 1) to confirm the existence of
ZIKV (Figure 6G,H), whereas the Western blot assay was carried out to detect the NS1 protein in the
supernatants and lysates of cells (Figure 6I).
Table 1. Primers used for RT-qPCR.




Figure 6. Detection of the ZIKV-NS1 protein in cell culture supernatants and lyates, as well as sera of
animal infection model by the DAS-ELISA. Supernatants (A,B) and cell lysates (C,D) of Vero and BHK
cells infected with ZIKV from 12, 24, 36, 48, 60, and 72 h were detected by DAS-ELISA. (E,F) Sera of tree
shrews infected with ZIKV from 1 to 12 days were detected by DAS-ELISA. A Real-time quantitative
reverse transcription polymerase chain reaction analysis of the supernatant of Vero, BHK (G) and the
sera of tree shrews (H) after infected with ZIKV. (I) Western blot assay of supernatants and cell lysates
of BHK and Vero cells infected with ZIKV.
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4. Discussion
The ZIKV is an emerging mosquito-transmitted flavivirus that causes severe disease, including
congenital birth defects during pregnancy [3]. Recently, an outbreak of the ZIKV in Northeast Brazil
led to an alarming number of babies born with microcephaly in this region [29]. Based on the current
clinical manifestations, it is very difficult to detect the ZIKV, especially in the early stages of infection.
Regardless, the early diagnosis of ZIKV infection is important because it is a major factor in the
treatment of patients and in the control of future outbreaks [30].
Traditional diagnostic methods that involve serological techniques and virus isolation are
considered as the golden methods. However, these methods are time consuming, with low specificity.
Fluorescence quantitative polymerase chain reaction (PCR) has been widely used in the detection of
the ZIKV, due to its high sensitivity and specificity [31]. Although this method is reliable, most regions
of the world do not have access to the expensive equipment, as well as the stable power required to
operate the system. Due to the limited window period of virus detection, it is difficult to diagnose
patients one to two weeks after the onset of symptoms [25,32].
Thus, it is very important that this issue of virus detection be addressed. A rapid, accurate,
and sensitive diagnostic technique is urgently needed for early detection of ZIKV-infected patients,
which can effectively control ZIKV transmission.
In this study, the NS1 protein was purified and used as antigen to immunize rabbit and mice.
Nine mAbs and one pAb were prepared and screened using ELISA, Western blot, and indirect
immunofluorescent assay. Based on the two Abs, the DAS-ELISA was developed for the detection of the
ZIKV-NS1 protein. The specificity and sensitivity of the DAS-ELISA were successfully demonstrated.
Moreover, the practical application of the DAS-ELISA was also determined using the supernatants
and lysates from Vero and BHK cells, as well as the serum of tree shrews that were infected with ZIKV.
Moreover, all samples used for the DAS-ELISA assay were screened by RT-qPCR and Western blot to
confirm the existence of the ZIKV. The results showed that ZIKV existed in the supernatants of infected
Vero, BHK cells, and the sera of infected tree shrews. In addition, we observed the natural ZIKV-NS1
protein secreted into the cell culture supernatant. Furthermore, the ZIKV tree shrew model confirmed
the accuracy of the DAS-ELISA we established. Figure 6E,F revealed that the native ZIKV-NS1 protein
was present in the serum from two to eight days after infection. However, we found that the RNA of the
ZIKV was detectable by RT-qPCR at three days after infection in tree shrews, and it was undetectable
after three days. Compared to RT-qPCR, the DAS-ELISA can monitor the presence of the NS1 protein
from two to eight days. Therefore, the DAS-ELISA developed here can accurately and quickly detect
the ZIKV.
Due to the lack of human clinical samples, we could not use the DAS-ELISA to screen the sera
from patients infected with the ZIKV. In cases requiring the screening of clinical samples, the sera of
ZIKV-infected patients were collected and added for DAS-ELISA according to the above procedures.
Positive results were defined as the ratio of the value to the background value that was greater than
2.1, which was biologically significant. Furthermore, the positive results could be judged by the naked
eye, as the solution was yellow after adding 50 μL of 2 M H2SO4. The DAS-ELISA developed here,
like many other rapid detection methods, is not guaranteed to generate accurate diagnoses 100% of
the time. Regardless of the positive results obtained from nucleic acid tests, the DAS-ELISA or another
assays, still requires a second or even a third method to confirm the results.
In conclusion, a rapid, sensitive, and reliable method for the detection of ZIKV antigens was
developed based on the sandwich ELISA. By targeting the NS1 protein, two Abs were prepared and
screened by the DAS-ELISA. The specificity, sensitivity, and practical application of the DAS-ELISA
were successfully established for monitoring ZIKV infection. Therefore, the DAS-ELISA developed
in this work can serve as a potential tool for monitoring the virus in a variety of clinical samples and
guiding the timely treatment of patients.
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Abstract: Zika virus (ZIKV) has spread widely in the Pacific and recently throughout the Americas.
Unless detected by RT-PCR, confirming an acute ZIKV infection can be challenging. We developed
and validated a multiplexed flavivirus immunoglobulin M (IgM) microsphere immunoassay
(flaviMIA) which can differentiate ZIKV-specific IgM from that due to other flavivirus infections in
humans. The flaviMIA bound 12 inactivated flavivirus antigens, including those from ZIKV and
yellow fever virus (YFV), to distinct anti-flavivirus antibody coupled beads. These beads were used
to interrogate sera from patients with suspected ZIKV infection following travel to relevant countries.
FlaviMIA results were validated by comparison to the ZIKV plaque reduction neutralization test
(PRNT). The results highlight the complexity of serological ZIKV diagnosis, particularly in patients
previously exposed to, or vaccinated against, other flaviviruses. We confirmed 99 patients with
ZIKV infection by a combination of RT-PCR and serology. Importantly, ZIKV antibodies could be
discriminated from those ascribed to other flavivirus infections. Serological results were sometimes
confounded by the presence of pre-existing antibodies attributed to previous flavivirus infection
or vaccination. Where RT-PCR results were negative, testing of appropriately timed paired sera
was necessary to demonstrate seroconversion or differentiation of recent from past infection with or
exposure to ZIKV.
Keywords: Zika virus; serology; flavivirus; microsphere immunoassay; validated; optimised;
dengue virus
1. Introduction
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) assigned to the genus Flavivirus of the
family Flaviviridae. The virus was identified in 1947 in Uganda [1]. Following outbreaks in western
Pacific and southern Pacific regions, ZIKV has been grouped into three genetically distinct lineages,
East African, West African and Asian. Most infections have been reported to be asymptomatic [2].
When present, signs and symptoms are nonspecific and overlap with those due to other often
co-circulating arboviruses including dengue virus (DENV) [3]. A suspected human case of ZIKV
disease may include rash, fever, conjunctivitis, arthralgia, arthritis, myalgia, headache, malaise and
fatigue [4]. After an outbreak in French Polynesia in 2013–2014, neurological complications and
congenital cerebral malformations were identified [3,5]. From 2015, a relationship between ZIKV,
congenital infection and central nervous system malformation and disease became known as congenital
Zika virus syndrome [6–8]. Where resources permit, PCR-based molecular diagnostics are used to
support clinical decision-making by detecting acute infection. Molecular methods to detect arboviruses
Viruses 2018, 10, 253; doi:10.3390/v10050253 www.mdpi.com/journal/viruses514
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are less effective when samples have low viral loads such as occurs during the short-lived viremia
caused by ZIKV. Serology extends the infection identification window but is often cross-reactive; that is,
antibodies triggered by one flavivirus infection may react with various other flaviviruses. In some
instances, an extended panel of serological virus testing may assist in getting a specific diagnosis.
We previously described an IgM capture ELISA (MAC-ELISA) which could sensitively and
specifically differentiate between infections due to any of the four DENV serotypes, Japanese
encephalitis virus (JEV), Murray Valley encephalitis virus (MVEV), Kunjin virus (KUNV), Alfuy virus
(ALFV), Kokobera (KOKV) and Stratford virus (STRV) [9]. We subsequently developed a novel
multiplexed flavivirus IgM typing microsphere immunoassay (flaviMIA) to replace the MAC-ELISA,
with the inclusion of YFV and eventually, in response to the sudden outbreak across the South Pacific
region, ZIKV. We use the flaviMIA diagnostic assay to differentiate IgM antibodies to locally acquired
and commonly imported flaviviruses [10].
We describe the development, validation, challenges and application of the flaviMIA consisting
of a panel of 12 flaviviruses which are either endemic or relevant to travelers visiting or returning to
Australia. The flaviMIA allows identification of plaque reduction neutralization test (PRNT)-confirmed
ZIKV-specific IgM among sera sent to a public health virology laboratory for characterization.
2. Materials and Methods
2.1. Bead Coupling to Monoclonal Antibody for FlaviMIA
Bio-Plex Pro Magnetic carboxylated beads (Bio-Rad, Hercules, CA, USA) were coupled to the
6B6C-1 flavivirus monoclonal antibody [11] using a Bio-Plex Amine Coupling Kit (Bio-Rad, USA).
Generally, 1.25 × 106 beads were coupled to approximately 10–12 μg of antibody. The antibody was
either purified in-house from stocks of murine ascitic fluid, or obtained commercially (Millipore,
Burlington, MA, USA). Coupled microspheres were stored at 4 ◦C at approximately 107 beads per mL.
2.2. Production of Purified Whole Virus Antigen Preparations for FlaviMIA
ZIKV strain MR766 was sourced from the American Type Culture Collection (Manassas, VA,
USA). This was the only strain available at short notice permitting us to rapidly develop tests in
response to a public health need. The literature suggests there is only a single serotype of ZIKV
and there is no evidence that different phylogenetic lineages react differently to IgG and IgM [12].
The vaccine strain of YFV (17D) was used to prepare YFV antigen. Other flaviviruses (DENV
serotypes 1–4, JEV, MVEV, KUNV, ALFV, KOKV and STRV) were as described previously [9,13].
ZIKV was cultured in the C6/36 mosquito cell line for seven days in Gibco Opti-MEM Reduced
Serum Medium (Thermo Fisher Scientific, Waltham, MA) + 0.2% Bovine Serum Albumin Fraction
V (Thermo Fisher Scientific, Waltham, MA, USA) followed by virus inactivation for 24 h using
binary ethyleneimine (BEI) prepared from 2-Bromoethylamine hydrobromide (Sigma-Aldrich, St.
Louis, MO, USA [14]). ZIKV was concentrated from the supernatant using Amicon Ultra 3 kDa
centrifugal filters (Millipore, USA), following which the viral inactivation was confirmed by three
serial passages in C6/36 cells followed by immunofluorescence testing using a panel of monoclonal
antibodies. The other flaviviruses were prepared by cross-flow filtration and inactivated as previously
described [14]. Where required, the preparations were further concentrated using Amicon filters as
described above. Mock (control) preparations were created from uninfected cells.
2.3. Binding of Flavivirus Preparations to Monoclonal Antibody-Coupled Microspheres for FlaviMIA
Each inactivated virus preparation was pre-titrated to determine optimal working dilution by
flaviMIA testing of serial two-fold dilutions against known positive human sera and selecting the
dilution giving maximum reactivity. Each virus preparation was diluted to 4 mL in MIA buffer
(PBS + BSA (Sigma-Aldrich, USA) + ProClin300 (Sigma-Aldrich, USA) as a preservative) then mixed
with its corresponding 6B6C-1-coupled beadset at 1:20. The virus–bead mixes were stored in
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light-resistant 4 mL bottles (Amber bottles, Nalgene, Rochester, NY, USA) which were incubated
at room temperature on a shaker for several hours after which they were stored at 4 ◦C.
2.4. Reference Sera
Because infections by various viruses included in the flaviMIA occur infrequently (e.g., MVEV,
ALFV, and STRV), characterized clinical reference sera are rare and often unavailable commercially.
Where possible, reference sera were sourced from IgM positive patients with RT-PCR-confirmed
recent flavivirus infections who were willing to donate a large volume of sera for laboratory quality
assurance purposes. When this was not possible, control sera were constructed by pooling reactive
patient samples.
2.5. Flavivirus Screening Assays
Patient serum samples referred to our laboratory from public hospitals or private diagnostic
laboratories specifically for flavivirus serology were first screened for flavivirus IgG and IgM by
in-house ELISAs (Figure 1). These ELISAs employ a pool of flaviviruses, as listed above, prepared
using pre-titrated antigens at equivalent dilutions, combined into a 100 mL volume in 1× Milk
Diluent (prepared from Milk Diluent/Blocking Solution Concentrate (Kirkegaard & Perry Laboratories,
Gaithersburg, MD, USA)). A control pool was prepared from a mock antigen preparation from
uninfected cells at the same combined dilution as the viral antigens. Specimens which exhibited
flavivirus IgG reactivity in the absence of IgM by ELISA were reported as resulting from probable past
flavivirus infections and a follow-up specimen was requested. Specimens giving positive results in
the flavivirus IgM MAC-ELISA were then tested by flaviMIA to determine the specificity of the IgM,
if possible (Figure 1).
Figure 1. Test algorithm for flavivirus serology requests. When requested, sera are screened
for flavivirus IgG and IgM by in-house ELISAs employing a pool of purified flaviviruses.
Specimens determined to be reactive or equivocal in the flavivirus MAC-ELISA are then tested by the
multiplexed flavivirus IgM typing microsphere immunoassay (flaviMIA). Specific RT-PCR tests may
also be conducted on the sample as appropriate.
516
Viruses 2018, 10, 253
Upon request, sera were also tested using two real-time RT-PCRs targeting the Asian lineage ZIKV
non-structural protein 1 or envelope gene (Figure S1) [10]. A validated, previously described African
lineage ZIKV real-time RT-PCR assay was available if travel history indicated a need. Both RT-PCRs
were challenged using samples known to be positive for Chikungunya virus, each of the four DENV
serotypes as well as a range of related sample types submitted for viral investigations of patients
with related clinical presentations. Both tests were 100% specific. Briefly, 5 μL of RNA extracted from
patient samples using the BioRobot® Universal System and QIAamp One-For-All Nucleic Acid Kit,
(Qiagen, Hilden, Germany) or EZ1 and Virus Mini Kit v2.0, (Qiagen, Hilden, Germany) were added to
15 μL RT-PCR reactions (SSIII Platinum One-Step qRT-PCR System, Invitrogen, Carlsbad, CA, USA;
oligonucleotide sequences described previously [10]) and amplified using a RotorGene thermal cycler
(Qiagen, Hilden, Germany). Samples were reverse transcribed for 5 min at 50 ◦C, incubated at 95 ◦C
for 2 min, and then subjected to 40 cycles of 95 ◦C for 3 s and 60 ◦C for 30 s.
2.6. Flavivirus-Specific IgM Serology—FlaviMIA
Flavivirus IgM ELISA-positive serum specimens were treated with rheumatoid factor (RF)
removal reagent (RF absorbent, Dade Behring, Deerfield, IL, USA) to remove potentially interfering
IgG and rheumatoid factor. This was performed in a microtiter plate with 5 μL serum diluted 1:20 in
95 μL MIA buffer. RF removal reagent was added (100 μL) to each well, followed by incubation at
room temperature for 15 min and a final dilution of 1:800 in MIA buffer.
The flaviMIA antibody binding reaction was then performed in 96-well filter plates (Millipore,
USA), in wells pre-wetted with PBS-Tween. Each flavivirus and control beadset were further diluted
1:20 in MIA buffer in sufficient volume for the number of samples being tested. The bead mixture was
added to the wells of the plate at 100 μL per well followed by washing in PBS-Tween using a Bio-Plex
Pro II washer. Diluted sera were added to the plate, along with a specific positive control serum for
each virus, and a negative serum in duplicate. The plate was incubated at room temperature with
shaking for 45 min after which the washing was repeated. Phycoerythrin-labelled donkey anti-human
IgM antibody (Jackson Immuno Research, West Grove, PA, USA) was diluted to previously-determined
optimal concentration in MIA buffer and added to each well of the plate. Incubation and wash steps
were repeated and the beads were resuspended in each well by addition of 150 μL MIA buffer.
The plate was read on a Bio-Plex 200 instrument (Bio-Rad, USA), with 100 beads per well read
in 100 μL of buffer using Bio-Plex Manager® software (Version 6.0, Bio-Rad, Hercules, CA, USA).
Results were exported to Microsoft Excel® and presented graphically for easier determination of
specificity and analysis. A mean fluorescent intensity (MFI) cut-off of 2000 units was assigned based
on comparison to RT-PCR-confirmed dengue sera; values above 2000 were considered a positive result.
Specificity determinations were based on the MFI result of one viral beadset preparation being 1.5 times
higher than the MFI of any other beadset in the panel. Where a single virus-specific IgM could not be
determined, i.e., if there was reactivity to two or more flaviviruses in the panel (excluding between
dengue serotypes) the result was reported as “cross-reactive” (Figure 2). This cross-reactivity is known
to occur in human sera following infection with a single virus, but the possibility of co-infection with
at least two viruses is also known to occur and should be considered a possibility.
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Figure 2. Multiplexed flavivirus IgM microsphere immunoassay (flaviMIA) result examples
highlighting specific and cross-reactive IgM reactivity. (A) The intensity of the anti-ZIKV IgM signal,
reported as mean fluorescence intensity (MFI, y-axis) compared to 11 other viruses (x-axis) used in
the flaviMIA defined this sample from Patient Reference No. 7 as clearly containing ZIKV-specific
IgM. (B) This ZIKV RNA positive representative sample from Patient Reference No. 11 was classified
as having cross-reactive IgM towards both ZIKV and DENV. Red shading indicates the MFI signal
range from a seronegative result; green shading indicates the region into which seropositive results
fall. DENV, Dengue virus; JEV, Japanese encephalitis virus; MVEV, Murray Valley encephalitis virus;
KUNV, Kunjin virus; ALFV, Alfuy virus; KOKV, Kokobera virus; STRV, Stratford virus; YFV, Yellow
fever virus; ZIKV, Zika virus.
2.7. ZIKV PRNT
Because PRNT is considered a gold standard assay for confirmation of flavivirus antibodies,
a ZIKV PRNT was conducted to interrogate ZIKV results from the ZIKV component of the flaviMIA.
Sera were screened at a dilution of 1:10 after incubation at 37 ◦C for 90 min with an equivalent
volume of diluted ZIKV MR766 whole virus antigen preparation. Serum from a confirmed ZIKV
Asian lineage infected patient was used as a positive control and a pool of flavivirus negative sera
was used as the negative control. ZIKV was pre-titrated to give approximately 75 plaques per well
of a 6-well plate. After incubation, 100 μL of each serum/virus mix was inoculated in duplicate
into 6-well plates seeded one day previously with Vero cells (ATCC® CCL-81TM). Following virus
absorption for 60 min, the cells were overlaid with a medium containing Gibco Opti-MEM (Thermo
Fisher Scientific, Waltham, MA, USA), 3% foetal bovine serum (In Vitro Technologies, Noble Park
North, Australia) and 1.5% carboxymethylcellulose (Sigma Aldrich, USA). The Vero cell plates were
then incubated for seven days, after which the supernatant was removed and the cells washed with
PBS and stained with naphthalene black stain (0.1% (w/v) naphthol Blue Black, 6% (v/v) glacial acetic
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acid, 1.36% sodium acetate). Plaques were counted and sera (at 1:10) demonstrating >90% plaque




For the purpose of validation of the assay for ZIKV diagnosis, 38 acute phase sera and
25 convalescent phase (collected > 7 days after the first) sera from patients positive for ZIKV (RT-PCR
or PRNT confirmed cases) but who have no serological evidence of previous flavivirus infection
(primary ZIKV cases), 834 acute and convalescent-phase sera known to be positive for one of nine
other flaviviruses and 70 flavivirus IgG and IgM screening ELISA negative sera were analyzed by
flaviMIA (Table S1). The sensitivity was found to be 47.4% for acute sera and 100% for convalescent
sera. Specificity of the assay was found to be 100%. The flaviMIA processing time varies depending on
number of samples per run, but can be completed in as little as 2.5 h.
A strain from the ZIKV Asian lineage [15] was isolated from an infected traveler and used to
create a purified whole virus antigen preparation to test representative sera to investigate whether
both lineages performed similarly. Parallel testing of serum from six ZIKV-infected patients showed
no significant titer differences between the African lineage and Asian lineage antigens (less than a
two-fold difference in PRNT90 titer).
3.2. Analysis of Patient Samples
In responding to clinical and public health need, our laboratory has identified a total of 101 patients
with flaviMIA results indicating specific IgM to ZIKV (Table 1). Of these, 43 were determined to be
recent primary ZIKV infections (no serological evidence of previous flavivirus infection, Group 1)
and 21 were recent secondary infections (flavivirus IgG or IgM in the acute sample suggestive of
previous infection by, or vaccination with, another flavivirus, Group 2). A further 14 were determined
as past ZIKV infections with persistent IgM as no change in antibody level was detected between acute
and convalescent paired sera (Group 3). Two patients had serological results consistent with a recent
dengue infection with a history of ZIKV infection, however concurrent infection with both viruses
could not be excluded (Group 4). For 19 patients, ZIKV specific IgM was detected by flaviMIA and
confirmed by PRNT, however, in the absence of a convalescent specimen collected ≥7 days post-onset,
ZIKV infection could not be determined as having occurred recently (Group 5). A further two patients
were found to be flaviMIA positive with ZIKV specific IgM but were neither RT-PCR nor PRNT
positive and therefore could not be confirmed as ZIKV positive. One of these (Reference No. 56) was
identified as a false ZIKV IgM positive as seroconversion was not demonstrated. The other (Reference
No. 77) may have been collected too early in infection for neutralizing antibodies to be detected,
but could not be excluded as a false positive.
3.3. Patients with Recent Primary ZIKV Infections
Of the 43 patients determined as having recent primary ZIKV infection, 23 (53.5%) had acute
samples which were negative by flaviMIA while 20 (46.5%) were positive. All but one of the positive
sera had specific ZIKV IgM. Twenty-eight (65.1%) of the 43 patients had a follow-up sample collected.
In 27 patients, the flaviMIA was specific for ZIKV, while the other patient exhibited cross-reactivity to
other flaviviruses (ZIKV positive, but reactivity also detected to DENV, JEV, ALFV and STRV).
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3.4. Patients with Recent Secondary ZIKV Infections
Our laboratory also tested samples from 21 patients whose results indicated that infection with
ZIKV was secondary to a previous flavivirus infection. Previous infection was determined by the
presence of flavivirus IgG (detected by ELISA) concurrent with the detection of ZIKV RNA or in one
case (Reference No. 24) Flavivirus IgG in the absence of IgM within five days of return from overseas
travel. Of the 21 acute sera, nine (42.9%) were negative and the remainder were positive by flaviMIA.
Six of the flaviMIA positive sera were ZIKV IgM specific, two were cross-reactive between ZIKV and at
least one other virus, while the remainder had IgM that specifically reacted to either DENV-2 or DENV-4
(both suggesting previous infection with these dengue serotypes) and two to YFV (consistent with
previous vaccination with YFV associated with travel to South America). Unfortunately, these prior
infections could not be confirmed (by PRNT) owing to routinely insufficient sample volume, however
pre-existing specific antibodies were confirmed by indirect fluorescent antibody test.
A convalescent serum sample was collected from 12 of the patients and each was tested in
parallel with its paired acute serum to demonstrate change in antibody levels. Eight of the follow-up
sera were positive and specific for ZIKV IgM including the acute sample with initial DENV-4
IgM (Reference No. 8), three from initially negative patients, three from the initially ZIKV-specific
patients, and from one patient whose acute sample was YFV IgM reactive (Reference No. 83).
Three further patients had cross-reactive IgM in the convalescent sample, two from initially negative
patients (Reference No. 23 and 36) and one from the DENV-2 specific patient (Reference No. 11).
One convalescent specimen (Reference No. 10) was DENV-2 specific by flaviMIA with ZIKV infection
clearly demonstrated by both RNA detection and PRNT. Co-infection of ZIKV and DENV in this
patient cannot be excluded, although DENV RNA was not detected.
3.5. Patients with Past ZIKV Infection
Past ZIKV infection was demonstrated in 14 patients by parallel testing demonstrating stable
antibody levels between the samples. One of the 14 acute samples had cross-reactive IgM
(Reference No. 90) while the remainder were ZIKV IgM specific. All convalescent sera were ZIKV-IgM
specific and all were confirmed by PRNT.
3.6. Patients with ZIKV/DENV IgM
Patient Reference No. 17 had a single sample which was DENV-1 RNA positive, but the flaviMIA
result was ZIKV IgM specific. The sample was also positive by ZIKV PRNT, suggesting previous
infection or exposure to ZIKV. Balmaseda et al. reported DENV-1 to be the most common DENV to
cross-react with ZIKV [16].
Patient Reference No. 22 was found to have ZIKV-specific IgM and ZIKV neutralizing antibodies
in the acute sample, while the flaviMIA result on the convalescent sample showed cross-reactive
IgM between ZIKV and DENV. This result is suggestive of dengue infection secondary to an earlier
infection or exposure to ZIKV.
4. Discussion
Huge numbers of suspected ZIKV infections were recorded across the Americas in 2015 and
2016 but most were not confirmed by laboratory methods. This and other regions have co-circulating
viruses which can produce a clinically indistinguishable initial picture to that from ZIKV infection.
Laboratory methods are the only way to ensure accurate diagnoses. With the discovery of congenital
Zika virus syndrome, robust diagnosis to support patient prognosis has become more urgent however,
definitive results require a complex and resource intensive process. Molecular methods used on serum
samples rapidly, sensitively and accurately identify ZIKV RNA but suffer from the short window of
detection using sera. Whole blood and urine may extend this window over testing of sera alone [17,18].
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Other researchers have described new serological tests incorporating panels of flaviviruses but
these usually include fewer virus targets than we have, are region-specific, or use recombinant rather
than whole-virus antigens [16,19–22]. One MIA method included an avidity determination step to
reduce weaker, presumably less specific, false positive reactions, to good effect in known ZIKV or
DENV infected returning travelers or among Swedish blood donors [23]. However, this method yielded
low MFI values compared to the flaviMIA. Avidity testing also aided a new microarray platform which
performed better on convalescent than acute samples [22]. New and traditional culture-based methods
have also been described, but results can take days rather than hours, may remain unclear without
additional testing and generally only account for a subset of flaviviruses [24]. Each of these approaches
has advantages and disadvantages but it is important to include a well characterized specimen panel
assembled from travelers with a potentially complex history of past flavivirus exposures.
Paired sera, collected two weeks apart, are essential for antibody-based identification of virus
infection and serology is important to support the diagnosis of ZIKV infection. Despite only 60.6% of
our sera being paired, the addition of a convalescent sample frequently permitted clarification of an
initially unclear result as when IgM persisted from a past flavivirus infection or vaccination. This has
been reported by others [25]. Hence, an acute and a convalescent serum pair are desirable to measure a
seroconversion, a significant rise in specific antibody titer or a drop in titer against an unexpected virus.
Reactive flavivirus serology results on single samples cannot be reliably interpreted [24]. For some
patients with a clinical picture of ZIKV but a negative or equivocal or cross-reactive result from an
acute serum, collecting a convalescent serum can mean prolonging the final result. This is especially
unsatisfactory for pregnant women. Alternative rapid methods are needed, or testing of whole blood
or urine samples using RT-PCR, which are known to contain signs of virus for longer than serum.
In our study, a combination of RT-PCR and flavivirus serology identified and confirmed the
presence of ZIKV infection in 99 suspected cases. By combining molecular and serological techniques,
we could differentiate primary from secondary infections and recent from past infections in most cases
as described by others [26]. The difficulties of flavivirus laboratory investigations were exemplified by
results from two patients with evidence of past exposure to DENV (they were defined as secondary
flavivirus infections because of the presence of DENV IgG who were producing IgM which was
specific to DENV but not to the RT-PCR-positive current ZIKV infection. This may represent a new
DENV co-infection but is more likely to be evidence of “original antigenic sin” [27,28]; the anamnestic
production of antibody to a past (DENV) infection, resulting from a new yet different (ZIKV) infection
prior to the development of specific antibodies to the more recently encountered virus. Either outcome
would be unsurprising in travelers from geographic regions where a range of arboviruses may
co-circulate. Possible ZIKV co-infections are being reported more often as investigations broaden and
more inclusive testing protocols are employed [29–31]. A multifaceted approach to testing, rather than
reliance solely on RT-PCR or serology, would ideally improve results [32].
Patients originating from some areas of the world may have been exposed to multiple flaviviruses
over a lifetime. Among primary ZIKV infections, we found antibody reactivity by flaviMIA was
usually specific when follow-up samples were available and collected within a relevant time-frame
from onset of disease. In the case of secondary infections however, results were often less clear, with the
earliest detected antibody often directed towards a presumed earlier virus, or to prior YFV vaccination.
The flaviMIA is a specialized technique requiring an experienced laboratory. The use of a
multi-target antibody testing protocol such as this for screening samples from patients with suspected
flavivirus infections benefits from including viral targets most appropriate to a patient’s exposure
history [13].
The results of our study suggest that all patients with suspected ZIKV infection should have a
submitted specimen tested initially by RT-PCR (see Supplementary Materials). Where RNA is detected,
ZIKV infection is confirmed without further testing. However, where specimens are negative by
RT-PCR (due to late collection, poor sample quality or low viral load), then the flaviMIA is useful
to determine presence and specificity of flavivirus IgM. In some cases, PRNT may be required to
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confirm ZIKV infection. We suggest that a minimum of 1 mL of serum be supplied for testing to ensure
sufficient is available for all tests that may be required.
Our in-house flaviMIA protocol affords broad concurrent flavivirus serodiagnostic capacity.
In our professional laboratory setting, it proved easy to use, was amenable to high throughput testing,
had a short turnaround time and generated reproducible results. The flaviMIA was rapid in both
analysis time and in interpretation of results. However, our results highlight the complexities of
flavivirus diagnostic serology, which can be confounded by several factors including the presence
of cross-reactive antibodies and high titers of specific antibody to antigenically different viruses that
have resulted from recent or concurrent infection, vaccination or because of an anamnestic response
triggered by a new ZIKV infection.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/5/253/s1,
Figure S1: Comprehensive testing algorithm for ZIKV requests, Table S1: Validation of flaviMIA.
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Abstract: In the absence of viremia, the diagnostics of Zika virus (ZIKV) infections must rely on
serological techniques. In order to improve the serological diagnosis of ZIKV, ZIKV-IgA and ZIKV-IgG
avidity assays were evaluated. Forty patients returning from ZIKV endemic areas, with confirmed or
suspected ZIKV infections were studied. Samples were classified as early acute, acute and late acute
according to the number of days post illness onset. Low avidity IgG was only detected at acute and
late acute stages and IgA mostly at the early acute and acute stages. The date of sampling provides
useful information and can help to choose the best technique to use at a determined moment in time
and to interpret low avidity IgG and IgA results, improving the serological diagnosis of ZIKV.
Keywords: Zika virus; dengue virus; secondary infections; cross-reactions; IgA; IgG avidity tests
1. Introduction
Zika virus (ZIKV), an emerging flavivirus transmitted mainly by mosquitos from the genus Aedes,
is a cause of public health concern. Prior to 2015, ZIKV outbreaks occurred in Africa, Southeast Asia,
and the Pacific Islands. In May 2015, the Pan American Health Organization issued an alert regarding
the first confirmed ZIKV infections in Brazil [1]. Between 2015 and 2016, large outbreaks occurred in
many countries in South and Central America as well as in the Caribbean [2]. Travelling for work or
tourism between Portugal and Spain and Latin America is very common. Portugal reported ZIKV
infections imported from Brazil for the first time in June 2015 [3]. In Spain, the first case of imported
ZIKV infection was confirmed in January 2016 [4]. Shortly after, in March 2016, vertical transmission
in an imported case was detected, in a 17-week pregnant woman [5].
ZIKV disease can be diagnosed within two weeks after onset of symptoms in serum or plasma,
and up to three weeks in urine by real-time PCR (RT-PCR) [6]. However, in the absence of detectable
ZIKV RNA or available molecular techniques, the only diagnostic methodology available is serology.
The current knowledge on ZIKV antibody kinetics is still limited. In addition, the cross-reactivity
between ZIKV and other flaviviruses complicates serology. Thus, a positive result should always be
Viruses 2019, 11, 179; doi:10.3390/v11020179 www.mdpi.com/journal/viruses529
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confirmed by neutralization tests (NT), and even this assay is not always able to provide a definitive
determination of the specific flavivirus causing the infection, particularly in individuals with a history
of flavivirus infection or vaccination [6,7].
The co-circulation of DENV and ZIKV in some regions and the possibility of reinfections by
the four DENV serotypes and/or ZIKV highlight the need for reliable serological tests when no
molecular tools are available, or when viremia drops to undetectable levels in the patients. One way of
discriminating infections between related viruses is to characterize IgG avidity [8]. Immunoglobulin
G avidity is low after primary antigenic challenge but increases throughout progressively during
subsequent weeks and months due to affinity maturation and antigen-driven B-cell selection. Avidity
assays have been used to differentiate between acute or primary infection and persistent infection,
recurrent infection, or reactivated disease in a number of infections and have been successfully used
for flaviviruses such as West Nile and dengue viruses [8–12]. On the other hand, the IgA response has
also been used as an indicator of recent and active infections in dengue and West Nile cases [13,14].
The objective of this study was to evaluate ZIKV IgG avidity and ZIKV IgA in their application of
diagnosis of ZIKV infections.
2. Materials and Methods
2.1. Studied Samples
A total of 79 serum samples, collected from 56 individuals were analyzed. These included 62
samples from 40 patients returning from ZIKV endemic areas in 2015–2016 and received for ZIKV
diagnostics at the National Health institutes in Portugal and Spain. As controls, 16 patients (17 samples)
with known recent or past DENV infection (15 collected in 2012, before the outbreak in the Americas,
and one in 2016), were studied. The study was approved by the Ethical Committee of the Institute of
Health Carlos III (code: CEI PI 70_2018).
These patients were organized in three groups: (I) 29 patients (43 samples) with ZIKV infection
(cases confirmed by positive RT-PCR in at least one of the available samples for each patient) (Table 1);
(II) 11 patients (19 samples) with serological suspicion of ZIKV infection (seroconversion and/or
positive IgG and IgM and negative RT PCR) (Table 2); (III and IV) the control group, including patients
with known recent (nine patients, 10 samples) or past (seven patients, seven samples) DENV infection
(Table 3).
Time elapsed after illness onset (days post symptom onset, dpso) was available for 60 samples
(39 patients) in groups I and II, allowing us to classify the samples according to their infectious stage
as early acute (≤5 dpso, n = 18), acute (6–20 dpso, n = 25) and late acute (>20 dpso, n = 17) [7,15].
2.2. Serological Diagnostic
IgM and IgG for DENV were determined using commercial ELISA (Panbio, Standard Diagnostics
Inc., Geonggi-do, South Korea) (Spanish samples) or by in-house immunofluorescence as previously
described [3] (Portuguese samples); IgM and IgG for ZIKV were determined using commercial ELISA
kits (Euroimmun, Lübeck, Germany). DENV IgM in ELISA was confirmed by a background assay as
described [10].
ZIKV-IgG avidity and ZIKV-IgA were tested by ELISA (Euroimmun, Lübeck, Germany) according
to the manufacturer’s instructions. Samples with ratio avidity index (RAI) lower than 40% were
regarded as having low avidity and those with RAI higher than 60% as having high avidity. Values
between 40% and 60% were considered equivocal. Serum dilutions started at 1:101. As advised,
when the OD was >1.2 without urea treatment and the RAI was >60%, we did fourfold dilutions,
until the OD was <1.2, to avoid false high avidity results, according to manufacturer´s instructions.
Whenever the OD reached a value of less than 0.140 without urea treatment after tentative dilutions,
we considered as the final result the RAI’s of the last dilution with a valuable result. Results were
deemed as inconclusive when IgG dropped to a negative value after the next dilution. For the ZIKV
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IgA assay samples were classified according to the ratio referred to a calibrator as positive (ratio was
>1.1), equivocal (0.8–1.1) or negative (<0.8). All ZIKV ELISA tests were based on the NS1 protein.
Neutralizing antibodies were detected by an in house neutralization test, using Vero E6 cells
and 100 TCID50% of ZIKV (strain MR-766). Samples were titrated in two-fold dilutions from 1/32.
neutralization titers <1/32 were considered indicative of the absence of ZIKV neutralizing antibodies.
Specificity and sensitivity were calculated for ZIKV-IgG avidity and ZIKV-IgA. These parameters
were also calculated for both techniques together, considering as positive the patients positive for
both approaches.
2.3. Molecular Diagnostics
RT PCR for ZIKV was performed with RealStar®Zika Virus (altona Diagnostics, Hamburg,
Germany) at Institute of Health Carlos III (Spain) or with the RT-PCR as previously described [16] at the
National Institute of Health Dr. Ricardo Jorge (Portugal). Positive results were confirmed in a second
amplification using the method described by Balm and co-workers with slight modifications [17].
The performance in both countries has been evaluated through external quality assays [18] showing
equivalent results.
3. Results
All patients in whom ZIKV infection was confirmed or suspected were infected in countries
from the Caribbean, South and Central America except for patient P4 who had sexually acquired the
infection (Tables 1 and 2).
In group I (Table 1), regarding dpso, from 29 RT PCR positive samples, 15 were classified as early
acute infections, 13 as acute and only one patient, a pregnant woman, presented a positive RT PCR
result in a late acute infection (32 dpso). IgM was present in 14 samples (from 13 patients), ranging
from 3–58 dpso (median 20), one at the early acute stage, six at acute stage and seven at the late acute
stage. IgG was detected in 23 samples from 21 patients, ranging from 3–261 dpso (median 11), four at
the early acute stage, 10 at the acute stage and nine at the late acute stage. Nine samples (from nine
patients) presented low avidity (7–58 dpso, median = 21), three at acute and six at the late acute stage.
Two patients presented high avidity results, at a late acute stage (36 and 261 dpso). IgA was present
in 19 samples from 17 patients, ranging from 3–27 dpso (median 10), three at the early acute stage,
13 at acute stage and three at late acute stage. In this group, five samples from five patients presented
DENV IgM positive results and 28 samples from 21 patients were positive for DENV IgG.
In group II (Table 2), there were 10 samples (from eight patients) with IgM positive results (9–45
dpso; median = 15). Eight of those samples were collected at acute stage, one at a late acute stage and
one was unknown. Regarding IgG, 14 samples (10 patients) were positive (10–76 dpso; median = 24.5),
six at acute stage, six at late acute stage and two unknown. Low avidity was observed in nine samples
(8 patients; 10–49 dpso; median = 17.5) five at the acute stage and three at the late acute stage. A high
avidity result was presented by a patient at 19 dpso (late acute stage). IgA was present in 11 samples
from nine patients (7–19 dpso; median = 13), one at the early acute stage and eight at the acute stage.
In Group II, three patients also showed DENV IgM and 15 samples (9 patients) presented DENV IgG.
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In group III (Table 3), three patients showed ZIKV low avidity IgG (P44/S1, P45/S1 and P52/S1,
and three were equivocal (P42/S1, P53/S1 and P56/S1). In relation to ZIKV IgA, only one sample
(P56/S1) showed an equivocal result. All the other samples were negative for IgA.
Figure 1A,B summarize the serological results for samples from groups I and II for low avidity
IgG and IgA, respectively, related to the ZIKV infectious stages.
  
(A) (B) 
Figure 1. Serological testing in patients from groups I and II. (A) ZIKV IgG avidity results; (B) ZIKV
IgA Results.
In their application to identify ZIKV recent infection cases, the avidity IgG testing showed a
sensitivity value of 42.5% (17/40), (95% confidence interval [CI]: 28.5–57.8), being the specificity 62.5
(10/16) (95%CI: 38.6–81.5). Regarding ZIKV-IgA, sensitivity was 65% (26/40) (95%CI: 49.5–77.9)
and specificity was 93.8% (15/16) (95%CI: 71.7–98.9). For both approaches simultaneously,
the corresponding figures were 25% (10/40) (95% CI 14.2–40.2) and 100% (16/16) (CI95%: 80.6–100).
4. Discussion
All patients with suspected or confirmed ZIKV infection had traveled to countries with
co-circulation of ZIKV and DENV. In our study five ZIKV PCR positive patients also presented
with DENV-IgM positive results and/or low avidity and/or IgA positive results for ZIKV. Similar
results were also obtained in Group II, with three patients presenting serological positive samples
for both viruses. Steinhagen et al. [7], using the same assay we used here (NS1-based ELISA’s),
found no cross-reactivity between ZIKV and DENV IgM. As such, our results can lead us to the
suspicion of co-infection or, at least, shortly followed sequential infections with both viruses. Two
cases of co-infection have already been reported in Pernambuco, Brazil, during a DENV outbreak
in 2016 [19]. Other two in New Caledonia, 2014, one of those being autochthonous and the other
a patient returning from the French Polynesia [20]. However, cross reactivity between ZIKV and
DENV is well known [21,22]. In one study, sera from both DENV-naive and DENV pre-immune ZIKV
patients strongly bound to ZIKV as well as DENV, with cross-reactive antibodies targeting both E and
NS1 proteins. The four patient samples in that study were from primary ZIKV cases, where infection
occurred during travel to ZIKV-afflicted areas [21]. Moreover, Lanciotti and colleagues [23] suggested
that if ZIKV is causing secondary infections in a population with DENV (or other flaviviruses)
background immunity, extensive cross-reactivity in the dengue IgM assay can occur. In this way,
ultimate confirmation of co-infection would only rely on PCR positive results for both viruses.
Unfortunately, by the time of this study, there was no sample available to perform DENV PCR.
All these facts reinforce the need for serological tools to understand the time of infection in the
absence of active viremia. This discrimination is very important due to the clinical role of ZIKV
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infections in pregnancy, which can result in fetal malformations, or in men that can transmit the virus
sexually [24,25].
Overall, we had positive ZIKV-IgM results from day three to day 45. A recent similar study
reported positive ZIKV-IgM results as early as day two and until 42 dpso [26]. Then again, Kadkhoda
et al., using the same assay were able to detect positive IgM only at five dpso, testing a limited number
of samples (n = 13) [27]. In the present study, ZIKV IgM was not detected in 13 out of 29 PCR positive
patients. For seven of those 14 patients, the antibodies probably had not yet reached detectable levels,
since samples were collected at the early acute stage (≤5 dpso), as previously reported [7] but we
also cannot also exclude that the sensitivity of the technique may play its role in the results. Also,
intrinsic immune factors cannot be discarded and might account for differences between individuals
or populations, as reported by Lustig and colleagues who observed that ZIKV-IgM kinetics differed in
Israeli, European and Chilean travelers [26]. Alternatively, the absence of IgM anti-ZIKV at acute stages
concomitantly with high IgG ratio in some patients, may indicate a secondary infection. According to
our cases, an IgG ratio > 2.0 was often associated with equivocal or inconclusive avidity IgG results
and accompanied by a negative ZIKV-IgM result. Similar results were reported for DENV, where in
secondary infections, the IgM response was variable or absent, accompanied by a dramatic increase in
IgG antibodies [7,28]. Analogous kinetics has also been observed for ZIKV primary and secondary
infections during the ZIKV epidemic in Micronesia in 2007 [23]. All these results strongly suggest than
previous flavivirus infection could have an important impact on the interpretation of ZIKV avidity
assay. According to the manufacturer of the kit, false high avidity values may be recorded due to high
levels of antibodies, which may have been the case of patient P32, Table 2, whose follow up sample
was taken 19 dpso. In contrast, the high avidity result for sample P27/S3, (Table 1), was expected since
it represented a follow up sample taken nine months after onset of symptoms.
In relation to IgA testing, positive results were obtained in nine samples (eight patients) from
ZIKV infections, negative for IgM, two of them at the early acute stage, suggesting that IgA is detectable
before IgM. Interestingly, Balmaseda and colleagues suggested that detection of IgA is more sensitive
than IgM [29]. The majority of our ZIKV IgA positive results were obtained in samples collected at
the early acute and acute stages and only three at the late acute stage (S21/S2, 27 dpso, P28/S2, 21
dpso and P29/S2, 24 dpso, Table 1). Individual kinetics may be observed but, in general, IgA seems
to be of rapid appearance and short duration. As an example, in patient P33 with available paired
samples (Table 2), there was a positive IgA result on day nine which turned negative on day 30. These
results are in accordance with previous studies for other flaviviruses [13,14,27]. These facts can indicate
that ZIKV IgA might support recent ZIKV infection, thereby adding a tool for acute ZIKV infection
diagnostics with acceptable specificity and high sensitivity, as suggested by Zhang and colleagues [30].
Nearly all the patients in Group II showed some indicators of recent ZIKV infection even though
samples had not been tested or were PCR-negative (Table 2). Thus, all the patients in this group could
be considered infected by ZIKV.
In groups III and IV (recent and past DENV infections) three patients showed ZIKV low avidity
IgG (samples P44/S1, P45/S1 and P52/S1, Table 3). One of them, P44, worked on a cruise ship and was
exposed to DENV, acquiring the infection during the outbreak occurred in Madeira Island [31]; this
patient could have travelled to various countries and been exposed to other flaviviruses, namely by
vaccination for Yellow Fever, Japanese Encephalitis or Tick-Borne Encephalitis viruses. For the other
two patients there was no available information and thus we cannot totally exclude the possibility of a
ZIKV infection in none of them, in despite of the year in which the samples were taken (before the
Zika outbreak in the Americas). The three low and three equivocal ZIKA avidity results from Table 3,
that are from patients assumed to have solely a dengue or other flavivirus infection, illustrates the
on-going cross-reactivity within the flavivirus group. No positive results were obtained using the IgA
assay (only a sample showed an equivocal one), thus ensuring the specificity of this approach.
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The main limitation of this paper was the selection of samples, especially the controls. Control
cases were retrospectively selected as having a recent or past DENV infection, prior to the ZIKV
epidemics in the Americas. This selection was based on the fact that both viruses share epidemiological
and clinical issues, and a high degree of cross reactivity. Furthermore, the selection of the controls did
not consider the time elapsed after the onset, making difficult the comparison of cases and controls.
The selection of samples has, as well, impact on the sensitivity and specificity of the assays in evaluation,
being especially important for the calculation of specificity.
5. Conclusions
Simultaneous ZIKV IgM, low avidity IgG and IgA positive results seem to corroborate a recent
ZIKV infection. However, the serological diagnosis of ZIKV in symptomatic patients should be
supported by careful inquiry at the time of admission. The date of symptom onset together with
the date of sample collection thus provides useful information and may help interpret ZIKV low
avidity IgG and IgA. In the early acute and acute stages of the infection, IgA tests seem to be more
valuable, while low avidity IgG appears to be more useful at the acute and late acute stages. Lastly,
the combined use of both techniques seems preferable in order to avoid false positive results. Further
studies, with a larger number of patients, with follow up samples, would be necessary to clarify the
kinetics of ZIKV antibodies, and the maturation of IgG avidity.
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